assay_id,relationship_type,variant_id,cell_id,assay_strain,description,curated_by,src_assay_id,assay_cell_type,assay_category,tissue_id,tid,bao_format,assay_type,assay_subcellular_fraction,doc_id,assay_test_type,assay_organism,assay_tax_id
1,H,,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,Autocuration,,,,,12052,BAO_0000019,B,,11087,,,
2,U,,,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,Autocuration,,,,,22226,BAO_0000219,F,,684,,,
3,U,,,,,Autocuration,,,,,22226,BAO_0000019,B,,15453,,,
4,H,,,,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,Autocuration,,,,,104729,BAO_0000249,B,,17841,,Bos taurus,9913.0
5,N,,163.0,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),Intermediate,,143B,,,80001,BAO_0000219,F,,17430,,Homo sapiens,9606.0
6,N,,163.0,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),Intermediate,,143B,,,80001,BAO_0000219,F,,17430,,Homo sapiens,9606.0
7,N,,163.0,,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,Intermediate,,143B,,,80001,BAO_0000219,F,,13799,,Mus musculus,10090.0
8,N,,163.0,,In vitro cell cytotoxicity was determined against 143B cell line,Expert,,143B,,,80001,BAO_0000219,F,,17774,,Homo sapiens,9606.0
9,N,,163.0,,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,Intermediate,,143B,,,80001,BAO_0000219,F,,3801,,Homo sapiens,9606.0
10,N,,163.0,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,Intermediate,,143B,,,80001,BAO_0000219,F,,17430,,Homo sapiens,9606.0
11,N,,163.0,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,Intermediate,,143B,,,80001,BAO_0000219,F,,17430,,Homo sapiens,9606.0
12,N,,163.0,,In vitro cell cytotoxicity was determined against 143B-LTK cell line,Expert,,143B,,,80001,BAO_0000219,F,,17774,,Homo sapiens,9606.0
13,N,,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Intermediate,,,,,50185,BAO_0000218,F,,11324,,Staphylococcus aureus,1280.0
14,N,,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Intermediate,,,,,50185,BAO_0000218,F,,11324,,Staphylococcus aureus,1280.0
15,N,,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Intermediate,,,,,50185,BAO_0000218,F,,11324,,Staphylococcus aureus,1280.0
16,N,,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Intermediate,,,,,50185,BAO_0000218,F,,11324,,Staphylococcus aureus,1280.0
17,D,,,,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,Expert,,,,,100122,BAO_0000357,A,,11347,,Rattus norvegicus,10116.0
18,H,,,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),Autocuration,,,,,12054,BAO_0000357,B,,16474,,,
19,H,,,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,Autocuration,,,,,12054,BAO_0000019,B,,10091,,,
20,H,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),Autocuration,,,,,12054,BAO_0000357,B,,16474,,,
21,H,,,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),Autocuration,,,,,12054,BAO_0000357,B,,16474,,,
22,H,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),Autocuration,,,,,12054,BAO_0000357,B,,16474,,,
23,H,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,Autocuration,,,,,12054,BAO_0000357,B,,16474,,,
24,H,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,Autocuration,,,,,12054,BAO_0000357,B,,16474,,,
25,U,,,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",Autocuration,,,,,22226,BAO_0000219,B,,14352,,,
26,H,,,,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,Autocuration,,,,,12054,BAO_0000357,B,,5646,,Oryctolagus cuniculus,9986.0
27,H,,,,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),Autocuration,,,,,12054,BAO_0000357,B,,5646,,Oryctolagus cuniculus,9986.0
28,H,,,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,Autocuration,,,,,12426,BAO_0000219,B,,10997,,,
29,H,,,,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,Autocuration,,,,,12054,BAO_0000357,B,,6309,,soya bean,3847.0
30,H,,,,Inhibitory activity against soybean 15-lipoxygenase was evaluated,Autocuration,,,,,12054,BAO_0000357,B,,167,,Glycine max,3847.0
31,H,,,,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,Autocuration,,,,,12054,BAO_0000357,B,,167,,Glycine max,3847.0
32,H,,,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,Autocuration,,,,,12054,BAO_0000357,B,,11087,,Glycine max,3847.0
33,H,,,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,Autocuration,,,,,12054,BAO_0000357,B,,11087,,Glycine max,3847.0
34,H,,,,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,Autocuration,,,,,12054,BAO_0000357,B,,13622,,Glycine max,3847.0
35,H,,,,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,Autocuration,,,,,12054,BAO_0000357,B,,13622,,Glycine max,3847.0
36,U,,,,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,Autocuration,,,,,22226,BAO_0000019,A,,11347,,Rattus norvegicus,10116.0
37,U,,,,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,Autocuration,,,,,22226,BAO_0000019,B,,5926,,Escherichia coli,562.0
38,U,,,,Dissociation constant with dimeric 16S rRNA RNA construct B,Autocuration,,,,,22226,BAO_0000019,B,,4567,,,
39,M,,,,Dissociation constant towards 16S rRNA construct A,Intermediate,,,,,22222,BAO_0000225,B,,3782,,,
40,M,,,,Dissociation constant towards 16S rRNA construct B,Intermediate,,,,,22222,BAO_0000225,B,,3782,,,
41,M,,,,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,Expert,,,,,100263,BAO_0000225,B,,4466,,Escherichia coli,562.0
42,M,,,,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,Expert,,,,,100263,BAO_0000225,B,,6592,,Escherichia coli,562.0
43,H,,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),Autocuration,,,,,13053,BAO_0000019,B,,898,,,
44,H,,,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),Autocuration,,,,,13053,BAO_0000019,B,,898,,,
45,H,,,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,Autocuration,,,,,20001,BAO_0000019,B,,13163,,Homo sapiens,9606.0
46,H,,,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,Autocuration,,,,,20001,BAO_0000019,B,,13163,,Homo sapiens,9606.0
47,D,,,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",Expert,,,,,12971,BAO_0000019,B,,10691,,Rattus norvegicus,10116.0
48,D,,,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",Expert,,,,,12971,BAO_0000019,B,,10691,,Rattus norvegicus,10116.0
49,D,,,,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",Expert,,,,,12971,BAO_0000019,B,,10691,,Rattus norvegicus,10116.0
50,D,,,,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",Expert,,,,,12971,BAO_0000019,B,,10691,,Rattus norvegicus,10116.0
51,H,,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),Autocuration,,,,,13053,BAO_0000019,B,,898,,,
52,H,,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),Autocuration,,,,,11512,BAO_0000357,B,,912,,,
53,H,,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,Autocuration,,,,,11512,BAO_0000357,B,,912,,,
54,H,,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,Autocuration,,,,,11512,BAO_0000357,B,,912,,,
55,D,,,,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,Autocuration,,,,,104740,BAO_0000249,B,Membranes,15103,,Rattus norvegicus,10116.0
56,N,,506.0,,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,Intermediate,,1A9,,,80002,BAO_0000219,F,,5116,,Homo sapiens,9606.0
57,D,,,,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,Autocuration,,Oocytes,,,104835,BAO_0000219,F,,14578,,Rattus norvegicus,10116.0
58,D,,,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,Autocuration,,Oocytes,,,104821,BAO_0000219,F,,14578,,Rattus norvegicus,10116.0
59,D,,,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,Autocuration,,Oocytes,,,104848,BAO_0000219,F,,14578,,Rattus norvegicus,10116.0
60,N,,506.0,,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,Expert,,1A9,,,80002,BAO_0000219,F,,4787,,Homo sapiens,9606.0
61,N,,506.0,,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,Intermediate,,1A9,,,80002,BAO_0000219,F,,4787,,Homo sapiens,9606.0
62,N,,506.0,,Cytotoxic activity against human ovarian cancer (1A9) cell line,Intermediate,,1A9,,,80002,BAO_0000219,F,,3547,,Homo sapiens,9606.0
63,N,,506.0,,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,Intermediate,,1A9,,,80002,BAO_0000219,F,,3547,,Homo sapiens,9606.0
64,N,,506.0,,Effective dose of compound against replication of 1A9 cell line was evaluated,Intermediate,,1A9,,,80002,BAO_0000219,F,,6726,,Homo sapiens,9606.0
65,N,,506.0,,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,Expert,,1A9,,,80002,BAO_0000219,F,,3455,,Homo sapiens,9606.0
66,N,,506.0,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),Intermediate,,1A9,,,80002,BAO_0000219,F,,5726,,Homo sapiens,9606.0
67,N,,506.0,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,Intermediate,,1A9,,,80002,BAO_0000219,F,,5726,,Homo sapiens,9606.0
68,N,,506.0,,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,Intermediate,,1A9,,,80002,BAO_0000219,F,,5726,,Homo sapiens,9606.0
69,N,,506.0,,Inhibitory activity against Taxol resistant 1A9 cell lines,Intermediate,,1A9,,,80002,BAO_0000219,F,,3395,,Homo sapiens,9606.0
70,N,,506.0,,Cytotoxicity against human ovarian cancer (1A9) cell lines.,Expert,,1A9,,,80002,BAO_0000219,F,,3415,,Homo sapiens,9606.0
71,N,,506.0,,Percentage inhibition of human ovarian cancer (1A9) cell lines.,Expert,,1A9,,,80002,BAO_0000219,F,,3415,,Homo sapiens,9606.0
72,N,,506.0,,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,Expert,,1A9,,,80002,BAO_0000219,F,,17099,,Homo sapiens,9606.0
73,N,,506.0,,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,Intermediate,,1A9,,,80002,BAO_0000219,F,,17099,,Homo sapiens,9606.0
74,N,,506.0,,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,Intermediate,,1A9,,,80002,BAO_0000219,F,,17099,,Homo sapiens,9606.0
75,N,,506.0,,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,Intermediate,,1A9,,,80002,BAO_0000219,F,,17099,,Homo sapiens,9606.0
76,N,,503.0,,Inhibitory concentration against Jurkat cells,Intermediate,,Jurkat,,,81072,BAO_0000219,F,,17721,,Homo sapiens,9606.0
77,U,,,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,Intermediate,,,,,22226,BAO_0000019,F,,1229,,,
78,D,,,,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,Expert,,,,,100121,BAO_0000357,A,,11347,,Rattus norvegicus,10116.0
79,H,,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",Expert,,,,,11231,BAO_0000357,B,,17117,,,
80,H,,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",Expert,,,,,11231,BAO_0000357,B,,17117,,,
81,H,,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",Expert,,,,,11231,BAO_0000357,B,,17117,,,
82,H,,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",Autocuration,,,,,11231,BAO_0000251,B,Microsomes,11375,,Candida albicans,5476.0
83,H,,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",Autocuration,,,,,11231,BAO_0000251,B,Microsomes,11375,,Candida albicans,5476.0
84,H,,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",Autocuration,,,,,11231,BAO_0000251,B,Microsomes,11375,,Saccharomyces cerevisiae,4932.0
85,H,,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",Autocuration,,,,,11231,BAO_0000251,B,Microsomes,11375,,Saccharomyces cerevisiae,4932.0
86,H,,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",Autocuration,,,,2107.0,12083,BAO_0000251,B,Microsomes,11375,,Sus scrofa,9823.0
87,H,,,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",Autocuration,,,,,11231,BAO_0000019,B,,791,,Rattus norvegicus,10116.0
88,H,,,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",Autocuration,,,,,11231,BAO_0000019,B,,791,,Rattus norvegicus,10116.0
89,H,,,,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",Autocuration,,,,,11231,BAO_0000019,B,,791,,Rattus norvegicus,10116.0
90,D,,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",Autocuration,,,,2107.0,12083,BAO_0000251,B,Microsomes,11375,,Rattus norvegicus,10116.0
91,D,,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Autocuration,,,,2107.0,12083,BAO_0000251,B,Microsomes,11375,,Rattus norvegicus,10116.0
92,D,,,,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Autocuration,,,,2107.0,12083,BAO_0000251,B,Microsomes,153,,Rattus norvegicus,10116.0
93,H,,,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),Expert,,,,,11377,BAO_0000357,B,,8269,,,
94,H,,,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,Expert,,,,,11377,BAO_0000357,B,,8269,,,
95,N,,726.0,,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,Expert,,HepG2,,,81020,BAO_0000219,F,,17653,,Homo sapiens,9606.0
96,N,,726.0,,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,Intermediate,,HepG2,,,81020,BAO_0000219,F,,14277,,Homo sapiens,9606.0
97,N,,726.0,,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,Intermediate,,HepG2,,,81020,BAO_0000219,F,,1717,,Homo sapiens,9606.0
98,N,,726.0,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,Intermediate,,HepG2,,,81020,BAO_0000219,F,,14091,,Homo sapiens,9606.0
99,N,,726.0,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,Intermediate,,HepG2,,,81020,BAO_0000219,F,,14091,,Homo sapiens,9606.0
100,N,,,,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,Expert,,,,,50606,BAO_0000218,F,,17653,,Hepatitis B virus,10407.0
101,N,,726.0,,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,Intermediate,,HepG2,,,81020,BAO_0000219,F,,13105,,Homo sapiens,9606.0
102,N,,726.0,,Concentration required to inhibit 50% of 2.2.15 cell line,Intermediate,,HepG2,,,81020,BAO_0000219,F,,1717,,Homo sapiens,9606.0
103,N,,726.0,,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,Intermediate,,HepG2,,,81020,BAO_0000219,A,,13105,,Homo sapiens,9606.0
104,N,,,,Cytotoxic activity of compound against uninfected 2.2.15 cells.,Intermediate,,2.2.15,,,50587,BAO_0000218,F,,13600,,Homo sapiens,9606.0
105,N,,,,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,Intermediate,,2.2.15,,,50587,BAO_0000218,F,,13467,,Homo sapiens,9606.0
106,N,,,,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",Expert,,2.2.15,,,50606,BAO_0000218,F,,17477,,Hepatitis B virus,10407.0
107,N,,,,In vitro anti-HBV activity in 2.2.15 cells,Intermediate,,2.2.15,,,50587,BAO_0000218,F,,1593,,Homo sapiens,9606.0
108,N,,,,In vitro anti-HBV activity in 2.2.15 cells; Not determined,Intermediate,,2.2.15,,,50587,BAO_0000218,F,,1593,,Homo sapiens,9606.0
109,N,,,,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,Intermediate,,2.2.15,,,50587,BAO_0000218,F,,15089,,Homo sapiens,9606.0
110,N,,,,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,Intermediate,,2.2.15,,,50587,BAO_0000218,F,,15089,,Homo sapiens,9606.0
111,N,,,,Cytotoxicity in 2.2.15 cells,Intermediate,,2.2.15,,,50587,BAO_0000218,F,,1593,,Homo sapiens,9606.0
112,N,,,,Cytotoxicity in 2.2.15 cells; Not determined,Intermediate,,2.2.15,,,50587,BAO_0000218,F,,1593,,Homo sapiens,9606.0
113,N,,,,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,Intermediate,,2.2.15,,,50587,BAO_0000218,F,,13600,,Homo sapiens,9606.0
114,N,,,,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,Intermediate,,2.2.15,,,50587,BAO_0000218,F,,13467,,Homo sapiens,9606.0
115,N,,,,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,Intermediate,,2.2.15,,,50587,BAO_0000218,F,,13467,,Homo sapiens,9606.0
116,N,,726.0,,Antiviral activity against HBV was determined in 2.215 cell line,Intermediate,,HepG2,,,81020,BAO_0000219,F,,14764,,Homo sapiens,9606.0
117,U,,,,Inhibition of 20-HETE synthesis in human renal microsomes,Autocuration,,,,,22226,BAO_0000251,B,Microsomes,6531,,Homo sapiens,9606.0
118,U,,,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,Autocuration,,,,,22226,BAO_0000019,B,,17322,,,
119,N,,388.0,,Inhibitory concentration against 2008 (ovarian) cells,Intermediate,,2008,,,80612,BAO_0000219,F,,17072,,Homo sapiens,9606.0
120,N,,388.0,,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,Intermediate,,2008,,,80612,BAO_0000219,F,,16936,,Homo sapiens,9606.0
121,N,,388.0,,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),Intermediate,,2008,,,80612,BAO_0000219,F,,16936,,Homo sapiens,9606.0
122,N,,388.0,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,Intermediate,,2008,,,80612,BAO_0000219,F,,17146,,Homo sapiens,9606.0
123,N,,388.0,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,Intermediate,,2008,,,80612,BAO_0000219,F,,17146,,Homo sapiens,9606.0
124,N,,561.0,,In vitro inhibition of 2008/R ovarian cancer cell line,Intermediate,,2008/R,,,80613,BAO_0000219,F,,10797,,Homo sapiens,9606.0
125,N,,561.0,,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,Intermediate,,2008/R,,,80613,BAO_0000219,F,,10797,,Homo sapiens,9606.0
126,N,,389.0,,In vitro inhibition of 2008/S ovarian cancer cell line,Intermediate,,2008/S,,,80614,BAO_0000219,F,,10797,,Homo sapiens,9606.0
127,N,,389.0,,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,Intermediate,,2008/S,,,80614,BAO_0000219,F,,10797,,Homo sapiens,9606.0
128,S,,,,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,Expert,,,,,100256,BAO_0000220,B,,4823,,Homo sapiens,9606.0
129,S,,,,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,Intermediate,,,,,100256,BAO_0000220,B,,12912,,Homo sapiens,9606.0
130,S,,,,Inhibition of chymotrypsin-like activity of 20S proteasome,Expert,,,,,100256,BAO_0000220,B,,2957,,,
131,S,,,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,Expert,,,,,100256,BAO_0000220,B,,2957,,,
132,S,,,,Inhibitory activity against 20S proteosome,Intermediate,,,,,100256,BAO_0000220,B,,3260,,,
133,U,,,,Compound was tested for inhibitory activity against tryptase,Autocuration,,,,,22226,BAO_0000019,B,,3451,,Homo sapiens,9606.0
134,N,,726.0,,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,Intermediate,,HepG2,,,81020,BAO_0000219,F,,13885,,Homo sapiens,9606.0
135,N,,726.0,,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,Intermediate,,HepG2,,,81020,BAO_0000219,F,,13885,,Homo sapiens,9606.0
136,U,,,,Compound was tested for the inhibition of Alpha-glucosidase,Autocuration,,,,,22226,BAO_0000019,B,,3676,,,
137,H,,,,Inhibitory concentration against human neutrophil elastase (HNE),Autocuration,,,,,235,BAO_0000357,B,,6043,,,
138,U,,,,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,Autocuration,,,,948.0,22226,BAO_0000218,F,,11140,,Rattus norvegicus,10116.0
139,H,,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,Autocuration,,,,,19640,BAO_0000019,F,,10543,,,
140,H,,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,Expert,,,,,19640,BAO_0000019,F,,10543,,,
141,H,,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,Autocuration,,,,,19640,BAO_0000357,B,,10543,,,
142,H,,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,Expert,,,,,19640,BAO_0000019,F,,10543,,,
143,N,,524.0,,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,Intermediate,,P338,,,80360,BAO_0000219,F,,11365,,Mus musculus,10090.0
144,N,,524.0,,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,Intermediate,,P338,,,80360,BAO_0000219,F,,11365,,Mus musculus,10090.0
145,N,,554.0,,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,Intermediate,,PBL,,,80384,BAO_0000219,F,,11803,,Homo sapiens,9606.0
146,U,,,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,Autocuration,,,,,22226,BAO_0000019,F,,11803,,Ovis aries,9940.0
147,U,,,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,Autocuration,,,,,22226,BAO_0000019,F,,11803,,Ovis aries,9940.0
148,H,,,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),Autocuration,,,,,191,BAO_0000357,B,,12278,,,
149,U,,,,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,Autocuration,,,,,22226,BAO_0000019,F,,8249,,Homo sapiens,9606.0
150,U,,,,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,Autocuration,,,,,22226,BAO_0000019,F,,8249,,Homo sapiens,9606.0
151,U,,635.0,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,Autocuration,,CCRF-CEM,,,22226,BAO_0000219,F,,8249,,Homo sapiens,9606.0
152,U,,635.0,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,Autocuration,,CCRF-CEM,,,22226,BAO_0000219,F,,8249,,Homo sapiens,9606.0
153,U,,635.0,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,Autocuration,,CCRF-CEM,,,22226,BAO_0000219,F,,8249,,Homo sapiens,9606.0
154,U,,635.0,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,Autocuration,,CCRF-CEM,,,22226,BAO_0000219,F,,8249,,Homo sapiens,9606.0
155,U,,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,Autocuration,,,,,22226,BAO_0000019,F,,8249,,Homo sapiens,9606.0
156,U,,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,Autocuration,,,,,22226,BAO_0000019,F,,8249,,Homo sapiens,9606.0
157,H,,,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,Autocuration,,,,,104290,BAO_0000249,B,,16992,,,
158,N,,,,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,Intermediate,,,,,50264,BAO_0000218,F,,10543,,Streptococcus pyogenes,1314.0
159,N,,,,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),Intermediate,,,,,50527,BAO_0000218,F,,17833,,Human herpesvirus 3,10335.0
160,N,,468.0,,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,Expert,,HEL,,,50527,BAO_0000218,F,,17290,,vericilla zoster virus,10335.0
161,N,,,,Antiviral activity against 07/1 strain of VZV; ND: No data,Intermediate,,,,,50527,BAO_0000218,F,,17290,,vericilla zoster virus,10335.0
162,N,,,,Antiviral activity against 07/1 strain of VZV; ND=No data,Intermediate,,,,,50527,BAO_0000218,F,,17290,,vericilla zoster virus,10335.0
163,N,,,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",Intermediate,,,,,50145,BAO_0000218,F,,10932,,escherichia cloac,561.0
164,U,,,,Ratio of Ki at A2 to Ki at A1 receptors,Autocuration,,,,,22226,BAO_0000019,B,,9707,,,
165,H,,,,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",Expert,,,,,11143,BAO_0000249,B,,2346,,Candida albicans,5476.0
166,H,,,,"Inhibition of 1,3-beta-glucan synthase",Expert,,,,,18077,BAO_0000357,B,,2205,,Candida glabrata CBS 138,284593.0
167,N,,832.0,,Inhibition of growth of 1-87 human tumor cell line,Intermediate,,1-87 tumor cell line,,,80609,BAO_0000219,F,,11900,,Homo sapiens,9606.0
168,D,,,,Inhibition of 1-lipoxygenase (LOX)in RBL cells,Expert,,,,,12166,BAO_0000219,B,,14864,,Rattus norvegicus,10116.0
169,D,,,,Inhibitory activity against soybean 1-lipoxygenase (SLO),Autocuration,,,,,100171,BAO_0000357,B,,16474,,Glycine max,3847.0
170,D,,,,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,Autocuration,,,,,100171,BAO_0000357,B,,16474,,Glycine max,3847.0
171,D,,,,% inhibition against soybean 1-lipoxygenase (SLO),Autocuration,,,,,100171,BAO_0000357,B,,16474,,Glycine max,3847.0
172,D,,,,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,Autocuration,,,,,100171,BAO_0000357,B,,16474,,Glycine max,3847.0
173,D,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,Autocuration,,,,,100171,BAO_0000357,B,,3094,,Glycine max,3847.0
174,D,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,Autocuration,,,,,100171,BAO_0000357,B,,3094,,Glycine max,3847.0
175,D,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,Autocuration,,,,,100171,BAO_0000357,B,,3094,,Glycine max,3847.0
176,D,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,Autocuration,,,,,100171,BAO_0000357,B,,3094,,Glycine max,3847.0
177,D,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,Autocuration,,,,,100171,BAO_0000357,B,,3094,,Glycine max,3847.0
178,D,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,Autocuration,,,,,100171,BAO_0000357,B,,3094,,Glycine max,3847.0
179,D,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,Autocuration,,,,,100171,BAO_0000357,B,,3094,,Glycine max,3847.0
180,D,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,Autocuration,,,,,100171,BAO_0000357,B,,3094,,Glycine max,3847.0
181,D,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,Autocuration,,,,,100171,BAO_0000357,B,,3094,,Glycine max,3847.0
182,D,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,Autocuration,,,,,100171,BAO_0000357,B,,3094,,Glycine max,3847.0
183,D,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,Autocuration,,,,,100171,BAO_0000357,B,,3094,,Glycine max,3847.0
184,U,,,,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,Autocuration,,,,,22226,BAO_0000019,B,,10413,,Mus musculus,10090.0
185,N,,294.0,,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),Intermediate,,C3H 10T1/2,,,80049,BAO_0000219,F,,16929,,Mus musculus,10090.0
186,U,,,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,Intermediate,,,,,22226,BAO_0000019,F,,1229,,,
187,H,,,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),Autocuration,,,,,11489,BAO_0000357,B,,16587,,,
188,H,,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),Autocuration,,,,,11862,BAO_0000357,B,,16587,,,
189,H,,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,Autocuration,,,,,11862,BAO_0000357,B,,16587,,,
190,H,,,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,Autocuration,,,,,11489,BAO_0000357,B,,16587,,,
191,H,,,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,Autocuration,,,,,11862,BAO_0000357,B,,16587,,,
192,D,,,,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,Expert,,,,,12347,BAO_0000019,F,,8058,,Bos taurus,9913.0
193,D,,,,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,Expert,,,,,100120,BAO_0000357,B,,9065,,Rattus norvegicus,10116.0
194,D,,,,Inhibition of 11 beta-hydroxylase from rat adrenal gland,Expert,,,,2369.0,100120,BAO_0000357,B,,8865,,Rattus norvegicus,10116.0
195,D,,,,Inhibition of rat adrenal 11-beta-hydroxylase,Expert,,,,,100120,BAO_0000357,B,,9066,,Rattus norvegicus,10116.0
196,D,,,,Inhibition of rat adrenal 11-beta-hydroxylase,Expert,,,,,100120,BAO_0000357,B,,8394,,Rattus norvegicus,10116.0
197,D,,,,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,Expert,,,,,100120,BAO_0000357,B,,8394,,Rattus norvegicus,10116.0
198,H,,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,Autocuration,,,,,10328,BAO_0000019,B,,6431,,,
199,H,,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,Autocuration,,,,,11490,BAO_0000357,B,,6431,,,
200,H,,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,Autocuration,,,,,11490,BAO_0000357,B,,6431,,,
201,H,,,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,Autocuration,,,,,11134,BAO_0000019,F,,9295,,,
202,H,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,Autocuration,,,,,12052,BAO_0000019,B,,10193,,,
203,H,,,,Compound was tested in vitro for inhibition of 12-LO human platelet,Autocuration,,,,,11134,BAO_0000019,B,,13622,,,
204,H,,,,Inhibitory concentration against human platelet 12-lipoxygenase,Autocuration,,,,,11134,BAO_0000019,F,,12079,,,
205,H,,,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,Autocuration,,,,,11134,BAO_0000019,B,,13622,,,
206,D,,,,Inhibitory concentration against human platelet 12-lipoxygenase,Autocuration,,,,,11134,BAO_0000019,F,,12079,,Homo sapiens,9606.0
207,H,,,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,Expert,,,,,11835,BAO_0000019,B,,13500,,,
208,H,,,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,Expert,,,,,11601,BAO_0000357,B,,13723,,,
209,H,,,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),Autocuration,,,,,11134,BAO_0000019,B,,16474,,,
210,H,,,,Inhibitory activity against human platelet 12-lipoxygenase,Autocuration,,,,,11134,BAO_0000019,B,,1630,,,
211,H,,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,Autocuration,,,,,11134,BAO_0000019,B,,167,,,
212,H,,,,% inhibition against human platelet 12-lipoxygenase (12-HLO),Autocuration,,,,,11134,BAO_0000019,B,,16474,,,
213,H,,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,Autocuration,,,,,11134,BAO_0000019,B,,167,,,
214,H,,,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,Autocuration,,,,,11134,BAO_0000019,B,,16474,,,
215,H,,,,Inhibitory activity towards porcine 12-lipoxygenase,Autocuration,,,,,11601,BAO_0000357,B,,10091,,,
216,H,,,,Tested for inhibition against porcine 12-LO,Autocuration,,,,,11601,BAO_0000357,B,,11966,,,
217,H,,,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,Autocuration,,,,,12052,BAO_0000019,B,,951,,,
218,H,,,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,Autocuration,,,,,12052,BAO_0000019,B,,10997,,,
219,H,,,,In vitro inhibition of rat platelet 12-lipoxygenase,Expert,,,,,12052,BAO_0000019,B,,10193,,,
220,H,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,Autocuration,,,,,12052,BAO_0000019,B,,10193,,,
221,H,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,Autocuration,,,,,12052,BAO_0000019,B,,10193,,,
222,H,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,Autocuration,,,,,12052,BAO_0000019,B,,10193,,,
223,H,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,Autocuration,,,,,12052,BAO_0000019,B,,10193,,,
224,H,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,Autocuration,,,,,12052,BAO_0000019,B,,10193,,,
225,H,,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,Autocuration,,,,,12052,BAO_0000019,B,,11087,,,
226,N,,621.0,,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,Intermediate,,41M,,,80007,BAO_0000219,F,,15569,,Homo sapiens,9606.0
227,N,,621.0,,In vitro antitumor activity against 41M cell line.,Expert,,41M,,,80007,BAO_0000219,F,,12989,,Homo sapiens,9606.0
228,N,,621.0,,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,Intermediate,,41M,,,80007,BAO_0000219,F,,16745,,Homo sapiens,9606.0
229,N,,621.0,,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,Intermediate,,41M,,,80007,BAO_0000219,F,,15569,,Homo sapiens,9606.0
230,N,,621.0,,In vitro antitumor activity against 41McisR cell line.,Expert,,41M,,,80007,BAO_0000219,F,,12989,,Homo sapiens,9606.0
231,N,,621.0,,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,Expert,,41M,,,80007,BAO_0000219,F,,12989,,Homo sapiens,9606.0
232,N,,621.0,,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,Intermediate,,41M,,,80007,BAO_0000219,F,,16745,,Homo sapiens,9606.0
233,D,,,,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),Expert,,,,,84,BAO_0000357,B,,6210,,Homo sapiens,9606.0
234,D,,,,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),Expert,,,,,68,BAO_0000357,B,,6210,,Homo sapiens,9606.0
235,H,,,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),Expert,,,,,68,BAO_0000357,B,,6226,,,
236,H,,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,Expert,,,,,10201,BAO_0000357,B,,17855,,,
237,H,,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,Expert,,,,,10201,BAO_0000357,B,,17855,,,
238,H,,,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,Expert,,,,,10201,BAO_0000357,B,,17855,,,
239,H,,,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",Autocuration,,,,,12220,BAO_0000357,B,,10413,,,
240,H,,,,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",Autocuration,,,,,11303,BAO_0000357,B,,10413,,Escherichia coli,562.0
241,H,,,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",Autocuration,,,,,11303,BAO_0000357,B,,10413,,Escherichia coli,562.0
242,H,,,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",Autocuration,,,,,11303,BAO_0000357,B,,10413,,Escherichia coli,562.0
243,H,,,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",Autocuration,,,,,12220,BAO_0000357,B,,10413,,,
244,H,,,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",Autocuration,,,,,12220,BAO_0000357,B,,10413,,,
245,H,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",Autocuration,,,,,11303,BAO_0000357,B,,7587,,Sus scrofa,9823.0
246,H,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",Autocuration,,,,,11303,BAO_0000019,B,,7587,,Sus scrofa,9823.0
247,H,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",Autocuration,,,,,11303,BAO_0000357,B,,7587,,Sus scrofa,9823.0
248,H,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",Autocuration,,,,,11303,BAO_0000357,B,,7587,,Sus scrofa,9823.0
249,H,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",Autocuration,,,,,11303,BAO_0000357,B,,7587,,Sus scrofa,9823.0
250,H,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",Autocuration,,,,,11303,BAO_0000019,B,,7587,,Sus scrofa,9823.0
251,H,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",Autocuration,,,,,11303,BAO_0000019,B,,7587,,Sus scrofa,9823.0
252,H,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",Autocuration,,,,,11303,BAO_0000019,B,,7587,,Sus scrofa,9823.0
253,H,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",Autocuration,,,,,11303,BAO_0000019,B,,7587,,Sus scrofa,9823.0
254,H,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",Autocuration,,,,,11303,BAO_0000019,B,,7587,,Sus scrofa,9823.0
255,H,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",Autocuration,,,,,11303,BAO_0000357,B,,7587,,Sus scrofa,9823.0
256,H,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",Autocuration,,,,,11303,BAO_0000019,B,,7587,,Sus scrofa,9823.0
257,H,,,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",Autocuration,,,,,11303,BAO_0000357,B,,7323,,,
258,U,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",Autocuration,,,,,22226,BAO_0000019,B,,7587,,Sus scrofa,9823.0
259,U,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",Autocuration,,,,,22226,BAO_0000019,B,,7587,,Sus scrofa,9823.0
260,H,,,,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,Expert,,,,,100249,BAO_0000357,B,,13750,,Saccharomyces cerevisiae,4932.0
261,U,,,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,Autocuration,,,,,22226,BAO_0000019,B,,7662,,Rattus norvegicus,10116.0
262,U,,,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,Autocuration,,,,,22226,BAO_0000019,B,,7662,,Rattus norvegicus,10116.0
263,U,,,,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",Autocuration,,,,,22226,BAO_0000019,B,,7662,,Rattus norvegicus,10116.0
264,H,,,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",Autocuration,,,,,104698,BAO_0000019,F,,12211,,,
265,H,,,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",Autocuration,,,,,104698,BAO_0000019,F,,12211,,,
266,D,,,,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,Intermediate,,,,2116.0,20033,BAO_0000221,F,,12211,,Cavia porcellus,10141.0
267,H,,,,Stimulatory activity of intragastric pressure was tested in the rat,Expert,,,,,10623,BAO_0000019,F,,12211,,,
268,H,,,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,Autocuration,,,,,121,BAO_0000357,B,,15453,,,
269,U,,,,Dose to reduce neuronal firing against 5-HT cells in rats (iv),Autocuration,,,,,22226,BAO_0000218,F,,11884,,Rattus norvegicus,10116.0
270,H,,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,Autocuration,,,,,12688,BAO_0000019,F,,7185,,,
271,D,,,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,Expert,,,,,121,BAO_0000357,B,,6876,,Homo sapiens,9606.0
272,D,,,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,Expert,,,,,121,BAO_0000357,B,,6876,,Homo sapiens,9606.0
273,H,,,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,Autocuration,,,,,12198,BAO_0000019,F,,11863,,,
274,H,,,,Inhibition constant of high-affinity 5-HT uptake,Autocuration,,,,,12198,BAO_0000357,B,,11863,,,
275,H,,,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,Autocuration,,,,,12198,BAO_0000019,F,,11863,,,
276,H,,,,Maximum rate was determined for high affinity transport of 5-HT,Autocuration,,,,,12198,BAO_0000019,F,,11863,,,
277,H,,,,Compound was tested for agonistic activity against 5-HT uptake,Autocuration,,,,,104714,BAO_0000019,F,,4639,,,
278,H,,,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,Expert,,,,,10577,BAO_0000019,B,,15796,,,
279,H,,,,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,Expert,,,,,105,BAO_0000357,B,,15796,,Bos taurus,9913.0
280,D,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,Autocuration,,,,,104744,BAO_0000224,B,,12801,,Rattus norvegicus,10116.0
281,H,,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,Autocuration,,,,,104744,BAO_0000224,B,,12801,,,
282,H,,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,Autocuration,,,,,104744,BAO_0000249,B,Membranes,12120,,,
283,H,,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,Autocuration,,,,,104744,BAO_0000249,B,Membranes,12120,,,
284,H,,,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,Autocuration,,,,,104744,BAO_0000019,B,,11963,,,
285,H,,,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,Autocuration,,,,,51,BAO_0000019,F,,11701,,,
286,H,,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,9995,,,
287,H,,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,9995,,,
288,H,,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,9995,,,
289,H,,,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),Autocuration,,,,,10576,BAO_0000218,F,,16394,In vivo,,
290,D,,,,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,Intermediate,,,,,105570,BAO_0000019,F,,11574,,Cavia porcellus,10141.0
291,H,,449.0,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,Autocuration,,CHO,,,279,BAO_0000219,B,,15779,,,
292,H,,,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,15363,,,
293,D,,,,Efficacy against 5-hydroxytryptamine 2A receptor,Expert,,,,,12687,BAO_0000019,F,,15363,,Rattus norvegicus,10116.0
294,H,,,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,Expert,,,,,12687,BAO_0000019,F,,15329,,,
295,H,,,,Relative potency towards 5-HT2A receptor of rat tail artery,Expert,,,,,12687,BAO_0000019,F,,15329,,,
296,H,,,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,Expert,,,,,12687,BAO_0000019,F,,15329,,,
297,H,,,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,Expert,,,,,12687,BAO_0000019,F,,15329,,,
298,H,,,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,Autocuration,,,,,12687,BAO_0000019,F,,15329,,,
299,H,,,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,Expert,,,,,12687,BAO_0000019,F,,15329,,,
300,D,,,,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,Intermediate,,,,2116.0,20033,BAO_0000221,F,,273,,Cavia porcellus,10141.0
301,D,,,,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),Intermediate,,,,2116.0,20033,BAO_0000221,F,,273,,Cavia porcellus,10141.0
302,D,,,,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,Intermediate,,,,2116.0,20033,BAO_0000221,F,,273,,Cavia porcellus,10141.0
303,H,,,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,Autocuration,,,,,10623,BAO_0000357,B,,12092,,,
304,D,,,,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,Expert,,,,,10623,BAO_0000019,F,,1317,,Rattus norvegicus,10116.0
305,H,,,,Binding affinity against 5-hydroxytryptamine 4 receptor,Expert,,,,,168,BAO_0000357,B,,12409,,,
306,U,,,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,Autocuration,,,,,22226,BAO_0000019,B,,11126,,Gallus gallus,9031.0
307,U,,,,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,Autocuration,,,,,22226,BAO_0000019,F,,11126,,Homo sapiens,9606.0
308,U,,,,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,Autocuration,,,,,22226,BAO_0000019,F,,11126,,Homo sapiens,9606.0
309,N,,649.0,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,Autocuration,,HL-60,,,80156,BAO_0000219,B,,11126,,Homo sapiens,9606.0
310,U,,,,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,Autocuration,,,,,22226,BAO_0000019,B,,11126,,Homo sapiens,9606.0
311,U,,,,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,Autocuration,,,,,22226,BAO_0000019,B,,11126,,Homo sapiens,9606.0
312,D,,,,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,Autocuration,,Oocytes,,,104703,BAO_0000219,B,,17807,,Homo sapiens,9606.0
313,S,,,,Chymotryptic inhibitory activity against 26S proteasome,Intermediate,,,,,100256,BAO_0000220,F,,16575,,,
314,S,,,,Inhibitory activity against 26S proteasome degradation of IkB,Intermediate,,,,,100256,BAO_0000220,B,,15407,,,
315,N,,478.0,,In vitro inhibition of 2780/DOX ovarian cancer cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,10797,,Homo sapiens,9606.0
316,N,,478.0,,In vitro inhibition of 2780/S ovarian cancer cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,10797,,Homo sapiens,9606.0
317,U,,,,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,Autocuration,,,,,22226,BAO_0000019,F,,3469,,Homo sapiens,9606.0
318,M,,,,Association constant for binding to AATT 28-mer AATT hairpin,Intermediate,,,,,22222,BAO_0000225,B,,16037,,,
319,M,,,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,Intermediate,,,,,22222,BAO_0000225,B,,16037,,,
320,M,,,,Reaction Rate Parameter for 28-mer AATT hairpin,Intermediate,,,,,22222,BAO_0000225,B,,16037,,,
321,M,,,,Reaction Rate Parameter for 28-mer AATT hairpin,Intermediate,,,,,22222,BAO_0000225,B,,16037,,,
322,U,,,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),Autocuration,,,,,22226,BAO_0000019,F,,16524,,Homo sapiens,9606.0
323,U,,,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),Autocuration,,,,,22226,BAO_0000019,F,,16524,,Homo sapiens,9606.0
324,U,,,,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,Autocuration,,,,,22226,BAO_0000019,F,,16524,,Homo sapiens,9606.0
325,U,,,,Cytotoxicity against cell line 2SC/20 determined by MTT test,Autocuration,,,,,22226,BAO_0000019,F,,16758,,Cricetulus griseus,10029.0
326,U,,,,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,Autocuration,,,,,22226,BAO_0000019,F,,16758,,Cricetulus griseus,10029.0
327,U,,,,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,Autocuration,,,,,22226,BAO_0000019,F,,16758,,Cricetulus griseus,10029.0
328,H,,,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,Autocuration,,,,,241,BAO_0000357,B,,14360,,,
329,D,,,,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,Expert,,,,,241,BAO_0000357,B,,14360,,Homo sapiens,9606.0
330,U,,,,Selectivity ratio of ID50 in liver and heart,Autocuration,,,,,22226,BAO_0000019,B,,9964,,Rattus norvegicus,10116.0
331,H,,,,"Selectivity, ratio of relative ID50 in liver and heart",Autocuration,,,,,12132,BAO_0000019,B,,9964,,,
332,H,,,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,Autocuration,,,,,12132,BAO_0000019,B,,9964,,,
333,H,,,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",Autocuration,,,,,12132,BAO_0000218,B,,9964,,,
334,H,,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",Autocuration,,,,,12132,BAO_0000218,B,,9964,,,
335,H,,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",Autocuration,,,,,12132,BAO_0000218,B,,9964,In vivo,,
336,H,,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",Autocuration,,,,,12132,BAO_0000218,F,,9964,In vivo,,
337,U,,,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",Autocuration,,,,,22226,BAO_0000019,B,,9964,,,
338,H,,,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,Autocuration,,,,,12132,BAO_0000019,B,,9964,,,
339,U,,,,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",Autocuration,,,,,22226,BAO_0000019,B,,9964,,Homo sapiens,9606.0
340,H,,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,Autocuration,,,,,12132,BAO_0000019,B,,9964,,,
341,H,,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,Autocuration,,,,,12132,BAO_0000019,F,,9964,,,
342,H,,,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",Autocuration,,,,,12132,BAO_0000019,B,,9964,,,
343,U,,,,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",Autocuration,,,,,22226,BAO_0000218,B,,9964,,Rattus norvegicus,10116.0
344,H,,,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,Autocuration,,,,,12132,BAO_0000218,B,,9964,In vivo,,
345,H,,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",Autocuration,,,,,12132,BAO_0000218,B,,9964,,,
346,U,,,,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",Autocuration,,,,,22226,BAO_0000218,B,,9964,,Rattus norvegicus,10116.0
347,H,,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",Autocuration,,,,,12132,BAO_0000019,B,,9964,,,
348,H,,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",Autocuration,,,,,12132,BAO_0000019,F,,9964,,,
349,U,,,,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",Autocuration,,,,,22226,BAO_0000019,B,,3796,,Rattus norvegicus,10116.0
350,H,,,,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,Autocuration,,,,,19690,BAO_0000357,B,,4251,,Escherichia coli,562.0
351,H,,,,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,Autocuration,,,,,19690,BAO_0000357,B,,4251,,Escherichia coli,562.0
352,H,,,,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,Autocuration,,,,,19690,BAO_0000357,B,,4251,,Escherichia coli,562.0
353,H,,,,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,Autocuration,,,,,19690,BAO_0000357,B,,4251,,Escherichia coli,562.0
354,H,,,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,Autocuration,,,,,19690,BAO_0000357,B,,166,,,
355,H,,,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,Autocuration,,,,,19690,BAO_0000357,B,,17861,,,
356,H,,,,Inhibition constant against 3-dehydroquinate synthase,Autocuration,,,,,19690,BAO_0000357,B,,166,,,
357,H,,,,Association rate constant against 3-dehydroquinate synthase,Autocuration,,,,,19690,BAO_0000357,B,,166,,,
358,H,,,,Rate constant against 3-dehydroquinate synthase,Autocuration,,,,,19690,BAO_0000357,B,,166,,,
359,U,,,,Inhibitory activity against fuc-TVII,Autocuration,,,,,22226,BAO_0000019,B,,3548,,,
360,D,,,,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Autocuration,,,,2107.0,12236,BAO_0000251,B,Microsomes,9877,,Rattus norvegicus,10116.0
361,D,,,,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Autocuration,,,,2107.0,12236,BAO_0000251,B,Microsomes,9877,,Rattus norvegicus,10116.0
362,D,,,,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Autocuration,,,,2107.0,12236,BAO_0000251,B,Microsomes,9877,,Rattus norvegicus,10116.0
363,D,,,,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Autocuration,,,,2107.0,12236,BAO_0000251,B,Microsomes,9877,,Rattus norvegicus,10116.0
364,D,,,,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Autocuration,,,,2107.0,12236,BAO_0000251,B,Microsomes,9877,,Rattus norvegicus,10116.0
365,D,,,,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,Autocuration,,,,2107.0,12236,BAO_0000251,B,Microsomes,9877,,Rattus norvegicus,10116.0
366,D,,,,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,Autocuration,,,,2107.0,12236,BAO_0000251,B,Microsomes,9877,,Rattus norvegicus,10116.0
367,D,,,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,Autocuration,,,,2107.0,12236,BAO_0000251,B,Microsomes,9877,,Rattus norvegicus,10116.0
368,D,,,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,Autocuration,,,,2107.0,12236,BAO_0000251,B,Microsomes,9877,,Rattus norvegicus,10116.0
369,D,,,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,Autocuration,,,,2107.0,12236,BAO_0000251,B,Microsomes,9877,,Rattus norvegicus,10116.0
370,D,,,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,Autocuration,,,,2107.0,12236,BAO_0000251,B,Microsomes,9877,,Rattus norvegicus,10116.0
371,H,,,,Inhibitory activity against 3-phosphoglycerate kinase.,Autocuration,,,,,104832,BAO_0000224,B,,3003,,,
372,H,,,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,Autocuration,,,,,104832,BAO_0000224,B,,3003,,,
373,H,,,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",Autocuration,,,,,104832,BAO_0000224,B,,3003,,,
374,D,,,,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,Expert,,,,,10612,BAO_0000357,B,,17185,,Homo sapiens,9606.0
375,N,,844.0,,Cytotoxicity on 3677 melanoma cells,Intermediate,,3677 melanoma cell line,,,80616,BAO_0000219,F,,6072,,Homo sapiens,9606.0
376,N,,844.0,,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,Intermediate,,3677 melanoma cell line,,,80616,BAO_0000219,F,,6072,,Homo sapiens,9606.0
377,N,,700.0,,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,Intermediate,,MC-38,,,80617,BAO_0000219,F,,5018,,Mus musculus,10090.0
378,U,,,,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,Intermediate,,,,,22226,BAO_0000019,F,,2852,,Homo sapiens,9606.0
379,U,,798.0,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,Autocuration,,B16,,,22226,BAO_0000218,F,,8663,,,
380,U,,798.0,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,Autocuration,,B16,,,22226,BAO_0000218,F,,8663,,,
381,D,,,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,Expert,,,,,12464,BAO_0000019,F,,3245,,Human rhinovirus 14,12131.0
382,N,,,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,Intermediate,,,,,50085,BAO_0000218,F,,3245,,Human rhinovirus sp.,169066.0
383,N,,,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,Intermediate,,,,,50679,BAO_0000218,F,,3877,,human rhinovirus type 14,169066.0
384,N,,,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,Intermediate,,,,,50679,BAO_0000218,F,,3877,,human rhinovirus type 14,169066.0
385,D,,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,Expert,,,,,12464,BAO_0000019,F,,5861,,Human rhinovirus 14,12131.0
386,D,,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,Expert,,,,,12464,BAO_0000019,F,,5861,,Human rhinovirus 14,12131.0
387,D,,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,Expert,,,,,12464,BAO_0000019,F,,5861,,Human rhinovirus 14,12131.0
388,D,,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,Expert,,,,,12464,BAO_0000019,F,,5861,,Human rhinovirus 14,12131.0
389,N,,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,Intermediate,,,,,50665,BAO_0000218,F,,13748,,Enterovirus,12059.0
390,N,,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,Intermediate,,,,,50665,BAO_0000218,F,,13748,,Enterovirus,12059.0
391,N,,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,Intermediate,,,,,50665,BAO_0000218,F,,13748,,Enterovirus,12059.0
392,N,,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,Intermediate,,,,,50665,BAO_0000218,F,,13748,,Enterovirus,12059.0
393,H,,,,Inhibition of human rhinovirus 3C protease,Expert,,,,,12464,BAO_0000357,B,,13748,,Human rhinovirus B,147712.0
394,U,,,,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,Autocuration,,,,,22226,BAO_0000019,B,,17699,,Homo sapiens,9606.0
395,N,,833.0,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),Intermediate,,3EM 37,,,80619,BAO_0000218,F,,7145,,Mus musculus,10090.0
396,N,,833.0,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),Intermediate,,3EM 37,,,80619,BAO_0000218,F,,7145,,Mus musculus,10090.0
397,N,,833.0,,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),Intermediate,,3EM 37,,,80619,BAO_0000218,F,,7145,,Mus musculus,10090.0
398,N,,833.0,,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),Intermediate,,3EM 37,,,80619,BAO_0000218,F,,7145,,Mus musculus,10090.0
399,N,,833.0,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,Intermediate,,3EM 37,,,80619,BAO_0000218,F,,7145,,Mus musculus,10090.0
400,N,,833.0,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,Intermediate,,3EM 37,,,80619,BAO_0000218,F,,7145,,Mus musculus,10090.0
401,N,,847.0,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,Intermediate,,3LL cell line,,,80620,BAO_0000218,F,,5325,,Mus musculus,10090.0
402,N,,847.0,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,Intermediate,,3LL cell line,,,80620,BAO_0000218,F,,5325,,Mus musculus,10090.0
403,N,,847.0,,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,Expert,,3LL cell line,,,80620,BAO_0000218,F,,5325,,Mus musculus,10090.0
404,N,,847.0,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,Mus musculus,10090.0
405,N,,847.0,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,Mus musculus,10090.0
406,N,,847.0,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,Mus musculus,10090.0
407,N,,847.0,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,Mus musculus,10090.0
408,N,,847.0,,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,Mus musculus,10090.0
409,N,,847.0,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,Mus musculus,10090.0
410,N,,847.0,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,Mus musculus,10090.0
411,N,,847.0,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,Mus musculus,10090.0
412,N,,847.0,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,Mus musculus,10090.0
413,N,,847.0,,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,Mus musculus,10090.0
414,N,,847.0,,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,Mus musculus,10090.0
415,N,,847.0,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,Mus musculus,10090.0
416,N,,847.0,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,Mus musculus,10090.0
417,N,,847.0,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,Mus musculus,10090.0
418,N,,847.0,,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,Mus musculus,10090.0
419,N,,847.0,,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,Mus musculus,10090.0
420,N,,847.0,,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,Mus musculus,10090.0
421,N,,847.0,,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,Mus musculus,10090.0
422,N,,847.0,,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,Mus musculus,10090.0
423,N,,847.0,,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,Mus musculus,10090.0
424,N,,847.0,,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,Mus musculus,10090.0
425,N,,847.0,,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,Mus musculus,10090.0
426,N,,847.0,,spermine levels in 3LL cells after the treatment of 1 uM of Compound,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,Mus musculus,10090.0
427,N,,847.0,,spermine levels in 3LL cells after the treatment of 10 uM of Compound,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,Mus musculus,10090.0
428,N,,847.0,,spermine levels in 3LL cells after the treatment of 250 uM of Compound,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,Mus musculus,10090.0
429,N,,847.0,,spermine levels in 3LL cells after the treatment of 50 uM of Compound,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,Mus musculus,10090.0
430,N,,971.0,,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,Intermediate,,3LLD122,,,80621,BAO_0000219,F,,15547,,Homo sapiens,9606.0
431,U,,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,Autocuration,,,,,22226,BAO_0000218,F,,8663,,,
432,U,,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,Autocuration,,,,,22226,BAO_0000218,F,,8663,,,
433,U,,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,Autocuration,,,,,22226,BAO_0000218,F,,8663,,,
434,U,,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,Autocuration,,,,,22226,BAO_0000218,F,,8663,,,
435,N,,723.0,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,4504,,Mus musculus,10090.0
436,N,,723.0,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,4504,,Mus musculus,10090.0
437,H,,723.0,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,Expert,,NIH3T3,,,11169,BAO_0000219,F,,12695,,,
438,N,,723.0,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,12695,,Mus musculus,10090.0
439,N,,723.0,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,12695,,Mus musculus,10090.0
440,N,,723.0,,Effective dose against murine 3T3 fibroblasts cells,Expert,,NIH3T3,,,80951,BAO_0000219,F,,17642,,Mus musculus,10090.0
441,N,,723.0,,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,Expert,,NIH3T3,,,80951,BAO_0000219,F,,17642,,Mus musculus,10090.0
442,N,,723.0,,Cytotoxic effect on 3T3 cells,Expert,,NIH3T3,,,80951,BAO_0000219,F,,12340,,Mus musculus,10090.0
443,N,,723.0,,Cytotoxic effect on 3T3 cells,Expert,,NIH3T3,,,80951,BAO_0000219,F,,12340,,Mus musculus,10090.0
444,N,,723.0,,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,12716,,Mus musculus,10090.0
445,N,,723.0,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,6277,,Mus musculus,10090.0
446,N,,723.0,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,6277,,Mus musculus,10090.0
447,N,,723.0,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,Expert,,NIH3T3,,,80951,BAO_0000219,F,,6277,,Mus musculus,10090.0
448,N,,723.0,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,Expert,,NIH3T3,,,80951,BAO_0000219,F,,6277,,Mus musculus,10090.0
449,N,,723.0,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,6277,,Mus musculus,10090.0
450,N,,723.0,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,Expert,,NIH3T3,,,80951,BAO_0000219,F,,6277,,Mus musculus,10090.0
451,N,,723.0,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,Expert,,NIH3T3,,,80951,BAO_0000219,F,,6277,,Mus musculus,10090.0
452,N,,723.0,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,6277,,Mus musculus,10090.0
453,N,,723.0,,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,Expert,,NIH3T3,,,80951,BAO_0000218,F,,17780,,Mus musculus,10090.0
454,D,,,,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,Autocuration,,,,,104860,BAO_0000219,F,,12751,,Mus musculus,10090.0
455,N,,723.0,,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,Expert,,NIH3T3,,,80951,BAO_0000219,F,,12380,,Mus musculus,10090.0
456,N,,723.0,,Inhibitory activity against 3T3 cell line,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,14892,,Mus musculus,10090.0
457,N,,723.0,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,12695,,Mus musculus,10090.0
458,H,,,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,Expert,,,,,11169,BAO_0000019,F,,12695,,,
459,N,,723.0,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,12695,,Mus musculus,10090.0
460,N,,723.0,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,12695,,Mus musculus,10090.0
461,H,,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,Expert,,,,,11169,BAO_0000019,F,,12695,,,
462,H,,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,Expert,,,,,11169,BAO_0000019,F,,12695,,,
463,N,,723.0,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,6277,,Mus musculus,10090.0
464,N,,723.0,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,Expert,,NIH3T3,,,80951,BAO_0000219,F,,6277,,Mus musculus,10090.0
465,D,,723.0,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,Expert,,NIH3T3,,,9,BAO_0000219,F,,4959,,Homo sapiens,9606.0
466,D,,723.0,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),Expert,,NIH3T3,,,9,BAO_0000219,F,,4959,,Homo sapiens,9606.0
467,D,,723.0,,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,Expert,,NIH3T3,,,188,BAO_0000219,F,,4959,,Homo sapiens,9606.0
468,D,,723.0,,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),Expert,,NIH3T3,,,188,BAO_0000219,F,,4959,,Homo sapiens,9606.0
469,N,,723.0,,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,12082,,Mus musculus,10090.0
470,N,,723.0,,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,12082,,Mus musculus,10090.0
471,N,,723.0,,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,12082,,Mus musculus,10090.0
472,N,,723.0,,Inhibitory concentration was calculated on 3T3 cells by using growth assay,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,12082,,Mus musculus,10090.0
473,N,,723.0,,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,2643,,Mus musculus,10090.0
474,N,,723.0,,Inhibition of Swiss 3T3 mouse fibroblast proliferation,Expert,,NIH3T3,,,80951,BAO_0000219,F,,11926,,Mus musculus,10090.0
475,N,,723.0,,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,Intermediate,,NIH3T3,,,80951,BAO_0000219,A,,15204,,Mus musculus,10090.0
476,N,,723.0,,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,Expert,,NIH3T3,,,80951,BAO_0000219,F,,15992,,Mus musculus,10090.0
477,N,,723.0,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,16279,,Mus musculus,10090.0
478,N,,723.0,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,16279,,Mus musculus,10090.0
479,N,,723.0,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,16279,,Mus musculus,10090.0
480,N,,723.0,,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,16279,,Mus musculus,10090.0
481,N,,723.0,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,16279,,Mus musculus,10090.0
482,N,,723.0,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,16279,,Mus musculus,10090.0
483,N,,723.0,,Inhibition of swiss 3T3 mouse fibroblast proliferation,Expert,,NIH3T3,,,80951,BAO_0000219,F,,12831,,Mus musculus,10090.0
484,N,,723.0,,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,13497,,Mus musculus,10090.0
485,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,Intermediate,,3T3-L1,,,80006,BAO_0000218,F,,13715,,,
486,N,,620.0,,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,Intermediate,,3T3-L1,,,80006,BAO_0000219,F,,13618,,Mus musculus,10090.0
487,N,,620.0,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,Intermediate,,3T3-L1,,,80006,BAO_0000219,F,,11902,,Mus musculus,10090.0
488,N,,620.0,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,Intermediate,,3T3-L1,,,80006,BAO_0000219,F,,11902,,Mus musculus,10090.0
489,N,,620.0,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,Intermediate,,3T3-L1,,,80006,BAO_0000219,F,,11902,,Mus musculus,10090.0
490,N,,620.0,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",Intermediate,,3T3-L1,,,80006,BAO_0000218,F,,14840,,Mus musculus,10090.0
491,N,,620.0,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",Intermediate,,3T3-L1,,,80006,BAO_0000218,F,,14840,,Mus musculus,10090.0
492,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,Intermediate,,3T3-L1,,,80006,BAO_0000219,F,,13715,,,
493,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,Intermediate,,3T3-L1,,,80006,BAO_0000219,F,,13715,,,
494,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,Intermediate,,3T3-L1,,,80006,BAO_0000219,F,,13715,,,
495,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,Intermediate,,3T3-L1,,,80006,BAO_0000219,F,,13715,,,
496,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,Intermediate,,3T3-L1,,,80006,BAO_0000219,F,,13715,,,
497,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,Intermediate,,3T3-L1,,,80006,BAO_0000218,F,,13715,,,
498,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,Intermediate,,3T3-L1,,,80006,BAO_0000218,F,,13715,,,
499,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,Intermediate,,3T3-L1,,,80006,BAO_0000218,F,,13715,,,
500,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,Intermediate,,3T3-L1,,,80006,BAO_0000218,F,,13715,,,
501,N,,620.0,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,Expert,,3T3-L1,,,80006,BAO_0000218,F,,13715,,,
502,N,,620.0,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,Expert,,3T3-L1,,,80006,BAO_0000218,F,,13715,,,
503,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,Intermediate,,3T3-L1,,,80006,BAO_0000218,F,,13715,,,
504,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,Intermediate,,3T3-L1,,,80006,BAO_0000218,F,,13715,,,
505,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,Intermediate,,3T3-L1,,,80006,BAO_0000218,F,,13715,,,
506,N,,620.0,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,Expert,,3T3-L1,,,80006,BAO_0000218,F,,13715,,,
507,N,,620.0,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,Expert,,3T3-L1,,,80006,BAO_0000218,F,,13715,,,
508,N,,620.0,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,Expert,,3T3-L1,,,80006,BAO_0000218,F,,13715,,,
509,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,Intermediate,,3T3-L1,,,80006,BAO_0000219,F,,13715,,,
510,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,Intermediate,,3T3-L1,,,80006,BAO_0000219,F,,13715,,,
511,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,Intermediate,,3T3-L1,,,80006,BAO_0000219,F,,13715,,,
512,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,Intermediate,,3T3-L1,,,80006,BAO_0000218,F,,13715,,,
513,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,Intermediate,,3T3-L1,,,80006,BAO_0000218,F,,13715,,,
514,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,Intermediate,,3T3-L1,,,80006,BAO_0000218,F,,13715,,,
515,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,Intermediate,,3T3-L1,,,80006,BAO_0000218,F,,13715,,,
516,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,Intermediate,,3T3-L1,,,80006,BAO_0000218,F,,13715,,,
517,H,,620.0,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,Expert,,3T3-L1,,,11214,BAO_0000219,F,,6411,,,
518,N,,620.0,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,Intermediate,,3T3-L1,,,80006,BAO_0000219,F,,6411,,Mus musculus,10090.0
519,H,,620.0,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,Expert,,3T3-L1,,,11214,BAO_0000219,F,,6411,,,
520,N,,620.0,,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,Expert,,3T3-L1,,,80006,BAO_0000219,F,,3966,,Mus musculus,10090.0
521,N,,620.0,,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,Intermediate,,3T3-L1,,,80006,BAO_0000219,F,,3966,,Mus musculus,10090.0
522,N,,620.0,,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,Expert,,3T3-L1,,,80006,BAO_0000219,F,,15556,,Mus musculus,10090.0
523,N,,620.0,,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,Expert,,3T3-L1,,,80006,BAO_0000219,F,,5845,,Mus musculus,10090.0
524,N,,620.0,,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,Expert,,3T3-L1,,,80006,BAO_0000219,F,,14422,,Mus musculus,10090.0
525,N,,620.0,,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,Expert,,3T3-L1,,,80006,BAO_0000219,F,,5845,,Mus musculus,10090.0
526,N,,620.0,,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,Expert,,3T3-L1,,,80006,BAO_0000219,F,,14508,,Mus musculus,10090.0
527,N,,620.0,,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,Expert,,3T3-L1,,,80006,BAO_0000219,F,,14508,,Mus musculus,10090.0
528,N,,620.0,,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,Expert,,3T3-L1,,,80006,BAO_0000219,F,,14508,,Mus musculus,10090.0
529,N,,1118.0,,Inhibitory activity against rat fibroblast (3Y1) cell line,Intermediate,,3Y1 cell line,,,80622,BAO_0000219,F,,6349,,Rattus norvegicus,10116.0
530,N,,1118.0,,Mean concentration causing inhibition of cell growth in 3Y1 cells.,Expert,,3Y1 cell line,,,80622,BAO_0000219,F,,15899,,Rattus norvegicus,10116.0
531,N,,1118.0,,Cytotoxicity in 3Y1 cells.,Expert,,3Y1 cell line,,,80622,BAO_0000219,F,,15899,,Rattus norvegicus,10116.0
532,N,,1118.0,,Cytostatic effect in 3Y1 cells.,Expert,,3Y1 cell line,,,80622,BAO_0000219,F,,15899,,Rattus norvegicus,10116.0
533,N,,1118.0,,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",Intermediate,,3Y1 cell line,,,80622,BAO_0000219,F,,15899,,Rattus norvegicus,10116.0
534,N,,1118.0,,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,Expert,,3Y1 cell line,,,80622,BAO_0000219,F,,17038,,Rattus norvegicus,10116.0
535,U,,,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,Autocuration,,,,,22226,BAO_0000019,B,,12421,,,
536,U,,,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,Autocuration,,,,,22226,BAO_0000019,B,,12947,,,
537,U,,,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,Autocuration,,,,,22226,BAO_0000019,B,,12947,,,
538,D,,,,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,Expert,,,,,11607,BAO_0000019,B,,4896,,Sus scrofa,9823.0
539,H,,,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,Autocuration,,,,,11607,BAO_0000019,B,,6148,,,
540,H,,,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,Autocuration,,,,,11607,BAO_0000019,B,,16432,,,
541,H,,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,Expert,,,,,11607,BAO_0000019,B,,4978,,,
542,H,,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),Expert,,,,,11607,BAO_0000019,B,,4978,,,
543,H,,,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,Autocuration,,,,,11607,BAO_0000019,B,,3723,,,
544,H,,,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),Autocuration,,,,,11607,BAO_0000357,B,,3518,,,
545,H,,,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,Autocuration,,,,,11607,BAO_0000019,B,,4164,,,
546,H,,,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,Autocuration,,,,,11607,BAO_0000019,B,,3518,,,
547,D,,,,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,Expert,,,,,11607,BAO_0000019,B,,4164,,Sus scrofa,9823.0
548,H,,,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,Autocuration,,,,,11607,BAO_0000019,B,,3518,,,
549,H,,,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),Autocuration,,,,,11607,BAO_0000357,B,,3518,,,
550,H,,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,Autocuration,,,,,11607,BAO_0000019,B,,4978,,,
551,H,,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),Autocuration,,,,,11607,BAO_0000019,B,,4978,,,
552,H,,,,Binding affinity against melatonin (MT1) receptor (pC1),Autocuration,,,,,104733,BAO_0000224,B,,6455,,,
553,U,,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,Autocuration,,,,,22226,BAO_0000019,B,,2222,,,
554,U,,,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,Autocuration,,,,,22226,BAO_0000019,B,,13020,,,
555,U,,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,Autocuration,,,,,22226,BAO_0000019,B,,13021,,,
556,H,,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,Autocuration,,,,,10619,BAO_0000357,B,,14532,,,
557,H,,,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,Autocuration,,,,,10619,BAO_0000357,B,,14118,,,
558,H,,,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,Autocuration,,,,10000000.0,51,BAO_0000221,B,,11884,,,
559,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,Expert,,,,,51,BAO_0000357,B,,13969,,,
560,H,,,,Binding affinity for 5-hydroxytryptamine 1A receptor,Expert,,,,,51,BAO_0000357,B,,13392,,,
561,H,,,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,Expert,,,,,51,BAO_0000019,B,,14430,,,
562,H,,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,12248,,,
563,H,,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,12249,,,
564,H,,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,9995,,,
565,H,,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,9995,,,
566,H,,,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,9995,,,
567,H,,,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,9995,,,
568,H,,,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,9995,,,
569,H,,,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,12249,,,
570,H,,,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",Autocuration,,,,10000000.0,51,BAO_0000221,B,,11799,,,
571,D,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,Expert,,,,,10576,BAO_0000249,B,Membranes,14331,,Rattus norvegicus,10116.0
572,H,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,Expert,,,,10000000.0,51,BAO_0000221,B,,11884,,Bos taurus,9913.0
573,H,,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,Autocuration,,,,10000000.0,51,BAO_0000221,B,,14331,,,
574,H,,,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,11701,,,
575,H,,,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,Expert,,,,10000000.0,51,BAO_0000221,B,,11701,,,
576,H,,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,12248,,,
577,H,,449.0,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,Autocuration,,CHO,,,51,BAO_0000219,B,,12248,,,
578,H,,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Expert,,,,10000000.0,51,BAO_0000221,B,,12248,,,
579,H,,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Expert,,,,10000000.0,51,BAO_0000221,B,,12249,,,
580,H,,449.0,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,Autocuration,,CHO,,,51,BAO_0000219,B,,12248,,,
581,H,,,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",Expert,,,,10000000.0,51,BAO_0000221,B,,11799,,,
582,H,,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,Autocuration,,,,,51,BAO_0000357,B,,634,,,
583,H,,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,9995,,,
584,H,,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,9995,,,
585,H,,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,9995,,,
586,H,,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,9995,,,
587,H,,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,9995,,,
588,H,,,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,Expert,,,,10000000.0,51,BAO_0000218,B,,12210,,,
589,H,,,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,Expert,,,,10000000.0,51,BAO_0000221,B,,13311,,,
590,D,,449.0,,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",Expert,,CHO,,,51,BAO_0000219,B,,2331,,Homo sapiens,9606.0
591,H,,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,Autocuration,,,,,51,BAO_0000019,F,,1375,,Cavia porcellus,10141.0
592,H,,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,Autocuration,,,,,51,BAO_0000019,F,,1375,,Cavia porcellus,10141.0
593,H,,,,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,Autocuration,,,,10000000.0,51,BAO_0000221,F,,11574,,Cavia porcellus,10141.0
594,H,,,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,Autocuration,,,,2116.0,51,BAO_0000221,B,,12867,,Cavia porcellus,10141.0
595,H,,,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Autocuration,,,,2116.0,51,BAO_0000221,B,,12867,,Cavia porcellus,10141.0
596,H,,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,Autocuration,,,,2116.0,51,BAO_0000221,B,,12867,,Cavia porcellus,10141.0
597,H,,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Autocuration,,,,2116.0,51,BAO_0000221,B,,12867,,Cavia porcellus,10141.0
598,H,,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Autocuration,,,,2116.0,51,BAO_0000221,B,,12867,,Cavia porcellus,10141.0
599,H,,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,Autocuration,,,,2116.0,51,BAO_0000221,B,,12867,,Cavia porcellus,10141.0
600,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,11574,,Cavia porcellus,10141.0
601,H,,,,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,13114,,Cavia porcellus,10141.0
602,H,,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,13181,,Cavia porcellus,10141.0
603,H,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,Autocuration,,,,10000000.0,106,BAO_0000221,B,,10639,,Cavia porcellus,10141.0
604,H,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,Autocuration,,,,10000000.0,106,BAO_0000221,F,,10639,,Cavia porcellus,10141.0
605,H,,449.0,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),Autocuration,,CHO,,,11863,BAO_0000218,B,,11883,,Cricetulus griseus,10029.0
606,H,,,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,17785,,,
607,H,,308.0,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,Autocuration,,HeLa,,,51,BAO_0000219,F,,1558,,,
608,H,,308.0,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,Autocuration,,HeLa,,,51,BAO_0000219,F,,1558,,,
609,H,,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000019,F,,15740,,,
610,H,,449.0,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,Autocuration,,CHO,,,51,BAO_0000219,F,,17624,,,
611,H,,449.0,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,Expert,,CHO,,,51,BAO_0000219,F,,17624,,,
612,H,,449.0,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,Autocuration,,CHO,,,51,BAO_0000219,F,,17624,,,
613,H,,449.0,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,Autocuration,,CHO,,,51,BAO_0000219,F,,17624,,,
614,H,,449.0,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,Expert,,CHO,,,51,BAO_0000219,B,,17624,,,
615,H,,449.0,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,Expert,,CHO,,,51,BAO_0000219,B,,17624,,,
616,H,,449.0,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,Autocuration,,CHO,,,51,BAO_0000219,B,,17624,,,
617,H,,,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,Autocuration,,,,,51,BAO_0000219,F,,14256,,,
618,D,,308.0,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,Expert,,HeLa,,,51,BAO_0000219,B,,3445,,Homo sapiens,9606.0
619,D,,308.0,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,Expert,,HeLa,,,51,BAO_0000219,B,,3445,,Homo sapiens,9606.0
620,D,,449.0,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,Expert,,CHO,,,51,BAO_0000219,B,,17200,,Homo sapiens,9606.0
621,D,,449.0,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,Expert,,CHO,,,51,BAO_0000219,B,,17200,,Homo sapiens,9606.0
622,H,,,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000019,F,,15180,,,
623,H,,,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000019,F,,15180,,,
624,H,,,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",Autocuration,,,,,51,BAO_0000019,F,,16026,,,
625,H,,449.0,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,Autocuration,,CHO,,,51,BAO_0000219,F,,2759,,,
626,D,,449.0,,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),Expert,,CHO,,,51,BAO_0000219,F,,2759,,Homo sapiens,9606.0
627,H,,449.0,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),Autocuration,,CHO,,,51,BAO_0000219,F,,2759,,,
628,D,,449.0,,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),Expert,,CHO,,,51,BAO_0000219,F,,2759,,Homo sapiens,9606.0
629,H,,449.0,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,Autocuration,,CHO,,,51,BAO_0000219,F,,2759,,,
630,H,,449.0,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),Autocuration,,CHO,,,51,BAO_0000219,F,,2759,,,
631,D,,449.0,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),Expert,,CHO,,,51,BAO_0000219,F,,2759,,Homo sapiens,9606.0
632,H,,449.0,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),Autocuration,,CHO,,,51,BAO_0000219,F,,2759,,,
633,D,,449.0,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),Expert,,CHO,,,51,BAO_0000219,F,,2759,,Homo sapiens,9606.0
634,D,,,,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,Expert,,,,,51,BAO_0000019,F,,3445,,Homo sapiens,9606.0
635,D,,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",Expert,,,,,51,BAO_0000019,F,,5272,,Homo sapiens,9606.0
636,D,,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",Expert,,,,,51,BAO_0000019,F,,5272,,Homo sapiens,9606.0
637,D,,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",Expert,,,,,51,BAO_0000019,F,,5272,,Homo sapiens,9606.0
638,H,,449.0,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,Autocuration,,CHO,,,51,BAO_0000219,F,,17624,,,
639,H,,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,Autocuration,,CHO,,,51,BAO_0000219,F,,17624,,,
640,H,,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,Autocuration,,CHO,,,51,BAO_0000219,F,,17624,,,
641,H,,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,Expert,,CHO,,,51,BAO_0000219,F,,17624,,,
642,H,,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,Autocuration,,CHO,,,51,BAO_0000219,F,,17624,,,
643,H,,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,Autocuration,,CHO,,,51,BAO_0000219,F,,17624,,,
644,H,,449.0,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,Autocuration,,CHO,,,51,BAO_0000219,F,,17624,,,
645,H,,449.0,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,Autocuration,,CHO,,,51,BAO_0000219,F,,17624,,,
646,H,,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,Expert,,CHO,,,51,BAO_0000219,F,,17624,,,
647,H,,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,Autocuration,,CHO,,,51,BAO_0000219,F,,17624,,,
648,H,,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,Autocuration,,CHO,,,51,BAO_0000219,F,,17624,,,
649,H,,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,Autocuration,,CHO,,,51,BAO_0000219,F,,17624,,,
650,H,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",Autocuration,,,,,51,BAO_0000019,F,,6563,,,
651,H,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",Autocuration,,,,,51,BAO_0000019,F,,6563,,,
652,H,,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,Autocuration,,,,,51,BAO_0000019,F,,6563,,,
653,H,,722.0,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,Autocuration,,HEK293,,,51,BAO_0000219,F,,17296,,,
654,D,,,,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",Expert,,,,,51,BAO_0000019,F,,6876,,Homo sapiens,9606.0
655,H,,,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",Expert,,,,,51,BAO_0000019,F,,6876,,,
656,D,,,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,Expert,,,,,51,BAO_0000019,F,,5272,,Homo sapiens,9606.0
657,D,,,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,Expert,,,,,51,BAO_0000019,F,,5272,,Homo sapiens,9606.0
658,H,,,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",Autocuration,,,,,51,BAO_0000019,F,,5548,,,
659,H,,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",Expert,,,,,51,BAO_0000019,F,,5548,,,
660,H,,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",Autocuration,,,,,51,BAO_0000019,F,,5548,,,
661,H,,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",Autocuration,,,,,51,BAO_0000019,F,,5548,,,
662,H,,,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",Expert,,,,,51,BAO_0000019,F,,5929,,,
663,D,,,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",Expert,,,,,51,BAO_0000019,F,,5929,,Homo sapiens,9606.0
664,D,,,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",Expert,,,,,51,BAO_0000019,F,,5929,,Homo sapiens,9606.0
665,H,,,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",Autocuration,,,,,51,BAO_0000019,F,,16245,,,
666,H,,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",Expert,,,,,51,BAO_0000019,F,,5640,,,
667,H,,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",Autocuration,,,,,51,BAO_0000019,F,,5640,,,
668,H,,449.0,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,Autocuration,,CHO,,,51,BAO_0000219,F,,14509,,,
669,H,,449.0,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,Expert,,CHO,,,51,BAO_0000219,F,,14509,,,
670,H,,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,Autocuration,,,,,51,BAO_0000357,B,,15331,,,
671,H,,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,Autocuration,,,,,51,BAO_0000357,B,,15331,,,
672,H,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",Autocuration,,,,,51,BAO_0000019,F,,6563,,,
673,H,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",Autocuration,,,,,51,BAO_0000019,F,,6563,,,
674,H,,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,Autocuration,,,,,51,BAO_0000019,F,,6563,,,
675,D,,,,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,Expert,,,,,51,BAO_0000019,F,,6563,,Homo sapiens,9606.0
676,H,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",Autocuration,,,,,51,BAO_0000019,F,,6563,,,
677,D,,,,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,Expert,,,,,51,BAO_0000019,F,,5272,,Homo sapiens,9606.0
678,D,,,,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",Expert,,,,,51,BAO_0000019,F,,5272,,Homo sapiens,9606.0
679,D,,,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",Expert,,,,,51,BAO_0000019,F,,5272,,Homo sapiens,9606.0
680,D,,,,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,Expert,,,,,51,BAO_0000019,F,,5272,,Homo sapiens,9606.0
681,D,,,,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,Expert,,,,,51,BAO_0000019,F,,5272,,Homo sapiens,9606.0
682,D,,,,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",Expert,,,,,51,BAO_0000019,F,,5272,,Homo sapiens,9606.0
683,D,,,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",Expert,,,,,51,BAO_0000019,F,,5272,,Homo sapiens,9606.0
684,D,,,,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,Expert,,,,,51,BAO_0000019,F,,5272,,Homo sapiens,9606.0
685,D,,,,Inhibition of human 5-hydroxytryptamine 1A receptor,Expert,,,,,51,BAO_0000357,B,,16146,,Homo sapiens,9606.0
686,H,,449.0,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,Autocuration,,CHO,,,51,BAO_0000219,B,,17624,,,
687,D,,722.0,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,Expert,,HEK293,,,105,BAO_0000219,B,,13706,,,
688,H,,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,Autocuration,,CHO,,,51,BAO_0000219,B,,15250,,,
689,H,,449.0,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,Autocuration,,CHO,,,51,BAO_0000219,F,,17624,,,
690,H,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,Expert,,,,,51,BAO_0000357,B,,6861,,,
691,D,,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,Expert,,,,,51,BAO_0000357,B,,17200,,Homo sapiens,9606.0
692,H,,449.0,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,Autocuration,,CHO,,,51,BAO_0000219,B,,17624,,,
693,H,,449.0,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,Autocuration,,CHO,,,51,BAO_0000219,B,,17624,,,
694,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,Autocuration,,,,,22226,BAO_0000218,F,,12058,In vivo,Rattus norvegicus,10116.0
695,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,Autocuration,,,,,22226,BAO_0000218,F,,12058,In vivo,Rattus norvegicus,10116.0
696,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,Autocuration,,,,,22226,BAO_0000218,F,,12058,In vivo,Rattus norvegicus,10116.0
697,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,Autocuration,,,,,22226,BAO_0000218,F,,12058,In vivo,Rattus norvegicus,10116.0
698,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,Autocuration,,,,,22226,BAO_0000218,F,,12058,In vivo,Rattus norvegicus,10116.0
699,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,Autocuration,,,,,22226,BAO_0000218,F,,12058,In vivo,Rattus norvegicus,10116.0
700,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,Autocuration,,,,,22226,BAO_0000218,F,,12058,In vivo,Rattus norvegicus,10116.0
701,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,Autocuration,,,,,22226,BAO_0000218,F,,12058,In vivo,Rattus norvegicus,10116.0
702,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,Autocuration,,,,,22226,BAO_0000218,F,,12058,In vivo,Rattus norvegicus,10116.0
703,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,Autocuration,,,,,22226,BAO_0000218,F,,12058,In vivo,Rattus norvegicus,10116.0
704,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,Autocuration,,,,,22226,BAO_0000218,F,,12058,In vivo,Rattus norvegicus,10116.0
705,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,Autocuration,,,,,22226,BAO_0000218,F,,12058,In vivo,Rattus norvegicus,10116.0
706,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,Autocuration,,,,,22226,BAO_0000218,F,,12058,In vivo,Rattus norvegicus,10116.0
707,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,Autocuration,,,,,22226,BAO_0000218,F,,12058,In vivo,Rattus norvegicus,10116.0
708,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,Autocuration,,,,,22226,BAO_0000218,F,,12058,In vivo,Rattus norvegicus,10116.0
709,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,Autocuration,,,,,22226,BAO_0000218,F,,12058,In vivo,Rattus norvegicus,10116.0
710,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,Autocuration,,,,,22226,BAO_0000218,F,,12058,In vivo,Rattus norvegicus,10116.0
711,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,Autocuration,,,,,22226,BAO_0000218,F,,12058,In vivo,Rattus norvegicus,10116.0
712,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,Autocuration,,,,,22226,BAO_0000218,F,,12058,In vivo,Rattus norvegicus,10116.0
713,H,,,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,Autocuration,,,,,105093,BAO_0000019,B,,11440,,,
714,H,,,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,Autocuration,,,,1898.0,11923,BAO_0000249,B,,6238,,,
715,H,,,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,Autocuration,,,,,10577,BAO_0000019,B,,10046,,,
716,H,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,Autocuration,,,,,10577,BAO_0000019,B,,10046,,,
717,H,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,Expert,,,,,10577,BAO_0000019,B,,10046,,,
718,H,,,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",Autocuration,,,,,55,BAO_0000357,B,,167,,,
719,H,,,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",Autocuration,,,,,55,BAO_0000357,B,,167,,,
720,H,,,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),Autocuration,,,,,12166,BAO_0000019,F,,11520,,,
721,H,,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,Autocuration,,,,,12166,BAO_0000019,F,,11520,,,
722,H,,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,Autocuration,,,,,12166,BAO_0000019,F,,11520,,,
723,H,,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,Autocuration,,,,,12166,BAO_0000019,F,,11520,,,
724,H,,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,Autocuration,,,,,55,BAO_0000019,F,,135,,Cavia porcellus,10141.0
725,H,,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,Autocuration,,,,,55,BAO_0000019,F,,135,,Cavia porcellus,10141.0
726,H,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,Autocuration,,,,,55,BAO_0000019,B,,11311,,Cavia porcellus,10141.0
727,H,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,Autocuration,,,,,55,BAO_0000357,B,,10193,,Cavia porcellus,10141.0
728,D,,,,Inhibitory concentration against 5-lipoxygenase from human whole blood,Expert,,,,,55,BAO_0000357,B,,12281,,Homo sapiens,9606.0
729,H,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],Autocuration,,,,,55,BAO_0000219,B,,11311,,,
730,H,,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,Autocuration,,,,,17087,BAO_0000218,F,,12576,,,
731,H,,,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,Autocuration,,,,,17087,BAO_0000357,B,,12281,,,
732,H,,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,Autocuration,,,,,17087,BAO_0000218,F,,12576,,,
733,H,,,,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,Expert,,,,,55,BAO_0000019,B,,11089,,Sus scrofa,9823.0
734,H,,,,In vitro inhibition of rat 5-Lipoxygenase,Expert,,,,,12166,BAO_0000357,B,,11006,,,
735,D,,,,Inhibitory activity against 5-Lipoxygenase,Expert,,,,,12166,BAO_0000357,B,,11481,,Rattus norvegicus,10116.0
736,H,,702.0,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,Expert,,RBL-1,,,12166,BAO_0000219,B,,10864,,,
737,H,,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),Autocuration,,RBL-1,,,12166,BAO_0000219,B,,3595,,,
738,H,,702.0,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,11311,,,
739,H,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,Autocuration,,,,,12166,BAO_0000019,B,,11311,,,
740,H,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],Autocuration,,,,,12166,BAO_0000219,B,,11311,,,
741,H,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,Autocuration,,,,,12166,BAO_0000357,B,,11006,,,
742,H,,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,3595,,,
743,H,,,,The compound was tested for inhibition of isolated 5-Lipoxygenase,Autocuration,,,,,12166,BAO_0000357,B,,11311,,,
744,U,,,,Ratio of IC50 against 5-LO and COX,Autocuration,,,,,22226,BAO_0000019,B,,11481,,Rattus norvegicus,10116.0
745,H,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,Autocuration,,,,,12166,BAO_0000357,B,,11006,,,
746,H,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,Autocuration,,,,,12166,BAO_0000357,B,,11006,,,
747,H,,,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,Autocuration,,,,,12166,BAO_0000219,B,,11311,,,
748,H,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,Autocuration,,,,,12166,BAO_0000019,F,,11006,,,
749,H,,,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,Autocuration,,,,2367.0,120,BAO_0000357,B,,4288,,,
750,U,,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,Autocuration,,,,,22226,BAO_0000019,B,,7587,,Columba livia,8932.0
751,U,,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,Autocuration,,,,,22226,BAO_0000019,B,,7587,,Columba livia,8932.0
752,U,,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,Autocuration,,,,,22226,BAO_0000019,B,,7587,,Columba livia,8932.0
753,H,,,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,Autocuration,,,,,10732,BAO_0000357,B,,11249,,,
754,D,,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,Expert,,,,,12198,BAO_0000019,F,,8003,,Rattus norvegicus,10116.0
755,D,,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),Expert,,,,,12198,BAO_0000019,F,,8003,,Rattus norvegicus,10116.0
756,D,,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),Expert,,,,,12198,BAO_0000019,F,,8003,,Rattus norvegicus,10116.0
757,H,,,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,Expert,,,,10000000.0,10576,BAO_0000221,B,,12416,,,
758,H,,,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,Autocuration,,,,,51,BAO_0000357,B,,16293,,,
759,U,,,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,Autocuration,,,,,22226,BAO_0000019,B,,13047,,Oryctolagus cuniculus,9986.0
760,U,,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,Autocuration,,,,,22226,BAO_0000019,B,,13047,,Oryctolagus cuniculus,9986.0
761,U,,,,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,Autocuration,,,,,22226,BAO_0000019,B,,13047,,Oryctolagus cuniculus,9986.0
762,U,,,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,Autocuration,,,,,22226,BAO_0000019,B,,13047,,Oryctolagus cuniculus,9986.0
763,H,,,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,Autocuration,,,,10000000.0,104744,BAO_0000221,B,,10085,,,
764,H,,,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,Autocuration,,,,10000000.0,104744,BAO_0000221,B,,10085,,,
765,H,,,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,Autocuration,,,,10000000.0,104744,BAO_0000221,B,,10085,,,
766,H,,,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,Autocuration,,,,,104744,BAO_0000249,B,Membranes,9841,,,
767,D,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,Autocuration,,,,,104744,BAO_0000249,B,,8822,,Rattus norvegicus,10116.0
768,D,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,Autocuration,,,,,104744,BAO_0000019,B,,9806,,Rattus norvegicus,10116.0
769,D,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,Autocuration,,,,,104744,BAO_0000019,B,,9806,,Rattus norvegicus,10116.0
770,H,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,Autocuration,,,,,104744,BAO_0000224,B,,8868,,,
771,H,,,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,Autocuration,,,,10000000.0,104744,BAO_0000221,B,,9036,,,
772,H,,,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,Autocuration,,,,10000000.0,104744,BAO_0000221,B,,11374,,,
773,H,,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,Autocuration,,,,,104744,BAO_0000224,B,,10881,,,
774,H,,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,Autocuration,,,,,104744,BAO_0000019,B,,8822,,,
775,D,,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,Autocuration,,,,,104744,BAO_0000249,B,,9806,,Rattus norvegicus,10116.0
776,H,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,Autocuration,,,,,104744,BAO_0000019,B,,15463,,,
777,H,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,Autocuration,,,,,104744,BAO_0000019,B,,15463,,,
778,H,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,Autocuration,,,,955.0,104744,BAO_0000221,B,,14542,,,
779,H,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,Autocuration,,,,955.0,104744,BAO_0000221,B,,14542,,,
780,H,,,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,Autocuration,,,,,104744,BAO_0000019,B,,8569,,,
781,D,,,,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,Autocuration,,,,,104744,BAO_0000224,B,,10062,,Rattus norvegicus,10116.0
782,H,,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,Autocuration,,,,,104744,BAO_0000224,B,,4771,,,
783,H,,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,Autocuration,,,,,104744,BAO_0000224,B,,10062,,,
784,H,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,Autocuration,,,,,104744,BAO_0000224,B,,10062,,,
785,H,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,Autocuration,,,,,104744,BAO_0000224,B,,10062,,,
786,H,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,Autocuration,,,,,104744,BAO_0000019,B,,15463,,,
787,H,,,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,Autocuration,,,,,104744,BAO_0000019,B,,15463,,,
788,H,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,Autocuration,,,,,104744,BAO_0000224,B,,9098,,,
789,U,,,,Affinity for 5-hydroxytryptamine 1 receptor,Autocuration,,,,,22226,BAO_0000019,B,,3070,,Rattus norvegicus,10116.0
790,H,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,Autocuration,,,,955.0,104744,BAO_0000221,B,,14542,,,
791,H,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,Autocuration,,,,955.0,104744,BAO_0000221,B,,14542,,,
792,H,,,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,Autocuration,,,,,104744,BAO_0000224,B,,6398,,,
793,H,,,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,Autocuration,,,,955.0,104744,BAO_0000221,B,,1344,,,
794,H,,,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,Autocuration,,,,,104744,BAO_0000019,B,,11963,,,
795,U,,,,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,Autocuration,,,,,22226,BAO_0000019,B,,8908,,Rattus norvegicus,10116.0
796,H,,,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,Autocuration,,,,,104744,BAO_0000019,B,,9098,,,
797,D,,,,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,Autocuration,,,,,104744,BAO_0000019,B,,8841,,Rattus norvegicus,10116.0
798,U,,,,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,Autocuration,,,,,22226,BAO_0000019,B,,8814,,Rattus norvegicus,10116.0
799,H,,,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,Autocuration,,,,,104744,BAO_0000019,B,,11752,,,
800,H,,,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,Autocuration,,,,955.0,104744,BAO_0000221,B,,11642,,,
801,H,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,Autocuration,,,,,104744,BAO_0000019,B,,11642,,,
802,H,,,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,Autocuration,,,,955.0,104744,BAO_0000220,B,,9231,,,
803,H,,,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,Autocuration,,,,955.0,104744,BAO_0000221,B,,11351,,,
804,U,,,,Compound was tested for binding affinity against 5-HT1 receptor,Autocuration,,,,,22226,BAO_0000019,B,,4639,,,
805,U,,,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,Autocuration,,,,,22226,BAO_0000019,B,,1205,,,
806,H,,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,Expert,,,,,10576,BAO_0000357,B,,10025,,,
807,H,,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",Autocuration,,,,,10576,BAO_0000249,F,,13241,,,
808,H,,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,Autocuration,,,,,10576,BAO_0000218,F,,16245,In vivo,,
809,H,,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,Autocuration,,,,,10576,BAO_0000218,F,,16245,In vivo,,
810,H,,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,Autocuration,,,,,10576,BAO_0000019,F,,12438,,,
811,H,,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,Autocuration,,,,,10576,BAO_0000218,F,,16245,In vivo,,
812,H,,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,Autocuration,,,,,10576,BAO_0000218,F,,16245,In vivo,,
813,H,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,Autocuration,,,,,10576,BAO_0000019,F,,15740,,,
814,H,,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,Autocuration,,,,,10576,BAO_0000219,F,,15535,,,
815,H,,,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,Expert,,,,,51,BAO_0000219,F,,15535,,,
816,H,,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,Autocuration,,,,,10576,BAO_0000219,F,,15535,,,
817,H,,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,Expert,,,,,10576,BAO_0000249,B,,9888,,,
818,H,,,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10085,,,
819,H,,,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10085,,,
820,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,Expert,,,,,10576,BAO_0000249,B,Membranes,17331,,,
821,D,,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,Expert,,,,10000000.0,10576,BAO_0000221,B,,10845,,Rattus norvegicus,10116.0
822,D,,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,Expert,,,,10000000.0,10576,BAO_0000221,B,,10845,,Rattus norvegicus,10116.0
823,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,Expert,,,,10000000.0,10576,BAO_0000221,B,,10845,,,
824,D,,,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,Expert,,,,10000000.0,10576,BAO_0000221,B,,10845,,Rattus norvegicus,10116.0
825,D,,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,Expert,,,,10000000.0,10576,BAO_0000221,B,,10845,,Rattus norvegicus,10116.0
826,H,,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,Expert,,,,,10576,BAO_0000357,B,,13730,,,
827,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,Expert,,,,,10576,BAO_0000249,B,,13508,,,
828,H,,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,Expert,,,,10000000.0,10576,BAO_0000249,B,,13508,,,
829,H,,,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Expert,,,,10000000.0,10576,BAO_0000221,B,,12073,,,
830,H,,,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,4671,,,
831,H,,,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,Expert,,,,10000000.0,10576,BAO_0000221,B,,13631,,,
832,H,,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,Autocuration,,,,,10576,BAO_0000357,B,,12438,,,
833,H,,,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,Autocuration,,,,,10576,BAO_0000019,B,,10483,,,
834,H,,,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10483,,,
835,H,,,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,Intermediate,,,,,10576,BAO_0000249,B,,12352,,,
836,H,,,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,Autocuration,,,,10000000.0,10576,BAO_0000249,B,,14732,,,
837,D,,,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,Expert,,,,,10576,BAO_0000019,B,,11049,,Rattus norvegicus,10116.0
838,D,,,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,Expert,,,,,10576,BAO_0000019,B,,11049,,Rattus norvegicus,10116.0
839,H,,,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",Expert,,,,,10576,BAO_0000249,B,,13657,,,
840,H,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,Autocuration,,,,,10576,BAO_0000019,B,,11473,,,
841,H,,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,Autocuration,,,,,10576,BAO_0000249,B,,2014,,,
842,H,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Expert,,,,10000000.0,10576,BAO_0000221,B,,3086,,,
843,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,Expert,,,,,10576,BAO_0000019,B,,15854,,,
844,H,,,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,Expert,,,,10000000.0,10576,BAO_0000221,B,,10922,,,
845,H,,,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,Expert,,,,10000000.0,10576,BAO_0000221,B,,13346,,,
846,H,,,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,Expert,,,,,10576,BAO_0000357,B,,15311,,,
847,H,,,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10922,,,
848,H,,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,Autocuration,,,,,10576,BAO_0000357,B,,10025,,,
849,H,,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,Expert,,,,,10576,BAO_0000357,B,,10025,,,
850,H,,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,Autocuration,,,,,10576,BAO_0000019,B,,9742,,,
851,H,,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,Autocuration,,,,,10576,BAO_0000019,F,,9742,,,
852,H,,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,Expert,,,,,10576,BAO_0000019,B,,12304,,,
853,H,,,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,15789,,,
854,H,,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",Autocuration,,,,,10576,BAO_0000019,B,,9912,,,
855,H,,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",Autocuration,,,,,10576,BAO_0000019,B,,9912,,,
856,H,,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",Autocuration,,,,,10576,BAO_0000019,B,,9912,,,
857,H,,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,Expert,,,,,10576,BAO_0000019,B,,16693,,,
858,H,,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,Expert,,,,,10576,BAO_0000357,B,,13276,,,
859,H,,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,12678,,,
860,H,,,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,Autocuration,,,,,10576,BAO_0000357,B,,11825,,,
861,H,,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,Expert,,,,,10576,BAO_0000357,B,,12443,,,
862,H,,,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,Expert,,,,,10576,BAO_0000357,B,,13830,,,
863,H,,,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,Expert,,,,10000000.0,10576,BAO_0000249,B,,14286,,,
864,D,,,,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Expert,,,,10000000.0,10576,BAO_0000221,B,,14356,,Rattus norvegicus,10116.0
865,H,,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,10576,BAO_0000357,B,,15306,,,
866,H,,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),Expert,,,,,10576,BAO_0000357,B,,15306,,,
867,D,,,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",Expert,,,,,10576,BAO_0000249,F,,16616,,Rattus norvegicus,10116.0
868,H,,,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",Autocuration,,,,10000000.0,10576,BAO_0000221,B,,3651,,,
869,H,,,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,,,10000000.0,10576,BAO_0000221,F,,14331,,,
870,H,,,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,,,10000000.0,10576,BAO_0000221,F,,14331,,,
871,D,,,,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,Expert,,,,,10576,BAO_0000357,B,,14178,,Rattus norvegicus,10116.0
872,D,,,,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,Expert,,,,,10576,BAO_0000019,B,,10639,,Rattus norvegicus,10116.0
873,H,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,12306,,,
874,D,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,Expert,,,,,10576,BAO_0000357,B,,1348,,Rattus norvegicus,10116.0
875,H,,,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,13605,,,
876,H,,449.0,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,Autocuration,,CHO,,,51,BAO_0000219,B,,17624,,,
877,H,,449.0,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,Autocuration,,CHO,,,51,BAO_0000219,F,,17624,,,
878,H,,449.0,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,Autocuration,,CHO,,,51,BAO_0000219,F,,17624,,,
879,H,,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,15267,,,
880,H,,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,Autocuration,,,,,51,BAO_0000357,B,,16532,,,
881,H,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",Autocuration,,,,,51,BAO_0000019,F,,6563,,,
882,H,,449.0,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,Autocuration,,CHO,,,51,BAO_0000219,B,,4751,,,
883,H,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,15463,,,
884,H,,,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),Autocuration,,,,,51,BAO_0000357,B,,3805,,,
885,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,51,BAO_0000357,B,,5640,,,
886,H,,,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,Autocuration,,,,,51,BAO_0000357,B,,6563,,,
887,H,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,Autocuration,,,,,51,BAO_0000357,B,,5548,,,
888,H,,,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,6347,,,
889,H,,722.0,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,Autocuration,,HEK293,,,51,BAO_0000219,F,,17296,,,
890,H,,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,Autocuration,,,,,51,BAO_0000019,B,,13047,,,
891,H,,,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,Autocuration,,,,,51,BAO_0000357,B,,15740,,,
892,H,,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",Expert,,,,,51,BAO_0000019,F,,5640,,,
893,H,,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",Autocuration,,,,,51,BAO_0000019,F,,5640,,,
894,H,,308.0,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,Expert,,HeLa,,,51,BAO_0000219,B,,17211,,,
895,H,,449.0,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,Autocuration,,CHO,,,51,BAO_0000219,B,,4751,,,
896,D,,,,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,Expert,,,,,51,BAO_0000357,B,,6491,,Homo sapiens,9606.0
897,H,,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,Autocuration,,,,,51,BAO_0000357,B,,4707,,,
898,D,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,Expert,,,,,51,BAO_0000357,B,,13910,,Homo sapiens,9606.0
899,H,,308.0,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,Autocuration,,HeLa,,,51,BAO_0000219,B,,16190,,,
900,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,51,BAO_0000357,B,,16633,,,
901,H,,449.0,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,Autocuration,,CHO,,,51,BAO_0000219,B,,11898,,,
902,H,,449.0,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,Autocuration,,CHO,,,51,BAO_0000219,B,,11898,,,
903,H,,,,Binding affinity against human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,14331,,,
904,H,,449.0,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,Expert,,CHO,,,51,BAO_0000219,B,,17624,,,
905,H,,449.0,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,Autocuration,,CHO,,,51,BAO_0000219,B,,17624,,,
906,H,,,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,3307,,,
907,D,,449.0,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,Expert,,CHO,,,51,BAO_0000219,B,,6563,,Homo sapiens,9606.0
908,H,,,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,51,BAO_0000019,B,,14165,,,
909,H,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,Autocuration,,,,,51,BAO_0000357,B,,5732,,,
910,H,,,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,Expert,,,,,51,BAO_0000357,B,,13366,,,
911,H,,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,17626,,,
912,H,,308.0,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,Expert,,HeLa,,,51,BAO_0000219,B,,6588,,,
913,H,,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,Autocuration,,,,,51,BAO_0000357,B,,16209,,,
914,H,,,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,51,BAO_0000357,B,,15463,,,
915,H,,,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,51,BAO_0000357,B,,15463,,,
916,H,,,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,Autocuration,,,,,51,BAO_0000357,B,,14770,,,
917,H,,1167.0,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),Autocuration,,Cell line,,,51,BAO_0000219,B,,16245,,,
918,H,,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),Autocuration,,,,,51,BAO_0000019,B,,16245,,,
919,H,,,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,51,BAO_0000357,B,,5548,,,
920,H,,,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Expert,,,,,51,BAO_0000357,B,,5548,,,
921,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,51,BAO_0000357,B,,5548,,,
922,H,,,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,Expert,,,,,51,BAO_0000357,B,,6876,,,
923,H,,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,51,BAO_0000357,B,,2598,,,
924,H,,,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,Expert,,,,,51,BAO_0000357,B,,17785,,,
925,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,6013,,,
926,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,Expert,,,,,51,BAO_0000357,B,,5929,,,
927,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,51,BAO_0000357,B,,16633,,,
928,H,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,Autocuration,,,,,51,BAO_0000357,B,,1558,,,
929,H,,,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Expert,,,,,51,BAO_0000357,B,,16026,,,
930,H,,,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,Autocuration,,,,,51,BAO_0000219,B,,12469,,,
931,D,,,,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,Expert,,,,,51,BAO_0000357,B,,15874,,Homo sapiens,9606.0
932,H,,,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,Autocuration,,,,,51,BAO_0000357,B,,15874,,,
933,H,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,3935,,,
934,H,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,15818,,,
935,H,,485.0,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,Autocuration,,CHO-K1,,,51,BAO_0000219,B,,13706,,,
936,H,,485.0,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,Expert,,CHO-K1,,,51,BAO_0000219,F,,13729,,,
937,H,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000019,B,,15413,,,
938,H,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),Autocuration,,,,,51,BAO_0000019,B,,15413,,,
939,H,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),Autocuration,,,,,51,BAO_0000019,B,,15413,,,
940,H,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,Autocuration,,,,,51,BAO_0000019,B,,15413,,,
941,D,,308.0,,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,Expert,,HeLa,,,51,BAO_0000219,B,,3445,,Homo sapiens,9606.0
942,H,,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,15740,,,
943,H,,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,Autocuration,,,,,51,BAO_0000357,B,,15740,,,
944,H,,,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,17626,,,
945,D,,,,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,Expert,,,,,51,BAO_0000357,B,,4234,,Homo sapiens,9606.0
946,H,,,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,Expert,,,,,51,BAO_0000357,B,,5640,,,
947,H,,,,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,Expert,,,,,51,BAO_0000357,B,,5272,,Rattus norvegicus,10116.0
948,H,,449.0,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,Autocuration,,CHO,,,51,BAO_0000219,B,,4622,,,
949,H,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,Expert,,,,,51,BAO_0000019,B,,17085,,,
950,H,,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,Autocuration,,,,,51,BAO_0000357,B,,3025,,,
951,H,,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,Expert,,,,,51,BAO_0000357,B,,15315,,,
952,H,,,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,Autocuration,,,,,51,BAO_0000357,B,,15267,,,
953,H,,308.0,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,Autocuration,,HeLa,,,51,BAO_0000219,B,,17158,,,
954,D,,308.0,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,Expert,,HeLa,,,51,BAO_0000219,B,,14214,,Homo sapiens,9606.0
955,H,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,51,BAO_0000357,B,,17133,,,
956,H,,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,Autocuration,,,,,51,BAO_0000357,B,,16532,,,
957,D,,,,Affinity for 5-hydroxytryptamine 1A receptor subtype,Expert,,,,,51,BAO_0000357,B,,2391,,Homo sapiens,9606.0
958,H,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,Autocuration,,,,,51,BAO_0000019,B,,14447,,,
959,H,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,Autocuration,,,,,51,BAO_0000019,B,,14447,,,
960,H,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,Autocuration,,,,,51,BAO_0000357,B,,15086,,,
961,D,,,,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,Expert,,,,,51,BAO_0000357,B,,13051,,Homo sapiens,9606.0
962,H,,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",Autocuration,,,,,51,BAO_0000019,F,,16026,,,
963,H,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,Expert,,,,,51,BAO_0000019,B,,17085,,,
964,H,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,51,BAO_0000357,B,,17133,,,
965,H,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,Autocuration,,,,,51,BAO_0000357,B,,17133,,,
966,H,,308.0,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,Autocuration,,HeLa,,,51,BAO_0000219,B,,17211,,,
967,H,,308.0,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,Autocuration,,HeLa,,,51,BAO_0000219,B,,17211,,,
968,H,,308.0,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,Autocuration,,HeLa,,,51,BAO_0000219,B,,17211,,,
969,H,,308.0,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,Autocuration,,HeLa,,,51,BAO_0000219,B,,17211,,,
970,H,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",Autocuration,,,,,51,BAO_0000019,F,,16394,,,
971,H,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",Autocuration,,,,,51,BAO_0000019,F,,16394,,,
972,H,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",Autocuration,,,,,51,BAO_0000019,F,,16394,,,
973,H,,,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,Autocuration,,,,,51,BAO_0000218,F,,16394,In vivo,,
974,H,,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,Autocuration,,,,,51,BAO_0000019,B,,16394,,,
975,H,,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,Autocuration,,,,,51,BAO_0000019,F,,15740,,,
976,H,,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,Autocuration,,,,,51,BAO_0000019,F,,15740,,,
977,H,,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,15740,,,
978,H,,722.0,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,Autocuration,,HEK293,,,51,BAO_0000219,F,,17296,,,
979,H,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",Expert,,,,,51,BAO_0000019,F,,5640,,,
980,H,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",Autocuration,,,,,51,BAO_0000019,F,,5640,,,
981,H,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",Autocuration,,,,,51,BAO_0000019,F,,5640,,,
982,H,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",Autocuration,,,,,51,BAO_0000019,F,,5640,,,
983,H,,449.0,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,Autocuration,,CHO,,,51,BAO_0000219,F,,2759,,,
984,H,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",Autocuration,,,,,51,BAO_0000019,F,,16394,,,
985,D,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",Expert,,,,,51,BAO_0000019,F,,16394,,Homo sapiens,9606.0
986,D,,,,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,Expert,,,,,51,BAO_0000019,F,,3445,,Homo sapiens,9606.0
987,H,,449.0,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,Expert,,CHO,,,51,BAO_0000219,B,,4316,,,
988,H,,,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,Expert,,,,,51,BAO_0000019,B,,4316,,,
989,D,,,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,Expert,,,,,51,BAO_0000019,F,,15180,,Homo sapiens,9606.0
990,D,,,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,Expert,,,,,51,BAO_0000019,F,,15180,,Homo sapiens,9606.0
991,H,,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,Autocuration,,,,,51,BAO_0000019,F,,15042,,,
992,H,,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,Autocuration,,,,,51,BAO_0000019,F,,15042,,,
993,H,,,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000019,F,,15042,,,
994,H,,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,Autocuration,,,,,51,BAO_0000019,F,,15042,,,
995,H,,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,Autocuration,,,,,51,BAO_0000019,F,,15042,,,
996,H,,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,Autocuration,,,,,51,BAO_0000019,F,,15042,,,
997,H,,,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000019,F,,15042,,,
998,D,,308.0,,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,Expert,,HeLa,,,51,BAO_0000219,F,,15180,,Homo sapiens,9606.0
999,D,,308.0,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,Expert,,HeLa,,,51,BAO_0000219,F,,15180,,Homo sapiens,9606.0
1000,D,,308.0,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,Expert,,HeLa,,,51,BAO_0000219,F,,15180,,Homo sapiens,9606.0
1001,H,,,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",Autocuration,,,,,51,BAO_0000019,F,,16245,,,
1002,H,,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",Autocuration,,,,,51,BAO_0000019,F,,16026,,,
1003,H,,722.0,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,Autocuration,,HEK293,,,51,BAO_0000219,F,,17296,,,
1004,H,,449.0,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),Autocuration,,CHO,,,51,BAO_0000219,F,,2759,,,
1005,H,,449.0,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,Autocuration,,CHO,,,51,BAO_0000219,F,,2759,,,
1006,D,,449.0,,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),Expert,,CHO,,,51,BAO_0000219,F,,2759,,Homo sapiens,9606.0
1007,H,,449.0,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),Autocuration,,CHO,,,51,BAO_0000219,F,,2759,,,
1008,H,,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,Expert,,,,,51,BAO_0000219,F,,15419,,,
1009,H,,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,Autocuration,,,,,51,BAO_0000219,F,,15419,,,
1010,H,,,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",Autocuration,,,,,51,BAO_0000019,F,,16026,,,
1011,H,,,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,Expert,,,,,51,BAO_0000219,B,,1414,In vitro,,
1012,H,,,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,Expert,,,,,51,BAO_0000219,B,,1414,In vitro,,
1013,H,,,,Binding activity radioligand.,Autocuration,,,,,51,BAO_0000357,B,,12861,,,
1014,H,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,Autocuration,,,,,51,BAO_0000019,B,,12861,,,
1015,H,,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,5104,,,
1016,H,,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,5105,,,
1017,H,,,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,16312,,,
1018,D,,,,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,Expert,,,,,51,BAO_0000357,B,,15180,,Homo sapiens,9606.0
1019,H,,,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,5033,,,
1020,D,,449.0,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,Expert,,CHO,,,51,BAO_0000219,B,,16909,,Homo sapiens,9606.0
1021,H,,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000019,F,,2590,,,
1022,H,,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,Autocuration,,,,,51,BAO_0000019,F,,2590,,,
1023,H,,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,Expert,,,,,51,BAO_0000019,B,,16394,,,
1024,D,,722.0,,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,Expert,,HEK293,,,51,BAO_0000219,B,,4540,,Homo sapiens,9606.0
1025,H,,722.0,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,Autocuration,,HEK293,,,51,BAO_0000219,B,,17296,,,
1026,H,,722.0,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,Autocuration,,HEK293,,,51,BAO_0000219,B,,17296,,,
1027,H,,722.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,Autocuration,,HEK293,,,51,BAO_0000219,B,,15779,,,
1028,H,,722.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,Autocuration,,HEK293,,,51,BAO_0000219,B,,15779,,,
1029,H,,722.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,Autocuration,,HEK293,,,51,BAO_0000219,B,,15779,,,
1030,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,51,BAO_0000357,B,,6166,,,
1031,H,,722.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,Autocuration,,HEK293,,,51,BAO_0000219,B,,15779,,,
1032,H,,722.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,Autocuration,,HEK293,,,51,BAO_0000219,B,,4199,,,
1033,H,,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,Autocuration,,,,,51,BAO_0000219,B,,15316,,,
1034,H,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,14875,,,
1035,H,,308.0,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,Expert,,HeLa,,,51,BAO_0000219,B,,14727,,,
1036,H,,,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,Expert,,,,,51,BAO_0000019,B,,14727,,,
1037,H,,722.0,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,Autocuration,,HEK293,,,51,BAO_0000219,B,,15146,,,
1038,H,,722.0,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,Autocuration,,HEK293,,,51,BAO_0000219,B,,5213,,,
1039,H,,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,Autocuration,,,,,51,BAO_0000219,B,,16429,,,
1040,D,,308.0,,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,Expert,,HeLa,,,51,BAO_0000219,B,,15042,,Homo sapiens,9606.0
1041,H,,722.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,Autocuration,,HEK293,,,51,BAO_0000219,B,,14818,,,
1042,H,,722.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",Autocuration,,HEK293,,,51,BAO_0000219,B,,4829,,,
1043,D,,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,Expert,,,,,51,BAO_0000357,B,,17200,,,
1044,D,,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,13051,,Homo sapiens,9606.0
1045,H,,,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,Autocuration,,,,,106,BAO_0000357,B,,5486,,,
1046,H,,,,Binding affinity against 5-HT1D receptor,Autocuration,,,,,105,BAO_0000357,B,,5254,,,
1047,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,105,BAO_0000357,B,,5254,,,
1048,H,,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,Autocuration,,,,,107,BAO_0000357,B,,15331,,,
1049,H,,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,Autocuration,,,,,10576,BAO_0000357,B,,13506,,Homo sapiens,9606.0
1050,H,,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,15267,,,
1051,H,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,Autocuration,,,,,11863,BAO_0000218,F,,16616,In vivo,,
1052,H,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,Autocuration,,,,,11863,BAO_0000218,F,,16616,In vivo,,
1053,H,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,Autocuration,,,,,11863,BAO_0000218,F,,16616,In vivo,,
1054,D,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,Expert,,,,,11863,BAO_0000218,F,,16616,,Mus musculus,10090.0
1055,D,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,Expert,,,,,11863,BAO_0000218,F,,16616,,Mus musculus,10090.0
1056,D,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,Expert,,,,,11863,BAO_0000218,F,,16616,,Mus musculus,10090.0
1057,D,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,Expert,,,,,11863,BAO_0000218,F,,16616,,Mus musculus,10090.0
1058,D,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,Expert,,,,,11863,BAO_0000218,F,,16616,,Mus musculus,10090.0
1059,D,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,Expert,,,,,11863,BAO_0000218,F,,16616,,Mus musculus,10090.0
1060,H,,,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,Autocuration,,,,10000000.0,11863,BAO_0000221,B,,10297,,,
1061,H,,,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,Expert,,,,,11863,BAO_0000357,B,,13704,,,
1062,D,,,,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,Expert,,,,10000000.0,11863,BAO_0000221,B,,10297,,Mus musculus,10090.0
1063,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,Autocuration,,,,10000000.0,11863,BAO_0000221,B,,10297,,,
1064,D,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,Expert,,,,10000000.0,11863,BAO_0000221,B,,10297,,Mus musculus,10090.0
1065,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,Autocuration,,,,10000000.0,11863,BAO_0000221,B,,10297,,,
1066,H,,,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,Autocuration,,,,,11863,BAO_0000357,B,,217,,,
1067,D,,,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,Expert,,,,10000000.0,11863,BAO_0000221,B,,10297,,Mus musculus,10090.0
1068,H,,,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,4921,,Sus scrofa,9823.0
1069,H,,,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,Autocuration,,,,,51,BAO_0000357,B,,4921,,Sus scrofa,9823.0
1070,H,,,,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,Autocuration,,,,,51,BAO_0000019,B,,4996,,Sus scrofa,9823.0
1071,H,,,,Compound was evaluated for the binding affinity at 5- HT1A receptor,Autocuration,,,,,51,BAO_0000357,B,,12918,,Sus scrofa,9823.0
1072,H,,,,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,Autocuration,,,,,51,BAO_0000019,B,,5333,,Sus scrofa,9823.0
1073,H,,,,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,Autocuration,,,,,51,BAO_0000019,B,,4437,,Sus scrofa,9823.0
1074,H,,,,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,Autocuration,,,,,51,BAO_0000019,B,,1742,,Sus scrofa,9823.0
1075,H,,,,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,Expert,,,,,51,BAO_0000357,B,,16688,,Sus scrofa,9823.0
1076,H,,,,Binding activity radioligand.,Autocuration,,,,,51,BAO_0000357,B,,12861,,Sus scrofa,9823.0
1077,H,,,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,Expert,,,,,51,BAO_0000019,B,,12861,,Sus scrofa,9823.0
1078,H,,,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,Autocuration,,,,,51,BAO_0000019,B,,12861,,Sus scrofa,9823.0
1079,H,,,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,Expert,,,,,10624,BAO_0000019,B,,12490,,,
1080,H,,,,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,Expert,,,,,51,BAO_0000019,B,,11828,,Sus scrofa,9823.0
1081,H,,,,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,Autocuration,,,,10000000.0,51,BAO_0000221,B,,11866,,Sus scrofa,9823.0
1082,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,Autocuration,,,,,51,BAO_0000249,B,,12827,,Sus scrofa,9823.0
1083,H,,,,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,Autocuration,,,,,51,BAO_0000019,B,,12918,,Sus scrofa,9823.0
1084,H,,,,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,Expert,,,,,51,BAO_0000019,F,,12919,,Sus scrofa,9823.0
1085,H,,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,Autocuration,,,,,51,BAO_0000019,B,,13047,,Oryctolagus cuniculus,9986.0
1086,D,,,,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,Expert,,,,,10576,BAO_0000249,B,,15796,,Rattus norvegicus,10116.0
1087,D,,,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",Expert,,,,10000000.0,10576,BAO_0000221,B,,3651,,Rattus norvegicus,10116.0
1088,H,,,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,Autocuration,,,,,10576,BAO_0000357,B,,188,,,
1089,D,,,,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",Expert,,,,,10576,BAO_0000249,F,Membranes,16616,,Rattus norvegicus,10116.0
1090,D,,,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Expert,,,,10000000.0,10576,BAO_0000249,F,Membranes,16616,,Rattus norvegicus,10116.0
1091,H,,,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,12306,,,
1092,D,,,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,Expert,,,,10000000.0,10576,BAO_0000221,B,,17167,,Rattus norvegicus,10116.0
1093,H,,,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,Autocuration,,,,,10576,BAO_0000019,B,,14776,,,
1094,H,,,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,Expert,,,,,10576,BAO_0000357,B,,12158,,,
1095,H,,,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,Autocuration,,,,,10576,BAO_0000357,B,,13481,,,
1096,H,,,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,Autocuration,,,,,10576,BAO_0000219,B,,13427,In vitro,,
1097,H,,,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,Autocuration,,,,,10576,BAO_0000357,B,,10210,,,
1098,H,,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,Autocuration,,,,,10576,BAO_0000249,B,Membranes,10205,,,
1099,H,,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,Autocuration,,,,,10576,BAO_0000249,B,Membranes,10205,,,
1100,H,,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,Expert,,,,,10576,BAO_0000249,B,Membranes,10205,,,
1101,D,,,,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,Expert,,,,,10576,BAO_0000357,B,,12280,,Rattus norvegicus,10116.0
1102,H,,,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,Expert,,,,,10576,BAO_0000357,B,,17386,,,
1103,H,,,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,Expert,,,,,10576,BAO_0000357,B,,13654,,,
1104,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,14423,,,
1105,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,15412,,,
1106,H,,,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,12073,,,
1107,D,,,,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,Expert,,,,,10576,BAO_0000357,B,,4101,,Rattus norvegicus,10116.0
1108,H,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,10576,BAO_0000357,B,,10062,,,
1109,H,,,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,10576,BAO_0000249,B,,6238,,,
1110,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,Autocuration,,,,,10576,BAO_0000357,B,,16273,,,
1111,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,Autocuration,,,,,10576,BAO_0000357,B,,11139,,,
1112,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,Expert,,,,,10576,BAO_0000019,B,,16796,,,
1113,D,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Expert,,,,955.0,10576,BAO_0000221,B,,9548,,Rattus norvegicus,10116.0
1114,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Autocuration,,,,955.0,10576,BAO_0000221,B,,10381,,,
1115,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,10576,BAO_0000249,B,,13408,,,
1116,D,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,Expert,,,,10000000.0,10576,BAO_0000221,B,,13825,,Rattus norvegicus,10116.0
1117,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,Expert,,,,10000000.0,10576,BAO_0000221,B,,11147,,,
1118,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,10576,BAO_0000249,B,,10552,,,
1119,H,,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",Autocuration,,,,2435.0,10576,BAO_0000249,B,,10552,,,
1120,D,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,Expert,,,,,10576,BAO_0000249,B,Membranes,17136,,Rattus norvegicus,10116.0
1121,D,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,Expert,,,,,10576,BAO_0000249,B,Membranes,5778,,Rattus norvegicus,10116.0
1122,H,,,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,13481,,,
1123,H,,,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,13481,,,
1124,H,,,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,Intermediate,,,,10000000.0,10576,BAO_0000221,B,,13630,,,
1125,H,,,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,Expert,,,,,10576,BAO_0000249,B,,16245,,,
1126,H,,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,14509,,,
1127,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,Expert,,,,10000000.0,10576,BAO_0000221,B,,14509,,,
1128,H,,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,14509,,,
1129,H,,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,14509,,,
1130,H,,,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,Expert,,,,,10576,BAO_0000019,B,,14256,,,
1131,H,,,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,Autocuration,,,,,10576,BAO_0000357,B,,11139,,,
1132,D,,,,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,Expert,,,,,10576,BAO_0000019,B,,11047,,Rattus norvegicus,10116.0
1133,D,,,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,Expert,,,,,10576,BAO_0000019,B,,11047,,Rattus norvegicus,10116.0
1134,D,,,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,Expert,,,,,10576,BAO_0000019,B,,11047,,Rattus norvegicus,10116.0
1135,D,,485.0,,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,Expert,,CHO-K1,,,10576,BAO_0000219,B,,2395,,Rattus norvegicus,10116.0
1136,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,Autocuration,,,,,10576,BAO_0000357,B,,9699,,,
1137,D,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,Expert,,,,10000000.0,10576,BAO_0000221,B,,12028,,Rattus norvegicus,10116.0
1138,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,12028,,,
1139,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,Autocuration,,,,,10576,BAO_0000019,B,,5815,,,
1140,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,Expert,,,,,10576,BAO_0000019,B,,16616,,,
1141,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,Autocuration,,,,,10576,BAO_0000019,B,,5815,,,
1142,H,,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",Autocuration,,,,10000000.0,10576,BAO_0000221,B,,2761,,,
1143,H,,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,Expert,,,,,10576,BAO_0000357,B,,13133,,,
1144,H,,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,Autocuration,,,,,10576,BAO_0000019,B,,10444,,,
1145,D,,,,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,Expert,,,,,10576,BAO_0000357,B,,13278,,Rattus norvegicus,10116.0
1146,H,,,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,Autocuration,,,,,10576,BAO_0000357,B,,15874,,,
1147,H,,,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",Autocuration,,,,2435.0,10576,BAO_0000249,B,Membranes,10552,,,
1148,H,,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),Autocuration,,,,,10576,BAO_0000357,B,,11130,,,
1149,H,,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),Autocuration,,,,,10576,BAO_0000218,B,,11130,In vivo,,
1150,H,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,Autocuration,,,,955.0,10576,BAO_0000221,B,,14542,,,
1151,D,,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,Expert,,,,,10576,BAO_0000357,B,,13670,,Rattus norvegicus,10116.0
1152,H,,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,Expert,,,,,10576,BAO_0000249,B,,9888,,,
1153,D,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,Expert,,,,,10576,BAO_0000249,B,Membranes,3678,,Rattus norvegicus,10116.0
1154,H,,,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,11332,,,
1155,H,,,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,11332,,,
1156,H,,,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,Expert,,,,,10576,BAO_0000357,B,,1185,,,
1157,H,,,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,Expert,,,,,10576,BAO_0000249,B,,2014,,,
1158,H,,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,Autocuration,,,,,10576,BAO_0000357,B,,1185,,,
1159,H,,,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,Expert,,,,,10576,BAO_0000019,B,,14429,,,
1160,H,,,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",Expert,,,,,10576,BAO_0000019,B,,16288,,,
1161,D,,,,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,Expert,,,,,10576,BAO_0000019,B,,5432,,Rattus norvegicus,10116.0
1162,H,,,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,Autocuration,,,,,10576,BAO_0000019,B,,14429,,,
1163,H,,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,Expert,,,,,10576,BAO_0000357,B,,13672,,,
1164,H,,,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,Expert,,,,10000000.0,10576,BAO_0000221,B,,11296,,,
1165,H,,,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,Autocuration,,,,,10576,BAO_0000357,B,,11296,,,
1166,H,,449.0,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,Expert,,CHO,,,10576,BAO_0000219,B,,14749,,,
1167,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,Expert,,,,,10576,BAO_0000019,B,,15086,,,
1168,H,,,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,13462,,,
1169,H,,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,Autocuration,,,,,10576,BAO_0000019,B,,15363,,,
1170,H,,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,Autocuration,,,,,10576,BAO_0000019,B,,15363,,,
1171,H,,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,Autocuration,,,,,10576,BAO_0000357,B,,10796,,,
1172,H,,,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,Expert,,,,955.0,10576,BAO_0000221,B,,12816,,,
1173,H,,,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,Expert,,,,10000000.0,10576,BAO_0000221,B,,13542,,,
1174,H,,,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,Expert,,,,,10576,BAO_0000019,B,,13308,,,
1175,H,,,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,Expert,,,,10000000.0,10576,BAO_0000221,B,,13541,,,
1176,H,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,,,
1177,H,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,,,
1178,H,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,,,
1179,H,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,,,
1180,H,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,,,
1181,H,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,,,
1182,H,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,,,
1183,H,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,,,
1184,H,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,,,
1185,H,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,,,
1186,H,,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,,,
1187,H,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,,,
1188,H,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,,,
1189,D,,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,Expert,,,,10000000.0,10576,BAO_0000221,B,,10058,,Rattus norvegicus,10116.0
1190,H,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,,,
1191,H,,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,,,
1192,H,,,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,Expert,,,,,10576,BAO_0000019,B,,12879,,,
1193,H,,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,Expert,,,,,10576,BAO_0000019,B,,11964,,,
1194,H,,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),Autocuration,,,,,10576,BAO_0000019,B,,11964,,,
1195,H,,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),Autocuration,,,,,10576,BAO_0000019,B,,11964,,,
1196,H,,,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Expert,,,,955.0,10576,BAO_0000221,B,,9548,,,
1197,H,,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,Expert,,,,,10576,BAO_0000019,B,,9098,,,
1198,H,,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,Autocuration,,,,,10576,BAO_0000019,B,,9098,,,
1199,H,,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,Autocuration,,,,,10576,BAO_0000019,B,,9098,,,
1200,H,,449.0,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,Expert,,CHO,,,10576,BAO_0000219,B,,13248,,,
1201,H,,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,Expert,,,,,10576,BAO_0000249,B,,3147,,,
1202,H,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,Expert,,,,,10576,BAO_0000019,B,,13949,,,
1203,H,,449.0,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),Autocuration,,CHO,,,10576,BAO_0000218,B,,11883,,,
1204,H,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),Autocuration,,,,,10576,BAO_0000218,B,,11883,,,
1205,D,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,Expert,,,,,10576,BAO_0000357,B,,11883,,Rattus norvegicus,10116.0
1206,H,,,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,Expert,,,,,10576,BAO_0000249,B,Membranes,15535,,,
1207,H,,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,Autocuration,,,,,10576,BAO_0000249,B,,15535,,,
1208,H,,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,Autocuration,,,,,10576,BAO_0000249,B,,15535,,,
1209,D,,449.0,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,Expert,,CHO,,,51,BAO_0000219,B,,16372,,Homo sapiens,9606.0
1210,H,,,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,Expert,,,,,10576,BAO_0000249,B,,14608,,,
1211,D,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,Expert,,,,10000000.0,10576,BAO_0000221,B,,4795,,Rattus norvegicus,10116.0
1212,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,10576,BAO_0000357,B,,13863,,,
1213,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,Autocuration,,,,,10576,BAO_0000357,B,,13863,,,
1214,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,Autocuration,,,,,10576,BAO_0000357,B,,13863,,,
1215,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,Autocuration,,,,,10576,BAO_0000357,B,,13863,,,
1216,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,Autocuration,,,,,10576,BAO_0000357,B,,13863,,,
1217,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,Autocuration,,,,,10576,BAO_0000357,B,,13863,,,
1218,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,Autocuration,,,,,10576,BAO_0000357,B,,13863,,,
1219,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,Autocuration,,,,,10576,BAO_0000357,B,,13863,,,
1220,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,Autocuration,,,,,10576,BAO_0000357,B,,13863,,,
1221,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,Autocuration,,,,,10576,BAO_0000357,B,,13863,,,
1222,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,Autocuration,,,,,10576,BAO_0000357,B,,13863,,,
1223,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,Autocuration,,,,,10576,BAO_0000357,B,,13863,,,
1224,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,Autocuration,,,,,10576,BAO_0000357,B,,13863,,,
1225,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,Autocuration,,,,,10576,BAO_0000357,B,,13863,,,
1226,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,Autocuration,,,,,10576,BAO_0000357,B,,13863,,,
1227,H,,,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,Autocuration,,,,,10576,BAO_0000019,B,,9742,,,
1228,H,,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,10576,BAO_0000357,B,,12073,,,
1229,H,,,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,Autocuration,,,,,10576,BAO_0000357,B,,4101,,,
1230,H,,,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,Autocuration,,,,,10576,BAO_0000019,B,,15360,,,
1231,H,,,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,11576,,,
1232,H,,,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,Expert,,,,,10576,BAO_0000019,B,,5834,,,
1233,D,,485.0,,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,Expert,,CHO-K1,,,10576,BAO_0000219,B,,2395,,Rattus norvegicus,10116.0
1234,H,,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,Autocuration,,,,,10576,BAO_0000019,B,,1375,,,
1235,H,,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,Autocuration,,,,,10576,BAO_0000019,B,,1375,,,
1236,H,,,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),Autocuration,,,,,10576,BAO_0000357,B,,3967,,,
1237,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,Expert,,,,,10576,BAO_0000357,B,,12884,,,
1238,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,Expert,,,,,10576,BAO_0000357,B,,2343,,,
1239,H,,,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",Autocuration,,,,,10576,BAO_0000019,B,,11511,,,
1240,D,,,,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",Expert,,,,,10576,BAO_0000019,B,,11511,,Rattus norvegicus,10116.0
1241,H,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,Autocuration,,,,,10576,BAO_0000218,F,,16394,In vivo,,
1242,H,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),Autocuration,,,,,10576,BAO_0000218,F,,16394,In vivo,,
1243,H,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),Autocuration,,,,,10576,BAO_0000218,F,,16394,In vivo,,
1244,H,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),Autocuration,,,,,10576,BAO_0000218,F,,16394,In vivo,,
1245,H,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),Autocuration,,,,,10576,BAO_0000218,F,,16394,In vivo,,
1246,H,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),Autocuration,,,,,10576,BAO_0000218,F,,16394,In vivo,,
1247,H,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),Autocuration,,,,,10576,BAO_0000218,F,,16394,In vivo,,
1248,H,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),Autocuration,,,,,10576,BAO_0000218,F,,16394,In vivo,,
1249,H,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),Autocuration,,,,,10576,BAO_0000218,F,,16394,In vivo,,
1250,H,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),Autocuration,,,,,10576,BAO_0000218,F,,16394,In vivo,,
1251,H,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),Autocuration,,,,,10576,BAO_0000218,F,,16394,In vivo,,
1252,H,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),Autocuration,,,,,10576,BAO_0000218,F,,16394,In vivo,,
1253,H,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),Autocuration,,,,,10576,BAO_0000218,F,,16394,In vivo,,
1254,H,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),Autocuration,,,,,10576,BAO_0000218,F,,16394,In vivo,,
1255,H,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,Autocuration,,,,,10576,BAO_0000218,F,,16394,In vivo,,
1256,D,,,,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",Expert,,,,,10576,BAO_0000249,F,Membranes,16616,,Rattus norvegicus,10116.0
1257,H,,,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,Autocuration,,,,,10576,BAO_0000019,B,,16796,,,
1258,H,,,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,Autocuration,,,,,10576,BAO_0000019,B,,16796,,,
1259,H,,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,Autocuration,,,,,10576,BAO_0000357,B,,15629,,,
1260,H,,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",Autocuration,,,,,10576,BAO_0000249,F,,13241,,,
1261,H,,,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Expert,,,,10000000.0,10576,BAO_0000221,B,,12073,,,
1262,H,,,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,Autocuration,,,,10000000.0,10576,BAO_0000249,B,,14286,,,
1263,H,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,Autocuration,,,,955.0,10576,BAO_0000221,B,,14542,,,
1264,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,Autocuration,,,,,10576,BAO_0000019,F,,13630,,,
1265,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,Autocuration,,,,,10576,BAO_0000019,F,,13630,,,
1266,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,Autocuration,,,,,10576,BAO_0000019,F,,13630,,,
1267,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,Autocuration,,,,,10576,BAO_0000019,F,,13630,,,
1268,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,Expert,,,,,10576,BAO_0000019,F,,13630,,,
1269,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,Autocuration,,,,,10576,BAO_0000019,F,,13630,,,
1270,D,,,,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,Expert,,,,,10576,BAO_0000019,F,,13630,,Rattus norvegicus,10116.0
1271,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,Autocuration,,,,,10576,BAO_0000019,F,,13630,,,
1272,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,Expert,,,,,10576,BAO_0000019,F,,13630,,,
1273,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,Autocuration,,,,,10576,BAO_0000019,F,,13630,,,
1274,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,Expert,,,,,10576,BAO_0000019,F,,13630,,,
1275,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,Autocuration,,,,,10576,BAO_0000019,F,,13630,,,
1276,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,Expert,,,,,10576,BAO_0000019,F,,13630,,,
1277,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,Autocuration,,,,,10576,BAO_0000019,F,,13630,,,
1278,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,Autocuration,,,,,10576,BAO_0000019,F,,13630,,,
1279,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,Autocuration,,,,,10576,BAO_0000019,F,,13630,,,
1280,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,Expert,,,,,10576,BAO_0000019,F,,13630,,,
1281,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,Expert,,,,,10576,BAO_0000019,F,,13630,,,
1282,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,Autocuration,,,,,10576,BAO_0000019,F,,13630,,,
1283,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,Expert,,,,,10576,BAO_0000019,F,,13630,,,
1284,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,Autocuration,,,,,10576,BAO_0000019,F,,13630,,,
1285,H,,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,Autocuration,,,,,10576,BAO_0000019,F,,13630,,,
1286,H,,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,Autocuration,,,,,10576,BAO_0000019,F,,13630,,,
1287,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,Autocuration,,,,,10576,BAO_0000019,F,,13630,,,
1288,H,,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,9783,,,
1289,H,,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,Expert,,,,10000000.0,10576,BAO_0000221,B,,9783,,,
1290,D,,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,Expert,,,,,10576,BAO_0000249,B,Membranes,14331,,Rattus norvegicus,10116.0
1291,H,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,Expert,,,,10000000.0,10576,BAO_0000221,B,,15260,,,
1292,H,,,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,15260,,,
1293,H,,,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,15260,,,
1294,D,,,,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",Expert,,,,,10576,BAO_0000249,F,,16616,,Rattus norvegicus,10116.0
1295,H,,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,Autocuration,,,,,10576,BAO_0000357,B,,15629,,,
1296,H,,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,Autocuration,,,,,10576,BAO_0000019,B,,15086,,,
1297,H,,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,Expert,,,,,10576,BAO_0000019,F,,5717,,,
1298,H,,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,Autocuration,,,,,10576,BAO_0000357,B,,12652,,,
1299,H,,,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,14608,,,
1300,H,,,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,12306,,,
1301,H,,,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,12306,,,
1302,D,,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,Expert,,,,,10576,BAO_0000357,B,,15247,,Rattus norvegicus,10116.0
1303,H,,,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,Expert,,,,10000000.0,10576,BAO_0000221,B,,17529,,,
1304,H,,,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,14826,,,
1305,H,,,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,14826,,,
1306,H,,,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,13241,,,
1307,H,,,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,14093,,,
1308,H,,,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,14093,,,
1309,H,,,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,Autocuration,,,,955.0,10576,BAO_0000221,B,,14442,,,
1310,H,,,,Affinity for 5-hydroxytryptamine 1A receptor site,Autocuration,,,,,10576,BAO_0000357,B,,9919,,,
1311,H,,,,Affinity for 5-hydroxytryptamine 1A receptor site,Autocuration,,,,,10576,BAO_0000357,B,,9919,,,
1312,H,,,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,11440,,,
1313,H,,,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,Autocuration,,,,,10576,BAO_0000357,B,,11257,,,
1314,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,Expert,,,,,10576,BAO_0000357,B,,10330,,,
1315,D,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,Expert,,,,10000000.0,10576,BAO_0000221,B,,17331,,Rattus norvegicus,10116.0
1316,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,Expert,,,,,10576,BAO_0000249,B,,16567,,,
1317,D,,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",Expert,,,,,10576,BAO_0000019,B,,12058,,Rattus norvegicus,10116.0
1318,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,9699,,,
1319,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,Autocuration,,,,,10576,BAO_0000357,B,,9547,,,
1320,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,Autocuration,,,,,10576,BAO_0000357,B,,10330,,,
1321,H,,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,Autocuration,,,,,10576,BAO_0000357,B,,14331,,,
1322,D,,,,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,Expert,,,,,10576,BAO_0000019,B,,14060,,Rattus norvegicus,10116.0
1323,H,,,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,14744,,,
1324,H,,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,Autocuration,,,,,10576,BAO_0000357,B,,13506,,,
1325,H,,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,Expert,,,,955.0,10576,BAO_0000221,B,,10862,,,
1326,H,,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,Expert,,,,955.0,10576,BAO_0000221,B,,10862,,,
1327,H,,,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,Expert,,,,,10576,BAO_0000357,B,,10062,,,
1328,H,,,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,Autocuration,,,,,10576,BAO_0000357,B,,12073,,,
1329,H,,,,GTPgammaS radioligand binding assay,Autocuration,,,,,106,BAO_0000357,B,,14875,,,
1330,H,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,Autocuration,,,,,106,BAO_0000357,B,,2391,,,
1331,H,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,Autocuration,,,,,106,BAO_0000019,F,,2391,,,
1332,H,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,Autocuration,,,,,106,BAO_0000019,F,,2391,,,
1333,H,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,Autocuration,,,,,106,BAO_0000357,B,,2391,,,
1334,H,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,Autocuration,,,,,106,BAO_0000357,B,,2391,,,
1335,H,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,Autocuration,,,,,106,BAO_0000019,F,,2391,,,
1336,H,,308.0,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,Expert,,HeLa,,,106,BAO_0000219,B,,17211,,,
1337,H,,308.0,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,Autocuration,,HeLa,,,106,BAO_0000219,B,,17211,,,
1338,D,,,,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,Expert,,,,,106,BAO_0000357,B,,6491,,Homo sapiens,9606.0
1339,H,,449.0,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,Autocuration,,CHO,,,106,BAO_0000219,B,,16190,,,
1340,H,,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,Autocuration,,,,,106,BAO_0000019,B,,14165,,,
1341,H,,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,Autocuration,,,,,106,BAO_0000019,B,,14165,,,
1342,D,,,,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,Expert,,,,,106,BAO_0000357,B,,4234,,Homo sapiens,9606.0
1343,H,,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,Expert,,,,,106,BAO_0000219,B,,6328,,,
1344,H,,,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,Autocuration,,,,,106,BAO_0000357,B,,14770,,,
1345,H,,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,Autocuration,,,,,106,BAO_0000357,B,,2598,,,
1346,H,,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,Expert,,,,,106,BAO_0000357,B,,6897,,,
1347,H,,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,Autocuration,,,,,106,BAO_0000357,B,,6897,,,
1348,H,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,Autocuration,,,,,106,BAO_0000357,B,,6013,,,
1349,H,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,Expert,,,,,106,BAO_0000357,B,,5843,,,
1350,H,,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,Expert,,,,,106,BAO_0000357,B,,14454,,,
1351,H,,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,Autocuration,,,,,106,BAO_0000357,B,,16209,,,
1352,H,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,Autocuration,,,,,106,BAO_0000357,B,,3935,,,
1353,H,,485.0,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,Expert,,CHO-K1,,,106,BAO_0000219,F,,13729,,,
1354,H,,,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,Expert,,,,,106,BAO_0000019,F,,14251,,,
1355,H,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,Expert,,,,,106,BAO_0000019,B,,17085,,,
1356,H,,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,Autocuration,,,,,106,BAO_0000357,B,,3025,,,
1357,H,,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,Expert,,,,,106,BAO_0000357,B,,15315,,,
1358,D,,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,Expert,,,,,106,BAO_0000219,B,,14214,,Homo sapiens,9606.0
1359,D,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,Expert,,,,,106,BAO_0000357,B,,3804,,Homo sapiens,9606.0
1360,D,,,,Affinity for 5-hydroxytryptamine 1B receptor subtype,Expert,,,,,106,BAO_0000357,B,,2391,,Homo sapiens,9606.0
1361,D,,,,Binding affinity for human 5-hydroxytryptamine 1B receptor,Expert,,,,,106,BAO_0000357,B,,4175,,Homo sapiens,9606.0
1362,H,,449.0,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,Autocuration,,CHO,,,106,BAO_0000219,B,,17296,,,
1363,H,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,Expert,,,,,106,BAO_0000019,B,,17085,,,
1364,H,,308.0,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,Autocuration,,HeLa,,,106,BAO_0000219,B,,17211,,,
1365,H,,308.0,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,Autocuration,,HeLa,,,106,BAO_0000219,B,,17211,,,
1366,H,,308.0,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,Autocuration,,HeLa,,,106,BAO_0000219,B,,17211,,,
1367,D,,,,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,Expert,,,,,106,BAO_0000357,B,,15926,,Homo sapiens,9606.0
1368,H,,485.0,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,Autocuration,,CHO-K1,,,106,BAO_0000219,B,,16312,,,
1369,H,,,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,Expert,,,,,106,BAO_0000357,B,,5843,,,
1370,H,,,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,Autocuration,,,,,106,BAO_0000357,B,,5843,,,
1371,H,,485.0,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,Expert,,CHO-K1,,,106,BAO_0000219,B,,16312,,,
1372,D,,,,Binding activity against human 5-hydroxytryptamine 1B receptor,Expert,,,,,106,BAO_0000357,B,,15926,,Homo sapiens,9606.0
1373,D,,,,Binding activity against human 5-hydroxytryptamine 1B receptor,Expert,,,,,106,BAO_0000357,B,,15926,,Homo sapiens,9606.0
1374,D,,449.0,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,Expert,,CHO,,,106,BAO_0000219,B,,4540,,Homo sapiens,9606.0
1375,H,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,Autocuration,,,,,106,BAO_0000357,B,,6166,,,
1376,H,,449.0,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,Autocuration,,CHO,,,106,BAO_0000219,B,,17296,,,
1377,H,,449.0,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,Autocuration,,CHO,,,106,BAO_0000219,B,,17296,,,
1378,H,,449.0,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,Autocuration,,CHO,,,106,BAO_0000219,B,,17296,,,
1379,H,,449.0,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,Autocuration,,CHO,,,106,BAO_0000219,B,,15779,,,
1380,H,,449.0,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,Autocuration,,CHO,,,106,BAO_0000219,B,,15779,,,
1381,H,,449.0,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,Autocuration,,CHO,,,106,BAO_0000219,B,,15779,,,
1382,H,,449.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,Autocuration,,CHO,,,106,BAO_0000219,B,,4199,,,
1383,D,,,,Binding affinity for human 5-hydroxytryptamine 1B receptor,Expert,,,,,106,BAO_0000357,B,,14875,,Homo sapiens,9606.0
1384,H,,449.0,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,Autocuration,,CHO,,,106,BAO_0000219,B,,15146,,,
1385,H,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,Autocuration,,,,,106,BAO_0000357,B,,5213,,,
1386,H,,449.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,Autocuration,,CHO,,,106,BAO_0000219,B,,14818,,,
1387,H,,449.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",Autocuration,,CHO,,,106,BAO_0000219,B,,4829,,,
1388,H,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,Expert,,,,,106,BAO_0000019,F,,14454,,,
1389,H,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,Expert,,,,,106,BAO_0000019,F,,14454,,,
1390,H,,449.0,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",Autocuration,,CHO,,,106,BAO_0000219,F,,14875,,,
1391,H,,449.0,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",Autocuration,,CHO,,,106,BAO_0000219,F,,14875,,,
1392,H,,,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",Autocuration,,,,,105,BAO_0000019,F,,15250,,,
1393,H,,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,Autocuration,,CHO,,,105,BAO_0000219,B,,15250,,,
1394,H,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,Autocuration,,,,,17105,BAO_0000357,B,,15086,,,
1395,H,,,,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,Autocuration,,,,,106,BAO_0000019,F,,3025,,Oryctolagus cuniculus,9986.0
1396,H,,,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,Autocuration,,,,,106,BAO_0000019,B,,14998,,Oryctolagus cuniculus,9986.0
1397,H,,,,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",Intermediate,,,,,106,BAO_0000019,B,,14998,,Oryctolagus cuniculus,9986.0
1398,H,,,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,Autocuration,,,,,106,BAO_0000019,B,,14998,,Oryctolagus cuniculus,9986.0
1399,H,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,Expert,,,,,10577,BAO_0000357,B,,13969,,,
1400,D,,,,Binding affinity for 5-hydroxytryptamine 1B receptor,Intermediate,,,,,10577,BAO_0000357,B,,13392,,,
1401,D,,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,Expert,,,,2435.0,10577,BAO_0000019,B,,3651,,Rattus norvegicus,10116.0
1402,H,,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,Expert,,,,,10577,BAO_0000357,B,,10025,,,
1403,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,Autocuration,,,,,10576,BAO_0000357,B,,13863,,,
1404,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,Autocuration,,,,,10576,BAO_0000357,B,,13863,,,
1405,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,Autocuration,,,,,10576,BAO_0000357,B,,13863,,,
1406,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,Autocuration,,,,,10576,BAO_0000357,B,,13863,,,
1407,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,Autocuration,,,,,10576,BAO_0000357,B,,13863,,,
1408,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,Autocuration,,,,,10576,BAO_0000357,B,,13863,,,
1409,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,Autocuration,,,,10000000.0,10576,BAO_0000249,B,,4622,,,
1410,H,,,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,Intermediate,,,,,10576,BAO_0000019,B,,14911,,,
1411,H,,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,12678,,,
1412,H,,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,Expert,,,,10000000.0,10576,BAO_0000221,B,,12678,,,
1413,H,,,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,Expert,,,,10000000.0,10576,BAO_0000221,B,,14235,,,
1414,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,Expert,,,,10000000.0,10576,BAO_0000221,B,,14949,,,
1415,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,Expert,,,,10000000.0,10576,BAO_0000221,B,,14949,,,
1416,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,Expert,,,,10000000.0,10576,BAO_0000221,B,,14949,,,
1417,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,Expert,,,,10000000.0,10576,BAO_0000221,B,,14949,,,
1418,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,Expert,,,,10000000.0,10576,BAO_0000221,B,,14949,,,
1419,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,Expert,,,,,10576,BAO_0000249,B,,16118,,,
1420,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,Autocuration,,,,,10576,BAO_0000249,B,,3268,,,
1421,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,Autocuration,,,,,10576,BAO_0000249,B,,3268,,,
1422,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,Expert,,,,,10576,BAO_0000357,B,,16117,,,
1423,H,,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,Expert,,,,10000000.0,10576,BAO_0000221,B,,9783,,,
1424,H,,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,9783,,,
1425,D,,,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,Expert,,,,10000000.0,10576,BAO_0000221,B,,14356,,Rattus norvegicus,10116.0
1426,H,,,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,10576,BAO_0000019,F,,15740,,,
1427,H,,,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,12306,,,
1428,D,,,,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,Expert,,,,10000000.0,10576,BAO_0000221,B,,13348,,Rattus norvegicus,10116.0
1429,H,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,Autocuration,,,,,10576,BAO_0000249,B,,10394,,,
1430,H,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,15260,,,
1431,H,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,Expert,,,,10000000.0,10576,BAO_0000221,B,,10046,,,
1432,H,,,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,Intermediate,,,,10000000.0,10576,BAO_0000221,F,,15260,,,
1433,H,,,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,10576,BAO_0000357,B,,12851,,,
1434,D,,,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,Expert,,,,10000000.0,10576,BAO_0000221,B,,2148,,Rattus norvegicus,10116.0
1435,H,,,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,Expert,,,,,10576,BAO_0000357,B,,13134,,,
1436,H,,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,Autocuration,,,,,10576,BAO_0000019,B,,12462,,,
1437,H,,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,Expert,,,,,10576,BAO_0000019,B,,12462,,,
1438,H,,449.0,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,Autocuration,,CHO,,,10576,BAO_0000219,B,,12462,,,
1439,H,,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,Expert,,,,,10576,BAO_0000357,B,,11933,,,
1440,H,,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,Autocuration,,,,,10576,BAO_0000357,B,,11933,,,
1441,D,,,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,Expert,,,,10000000.0,10576,BAO_0000221,B,,403,,Rattus norvegicus,10116.0
1442,H,,,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,15538,,,
1443,H,,,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,15538,,,
1444,H,,,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,15538,,,
1445,H,,,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,Intermediate,,,,,10576,BAO_0000019,B,,12464,,,
1446,H,,,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,Expert,,,,,10576,BAO_0000357,B,,1455,,,
1447,H,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,Autocuration,,,,,10576,BAO_0000357,B,,12652,,,
1448,H,,,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,12639,,,
1449,H,,,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,Expert,,,,,10576,BAO_0000249,B,,13949,,,
1450,D,,,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,Expert,,,,,10576,BAO_0000357,B,,12463,,Rattus norvegicus,10116.0
1451,H,,,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,Expert,,,,10000000.0,10576,BAO_0000221,B,,14829,,,
1452,H,,,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,14829,,,
1453,H,,,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,Autocuration,,,,,10576,BAO_0000357,B,,12092,,,
1454,H,,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,Autocuration,,,,,10576,BAO_0000249,B,,403,,,
1455,H,,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,Autocuration,,,,,10576,BAO_0000249,B,,403,,,
1456,H,,,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,Expert,,,,,10576,BAO_0000357,B,,3967,,,
1457,D,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,Expert,,,,,10576,BAO_0000019,B,,12771,,Rattus norvegicus,10116.0
1458,H,,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,Autocuration,,,,,10576,BAO_0000019,B,,15086,,,
1459,H,,,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,14909,,,
1460,H,,,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,Expert,,,,10000000.0,10576,BAO_0000221,B,,14949,,,
1461,D,,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,Expert,,,,10000000.0,10576,BAO_0000221,B,,2309,,Rattus norvegicus,10116.0
1462,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,Expert,,,,,10576,BAO_0000357,B,,4170,,,
1463,D,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,Expert,,,,10000000.0,10576,BAO_0000221,B,,11642,,Rattus norvegicus,10116.0
1464,H,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,11642,,,
1465,H,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,12953,,,
1466,H,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,12953,,,
1467,H,,,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,Expert,,,,10000000.0,10576,BAO_0000221,B,,12953,,,
1468,H,,449.0,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",Expert,,CHO,,,10576,BAO_0000219,B,,12903,,,
1469,H,,,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,Expert,,,,,10576,BAO_0000357,B,,12536,,,
1470,H,,,,The inhibition activity of 5-HT1A at 1 uM,Autocuration,,,,,10576,BAO_0000357,B,,10058,,,
1471,H,,485.0,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",Expert,,CHO-K1,,,10576,BAO_0000219,B,,12902,,,
1472,H,,,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,Expert,,,,,10576,BAO_0000249,B,,14057,,,
1473,H,,,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,Autocuration,,,,,10576,BAO_0000357,B,,11296,,,
1474,H,,,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,11296,,,
1475,H,,,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,Expert,,,,10000000.0,10576,BAO_0000221,B,,11296,,,
1476,D,,,,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,Expert,,,,,10576,BAO_0000249,F,Membranes,16616,,Rattus norvegicus,10116.0
1477,D,,,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Expert,,,,10000000.0,10576,BAO_0000249,F,Membranes,16616,,Rattus norvegicus,10116.0
1478,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,Autocuration,,,,,10576,BAO_0000019,B,,16567,,,
1479,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,Autocuration,,,,,10576,BAO_0000019,B,,16567,,,
1480,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,Autocuration,,,,,10576,BAO_0000019,B,,16567,,,
1481,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,Autocuration,,,,,10576,BAO_0000019,B,,16567,,,
1482,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,Autocuration,,,,,10576,BAO_0000249,B,,17136,,,
1483,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,Autocuration,,,,,10576,BAO_0000249,B,,17136,,,
1484,D,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,Expert,,,,,10576,BAO_0000019,B,,16616,,Rattus norvegicus,10116.0
1485,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,17331,,,
1486,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,17331,,,
1487,D,,,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,Expert,,,,10000000.0,10576,BAO_0000221,B,,17167,,Rattus norvegicus,10116.0
1488,H,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,Autocuration,,,,,10576,BAO_0000019,F,,15740,,,
1489,H,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,Autocuration,,,,,10576,BAO_0000019,F,,15740,,,
1490,H,,,,Ratio of binding affinity to 5-HT 1A and D2 receptor,Autocuration,,,,,10576,BAO_0000357,B,,4671,,,
1491,H,,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,,,
1492,H,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,,,
1493,H,,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,,,
1494,H,,,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,10576,BAO_0000357,B,,12073,,,
1495,H,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),Autocuration,,,,,10576,BAO_0000249,B,,2759,,,
1496,H,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),Autocuration,,,,,10576,BAO_0000249,F,,2759,,,
1497,H,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),Autocuration,,,,,10576,BAO_0000249,B,,2759,,,
1498,H,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),Autocuration,,,,,10576,BAO_0000249,F,,2759,,,
1499,H,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,Autocuration,,,,,10576,BAO_0000249,F,,2759,,,
1500,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Autocuration,,,,955.0,10576,BAO_0000249,B,,9737,,,
1501,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,Autocuration,,,,,10576,BAO_0000019,B,,9737,,,
1502,H,,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,Expert,,,,,10576,BAO_0000019,F,,5717,,,
1503,H,,,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,12253,,,
1504,H,,,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,Autocuration,,,,,10576,BAO_0000019,B,,14025,,,
1505,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,Expert,,,,,10576,BAO_0000249,B,,10425,,,
1506,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,Autocuration,,,,,10576,BAO_0000019,B,,14998,,,
1507,H,,,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,13694,,,
1508,H,,,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,13694,,,
1509,H,,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,Autocuration,,,,,10576,BAO_0000357,B,,4342,,,
1510,D,,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,Expert,,,,,10576,BAO_0000357,B,,12936,,Rattus norvegicus,10116.0
1511,D,,,,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,Expert,,,,,10576,BAO_0000019,B,,13144,,Rattus norvegicus,10116.0
1512,H,,,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,Expert,,,,,10576,BAO_0000019,B,,13343,,,
1513,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,Expert,,,,,10576,BAO_0000357,B,,12132,,,
1514,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,Expert,,,,,10576,BAO_0000019,B,,15419,,,
1515,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,1479,,,
1516,H,,,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,Expert,,,,,10576,BAO_0000019,B,,14287,,,
1517,H,,,,Binding affinity at 5-hydroxytryptamine 1A receptor,Expert,,,,,10576,BAO_0000357,B,,13116,,,
1518,D,,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,Expert,,,,,10576,BAO_0000249,B,Membranes,2759,,Rattus norvegicus,10116.0
1519,H,,,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,Autocuration,,,,,10576,BAO_0000249,B,,2759,,,
1520,H,,,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",Expert,,,,,10576,BAO_0000019,B,,14748,,,
1521,H,,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,Autocuration,,,,,10576,BAO_0000019,B,,12304,,,
1522,D,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,Expert,,,,10000000.0,10576,BAO_0000221,B,,12409,,Rattus norvegicus,10116.0
1523,D,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,Expert,,,,10000000.0,10576,BAO_0000221,B,,12409,,Rattus norvegicus,10116.0
1524,H,,,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,13267,,,
1525,H,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,Autocuration,,,,,10576,BAO_0000357,B,,15194,,,
1526,H,,,,pKi value against rat 5-hydroxytryptamine 1A receptor.,Expert,,,,,10576,BAO_0000357,B,,14256,,,
1527,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,Autocuration,,,,,10576,BAO_0000019,B,,16567,,,
1528,H,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,Autocuration,,,,,10576,BAO_0000019,F,,15740,,,
1529,D,,,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,Expert,,,,,12687,BAO_0000357,B,,13278,,Rattus norvegicus,10116.0
1530,H,,,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,Expert,,,,,10626,BAO_0000249,B,Membranes,1970,,,
1531,H,,,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,Autocuration,,,,955.0,10576,BAO_0000221,B,,10034,,,
1532,H,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,Autocuration,,,,,51,BAO_0000019,B,,13348,,Rattus norvegicus,10116.0
1533,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,Autocuration,,,,,10576,BAO_0000019,F,,13630,,,
1534,H,,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,Autocuration,,,,955.0,10576,BAO_0000221,B,,10862,,,
1535,H,,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",Autocuration,,,,,10576,BAO_0000019,B,,12058,,,
1536,H,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,4639,,,
1537,H,,,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,Expert,,,,,51,BAO_0000357,B,,15453,,,
1538,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,Expert,,,,,51,BAO_0000357,B,,4820,,,
1539,H,,,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,1089,,,
1540,H,,,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,Autocuration,,,,,51,BAO_0000249,B,Brain membranes,386,,,
1541,H,,,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,Autocuration,,,,,51,BAO_0000357,B,,6011,,,
1542,H,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,5014,,,
1543,H,,,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,Expert,,,,,51,BAO_0000357,B,,4402,,,
1544,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,Expert,,,,,51,BAO_0000357,B,,17066,,,
1545,H,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,Autocuration,,,,,51,BAO_0000357,B,,17515,,,
1546,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,2474,,,
1547,H,,,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,Autocuration,,,,,51,BAO_0000357,B,,4775,,,
1548,D,,,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,Expert,,,,,51,BAO_0000357,B,,14294,,Homo sapiens,9606.0
1549,D,,,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,Expert,,,,,51,BAO_0000357,B,,14294,,Homo sapiens,9606.0
1550,H,,449.0,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,Autocuration,,CHO,,,51,BAO_0000219,B,,12249,,,
1551,H,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,Expert,,,,,51,BAO_0000219,B,,11376,,,
1552,H,,,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,51,BAO_0000218,B,,2474,In vivo,,
1553,H,,,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,13311,,,
1554,H,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,Autocuration,,,,,51,BAO_0000357,B,,4373,,,
1555,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,Expert,,,,,51,BAO_0000357,B,,1633,,,
1556,H,,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,Autocuration,,,,,51,BAO_0000357,B,,11866,,,
1557,H,,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,Autocuration,,,,,51,BAO_0000357,B,,4373,,,
1558,H,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,4687,,,
1559,H,,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,Autocuration,,,,,11863,BAO_0000357,B,,16946,,,
1560,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,Autocuration,,,,,11863,BAO_0000357,B,,13291,,,
1561,H,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,Autocuration,,,,,11863,BAO_0000357,B,,14159,,,
1562,H,,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,Autocuration,,,,,11863,BAO_0000357,B,,10812,,,
1563,D,,449.0,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,Expert,,CHO,,,11863,BAO_0000219,B,,3032,,Mus musculus,10090.0
1564,H,,,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,Autocuration,,,,,11863,BAO_0000357,B,,16655,,,
1565,H,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,Autocuration,,,,,11863,BAO_0000357,B,,14532,,,
1566,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,11863,BAO_0000357,B,,13944,,,
1567,H,,,,Binding affinity against serotonergic 5-HT1a receptor,Autocuration,,,,,11863,BAO_0000357,B,,13033,,,
1568,H,,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,11863,BAO_0000357,B,,10321,,,
1569,D,,,,Binding affinity for 5-hydroxytryptamine 1A receptor,Expert,,,,,11863,BAO_0000357,B,,2968,,Mus musculus,10090.0
1570,H,,,,Binding affinity at 5-hydroxytryptamine 1A receptor,Autocuration,,,,,11863,BAO_0000357,B,,13964,,,
1571,H,,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",Autocuration,,,,,11863,BAO_0000357,B,,15527,,,
1572,H,,449.0,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,Autocuration,,CHO,,,11863,BAO_0000219,B,,12248,,,
1573,H,,449.0,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,Autocuration,,CHO,,,11863,BAO_0000219,B,,12249,,,
1574,H,,,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,11863,BAO_0000357,B,,15120,,,
1575,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,Autocuration,,,,,11863,BAO_0000357,B,,13313,,,
1576,H,,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,11863,BAO_0000218,B,,2613,,,
1577,H,,,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,Autocuration,,,,,11863,BAO_0000357,B,,16700,,,
1578,H,,,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,Autocuration,,,,,11863,BAO_0000357,B,,2201,,,
1579,D,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,Expert,,,,,11863,BAO_0000357,B,,1274,,Mus musculus,10090.0
1580,H,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,Autocuration,,,,,11863,BAO_0000357,B,,1317,,,
1581,H,,,,Tested against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,11863,BAO_0000357,B,,12146,,,
1582,H,,,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,11863,BAO_0000357,B,,14059,,,
1583,H,,,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,Expert,,,,,106,BAO_0000019,B,,14025,,Oryctolagus cuniculus,9986.0
1584,H,,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,Autocuration,,,,,106,BAO_0000019,B,,14025,,Oryctolagus cuniculus,9986.0
1585,D,,722.0,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,Intermediate,,HEK293,,,105571,BAO_0000219,B,,14447,,Gorilla gorilla,9593.0
1586,H,,,,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,Autocuration,,,,,106,BAO_0000218,F,,3025,In vivo,Cavia porcellus,10141.0
1587,H,,,,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,Autocuration,,,,,106,BAO_0000218,F,,3025,In vivo,Cavia porcellus,10141.0
1588,H,,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,Autocuration,,,,,106,BAO_0000019,F,,15329,,Cavia porcellus,10141.0
1589,H,,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,Autocuration,,,,,106,BAO_0000019,F,,15329,,Cavia porcellus,10141.0
1590,H,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,Autocuration,,,,,106,BAO_0000019,F,,15847,,Cavia porcellus,10141.0
1591,H,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,Autocuration,,,,,106,BAO_0000019,F,,15847,,Cavia porcellus,10141.0
1592,H,,,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,Autocuration,,,,,106,BAO_0000019,F,,14165,,,
1593,H,,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),Autocuration,,,,,106,BAO_0000019,F,,14214,,,
1594,H,,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),Autocuration,,,,,106,BAO_0000019,F,,14214,,,
1595,D,,,,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,Expert,,,,,106,BAO_0000019,F,,14214,,Homo sapiens,9606.0
1596,D,,485.0,,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,Expert,,CHO-K1,,,106,BAO_0000219,F,,13729,,Homo sapiens,9606.0
1597,H,,449.0,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,Autocuration,,CHO,,,106,BAO_0000219,F,,3025,,,
1598,H,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,Autocuration,,,,,106,BAO_0000357,B,,2391,,,
1599,H,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,Autocuration,,,,,106,BAO_0000019,F,,2391,,,
1600,H,,449.0,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",Expert,,CHO,,,106,BAO_0000219,F,,14956,,,
1601,H,,449.0,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,Autocuration,,CHO,,,106,BAO_0000219,F,,2598,,,
1602,H,,449.0,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,Autocuration,,CHO,,,106,BAO_0000219,F,,2598,,,
1603,H,,449.0,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,Autocuration,,CHO,,,106,BAO_0000219,F,,2598,,,
1604,H,,449.0,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,Autocuration,,CHO,,,106,BAO_0000219,F,,2598,,,
1605,H,,,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",Expert,,,,,106,BAO_0000019,F,,14956,,,
1606,H,,,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",Autocuration,,,,,106,BAO_0000019,F,,14956,,,
1607,D,,,,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,Expert,,,,,106,BAO_0000357,B,,14214,,Homo sapiens,9606.0
1608,H,,449.0,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,Expert,,CHO,,,106,BAO_0000219,B,,3463,,,
1609,H,,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,Autocuration,,,,,106,BAO_0000357,B,,15331,,,
1610,D,,,,Binding affinity against 5-hydroxytryptamine 1B receptor,Expert,,,,,106,BAO_0000357,B,,16146,,Homo sapiens,9606.0
1611,D,,449.0,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,Expert,,CHO,,,106,BAO_0000219,B,,14159,,Homo sapiens,9606.0
1612,H,,449.0,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,Expert,,CHO,,,106,BAO_0000219,B,,14158,,,
1613,H,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,Autocuration,,,,,106,BAO_0000357,B,,14159,,,
1614,H,,449.0,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,Expert,,CHO,,,106,BAO_0000219,B,,15250,,,
1615,H,,449.0,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,Expert,,CHO,,,106,BAO_0000219,B,,15250,,,
1616,H,,449.0,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,Expert,,CHO,,,106,BAO_0000219,B,,15331,,,
1617,H,,449.0,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,Expert,,CHO,,,106,BAO_0000219,B,,15332,,,
1618,H,,449.0,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,Expert,,CHO,,,106,BAO_0000219,B,,14956,,,
1619,H,,,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),Autocuration,,,,,106,BAO_0000357,B,,3805,,,
1620,H,,,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,Autocuration,,,,,106,BAO_0000357,B,,14875,,,
1621,H,,,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),Autocuration,,,,,105,BAO_0000019,F,,14454,,Oryctolagus cuniculus,9986.0
1622,H,,,,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),Expert,,,,,105,BAO_0000019,F,,14454,,Oryctolagus cuniculus,9986.0
1623,H,,,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),Autocuration,,,,,105,BAO_0000357,B,,16288,,,
1624,H,,,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),Autocuration,,,,,105,BAO_0000357,B,,16288,,,
1625,H,,,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000357,B,,16312,,,
1626,H,,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,Expert,,,,,105,BAO_0000357,B,,1348,,Bos taurus,9913.0
1627,H,,,,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,Autocuration,,,,,105,BAO_0000357,B,,5834,,Bos taurus,9913.0
1628,H,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,Autocuration,,,,2435.0,105,BAO_0000019,B,,13366,,Bos taurus,9913.0
1629,H,,,,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,Expert,,,,,105,BAO_0000357,B,,1414,,Bos taurus,9913.0
1630,H,,,,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,Autocuration,,,,,105,BAO_0000019,B,,14998,,Bos taurus,9913.0
1631,H,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,Autocuration,,,,,105,BAO_0000357,B,,11473,,Bos taurus,9913.0
1632,H,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,Autocuration,,,,,105,BAO_0000357,B,,11473,,Bos taurus,9913.0
1633,H,,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,Autocuration,,,,,105,BAO_0000357,B,,10639,,Bos taurus,9913.0
1634,H,,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,Autocuration,,,,,105,BAO_0000357,B,,10639,,Bos taurus,9913.0
1635,H,,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,Autocuration,,,,,105,BAO_0000357,B,,1375,,Bos taurus,9913.0
1636,H,,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,Autocuration,,,,,105,BAO_0000357,B,,1375,,Bos taurus,9913.0
1637,H,,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,Autocuration,,,,,105,BAO_0000357,B,,16532,,Bos taurus,9913.0
1638,H,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,Autocuration,,,,,105,BAO_0000357,B,,11147,,Bos taurus,9913.0
1639,H,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,Autocuration,,,,2435.0,105,BAO_0000019,B,,13366,,Bos taurus,9913.0
1640,H,,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,Autocuration,,,,,105,BAO_0000019,B,,10444,,Bos taurus,9913.0
1641,H,,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,Autocuration,,,,,105,BAO_0000357,B,,16532,,Bos taurus,9913.0
1642,H,,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,Autocuration,,,,,105,BAO_0000357,B,,16532,,Bos taurus,9913.0
1643,H,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,Autocuration,,,,,105,BAO_0000249,B,,12827,,Bos taurus,9913.0
1644,H,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,Autocuration,,,,,105,BAO_0000249,B,,12827,,Bos taurus,9913.0
1645,H,,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Expert,,,,,105,BAO_0000019,F,,12919,,Bos taurus,9913.0
1646,H,,,,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,Autocuration,,,,,105,BAO_0000019,B,,14025,,Bos taurus,9913.0
1647,H,,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Expert,,,,,105,BAO_0000019,F,,12919,,Bos taurus,9913.0
1648,H,,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Expert,,,,,105,BAO_0000019,F,,12919,,Bos taurus,9913.0
1649,H,,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Expert,,,,,105,BAO_0000019,F,,12919,,Bos taurus,9913.0
1650,H,,722.0,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,Autocuration,,HEK293,,,105,BAO_0000219,B,,14447,,Gorilla gorilla,9593.0
1651,D,,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,Intermediate,,,,,105570,BAO_0000019,B,,1375,,Cavia porcellus,10141.0
1652,D,,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,Intermediate,,,,,105570,BAO_0000019,B,,1375,,Cavia porcellus,10141.0
1653,D,,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,Intermediate,,,,,105570,BAO_0000019,F,,12409,,Cavia porcellus,10141.0
1654,D,,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Intermediate,,,,,105570,BAO_0000019,F,,12409,,Cavia porcellus,10141.0
1655,D,,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,Intermediate,,,,,105570,BAO_0000019,F,,12409,,Cavia porcellus,10141.0
1656,D,,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,Intermediate,,,,,105570,BAO_0000019,F,,12409,,Cavia porcellus,10141.0
1657,D,,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,Intermediate,,,,,105570,BAO_0000019,F,,12409,,Cavia porcellus,10141.0
1658,D,,,,Binding affinity against 5-hydroxytryptamine 1D receptor,Intermediate,,,,,105570,BAO_0000357,B,,11574,,Cavia porcellus,10141.0
1659,D,,,,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,Intermediate,,,,,105570,BAO_0000357,B,,1558,,Cavia porcellus,10141.0
1660,D,,,,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Intermediate,,,,,105570,BAO_0000218,F,,12409,,Cavia porcellus,10141.0
1661,D,,,,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Intermediate,,,,,105570,BAO_0000218,F,,12409,,Cavia porcellus,10141.0
1662,D,,,,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Intermediate,,,,,105570,BAO_0000218,F,,12409,,Cavia porcellus,10141.0
1663,D,,,,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,Intermediate,,,,,105570,BAO_0000218,F,,12409,,Cavia porcellus,10141.0
1664,D,,,,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,Intermediate,,,,,105570,BAO_0000019,B,,12253,,Cavia porcellus,10141.0
1665,D,,,,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,Intermediate,,,,,105570,BAO_0000357,B,,12936,,Cavia porcellus,10141.0
1666,H,,,,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,Autocuration,,,,,105,BAO_0000019,B,,13181,,Cavia porcellus,10141.0
1667,D,,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,Intermediate,,,,2435.0,105570,BAO_0000357,B,,12409,,Cavia porcellus,10141.0
1668,D,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,Intermediate,,,,,105570,BAO_0000357,B,,10639,,Cavia porcellus,10141.0
1669,H,,,,Binding affinity against 5-hydroxytryptamine 1D receptor,Autocuration,,,,,51,BAO_0000357,B,,5254,,,
1670,H,,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,Autocuration,,,,,106,BAO_0000357,B,,13051,,,
1671,H,,,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,Expert,,,,,105,BAO_0000019,F,,3463,,,
1672,H,,,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000019,F,,15315,,,
1673,H,,,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000019,F,,6011,,,
1674,D,,449.0,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",Expert,,CHO,,,105,BAO_0000219,F,,14159,,Homo sapiens,9606.0
1675,H,,449.0,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",Autocuration,,CHO,,,105,BAO_0000219,F,,14159,,,
1676,H,,449.0,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,Expert,,CHO,,,105,BAO_0000219,B,,15250,,,
1677,H,,449.0,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,Autocuration,,CHO,,,105,BAO_0000219,B,,15250,,,
1678,H,,449.0,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",Expert,,CHO,,,105,BAO_0000219,F,,15331,,,
1679,D,,449.0,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",Expert,,CHO,,,105,BAO_0000219,F,,15332,,Homo sapiens,9606.0
1680,H,,449.0,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",Expert,,CHO,,,105,BAO_0000219,F,,15332,,,
1681,H,,449.0,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",Autocuration,,CHO,,,105,BAO_0000219,F,,3294,,,
1682,H,,449.0,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",Expert,,CHO,,,105,BAO_0000219,F,,14158,,,
1683,H,,449.0,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",Expert,,CHO,,,105,BAO_0000219,F,,14956,,,
1684,H,,,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000019,F,,12469,,,
1685,H,,449.0,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,Expert,,CHO,,,105,BAO_0000219,F,,3463,,,
1686,D,,449.0,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",Expert,,CHO,,,105,BAO_0000219,F,,15250,,Homo sapiens,9606.0
1687,D,,449.0,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",Expert,,CHO,,,105,BAO_0000219,F,,15250,,Homo sapiens,9606.0
1688,H,,,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",Expert,,,,,105,BAO_0000019,F,,14956,,,
1689,H,,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",Autocuration,,,,,105,BAO_0000019,F,,14159,,,
1690,D,,,,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",Expert,,,,,105,BAO_0000019,F,,14159,,Homo sapiens,9606.0
1691,D,,449.0,,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,Expert,,CHO,,,105,BAO_0000219,F,,14499,,Homo sapiens,9606.0
1692,H,,,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000019,F,,15315,,,
1693,H,,,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),Autocuration,,,,,105,BAO_0000219,B,,3294,In vitro,,
1694,H,,449.0,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,Expert,,CHO,,,105,BAO_0000219,B,,3463,,,
1695,H,,,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,Autocuration,,,,,105,BAO_0000357,B,,15331,,,
1696,D,,449.0,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,Expert,,CHO,,,105,BAO_0000219,B,,14159,,Homo sapiens,9606.0
1697,H,,449.0,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,Expert,,CHO,,,105,BAO_0000219,B,,14158,,,
1698,H,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000357,B,,14159,,,
1699,H,,449.0,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,Expert,,CHO,,,105,BAO_0000219,B,,15250,,,
1700,H,,449.0,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,Expert,,CHO,,,105,BAO_0000219,B,,15250,,,
1701,H,,449.0,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,Expert,,CHO,,,105,BAO_0000219,B,,15331,,,
1702,D,,449.0,,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,Expert,,CHO,,,105,BAO_0000219,B,,15332,,Homo sapiens,9606.0
1703,D,,449.0,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,Expert,,CHO,,,105,BAO_0000219,B,,14499,,Homo sapiens,9606.0
1704,H,,449.0,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,Expert,,CHO,,,105,BAO_0000219,B,,15332,,,
1705,H,,449.0,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,Expert,,CHO,,,105,BAO_0000219,B,,14956,,,
1706,H,,,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),Autocuration,,,,,105,BAO_0000357,B,,3805,,,
1707,D,,449.0,,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,Expert,,CHO,,,105,BAO_0000219,B,,6011,,Homo sapiens,9606.0
1708,H,,449.0,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,Autocuration,,CHO,,,105,BAO_0000219,B,,16190,,,
1709,H,,,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,Autocuration,,,,,105,BAO_0000019,B,,14165,,,
1710,D,,,,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,Expert,,,,,105,BAO_0000357,B,,4234,,Homo sapiens,9606.0
1711,H,,,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",Autocuration,,,,,105,BAO_0000357,B,,15527,,,
1712,H,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,Expert,,,,,105,BAO_0000219,B,,6328,,,
1713,H,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,Autocuration,,,,,105,BAO_0000357,B,,16209,,,
1714,H,,,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,Autocuration,,,,,105,BAO_0000357,B,,14770,,,
1715,H,,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,Autocuration,,,,,105,BAO_0000357,B,,2598,,,
1716,H,,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,Expert,,,,,105,BAO_0000357,B,,6897,,,
1717,H,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000357,B,,6013,,,
1718,H,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,Expert,,,,,105,BAO_0000357,B,,5843,,,
1719,H,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,Expert,,,,,105,BAO_0000357,B,,14454,,,
1720,H,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,Autocuration,,,,,105,BAO_0000357,B,,14454,,,
1721,H,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,Autocuration,,,,,105,BAO_0000357,B,,14454,,,
1722,H,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000357,B,,15818,,,
1723,H,,485.0,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,Expert,,CHO-K1,,,105,BAO_0000219,F,,13729,,,
1724,D,,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),Expert,,,,,105,BAO_0000219,B,,6011,In vitro,Homo sapiens,9606.0
1725,D,,,,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,Expert,,,,,105,BAO_0000357,B,,4234,,Homo sapiens,9606.0
1726,H,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,Expert,,,,,105,BAO_0000019,B,,17085,,,
1727,H,,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,Autocuration,,,,,105,BAO_0000357,B,,3025,,,
1728,H,,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,Expert,,,,,105,BAO_0000357,B,,15315,,,
1729,D,,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,Expert,,,,,105,BAO_0000219,B,,14214,,Homo sapiens,9606.0
1730,D,,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,Expert,,,,,105,BAO_0000357,B,,3804,,Homo sapiens,9606.0
1731,H,,,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,Autocuration,,,,,105,BAO_0000357,B,,16700,,,
1732,D,,,,Affinity for 5-hydroxytryptamine 1D receptor subtype,Expert,,,,,105,BAO_0000357,B,,2391,,Homo sapiens,9606.0
1733,D,,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,Expert,,,,,105,BAO_0000357,B,,4175,,Homo sapiens,9606.0
1734,H,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000019,B,,17085,,,
1735,H,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,Expert,,,,,105,BAO_0000019,B,,17085,,,
1736,D,,,,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,Expert,,,,,105,BAO_0000357,B,,15926,,Homo sapiens,9606.0
1737,H,,485.0,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,Autocuration,,CHO-K1,,,105,BAO_0000219,B,,16312,,,
1738,H,,485.0,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,Autocuration,,CHO-K1,,,105,BAO_0000219,B,,16312,,,
1739,H,,449.0,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,Autocuration,,CHO,,,104802,BAO_0000219,B,,14956,,,
1740,H,,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",Autocuration,,,,,105,BAO_0000019,F,,3294,,,
1741,H,,,,Binding activity radioligand.,Autocuration,,,,,105,BAO_0000357,B,,12861,,,
1742,H,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,Autocuration,,,,,105,BAO_0000019,B,,12861,,,
1743,H,,485.0,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,Expert,,CHO-K1,,,105,BAO_0000219,B,,16312,,,
1744,H,,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000357,B,,5104,,,
1745,H,,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000357,B,,5105,,,
1746,H,,,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000357,B,,14499,,,
1747,D,,,,Binding activity against human 5-hydroxytryptamine 1D receptor,Expert,,,,,105,BAO_0000357,B,,15926,,Homo sapiens,9606.0
1748,D,,449.0,,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,Expert,,CHO,,,105,BAO_0000219,B,,4540,,Homo sapiens,9606.0
1749,H,,449.0,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,Autocuration,,CHO,,,105,BAO_0000219,B,,15779,,,
1750,H,,449.0,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,Autocuration,,CHO,,,105,BAO_0000219,B,,15779,,,
1751,H,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000357,B,,6166,,,
1752,H,,449.0,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,Autocuration,,CHO,,,105,BAO_0000219,B,,15779,,,
1753,H,,449.0,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,Autocuration,,CHO,,,105,BAO_0000219,B,,15779,,,
1754,H,,722.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,Autocuration,,HEK293,,,105,BAO_0000219,B,,17451,,,
1755,H,,722.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,Autocuration,,HEK293,,,105,BAO_0000219,B,,17451,,,
1756,H,,722.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,Autocuration,,HEK293,,,105,BAO_0000219,B,,17451,,,
1757,H,,449.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,Autocuration,,CHO,,,105,BAO_0000219,B,,4199,,,
1758,D,,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,Expert,,,,,105,BAO_0000357,B,,14875,,Homo sapiens,9606.0
1759,H,,449.0,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,Autocuration,,CHO,,,105,BAO_0000219,B,,15146,,,
1760,H,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,Autocuration,,,,,105,BAO_0000357,B,,5213,,,
1761,H,,449.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,Autocuration,,CHO,,,105,BAO_0000219,B,,14818,,,
1762,H,,449.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",Autocuration,,CHO,,,105,BAO_0000219,B,,4829,,,
1763,H,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,Expert,,,,,105,BAO_0000019,F,,14454,,,
1764,H,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,Expert,,,,,105,BAO_0000019,F,,14454,,,
1765,H,,,,Binding affinity against 5-HT2C receptor,Autocuration,,,,,108,BAO_0000357,B,,5254,,,
1766,H,,,,Binding affinity against 5-hydroxytryptamine 1D receptor,Autocuration,,,,,108,BAO_0000357,B,,5254,,,
1767,H,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,Autocuration,,,,,10577,BAO_0000357,B,,10639,,,
1768,H,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,Autocuration,,,,,10577,BAO_0000019,F,,10639,,,
1769,H,,,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",Expert,,,,,10577,BAO_0000019,B,,12352,,,
1770,H,,,,Binding affinity towards 5-HT1B was determined,Autocuration,,,,,10577,BAO_0000357,B,,9098,,,
1771,H,,,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,Expert,,,,,10577,BAO_0000019,B,,14430,,,
1772,H,,,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",Expert,,,,,10577,BAO_0000019,B,,13657,,,
1773,H,,,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",Autocuration,,,,,10577,BAO_0000019,B,,13657,,,
1774,H,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,Expert,,,,,10577,BAO_0000019,B,,15854,,,
1775,D,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,Expert,,,,,10577,BAO_0000019,B,,10639,,Rattus norvegicus,10116.0
1776,H,,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,Autocuration,,,,,10577,BAO_0000357,B,,10025,,,
1777,H,,,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",Autocuration,,,,,10577,BAO_0000357,B,,10025,,,
1778,H,,,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,Autocuration,,,,,10577,BAO_0000249,B,,14286,,,
1779,H,,,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,Autocuration,,,,2435.0,10577,BAO_0000019,B,,3651,,,
1780,D,,,,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,Expert,,,,,10577,BAO_0000357,B,,14178,,Rattus norvegicus,10116.0
1781,H,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,Autocuration,,,,,10577,BAO_0000019,B,,10639,,,
1782,H,,,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,Autocuration,,,,2435.0,10577,BAO_0000019,B,,13605,,,
1783,H,,,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,Autocuration,,,,2435.0,10577,BAO_0000019,B,,5834,,,
1784,H,,,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,Autocuration,,,,2435.0,10577,BAO_0000357,B,,10922,,,
1785,H,,,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,Autocuration,,,,,10577,BAO_0000249,B,,14286,,,
1786,H,,,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,Autocuration,,,,,10577,BAO_0000357,B,,11825,,,
1787,H,,,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,Autocuration,,,,2435.0,10577,BAO_0000019,B,,14826,,,
1788,H,,,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,Autocuration,,,,2435.0,10577,BAO_0000019,B,,9699,,,
1789,H,,,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,Autocuration,,,,,10577,BAO_0000019,B,,14423,,,
1790,H,,,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,Expert,,,,,10577,BAO_0000357,B,,10062,,,
1791,H,,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,Autocuration,,,,,10577,BAO_0000357,B,,10062,,,
1792,D,,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,Expert,,,,,10577,BAO_0000357,B,,12280,,Rattus norvegicus,10116.0
1793,H,,,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,Autocuration,,,,2435.0,10577,BAO_0000357,B,,15412,,,
1794,H,,,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,Autocuration,,,,2435.0,10577,BAO_0000357,B,,15412,,,
1795,H,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,Autocuration,,,,,10577,BAO_0000357,B,,10062,,,
1796,H,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,Autocuration,,,,,10577,BAO_0000357,B,,11147,,,
1797,H,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,Autocuration,,,,,10577,BAO_0000019,B,,9547,,,
1798,H,,,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,Autocuration,,,,,10577,BAO_0000019,B,,10444,,,
1799,H,,,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,Autocuration,,,,2435.0,10577,BAO_0000019,B,,12469,,,
1800,H,,,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,Expert,,,,,10577,BAO_0000019,B,,9098,,,
1801,H,,,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,Autocuration,,,,,10577,BAO_0000019,B,,9098,,,
1802,H,,,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,Autocuration,,,,,10577,BAO_0000357,B,,9699,,,
1803,H,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,Autocuration,,,,,10577,BAO_0000249,B,,10394,,,
1804,H,,,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,Autocuration,,,,,10577,BAO_0000357,B,,12092,,,
1805,H,,,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,Autocuration,,,,,10577,BAO_0000357,B,,16700,,,
1806,D,,,,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,Expert,,,,,10577,BAO_0000249,B,,403,,Rattus norvegicus,10116.0
1807,D,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,Expert,,,,,10577,BAO_0000357,B,,12771,,Rattus norvegicus,10116.0
1808,H,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,Autocuration,,,,,10577,BAO_0000019,B,,11642,,,
1809,H,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,Autocuration,,,,,10577,BAO_0000357,B,,12953,,,
1810,H,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,Autocuration,,,,,10577,BAO_0000357,B,,12953,,,
1811,H,,,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,Expert,,,,2435.0,10577,BAO_0000019,B,,12953,,,
1812,H,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,Autocuration,,,,,10577,BAO_0000357,B,,12953,,,
1813,H,,,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Autocuration,,,,955.0,10577,BAO_0000249,B,,9737,,,
1814,H,,,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,Autocuration,,,,,10577,BAO_0000019,B,,9737,,,
1815,H,,,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Autocuration,,,,955.0,10577,BAO_0000249,B,,9737,,,
1816,H,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,Autocuration,,,,,10577,BAO_0000357,B,,12827,,,
1817,H,,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,Autocuration,,,,,10577,BAO_0000357,B,,5033,,,
1818,D,,,,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,Expert,,,,,10577,BAO_0000019,B,,9786,,Rattus norvegicus,10116.0
1819,H,,,,Binding affinity at 5-hydroxytryptamine 1B receptor,Expert,,,,,10577,BAO_0000357,B,,13116,,,
1820,H,,,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,Autocuration,,,,,10577,BAO_0000019,B,,16429,,,
1821,D,,,,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,Expert,,,,,10577,BAO_0000249,B,,12409,,Rattus norvegicus,10116.0
1822,H,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,Autocuration,,,,,10577,BAO_0000357,B,,15194,,,
1823,H,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,Autocuration,,,,,10577,BAO_0000357,B,,15194,,,
1824,H,,,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,Autocuration,,,,,104686,BAO_0000019,B,,5486,,,
1825,H,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,Autocuration,,,,,106,BAO_0000357,B,,4639,,,
1826,H,,,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,Autocuration,,,,,106,BAO_0000249,B,Brain membranes,386,,,
1827,H,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,Autocuration,,,,,106,BAO_0000357,B,,2474,,,
1828,H,,,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,Autocuration,,,,,106,BAO_0000357,B,,6011,,,
1829,H,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,Autocuration,,,,,106,BAO_0000357,B,,5014,,,
1830,H,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,Autocuration,,,,,106,BAO_0000357,B,,17515,,,
1831,H,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,Autocuration,,,,,106,BAO_0000357,B,,4373,,,
1832,H,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,Expert,,,,,106,BAO_0000357,B,,1633,,,
1833,H,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,Autocuration,,,,,106,BAO_0000357,B,,1633,,,
1834,H,,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,Autocuration,,,,,106,BAO_0000357,B,,4373,,,
1835,H,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,Autocuration,,,,,106,BAO_0000357,B,,4687,,,
1836,H,,,,Binding affinity against 5-hydroxytryptamine 1B receptor,Autocuration,,,,,106,BAO_0000357,B,,11574,,,
1837,H,,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,Autocuration,,,,,106,BAO_0000357,B,,10321,,,
1838,H,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,Autocuration,,,,,106,BAO_0000357,B,,15527,,,
1839,H,,,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,Autocuration,,,,,106,BAO_0000357,B,,17200,,,
1840,H,,,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,Autocuration,,,,,104802,BAO_0000224,B,,14423,,,
1841,H,,,,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,Autocuration,,,,,108,BAO_0000357,B,,5834,,Bos taurus,9913.0
1842,H,,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,Autocuration,,,,,108,BAO_0000357,B,,11473,,Sus scrofa,9823.0
1843,H,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,Autocuration,,,,,108,BAO_0000357,B,,11473,,Sus scrofa,9823.0
1844,H,,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,Autocuration,,,,,108,BAO_0000357,B,,10639,,Sus scrofa,9823.0
1845,H,,,,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,Autocuration,,,,,108,BAO_0000357,B,,10639,,Sus scrofa,9823.0
1846,H,,,,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,Autocuration,,,,,108,BAO_0000357,B,,14331,,Sus scrofa,9823.0
1847,H,,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,Autocuration,,,,,108,BAO_0000357,B,,10796,,Sus scrofa,9823.0
1848,H,,,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,Expert,,,,,108,BAO_0000357,B,,9098,,Sus scrofa,9823.0
1849,H,,,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,Expert,,,,,108,BAO_0000357,B,,14331,,Sus scrofa,9823.0
1850,H,,,,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,Expert,,,,,108,BAO_0000019,B,,11828,,Sus scrofa,9823.0
1851,H,,,,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,Autocuration,,,,,108,BAO_0000357,B,,11866,,Sus scrofa,9823.0
1852,H,,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,Autocuration,,,,,108,BAO_0000019,B,,13047,,Oryctolagus cuniculus,9986.0
1853,D,,,,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,Autocuration,,,,,12689,BAO_0000357,B,,188,,Rattus norvegicus,10116.0
1854,D,,,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,Autocuration,,,,,12689,BAO_0000357,B,,11825,,Rattus norvegicus,10116.0
1855,D,,,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,Autocuration,,,,,12689,BAO_0000357,B,,11825,,Rattus norvegicus,10116.0
1856,D,,,,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,Expert,,,,,12689,BAO_0000019,B,,11624,,Rattus norvegicus,10116.0
1857,D,,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,Autocuration,,,,,12689,BAO_0000357,B,,11139,,Rattus norvegicus,10116.0
1858,D,,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,Autocuration,,,,,12689,BAO_0000357,B,,11147,,Rattus norvegicus,10116.0
1859,D,,,,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,Autocuration,,,,,12689,BAO_0000019,B,,10444,,Rattus norvegicus,10116.0
1860,D,,,,Binding affinity against 5-hydroxytryptamine 1C receptor,Expert,,,,,12689,BAO_0000357,B,,11624,,Rattus norvegicus,10116.0
1861,D,,,,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Autocuration,,,,,12689,BAO_0000019,B,,11662,,Rattus norvegicus,10116.0
1862,D,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Autocuration,,,,,12689,BAO_0000019,B,,11662,,Rattus norvegicus,10116.0
1863,D,,,,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Expert,,,,,12689,BAO_0000019,B,,11662,,Rattus norvegicus,10116.0
1864,D,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Autocuration,,,,,12689,BAO_0000019,B,,11662,,Rattus norvegicus,10116.0
1865,D,,,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,Autocuration,,,,,12689,BAO_0000357,B,,9098,,Rattus norvegicus,10116.0
1866,D,,,,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,Autocuration,,,,,12689,BAO_0000249,B,,10394,,Rattus norvegicus,10116.0
1867,H,,,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,Expert,,,,,12689,BAO_0000357,B,,11933,,,
1868,D,,,,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,Autocuration,,,,,12689,BAO_0000357,B,,12092,,Rattus norvegicus,10116.0
1869,D,,,,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,Autocuration,,,,,12689,BAO_0000019,B,,12253,,Rattus norvegicus,10116.0
1870,D,,722.0,,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,Autocuration,,HEK293,,,12689,BAO_0000219,B,,12253,,Rattus norvegicus,10116.0
1871,H,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,Autocuration,,,,,108,BAO_0000357,B,,1558,,,
1872,H,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,Autocuration,,,,,108,BAO_0000357,B,,2474,,,
1873,H,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,Autocuration,,,,,108,BAO_0000357,B,,2474,,,
1874,H,,,,Binding affinity against 5-hydroxytryptamine 1C receptor,Autocuration,,,,,12689,BAO_0000357,B,,11574,,,
1875,H,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,Autocuration,,,,,12689,BAO_0000357,B,,1558,,,
1876,H,,,,Binding affinity against 5-hydroxytryptamine 1C receptor,Autocuration,,,,,12689,BAO_0000357,B,,13944,,,
1877,H,,,,Binding affinity against serotonergic 5-HT1c receptor,Autocuration,,,,,12689,BAO_0000357,B,,13033,,,
1878,H,,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,Autocuration,,,,,12689,BAO_0000357,B,,10321,,,
1879,H,,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,Autocuration,,,,,12689,BAO_0000357,B,,11866,,,
1880,H,,,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),Autocuration,,,,,105,BAO_0000019,B,,14454,,Oryctolagus cuniculus,9986.0
1881,H,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,Autocuration,,,,,104686,BAO_0000224,B,,11574,,,
1882,H,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,Autocuration,,,,,104686,BAO_0000224,B,,11574,,,
1883,H,,,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,Autocuration,,,,,104686,BAO_0000019,B,,13631,,,
1884,D,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,Autocuration,,,,,104686,BAO_0000019,B,,9630,,Rattus norvegicus,10116.0
1885,D,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,Autocuration,,,,,104686,BAO_0000249,B,,8822,,Rattus norvegicus,10116.0
1886,D,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,Autocuration,,,,955.0,104686,BAO_0000221,B,,9064,,Rattus norvegicus,10116.0
1887,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,Autocuration,,,,,104686,BAO_0000224,B,,8868,,,
1888,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,Autocuration,,,,,104686,BAO_0000224,B,,9064,,,
1889,H,,,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,Autocuration,,,,,104686,BAO_0000019,B,,9806,,,
1890,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,Autocuration,,,,,104686,BAO_0000224,B,,9098,,,
1891,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,Autocuration,,,,,104686,BAO_0000224,B,,8868,,,
1892,H,,,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,Autocuration,,,,,104686,BAO_0000224,B,,12765,,,
1893,H,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,Autocuration,,,,,104686,BAO_0000019,B,,11049,,,
1894,H,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,Autocuration,,,,,104686,BAO_0000019,B,,11049,,,
1895,H,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,Autocuration,,,,,104686,BAO_0000019,B,,11049,,,
1896,H,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,Autocuration,,,,,104686,BAO_0000019,B,,11049,,,
1897,H,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,Autocuration,,,,,104686,BAO_0000019,B,,11049,,,
1898,H,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,Autocuration,,,,,104686,BAO_0000019,B,,11473,,,
1899,H,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,Autocuration,,,,,104686,BAO_0000019,B,,11473,,,
1900,H,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,Autocuration,,,,,104686,BAO_0000019,B,,3086,,,
1901,H,,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,Autocuration,,,,,104686,BAO_0000019,B,,11049,,,
1902,H,,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,Autocuration,,,,,104686,BAO_0000019,B,,11049,,,
1903,H,,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,Autocuration,,,,,104686,BAO_0000019,B,,10639,,,
1904,H,,,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,Autocuration,,,,,104686,BAO_0000019,B,,10922,,,
1905,D,,,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Autocuration,,,,955.0,104686,BAO_0000221,B,,9064,,Rattus norvegicus,10116.0
1906,H,,,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,Autocuration,,,,955.0,104686,BAO_0000221,B,,10748,,,
1907,H,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,Autocuration,,,,,104686,BAO_0000249,B,Membranes,11614,,,
1908,H,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,Autocuration,,,,,104686,BAO_0000249,B,Membranes,11615,,,
1909,H,,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,11615,,,
1910,H,,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,Autocuration,,,,,104686,BAO_0000249,B,Membranes,11614,,,
1911,H,,,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,Autocuration,,,,,104686,BAO_0000224,B,,11702,,,
1912,H,,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,Autocuration,,,,,104686,BAO_0000224,B,,11702,,,
1913,D,,,,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,11702,,Rattus norvegicus,10116.0
1914,H,,,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,Autocuration,,,,,104686,BAO_0000224,B,,11702,,,
1915,H,,,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,Autocuration,,,,,104686,BAO_0000019,B,,13346,,,
1916,H,,,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,10025,,,
1917,H,,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,Autocuration,,,,,104686,BAO_0000224,B,,10025,,,
1918,H,,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",Autocuration,,,,,104686,BAO_0000224,B,,10025,,,
1919,H,,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,Autocuration,,,,,104686,BAO_0000224,B,,9036,,,
1920,H,,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,Autocuration,,,,,104686,BAO_0000224,B,,9036,,,
1921,H,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,Autocuration,,,,,104686,BAO_0000019,B,,9161,,,
1922,H,,,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,Autocuration,,,,,104686,BAO_0000019,B,,12304,,,
1923,H,,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,Autocuration,,,,,104686,BAO_0000224,B,,13276,,,
1924,H,,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,Autocuration,,,,,104686,BAO_0000224,B,,11825,,,
1925,H,,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,Autocuration,,,,,104686,BAO_0000224,B,,12443,,,
1926,H,,,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,13830,,,
1927,H,,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,Autocuration,,,,,104686,BAO_0000249,B,Membranes,9592,,,
1928,H,,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,Autocuration,,,,,104686,BAO_0000249,B,Membranes,9592,,,
1929,H,,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,Autocuration,,,,,104686,BAO_0000224,B,,10881,,,
1930,H,,,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,Autocuration,,,,,104686,BAO_0000019,B,,13605,,,
1931,D,,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,11624,,Rattus norvegicus,10116.0
1932,H,,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,Autocuration,,,,,104686,BAO_0000224,B,,4101,,,
1933,H,,,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,Autocuration,,,,,104686,BAO_0000224,B,,4101,,,
1934,H,,,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,Autocuration,,,,,104686,BAO_0000019,B,,15360,,,
1935,H,,,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,Autocuration,,,,,104686,BAO_0000019,B,,11576,,,
1936,H,,,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,Autocuration,,,,,104686,BAO_0000019,B,,5834,,,
1937,D,,485.0,,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,Autocuration,,CHO-K1,,,104686,BAO_0000219,B,,2395,,Rattus norvegicus,10116.0
1938,H,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,Autocuration,,,,,104686,BAO_0000249,B,Membranes,11965,,,
1939,H,,,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),Autocuration,,,,,104686,BAO_0000224,B,,3967,,,
1940,H,,,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),Autocuration,,,,,104686,BAO_0000249,B,Brain membranes,11130,,,
1941,H,,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,Autocuration,,,,,104686,BAO_0000219,B,,13427,In vitro,,
1942,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,9443,,,
1943,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,Autocuration,,,,,104686,BAO_0000224,B,,9443,,,
1944,H,,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,Autocuration,,,,,104686,BAO_0000224,B,,11825,,,
1945,H,,,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,Autocuration,,,,,104686,BAO_0000249,B,Membranes,12120,,,
1946,H,,,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,Autocuration,,,,,104686,BAO_0000249,B,Membranes,12120,,,
1947,H,,,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,Autocuration,,,,1515.0,104686,BAO_0000019,F,,11963,,,
1948,H,,,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000019,B,,9069,,,
1949,H,,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,Autocuration,,,,,104686,BAO_0000224,B,,8868,,,
1950,H,,,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,Autocuration,,,,,10624,BAO_0000357,B,,17200,,,
1951,H,,,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,Autocuration,,,,,10624,BAO_0000357,B,,17200,,,
1952,H,,,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,Expert,,,,,17106,BAO_0000357,B,,13969,,,
1953,D,,,,Binding affinity for 5-hydroxytryptamine 1D receptor,Expert,,,,,17106,BAO_0000357,B,,13392,,,
1954,H,,,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,Autocuration,,,,,17106,BAO_0000249,B,,1742,,,
1955,H,,,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,Autocuration,,,,,17106,BAO_0000249,B,,1742,,,
1956,H,,,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,Autocuration,,,,2435.0,17106,BAO_0000357,B,,14331,,,
1957,H,,,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,Autocuration,,,,,17106,BAO_0000019,F,,12861,,,
1958,H,,,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,Expert,,,,,17106,BAO_0000019,B,,12861,,,
1959,H,,,,Binding activity radioligand.,Autocuration,,,,,17106,BAO_0000357,B,,12861,,,
1960,H,,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,Autocuration,,,,,17106,BAO_0000019,B,,12861,,,
1961,H,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,Expert,,,,,17106,BAO_0000019,B,,12861,,,
1962,H,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,Autocuration,,,,,17106,BAO_0000019,B,,12861,,,
1963,H,,,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,Autocuration,,,,,17106,BAO_0000249,B,,675,,,
1964,H,,,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,Expert,,,,,17106,BAO_0000019,B,,12490,,,
1965,H,,,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,Expert,,,,,17106,BAO_0000249,B,,11828,,,
1966,H,,,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,Autocuration,,,,,17106,BAO_0000357,B,,11866,,,
1967,H,,,,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,Autocuration,,,,,105,BAO_0000357,B,,773,,Sus scrofa,9823.0
1968,H,,,,The compound was tested for intrinsic activity against 5-HT1D receptor,Expert,,,,,105,BAO_0000357,B,,13047,,Oryctolagus cuniculus,9986.0
1969,H,,,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,Autocuration,,,,,105,BAO_0000019,B,,13047,,Oryctolagus cuniculus,9986.0
1970,H,,,,The compound was tested for binding affinity against 5-HT1D receptor,Expert,,,,,105,BAO_0000357,B,,13047,,Oryctolagus cuniculus,9986.0
1971,H,,,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,Autocuration,,,,,10578,BAO_0000357,B,,188,,,
1972,H,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,Autocuration,,,,,10578,BAO_0000019,F,,10639,,,
1973,H,,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,Autocuration,,,,,10578,BAO_0000019,F,,12438,,,
1974,H,,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,Autocuration,,,,,10578,BAO_0000357,B,,12438,,,
1975,H,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,Expert,,,,,10578,BAO_0000019,B,,15854,,,
1976,H,,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,Autocuration,,,,,10578,BAO_0000249,B,,10394,,,
1977,H,,,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,Autocuration,,,,,10578,BAO_0000357,B,,12092,,,
1978,H,,,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,Expert,,,,,10578,BAO_0000019,B,,3389,,,
1979,H,,,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,Autocuration,,,,,105,BAO_0000357,B,,6011,,,
1980,H,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000357,B,,4639,,,
1981,H,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,Autocuration,,,,,105,BAO_0000357,B,,2474,,,
1982,H,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000357,B,,5014,,,
1983,H,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,Autocuration,,,,,105,BAO_0000357,B,,17515,,,
1984,H,,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,Autocuration,,,,,105,BAO_0000357,B,,11866,,,
1985,H,,,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000357,B,,4687,,,
1986,H,,,,Tested against 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000357,B,,12146,,,
1987,H,,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,Autocuration,,,,,105,BAO_0000357,B,,10321,,,
1988,H,,722.0,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,Autocuration,,HEK293,,,105,BAO_0000219,B,,13267,,,
1989,D,,,,Binding affinity against 5-Hydroxytryptamine 1D receptor,Expert,,,,,105,BAO_0000357,B,,1274,,Homo sapiens,9606.0
1990,H,,,,,Autocuration,,,,,105,BAO_0000357,B,,15250,,,
1991,H,,485.0,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,Autocuration,,CHO-K1,,,106,BAO_0000219,B,,13706,,,
1992,H,,485.0,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,Autocuration,,CHO-K1,,,105,BAO_0000219,B,,13706,,,
1993,H,,722.0,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,Autocuration,,HEK293,,,105,BAO_0000219,B,,13706,,,
1994,H,,722.0,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,Autocuration,,HEK293,,,105,BAO_0000219,B,,13706,,,
1995,H,,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,Autocuration,,,,,105,BAO_0000019,B,,13047,,,
1996,H,,,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,Autocuration,,,,,105,BAO_0000357,B,,13366,,,
1997,H,,,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,Expert,,,,,105,BAO_0000357,B,,13366,,,
1998,H,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,Autocuration,,,,,105,BAO_0000357,B,,1558,,,
1999,H,,485.0,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",Expert,,CHO-K1,,,105,BAO_0000219,B,,12902,,,
2000,H,,485.0,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,Autocuration,,CHO-K1,,,105,BAO_0000219,B,,13706,,,
2001,H,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,Autocuration,,,,,105,BAO_0000019,F,,13706,,,
2002,H,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,Autocuration,,,,,105,BAO_0000019,F,,13706,,,
2003,H,,,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,Autocuration,,,,,105,BAO_0000019,F,,14251,,,
2004,H,,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,Autocuration,,,,,105,BAO_0000019,F,,14251,,,
2005,H,,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,Autocuration,,,,,105,BAO_0000019,F,,14251,,,
2006,H,,,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,Autocuration,,,,,105,BAO_0000357,B,,13313,,,
2007,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,Autocuration,,,,,105,BAO_0000357,B,,13313,,,
2008,H,,,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,Autocuration,,,,,105,BAO_0000357,B,,13366,,,
2009,H,,,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,Expert,,,,,105,BAO_0000357,B,,13051,,,
2010,H,,449.0,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",Expert,,CHO,,,105,BAO_0000219,B,,12903,,,
2011,D,,,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,Autocuration,,,,,105,BAO_0000219,B,,12469,,Homo sapiens,9606.0
2012,H,,,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,Autocuration,,,,,17106,BAO_0000357,B,,5619,,,
2013,H,,,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,Autocuration,,,,,105,BAO_0000019,B,,13047,,Oryctolagus cuniculus,9986.0
2014,H,,,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,Autocuration,,,,,105,BAO_0000357,B,,16633,,,
2015,H,,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,Autocuration,,,,,105,BAO_0000357,B,,16633,,,
2016,H,,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,Autocuration,,,,,105,BAO_0000357,B,,16633,,,
2017,H,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,105,BAO_0000357,B,,16633,,,
2018,H,,,,Affinity against 5-hydroxytryptamine 1D receptor alpha,Autocuration,,,,,105,BAO_0000357,B,,3269,,,
2019,H,,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,Expert,,,,,105,BAO_0000357,B,,12409,,,
2020,H,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,Autocuration,,,,,106,BAO_0000019,F,,13706,,,
2021,H,,722.0,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,Autocuration,,HEK293,,,106,BAO_0000219,B,,13706,,,
2022,H,,722.0,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,Autocuration,,HEK293,,,106,BAO_0000219,B,,13706,,,
2023,H,,449.0,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",Autocuration,,CHO,,,106,BAO_0000219,B,,12903,,,
2024,H,,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,Autocuration,,,,,106,BAO_0000019,B,,13047,,,
2025,D,,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,Expert,,,,,106,BAO_0000357,B,,13366,,,
2026,D,,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,Expert,,,,,106,BAO_0000357,B,,13366,,,
2027,D,,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,Expert,,,,,106,BAO_0000357,B,,13366,,,
2028,H,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,106,BAO_0000357,B,,13366,,,
2029,H,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,106,BAO_0000357,B,,13366,,,
2030,H,,449.0,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,Autocuration,,CHO,,,106,BAO_0000219,B,,12469,,,
2031,H,,485.0,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,Autocuration,,CHO-K1,,,106,BAO_0000219,B,,13706,,,
2032,H,,485.0,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,Autocuration,,CHO-K1,,,106,BAO_0000219,B,,13706,,,
2033,H,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,Autocuration,,,,,106,BAO_0000019,F,,13706,,,
2034,H,,485.0,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",Expert,,CHO-K1,,,106,BAO_0000219,B,,12902,,,
2035,H,,,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,Expert,,,,,105,BAO_0000357,B,,13051,,,
2036,H,,449.0,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",Expert,,CHO,,,106,BAO_0000219,B,,12903,,,
2037,H,,485.0,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,Autocuration,,CHO-K1,,,105,BAO_0000219,F,,1558,,,
2038,H,,485.0,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,Autocuration,,CHO-K1,,,105,BAO_0000219,F,,1558,,,
2039,H,,485.0,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,Autocuration,,CHO-K1,,,105,BAO_0000219,F,,1558,,,
2040,H,,485.0,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,Autocuration,,CHO-K1,,,105,BAO_0000219,F,,1558,,,
2041,H,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,Autocuration,,,,,105,BAO_0000357,B,,1558,,,
2042,H,,,,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,Autocuration,,,,,106,BAO_0000019,B,,13047,,Oryctolagus cuniculus,9986.0
2043,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,Autocuration,,,,,105,BAO_0000357,B,,13313,,,
2044,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,Autocuration,,,,,105,BAO_0000357,B,,13313,,,
2045,H,,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,Expert,,,,,105,BAO_0000357,B,,12409,,,
2046,H,,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,Autocuration,,CHO,,,10618,BAO_0000219,B,,15250,,,
2047,D,,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,Expert,,,,,10618,BAO_0000357,B,,1348,,Homo sapiens,9606.0
2048,H,,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,Autocuration,,,,,10618,BAO_0000357,B,,1348,,,
2049,D,,,,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,Expert,,,,,10618,BAO_0000357,B,,4234,,Homo sapiens,9606.0
2050,H,,,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,Autocuration,,,,,10618,BAO_0000357,B,,16209,,,
2051,H,,,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,Autocuration,,,,,10618,BAO_0000019,B,,10444,,,
2052,H,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,Autocuration,,,,,10618,BAO_0000357,B,,3935,,,
2053,H,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,Autocuration,,,,,10618,BAO_0000357,B,,15818,,,
2054,H,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,Autocuration,,,,,10618,BAO_0000019,B,,17085,,,
2055,D,,449.0,,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,Expert,,CHO,,,10618,BAO_0000219,B,,12936,,Homo sapiens,9606.0
2056,H,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,Autocuration,,,,,10618,BAO_0000357,B,,6166,,,
2057,H,,449.0,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,Autocuration,,CHO,,,10618,BAO_0000219,B,,15779,,,
2058,H,,449.0,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,Autocuration,,CHO,,,10618,BAO_0000219,B,,15779,,,
2059,H,,449.0,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,Autocuration,,CHO,,,10618,BAO_0000219,B,,15779,,,
2060,H,,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,Autocuration,,,,,10618,BAO_0000357,B,,13181,,,
2061,H,,449.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,Autocuration,,CHO,,,10618,BAO_0000219,B,,4199,,,
2062,H,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,Autocuration,,,,,10618,BAO_0000357,B,,14875,,,
2063,H,,449.0,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,Autocuration,,CHO,,,10618,BAO_0000219,B,,15146,,,
2064,H,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,Autocuration,,,,,10618,BAO_0000357,B,,5213,,,
2065,H,,,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,Autocuration,,,,,10618,BAO_0000357,B,,12146,,,
2066,H,,449.0,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,Autocuration,,CHO,,,10618,BAO_0000219,B,,13267,,,
2067,H,,449.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,Autocuration,,CHO,,,10618,BAO_0000219,B,,14818,,,
2068,H,,449.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",Autocuration,,CHO,,,10618,BAO_0000219,B,,4829,,,
2069,H,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,Autocuration,,,,,10618,BAO_0000357,B,,4373,,,
2070,H,,,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,Autocuration,,,,,10618,BAO_0000357,B,,4373,,,
2071,H,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,Autocuration,,,,,10618,BAO_0000357,B,,14159,,,
2072,H,,,,Binding affinity towards 5-hydroxytryptamine 1E receptor,Autocuration,,,,,10618,BAO_0000357,B,,16633,,,
2073,H,,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",Autocuration,,,,,279,BAO_0000019,F,,17085,,,
2074,H,,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",Expert,,,,,279,BAO_0000019,F,,17085,,,
2075,H,,,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,Autocuration,,,,,279,BAO_0000019,F,,16209,,,
2076,H,,,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,Autocuration,,,,,279,BAO_0000019,F,,16209,,,
2077,H,,,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",Expert,,,,,279,BAO_0000019,F,,17085,,,
2078,H,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,Autocuration,,,,,279,BAO_0000357,B,,14159,,,
2079,H,,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,Autocuration,,CHO,,,279,BAO_0000219,B,,15250,,,
2080,H,,,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),Autocuration,,,,,279,BAO_0000357,B,,3805,,,
2081,H,,449.0,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,Autocuration,,CHO,,,279,BAO_0000219,B,,16190,,,
2082,H,,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,Autocuration,,,,,279,BAO_0000357,B,,16190,,,
2083,H,,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,Autocuration,,,,,279,BAO_0000357,B,,16209,,,
2084,H,,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,Autocuration,,,,,279,BAO_0000357,B,,16209,,,
2085,H,,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,Autocuration,,,,,279,BAO_0000357,B,,16209,,,
2086,H,,,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,Autocuration,,,,,279,BAO_0000357,B,,6866,,,
2087,H,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,Expert,,,,,279,BAO_0000019,B,,17085,,,
2088,H,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,Autocuration,,,,,279,BAO_0000357,B,,16312,,,
2089,H,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,Autocuration,,,,,279,BAO_0000357,B,,6166,,,
2090,H,,449.0,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,Autocuration,,CHO,,,279,BAO_0000219,B,,15779,,,
2091,H,,449.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,Autocuration,,CHO,,,279,BAO_0000219,B,,4199,,,
2092,H,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,Autocuration,,,,,279,BAO_0000357,B,,14875,,,
2093,H,,449.0,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,Autocuration,,CHO,,,279,BAO_0000219,B,,15146,,,
2094,H,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,Autocuration,,,,,279,BAO_0000357,B,,5213,,,
2095,H,,449.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,Autocuration,,CHO,,,279,BAO_0000219,B,,14818,,,
2096,H,,449.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",Autocuration,,CHO,,,279,BAO_0000219,B,,4829,,,
2097,H,,449.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",Autocuration,,CHO,,,279,BAO_0000219,B,,4829,,,
2098,H,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,Autocuration,,,,,279,BAO_0000357,B,,4373,,,
2099,H,,,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,Autocuration,,,,,279,BAO_0000357,B,,4373,,,
2100,H,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,Autocuration,,,,,279,BAO_0000357,B,,5014,,,
2101,H,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",Autocuration,,,,,104686,BAO_0000019,B,,11662,,,
2102,H,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",Autocuration,,,,,104686,BAO_0000019,B,,11662,,,
2103,H,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",Autocuration,,,,,104686,BAO_0000019,B,,11662,,,
2104,H,,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000019,B,,14093,,,
2105,H,,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",Autocuration,,,,,104686,BAO_0000218,F,,11200,In vivo,,
2106,H,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,Autocuration,,,,,104686,BAO_0000019,F,,11200,,,
2107,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,Intermediate,,,,,17005,BAO_0000019,B,,12352,,,
2108,U,,,,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",Autocuration,,,,,22226,BAO_0000019,B,,13657,,Bos taurus,9913.0
2109,U,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,Autocuration,,,,,22226,BAO_0000019,B,,14331,,Bos taurus,9913.0
2110,U,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,Autocuration,,,,,22226,BAO_0000019,B,,14331,,Bos taurus,9913.0
2111,U,,,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,Autocuration,,,,,22226,BAO_0000019,B,,14331,,,
2112,H,,,,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,Autocuration,,,,,104784,BAO_0000019,B,,12685,,Cavia porcellus,10141.0
2113,H,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,Autocuration,,,,,104784,BAO_0000019,B,,14389,,Cavia porcellus,10141.0
2114,H,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,Autocuration,,,,,104784,BAO_0000019,B,,14386,,Cavia porcellus,10141.0
2115,H,,,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,Autocuration,,,,,104784,BAO_0000224,B,,5732,,,
2116,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,Autocuration,,,,,104784,BAO_0000224,B,,16293,,,
2117,H,,,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104784,BAO_0000224,B,,2078,,,
2118,H,,,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,Autocuration,,,,,10209,BAO_0000357,B,,5486,,,
2119,H,,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,Autocuration,,,,,104826,BAO_0000218,B,,11820,In vivo,,
2120,H,,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,Autocuration,,,,,104826,BAO_0000019,B,,10297,,,
2121,H,,,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,Autocuration,,,,,104826,BAO_0000224,B,,13704,,,
2122,D,,,,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,Autocuration,,,,,104826,BAO_0000019,B,,10297,,Mus musculus,10090.0
2123,H,,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,Autocuration,,,,,104826,BAO_0000218,B,,11820,In vivo,,
2124,D,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,Autocuration,,,,,104826,BAO_0000019,B,,10297,,Mus musculus,10090.0
2125,H,,,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104826,BAO_0000224,B,,11555,,,
2126,H,,,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,Autocuration,,,,,104826,BAO_0000224,B,,11555,,,
2127,H,,,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,Autocuration,,,,,104826,BAO_0000224,B,,11555,,,
2128,D,,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,Autocuration,,,,,104826,BAO_0000019,B,,10297,,Mus musculus,10090.0
2129,H,,,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,Autocuration,,,,,104784,BAO_0000224,B,,16688,,Sus scrofa,9823.0
2130,H,,,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,Autocuration,,,,,104784,BAO_0000224,B,,16688,,Sus scrofa,9823.0
2131,U,,,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,Autocuration,,,,,22226,BAO_0000221,B,,5333,,,
2132,U,,,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,Autocuration,,,,,22226,BAO_0000221,B,,4437,,,
2133,H,,,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,Autocuration,,,,,17005,BAO_0000357,B,,5033,,Sus scrofa,9823.0
2134,H,,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000019,B,,15267,,,
2135,H,,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000019,B,,15267,,,
2136,H,,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,Autocuration,,,,,104826,BAO_0000019,B,,11820,,,
2137,H,,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,9069,,,
2138,D,,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,Autocuration,,,,,104686,BAO_0000019,B,,9162,,Rattus norvegicus,10116.0
2139,H,,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,Autocuration,,,,,104686,BAO_0000019,B,,9162,,,
2140,H,,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,Autocuration,,,,,104686,BAO_0000019,B,,9162,,,
2141,H,,,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,Autocuration,,,,,104686,BAO_0000019,F,,10428,,,
2142,H,,,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,Autocuration,,,,,104686,BAO_0000019,B,,9628,,,
2143,H,,,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,12704,,,
2144,D,,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,Autocuration,,,,,104686,BAO_0000224,B,,15453,,Rattus norvegicus,10116.0
2145,H,,,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,Autocuration,,,,,104686,BAO_0000224,B,,188,,,
2146,H,,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,Autocuration,,,,,104686,BAO_0000224,B,,10349,,,
2147,H,,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,Autocuration,,,,,104686,BAO_0000224,B,,10349,,,
2148,H,,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,Autocuration,,,,,104686,BAO_0000224,B,,8868,,,
2149,H,,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,Autocuration,,,,,104686,BAO_0000224,B,,10025,,,
2150,H,,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",Autocuration,,,,,104686,BAO_0000224,B,,10025,,,
2151,H,,,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,11702,,,
2152,H,,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,11702,,,
2153,H,,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,Autocuration,,,,,104686,BAO_0000224,B,,11702,,,
2154,H,,,,Compound was tested for the inhibition of quipazine induced head twitches in rats,Autocuration,,,,,104686,BAO_0000019,F,,11702,,,
2155,H,,,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,Autocuration,,,,,104686,BAO_0000019,F,,11702,,,
2156,H,,,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,Autocuration,,,,10000000.0,104686,BAO_0000221,B,,10085,,,
2157,H,,,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,Autocuration,,,,10000000.0,104686,BAO_0000221,B,,10085,,,
2158,D,,,,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,Autocuration,,,,955.0,104686,BAO_0000221,B,,9630,,Rattus norvegicus,10116.0
2159,H,,,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,Autocuration,,,,,104686,BAO_0000019,B,,11070,,,
2160,H,,,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,Autocuration,,,,,104686,BAO_0000249,B,Membranes,9841,,,
2161,H,,,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,Autocuration,,,,,104686,BAO_0000249,B,Membranes,9841,,,
2162,H,,,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,Autocuration,,,,,104686,BAO_0000019,B,,13291,,,
2163,H,,,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,Autocuration,,,,,104686,BAO_0000019,F,,10590,,,
2164,D,,,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Autocuration,,,,955.0,104686,BAO_0000221,B,,9064,,Rattus norvegicus,10116.0
2165,D,,,,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,Autocuration,,,,,104686,BAO_0000249,B,Membranes,12268,,Rattus norvegicus,10116.0
2166,H,,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,Autocuration,,,,955.0,104686,BAO_0000221,B,,13508,,,
2167,H,,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,Autocuration,,,,,104686,BAO_0000019,F,,11279,,,
2168,H,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,Autocuration,,,,,104686,BAO_0000019,F,,11200,,,
2169,H,,,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,Autocuration,,,,,104686,BAO_0000019,F,,11200,,,
2170,H,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,Autocuration,,,,,104686,BAO_0000019,F,,11200,,,
2171,H,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,Autocuration,,,,,104686,BAO_0000019,F,,11200,,,
2172,H,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,Autocuration,,,,,104686,BAO_0000019,F,,11200,,,
2173,H,,,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,Autocuration,,,,955.0,104686,BAO_0000220,B,,9231,,,
2174,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,Autocuration,,,,,104686,BAO_0000019,B,,9737,,,
2175,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Autocuration,,,,955.0,104686,BAO_0000249,B,,9737,,,
2176,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,Autocuration,,,,,104686,BAO_0000019,B,,9737,,,
2177,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,Autocuration,,,,,104686,BAO_0000019,B,,9737,,,
2178,D,,,,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000019,B,,11828,,Rattus norvegicus,10116.0
2179,H,,,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,Autocuration,,,,,104686,BAO_0000019,B,,12253,,,
2180,H,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,Autocuration,,,,,104686,BAO_0000019,B,,12253,,,
2181,H,,,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",Autocuration,,,,,104686,BAO_0000019,F,,11279,,,
2182,H,,,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,Autocuration,,,,,104686,BAO_0000019,B,,11866,,,
2183,D,,,,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,Autocuration,,,,,104686,BAO_0000224,B,,14424,,Rattus norvegicus,10116.0
2184,D,,,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000019,B,,15180,,Rattus norvegicus,10116.0
2185,D,,,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000019,B,,15180,,Rattus norvegicus,10116.0
2186,D,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,Autocuration,,,,,104686,BAO_0000019,B,,9786,,Rattus norvegicus,10116.0
2187,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,Autocuration,,,,,104686,BAO_0000224,B,,12132,,,
2188,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,Autocuration,,,,,104686,BAO_0000249,B,,5486,,,
2189,H,,,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000019,B,,15316,,,
2190,H,,,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,Autocuration,,,,,104686,BAO_0000019,B,,16429,,,
2191,H,,,,pKi value for 5-hydroxytryptamine 2 receptor binding site,Autocuration,,,,,104686,BAO_0000224,B,,14617,,,
2192,H,,,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,Autocuration,,,,955.0,104686,BAO_0000221,B,,11351,,,
2193,H,,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,Autocuration,,,,,104686,BAO_0000019,F,,11279,,,
2194,H,,,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,Autocuration,,,,,105075,BAO_0000019,B,,9523,,,
2195,H,,,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,Autocuration,,,,,105075,BAO_0000019,B,,9523,,,
2196,H,,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,Autocuration,,,,,105075,BAO_0000019,B,,9523,,,
2197,H,,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,Autocuration,,,,,105075,BAO_0000019,B,,9523,,,
2198,H,,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,Autocuration,,,,,105075,BAO_0000019,B,,9523,,,
2199,H,,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,Autocuration,,,,,105075,BAO_0000019,B,,9523,,,
2200,H,,,,Hill coefficient of compound was determined,Autocuration,,,,,105075,BAO_0000224,B,,9523,,,
2201,U,,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,Autocuration,,,,,22226,BAO_0000019,B,,4771,,,
2202,D,,,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,Autocuration,,,,,104686,BAO_0000019,B,,5033,,Rattus norvegicus,10116.0
2203,H,,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,Expert,,,,,12687,BAO_0000019,B,,10845,,,
2204,H,,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,Expert,,,,,12687,BAO_0000019,B,,10845,,,
2205,H,,,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),Autocuration,,,,,12687,BAO_0000357,B,,16288,,,
2206,H,,,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),Autocuration,,,,,12687,BAO_0000019,B,,16288,,,
2207,H,,,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,Autocuration,,,,,12687,BAO_0000019,B,,16190,,,
2208,D,,,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,Autocuration,,,,,104686,BAO_0000224,B,,12463,,Rattus norvegicus,10116.0
2209,H,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",Autocuration,,,,,104686,BAO_0000224,B,,9699,,,
2210,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,Autocuration,,,,,104686,BAO_0000224,B,,9699,,,
2211,H,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",Autocuration,,,,,104686,BAO_0000019,B,,11662,,,
2212,H,,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104784,BAO_0000224,B,,1205,,,
2213,U,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,Autocuration,,,,,22226,BAO_0000219,B,,11376,,,
2214,H,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",Autocuration,,,,,104784,BAO_0000219,B,,11376,,,
2215,H,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104784,BAO_0000224,B,,4639,,,
2216,H,,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104784,BAO_0000224,B,,2222,,,
2217,H,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104784,BAO_0000224,B,,1558,,,
2218,H,,,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104784,BAO_0000224,B,,1089,,,
2219,H,,,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,Autocuration,,,,,104784,BAO_0000249,B,Brain membranes,386,,,
2220,H,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,Autocuration,,,,,104784,BAO_0000224,B,,2474,,,
2221,H,,,,Binding affinity towards 5-HT2 receptor,Autocuration,,,,,104784,BAO_0000224,B,,17066,,,
2222,H,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104784,BAO_0000224,B,,959,,,
2223,H,,,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,Autocuration,,,,,104784,BAO_0000224,B,,6398,,,
2224,H,,,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,Autocuration,,,,,104686,BAO_0000224,B,,11889,,,
2225,H,,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104784,BAO_0000224,B,,4221,,,
2226,H,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,Autocuration,,,,,104784,BAO_0000224,B,,11026,,,
2227,H,,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,Autocuration,,,,,104784,BAO_0000224,B,,11866,,,
2228,H,,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104784,BAO_0000224,B,,4221,,,
2229,U,,,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,Autocuration,,,,,22226,BAO_0000019,B,,13950,,,
2230,H,,,,5-hydroxytryptamine 2 receptor binding affinity,Autocuration,,,,,104784,BAO_0000224,B,,1263,,,
2231,H,,,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,Autocuration,,,,,17005,BAO_0000357,B,,13291,,,
2232,H,,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,Autocuration,,,,,17005,BAO_0000357,B,,10812,,,
2233,H,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,Autocuration,,,,,104784,BAO_0000224,B,,13020,,,
2234,H,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,Autocuration,,,,,104784,BAO_0000224,B,,13021,,,
2235,H,,,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,Autocuration,,,,,104784,BAO_0000224,B,,13020,,,
2236,H,,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,Autocuration,,,,,17005,BAO_0000357,B,,14532,,,
2237,H,,,,Binding affinity against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,17005,BAO_0000357,B,,13944,,,
2238,H,,,,Binding affinity against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,17005,BAO_0000357,B,,14331,,,
2239,H,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,Autocuration,,,,,17005,BAO_0000357,B,,14118,,,
2240,H,,,,Binding affinity against serotonergic 5-HT2 receptor,Autocuration,,,,,17005,BAO_0000357,B,,13033,,,
2241,H,,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,Autocuration,,,,,17005,BAO_0000357,B,,10321,,,
2242,H,,,,Compound was evaluated for the binding affinity at 5- HT2 receptor,Autocuration,,,,,17005,BAO_0000357,B,,12918,,,
2243,H,,,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,17005,BAO_0000357,B,,15120,,,
2244,H,,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,17005,BAO_0000218,B,,2613,,,
2245,D,,,,Inhibitory activity against cloned human 5-HT2 receptor,Autocuration,,,,,104784,BAO_0000224,B,,13378,,Homo sapiens,9606.0
2246,D,,449.0,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",Autocuration,,CHO,,,104784,BAO_0000219,B,,2331,,Homo sapiens,9606.0
2247,D,,449.0,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",Autocuration,,CHO,,,104784,BAO_0000219,B,,2331,,Homo sapiens,9606.0
2248,D,,449.0,,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",Autocuration,,CHO,,,104784,BAO_0000219,B,,2331,,Homo sapiens,9606.0
2249,D,,449.0,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",Autocuration,,CHO,,,104784,BAO_0000219,B,,2331,,Homo sapiens,9606.0
2250,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104784,BAO_0000224,B,,4170,,,
2251,H,,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,Autocuration,,,,,104784,BAO_0000224,B,,15453,,,
2252,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,,,,17005,BAO_0000357,B,,1479,,,
2253,H,,,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,Autocuration,,,,,104686,BAO_0000224,B,,11139,,,
2254,H,,,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,Expert,,,,,17005,BAO_0000357,B,,13969,,,
2255,H,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,Expert,,,,,17005,BAO_0000357,B,,13392,,,
2256,H,,,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,Expert,,,,,17005,BAO_0000019,B,,14430,,,
2257,H,,,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,13181,,Cavia porcellus,10141.0
2258,H,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,Autocuration,,,,,51,BAO_0000357,B,,17200,,,
2259,H,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,Autocuration,,,,,107,BAO_0000357,B,,17200,,,
2260,H,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,Autocuration,,,,,51,BAO_0000357,B,,17200,,,
2261,H,,,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,Autocuration,,,,,107,BAO_0000357,B,,13463,,,
2262,H,,449.0,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,Autocuration,,CHO,,,107,BAO_0000219,B,,6347,,,
2263,D,,449.0,,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,Expert,,CHO,,,107,BAO_0000219,F,,6857,,Homo sapiens,9606.0
2264,H,,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,Autocuration,,,,,107,BAO_0000219,F,,4176,,,
2265,H,,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,Autocuration,,,,,107,BAO_0000219,F,,4176,,,
2266,H,,,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,Autocuration,,,,,107,BAO_0000219,F,,4176,,,
2267,H,,449.0,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",Autocuration,,CHO,,,107,BAO_0000219,B,,6347,,,
2268,H,,449.0,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",Autocuration,,CHO,,,107,BAO_0000219,B,,6347,,,
2269,H,,,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,Autocuration,,,,,107,BAO_0000357,B,,15331,,,
2270,D,,,,Inhibition of human 5-hydroxytryptamine 2A receptor,Expert,,,,,107,BAO_0000357,B,,16146,,Homo sapiens,9606.0
2271,H,,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,Autocuration,,CHO,,,107,BAO_0000219,B,,15250,,,
2272,H,,,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,Expert,,,,,107,BAO_0000219,B,,13631,,,
2273,H,,,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),Autocuration,,,,,107,BAO_0000357,B,,3805,,,
2274,H,,449.0,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,Autocuration,,CHO,,,107,BAO_0000219,B,,4011,,,
2275,H,,449.0,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,Expert,,CHO,,,107,BAO_0000219,B,,4012,,,
2276,H,,307.0,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,Expert,,L929,,,107,BAO_0000219,B,,6366,,,
2277,H,,449.0,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,Expert,,CHO,,,107,BAO_0000219,B,,15949,,,
2278,H,,,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,Autocuration,,,,,107,BAO_0000019,F,,14093,,,
2279,H,,,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,Autocuration,,,,,107,BAO_0000019,F,,13481,,,
2280,H,,449.0,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,Autocuration,,CHO,,,107,BAO_0000219,B,,6347,,,
2281,H,,449.0,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,Autocuration,,CHO,,,107,BAO_0000219,B,,6347,,,
2282,H,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,Autocuration,,,,,107,BAO_0000019,F,,14093,,,
2283,H,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,Autocuration,,,,,107,BAO_0000019,F,,14093,,,
2284,H,,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,Autocuration,,,,,107,BAO_0000019,F,,13481,,,
2285,H,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,Autocuration,,,,,107,BAO_0000357,B,,14442,,,
2286,H,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,Autocuration,,,,,107,BAO_0000357,B,,14442,,,
2287,H,,,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,Autocuration,,,,,107,BAO_0000357,B,,14755,,,
2288,H,,,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,Autocuration,,,,,107,BAO_0000357,B,,16441,,,
2289,H,,,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,Autocuration,,,,,107,BAO_0000357,B,,14744,,,
2290,H,,449.0,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,Expert,,CHO,,,107,BAO_0000219,B,,16659,,,
2291,H,,,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,3307,,,
2292,D,,,,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,Expert,,,,,107,BAO_0000019,B,,6857,,Homo sapiens,9606.0
2293,H,,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,Expert,,,,,107,BAO_0000357,B,,5635,,,
2294,D,,,,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,Expert,,,,,107,BAO_0000357,B,,4234,,Homo sapiens,9606.0
2295,H,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,Autocuration,,,,,107,BAO_0000357,B,,15527,,,
2296,H,,449.0,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,Expert,,CHO,,,107,BAO_0000219,B,,6588,,,
2297,H,,,,Binding affinity towards human 5-HT2A receptor in BEK cells,Expert,,,,,107,BAO_0000219,B,,13631,,,
2298,H,,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,17723,,,
2299,H,,,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,Autocuration,,,,,107,BAO_0000357,B,,14770,,,
2300,D,,,,Binding affinity for human 5-hydroxytryptamine 2A receptor,Expert,,,,,107,BAO_0000357,B,,16293,,Homo sapiens,9606.0
2301,H,,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,Autocuration,,,,,107,BAO_0000357,B,,16209,,,
2302,H,,,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,Autocuration,,,,,107,BAO_0000219,B,,12469,,,
2303,H,,,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,15363,,,
2304,H,,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,15363,,,
2305,H,,,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",Expert,,,,,107,BAO_0000019,B,,16441,,,
2306,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,Autocuration,,,,,107,BAO_0000357,B,,8,,,
2307,H,,722.0,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,Autocuration,,HEK293,,,107,BAO_0000219,B,,4176,,,
2308,H,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000019,B,,17085,,,
2309,H,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,Autocuration,,,,,107,BAO_0000357,B,,17200,,,
2310,D,,,,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,Expert,,,,,107,BAO_0000357,B,,17200,,Homo sapiens,9606.0
2311,D,,449.0,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,Expert,,CHO,,,107,BAO_0000219,B,,4013,,Homo sapiens,9606.0
2312,H,,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,5088,,,
2313,D,,,,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,Expert,,,,,107,BAO_0000357,B,,5088,,Homo sapiens,9606.0
2314,H,,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,Autocuration,,,,,107,BAO_0000357,B,,5088,,,
2315,D,,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,Expert,,,,,107,BAO_0000357,B,,5088,,Homo sapiens,9606.0
2316,H,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,Autocuration,,,,,107,BAO_0000357,B,,5088,,,
2317,H,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,Autocuration,,,,,107,BAO_0000357,B,,5088,,,
2318,H,,,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,Autocuration,,,,,104686,BAO_0000019,B,,9786,,,
2319,D,,,,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,Autocuration,,,,,104686,BAO_0000019,B,,9205,,Rattus norvegicus,10116.0
2320,H,,,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,Autocuration,,,,,104686,BAO_0000224,B,,11257,,,
2321,H,,,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,Autocuration,,,,,104686,BAO_0000019,B,,9362,,,
2322,H,,,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,Autocuration,,,,,104686,BAO_0000019,B,,9362,,,
2323,H,,,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,Autocuration,,,,,104686,BAO_0000224,B,,10590,,,
2324,H,,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,Autocuration,,,,,104686,BAO_0000019,B,,10468,,,
2325,H,,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,Autocuration,,,,,104686,BAO_0000019,B,,13050,,,
2326,H,,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,Autocuration,,,,,104686,BAO_0000019,B,,11624,,,
2327,H,,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,Autocuration,,,,,104686,BAO_0000019,B,,10468,,,
2328,H,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,Autocuration,,,,,104686,BAO_0000224,B,,10330,,,
2329,H,,,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,Autocuration,,,,,104686,BAO_0000224,B,,10062,,,
2330,H,,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,11642,,,
2331,H,,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,10062,,,
2332,H,,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,Autocuration,,,,,104686,BAO_0000219,B,,13427,In vitro,,
2333,D,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,12280,,Rattus norvegicus,10116.0
2334,D,,,,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,Autocuration,,,,,104686,BAO_0000224,B,,4101,,Rattus norvegicus,10116.0
2335,H,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,10062,,,
2336,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,Autocuration,,,,,104686,BAO_0000224,B,,11147,,,
2337,D,,485.0,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,Autocuration,,CHO-K1,,,104686,BAO_0000219,B,,2395,,Rattus norvegicus,10116.0
2338,D,,485.0,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,Autocuration,,CHO-K1,,,104686,BAO_0000219,B,,2395,,Rattus norvegicus,10116.0
2339,D,,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,Autocuration,,,,,104686,BAO_0000019,B,,9098,,Rattus norvegicus,10116.0
2340,H,,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,Autocuration,,,,,104686,BAO_0000019,B,,9098,,,
2341,D,,,,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,Autocuration,,,,,104686,BAO_0000019,B,,9098,,Rattus norvegicus,10116.0
2342,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,9443,,,
2343,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,Autocuration,,,,,104686,BAO_0000224,B,,9443,,,
2344,H,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",Autocuration,,,,,104686,BAO_0000019,B,,9699,,,
2345,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,Autocuration,,,,,104686,BAO_0000019,B,,9699,,,
2346,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,Autocuration,,,,,104686,BAO_0000224,B,,9098,,,
2347,D,,,,Affinity for 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,3070,,Rattus norvegicus,10116.0
2348,H,,,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,Autocuration,,,,,104686,BAO_0000224,B,,9547,,,
2349,H,,,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,Autocuration,,,,,104686,BAO_0000019,B,,10444,,,
2350,H,,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,Autocuration,,,,,104686,BAO_0000019,B,,14617,,,
2351,H,,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,Autocuration,,,,,104686,BAO_0000019,B,,14617,,,
2352,H,,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),Autocuration,,,,,104686,BAO_0000224,B,,11130,,,
2353,H,,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),Autocuration,,,,,104686,BAO_0000218,B,,11130,In vivo,,
2354,H,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,Autocuration,,,,955.0,104686,BAO_0000221,B,,14542,,,
2355,H,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,Autocuration,,,,,104686,BAO_0000224,B,,2797,,,
2356,H,,,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,Autocuration,,,,,104686,BAO_0000019,B,,11332,,,
2357,H,,,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,Autocuration,,,,,104686,BAO_0000019,B,,11332,,,
2358,H,,,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,Autocuration,,,,1870.0,104686,BAO_0000019,B,,10752,,,
2359,H,,,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,1185,,,
2360,H,,,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,1185,,,
2361,D,,,,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,Autocuration,,,,,104686,BAO_0000224,B,,11624,,Rattus norvegicus,10116.0
2362,H,,,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,Autocuration,,,,,104686,BAO_0000019,B,,1344,,,
2363,D,,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,Autocuration,,,,2435.0,104686,BAO_0000019,B,,15453,,Rattus norvegicus,10116.0
2364,H,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",Autocuration,,,,,104686,BAO_0000019,B,,11662,,,
2365,H,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",Autocuration,,,,,104686,BAO_0000019,B,,11662,,,
2366,H,,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,10796,,,
2367,H,,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,9069,,,
2368,D,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,Autocuration,,,,,104686,BAO_0000019,B,,8814,,Rattus norvegicus,10116.0
2369,D,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,Autocuration,,,,,104686,BAO_0000019,B,,8908,,Rattus norvegicus,10116.0
2370,H,,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,Autocuration,,,,,104686,BAO_0000019,B,,9098,,,
2371,H,,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,Autocuration,,,,,104686,BAO_0000019,B,,9098,,,
2372,H,,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,Autocuration,,,,,104686,BAO_0000019,B,,9098,,,
2373,H,,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,Autocuration,,,,,104686,BAO_0000019,B,,9098,,,
2374,H,,,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,Autocuration,,,,,104686,BAO_0000249,B,,9098,,,
2375,H,,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,Autocuration,,,,,104686,BAO_0000019,B,,9098,,,
2376,H,,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,Autocuration,,,,,104686,BAO_0000019,B,,9098,,,
2377,H,,,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,Autocuration,,,,,104686,BAO_0000019,B,,9161,,,
2378,H,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,Autocuration,,,,,104686,BAO_0000019,B,,9161,,,
2379,H,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,Autocuration,,,,,104686,BAO_0000019,B,,9161,,,
2380,H,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,Autocuration,,,,,104686,BAO_0000019,B,,9161,,,
2381,H,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,Autocuration,,,,,104686,BAO_0000019,B,,9161,,,
2382,H,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,Autocuration,,,,,104686,BAO_0000019,B,,9161,,,
2383,H,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,Autocuration,,,,,104686,BAO_0000019,B,,9161,,,
2384,H,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,Autocuration,,,,,104686,BAO_0000019,B,,9161,,,
2385,H,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,Autocuration,,,,,104686,BAO_0000019,B,,9161,,,
2386,H,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,Autocuration,,,,,104686,BAO_0000019,B,,9161,,,
2387,H,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,Autocuration,,,,,104686,BAO_0000019,B,,9161,,,
2388,H,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,Autocuration,,,,,104686,BAO_0000019,B,,9161,,,
2389,H,,,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,Autocuration,,,,,104686,BAO_0000019,B,,12094,,,
2390,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,Autocuration,,,,,104686,BAO_0000249,B,,12018,,,
2391,H,,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,Autocuration,,,,,104686,BAO_0000249,B,,10394,,,
2392,H,,,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,15260,,,
2393,D,,,,Inhibitory constant against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,11624,,Rattus norvegicus,10116.0
2394,H,,,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,13654,,,
2395,H,,,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,Autocuration,,,,,104686,BAO_0000019,B,,9541,,,
2396,H,,,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,Autocuration,,,,,104686,BAO_0000224,B,,11933,,,
2397,H,,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,Autocuration,,,,,104686,BAO_0000019,B,,15538,,,
2398,H,,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,Autocuration,,,,,104686,BAO_0000019,B,,15538,,,
2399,H,,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,Autocuration,,,,,104686,BAO_0000019,B,,15538,,,
2400,D,,,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000019,B,,8841,,,
2401,H,,,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,Autocuration,,,,,104686,BAO_0000224,B,,1455,,,
2402,H,,,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,Autocuration,,,,,104686,BAO_0000224,B,,1455,,,
2403,H,,,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,Autocuration,,,,,104686,BAO_0000019,B,,11752,,,
2404,H,,,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,Autocuration,,,,955.0,104686,BAO_0000221,B,,11642,,,
2405,H,,,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,Autocuration,,,,,104686,BAO_0000224,B,,12092,,,
2406,H,,,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,Autocuration,,,,,104686,BAO_0000224,B,,3967,,,
2407,D,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,12771,,Rattus norvegicus,10116.0
2408,H,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,Autocuration,,,,,104686,BAO_0000019,B,,11642,,,
2409,H,,,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,Autocuration,,,,,104686,BAO_0000224,B,,11628,,,
2410,H,,,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,13654,,,
2411,H,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,Autocuration,,,,,104686,BAO_0000019,F,,11200,,,
2412,H,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,Autocuration,,,,,104686,BAO_0000019,F,,11200,,,
2413,H,,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",Autocuration,,,,,104686,BAO_0000218,F,,11200,In vivo,,
2414,H,,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",Autocuration,,,,,104686,BAO_0000218,F,,11200,In vivo,,
2415,H,,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",Autocuration,,,,,104686,BAO_0000218,F,,11200,In vivo,,
2416,H,,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",Autocuration,,,,,104686,BAO_0000218,F,,11200,In vivo,,
2417,H,,,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,Expert,,,,955.0,12687,BAO_0000221,B,,15436,,,
2418,D,,,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,Expert,,,,,12687,BAO_0000019,B,,15436,,Rattus norvegicus,10116.0
2419,H,,,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,Autocuration,,,,,12687,BAO_0000019,B,,14025,,,
2420,H,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,Autocuration,,,,,12687,BAO_0000357,B,,4342,,,
2421,D,,,,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,Expert,,,,,12687,BAO_0000019,B,,13735,,Rattus norvegicus,10116.0
2422,D,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,Expert,,,,,12687,BAO_0000357,B,,5816,,Rattus norvegicus,10116.0
2423,H,,,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,Expert,,,,,12687,BAO_0000019,B,,14287,,,
2424,H,,,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,Autocuration,,,,,12687,BAO_0000357,B,,15738,,,
2425,D,,,,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,Expert,,,,,12687,BAO_0000357,B,,15738,,Rattus norvegicus,10116.0
2426,H,,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,Autocuration,,,,,12687,BAO_0000019,B,,15026,,,
2427,H,,,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,Expert,,,,,12687,BAO_0000019,B,,16647,,,
2428,H,,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,Autocuration,,,,,12687,BAO_0000019,B,,16647,,,
2429,D,,,,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,Expert,,,,,12687,BAO_0000019,B,,13345,,Rattus norvegicus,10116.0
2430,H,,,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000249,B,Membranes,1543,,,
2431,H,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,Autocuration,,,,,12687,BAO_0000019,B,,12444,,,
2432,H,,,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,Expert,,,,,12687,BAO_0000019,B,,16404,,,
2433,H,,449.0,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,Autocuration,,CHO,,,12687,BAO_0000219,B,,16404,,,
2434,H,,,,Kinetic inhibition constant evaluated by measuring serotonergic activity,Expert,,,,,12687,BAO_0000357,B,,15577,,,
2435,H,,,,Serotonergic activity of the compound.,Autocuration,,,,,12687,BAO_0000357,B,,15577,,,
2436,H,,,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,Autocuration,,,,,12687,BAO_0000249,B,,2495,,,
2437,D,,,,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,Expert,,,,,12687,BAO_0000019,B,,15042,,Rattus norvegicus,10116.0
2438,H,,,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,Expert,,,,,12687,BAO_0000249,B,,15026,,,
2439,D,,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Expert,,,,,12687,BAO_0000019,F,,12919,,Rattus norvegicus,10116.0
2440,D,,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Expert,,,,,12687,BAO_0000019,F,,12919,,Rattus norvegicus,10116.0
2441,D,,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Expert,,,,,12687,BAO_0000019,F,,12919,,Rattus norvegicus,10116.0
2442,H,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,Autocuration,,,,,12687,BAO_0000357,B,,15194,,,
2443,H,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,Autocuration,,,,,12687,BAO_0000357,B,,15194,,,
2444,H,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,Expert,,,,,107,BAO_0000357,B,,4820,,,
2445,H,,,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,Autocuration,,,,,107,BAO_0000357,B,,6736,,,
2446,H,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,Autocuration,,,,,107,BAO_0000357,B,,5163,,,
2447,H,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,Autocuration,,,,,107,BAO_0000357,B,,5163,,,
2448,H,,,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,Autocuration,,,,,107,BAO_0000357,B,,6011,,,
2449,D,,,,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,Expert,,,,,107,BAO_0000357,B,,14294,,Homo sapiens,9606.0
2450,H,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,5014,,,
2451,H,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,Expert,,,,,107,BAO_0000357,B,,17066,,,
2452,H,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,Autocuration,,,,,107,BAO_0000357,B,,17515,,,
2453,H,,,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,Expert,,,,,107,BAO_0000357,B,,6736,,,
2454,H,,,,Affinity for 5-hydroxytryptamine 2A receptor,Expert,,,,,107,BAO_0000357,B,,5163,,,
2455,H,,723.0,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,Expert,,NIH3T3,,,107,BAO_0000219,B,,16911,,,
2456,H,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,Expert,,,,,107,BAO_0000357,B,,6841,,,
2457,H,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,Expert,,,,,107,BAO_0000357,B,,6119,,,
2458,H,,,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,3962,,,
2459,H,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,Autocuration,,,,,107,BAO_0000357,B,,4373,,,
2460,H,,,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,Autocuration,,,,,107,BAO_0000357,B,,4373,,,
2461,H,,,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000019,F,,3962,,,
2462,H,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,Expert,,,,,107,BAO_0000357,B,,1633,,,
2463,H,,,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,Autocuration,,,,,107,BAO_0000357,B,,4373,,,
2464,H,,,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,Expert,,,,,107,BAO_0000357,B,,6576,,,
2465,H,,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,4687,,,
2466,H,,,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,16946,,,
2467,H,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,14159,,,
2468,H,,449.0,,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,Expert,,CHO,,,107,BAO_0000219,B,,3032,,Mus musculus,10090.0
2469,H,,,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,16655,,,
2470,H,,,,Binding affinity at 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,13964,,,
2471,H,,,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,Expert,,,,,107,BAO_0000357,B,,16989,,,
2472,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,Autocuration,,,,,107,BAO_0000357,B,,16117,,,
2473,H,,,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,Autocuration,,,,,107,BAO_0000357,B,,16700,,,
2474,H,,,,Affinity against 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,3269,,,
2475,D,,,,Binding affinity against 5-Hydroxytryptamine 2A receptor,Expert,,,,,107,BAO_0000357,B,,1274,,Homo sapiens,9606.0
2476,H,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,Autocuration,,,,,107,BAO_0000357,B,,1317,,,
2477,H,,,,Tested against 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,12146,,,
2478,H,,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,Autocuration,,,,,105075,BAO_0000224,B,,12652,,,
2479,H,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,Autocuration,,,,,105075,BAO_0000224,B,,12652,,,
2480,H,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,Autocuration,,,,,105075,BAO_0000224,B,,12652,,,
2481,H,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,Autocuration,,,,,105075,BAO_0000224,B,,12652,,,
2482,H,,,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),Autocuration,,,,,107,BAO_0000357,B,,16647,,,
2483,D,,722.0,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,Expert,,HEK293,,,227,BAO_0000219,B,,15851,,Homo sapiens,9606.0
2484,D,,449.0,,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,Expert,,CHO,,,227,BAO_0000219,F,,6857,,Homo sapiens,9606.0
2485,H,,,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),Autocuration,,,,,227,BAO_0000357,B,,3805,,,
2486,D,,,,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,Expert,,,,,227,BAO_0000357,B,,6491,,Homo sapiens,9606.0
2487,H,,,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,Autocuration,,,,,227,BAO_0000019,F,,14093,,,
2488,H,,,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,Autocuration,,,,,227,BAO_0000019,F,,13481,,,
2489,H,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,Autocuration,,,,,227,BAO_0000019,F,,14093,,,
2490,H,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,Autocuration,,,,,227,BAO_0000019,F,,14093,,,
2491,H,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,Autocuration,,,,,227,BAO_0000019,F,,14093,,,
2492,H,,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,Autocuration,,,,,227,BAO_0000019,F,,13481,,,
2493,H,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,Autocuration,,,,,227,BAO_0000357,B,,14442,,,
2494,H,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,Autocuration,,,,,227,BAO_0000357,B,,14442,,,
2495,H,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,Autocuration,,,,,227,BAO_0000357,B,,14442,,,
2496,H,,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,12369,,,
2497,H,,,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,Expert,,,,,107,BAO_0000357,B,,12369,,,
2498,H,,,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,Expert,,,,,107,BAO_0000357,B,,12369,,,
2499,H,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,Autocuration,,,,,107,BAO_0000019,B,,14447,,,
2500,H,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,Autocuration,,,,,107,BAO_0000019,B,,14447,,,
2501,H,,723.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,Autocuration,,NIH3T3,,,107,BAO_0000219,B,,17451,,,
2502,H,,449.0,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Autocuration,,CHO,,,107,BAO_0000219,F,,6857,,,
2503,D,,449.0,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Expert,,CHO,,,107,BAO_0000219,F,,6857,,Homo sapiens,9606.0
2504,H,,,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,Autocuration,,,,,104817,BAO_0000224,B,,5635,,,
2505,H,,,,Binding activity radioligand.,Autocuration,,,,,107,BAO_0000357,B,,12861,,,
2506,H,,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,Autocuration,,,,,107,BAO_0000019,B,,12861,,,
2507,H,,307.0,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,Autocuration,,L929,,,107,BAO_0000219,B,,5105,,,
2508,H,,307.0,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,Expert,,L929,,,107,BAO_0000219,B,,5104,,,
2509,H,,307.0,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,Expert,,L929,,,107,BAO_0000219,B,,5105,,,
2510,H,,307.0,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,Autocuration,,L929,,,107,BAO_0000219,B,,5105,,,
2511,H,,,,Binding affinity against 5-HT2A receptor,Autocuration,,,,,107,BAO_0000357,B,,5254,,,
2512,H,,,,Binding affinity against 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,5254,,,
2513,H,,722.0,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,Autocuration,,HEK293,,,107,BAO_0000219,B,,13267,,,
2514,H,,722.0,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,Autocuration,,HEK293,,,107,BAO_0000219,B,,13267,,,
2515,D,,722.0,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,Expert,,HEK293,,,107,BAO_0000219,B,,14157,,Homo sapiens,9606.0
2516,D,,722.0,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Expert,,HEK293,,,107,BAO_0000219,B,,12936,,Homo sapiens,9606.0
2517,H,,,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,Expert,,,,,107,BAO_0000357,B,,14068,,,
2518,D,,722.0,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Expert,,HEK293,,,107,BAO_0000219,B,,12936,,Homo sapiens,9606.0
2519,D,,722.0,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Expert,,HEK293,,,107,BAO_0000219,B,,12936,,Homo sapiens,9606.0
2520,D,,722.0,,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,Expert,,HEK293,,,107,BAO_0000219,B,,4540,,Homo sapiens,9606.0
2521,H,,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,Expert,,,,,107,BAO_0000357,B,,6166,,,
2522,H,,722.0,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,Autocuration,,HEK293,,,107,BAO_0000219,B,,17296,,,
2523,H,,722.0,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,Autocuration,,HEK293,,,107,BAO_0000219,B,,17296,,,
2524,H,,722.0,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,Autocuration,,HEK293,,,107,BAO_0000219,B,,17296,,,
2525,D,,722.0,,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,Expert,,HEK293,,,107,BAO_0000219,B,,15779,,Homo sapiens,9606.0
2526,H,,722.0,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,Expert,,HEK293,,,107,BAO_0000219,B,,14391,,,
2527,H,,722.0,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",Expert,,HEK293,,,107,BAO_0000219,B,,15851,,,
2528,D,,722.0,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,Expert,,HEK293,,,107,BAO_0000219,B,,15851,,Homo sapiens,9606.0
2529,H,,722.0,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,Expert,,HEK293,,,107,BAO_0000219,B,,3832,,,
2530,H,,722.0,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,Expert,,HEK293,,,107,BAO_0000219,B,,3833,,,
2531,D,,722.0,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Expert,,HEK293,,,107,BAO_0000219,B,,12936,,Homo sapiens,9606.0
2532,H,,723.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,Autocuration,,NIH3T3,,,107,BAO_0000219,B,,17451,,,
2533,H,,723.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,Autocuration,,NIH3T3,,,107,BAO_0000219,B,,17451,,,
2534,H,,723.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,Autocuration,,NIH3T3,,,107,BAO_0000219,B,,17451,,,
2535,H,,722.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,Autocuration,,HEK293,,,107,BAO_0000219,B,,4199,,,
2536,H,,485.0,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,Autocuration,,CHO-K1,,,107,BAO_0000219,B,,1883,,,
2537,H,,485.0,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,Expert,,CHO-K1,,,107,BAO_0000219,B,,1883,,,
2538,D,,,,Binding affinity for human 5-hydroxytryptamine 2A receptor,Expert,,,,,107,BAO_0000357,B,,14875,,Homo sapiens,9606.0
2539,H,,722.0,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,Autocuration,,HEK293,,,107,BAO_0000219,B,,15146,,,
2540,H,,722.0,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,Autocuration,,HEK293,,,107,BAO_0000219,B,,5213,,,
2541,D,,449.0,,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,Expert,,CHO,,,107,BAO_0000219,B,,16404,,Homo sapiens,9606.0
2542,H,,722.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,Autocuration,,HEK293,,,107,BAO_0000219,B,,14818,,,
2543,H,,722.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",Autocuration,,HEK293,,,107,BAO_0000219,B,,4829,,,
2544,H,,723.0,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,Autocuration,,NIH3T3,,,10620,BAO_0000219,F,,12652,,,
2545,H,,723.0,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,Expert,,NIH3T3,,,107,BAO_0000219,B,,4682,,,
2546,H,,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,Autocuration,,,,,10620,BAO_0000019,F,,12652,,,
2547,H,,,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,Autocuration,,,,,10621,BAO_0000357,B,,4921,,,
2548,H,,,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,Autocuration,,,,,10621,BAO_0000357,B,,4921,,,
2549,H,,,,Binding affinity against rabbit aorta 5-HT2A receptor,Autocuration,,,,,107,BAO_0000357,B,,16312,,Oryctolagus cuniculus,9986.0
2550,H,,,,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,Expert,,,,,107,BAO_0000357,B,,14998,,Oryctolagus cuniculus,9986.0
2551,H,,,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,Expert,,,,,107,BAO_0000357,B,,14025,,Oryctolagus cuniculus,9986.0
2552,H,,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,Autocuration,,,,,107,BAO_0000019,B,,13047,,Oryctolagus cuniculus,9986.0
2553,H,,,,The compound was tested for binding affinity against 5-HT2A receptor,Expert,,,,,107,BAO_0000357,B,,13047,,Oryctolagus cuniculus,9986.0
2554,H,,485.0,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,Autocuration,,CHO-K1,,,10576,BAO_0000219,B,,1883,,,
2555,H,,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,Autocuration,,,,,12687,BAO_0000019,B,,13463,,,
2556,H,,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,Autocuration,,,,,12687,BAO_0000019,B,,13463,,,
2557,H,,,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,Autocuration,,,,945.0,12687,BAO_0000019,B,,13463,,,
2558,D,,,,Binding affinity for 5-HT 2A in rat stomach fundus,Expert,,,,945.0,12687,BAO_0000019,B,,13463,,Rattus norvegicus,10116.0
2559,H,,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,Autocuration,,,,,12687,BAO_0000019,B,,13463,,,
2560,H,,723.0,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,Expert,,NIH3T3,,,12687,BAO_0000219,B,,16326,,,
2561,H,,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000019,F,,14093,,,
2562,H,,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000019,F,,14093,,,
2563,H,,,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000357,B,,15740,,,
2564,H,,,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,Autocuration,,,,,12687,BAO_0000357,B,,16633,,,
2565,D,,,,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,Expert,,,,,12687,BAO_0000019,F,,17200,,Rattus norvegicus,10116.0
2566,H,,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000357,B,,17133,,,
2567,H,,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000357,B,,17133,,,
2568,H,,,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000357,B,,17133,,,
2569,H,,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,Autocuration,,,,,12687,BAO_0000219,F,,17200,,,
2570,H,,,,Efficacy at 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000019,F,,15363,,,
2571,H,,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),Autocuration,,,,,12687,BAO_0000357,B,,17200,,,
2572,D,,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),Expert,,,,,12687,BAO_0000357,B,,17200,,Rattus norvegicus,10116.0
2573,D,,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),Expert,,,,,12687,BAO_0000357,B,,17200,,Rattus norvegicus,10116.0
2574,D,,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,Expert,,,,,12687,BAO_0000219,F,,17200,,Rattus norvegicus,10116.0
2575,H,,,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,Autocuration,,,,,12687,BAO_0000219,F,,17200,,,
2576,H,,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000019,B,,17211,,,
2577,H,,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,Expert,,,,,12687,BAO_0000019,B,,17331,,,
2578,H,,,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,Expert,,,,,12687,BAO_0000249,B,,13565,,,
2579,H,,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,Expert,,,,,12687,BAO_0000357,B,,13730,,,
2580,H,,,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,Expert,,,,,12687,BAO_0000019,B,,12416,,,
2581,H,,,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000357,B,,15295,,,
2582,H,,,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,Autocuration,,,,,12687,BAO_0000019,B,,1742,,,
2583,H,,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000357,B,,15295,,,
2584,H,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,Expert,,,,,12687,BAO_0000019,B,,14970,,,
2585,H,,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,Expert,,,,,12687,BAO_0000019,B,,16693,,,
2586,D,,,,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,Expert,,,,,12687,BAO_0000019,B,,14776,,Rattus norvegicus,10116.0
2587,H,,,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,Autocuration,,,,,12687,BAO_0000249,B,,14286,,,
2588,D,,,,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,Expert,,,,,12687,BAO_0000019,B,,17200,,Rattus norvegicus,10116.0
2589,H,,,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),Expert,,,,,12687,BAO_0000357,B,,15306,,,
2590,D,,,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,Expert,,,,,12687,BAO_0000357,B,,14178,,Rattus norvegicus,10116.0
2591,D,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,Expert,,,,,12687,BAO_0000019,B,,14229,,Rattus norvegicus,10116.0
2592,H,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,Expert,,,,,12687,BAO_0000357,B,,12884,,,
2593,H,,,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",Expert,,,,,12687,BAO_0000357,B,,13149,,,
2594,D,,,,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,Expert,,,,,12687,BAO_0000019,B,,15295,,Rattus norvegicus,10116.0
2595,H,,,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,Autocuration,,,,,12687,BAO_0000357,B,,15740,,,
2596,H,,,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",Autocuration,,,,,12687,BAO_0000019,B,,15185,,,
2597,H,,,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",Autocuration,,,,,12687,BAO_0000019,B,,15185,,,
2598,H,,,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,Expert,,,,,12687,BAO_0000019,B,,17529,,,
2599,H,,,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,Autocuration,,,,,12687,BAO_0000019,B,,14826,,,
2600,H,,,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,Expert,,,,,12687,BAO_0000019,B,,17211,,,
2601,H,,,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,Autocuration,,,,,12687,BAO_0000019,B,,14826,,,
2602,H,,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000019,B,,14093,,,
2603,H,,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,Autocuration,,,,,12687,BAO_0000019,B,,14093,,,
2604,H,,723.0,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,Expert,,NIH3T3,,,12687,BAO_0000219,B,,13246,,,
2605,H,,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,Expert,,,,,12687,BAO_0000357,B,,13246,,,
2606,D,,,,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,Expert,,,,,12687,BAO_0000019,B,,15436,,Rattus norvegicus,10116.0
2607,D,,,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,Expert,,,,,12687,BAO_0000019,B,,15436,,Rattus norvegicus,10116.0
2608,H,,,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,Autocuration,,,,955.0,12687,BAO_0000221,B,,14442,,,
2609,H,,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,Expert,,,,,12687,BAO_0000357,B,,12457,,,
2610,H,,723.0,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,Expert,,NIH3T3,,,12687,BAO_0000219,B,,12457,,,
2611,H,,,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",Autocuration,,,,,12687,BAO_0000221,F,,14755,,,
2612,H,,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,Autocuration,,,,,12687,BAO_0000357,B,,4707,,,
2613,H,,,,Binding affinity against 5-hydroxytryptamine 2A receptor,Expert,,,,,12687,BAO_0000357,B,,13297,,,
2614,H,,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,Expert,,,,,12687,BAO_0000019,B,,17331,,,
2615,H,,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,Autocuration,,,,,12687,BAO_0000019,B,,4664,,,
2616,H,,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,Autocuration,,,,,12687,BAO_0000357,B,,16633,,,
2617,D,,723.0,,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,Expert,,NIH3T3,,,12687,BAO_0000219,B,,4664,,Rattus norvegicus,10116.0
2618,H,,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,Expert,,,,,12687,BAO_0000357,B,,16133,,,
2619,H,,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,Expert,,,,,12687,BAO_0000357,B,,16133,,,
2620,D,,,,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,Expert,,,,,12687,BAO_0000019,B,,14060,,Rattus norvegicus,10116.0
2621,H,,,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,Expert,,,,,12687,BAO_0000357,B,,16326,,,
2622,H,,449.0,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,Expert,,CHO,,,12687,BAO_0000219,B,,16659,,,
2623,H,,,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,Autocuration,,,,,12687,BAO_0000019,B,,14776,,,
2624,H,,,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,Autocuration,,,,,12687,BAO_0000357,B,,13481,,,
2625,H,,,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000357,B,,17386,,,
2626,D,,,,Binding affinity for 5-hydroxytryptamine 2A receptor,Expert,,,,,12687,BAO_0000357,B,,6611,,Rattus norvegicus,10116.0
2627,H,,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,Autocuration,,,,,12687,BAO_0000019,B,,14423,,,
2628,H,,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,Autocuration,,,,,12687,BAO_0000019,B,,15412,,,
2629,H,,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,Autocuration,,,,,12687,BAO_0000019,B,,15412,,,
2630,H,,,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,Autocuration,,,,,12687,BAO_0000019,B,,6238,,,
2631,H,,,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,Expert,,,,,12687,BAO_0000357,B,,6648,,,
2632,H,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,Expert,,,,,12687,BAO_0000357,B,,5667,,,
2633,D,,,,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,Expert,,,,,12687,BAO_0000357,B,,6611,,Rattus norvegicus,10116.0
2634,H,,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,Autocuration,,,,,12687,BAO_0000357,B,,13481,,,
2635,H,,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,Autocuration,,,,,12687,BAO_0000357,B,,13481,,,
2636,H,,723.0,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,Expert,,NIH3T3,,,12687,BAO_0000219,B,,15558,,,
2637,H,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000357,B,,6013,,,
2638,H,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,Autocuration,,,,,12687,BAO_0000357,B,,16633,,,
2639,H,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,Autocuration,,,,,12687,BAO_0000357,B,,6013,,,
2640,D,,,,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,Expert,,,,,12687,BAO_0000357,B,,6013,,Rattus norvegicus,10116.0
2641,H,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,Autocuration,,,,,12687,BAO_0000357,B,,6013,,,
2642,H,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,Expert,,,,,12687,BAO_0000357,B,,6013,,,
2643,H,,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,Autocuration,,,,,12687,BAO_0000357,B,,6013,,,
2644,H,,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,Autocuration,,,,,12687,BAO_0000357,B,,6013,,,
2645,H,,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000357,B,,16293,,,
2646,H,,723.0,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,Expert,,NIH3T3,,,12687,BAO_0000219,B,,17175,,,
2647,D,,,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,Expert,,,,,12687,BAO_0000357,B,,13278,,Rattus norvegicus,10116.0
2648,H,,,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,Autocuration,,,,5383.0,12687,BAO_0000019,B,,3682,,,
2649,H,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,Autocuration,,,,,12687,BAO_0000357,B,,2014,,,
2650,H,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,Autocuration,,,,,12687,BAO_0000357,B,,2014,,,
2651,H,,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,Autocuration,,,,,12687,BAO_0000357,B,,4932,,,
2652,H,,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,Autocuration,,,,,12687,BAO_0000019,B,,4932,,,
2653,H,,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000357,B,,3935,,,
2654,D,,,,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,Expert,,,,10000000.0,12687,BAO_0000221,B,,5432,,Rattus norvegicus,10116.0
2655,H,,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000357,B,,15818,,,
2656,H,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,Autocuration,,,,,12687,BAO_0000357,B,,13672,,,
2657,H,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,Autocuration,,,,,12687,BAO_0000357,B,,13672,,,
2658,H,,723.0,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,Expert,,NIH3T3,,,12687,BAO_0000219,B,,14749,,,
2659,H,,,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,Autocuration,,,,,12687,BAO_0000019,B,,13462,,,
2660,H,,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000357,B,,15740,,,
2661,H,,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,Expert,,,,,12687,BAO_0000019,B,,16647,,,
2662,H,,,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,Autocuration,,,,955.0,12687,BAO_0000221,B,,13345,,,
2663,H,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,Autocuration,,,,,12687,BAO_0000249,B,,16740,,,
2664,H,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,Autocuration,,,,,12687,BAO_0000249,B,,16740,,,
2665,D,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,Expert,,,,,12687,BAO_0000019,B,,15535,,Rattus norvegicus,10116.0
2666,H,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,Expert,,,,,12687,BAO_0000249,B,,16740,,,
2667,H,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,Autocuration,,,,,12687,BAO_0000249,B,,16740,,,
2668,H,,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,Autocuration,,,,,12687,BAO_0000249,B,,16740,,,
2669,D,,,,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,Expert,,,,,12687,BAO_0000019,B,,4795,,Rattus norvegicus,10116.0
2670,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,Expert,,,,,12687,BAO_0000019,B,,8,,,
2671,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,Autocuration,,,,,12687,BAO_0000019,B,,8,,,
2672,D,,,,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,Expert,,,,,12687,BAO_0000019,B,,17200,,Rattus norvegicus,10116.0
2673,D,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,Expert,,,,,12687,BAO_0000019,B,,2148,,Rattus norvegicus,10116.0
2674,D,,,,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",Expert,,,,,105102,BAO_0000224,B,,13345,,Rattus norvegicus,10116.0
2675,H,,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,Autocuration,,,,,12687,BAO_0000357,B,,5088,,,
2676,H,,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,Autocuration,,,,,12687,BAO_0000357,B,,5088,,,
2677,H,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,Autocuration,,,,,12687,BAO_0000357,B,,17133,,,
2678,D,,,,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,Expert,,,,,12687,BAO_0000357,B,,17133,,Rattus norvegicus,10116.0
2679,H,,,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,Autocuration,,,,,12687,BAO_0000357,B,,16532,,,
2680,H,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000357,B,,15086,,,
2681,D,,,,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Expert,,,,,12687,BAO_0000019,B,,2309,,Rattus norvegicus,10116.0
2682,H,,,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,Expert,,,,,12687,BAO_0000019,B,,12953,,,
2683,H,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,Autocuration,,,,,12687,BAO_0000019,B,,12953,,,
2684,H,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,Autocuration,,,,,12687,BAO_0000019,B,,12953,,,
2685,H,,449.0,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,Autocuration,,CHO,,,12687,BAO_0000219,B,,16659,,,
2686,H,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,Autocuration,,,,,12687,BAO_0000019,B,,16740,,,
2687,H,,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,Autocuration,,,,,12687,BAO_0000019,B,,16740,,,
2688,H,,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,Autocuration,,,,,12687,BAO_0000357,B,,17133,,,
2689,H,,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,Autocuration,,,,,12687,BAO_0000019,B,,17211,,,
2690,H,,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,Autocuration,,,,,12687,BAO_0000019,B,,17331,,,
2691,H,,,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,Autocuration,,,,,12687,BAO_0000218,B,,16633,,,
2692,H,,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,Autocuration,,,,,12687,BAO_0000218,B,,16633,,,
2693,H,,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,Autocuration,,,,,12687,BAO_0000218,B,,16633,,,
2694,H,,,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,Expert,,,,,12687,BAO_0000357,B,,15026,,,
2695,H,,,,Ratio of pKi of 5-HT2A to that of D2 receptor,Expert,,,,,12687,BAO_0000357,B,,15026,,,
2696,H,,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,Expert,,,,,105093,BAO_0000224,B,,16404,,,
2697,H,,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,Expert,,,,,105093,BAO_0000224,B,,16404,,,
2698,H,,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,Expert,,,,,105075,BAO_0000224,B,,16404,,,
2699,H,,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,Autocuration,,,,,12687,BAO_0000357,B,,16404,,,
2700,H,,,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,Expert,,,,,12687,BAO_0000357,B,,16326,,,
2701,H,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,Autocuration,,,,,12687,BAO_0000019,F,,15847,,,
2702,H,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,Autocuration,,,,,12687,BAO_0000019,F,,15847,,,
2703,H,,,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,Autocuration,,,,,12687,BAO_0000019,F,,15329,,,
2704,H,,,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,Expert,,,,1515.0,12687,BAO_0000019,F,,16404,,,
2705,H,,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,Expert,,,,1515.0,12687,BAO_0000019,F,,16404,,,
2706,H,,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,Autocuration,,,,1515.0,12687,BAO_0000019,F,,16404,,,
2707,H,,,,Binding activity radioligand.,Autocuration,,,,,12687,BAO_0000357,B,,12861,,,
2708,H,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,Expert,,,,,12687,BAO_0000019,B,,12861,,,
2709,H,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,Autocuration,,,,,12687,BAO_0000019,B,,12861,,,
2710,H,,,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,Expert,,,,,12687,BAO_0000019,B,,12490,,,
2711,H,,339.0,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,Autocuration,,N1E-115,,,12687,BAO_0000219,B,,12827,,,
2712,H,,339.0,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,Autocuration,,N1E-115,,,12687,BAO_0000219,B,,12827,,,
2713,H,,,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,Autocuration,,,,,12687,BAO_0000019,B,,12918,,,
2714,D,,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,Expert,,,,,12687,BAO_0000019,F,,12919,,Rattus norvegicus,10116.0
2715,H,,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,17723,,,
2716,H,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,6013,,,
2717,H,,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,16293,,,
2718,H,,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,Expert,,,,,108,BAO_0000019,B,,3857,,,
2719,H,,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,Expert,,,,,108,BAO_0000019,B,,3857,,,
2720,H,,,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,Expert,,,,,108,BAO_0000019,B,,3857,,,
2721,H,,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,15363,,,
2722,H,,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,15363,,,
2723,H,,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,Expert,,,,,108,BAO_0000019,B,,16441,,,
2724,H,,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,Expert,,,,,108,BAO_0000019,B,,16441,,,
2725,H,,722.0,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,Autocuration,,HEK293,,,108,BAO_0000219,B,,4176,,,
2726,H,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000019,B,,17085,,,
2727,D,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,Expert,,,,,108,BAO_0000357,B,,17200,,Homo sapiens,9606.0
2728,H,,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,Expert,,,,,108,BAO_0000357,B,,5088,,,
2729,H,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,Autocuration,,,,,108,BAO_0000357,B,,5088,,,
2730,H,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,Autocuration,,,,,108,BAO_0000357,B,,5088,,,
2731,H,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,Autocuration,,,,,108,BAO_0000357,B,,5088,,,
2732,H,,449.0,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,Autocuration,,CHO,,,108,BAO_0000219,B,,16659,,,
2733,H,,449.0,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,Autocuration,,CHO,,,108,BAO_0000219,B,,16659,,,
2734,H,,723.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,Autocuration,,NIH3T3,,,108,BAO_0000219,B,,17451,,,
2735,D,,449.0,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Expert,,CHO,,,108,BAO_0000219,F,,6857,,Homo sapiens,9606.0
2736,H,,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,Expert,,,,,108,BAO_0000019,B,,3857,,,
2737,H,,,,Binding activity radioligand.,Autocuration,,,,,108,BAO_0000357,B,,12861,,,
2738,H,,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,Autocuration,,,,,108,BAO_0000019,B,,12861,,,
2739,H,,449.0,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,Expert,,CHO,,,108,BAO_0000219,B,,5104,,,
2740,H,,449.0,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,Expert,,CHO,,,108,BAO_0000219,B,,5105,,,
2741,H,,449.0,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,Autocuration,,CHO,,,108,BAO_0000219,B,,5105,,,
2742,H,,,,Binding affinity against 5-HT2C receptor,Autocuration,,,,,108,BAO_0000357,B,,5254,,,
2743,H,,722.0,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,Autocuration,,HEK293,,,108,BAO_0000219,B,,13267,,,
2744,D,,722.0,,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,Expert,,HEK293,,,108,BAO_0000219,B,,14157,,Homo sapiens,9606.0
2745,D,,722.0,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,Expert,,HEK293,,,108,BAO_0000219,B,,12936,,Homo sapiens,9606.0
2746,H,,,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,Expert,,,,,108,BAO_0000357,B,,14068,,,
2747,D,,722.0,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,Expert,,HEK293,,,108,BAO_0000219,B,,12936,,Homo sapiens,9606.0
2748,D,,722.0,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,Expert,,HEK293,,,108,BAO_0000219,B,,4540,,Homo sapiens,9606.0
2749,D,,722.0,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,Expert,,HEK293,,,108,BAO_0000219,B,,4540,,Homo sapiens,9606.0
2750,H,,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,Autocuration,,,,,108,BAO_0000357,B,,6166,,,
2751,H,,722.0,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,Autocuration,,HEK293,,,108,BAO_0000219,B,,17296,,,
2752,H,,722.0,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,Autocuration,,HEK293,,,108,BAO_0000219,B,,17296,,,
2753,H,,722.0,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,Autocuration,,HEK293,,,108,BAO_0000219,B,,15779,,,
2754,H,,722.0,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,Autocuration,,HEK293,,,108,BAO_0000219,B,,15779,,,
2755,H,,722.0,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,Expert,,HEK293,,,108,BAO_0000219,B,,14391,,,
2756,H,,722.0,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",Autocuration,,HEK293,,,108,BAO_0000219,B,,15779,,,
2757,H,,722.0,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",Expert,,HEK293,,,108,BAO_0000219,B,,15851,,,
2758,D,,722.0,,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,Expert,,HEK293,,,108,BAO_0000219,B,,15851,,Homo sapiens,9606.0
2759,H,,722.0,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",Autocuration,,HEK293,,,108,BAO_0000219,B,,15779,,,
2760,H,,722.0,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,Expert,,HEK293,,,108,BAO_0000219,B,,3832,,,
2761,H,,722.0,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,Expert,,HEK293,,,108,BAO_0000219,B,,3833,,,
2762,H,,723.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,Autocuration,,NIH3T3,,,108,BAO_0000219,B,,17451,,,
2763,H,,722.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,Autocuration,,HEK293,,,108,BAO_0000219,B,,4199,,,
2764,H,,485.0,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,Expert,,CHO-K1,,,108,BAO_0000219,B,,1883,,,
2765,D,,,,Binding affinity against 5-hydroxytryptamine 2C receptor,Expert,,,,,108,BAO_0000357,B,,4321,,Homo sapiens,9606.0
2766,H,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,14875,,,
2767,H,,722.0,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,Autocuration,,HEK293,,,108,BAO_0000219,B,,15146,,,
2768,H,,722.0,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,Autocuration,,HEK293,,,108,BAO_0000219,B,,5213,,,
2769,H,,308.0,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,Autocuration,,HeLa,,,108,BAO_0000219,B,,16404,,,
2770,H,,,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,Autocuration,,,,,108,BAO_0000019,F,,13267,,,
2771,H,,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,Autocuration,,,,10000000.0,108,BAO_0000221,F,,13267,,,
2772,H,,722.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,Autocuration,,HEK293,,,108,BAO_0000219,B,,14818,,,
2773,H,,722.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",Autocuration,,HEK293,,,108,BAO_0000219,B,,4829,,,
2774,H,,,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,Autocuration,,,,,11864,BAO_0000357,B,,13463,,,
2775,H,,,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,Autocuration,,,,945.0,11864,BAO_0000019,B,,13463,,,
2776,H,,,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,Autocuration,,,,945.0,11864,BAO_0000019,B,,13463,,,
2777,H,,625.0,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,Autocuration,,A9,,,11864,BAO_0000219,F,,12652,,,
2778,H,,723.0,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,Autocuration,,NIH3T3,,,11864,BAO_0000219,B,,4682,,,
2779,H,,723.0,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,Autocuration,,NIH3T3,,,11864,BAO_0000219,B,,4682,,,
2780,H,,723.0,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,Autocuration,,NIH3T3,,,11864,BAO_0000219,B,,4682,,,
2781,H,,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,Autocuration,,,,,11864,BAO_0000019,F,,12652,,,
2782,H,,,,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,Autocuration,,,,945.0,12689,BAO_0000019,B,,13463,,Mus musculus,10090.0
2783,D,,,,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,Expert,,,,945.0,12689,BAO_0000019,B,,13463,,Rattus norvegicus,10116.0
2784,H,,,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,Expert,,,,,108,BAO_0000357,B,,13969,,,
2785,H,,,,Binding affinity for 5-hydroxytryptamine 2C receptor,Expert,,,,,108,BAO_0000357,B,,13392,,Sus scrofa,9823.0
2786,H,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,Expert,,,,,108,BAO_0000357,B,,13392,,,
2787,H,,,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,Expert,,,,,108,BAO_0000019,B,,14430,,,
2788,H,,,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,Autocuration,,,,,108,BAO_0000019,B,,1742,,,
2789,H,,,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,Autocuration,,,,,108,BAO_0000249,B,,14286,,,
2790,H,,,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,5619,,,
2791,H,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,15086,,,
2792,H,,,,Binding activity radioligand.,Autocuration,,,,,108,BAO_0000357,B,,12861,,,
2793,H,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,Expert,,,,,108,BAO_0000019,B,,12861,,,
2794,H,,,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,Autocuration,,,,,108,BAO_0000019,B,,12861,,,
2795,H,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,Autocuration,,,,,108,BAO_0000249,B,,12827,,,
2796,H,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,Autocuration,,,,,108,BAO_0000249,B,,12827,,,
2797,H,,,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,Expert,,,,,108,BAO_0000019,F,,12919,,Sus scrofa,9823.0
2798,H,,,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,Expert,,,,,108,BAO_0000019,F,,12919,,Sus scrofa,9823.0
2799,H,,,,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,Autocuration,,,,,108,BAO_0000357,B,,16429,,Sus scrofa,9823.0
2800,H,,,,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,Autocuration,,,,,108,BAO_0000019,B,,773,,Sus scrofa,9823.0
2801,H,,,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,5033,,Sus scrofa,9823.0
2802,H,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,Autocuration,,,,,12687,BAO_0000019,B,,12861,,,
2803,H,,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,Autocuration,,,,,12689,BAO_0000019,F,,14093,,,
2804,H,,,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,Expert,,,,,12689,BAO_0000357,B,,14970,,,
2805,H,,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,Autocuration,,,,,12689,BAO_0000357,B,,14970,,,
2806,H,,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,Autocuration,,,,,12689,BAO_0000357,B,,14970,,,
2807,D,,,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,Expert,,,,,12689,BAO_0000357,B,,14178,,Rattus norvegicus,10116.0
2808,D,,,,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,Expert,,,,,12689,BAO_0000357,B,,14178,,Rattus norvegicus,10116.0
2809,D,,,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,Expert,,,,,12689,BAO_0000249,B,Brain membranes,14229,,Rattus norvegicus,10116.0
2810,H,,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,Autocuration,,,,,12689,BAO_0000357,B,,16532,,,
2811,H,,,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,Autocuration,,,,,12689,BAO_0000019,B,,14826,,,
2812,H,,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,Autocuration,,,,,12689,BAO_0000019,B,,17211,,,
2813,H,,,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,Expert,,,,,12689,BAO_0000219,B,,17211,In vitro,,
2814,H,,723.0,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,Expert,,NIH3T3,,,12689,BAO_0000219,B,,13246,,,
2815,H,,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,Expert,,,,,12689,BAO_0000357,B,,13246,,,
2816,H,,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,Expert,,,,,12689,BAO_0000357,B,,12457,,,
2817,H,,723.0,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,Expert,,NIH3T3,,,12689,BAO_0000219,B,,12457,,,
2818,H,,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,Autocuration,,,,,12689,BAO_0000357,B,,4707,,,
2819,H,,,,Binding affinity against 5-hydroxytryptamine 2C receptor,Expert,,,,,12689,BAO_0000357,B,,13297,,,
2820,H,,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,Autocuration,,,,,12689,BAO_0000357,B,,16633,,,
2821,H,,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,Expert,,,,,12689,BAO_0000357,B,,16133,,,
2822,H,,,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,Expert,,,,,12689,BAO_0000357,B,,16326,,,
2823,H,,,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,Autocuration,,,,,12689,BAO_0000019,B,,14423,,,
2824,H,,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,Autocuration,,,,,12689,BAO_0000019,B,,15412,,,
2825,H,,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,Autocuration,,,,,12689,BAO_0000019,B,,15412,,,
2826,H,,625.0,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,Expert,,A9,,,12689,BAO_0000219,B,,15558,,,
2827,H,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,Autocuration,,,,,12689,BAO_0000357,B,,16633,,,
2828,H,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,Expert,,,,,12689,BAO_0000357,B,,6013,,,
2829,H,,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,Expert,,,,,12689,BAO_0000219,B,,17175,In vitro,,
2830,H,,,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,Autocuration,,,,,12689,BAO_0000219,B,,12469,,,
2831,H,,,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,Autocuration,,,,5383.0,12689,BAO_0000019,B,,3682,,,
2832,H,,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,Autocuration,,,,,12689,BAO_0000357,B,,4932,,,
2833,H,,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,Autocuration,,,,,12689,BAO_0000019,B,,4932,,,
2834,H,,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,Autocuration,,,,,12689,BAO_0000357,B,,3935,,,
2835,H,,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,Autocuration,,,,,12689,BAO_0000357,B,,15818,,,
2836,H,,,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,Autocuration,,,,,12689,BAO_0000357,B,,15818,,,
2837,H,,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,Expert,,,,,12689,BAO_0000219,B,,14749,,,
2838,H,,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,Autocuration,,,,,12689,BAO_0000357,B,,15740,,,
2839,D,,,,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,Expert,,,,,12689,BAO_0000357,B,,17133,,Rattus norvegicus,10116.0
2840,H,,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,Autocuration,,,,,12689,BAO_0000357,B,,16532,,,
2841,H,,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,Autocuration,,,,,12689,BAO_0000357,B,,12369,,,
2842,H,,,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,Expert,,,,,12689,BAO_0000219,B,,12369,,,
2843,D,,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,Expert,,,,,12689,BAO_0000019,B,,2309,,Rattus norvegicus,10116.0
2844,H,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,Autocuration,,,,,12689,BAO_0000357,B,,12953,,,
2845,H,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,Autocuration,,,,,12689,BAO_0000019,B,,12953,,,
2846,H,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,Autocuration,,,,,12689,BAO_0000357,B,,12953,,,
2847,H,,,,Binding affinity for 5-hydroxytryptamine 2C receptor,Expert,,,,,12689,BAO_0000357,B,,12953,,,
2848,H,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,Autocuration,,,,,12689,BAO_0000357,B,,17133,,,
2849,H,,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,Autocuration,,,,,12689,BAO_0000019,B,,17211,,,
2850,H,,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,Autocuration,,,,,12689,BAO_0000019,B,,17211,,,
2851,H,,,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,Autocuration,,,,,12689,BAO_0000019,B,,14025,,,
2852,H,,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,Autocuration,,,,,12689,BAO_0000019,B,,14998,,,
2853,H,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,Autocuration,,,,,12689,BAO_0000357,B,,4342,,,
2854,D,,,,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,Expert,,,,,12689,BAO_0000019,B,,13735,,Rattus norvegicus,10116.0
2855,H,,,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,Autocuration,,,,,12689,BAO_0000357,B,,13181,,,
2856,H,,485.0,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,Autocuration,,CHO-K1,,,12689,BAO_0000219,B,,1883,,,
2857,H,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,Autocuration,,,,,12689,BAO_0000357,B,,15194,,,
2858,H,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,Autocuration,,,,,12689,BAO_0000357,B,,15194,,,
2859,H,,,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,Autocuration,,,,,12689,BAO_0000019,F,,14579,,,
2860,H,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,4639,,,
2861,H,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,Expert,,,,,108,BAO_0000357,B,,4820,,,
2862,H,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,Autocuration,,,,,227,BAO_0000357,B,,14442,,,
2863,H,,,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,Autocuration,,,,,227,BAO_0000357,B,,14755,,,
2864,H,,,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,Autocuration,,,,,227,BAO_0000357,B,,14744,,,
2865,D,,,,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,Expert,,,,,227,BAO_0000019,B,,6857,,Homo sapiens,9606.0
2866,H,,,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,Autocuration,,,,,227,BAO_0000357,B,,16209,,,
2867,H,,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,Autocuration,,,,,227,BAO_0000357,B,,15363,,,
2868,H,,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,Autocuration,,,,,227,BAO_0000357,B,,15363,,,
2869,H,,,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,Autocuration,,,,,227,BAO_0000357,B,,15363,,,
2870,H,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,Autocuration,,,,,227,BAO_0000019,B,,17085,,,
2871,D,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,Expert,,,,,227,BAO_0000357,B,,17200,,Homo sapiens,9606.0
2872,D,,722.0,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,Expert,,HEK293,,,227,BAO_0000219,B,,15851,,Homo sapiens,9606.0
2873,D,,722.0,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,Expert,,HEK293,,,227,BAO_0000219,B,,15851,,Homo sapiens,9606.0
2874,D,,449.0,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Expert,,CHO,,,227,BAO_0000219,F,,6857,,Homo sapiens,9606.0
2875,D,,449.0,,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Expert,,CHO,,,227,BAO_0000219,F,,6857,,Homo sapiens,9606.0
2876,H,,722.0,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",Autocuration,,HEK293,,,227,BAO_0000219,B,,15779,,,
2877,H,,722.0,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,Expert,,HEK293,,,227,BAO_0000219,B,,15851,,,
2878,H,,722.0,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",Autocuration,,HEK293,,,227,BAO_0000219,B,,15779,,,
2879,D,,722.0,,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,Expert,,HEK293,,,227,BAO_0000219,B,,14157,,Homo sapiens,9606.0
2880,D,,722.0,,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,Expert,,HEK293,,,227,BAO_0000219,B,,4540,,Homo sapiens,9606.0
2881,H,,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,Autocuration,,,,,227,BAO_0000357,B,,6166,,,
2882,H,,722.0,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,Autocuration,,HEK293,,,227,BAO_0000219,B,,15779,,,
2883,H,,722.0,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,Expert,,HEK293,,,227,BAO_0000219,B,,14391,,,
2884,H,,722.0,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,Expert,,HEK293,,,227,BAO_0000219,B,,3832,,,
2885,H,,722.0,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,Expert,,HEK293,,,227,BAO_0000219,B,,3833,,,
2886,D,,722.0,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,Expert,,HEK293,,,227,BAO_0000219,B,,15851,,Homo sapiens,9606.0
2887,D,,722.0,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,Expert,,HEK293,,,227,BAO_0000219,B,,15851,,Homo sapiens,9606.0
2888,H,,722.0,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,Autocuration,,HEK293,,,227,BAO_0000219,B,,4199,,,
2889,H,,485.0,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,Expert,,CHO-K1,,,227,BAO_0000219,B,,1883,,,
2890,H,,,,Binding affinity against 5-hydroxytryptamine 2B receptor,Expert,,,,,227,BAO_0000357,B,,4321,,,
2891,H,,722.0,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,Autocuration,,HEK293,,,227,BAO_0000219,B,,15146,,,
2892,H,,722.0,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,Autocuration,,HEK293,,,227,BAO_0000219,B,,5213,,,
2893,H,,722.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,Autocuration,,HEK293,,,227,BAO_0000219,B,,14818,,,
2894,H,,722.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",Autocuration,,HEK293,,,227,BAO_0000219,B,,4829,,,
2895,H,,722.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",Autocuration,,HEK293,,,227,BAO_0000219,B,,4829,,,
2896,H,,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,Autocuration,,,,,227,BAO_0000019,B,,14025,,Oryctolagus cuniculus,9986.0
2897,H,,,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,Expert,,,,945.0,12688,BAO_0000019,B,,13463,,,
2898,H,,,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,Expert,,,,945.0,12688,BAO_0000357,B,,7259,,,
2899,H,,,,Affinity against serotonergic receptor in the isolated rat stomach fundus,Autocuration,,,,945.0,12688,BAO_0000357,B,,7259,,,
2900,D,,,,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,Expert,,,,945.0,12688,BAO_0000019,F,,7185,,Rattus norvegicus,10116.0
2901,D,,,,Antagonistic against 5-hydroxytryptamine 2B receptor,Expert,,,,,12688,BAO_0000019,F,,7185,,Rattus norvegicus,10116.0
2902,H,,,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,Autocuration,,,,945.0,12688,BAO_0000019,F,,13267,,,
2903,D,,,,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,Expert,,,,945.0,12688,BAO_0000357,B,,13735,,Rattus norvegicus,10116.0
2904,H,,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,Autocuration,,,,,12688,BAO_0000019,F,,15738,,,
2905,H,,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,Autocuration,,,,,12688,BAO_0000019,F,,15738,,,
2906,H,,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,Autocuration,,,,,12688,BAO_0000019,F,,15738,,,
2907,D,,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Expert,,,,945.0,12688,BAO_0000357,B,,12936,,Rattus norvegicus,10116.0
2908,D,,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Expert,,,,945.0,12688,BAO_0000357,B,,12936,,Rattus norvegicus,10116.0
2909,D,,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Expert,,,,945.0,12688,BAO_0000357,B,,12936,,Rattus norvegicus,10116.0
2910,D,,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Expert,,,,945.0,12688,BAO_0000357,B,,12936,,Rattus norvegicus,10116.0
2911,H,,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Autocuration,,,,945.0,12688,BAO_0000019,F,,16404,,,
2912,H,,,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Expert,,,,945.0,12688,BAO_0000019,F,,16404,,,
2913,H,,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,Autocuration,,,,945.0,12688,BAO_0000019,F,,16404,,,
2914,H,,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,Autocuration,,,,945.0,12688,BAO_0000019,F,,16404,,,
2915,D,,,,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,Expert,,,,945.0,12688,BAO_0000019,F,,16404,,Rattus norvegicus,10116.0
2916,H,,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,Autocuration,,,,1515.0,12688,BAO_0000019,F,,16404,,,
2917,H,,,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,Autocuration,,,,,12688,BAO_0000357,B,,7483,,,
2918,H,,,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,Expert,,,,,12688,BAO_0000357,B,,7483,,,
2919,H,,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,Autocuration,,,,,12688,BAO_0000357,B,,7483,,,
2920,H,,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,Autocuration,,,,,12688,BAO_0000357,B,,7483,,,
2922,D,,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Autocuration,,,,945.0,12688,BAO_0000019,F,,16404,,Rattus norvegicus,10116.0
2923,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,227,BAO_0000357,B,,6347,,,
2924,H,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,Autocuration,,,,,227,BAO_0000357,B,,4373,,,
2925,H,,,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,Autocuration,,,,,227,BAO_0000357,B,,4373,,,
2926,H,,,,Evaluated for the binding affinity to 5-HT 2B receptor,Autocuration,,,,,227,BAO_0000357,B,,4687,,,
2927,H,,,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,Autocuration,,,,,227,BAO_0000357,B,,16946,,,
2928,H,,,,Binding affinities against 5-hydroxytryptamine 2B receptor,Autocuration,,,,,227,BAO_0000357,B,,16633,,,
2929,H,,,,Binding affinities towards 5-hydroxytryptamine 2B receptor,Autocuration,,,,,227,BAO_0000357,B,,16633,,,
2930,H,,,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,Autocuration,,,,,227,BAO_0000357,B,,16633,,,
2931,H,,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,Expert,,,,,108,BAO_0000357,B,,15026,,,
2932,H,,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,Autocuration,,,,,108,BAO_0000357,B,,15738,,Bos taurus,9913.0
2933,H,,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,Autocuration,,,,,108,BAO_0000357,B,,15738,,Bos taurus,9913.0
2934,H,,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,Autocuration,,,,,108,BAO_0000357,B,,15738,,Bos taurus,9913.0
2935,H,,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,Autocuration,,,,,108,BAO_0000357,B,,15738,,Bos taurus,9913.0
2936,H,,,,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,Expert,,,,,108,BAO_0000357,B,,16404,,Bos taurus,9913.0
2937,H,,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,Expert,,,,,108,BAO_0000357,B,,15026,,Bos taurus,9913.0
2938,H,,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,Autocuration,,,,,108,BAO_0000357,B,,15738,,Bos taurus,9913.0
2939,H,,,,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,Autocuration,,,,,108,BAO_0000019,B,,16312,,Cavia porcellus,10141.0
2940,D,,,,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,Intermediate,,,,2435.0,20033,BAO_0000357,B,,5486,,Cavia porcellus,10141.0
2941,H,,,,Binding affinity against 5-HT1A receptor,Autocuration,,,,,51,BAO_0000357,B,,5254,,,
2942,H,,449.0,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,Expert,,CHO,,,108,BAO_0000219,F,,3857,,,
2943,D,,449.0,,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,Expert,,CHO,,,108,BAO_0000219,F,,6857,,Homo sapiens,9606.0
2944,H,,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,Autocuration,,,,,108,BAO_0000219,F,,4176,,,
2945,H,,449.0,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,Autocuration,,CHO,,,108,BAO_0000219,B,,6347,,,
2946,H,,449.0,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",Autocuration,,CHO,,,108,BAO_0000219,B,,6347,,,
2947,D,,,,Inhibition of human 5-hydroxytryptamine 2C receptor,Expert,,,,,108,BAO_0000357,B,,16146,,Homo sapiens,9606.0
2948,H,,,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),Autocuration,,,,,108,BAO_0000357,B,,3805,,,
2949,H,,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,Autocuration,,,,,108,BAO_0000019,B,,3857,,,
2950,H,,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,5635,,,
2951,H,,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,Autocuration,,,,,108,BAO_0000357,B,,5635,,,
2952,H,,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,Autocuration,,,,,108,BAO_0000357,B,,5635,,,
2953,H,,449.0,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,Expert,,CHO,,,108,BAO_0000219,B,,4012,,,
2954,H,,449.0,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,Expert,,CHO,,,108,BAO_0000219,B,,6366,,,
2955,H,,449.0,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,Expert,,CHO,,,108,BAO_0000219,B,,15949,,,
2956,H,,449.0,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,Autocuration,,CHO,,,108,BAO_0000219,B,,17211,,,
2957,D,,,,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,Expert,,,,,108,BAO_0000357,B,,6491,,Homo sapiens,9606.0
2958,H,,,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,Autocuration,,,,,108,BAO_0000019,F,,14093,,,
2959,H,,,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,Autocuration,,,,,108,BAO_0000019,F,,13481,,,
2960,H,,449.0,,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,Expert,,CHO,,,108,BAO_0000219,B,,6347,,Rattus norvegicus,10116.0
2961,H,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,Autocuration,,,,,108,BAO_0000019,F,,14093,,,
2962,H,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,Autocuration,,,,,108,BAO_0000019,F,,14093,,,
2963,H,,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,Autocuration,,,,,108,BAO_0000019,F,,13481,,,
2964,H,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,Autocuration,,,,,108,BAO_0000357,B,,14442,,,
2965,H,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,Autocuration,,,,,108,BAO_0000357,B,,14442,,,
2966,H,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,Autocuration,,,,,108,BAO_0000357,B,,14442,,,
2967,H,,,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,Autocuration,,,,,108,BAO_0000357,B,,14755,,,
2968,H,,,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,Autocuration,,,,,108,BAO_0000357,B,,14744,,,
2969,H,,449.0,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,Expert,,CHO,,,108,BAO_0000219,B,,16659,,,
2970,D,,,,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,Expert,,,,,108,BAO_0000019,B,,6857,,Homo sapiens,9606.0
2971,H,,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,Expert,,,,,108,BAO_0000357,B,,5635,,,
2972,D,,,,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,Expert,,,,,108,BAO_0000357,B,,4234,,Homo sapiens,9606.0
2973,H,,,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,Autocuration,,,,,108,BAO_0000357,B,,16209,,,
2974,D,,,,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,Autocuration,,,,,104698,BAO_0000249,B,Membranes,5778,,Rattus norvegicus,10116.0
2975,H,,,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,Autocuration,,,,,104698,BAO_0000223,B,,5094,,,
2976,D,,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,Autocuration,,,,,104698,BAO_0000019,B,,809,,Rattus norvegicus,10116.0
2977,H,,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,Autocuration,,,,,104698,BAO_0000019,B,,1578,,,
2978,H,,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,Autocuration,,,,,104698,BAO_0000019,B,,809,,,
2979,H,,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,Autocuration,,,,,104698,BAO_0000219,B,,12469,,,
2980,H,,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,Autocuration,,,,,104698,BAO_0000019,B,,14290,,,
2981,H,,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,Autocuration,,,,,104698,BAO_0000019,B,,14290,,,
2982,H,,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,Autocuration,,,,,104698,BAO_0000223,B,,10609,,,
2983,H,,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,Autocuration,,,,,104698,BAO_0000223,B,,10609,,,
2984,H,,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,Autocuration,,,,,104698,BAO_0000223,B,,10609,,,
2985,H,,,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",Autocuration,,,,,104698,BAO_0000249,B,,15253,,,
2986,H,,,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",Autocuration,,,,,104698,BAO_0000249,B,,15253,,,
2987,H,,,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,Autocuration,,,,,104698,BAO_0000249,B,Membranes,11683,,,
2988,H,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000223,B,,12092,,,
2989,H,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,Autocuration,,,,,104698,BAO_0000019,B,,1946,,,
2990,H,,,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,Autocuration,,,,,104698,BAO_0000223,B,,11623,,,
2991,H,,,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,Autocuration,,,,,104698,BAO_0000223,B,,11623,,,
2992,H,,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,Autocuration,,,,,104698,BAO_0000019,B,,14788,,,
2993,D,,,,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,Autocuration,,,,,104698,BAO_0000019,B,,5432,,Rattus norvegicus,10116.0
2994,H,,,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,Autocuration,,,,,104698,BAO_0000249,B,,14826,,,
2995,H,,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000223,B,,2222,,,
2996,H,,,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,Autocuration,,,,,104698,BAO_0000019,B,,11963,,,
2997,H,,,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,Autocuration,,,,,104698,BAO_0000019,B,,14145,,,
2998,H,,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,Autocuration,,,,,104698,BAO_0000019,B,,17819,,,
2999,H,,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,Autocuration,,,,,104698,BAO_0000249,B,,10394,,,
3000,H,,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,Autocuration,,,,,104698,BAO_0000249,B,,10394,,,
3001,H,,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,Autocuration,,,,,104698,BAO_0000019,B,,15034,,,
3002,H,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,Autocuration,,,,,104698,BAO_0000019,B,,691,,,
3003,H,,,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,Autocuration,,,,,104698,BAO_0000249,B,Membranes,12092,,,
3004,D,,,,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000223,B,,11752,,Rattus norvegicus,10116.0
3005,H,,,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,Autocuration,,,,955.0,104698,BAO_0000221,B,,11752,,,
3006,H,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,Autocuration,,,,,104698,BAO_0000019,B,,301,,,
3007,H,,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,Autocuration,,,,,104698,BAO_0000223,B,,16532,,,
3008,H,,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,Autocuration,,,,,104698,BAO_0000223,B,,16532,,,
3009,H,,,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,Autocuration,,,,,104698,BAO_0000223,B,,12092,,,
3010,H,,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,Autocuration,,,,,104698,BAO_0000223,B,,11684,,,
3011,H,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,Autocuration,,,,,104698,BAO_0000223,B,,11684,,,
3012,H,,,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,Autocuration,,,,,104698,BAO_0000019,B,,12953,,,
3013,H,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,Autocuration,,,,,104698,BAO_0000019,B,,12953,,,
3014,H,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,Autocuration,,,,,104698,BAO_0000223,B,,12953,,,
3015,H,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,Autocuration,,,,,104698,BAO_0000019,B,,12861,,,
3016,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3017,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3018,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3019,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3020,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3021,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3022,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3023,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3024,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3025,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3026,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3027,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3028,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3029,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3030,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3031,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3032,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3033,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3034,H,,,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,Autocuration,,,,,104698,BAO_0000019,F,,10609,,,
3035,H,,,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,Autocuration,,,,,104698,BAO_0000019,B,,12861,,,
3036,D,,,,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000019,B,,12861,,Rattus norvegicus,10116.0
3037,H,,,,Binding activity radioligand.,Autocuration,,,,,104698,BAO_0000223,B,,12861,,,
3038,H,,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,Autocuration,,,,,104698,BAO_0000249,B,Brain membranes,10728,,,
3039,H,,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,Autocuration,,,,,104698,BAO_0000249,B,Brain membranes,10728,,,
3040,H,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,Autocuration,,,,,108,BAO_0000357,B,,5163,,,
3041,H,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,Autocuration,,,,,108,BAO_0000357,B,,5163,,,
3042,H,,,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,Autocuration,,,,,108,BAO_0000357,B,,6011,,,
3043,H,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,5014,,,
3044,H,,,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,5635,,,
3045,H,,,,Affinity for 5-hydroxytryptamine 2C receptor,Expert,,,,,108,BAO_0000357,B,,5163,,,
3046,H,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,Autocuration,,,,,108,BAO_0000357,B,,6841,,,
3047,H,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,Expert,,,,,108,BAO_0000357,B,,6119,,,
3048,H,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,Autocuration,,,,,108,BAO_0000357,B,,4373,,,
3049,H,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,Autocuration,,,,,108,BAO_0000357,B,,1633,,,
3050,H,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,Expert,,,,,108,BAO_0000357,B,,1633,,,
3051,H,,,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,Autocuration,,,,,108,BAO_0000357,B,,4373,,,
3052,H,,,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,Expert,,,,,108,BAO_0000357,B,,6576,,,
3053,H,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,4687,,,
3054,H,,,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,Autocuration,,,,,108,BAO_0000357,B,,12146,,,
3055,H,,,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,Autocuration,,,,,108,BAO_0000357,B,,12146,,,
3056,H,,,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,16946,,,
3057,H,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,14159,,,
3058,H,,,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,Autocuration,,,,,108,BAO_0000357,B,,16700,,,
3059,H,,,,Affinity against 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,3269,,,
3060,D,,,,Binding affinity against 5-hydroxytryptamine 2C receptor,Expert,,,,,108,BAO_0000357,B,,1274,,Homo sapiens,9606.0
3061,H,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,Autocuration,,,,,108,BAO_0000357,B,,1317,,,
3062,H,,,,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,Autocuration,,,,,144,BAO_0000357,B,,5834,,Bos taurus,9913.0
3063,H,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,Autocuration,,,,,144,BAO_0000357,B,,11147,,Bos taurus,9913.0
3064,H,,,,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,Expert,,,,,104714,BAO_0000019,F,,14145,,Cavia porcellus,10141.0
3065,H,,,,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,Autocuration,,,,2116.0,104714,BAO_0000221,B,,10561,,Cavia porcellus,10141.0
3066,H,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,Autocuration,,,,,104714,BAO_0000019,F,,15847,,Cavia porcellus,10141.0
3067,H,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,Autocuration,,,,,104714,BAO_0000019,F,,15847,,Cavia porcellus,10141.0
3068,H,,,,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,Autocuration,,,,2116.0,104714,BAO_0000221,B,,10561,,Cavia porcellus,10141.0
3069,H,,,,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,Autocuration,,,,2116.0,104714,BAO_0000221,B,,11454,,Cavia porcellus,10141.0
3070,H,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,Autocuration,,,,,104714,BAO_0000019,F,,4639,,Cavia porcellus,10141.0
3071,H,,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,Autocuration,,,,,104714,BAO_0000019,F,,4639,,Cavia porcellus,10141.0
3072,H,,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,Autocuration,,,,,104714,BAO_0000019,F,,4639,,Cavia porcellus,10141.0
3073,H,,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,Autocuration,,,,,104714,BAO_0000019,F,,4639,,Cavia porcellus,10141.0
3074,H,,,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,Autocuration,,,,,104714,BAO_0000019,F,,4639,,Cavia porcellus,10141.0
3075,H,,,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,Autocuration,,,,,104714,BAO_0000019,F,,4639,,Cavia porcellus,10141.0
3076,H,,,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",Autocuration,,,,2116.0,104714,BAO_0000221,F,,15253,,Cavia porcellus,10141.0
3077,H,,,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",Autocuration,,,,2116.0,104714,BAO_0000221,F,,15253,,Cavia porcellus,10141.0
3078,H,,,,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,Autocuration,,,,2116.0,104714,BAO_0000221,F,,11963,,Cavia porcellus,10141.0
3079,H,,,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,Autocuration,,,,2116.0,104714,BAO_0000221,B,,1946,,Cavia porcellus,10141.0
3080,H,,,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,Autocuration,,,,2116.0,104714,BAO_0000221,B,,1946,,Cavia porcellus,10141.0
3081,H,,,,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,Autocuration,,,,,104714,BAO_0000223,B,,12045,,Cavia porcellus,10141.0
3082,H,,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Autocuration,,,,2116.0,104714,BAO_0000221,B,,1559,,Cavia porcellus,10141.0
3083,H,,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Autocuration,,,,2116.0,104714,BAO_0000221,F,,273,,Cavia porcellus,10141.0
3084,H,,,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),Autocuration,,,,2116.0,104714,BAO_0000221,F,,273,,Cavia porcellus,10141.0
3085,H,,,,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,Autocuration,,,,2116.0,104714,BAO_0000221,F,,188,,Cavia porcellus,10141.0
3086,H,,,,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,Autocuration,,,,2116.0,104714,BAO_0000221,F,,12919,,Cavia porcellus,10141.0
3087,H,,,,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,Autocuration,,,,2116.0,104714,BAO_0000221,F,,12918,,Cavia porcellus,10141.0
3088,H,,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Autocuration,,,,2116.0,104714,BAO_0000221,B,,1559,,Cavia porcellus,10141.0
3089,H,,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Autocuration,,,,2116.0,104714,BAO_0000221,F,,273,,Cavia porcellus,10141.0
3090,H,,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Autocuration,,,,2116.0,104714,BAO_0000221,B,,1559,,Cavia porcellus,10141.0
3091,H,,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,Autocuration,,,,2116.0,104714,BAO_0000221,B,,1559,,Cavia porcellus,10141.0
3092,H,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,Autocuration,,,,2116.0,104714,BAO_0000221,B,,1559,,Cavia porcellus,10141.0
3093,H,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,Autocuration,,,,2116.0,104714,BAO_0000221,B,,14424,,Cavia porcellus,10141.0
3094,U,,,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,Autocuration,,,,,22226,BAO_0000019,B,,13181,,Cavia porcellus,10141.0
3095,H,,,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,Autocuration,,,,,51,BAO_0000357,B,,5486,,,
3096,D,,,,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,Expert,,,,,104714,BAO_0000223,B,,6491,,Homo sapiens,9606.0
3097,H,,,,Binding affinity towards 5-HT3 receptor,Autocuration,,,,,104714,BAO_0000223,B,,6013,,,
3098,H,,,,Binding activity radioligand.,Autocuration,,,,,104714,BAO_0000223,B,,12861,,,
3099,H,,,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,Autocuration,,,,,104714,BAO_0000019,B,,12861,,,
3100,H,,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104714,BAO_0000223,B,,5104,,,
3101,H,,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104714,BAO_0000223,B,,5105,,,
3102,H,,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,Autocuration,,,,,104714,BAO_0000223,B,,5104,,,
3103,U,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,Autocuration,,,,,22226,BAO_0000019,B,,3935,,,
3104,H,,433.0,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,Expert,,NG108-15,,,105030,BAO_0000219,B,,13657,,,
3105,H,,,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",Autocuration,,,,,105030,BAO_0000218,B,,10369,In vivo,,
3106,H,,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),Autocuration,,,,,105030,BAO_0000019,B,,10369,,,
3107,H,,,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,Autocuration,,,,,105030,BAO_0000224,B,,12918,,,
3108,H,,,,Compound was evaluated for the binding affinity at 5- HT3 receptor,Autocuration,,,,,105030,BAO_0000224,B,,12918,,,
3109,H,,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),Autocuration,,,,,105030,BAO_0000019,B,,10369,,,
3110,H,,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,Autocuration,,,,,105030,BAO_0000019,B,,773,,,
3111,H,,,,5-hydroxytryptamine 3 receptor agonism in mouse,Autocuration,,,,,105030,BAO_0000218,F,,12918,,,
3112,H,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,Autocuration,,,,,105030,BAO_0000219,B,,10561,,,
3113,H,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,Autocuration,,,,,105030,BAO_0000019,B,,12827,,,
3114,H,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,Autocuration,,,,,105030,BAO_0000019,B,,12827,,,
3115,H,,,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,Autocuration,,,,,105030,BAO_0000224,B,,12918,,,
3116,H,,,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,Autocuration,,,,,105030,BAO_0000219,B,,273,,,
3117,H,,,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,Autocuration,,,,,105030,BAO_0000219,B,,273,,,
3118,H,,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,Autocuration,,,,,105030,BAO_0000224,B,,10561,,,
3119,H,,,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,Autocuration,,,,,105030,BAO_0000219,B,,5033,In vitro,,
3120,H,,339.0,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,Autocuration,,N1E-115,,,105030,BAO_0000219,B,,16429,,,
3121,H,,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,Autocuration,,,,,11765,BAO_0000019,B,,10322,,,
3122,H,,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,Autocuration,,,,,11765,BAO_0000219,B,,14331,,,
3123,D,,,,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,Autocuration,,,,,10630,BAO_0000357,B,,13462,,Mus musculus,10090.0
3124,H,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,Autocuration,,,,,17106,BAO_0000019,B,,12861,,,
3125,H,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,Autocuration,,,,,144,BAO_0000357,B,,15086,,Sus scrofa,9823.0
3126,H,,,,Binding activity radioligand.,Autocuration,,,,,144,BAO_0000357,B,,12861,,Sus scrofa,9823.0
3127,H,,,,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,Autocuration,,,,,104714,BAO_0000223,B,,10561,,Oryctolagus cuniculus,9986.0
3128,H,,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,Autocuration,,,,,104714,BAO_0000223,B,,10561,,Oryctolagus cuniculus,9986.0
3129,H,,,,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,Autocuration,,,,,104714,BAO_0000223,B,,10561,,Oryctolagus cuniculus,9986.0
3130,H,,,,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,Autocuration,,,,,104714,BAO_0000019,B,,10561,,Oryctolagus cuniculus,9986.0
3131,H,,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),Autocuration,,,,,104714,BAO_0000019,F,,273,,Oryctolagus cuniculus,9986.0
3132,H,,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),Autocuration,,,,,104714,BAO_0000019,F,,273,,Oryctolagus cuniculus,9986.0
3133,H,,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Autocuration,,,,2116.0,104714,BAO_0000221,F,,273,,Oryctolagus cuniculus,9986.0
3134,H,,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),Autocuration,,,,,104714,BAO_0000019,F,,273,,Oryctolagus cuniculus,9986.0
3135,H,,,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),Autocuration,,,,,104714,BAO_0000019,F,,273,,Oryctolagus cuniculus,9986.0
3136,H,,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),Autocuration,,,,,104714,BAO_0000019,F,,273,,Oryctolagus cuniculus,9986.0
3137,H,,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),Autocuration,,,,,104714,BAO_0000019,F,,273,,Oryctolagus cuniculus,9986.0
3138,H,,449.0,,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,Autocuration,,CHO,,,104714,BAO_0000219,B,,13047,,Oryctolagus cuniculus,9986.0
3139,D,,,,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000019,B,,1650,,Rattus norvegicus,10116.0
3140,H,,,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),Autocuration,,,,,12020,BAO_0000019,B,,16288,,,
3141,H,,,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),Autocuration,,,,,12020,BAO_0000357,B,,16288,,,
3142,D,,,,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,Autocuration,,,,,104698,BAO_0000019,B,,10254,,Rattus norvegicus,10116.0
3143,H,,,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",Autocuration,,,,,104698,BAO_0000019,B,,14532,,,
3144,H,,,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",Autocuration,,,,948.0,104698,BAO_0000218,F,,13392,In vivo,,
3145,H,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",Autocuration,,,,948.0,104698,BAO_0000019,F,,13392,,,
3146,H,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",Autocuration,,,,948.0,104698,BAO_0000019,F,,13392,,,
3147,H,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",Autocuration,,,,948.0,104698,BAO_0000019,F,,13392,,,
3148,H,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",Autocuration,,,,948.0,104698,BAO_0000019,F,,13392,,,
3149,H,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",Autocuration,,,,,104698,BAO_0000019,F,,13392,,,
3150,H,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",Autocuration,,,,,104698,BAO_0000019,F,,13392,,,
3151,H,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",Autocuration,,,,,104698,BAO_0000019,F,,13392,,,
3152,H,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",Autocuration,,,,,104698,BAO_0000019,F,,13392,,,
3153,D,,,,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),Autocuration,,,,,104698,BAO_0000218,F,,1089,In vivo,Rattus norvegicus,10116.0
3154,H,,,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),Autocuration,,,,,104698,BAO_0000218,F,,1089,In vivo,,
3155,D,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,Rattus norvegicus,10116.0
3156,D,,,,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,Autocuration,,,,,104698,BAO_0000019,F,,11454,,Rattus norvegicus,10116.0
3157,D,,,,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,Autocuration,,,,,104698,BAO_0000218,F,,12205,In vivo,Rattus norvegicus,10116.0
3158,D,,,,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),Autocuration,,,,,104698,BAO_0000019,F,,1089,,Rattus norvegicus,10116.0
3159,H,,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,Autocuration,,,,,104698,BAO_0000019,B,,5094,,,
3160,D,,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000019,B,,2622,,Rattus norvegicus,10116.0
3161,H,,,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000223,B,,245,,,
3162,H,,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,Autocuration,,,,,104698,BAO_0000019,B,,14788,,,
3163,H,,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,Autocuration,,,,,104698,BAO_0000019,B,,14788,,,
3164,H,,,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,Autocuration,,,,,104698,BAO_0000249,B,,3020,,,
3165,H,,,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,Autocuration,,,,,104698,BAO_0000019,B,,1742,,,
3166,H,,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,Autocuration,,,,955.0,104698,BAO_0000249,B,,17394,,,
3167,H,,,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,Autocuration,,,,955.0,104698,BAO_0000221,B,,17394,,,
3168,H,,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,Autocuration,,,,,104698,BAO_0000249,B,,17394,,,
3169,H,,,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,Autocuration,,,,,104698,BAO_0000249,B,,14286,,,
3170,H,,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,Autocuration,,,,,104698,BAO_0000019,B,,14178,,,
3171,D,,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,Autocuration,,,,,104698,BAO_0000019,B,,14178,,Rattus norvegicus,10116.0
3172,D,,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,Autocuration,,,,,104698,BAO_0000019,B,,14178,,Rattus norvegicus,10116.0
3173,D,,,,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000223,B,,14178,,Rattus norvegicus,10116.0
3174,H,,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,Autocuration,,,,,104698,BAO_0000019,B,,15034,,,
3175,H,,,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",Autocuration,,,,,104698,BAO_0000249,B,Membranes,1089,,,
3176,D,,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,Autocuration,,,,,104698,BAO_0000019,B,,1089,,Rattus norvegicus,10116.0
3177,H,,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,Autocuration,,,,,104698,BAO_0000223,B,,16532,,,
3178,D,,,,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000223,B,,12801,,Rattus norvegicus,10116.0
3179,H,,433.0,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),Autocuration,,NG108-15,,,104698,BAO_0000219,B,,15194,,,
3180,H,,433.0,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,Autocuration,,NG108-15,,,104698,BAO_0000219,B,,15194,,,
3181,H,,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,Autocuration,,,,,104698,BAO_0000019,B,,15194,,,
3182,H,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,Autocuration,,,,,104698,BAO_0000019,B,,15194,,,
3183,H,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,Autocuration,,,,,104698,BAO_0000019,B,,15194,,,
3184,H,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,Autocuration,,,,,104698,BAO_0000019,B,,15194,,,
3185,H,,,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,Autocuration,,,,,104698,BAO_0000019,F,,10610,,,
3186,D,,,,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,Autocuration,,,,,104698,BAO_0000019,F,,10355,,Rattus norvegicus,10116.0
3187,H,,,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",Autocuration,,,,,104698,BAO_0000019,F,,691,,,
3188,H,,,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,Autocuration,,,,,104698,BAO_0000218,F,,10611,,,
3189,H,,,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,Autocuration,,,,,104698,BAO_0000218,F,,12801,In vivo,,
3190,H,,,,Inhibition of 5-HT evoked reflex bradycardia in rat.,Autocuration,,,,,104698,BAO_0000218,F,,10609,,,
3191,H,,,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3192,H,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3193,H,,,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3194,D,,,,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,Rattus norvegicus,10116.0
3195,H,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3196,H,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3197,H,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3198,H,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3199,H,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3200,H,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3201,H,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3202,H,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3203,H,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3204,H,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3205,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3206,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3207,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3208,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3209,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3210,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3211,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3212,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3213,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3214,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3215,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3216,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3217,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3218,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3219,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,In vivo,,
3220,H,,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",Autocuration,,,,,104698,BAO_0000218,F,,670,,,
3221,H,,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",Autocuration,,,,,104698,BAO_0000218,F,,670,,,
3222,H,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,Autocuration,,,,,104698,BAO_0000218,F,,10321,In vivo,,
3223,H,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,Autocuration,,,,,104698,BAO_0000218,F,,10321,In vivo,,
3224,H,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,Autocuration,,,,,104698,BAO_0000218,F,,10321,In vivo,,
3225,H,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,Autocuration,,,,,104698,BAO_0000218,F,,10321,In vivo,,
3226,H,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,Autocuration,,,,,104698,BAO_0000218,F,,10321,In vivo,,
3227,H,,,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),Autocuration,,,,,104698,BAO_0000218,F,,10322,In vivo,,
3228,H,,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,Autocuration,,,,,104698,BAO_0000019,F,,15412,,,
3229,H,,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,Autocuration,,,,,104698,BAO_0000019,F,,15412,,,
3230,D,,,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000223,B,,15412,,Rattus norvegicus,10116.0
3231,H,,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,Autocuration,,,,,104698,BAO_0000019,F,,15412,,,
3232,D,,,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,Intermediate,,,,10000000.0,104698,BAO_0000221,B,,15412,,,
3233,D,,,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,Autocuration,,,,,104698,BAO_0000019,B,,15412,,Rattus norvegicus,10116.0
3234,D,,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000019,B,,17394,,Rattus norvegicus,10116.0
3235,H,,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000223,B,,12457,,,
3236,H,,,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000019,B,,12457,,,
3237,H,,,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,Autocuration,,,,,104698,BAO_0000019,B,,12205,,,
3238,H,,,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,Autocuration,,,,,104698,BAO_0000019,B,,14532,,,
3239,H,,,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,Autocuration,,,,,104698,BAO_0000019,B,,1122,,,
3240,H,,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,Autocuration,,,,,104698,BAO_0000019,B,,5094,,,
3241,D,,,,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,Intermediate,,,,2116.0,20033,BAO_0000221,F,,809,,Cavia porcellus,10141.0
3242,D,,,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,Intermediate,,,,2116.0,20033,BAO_0000221,F,,809,,Cavia porcellus,10141.0
3243,D,,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",Intermediate,,,,2116.0,20033,BAO_0000221,F,,14290,,Cavia porcellus,10141.0
3244,D,,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",Intermediate,,,,2116.0,20033,BAO_0000221,F,,14290,,Cavia porcellus,10141.0
3245,D,,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",Intermediate,,,,2116.0,20033,BAO_0000221,F,,14290,,Cavia porcellus,10141.0
3246,D,,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",Intermediate,,,,2116.0,20033,BAO_0000221,F,,14290,,Cavia porcellus,10141.0
3247,D,,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",Intermediate,,,,2116.0,20033,BAO_0000221,F,,14290,,Cavia porcellus,10141.0
3248,D,,,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,Intermediate,,,,2116.0,20033,BAO_0000221,F,,13961,,Cavia porcellus,10141.0
3249,D,,,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,Intermediate,,,,2116.0,20033,BAO_0000221,F,,13961,,Cavia porcellus,10141.0
3250,D,,,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,Intermediate,,,,2116.0,20033,BAO_0000221,F,,809,,Cavia porcellus,10141.0
3251,D,,,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,Intermediate,,,,2116.0,20033,BAO_0000221,F,,809,,Cavia porcellus,10141.0
3252,D,,,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,Intermediate,,,,2116.0,20033,BAO_0000221,F,,809,,Cavia porcellus,10141.0
3253,D,,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",Intermediate,,,,2116.0,20033,BAO_0000221,F,,14290,,Cavia porcellus,10141.0
3254,D,,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",Intermediate,,,,2116.0,20033,BAO_0000221,F,,14290,,Cavia porcellus,10141.0
3255,D,,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",Intermediate,,,,2116.0,20033,BAO_0000221,F,,14290,,Cavia porcellus,10141.0
3256,D,,,,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,Intermediate,,,,2116.0,20033,BAO_0000221,F,,14290,,Cavia porcellus,10141.0
3257,D,,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",Intermediate,,,,2116.0,20033,BAO_0000221,F,,14290,,Cavia porcellus,10141.0
3258,D,,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",Intermediate,,,,2116.0,20033,BAO_0000221,F,,14290,,Cavia porcellus,10141.0
3259,D,,,,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,Intermediate,,,,,20033,BAO_0000357,B,,15034,,Cavia porcellus,10141.0
3260,D,,,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,Intermediate,,,,2435.0,20033,BAO_0000249,B,,5094,,Cavia porcellus,10141.0
3261,D,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,Intermediate,,,,2435.0,20033,BAO_0000249,B,,5094,,Cavia porcellus,10141.0
3262,D,,,,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,Intermediate,,,,2435.0,20033,BAO_0000357,B,,5399,,Cavia porcellus,10141.0
3263,D,,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,Intermediate,,,,2435.0,20033,BAO_0000357,B,,17394,,Cavia porcellus,10141.0
3264,D,,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,Intermediate,,,,2435.0,20033,BAO_0000357,B,,17394,,Cavia porcellus,10141.0
3265,D,,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,Intermediate,,,,2435.0,20033,BAO_0000357,B,,17394,,Cavia porcellus,10141.0
3266,D,,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,Intermediate,,,,2116.0,20033,BAO_0000221,F,,13961,,Cavia porcellus,10141.0
3267,D,,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,Intermediate,,,,2116.0,20033,BAO_0000221,F,,13961,,Cavia porcellus,10141.0
3268,D,,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,Intermediate,,,,2116.0,20033,BAO_0000221,F,,13961,,Cavia porcellus,10141.0
3269,D,,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,Intermediate,,,,,20033,BAO_0000357,B,,16946,,Cavia porcellus,10141.0
3270,D,,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,Intermediate,,,,,20033,BAO_0000357,B,,16946,,Cavia porcellus,10141.0
3271,D,,,,Agonistic activity against 5-hydroxytryptamine 4 receptor,Intermediate,,,,,20033,BAO_0000019,F,,15034,,Cavia porcellus,10141.0
3272,D,,,,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,Intermediate,,,,,20033,BAO_0000019,F,,15034,,Cavia porcellus,10141.0
3273,D,,,,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,Intermediate,,,,,20033,BAO_0000019,F,,12918,,Cavia porcellus,10141.0
3274,D,,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,Intermediate,,,,,20033,BAO_0000357,B,,16946,,Cavia porcellus,10141.0
3275,D,,,,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,Intermediate,,,,2435.0,20033,BAO_0000357,B,,17394,,Cavia porcellus,10141.0
3276,D,,,,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,Intermediate,,,,2435.0,20033,BAO_0000357,B,,15034,,Cavia porcellus,10141.0
3277,D,,,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,Intermediate,,,,2435.0,20033,BAO_0000249,B,,5094,,Cavia porcellus,10141.0
3278,D,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,Intermediate,,,,2435.0,20033,BAO_0000249,B,,5094,,Cavia porcellus,10141.0
3279,D,,,,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,Intermediate,,,,2116.0,20033,BAO_0000221,B,,17358,,Cavia porcellus,10141.0
3280,D,,,,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,Expert,,,,,20033,BAO_0000357,B,,12953,,Cavia porcellus,10141.0
3281,D,,,,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,Intermediate,,,,,20033,BAO_0000357,B,,12953,,Cavia porcellus,10141.0
3282,D,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,Intermediate,,,,,20033,BAO_0000357,B,,12953,,Cavia porcellus,10141.0
3283,D,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,Intermediate,,,,,20033,BAO_0000357,B,,12953,,Cavia porcellus,10141.0
3284,D,,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,Intermediate,,,,2116.0,20033,BAO_0000221,F,,273,,Cavia porcellus,10141.0
3285,D,,,,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,Intermediate,,,,2116.0,20033,BAO_0000221,F,,12918,,Cavia porcellus,10141.0
3286,D,,,,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,Intermediate,,,,2116.0,20033,BAO_0000221,F,,12919,,Cavia porcellus,10141.0
3287,D,,,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,Intermediate,,,,2116.0,20033,BAO_0000221,F,,273,,Cavia porcellus,10141.0
3288,D,,,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,Intermediate,,,,2116.0,20033,BAO_0000221,F,,273,,Cavia porcellus,10141.0
3289,D,,,,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,Intermediate,,,,,20033,BAO_0000357,B,,13181,,Cavia porcellus,10141.0
3290,H,,,,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,Autocuration,,,,,168,BAO_0000357,B,,13181,,Cavia porcellus,10141.0
3291,D,,,,Antagonistic activity against 5-hydroxytryptamine 4 receptor,Intermediate,,,,,20033,BAO_0000019,F,,15034,,Cavia porcellus,10141.0
3292,D,,,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,Intermediate,,,,,20033,BAO_0000357,B,,5033,,Cavia porcellus,10141.0
3293,D,,,,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,Intermediate,,,,,20033,BAO_0000019,B,,1980,,Cavia porcellus,10141.0
3294,H,,722.0,,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,Autocuration,,HEK293,,,168,BAO_0000219,B,,13181,,Cavia porcellus,10141.0
3295,D,,,,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,Intermediate,,,,,20033,BAO_0000019,B,,14287,,Cavia porcellus,10141.0
3296,D,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,Intermediate,,,,,20033,BAO_0000357,B,,1317,,Cavia porcellus,10141.0
3297,D,,,,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,Intermediate,,,,,20033,BAO_0000357,B,,15316,,Cavia porcellus,10141.0
3298,D,,,,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,Intermediate,,,,2435.0,20033,BAO_0000357,B,,16429,,Cavia porcellus,10141.0
3299,D,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,Intermediate,,,,10000000.0,20033,BAO_0000221,B,,14818,,Cavia porcellus,10141.0
3300,D,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,Intermediate,,,,,20033,BAO_0000357,B,,15194,,Cavia porcellus,10141.0
3301,D,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,Intermediate,,,,,20033,BAO_0000357,B,,15194,,Cavia porcellus,10141.0
3302,D,,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,Intermediate,,,,2116.0,20033,BAO_0000221,F,,13961,,Cavia porcellus,10141.0
3303,H,,,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,Autocuration,,,,,108,BAO_0000357,B,,5486,,,
3304,H,,,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,Autocuration,,,,,168,BAO_0000357,B,,16209,,,
3305,H,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,Autocuration,,,,,168,BAO_0000019,B,,17085,,,
3306,H,,308.0,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,Autocuration,,HeLa,,,168,BAO_0000219,B,,4199,,,
3307,H,,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,Autocuration,,,,,168,BAO_0000357,B,,15146,,,
3308,H,,,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,Autocuration,,,,,168,BAO_0000357,B,,5213,,,
3309,H,,308.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",Autocuration,,HeLa,,,168,BAO_0000219,B,,4829,,,
3310,H,,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,Autocuration,,,,,10622,BAO_0000357,B,,17358,,,
3311,H,,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,Autocuration,,,,,10622,BAO_0000357,B,,17358,,,
3312,H,,,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,Autocuration,,,,,10622,BAO_0000219,B,,16946,,,
3313,H,,,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,Autocuration,,,,,10622,BAO_0000357,B,,17358,,,
3314,H,,,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,Autocuration,,,,2081.0,11249,BAO_0000019,F,,268,,,
3315,H,,,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,Autocuration,,,,2081.0,11249,BAO_0000019,F,,268,,,
3316,H,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,Autocuration,,,,,11249,BAO_0000357,B,,15086,,,
3317,H,,,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,Autocuration,,,,10000000.0,11249,BAO_0000221,B,,14875,,,
3318,H,,,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,Autocuration,,,,10000000.0,168,BAO_0000221,B,,13267,,Sus scrofa,9823.0
3319,H,,,,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,Autocuration,,,,,168,BAO_0000019,B,,13047,,Oryctolagus cuniculus,9986.0
3320,D,,,,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,Expert,,,,,10623,BAO_0000357,B,,1650,,Rattus norvegicus,10116.0
3321,H,,,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,Autocuration,,,,,10623,BAO_0000019,F,,567,,,
3322,H,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,Autocuration,,,,,10623,BAO_0000357,B,,17358,,,
3323,H,,,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,Autocuration,,,,,10623,BAO_0000357,B,,188,,,
3324,H,,,,lntrinsic activity relative to 5-HT receptor,Autocuration,,,,,10623,BAO_0000019,F,,670,,,
3325,H,,,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,Autocuration,,,,,10623,BAO_0000019,F,,204,,,
3326,H,,,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,Expert,,,,,10623,BAO_0000019,F,,1946,,,
3327,H,,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,Autocuration,,,,,10623,BAO_0000019,F,,6398,,,
3328,H,,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,Autocuration,,,,,10623,BAO_0000019,F,,6398,,,
3329,H,,,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,Autocuration,,,,,10623,BAO_0000019,F,,17358,,,
3330,H,,,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,Autocuration,,,,,10623,BAO_0000019,F,,6398,,,
3331,H,,,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,Expert,,,,,10623,BAO_0000357,B,,11752,,,
3332,H,,,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,Autocuration,,,,,10623,BAO_0000019,F,,809,,,
3333,D,,,,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,Expert,,,,,10623,BAO_0000357,B,,14178,,Rattus norvegicus,10116.0
3334,H,,,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,Autocuration,,,,,10623,BAO_0000357,B,,567,,,
3335,H,,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,Autocuration,,,,,10623,BAO_0000357,B,,1946,,,
3336,H,,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,Autocuration,,,,,10623,BAO_0000357,B,,1946,,,
3337,D,,,,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,Expert,,,,,10623,BAO_0000019,B,,13961,,Rattus norvegicus,10116.0
3338,H,,,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,Autocuration,,,,2435.0,10623,BAO_0000249,B,,6238,,,
3339,H,,,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,Autocuration,,,,,10623,BAO_0000249,B,,14290,,,
3340,H,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,Expert,,,,,10623,BAO_0000249,B,,14290,,,
3341,D,,,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,Expert,,,,2435.0,10623,BAO_0000019,B,,809,,Rattus norvegicus,10116.0
3342,H,,,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,Autocuration,,,,2435.0,10623,BAO_0000019,B,,1578,,,
3343,H,,,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,Expert,,,,2435.0,10623,BAO_0000249,B,,16709,,,
3344,H,,,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,Expert,,,,2435.0,10623,BAO_0000019,B,,1946,,,
3345,H,,,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,Expert,,,,2435.0,10623,BAO_0000249,B,,15253,,,
3346,H,,,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,Expert,,,,2435.0,10623,BAO_0000249,B,,4535,,,
3347,H,,,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,Expert,,,,,10623,BAO_0000249,B,,13961,,,
3348,H,,,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,Autocuration,,,,955.0,10623,BAO_0000221,F,,17358,,,
3349,H,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,Autocuration,,,,,10623,BAO_0000019,F,,15847,,,
3350,H,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,Autocuration,,,,,10623,BAO_0000019,F,,15847,,,
3351,H,,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,Autocuration,,,,,10623,BAO_0000019,F,,670,,,
3352,H,,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,Autocuration,,,,,10623,BAO_0000019,F,,670,,,
3353,H,,,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,Autocuration,,,,,10623,BAO_0000019,F,,1317,,,
3354,D,,,,Binding affinity against rat 5-hydroxytryptamine 4 receptor,Expert,,,,,10623,BAO_0000357,B,,12936,,Rattus norvegicus,10116.0
3355,H,,,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,Expert,,,,2435.0,10623,BAO_0000249,B,,4535,,,
3356,D,,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,Expert,,,,,10623,BAO_0000019,F,,14424,,Rattus norvegicus,10116.0
3357,H,,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,Expert,,,,,10623,BAO_0000019,F,,14424,,,
3358,H,,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,Expert,,,,,10623,BAO_0000019,F,,14424,,,
3359,D,,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,Expert,,,,,10623,BAO_0000019,F,,14424,,Rattus norvegicus,10116.0
3360,H,,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,Autocuration,,,,,10623,BAO_0000019,F,,14424,,,
3361,H,,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,Expert,,,,,10623,BAO_0000019,F,,14424,,,
3362,H,,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),Expert,,,,,10623,BAO_0000218,F,,14424,,,
3363,H,,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,Autocuration,,,,,10623,BAO_0000019,F,,14424,,,
3364,H,,,,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,Autocuration,,,,,168,BAO_0000019,F,,1980,,Rattus norvegicus,10116.0
3365,H,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,Autocuration,,,,,168,BAO_0000019,F,,4639,,,
3366,H,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,Autocuration,,,,,168,BAO_0000357,B,,17358,,,
3367,H,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,Autocuration,,,,,168,BAO_0000357,B,,17358,,,
3368,H,,,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,Autocuration,,,,,168,BAO_0000357,B,,17358,,,
3369,H,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,Autocuration,,,,,168,BAO_0000357,B,,1558,,,
3370,H,,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,Autocuration,,,,,168,BAO_0000019,F,,17358,,,
3371,H,,,,In vitro binding affinity towards 5-HT4 receptor was determined,Autocuration,,,,,168,BAO_0000357,B,,16117,,,
3372,H,,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,Autocuration,,,,,168,BAO_0000019,F,,17358,,,
3373,H,,,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,Autocuration,,,,,168,BAO_0000019,F,,17358,,,
3374,H,,,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,Autocuration,,,,,168,BAO_0000357,B,,17358,,,
3375,H,,,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,Autocuration,,,,,168,BAO_0000357,B,,17358,,,
3376,H,,,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,Autocuration,,,,,168,BAO_0000357,B,,17358,,,
3377,H,,,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,Autocuration,,,,,168,BAO_0000357,B,,17358,,,
3378,H,,,,Binding affinity against 5-Hydroxytryptamine 4 receptor,Expert,,,,,168,BAO_0000357,B,,1274,,,
3379,H,,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,Autocuration,,,,,104698,BAO_0000249,B,Brain membranes,10728,,,
3380,H,,,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,Autocuration,,,,,104698,BAO_0000249,B,Brain membranes,11695,,,
3381,H,,,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,Autocuration,,,,,104698,BAO_0000249,B,Brain membranes,11695,,,
3382,H,,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,Autocuration,,,,,104698,BAO_0000019,B,,12490,,,
3383,D,,,,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000019,B,,11828,,Rattus norvegicus,10116.0
3384,H,,,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,Autocuration,,,,10000000.0,104698,BAO_0000221,B,,12253,,,
3385,H,,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,Autocuration,,,,,104698,BAO_0000019,B,,10561,,,
3386,H,,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,Autocuration,,,,,104698,BAO_0000019,B,,10561,,,
3387,H,,,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,Autocuration,,,,,104698,BAO_0000019,F,,14432,,,
3388,D,,,,Binding affinity against rat 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000223,B,,12936,,Rattus norvegicus,10116.0
3389,D,,,,Binding affinity against 5-Hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000223,B,,1274,,Rattus norvegicus,10116.0
3390,H,,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,Autocuration,,,,,104698,BAO_0000019,B,,1980,,,
3391,H,,,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,Autocuration,,,,,104698,BAO_0000249,B,,670,,,
3392,D,,,,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,Autocuration,,,,,104698,BAO_0000019,B,,968,,Rattus norvegicus,10116.0
3393,H,,,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,Autocuration,,,,,104698,BAO_0000019,B,,14287,,,
3394,H,,,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,Autocuration,,,,,104698,BAO_0000019,B,,567,,,
3395,H,,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,104698,BAO_0000019,B,,13267,,,
3396,H,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,Autocuration,,,,,104698,BAO_0000249,B,,14826,,,
3397,H,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,Autocuration,,,,,104698,BAO_0000223,B,,15194,,,
3398,H,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,Autocuration,,,,,104698,BAO_0000223,B,,15194,,,
3399,D,,,,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000223,B,,10394,,Rattus norvegicus,10116.0
3400,D,,,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",Expert,,,,,10576,BAO_0000249,B,,13657,,,
3401,H,,,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,Autocuration,,,,955.0,12020,BAO_0000221,F,,1879,,,
3402,H,,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,Autocuration,,,,,12020,BAO_0000019,F,,1879,,,
3403,H,,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,Autocuration,,,,,12020,BAO_0000019,F,,1879,,,
3404,H,,,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,,,12020,BAO_0000218,F,,204,In vivo,,
3405,H,,,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,Autocuration,,,,,12020,BAO_0000019,B,,1879,,,
3406,H,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,,,12020,BAO_0000357,B,,1879,,,
3407,H,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,Autocuration,,,,,12020,BAO_0000019,B,,1879,,,
3408,H,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,Autocuration,,,,,12020,BAO_0000019,B,,1879,,,
3409,H,,,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",Autocuration,,,,,104698,BAO_0000019,B,,10641,,,
3410,H,,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,Autocuration,,,,,12020,BAO_0000019,B,,773,,,
3411,H,,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,Autocuration,,,,,104698,BAO_0000249,B,,11952,,,
3412,D,,,,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,Autocuration,,,,,12020,BAO_0000019,F,,14145,,Rattus norvegicus,10116.0
3413,H,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,Expert,,,,,144,BAO_0000357,B,,17066,,,
3414,H,,,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,Autocuration,,,,,104714,BAO_0000223,B,,6398,,,
3415,U,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,Autocuration,,,,,22226,BAO_0000019,B,,10321,,,
3416,H,,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,Autocuration,,,,,104714,BAO_0000019,F,,511,,,
3417,H,,,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104714,BAO_0000223,B,,4639,,,
3418,H,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104714,BAO_0000223,B,,4639,,,
3419,H,,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,Autocuration,,,,,104714,BAO_0000019,F,,4639,,Cavia porcellus,10141.0
3420,H,,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,Autocuration,,,,,104714,BAO_0000019,F,,4639,,Cavia porcellus,10141.0
3421,H,,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,Autocuration,,,,,104714,BAO_0000019,F,,4639,,Cavia porcellus,10141.0
3422,H,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104714,BAO_0000223,B,,1558,,,
3423,H,,,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,Autocuration,,,,,104714,BAO_0000019,F,,268,,,
3424,H,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,Autocuration,,,,,104714,BAO_0000223,B,,2474,,,
3425,H,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,Autocuration,,,,,104714,BAO_0000019,F,,5067,,,
3426,H,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,Autocuration,,,,,104714,BAO_0000019,F,,5067,,,
3427,H,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,Autocuration,,,,,104714,BAO_0000019,F,,5067,,,
3428,H,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,Autocuration,,,,,104714,BAO_0000223,B,,5067,,,
3429,H,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,Autocuration,,,,,104714,BAO_0000019,F,,5067,,,
3430,H,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,Autocuration,,,,,104714,BAO_0000019,F,,5067,,,
3431,H,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,Autocuration,,,,,104714,BAO_0000019,F,,5067,,,
3432,H,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,Autocuration,,,,,104714,BAO_0000223,B,,5067,,,
3433,H,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,Autocuration,,,,,104714,BAO_0000223,B,,5067,,,
3434,H,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,Autocuration,,,,,104714,BAO_0000019,F,,5067,,,
3435,H,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,Autocuration,,,,,104714,BAO_0000223,B,,5067,,,
3436,H,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104714,BAO_0000223,B,,5067,,,
3437,H,,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,Autocuration,,,,,104714,BAO_0000219,B,,14331,,,
3438,H,,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,Autocuration,,,,,104714,BAO_0000223,B,,5067,,,
3439,H,,433.0,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,Autocuration,,NG108-15,,,104714,BAO_0000219,B,,6179,,,
3440,H,,,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,Autocuration,,,,,104714,BAO_0000019,B,,4265,,,
3441,H,,433.0,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,Autocuration,,NG108-15,,,104714,BAO_0000219,B,,4265,,,
3442,H,,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,Autocuration,,,,,104714,BAO_0000223,B,,17358,,,
3443,H,,,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,Autocuration,,,,,104714,BAO_0000223,B,,17358,,,
3444,H,,,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,Autocuration,,,,,104714,BAO_0000219,B,,13628,In vitro,,
3445,H,,,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,Autocuration,,,,,104714,BAO_0000223,B,,4612,,,
3446,H,,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,Autocuration,,,,,104714,BAO_0000019,F,,17358,,,
3447,H,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,Autocuration,,,,,104714,BAO_0000019,F,,4639,,Cavia porcellus,10141.0
3448,H,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,Autocuration,,,,,104714,BAO_0000019,F,,4639,,Cavia porcellus,10141.0
3449,H,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,Autocuration,,,,,104714,BAO_0000019,F,,4639,,Cavia porcellus,10141.0
3450,H,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,Autocuration,,,,,104714,BAO_0000019,F,,4639,,Cavia porcellus,10141.0
3451,H,,,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,Autocuration,,,,,104714,BAO_0000223,B,,511,,,
3452,H,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104714,BAO_0000223,B,,1479,,,
3453,H,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,Autocuration,,,,,104714,BAO_0000223,B,,1317,,,
3454,H,,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,Autocuration,,,,,104714,BAO_0000223,B,,12146,,,
3455,H,,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,Autocuration,,,,,104714,BAO_0000223,B,,12146,,,
3456,H,,,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,Autocuration,,,,,104714,BAO_0000223,B,,13969,,,
3457,H,,,,Binding affinity for 5-hydroxytryptamine 2C receptor,Expert,,,,,108,BAO_0000357,B,,13392,,,
3458,H,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000223,B,,13392,,,
3459,H,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,Autocuration,,,,,144,BAO_0000357,B,,14159,,,
3460,H,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,,,144,BAO_0000357,B,,1558,,,
3461,H,,,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,Autocuration,,,,,144,BAO_0000357,B,,16655,,,
3462,H,,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,Autocuration,,,,,104714,BAO_0000223,B,,13020,,,
3463,H,,,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,Autocuration,,,,,104714,BAO_0000223,B,,13021,,,
3464,H,,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,Autocuration,,,,,104714,BAO_0000223,B,,13020,,,
3465,H,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,Autocuration,,,,,144,BAO_0000019,B,,10321,,,
3466,H,,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,,,144,BAO_0000357,B,,15818,,,
3467,H,,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,,,144,BAO_0000357,B,,15818,,,
3468,H,,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,Autocuration,,,,,144,BAO_0000357,B,,17358,,,
3469,H,,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,Autocuration,,,,,144,BAO_0000357,B,,2222,,,
3470,H,,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,Autocuration,,,,,144,BAO_0000019,B,,10322,,,
3471,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,Autocuration,,,,,144,BAO_0000357,B,,16117,,,
3472,H,,,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,Autocuration,,,,,144,BAO_0000357,B,,17200,,,
3473,H,,,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,Autocuration,,,,,144,BAO_0000019,F,,17358,,,
3474,H,,,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,Autocuration,,,,,144,BAO_0000357,B,,16700,,,
3475,H,,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,Autocuration,,,,,144,BAO_0000019,B,,1980,,,
3476,H,,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,Autocuration,,,,,144,BAO_0000019,B,,1980,,,
3477,H,,,,Binding affinity against the 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104714,BAO_0000223,B,,12409,,,
3478,H,,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,Autocuration,,,,,144,BAO_0000357,B,,4365,,,
3479,H,,,,Percent efficacy against 5-hydroxytryptamine 3A receptor,Autocuration,,,,,144,BAO_0000019,F,,4365,,,
3480,H,,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,Autocuration,,,,,144,BAO_0000357,B,,4365,,,
3481,D,,,,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,Expert,,Oocytes,,,12020,BAO_0000219,F,,6769,,Rattus norvegicus,10116.0
3482,D,,,,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,Expert,,Oocytes,,,12020,BAO_0000219,F,,6769,,Rattus norvegicus,10116.0
3483,D,,,,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,Expert,,Oocytes,,,12020,BAO_0000219,F,,6769,,Rattus norvegicus,10116.0
3484,D,,,,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,Intermediate,,,,2116.0,20033,BAO_0000221,F,,809,,Cavia porcellus,10141.0
3485,D,,,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,Intermediate,,,,2116.0,20033,BAO_0000221,F,,809,,Cavia porcellus,10141.0
3486,D,,,,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,Intermediate,,,,,20033,BAO_0000019,F,,14290,,Cavia porcellus,10141.0
3487,D,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,Intermediate,,,,2116.0,20033,BAO_0000221,B,,17358,,Cavia porcellus,10141.0
3488,D,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,Intermediate,,,,,20033,BAO_0000357,B,,17358,,Cavia porcellus,10141.0
3489,D,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,Intermediate,,,,2116.0,20033,BAO_0000221,B,,17358,,Cavia porcellus,10141.0
3490,H,,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,Autocuration,,,,2116.0,10209,BAO_0000221,B,,17386,,,
3491,H,,,,Affinity against 5-hydroxytryptamine 7 receptor,Autocuration,,,,,10209,BAO_0000357,B,,3269,,,
3492,H,,,,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,Autocuration,,,,,104841,BAO_0000224,B,,7721,,Cavia porcellus,10141.0
3493,H,,,,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,Autocuration,,,,,104841,BAO_0000224,B,,7721,,Cavia porcellus,10141.0
3494,H,,,,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,Autocuration,,,,2116.0,104841,BAO_0000221,B,,9117,,Cavia porcellus,10141.0
3495,H,,,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",Autocuration,,,,,104841,BAO_0000224,B,,7721,,Cavia porcellus,10141.0
3496,H,,,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",Autocuration,,,,,104841,BAO_0000224,B,,7721,,Cavia porcellus,10141.0
3497,H,,,,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,Autocuration,,,,,104841,BAO_0000019,F,,15796,,Cavia porcellus,10141.0
3498,H,,,,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,Autocuration,,,,,104841,BAO_0000019,F,,15796,,Cavia porcellus,10141.0
3499,D,,,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,Expert,,,,2081.0,168,BAO_0000219,B,,15650,,Homo sapiens,9606.0
3500,D,,,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,Expert,,,,2081.0,168,BAO_0000219,B,,15650,,Homo sapiens,9606.0
3501,D,,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",Autocuration,,,,,104841,BAO_0000019,F,,6866,,Homo sapiens,9606.0
3502,D,,,,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",Expert,,,,2081.0,168,BAO_0000219,F,,15650,,Homo sapiens,9606.0
3503,U,,,,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,Autocuration,,,,,22226,BAO_0000019,B,,10063,,Mus musculus,10090.0
3504,U,,,,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,Autocuration,,,,,22226,BAO_0000019,B,,12665,,Mus musculus,10090.0
3505,H,,,,5-hydroxytryptamine receptor binding affinity was determined in rats,Autocuration,,,,,104705,BAO_0000019,B,,7504,,,
3506,H,,,,Binding affinity at rat 5-hydroxytryptamine receptor.,Autocuration,,,,,104705,BAO_0000224,B,,7504,,,
3507,H,,,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,Autocuration,,,,,104705,BAO_0000019,B,,7038,,,
3508,H,,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,Autocuration,,,,,104705,BAO_0000224,B,,7626,,,
3509,H,,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,Autocuration,,,,,104705,BAO_0000224,B,,7626,,,
3510,H,,,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,Autocuration,,,,945.0,104705,BAO_0000019,F,,7185,,,
3511,H,,,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,Autocuration,,,,945.0,104705,BAO_0000019,F,,7185,,,
3512,H,,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,Autocuration,,,,,104705,BAO_0000019,F,,7185,,,
3513,H,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,Autocuration,,,,,104705,BAO_0000224,B,,6960,,,
3514,H,,,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",Autocuration,,,,,104705,BAO_0000224,B,,6960,,,
3515,H,,,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,12416,,,
3516,H,,,,Binding affinity for rat 5-hydroxytryptamine transporter.,Expert,,,,,12198,BAO_0000357,B,,15753,,,
3517,H,,,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,Autocuration,,,,,104705,BAO_0000019,B,,8062,,,
3518,D,,,,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,Autocuration,,,,,104705,BAO_0000019,B,,9036,,Rattus norvegicus,10116.0
3519,D,,,,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Autocuration,,,,,104705,BAO_0000224,B,,15067,,Rattus norvegicus,10116.0
3520,D,,,,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,Expert,,,,955.0,12198,BAO_0000019,F,,15753,,Rattus norvegicus,10116.0
3521,D,,,,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,Expert,,,,2037.0,12198,BAO_0000221,F,,15753,,Rattus norvegicus,10116.0
3522,D,,,,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,Autocuration,,,,,104705,BAO_0000019,B,,15295,,Rattus norvegicus,10116.0
3523,D,,,,Percent binding affinity against 5-hydroxytryptamine receptor,Autocuration,,,,,104705,BAO_0000224,B,,6347,,Rattus norvegicus,10116.0
3524,U,,,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,Autocuration,,,,,22226,BAO_0000019,B,,6763,,,
3525,D,,,,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,Autocuration,,,,,104705,BAO_0000224,B,,12092,,Rattus norvegicus,10116.0
3526,D,,,,Affinity against 5-hydroxytryptamine receptor was determined,Autocuration,,,,,104705,BAO_0000224,B,,1579,,Rattus norvegicus,10116.0
3527,D,,,,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,Autocuration,,,,945.0,104705,BAO_0000019,B,,1579,,Rattus norvegicus,10116.0
3528,D,,,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,Expert,,,,,121,BAO_0000219,B,,5963,In vitro,Homo sapiens,9606.0
3529,D,,,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,Expert,,,,,121,BAO_0000219,B,,5963,In vitro,Homo sapiens,9606.0
3530,H,,,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,Autocuration,,,,,18065,BAO_0000357,B,,5030,,,
3531,H,,,,Inhibition of 5-hydroxytryptamine reuptake,Expert,,,,,121,BAO_0000357,B,,15796,,,
3532,H,,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",Autocuration,,,,,18065,BAO_0000019,F,,15413,,,
3533,H,,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",Autocuration,,,,,18065,BAO_0000019,F,,15413,,,
3534,H,,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",Autocuration,,,,,18065,BAO_0000019,F,,15413,,,
3535,H,,,,Tested for 5-hydroxytryptamine receptor uptake,Autocuration,,,,,18065,BAO_0000019,F,,12409,,,
3536,D,,449.0,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,Expert,,CHO,,,51,BAO_0000219,B,,16909,,Homo sapiens,9606.0
3537,D,,,,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,Expert,,,,,51,BAO_0000019,F,,16909,,Homo sapiens,9606.0
3538,H,,,,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,Autocuration,,,,,10576,BAO_0000249,B,,15629,,Homo sapiens,9606.0
3539,H,,,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,Autocuration,,,,,10576,BAO_0000357,B,,15629,,,
3540,H,,,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,Expert,,,,,10576,BAO_0000249,B,,15629,,,
3541,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,Autocuration,,,,2435.0,10825,BAO_0000019,F,,10034,,,
3542,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,Autocuration,,,,2435.0,10825,BAO_0000019,F,,10034,,,
3543,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,Autocuration,,,,2435.0,10825,BAO_0000019,F,,10034,,,
3544,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,Autocuration,,,,2435.0,10825,BAO_0000019,F,,10034,,,
3545,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,Autocuration,,,,2435.0,10825,BAO_0000019,F,,10034,,,
3546,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,Autocuration,,,,2435.0,10825,BAO_0000019,F,,10034,,,
3547,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,Autocuration,,,,2435.0,10825,BAO_0000019,F,,10034,,,
3548,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,Autocuration,,,,2435.0,10825,BAO_0000019,F,,10034,,,
3549,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,Autocuration,,,,2435.0,10825,BAO_0000019,F,,10034,,,
3550,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,Autocuration,,,,2435.0,10825,BAO_0000019,F,,10034,,,
3551,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,Autocuration,,,,2435.0,10825,BAO_0000019,F,,10034,,,
3552,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,Autocuration,,,,349.0,10825,BAO_0000019,F,,10034,,,
3553,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,Autocuration,,,,349.0,10825,BAO_0000019,F,,10034,,,
3554,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,Autocuration,,,,349.0,10825,BAO_0000019,F,,10034,,,
3555,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,Autocuration,,,,349.0,10825,BAO_0000019,F,,10034,,,
3556,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,Autocuration,,,,349.0,10825,BAO_0000019,F,,10034,,,
3557,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,Autocuration,,,,349.0,10825,BAO_0000019,F,,10034,,,
3558,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,Autocuration,,,,349.0,10825,BAO_0000019,F,,10034,,,
3559,H,,,,Binding affinity against 5-hydroxytryptamine 4 receptor,Expert,,,,,168,BAO_0000357,B,,1274,,,
3560,H,,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,Autocuration,,,,,168,BAO_0000019,F,,17358,,,
3561,H,,,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,Autocuration,,,,,168,BAO_0000357,B,,14532,,,
3562,H,,,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,Expert,,,,,168,BAO_0000357,B,,16989,,,
3563,H,,,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,Autocuration,,,,,168,BAO_0000357,B,,17200,,,
3564,H,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor,Autocuration,,,,,168,BAO_0000357,B,,15779,,,
3565,H,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,Autocuration,,,,,168,BAO_0000357,B,,15779,,,
3566,H,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,Autocuration,,,,,168,BAO_0000357,B,,15779,,,
3567,H,,643.0,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,Autocuration,,COS-7,,,168,BAO_0000219,B,,15650,,,
3568,H,,643.0,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,Autocuration,,COS-7,,,168,BAO_0000219,B,,15650,,,
3569,H,,643.0,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,Autocuration,,COS-7,,,168,BAO_0000219,B,,15650,,,
3570,H,,643.0,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,Autocuration,,COS-7,,,168,BAO_0000219,B,,15650,,,
3571,H,,673.0,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,Autocuration,,C6,,,168,BAO_0000219,B,,17046,,,
3572,H,,673.0,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,Expert,,C6,,,168,BAO_0000219,B,,17046,,,
3573,H,,673.0,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,Expert,,C6,,,168,BAO_0000219,B,,15650,,,
3574,H,,673.0,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,Expert,,C6,,,168,BAO_0000219,B,,17046,,,
3575,H,,,,Binding affinity towards 5-hydroxytryptamine 5 receptor,Expert,,,,,10624,BAO_0000357,B,,17066,,,
3576,H,,,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,Autocuration,,,,,105,BAO_0000357,B,,17200,,,
3577,D,,,,Binding affinity against 5-hydroxytryptamine 5A receptor,Expert,,,,,10624,BAO_0000357,B,,16146,,Homo sapiens,9606.0
3578,H,,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,Autocuration,,CHO,,,10624,BAO_0000219,B,,15250,,,
3579,D,,,,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,Expert,,,,,10624,BAO_0000357,B,,6491,,Homo sapiens,9606.0
3580,D,,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor,Expert,,,,,10624,BAO_0000357,B,,17066,,Homo sapiens,9606.0
3581,D,,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,Expert,,,,,10624,BAO_0000357,B,,17066,,Homo sapiens,9606.0
3582,D,,,,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,Expert,,,,,10624,BAO_0000357,B,,4234,,Homo sapiens,9606.0
3583,H,,,,Binding affinity towards 5-HT5A receptor,Autocuration,,,,,10624,BAO_0000357,B,,6013,,,
3584,H,,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,Expert,,,,,10624,BAO_0000357,B,,17175,,,
3585,H,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,Autocuration,,,,,10624,BAO_0000357,B,,15818,,,
3586,H,,,,Binding affinity towards cloned human 5-HT5A receptor was determined,Autocuration,,,,,10624,BAO_0000357,B,,6166,,,
3587,H,,722.0,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,Autocuration,,HEK293,,,10624,BAO_0000219,B,,15779,,,
3588,H,,722.0,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,Autocuration,,HEK293,,,10624,BAO_0000219,B,,15779,,,
3589,H,,722.0,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),Autocuration,,HEK293,,,10624,BAO_0000219,B,,5213,,,
3590,D,,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,Expert,,,,,10625,BAO_0000357,B,,17066,,Mus musculus,10090.0
3591,D,,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,Expert,,,,,10625,BAO_0000357,B,,17066,,Mus musculus,10090.0
3592,D,,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,Expert,,,,,10625,BAO_0000357,B,,17066,,Mus musculus,10090.0
3593,D,,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,Expert,,,,,10625,BAO_0000357,B,,17066,,Mus musculus,10090.0
3594,D,,,,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,Expert,,,,,10625,BAO_0000357,B,,17066,,Mus musculus,10090.0
3595,H,,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,Expert,,,,,10625,BAO_0000357,B,,17175,,,
3596,H,,722.0,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,Autocuration,,HEK293,,,10576,BAO_0000219,B,,16190,,,
3597,H,,722.0,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,Autocuration,,HEK293,,,10626,BAO_0000219,B,,16190,,,
3598,H,,,,Binding affinity towards 5-HT5a receptor,Expert,,,,,10624,BAO_0000357,B,,4820,,,
3599,D,,,,Binding affinity towards 5-hydroxytryptamine 5A receptor,Expert,,,,,10624,BAO_0000357,B,,17066,,Homo sapiens,9606.0
3600,H,,,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,Expert,,,,,10624,BAO_0000357,B,,17066,,,
3601,H,,,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,Expert,,,,,10624,BAO_0000357,B,,17175,,,
3602,H,,,,Binding affinities against 5-hydroxytryptamine 5A receptor,Autocuration,,,,,10624,BAO_0000357,B,,16633,,,
3603,H,,,,Binding affinities towards 5-hydroxytryptamine 5A receptor,Autocuration,,,,,10624,BAO_0000357,B,,16633,,,
3604,H,,,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,Autocuration,,,,,10624,BAO_0000357,B,,16700,,,
3605,H,,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,Autocuration,,,,,104714,BAO_0000019,F,,4639,,Cavia porcellus,10141.0
3606,H,,,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,Autocuration,,,,,104714,BAO_0000223,B,,5486,,,
3607,D,,,,Inhibition of human 5-hydroxytryptamine 6 receptor,Expert,,,,,10627,BAO_0000357,B,,16146,,Homo sapiens,9606.0
3608,D,,,,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,Expert,,,,,10627,BAO_0000357,B,,17273,,Homo sapiens,9606.0
3609,H,,,,Inhibition against human 5-hydroxytryptamine 6 receptor,Autocuration,,,,,10627,BAO_0000357,B,,17687,,,
3610,D,,,,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,Expert,,,,,10627,BAO_0000357,B,,6491,,Homo sapiens,9606.0
3611,H,,308.0,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,Expert,,HeLa,,,10627,BAO_0000219,B,,16190,,,
3612,D,,,,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,Expert,,,,,10627,BAO_0000357,B,,17066,,Homo sapiens,9606.0
3613,D,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,Expert,,,,,10627,BAO_0000357,B,,17066,,Homo sapiens,9606.0
3614,D,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,Expert,,,,,10627,BAO_0000357,B,,17066,,Homo sapiens,9606.0
3615,D,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,Expert,,,,,10627,BAO_0000357,B,,17066,,Homo sapiens,9606.0
3616,D,,,,Binding affinity against 5-hydroxytryptamine 6 receptor,Expert,,,,,10627,BAO_0000357,B,,3555,,Homo sapiens,9606.0
3617,H,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,Expert,,,,,10627,BAO_0000357,B,,5808,,,
3618,H,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,Autocuration,,,,,10627,BAO_0000357,B,,6013,,,
3619,H,,722.0,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",Expert,,HEK293,,,10627,BAO_0000219,B,,15818,,,
3620,H,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,Autocuration,,,,,10627,BAO_0000357,B,,16209,,,
3621,H,,722.0,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,Expert,,HEK293,,,10627,BAO_0000219,B,,3935,,,
3622,H,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,Autocuration,,,,,10627,BAO_0000357,B,,15818,,,
3623,D,,722.0,,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,Expert,,HEK293,,,10627,BAO_0000219,B,,3805,,Homo sapiens,9606.0
3624,H,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,Expert,,,,,10627,BAO_0000019,B,,16441,,,
3625,H,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,Expert,,,,,10627,BAO_0000019,B,,16441,,,
3626,H,,643.0,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,Expert,,COS-7,,,10627,BAO_0000219,B,,6786,,,
3627,D,,,,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,Expert,,,,,10627,BAO_0000357,B,,4234,,Homo sapiens,9606.0
3628,H,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,Autocuration,,,,,10627,BAO_0000019,B,,17085,,,
3629,H,,,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,Autocuration,,,,,10627,BAO_0000357,B,,17200,,,
3630,H,,722.0,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,Autocuration,,HEK293,,,10627,BAO_0000219,B,,17451,,,
3631,H,,,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,Autocuration,,,,,10627,BAO_0000019,F,,3935,,,
3632,H,,,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,Autocuration,,,,,10627,BAO_0000357,B,,5033,,,
3633,H,,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,Expert,,,,,10627,BAO_0000357,B,,4540,,,
3634,D,,308.0,,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,Expert,,HeLa,,,10627,BAO_0000219,B,,4540,,Homo sapiens,9606.0
3635,D,,308.0,,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,Expert,,HeLa,,,10627,BAO_0000219,B,,4540,,Homo sapiens,9606.0
3636,H,,308.0,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,Autocuration,,HeLa,,,10627,BAO_0000219,B,,17296,,,
3637,H,,308.0,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,Autocuration,,HeLa,,,10627,BAO_0000219,B,,17296,,,
3638,H,,308.0,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,Autocuration,,HeLa,,,10627,BAO_0000219,B,,17296,,,
3639,H,,449.0,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,Autocuration,,CHO,,,10627,BAO_0000219,B,,15779,,,
3640,H,,722.0,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,Autocuration,,HEK293,,,10627,BAO_0000219,B,,15779,,,
3641,H,,722.0,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,Autocuration,,HEK293,,,10627,BAO_0000219,B,,15779,,,
3642,H,,722.0,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,Autocuration,,HEK293,,,10627,BAO_0000219,B,,15779,,,
3643,H,,308.0,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,Autocuration,,HeLa,,,10627,BAO_0000219,B,,15779,,,
3644,H,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,Autocuration,,,,,10627,BAO_0000357,B,,6166,,,
3645,H,,308.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,Autocuration,,HeLa,,,10627,BAO_0000219,B,,17451,,,
3646,H,,,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,Autocuration,,,,,10627,BAO_0000357,B,,15316,,,
3647,H,,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,Expert,,,,,10627,BAO_0000357,B,,4199,,,
3648,H,,308.0,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,Expert,,HeLa,,,10627,BAO_0000219,B,,15146,,,
3649,H,,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),Autocuration,,,,,10627,BAO_0000357,B,,5213,,,
3650,H,,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,Autocuration,,,,,10627,BAO_0000219,B,,16429,,,
3651,H,,308.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,Autocuration,,HeLa,,,10627,BAO_0000219,B,,14818,,,
3652,H,,308.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",Autocuration,,HeLa,,,10627,BAO_0000219,B,,4829,,,
3653,H,,308.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",Autocuration,,HeLa,,,10627,BAO_0000219,B,,4829,,,
3654,H,,308.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",Autocuration,,HeLa,,,10627,BAO_0000219,B,,4829,,,
3655,H,,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,Autocuration,,CHO,,,10628,BAO_0000219,B,,15250,,,
3656,H,,,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,Autocuration,,,,,10628,BAO_0000019,B,,14423,,,
3657,H,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,Autocuration,,,,,10628,BAO_0000357,B,,15086,,,
3658,H,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,Autocuration,,,,,10628,BAO_0000357,B,,4342,,,
3659,D,,308.0,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,Autocuration,,HeLa,,,10627,BAO_0000219,B,,16190,,Homo sapiens,9606.0
3660,H,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,Expert,,,,,10627,BAO_0000357,B,,4820,,,
3661,H,,,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,Autocuration,,,,,10627,BAO_0000357,B,,4639,,,
3662,D,,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,Expert,,,,,10627,BAO_0000019,F,,17066,,Homo sapiens,9606.0
3663,H,,,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,Autocuration,,,,,10627,BAO_0000357,B,,6011,,,
3664,H,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,Expert,,,,,10627,BAO_0000357,B,,17066,,,
3665,H,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,Autocuration,,,,,10627,BAO_0000357,B,,17515,,,
3666,H,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,Autocuration,,,,,10627,BAO_0000357,B,,5014,,,
3667,H,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,Autocuration,,,,,10627,BAO_0000357,B,,4373,,,
3668,H,,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,Expert,,,,,10627,BAO_0000019,F,,17066,,,
3669,H,,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,Expert,,,,,10627,BAO_0000019,F,,17066,,,
3670,H,,,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,Autocuration,,,,,10627,BAO_0000357,B,,4373,,,
3671,H,,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,Autocuration,,,,,10627,BAO_0000357,B,,4687,,,
3672,H,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,Autocuration,,,,,10627,BAO_0000357,B,,16946,,,
3673,H,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,Autocuration,,,,,10627,BAO_0000357,B,,16946,,,
3674,H,,,,Binding affinities against 5-hydroxytryptamine 6 receptor,Autocuration,,,,,10627,BAO_0000357,B,,16633,,,
3675,H,,,,Binding affinities towards 5-hydroxytryptamine 6 receptor,Autocuration,,,,,10627,BAO_0000357,B,,16633,,,
3676,D,,,,Binding affinity towards 5-hydroxytryptamine 6 receptor,Expert,,,,,10627,BAO_0000357,B,,17066,,Homo sapiens,9606.0
3677,H,,,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,Autocuration,,,,,10627,BAO_0000357,B,,16700,,,
3678,H,,,,Affinity against 5-hydroxytryptamine 6 receptor,Autocuration,,,,,10627,BAO_0000357,B,,3269,,,
3679,H,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],Autocuration,,,,,10627,BAO_0000357,B,,5486,,,
3680,D,,,,Inhibition of human 5-hydroxytryptamine 7 receptor,Expert,,,,,10209,BAO_0000357,B,,16146,,Homo sapiens,9606.0
3681,H,,722.0,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,Autocuration,,HEK293,,,10209,BAO_0000219,B,,5014,,,
3682,H,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,Autocuration,,,,,10209,BAO_0000357,B,,15463,,,
3683,H,,,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),Autocuration,,,,,10209,BAO_0000357,B,,3805,,,
3684,H,,722.0,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,Expert,,HEK293,,,10209,BAO_0000219,B,,5014,,,
3685,D,,,,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,Expert,,,,,10209,BAO_0000357,B,,6491,,Homo sapiens,9606.0
3686,H,,449.0,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,Autocuration,,CHO,,,10209,BAO_0000219,B,,16190,,,
3687,D,,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,Expert,,,,,10209,BAO_0000357,B,,17066,,Homo sapiens,9606.0
3688,D,,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,Expert,,,,,10209,BAO_0000357,B,,17066,,Homo sapiens,9606.0
3689,D,,,,Binding affinity against 5-hydroxytryptamine 7 receptor,Expert,,,,,10209,BAO_0000357,B,,3555,,Homo sapiens,9606.0
3690,H,,449.0,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,Expert,,CHO,,,10209,BAO_0000219,B,,6588,,,
3691,H,,,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,Autocuration,,,,,10209,BAO_0000357,B,,15463,,,
3692,H,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,Autocuration,,,,,10209,BAO_0000357,B,,6013,,,
3693,H,,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,Autocuration,,,,,10209,BAO_0000357,B,,16209,,,
3694,H,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,Autocuration,,,,,10209,BAO_0000357,B,,3935,,,
3695,H,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,Autocuration,,,,,10209,BAO_0000357,B,,15818,,,
3696,H,,722.0,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,Expert,,HEK293,,,10209,BAO_0000219,B,,5014,,,
3697,H,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,Expert,,,,,10209,BAO_0000019,B,,16441,,,
3698,H,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,Expert,,,,,10209,BAO_0000019,B,,16441,,,
3699,D,,,,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,Expert,,,,,10209,BAO_0000357,B,,4234,,Homo sapiens,9606.0
3700,H,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,Autocuration,,,,,10209,BAO_0000019,B,,17085,,,
3701,H,,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,Autocuration,,,,,10209,BAO_0000357,B,,17200,,,
3702,H,,449.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,Autocuration,,CHO,,,10209,BAO_0000219,B,,17451,,,
3703,H,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,Autocuration,,,,,10209,BAO_0000019,B,,17085,,,
3704,H,,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,Autocuration,,,,,10209,BAO_0000357,B,,5104,,,
3705,H,,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,Autocuration,,,,,10209,BAO_0000357,B,,5104,,,
3706,D,,643.0,,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,Expert,,COS-7,,,10209,BAO_0000219,B,,5033,,Homo sapiens,9606.0
3707,H,,643.0,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,Autocuration,,COS-7,,,10209,BAO_0000219,B,,5486,,,
3708,D,,722.0,,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,Expert,,HEK293,,,10209,BAO_0000219,B,,4540,,Homo sapiens,9606.0
3709,H,,,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,Expert,,,,,10209,BAO_0000357,B,,6166,,,
3710,H,,722.0,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,Expert,,HEK293,,,10209,BAO_0000219,B,,17342,,,
3711,H,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,Expert,,,,,10209,BAO_0000357,B,,17342,,,
3712,H,,,,Binding affinity against 5-hydroxytryptamine 7 human receptors,Autocuration,,,,,10209,BAO_0000357,B,,17296,,,
3713,H,,,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,Expert,,,,,10209,BAO_0000219,B,,16429,,,
3714,H,,722.0,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,Autocuration,,HEK293,,,10209,BAO_0000219,B,,15779,,,
3715,H,,722.0,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,Autocuration,,HEK293,,,10209,BAO_0000219,B,,15779,,,
3716,H,,722.0,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,Autocuration,,HEK293,,,10209,BAO_0000219,B,,15779,,,
3717,H,,722.0,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,Autocuration,,HEK293,,,10209,BAO_0000219,B,,15779,,,
3718,H,,722.0,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,Autocuration,,HEK293,,,10209,BAO_0000219,B,,15779,,,
3719,H,,449.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,Autocuration,,CHO,,,10209,BAO_0000219,B,,17451,,,
3720,H,,722.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),Autocuration,,HEK293,,,10209,BAO_0000219,B,,4199,,,
3721,D,,722.0,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,Expert,,HEK293,,,10209,BAO_0000219,B,,4199,,,
3722,H,,722.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),Autocuration,,HEK293,,,10209,BAO_0000219,B,,4199,,,
3723,D,,722.0,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,Intermediate,,HEK293,,,10209,BAO_0000219,B,,3680,,,
3724,D,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,Intermediate,,,,,10209,BAO_0000357,B,,3680,,,
3725,H,,643.0,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,Autocuration,,COS-7,,,10209,BAO_0000219,B,,15316,,,
3726,H,,722.0,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,Autocuration,,HEK293,,,10209,BAO_0000219,B,,15146,,,
3727,H,,722.0,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,Expert,,HEK293,,,10209,BAO_0000219,B,,5213,,,
3728,H,,722.0,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),Autocuration,,HEK293,,,10209,BAO_0000219,B,,5213,,,
3729,D,,722.0,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,Expert,,HEK293,,,10209,BAO_0000219,B,,14818,,Homo sapiens,9606.0
3730,H,,722.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,Autocuration,,HEK293,,,10209,BAO_0000219,B,,14818,,,
3731,H,,722.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,Autocuration,,HEK293,,,10209,BAO_0000219,B,,14818,,,
3732,H,,722.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",Autocuration,,HEK293,,,10209,BAO_0000219,B,,4829,,,
3733,D,,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,Autocuration,,,,,10209,BAO_0000357,B,,17200,,Homo sapiens,9606.0
3734,D,,,,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,Expert,,,,,10022,BAO_0000357,B,,17066,,Mus musculus,10090.0
3735,H,,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,Autocuration,,,,,10209,BAO_0000019,B,,14025,,Oryctolagus cuniculus,9986.0
3736,H,,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,Autocuration,,CHO,,,11923,BAO_0000219,B,,15250,,,
3737,H,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,Autocuration,,CHO,,,11923,BAO_0000219,B,,16372,,,
3738,H,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,Autocuration,,CHO,,,11923,BAO_0000219,B,,16372,,,
3739,H,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,Autocuration,,CHO,,,11923,BAO_0000219,B,,16372,,,
3740,H,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,Autocuration,,CHO,,,11923,BAO_0000219,B,,16372,,,
3741,H,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,Autocuration,,CHO,,,11923,BAO_0000219,B,,16372,,,
3742,H,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,Autocuration,,CHO,,,11923,BAO_0000219,B,,16372,,,
3743,H,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,Autocuration,,CHO,,,11923,BAO_0000219,B,,16372,,,
3744,H,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,Autocuration,,CHO,,,11923,BAO_0000219,B,,16372,,,
3745,H,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,Autocuration,,CHO,,,11923,BAO_0000219,B,,16372,,,
3746,H,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,Autocuration,,CHO,,,11923,BAO_0000219,B,,16372,,,
3747,H,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,Autocuration,,CHO,,,11923,BAO_0000219,B,,16372,,,
3748,H,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,Autocuration,,CHO,,,11923,BAO_0000219,B,,16372,,,
3749,H,,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,Expert,,,,,11923,BAO_0000357,B,,17066,,,
3750,D,,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,Expert,,,,,11923,BAO_0000357,B,,17066,,Rattus norvegicus,10116.0
3751,H,,,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,Expert,,,,,11923,BAO_0000357,B,,17386,,,
3752,H,,,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,Autocuration,,,,,11923,BAO_0000019,B,,14423,,,
3753,D,,,,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,Expert,,,,,11923,BAO_0000357,B,,15874,,Rattus norvegicus,10116.0
3754,D,,,,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,Expert,,,,,11923,BAO_0000357,B,,15874,,Rattus norvegicus,10116.0
3755,D,,449.0,,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,Expert,,CHO,,,11923,BAO_0000219,B,,16372,,Rattus norvegicus,10116.0
3756,H,,,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,Autocuration,,,,,11923,BAO_0000357,B,,4622,,,
3757,H,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,Autocuration,,,,,11923,BAO_0000357,B,,15086,,,
3758,H,,449.0,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",Autocuration,,CHO,,,11923,BAO_0000219,B,,16372,,,
3759,H,,449.0,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",Autocuration,,CHO,,,11923,BAO_0000219,B,,16372,,,
3760,H,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,Autocuration,,CHO,,,11923,BAO_0000219,B,,16372,,,
3761,H,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,Autocuration,,CHO,,,11923,BAO_0000219,B,,16372,,,
3762,H,,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,Autocuration,,,,2116.0,11923,BAO_0000221,F,,17386,,,
3763,H,,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,Autocuration,,,,2116.0,11923,BAO_0000221,F,,17386,,,
3764,H,,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,Autocuration,,,,2116.0,11923,BAO_0000221,F,,17386,,,
3765,D,,,,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,Expert,,,,,11923,BAO_0000249,B,Membranes,5831,,Rattus norvegicus,10116.0
3766,H,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,Autocuration,,,,,11923,BAO_0000357,B,,4342,,,
3767,H,,,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,Expert,,,,,11923,BAO_0000357,B,,17319,,,
3768,H,,,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,Expert,,,,1898.0,11923,BAO_0000019,B,,17342,,,
3769,H,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,Autocuration,,,,,11923,BAO_0000357,B,,17342,,,
3770,H,,,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,Expert,,,,1898.0,11923,BAO_0000249,B,,3680,,,
3771,H,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,Expert,,,,,11923,BAO_0000357,B,,3680,,,
3772,D,,722.0,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,Expert,,HEK293,,,11923,BAO_0000219,F,,17319,,Rattus norvegicus,10116.0
3773,D,,722.0,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,Expert,,HEK293,,,11923,BAO_0000219,F,,17319,,Rattus norvegicus,10116.0
3774,D,,722.0,,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,Autocuration,,HEK293,,,11923,BAO_0000219,F,,17319,,Rattus norvegicus,10116.0
3775,H,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,Expert,,,,,10209,BAO_0000357,B,,4820,,,
3776,H,,,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,Autocuration,,,,,10209,BAO_0000357,B,,4639,,,
3777,H,,,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,Autocuration,,,,,10209,BAO_0000357,B,,6011,,,
3778,D,,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,Expert,,,,,10209,BAO_0000357,B,,17066,,Homo sapiens,9606.0
3779,H,,,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,Expert,,,,,10209,BAO_0000357,B,,17066,,,
3780,H,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,Autocuration,,,,,10209,BAO_0000357,B,,17515,,,
3781,H,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,Autocuration,,,,,10209,BAO_0000357,B,,4373,,,
3782,H,,,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,Expert,,,,,10209,BAO_0000019,F,,17066,,,
3783,H,,,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,Autocuration,,,,,10209,BAO_0000357,B,,4373,,,
3784,H,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,Autocuration,,,,,10209,BAO_0000357,B,,4373,,,
3785,H,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,Autocuration,,,,,10209,BAO_0000357,B,,4687,,,
3786,H,,,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,Expert,,,,,10209,BAO_0000357,B,,17342,,,
3787,H,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,Autocuration,,,,,10209,BAO_0000357,B,,16946,,,
3788,H,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,Autocuration,,,,,10209,BAO_0000357,B,,16946,,,
3789,H,,,,Binding affinities against 5-hydroxytryptamine 7 receptor,Autocuration,,,,,10209,BAO_0000357,B,,16633,,,
3790,H,,,,Binding affinities towards 5-hydroxytryptamine 7 receptor,Autocuration,,,,,10209,BAO_0000357,B,,16633,,,
3791,H,,,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,Expert,,,,,10209,BAO_0000357,B,,17066,,,
3792,H,,,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,Autocuration,,,,,10209,BAO_0000357,B,,16700,,,
3793,H,,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,Autocuration,,,,2116.0,10209,BAO_0000221,B,,17386,,,
3794,H,,,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,Autocuration,,,,,55,BAO_0000019,F,,14080,,,
3795,D,,,,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,Expert,,,,,55,BAO_0000019,F,,14080,,Homo sapiens,9606.0
3796,H,,,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,Autocuration,,,,,55,BAO_0000357,B,,409,,,
3797,H,,,,In vitro inhibition of human recombinant lipoxygenase enzyme,Autocuration,,,,,55,BAO_0000357,B,,409,,,
3798,H,,,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,Autocuration,,,,,55,BAO_0000357,B,,409,,,
3799,H,,,,Inhibition of 5-lipoxygenase in human whole blood.,Expert,,,,178.0,55,BAO_0000357,B,,11090,,,
3800,H,,,,Inhibition of 5-lipoxygenase in human whole blood.,Expert,,,,178.0,55,BAO_0000357,B,,11090,,,
3801,H,,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,Autocuration,,,,,55,BAO_0000357,B,,948,,,
3802,H,,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),Autocuration,,,,,55,BAO_0000357,B,,948,,,
3803,H,,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,Expert,,,,,55,BAO_0000219,F,,13622,,,
3804,H,,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,Autocuration,,,,178.0,55,BAO_0000019,F,,13622,,,
3805,H,,,,In vitro inhibition of 5-lipoxygenase from human polymorphs,Autocuration,,,,,55,BAO_0000357,B,,9637,,,
3806,H,,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),Autocuration,,,,,55,BAO_0000357,B,,11320,,,
3807,H,,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,Expert,,,,,55,BAO_0000357,B,,11320,,,
3808,H,,,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,Autocuration,,,,,55,BAO_0000357,B,,6838,,,
3809,D,,,,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),Expert,,,,178.0,55,BAO_0000357,B,,17667,,Homo sapiens,9606.0
3810,H,,,,In vitro potency against human 5-Lipoxygenase,Autocuration,,,,,55,BAO_0000357,B,,12703,,,
3811,D,,,,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,Expert,,,,,55,BAO_0000019,F,,14312,,Homo sapiens,9606.0
3812,H,,,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,Autocuration,,,,178.0,55,BAO_0000019,F,,14312,,,
3813,H,,,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,Autocuration,,,,,55,BAO_0000019,F,,5364,,,
3814,H,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,Autocuration,,,,,55,BAO_0000219,B,,951,,,
3815,H,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,Autocuration,,,,,55,BAO_0000219,B,,951,,,
3816,H,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,Autocuration,,,,,55,BAO_0000219,B,,951,,,
3817,H,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,Autocuration,,,,,55,BAO_0000219,B,,951,,,
3818,H,,,,Inhibition of human 5-lipoxygenase in human cells,Autocuration,,,,,55,BAO_0000219,B,,12365,,,
3819,H,,,,Inhibition of human neutrophil 5-lipoxygenase,Expert,,,,,55,BAO_0000357,B,,10603,,,
3820,H,,,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,Autocuration,,,,,55,BAO_0000019,B,,10501,,,
3821,H,,,,Inhibition of 5-lipoxygenase from human whole blood,Expert,,,,178.0,55,BAO_0000357,B,,12281,,,
3822,H,,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,Autocuration,,,,,55,BAO_0000357,B,,2567,,,
3823,H,,,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,Autocuration,,,,,55,BAO_0000219,B,,2567,,,
3824,H,,,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,Expert,,,,,55,BAO_0000357,B,,10193,,,
3825,H,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,Autocuration,,,,,55,BAO_0000357,B,,10193,,,
3826,H,,,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,Expert,,,,,55,BAO_0000357,B,,13623,,,
3827,H,,,,Tested against 5-lipoxygenase,Autocuration,,,,,55,BAO_0000357,B,,12780,,,
3828,H,,,,Tested for activity against 5-Lipoxygenase (5-LO),Autocuration,,,,,55,BAO_0000357,B,,12780,,,
3829,H,,,,Tested for activity against 5-lipoxygenase,Autocuration,,,,,55,BAO_0000357,B,,12780,,,
3830,H,,,,Tested for inhibition of 5-HPETE production by human 5-LO,Autocuration,,,,,55,BAO_0000357,B,,11966,,,
3831,H,,,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,Autocuration,,,,,55,BAO_0000019,F,,5364,,,
3832,H,,,,Inhibition of Human 5-lipoxygenase,Expert,,,,,55,BAO_0000357,B,,13165,,,
3833,H,,,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,Autocuration,,,,,55,BAO_0000019,B,,5364,,,
3834,H,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],Autocuration,,,,,55,BAO_0000219,B,,11311,,,
3835,H,,,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],Autocuration,,,,,55,BAO_0000219,B,,11311,,,
3836,H,,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,Autocuration,,,,,55,BAO_0000019,B,,14863,,,
3837,H,,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,Autocuration,,,,,55,BAO_0000019,B,,14863,,,
3838,H,,,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),Autocuration,,,,178.0,55,BAO_0000357,B,,11087,,,
3839,H,,,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,Autocuration,,,,,55,BAO_0000357,B,,455,,,
3840,H,,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),Autocuration,,,,,55,BAO_0000357,B,,13183,,,
3841,H,,,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,Expert,,,,,55,BAO_0000019,B,,10319,,,
3842,H,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,Autocuration,,,,,55,BAO_0000357,B,,10193,,,
3843,H,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,Autocuration,,,,,55,BAO_0000219,B,,951,,,
3844,H,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,Autocuration,,,,,55,BAO_0000219,B,,951,,,
3845,H,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,Autocuration,,,,,55,BAO_0000219,B,,951,,,
3846,H,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,Autocuration,,,,,55,BAO_0000219,B,,951,,,
3847,H,,,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,Expert,,,,,55,BAO_0000357,B,,9859,,,
3848,H,,,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,Expert,,,,,55,BAO_0000357,B,,9859,,,
3849,H,,,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,Autocuration,,,,,55,BAO_0000357,B,,9859,,,
3850,H,,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,Autocuration,,,,,55,BAO_0000357,B,,2567,,,
3851,H,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,Autocuration,,,,,55,BAO_0000357,B,,10193,,,
3852,H,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,Autocuration,,,,,55,BAO_0000357,B,,10193,,,
3853,H,,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,Autocuration,,,,,55,BAO_0000019,B,,949,,,
3854,H,,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,Autocuration,,,,,55,BAO_0000019,B,,949,,,
3855,H,,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,Expert,,,,,55,BAO_0000357,B,,10603,,,
3856,H,,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,Expert,,,,,55,BAO_0000357,B,,10603,,,
3857,H,,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,Autocuration,,,,,55,BAO_0000019,F,,10603,,,
3858,H,,,,Inhibition of lipoxygenase at the concentration of 0.1 uM,Expert,,,,,55,BAO_0000357,B,,10603,,,
3859,H,,,,Inhibition of lipoxygenase at the concentration of 1 uM,Expert,,,,,55,BAO_0000357,B,,10603,,,
3860,H,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,Autocuration,,,,,55,BAO_0000357,B,,10193,,,
3861,D,,,,Inhibition of 5-Lipoxygenase (5-LOX),Expert,,,,,55,BAO_0000357,B,,14580,,Homo sapiens,9606.0
3862,H,,,,Inhibition of 5-lipoxygenase in mouse macrophages.,Expert,,,,,17087,BAO_0000357,B,,11090,,,
3863,H,,,,Inhibition of 5-lipoxygenase in mouse macrophages.,Expert,,,,,17087,BAO_0000357,B,,11090,,,
3864,H,,,,Inhibitory activity against lipoxygenase-2 in mice,Autocuration,,,,,17087,BAO_0000357,B,,6339,,,
3865,H,,,,Inhibitory activity against murine lipoxygenase-2.,Expert,,,,,17087,BAO_0000357,B,,6339,,,
3866,D,,,,Inhibition of 5-lipoxygenase from mouse macrophage,Expert,,,,,17087,BAO_0000357,B,,12281,,Mus musculus,10090.0
3867,H,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,Autocuration,,,,,17087,BAO_0000357,B,,11311,,,
3868,H,,,,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,Autocuration,,,,,55,BAO_0000019,B,,11089,,Sus scrofa,9823.0
3869,H,,,,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,Autocuration,,,,,55,BAO_0000019,B,,10091,,Sus scrofa,9823.0
3870,H,,,,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,Autocuration,,,,,55,BAO_0000019,B,,14352,,Oryctolagus cuniculus,9986.0
3871,D,,,,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,Expert,,,,,12166,BAO_0000019,B,,13329,,Rattus norvegicus,10116.0
3872,H,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",Autocuration,,,,,12166,BAO_0000019,B,,13329,,,
3873,H,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",Autocuration,,,,,12166,BAO_0000019,B,,13329,,,
3874,H,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",Autocuration,,,,,12166,BAO_0000019,B,,13329,,,
3875,H,,,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),Expert,,,,,12166,BAO_0000019,B,,13329,,,
3876,H,,,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",Expert,,,,,12166,BAO_0000019,B,,13329,,,
3877,H,,,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,Autocuration,,,,,12166,BAO_0000019,B,,13329,,,
3878,H,,,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),Autocuration,,,,,12166,BAO_0000019,B,,11311,,,
3879,H,,,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,Autocuration,,,,,12166,BAO_0000019,B,,11311,,,
3880,H,,702.0,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",Autocuration,,RBL-1,,,12166,BAO_0000219,B,,105,,,
3881,H,,702.0,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",Autocuration,,RBL-1,,,12166,BAO_0000219,B,,105,,,
3882,H,,,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),Autocuration,,,,,12166,BAO_0000357,B,,9138,,,
3883,H,,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",Autocuration,,,,,12166,BAO_0000357,B,,9138,,,
3884,H,,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",Autocuration,,,,,12166,BAO_0000357,B,,9138,,,
3885,H,,,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,Autocuration,,,,,12166,BAO_0000357,B,,14427,,,
3886,H,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",Autocuration,,,,,12166,BAO_0000019,B,,13329,,,
3887,H,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",Autocuration,,,,,12166,BAO_0000019,B,,13329,,,
3888,D,,663.0,,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,Expert,,RBL-2H3,,,12166,BAO_0000219,B,,14427,,Rattus norvegicus,10116.0
3889,H,,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,Autocuration,,,,,12166,BAO_0000357,B,,14427,,,
3890,H,,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,Autocuration,,,,,12166,BAO_0000357,B,,14427,,,
3891,H,,702.0,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,Expert,,RBL-1,,,12166,BAO_0000219,B,,10293,,,
3892,D,,702.0,,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,Expert,,RBL-1,,,12166,BAO_0000219,B,,338,,Rattus norvegicus,10116.0
3893,H,,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),Autocuration,,,,,12166,BAO_0000357,B,,303,,,
3894,H,,702.0,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,303,,,
3895,H,,702.0,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,Expert,,RBL-1,,,12166,BAO_0000219,B,,9247,,,
3896,H,,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9247,,,
3897,H,,702.0,,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,137,,,
3898,H,,,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,Expert,,,,,12166,BAO_0000357,B,,11481,,,
3899,H,,,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",Expert,,,,,12166,BAO_0000357,B,,11481,,,
3900,H,,,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,Expert,,,,,12166,BAO_0000357,B,,9029,,,
3901,H,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,Autocuration,,,,,12166,BAO_0000019,B,,1701,,,
3902,H,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,Autocuration,,,,,12166,BAO_0000019,B,,1701,,,
3903,H,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,Autocuration,,,,,12166,BAO_0000019,B,,1701,,,
3904,H,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,Autocuration,,,,,12166,BAO_0000019,B,,1701,,,
3905,H,,702.0,,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,Expert,,RBL-1,,,12166,BAO_0000219,F,,13358,,,
3906,H,,702.0,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,Expert,,RBL-1,,,12166,BAO_0000219,B,,1175,,,
3907,H,,702.0,,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,Expert,,RBL-1,,,12166,BAO_0000219,B,,8797,,,
3908,H,,,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,Autocuration,,,,,12166,BAO_0000019,B,,8797,,,
3909,D,,,,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,Expert,,,,,12166,BAO_0000357,B,,577,,Rattus norvegicus,10116.0
3910,H,,702.0,,In vitro inhibitory activity against RBL-1 5-LO,Expert,,RBL-1,,,12166,BAO_0000219,B,,9295,,,
3911,H,,702.0,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9295,,,
3912,H,,702.0,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9295,,,
3913,H,,,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,Autocuration,,,,,12166,BAO_0000218,B,,9295,,,
3914,H,,,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,Autocuration,,,,,12166,BAO_0000357,B,,9295,,,
3915,H,,,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,Autocuration,,,,,12166,BAO_0000218,B,,216,,,
3916,H,,702.0,,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,11090,,,
3917,H,,,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,Autocuration,,,,178.0,12166,BAO_0000019,B,,11090,,,
3918,H,,,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,Expert,,,,,12166,BAO_0000357,B,,10091,,,
3919,H,,,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,Autocuration,,,,,12166,BAO_0000019,F,,10274,,,
3920,H,,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,Autocuration,,,,,12166,BAO_0000219,F,,13622,,,
3921,H,,702.0,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,Expert,,RBL-1,,,12166,BAO_0000219,B,,12118,,,
3922,H,,,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,Expert,,,,,12166,BAO_0000357,B,,12576,,,
3923,H,,702.0,,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,Expert,,RBL-1,,,12166,BAO_0000219,B,,9546,,,
3924,H,,702.0,,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9521,,,
3925,H,,702.0,,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,Expert,,RBL-1,,,12166,BAO_0000219,B,,10626,,,
3926,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,,
3927,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,,
3928,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,,
3929,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,,
3930,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,,
3931,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,,
3932,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,,
3933,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,,
3934,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,,
3935,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,,
3936,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,,
3937,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,,
3938,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,,
3939,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,,
3940,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,,
3941,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,,
3942,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,,
3943,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,,
3944,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,,
3945,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,,
3946,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,,
3947,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,,
3948,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,,
3949,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,,
3950,H,,,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,Expert,,,,,12166,BAO_0000019,B,,9401,,,
3951,H,,,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,Autocuration,,,,,12166,BAO_0000019,B,,10325,,,
3952,H,,663.0,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,Expert,,RBL-2H3,,,12166,BAO_0000219,F,,1556,,,
3953,H,,663.0,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,Expert,,RBL-2H3,,,12166,BAO_0000219,F,,1556,,,
3954,D,,702.0,,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,Expert,,RBL-1,,,12166,BAO_0000219,B,,961,,Rattus norvegicus,10116.0
3955,H,,,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,Autocuration,,,,,12166,BAO_0000019,B,,6838,,,
3956,H,,,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),Expert,,,,,12166,BAO_0000019,B,,10325,,,
3957,D,,702.0,,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,Expert,,RBL-1,,,12166,BAO_0000219,B,,9209,,Rattus norvegicus,10116.0
3958,H,,702.0,,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,Expert,,RBL-1,,,12166,BAO_0000219,B,,11520,,,
3959,H,,,,In vitro inhibitory activity against 5-lipoxygenase was determined,Autocuration,,,,,12166,BAO_0000357,B,,137,,,
3960,H,,702.0,,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,4717,,,
3961,H,,702.0,,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,Expert,,RBL-1,,,12166,BAO_0000219,B,,10636,,,
3962,D,,,,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,Expert,,,,,12166,BAO_0000019,F,,14312,,Rattus norvegicus,10116.0
3963,H,,702.0,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,1203,,,
3964,H,,,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,Autocuration,,,,,12166,BAO_0000019,B,,1203,,,
3965,H,,702.0,,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,Expert,,RBL-1,,,12166,BAO_0000219,B,,13622,,,
3966,H,,,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,Autocuration,,,,,12166,BAO_0000357,B,,9793,,,
3967,D,,702.0,,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,Expert,,RBL-1,,,12166,BAO_0000219,B,,1143,,Rattus norvegicus,10116.0
3968,D,,702.0,,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,Expert,,RBL-1,,,12166,BAO_0000219,B,,11854,,Rattus norvegicus,10116.0
3969,H,,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),Autocuration,,RBL-1,,,12166,BAO_0000219,B,,3595,,,
3970,H,,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),Autocuration,,RBL-1,,,12166,BAO_0000219,B,,3595,,,
3971,D,,702.0,,Inhibition of 5-lipoxygenase in rat RBL-1 cells,Expert,,RBL-1,,,12166,BAO_0000219,B,,10501,,Rattus norvegicus,10116.0
3972,H,,702.0,,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,Expert,,RBL-1,,,12166,BAO_0000219,B,,12526,,,
3973,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,Autocuration,,,,349.0,10825,BAO_0000019,F,,10034,,,
3974,H,,,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,Autocuration,,,,349.0,10825,BAO_0000019,F,,10034,,,
3975,H,,,,Approximate dose levels for a half maximal reduction of 5-HTP levels,Autocuration,,,,,10825,BAO_0000019,F,,10034,,,
3976,H,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10046,,,
3977,H,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10046,,,
3978,H,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,Autocuration,,,,,10577,BAO_0000019,B,,10046,,,
3979,H,,,,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,Autocuration,,,,178.0,55,BAO_0000019,F,,12079,,Canis lupus familiaris,9615.0
3980,H,,,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,Autocuration,,,,178.0,55,BAO_0000019,F,,12079,,,
3981,H,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],Autocuration,,,,,12166,BAO_0000219,B,,11311,,,
3982,H,,,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,Expert,,,,,17140,BAO_0000219,B,,12338,,,
3983,H,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,Expert,,,,,17140,BAO_0000219,B,,12143,,,
3984,H,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),Autocuration,,,,,17140,BAO_0000219,B,,12143,,,
3985,H,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,Expert,,,,,17140,BAO_0000219,B,,12143,,,
3986,H,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,Autocuration,,,,,17140,BAO_0000219,B,,12143,,,
3987,H,,,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,Expert,,,,,17140,BAO_0000357,B,,12365,,,
3988,H,,,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,Expert,,,,,17140,BAO_0000357,B,,13500,,,
3989,H,,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
3990,H,,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
3991,H,,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
3992,H,,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
3993,H,,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
3994,H,,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
3995,H,,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
3996,H,,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
3997,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
3998,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
3999,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4000,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4001,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4002,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4003,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4004,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4005,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4006,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4007,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4008,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4009,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4010,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4011,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4012,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4013,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4014,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4015,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4016,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4017,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4018,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4019,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4020,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4021,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4022,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4023,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4024,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4025,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4026,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4027,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4028,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4029,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4030,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4031,H,,,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4032,H,,,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4033,H,,,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4034,H,,,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,In vivo,Canis lupus familiaris,9615.0
4035,H,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,Autocuration,,,,,55,BAO_0000218,B,,3595,,Canis lupus familiaris,9615.0
4036,H,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,Autocuration,,,,,55,BAO_0000218,B,,3595,,Canis lupus familiaris,9615.0
4037,H,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,Autocuration,,,,,55,BAO_0000218,B,,3595,,Canis lupus familiaris,9615.0
4038,H,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,Autocuration,,,,,55,BAO_0000218,B,,3595,,Canis lupus familiaris,9615.0
4039,H,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,Autocuration,,,,,55,BAO_0000218,B,,3595,,Canis lupus familiaris,9615.0
4040,H,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,Autocuration,,,,,55,BAO_0000218,B,,3595,,Canis lupus familiaris,9615.0
4041,H,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,Autocuration,,,,,55,BAO_0000218,B,,3595,,Canis lupus familiaris,9615.0
4042,H,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,Autocuration,,,,,55,BAO_0000218,B,,3595,,Canis lupus familiaris,9615.0
4043,H,,,,Ability to inhibit 5-lipoxygenase in guinea pig,Autocuration,,,,,55,BAO_0000357,B,,9203,,Cavia porcellus,10141.0
4044,H,,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),Expert,,,,,55,BAO_0000357,B,,82,,Cavia porcellus,10141.0
4045,H,,,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,Autocuration,,,,,55,BAO_0000357,B,,11090,,Cavia porcellus,10141.0
4046,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,B,,12832,,Cavia porcellus,10141.0
4047,H,,,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,Autocuration,,,,,55,BAO_0000357,B,,1065,,Cavia porcellus,10141.0
4048,H,,,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,Autocuration,,,,,55,BAO_0000357,B,,1065,,Cavia porcellus,10141.0
4049,H,,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,Expert,,,,,55,BAO_0000019,B,,12832,,Cavia porcellus,10141.0
4050,H,,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,Expert,,,,,55,BAO_0000019,B,,12832,,Cavia porcellus,10141.0
4051,H,,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,Autocuration,,,,,55,BAO_0000019,B,,12832,,Cavia porcellus,10141.0
4052,H,,,,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,Autocuration,,,,,55,BAO_0000019,B,,10504,,Cavia porcellus,10141.0
4053,H,,,,Inhibitory activity against 5-lipoxygenase,Autocuration,,,,,55,BAO_0000357,B,,7788,,Cavia porcellus,10141.0
4054,H,,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,Autocuration,,,,,55,BAO_0000357,B,,10001,,Cavia porcellus,10141.0
4055,H,,,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,Autocuration,,,,,55,BAO_0000357,B,,10193,,Cavia porcellus,10141.0
4056,H,,,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,Autocuration,,,,,55,BAO_0000357,B,,13243,,Cavia porcellus,10141.0
4057,H,,,,Inhibitory activity uM,Autocuration,,,,,55,BAO_0000357,B,,13243,,Cavia porcellus,10141.0
4058,H,,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,Autocuration,,,,,55,BAO_0000219,B,,969,,Cavia porcellus,10141.0
4059,H,,,,Inhibitory activity against 5-lipoxygenase at 10 uM,Autocuration,,,,,55,BAO_0000357,B,,10001,,Cavia porcellus,10141.0
4060,H,,,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,Autocuration,,,,,55,BAO_0000357,B,,7788,,Cavia porcellus,10141.0
4061,H,,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,Autocuration,,,,,55,BAO_0000357,B,,10001,,Cavia porcellus,10141.0
4062,H,,,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,Autocuration,,,,,55,BAO_0000357,B,,10193,,Cavia porcellus,10141.0
4063,H,,,,Inhibitory activity uM,Autocuration,,,,,55,BAO_0000357,B,,13243,,Cavia porcellus,10141.0
4064,H,,,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,Autocuration,,,,,55,BAO_0000357,B,,13243,,Cavia porcellus,10141.0
4065,H,,,,Inhibitory activity uM,Expert,,,,,55,BAO_0000357,B,,13243,,Cavia porcellus,10141.0
4066,H,,,,Inhibitory activity uM,Autocuration,,,,,55,BAO_0000019,F,,13243,,Cavia porcellus,10141.0
4067,H,,,,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,Autocuration,,,,,55,BAO_0000019,B,,10504,,Cavia porcellus,10141.0
4068,H,,,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,Autocuration,,,,,55,BAO_0000357,B,,7788,,Cavia porcellus,10141.0
4069,H,,,,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,Expert,,,,2116.0,55,BAO_0000221,F,,10546,,Cavia porcellus,10141.0
4070,H,,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),Autocuration,,,,,55,BAO_0000357,B,,13183,,,
4071,H,,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),Autocuration,,,,,55,BAO_0000357,B,,13183,,,
4072,H,,,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),Autocuration,,,,,55,BAO_0000357,B,,2578,,,
4073,H,,,,In vitro inhibition of human 5-Lipoxygenase.,Expert,,,,,55,BAO_0000357,B,,12780,,,
4074,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4075,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4076,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4077,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4078,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4079,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4080,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4081,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4082,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4083,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4084,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4085,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4086,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4087,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4088,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4089,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4090,U,,,,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4091,U,,,,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4092,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4093,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4094,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4095,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4096,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4097,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4098,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4099,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4100,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4101,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4102,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4103,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4104,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4105,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4106,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4107,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4108,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4109,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4110,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4111,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4112,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4113,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4114,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4115,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4116,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4117,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4118,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4119,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4120,U,,,,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4121,U,,,,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,Autocuration,,,,,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4122,U,,,,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4123,U,,,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4124,U,,,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4125,U,,,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4126,U,,,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4127,N,,741.0,,In vitro inhibition of 7226/S myeloma cancer cell line,Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,10797,,Homo sapiens,9606.0
4128,N,,993.0,,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),Intermediate,,BEL-7404 tumor cell line,,,80698,BAO_0000219,F,,6881,,Homo sapiens,9606.0
4129,N,,391.0,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,Intermediate,,786-0,,,80640,BAO_0000219,F,,3838,,Homo sapiens,9606.0
4130,N,,391.0,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,Intermediate,,786-0,,,80640,BAO_0000219,F,,3838,,Homo sapiens,9606.0
4131,N,,505.0,,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,Expert,,V79,,,81264,BAO_0000219,F,,12981,,Cricetulus griseus,10029.0
4132,N,,505.0,,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,Expert,,V79,,,81264,BAO_0000219,F,,12981,,Cricetulus griseus,10029.0
4133,N,,1119.0,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,Intermediate,,7800C1 cell line,,,80635,BAO_0000219,F,,7653,,Rattus norvegicus,10116.0
4134,N,,1119.0,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,Intermediate,,7800C1 cell line,,,80635,BAO_0000219,F,,7653,,Rattus norvegicus,10116.0
4135,N,,1119.0,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,Intermediate,,7800C1 cell line,,,80635,BAO_0000219,F,,7653,,Rattus norvegicus,10116.0
4136,N,,1119.0,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,Intermediate,,7800C1 cell line,,,80635,BAO_0000219,F,,7653,,Rattus norvegicus,10116.0
4137,N,,1119.0,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,Intermediate,,7800C1 cell line,,,80635,BAO_0000219,F,,7653,,Rattus norvegicus,10116.0
4138,N,,1119.0,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,Intermediate,,7800C1 cell line,,,80635,BAO_0000219,F,,7653,,Rattus norvegicus,10116.0
4139,N,,391.0,,In vitro antitumor activity against renal 786-0 tumor cell lines,Intermediate,,786-0,,,80640,BAO_0000219,F,,17229,,Homo sapiens,9606.0
4140,N,,391.0,,Cytotoxic activity against 786-0 Renal cancer cell line,Intermediate,,786-0,,,80640,BAO_0000219,F,,12858,,Homo sapiens,9606.0
4141,N,,391.0,,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,Intermediate,,786-0,,,80640,BAO_0000219,F,,16325,,Homo sapiens,9606.0
4142,N,,391.0,,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,Intermediate,,786-0,,,80640,BAO_0000219,F,,16325,,Homo sapiens,9606.0
4143,N,,391.0,,In vitro antitumor activity against human renal 786-0 cell line,Intermediate,,786-0,,,80640,BAO_0000219,F,,5858,,Homo sapiens,9606.0
4144,N,,391.0,,Inhibition of Renal cancer in 786-0 cancer cell lines,Intermediate,,786-0,,,80640,BAO_0000219,F,,16325,,Homo sapiens,9606.0
4145,N,,391.0,,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,Intermediate,,786-0,,,80640,BAO_0000219,F,,14696,,Homo sapiens,9606.0
4146,N,,391.0,,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,Intermediate,,786-0,,,80640,BAO_0000219,F,,3786,,Homo sapiens,9606.0
4147,N,,391.0,,inhibition of the growth of renal cancer(786-0) cell line,Intermediate,,786-0,,,80640,BAO_0000219,F,,14696,,Homo sapiens,9606.0
4148,N,,391.0,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),Intermediate,,786-0,,,80640,BAO_0000219,F,,14769,,Homo sapiens,9606.0
4149,N,,391.0,,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,Intermediate,,786-0,,,80640,BAO_0000219,F,,15354,,Homo sapiens,9606.0
4150,N,,391.0,,The IC50 value was measured on 786-0 cell line in ovarian tumor,Intermediate,,786-0,,,80640,BAO_0000219,F,,14255,,Homo sapiens,9606.0
4151,N,,391.0,,The IC50 value was measured on 786-0 cell line in ovarian tumor t,Intermediate,,786-0,,,80640,BAO_0000219,F,,14255,,Homo sapiens,9606.0
4152,N,,391.0,,The IC50 value was measured on 786-0 cell line in renal tumor type.,Intermediate,,786-0,,,80640,BAO_0000219,F,,14255,,Homo sapiens,9606.0
4153,N,,391.0,,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,Intermediate,,786-0,,,80640,BAO_0000219,F,,14696,,Homo sapiens,9606.0
4154,N,,391.0,,Tested for cytotoxic activity against renal cancer 786-0 cell line,Intermediate,,786-0,,,80640,BAO_0000219,F,,12016,,Homo sapiens,9606.0
4155,N,,391.0,,Compound was tested for growth inhibitory activity against 786-0 cell line,Intermediate,,786-0,,,80640,BAO_0000219,F,,2597,,Homo sapiens,9606.0
4156,H,,702.0,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,12526,,,
4157,H,,702.0,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,12526,,,
4158,H,,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,Autocuration,,,,,12166,BAO_0000019,B,,14799,,,
4159,H,,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),Expert,,RBL-1,,,12166,BAO_0000219,B,,3595,,,
4160,H,,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),Expert,,RBL-1,,,12166,BAO_0000219,B,,3595,,,
4161,H,,,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,Autocuration,,,,,12166,BAO_0000357,B,,12767,,,
4162,H,,,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,Autocuration,,,,,12166,BAO_0000219,B,,10997,,,
4163,H,,702.0,,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,11388,,,
4164,H,,,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,Autocuration,,,,,12166,BAO_0000357,B,,167,,,
4165,H,,,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",Autocuration,,,,,12166,BAO_0000357,B,,167,,,
4166,H,,,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,Expert,,,,,12166,BAO_0000357,B,,13744,,,
4167,H,,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,Autocuration,,,,,12166,BAO_0000357,B,,1630,,,
4168,H,,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),Autocuration,,,,,12166,BAO_0000357,B,,1630,,,
4169,D,,,,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",Expert,,,,,12166,BAO_0000019,B,,969,,Rattus norvegicus,10116.0
4170,H,,702.0,,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,13621,,,
4171,H,,,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,Autocuration,,,,,12166,BAO_0000357,B,,10089,,,
4172,H,,,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,Expert,,,,,12166,BAO_0000357,B,,10193,,,
4173,H,,,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,Autocuration,,,,,12166,BAO_0000357,B,,11966,,,
4174,H,,,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,Autocuration,,,,,12166,BAO_0000019,B,,12251,,,
4175,H,,702.0,,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),Autocuration,,RBL-1,,,12166,BAO_0000219,B,,211,,,
4176,H,,,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,Expert,,,,,12166,BAO_0000019,F,,12251,,,
4177,H,,702.0,,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,12495,,,
4178,H,,,,Tested for its inhibitory activity against 5-lipoxygenase,Autocuration,,,,,12166,BAO_0000357,B,,414,,,
4179,H,,,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,Autocuration,,,,,12166,BAO_0000357,B,,414,,,
4180,H,,,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",Expert,,,,,12166,BAO_0000019,B,,10325,,,
4181,H,,,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,Expert,,,,,12166,BAO_0000019,B,,11966,,,
4182,H,,702.0,,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,Expert,,RBL-1,,,12166,BAO_0000219,B,,165,,,
4183,H,,702.0,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,165,,,
4184,H,,702.0,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,165,,,
4185,H,,702.0,,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,Expert,,RBL-1,,,12166,BAO_0000219,B,,165,,,
4186,H,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,Autocuration,,,,,12166,BAO_0000218,B,,11311,,,
4187,H,,702.0,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,11311,,,
4188,H,,702.0,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,11311,,,
4189,H,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],Autocuration,,,,,12166,BAO_0000219,B,,11311,,,
4190,H,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),Autocuration,,,,,12166,BAO_0000219,B,,11311,,,
4191,H,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),Autocuration,,,,,12166,BAO_0000218,B,,11311,In vivo,,
4192,H,,663.0,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,Autocuration,,RBL-2H3,,,12166,BAO_0000219,F,,11311,,,
4193,H,,663.0,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,Autocuration,,RBL-2H3,,,12166,BAO_0000219,F,,11311,,,
4194,H,,,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],Autocuration,,,,,12166,BAO_0000019,B,,11311,,,
4195,H,,,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,Autocuration,,,,,12166,BAO_0000019,B,,11732,,,
4196,H,,,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,Expert,,,,,12166,BAO_0000019,B,,11732,,,
4197,H,,,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,Expert,,,,,12166,BAO_0000019,B,,11087,,,
4198,H,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,Autocuration,,,,,12166,BAO_0000019,B,,11087,,,
4199,H,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,11087,,,
4200,D,,,,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,Expert,,,,,12166,BAO_0000357,B,,11087,,Rattus norvegicus,10116.0
4201,H,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,496,,,
4202,H,,702.0,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,Expert,,RBL-1,,,12166,BAO_0000219,F,,13986,,,
4203,H,,,,Compound was evaluated for the inhibition of 5-lipoxygenase,Autocuration,,,,,12166,BAO_0000357,B,,11520,,,
4204,H,,702.0,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,10293,,,
4205,H,,702.0,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,303,,,
4206,H,,702.0,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,303,,,
4207,H,,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9247,,,
4208,D,,702.0,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,Expert,,RBL-1,,,12166,BAO_0000219,B,,9247,,Rattus norvegicus,10116.0
4209,H,,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9247,,,
4210,H,,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9247,,,
4211,H,,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9247,,,
4212,H,,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9247,,,
4213,H,,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9247,,,
4214,H,,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9247,,,
4215,D,,,,Inhibitory activity against 5-lipoxygenase at 10 uM,Expert,,,,,12166,BAO_0000357,B,,11481,,Rattus norvegicus,10116.0
4216,H,,,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,Autocuration,,,,,12166,BAO_0000357,B,,105,,,
4217,H,,,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,Expert,,,,,12166,BAO_0000357,B,,9029,,,
4218,H,,702.0,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,Expert,,RBL-1,,,12166,BAO_0000219,B,,1175,,,
4219,H,,702.0,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,12118,,,
4220,H,,702.0,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,12118,,,
4221,H,,702.0,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,12118,,,
4222,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,,
4223,H,,,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,Autocuration,,,,,12166,BAO_0000019,B,,9401,,,
4224,H,,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,Autocuration,,,,,12166,BAO_0000357,B,,137,,,
4225,H,,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,Autocuration,,,,,12166,BAO_0000357,B,,137,,,
4226,H,,702.0,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,4717,,,
4227,H,,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,3595,,,
4228,H,,702.0,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,10501,,,
4229,H,,702.0,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,10501,,,
4230,H,,702.0,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,10501,,,
4231,H,,702.0,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,12526,,,
4232,D,,702.0,,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,Expert,,RBL-1,,,12166,BAO_0000219,B,,14799,,Rattus norvegicus,10116.0
4233,H,,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,Autocuration,,,,,12166,BAO_0000019,B,,14799,,,
4234,H,,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,3595,,,
4235,H,,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,Expert,,RBL-1,,,12166,BAO_0000219,B,,3595,,,
4236,H,,702.0,,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,12526,,,
4237,H,,702.0,,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,12526,,,
4238,H,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,Autocuration,,,,,12166,BAO_0000019,B,,10193,,,
4239,H,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,Autocuration,,,,,12166,BAO_0000019,B,,10193,,,
4240,H,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,Autocuration,,,,,12166,BAO_0000019,B,,10193,,,
4241,H,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,Autocuration,,,,,12166,BAO_0000019,B,,10193,,,
4242,H,,,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),Expert,,,,,12166,BAO_0000357,B,,9138,,,
4243,H,,,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,Autocuration,,,,,12166,BAO_0000357,B,,9138,,,
4244,H,,,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,Autocuration,,,,,12166,BAO_0000019,B,,11966,,,
4245,H,,702.0,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,165,,,
4246,H,,702.0,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,165,,,
4247,H,,663.0,,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,Autocuration,,RBL-2H3,,,12166,BAO_0000219,B,,11311,,,
4248,H,,663.0,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,Autocuration,,RBL-2H3,,,12166,BAO_0000219,B,,11311,,,
4249,H,,663.0,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,Autocuration,,RBL-2H3,,,12166,BAO_0000219,F,,11311,,,
4250,H,,,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,Autocuration,,,,,12166,BAO_0000019,F,,11311,,,
4251,H,,,,The compound was tested for inhibition of isolated 5-lipoxygenase,Autocuration,,,,,12166,BAO_0000357,B,,11311,,,
4252,H,,663.0,,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,Autocuration,,RBL-2H3,,,12166,BAO_0000219,F,,11311,,,
4253,H,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,Autocuration,,,,,12166,BAO_0000019,B,,11087,,,
4254,H,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,Autocuration,,,,,12166,BAO_0000019,B,,11087,,,
4255,H,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,Autocuration,,,,,12166,BAO_0000019,B,,11087,,,
4256,H,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,Autocuration,,,,,12166,BAO_0000019,B,,11087,,,
4257,H,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,Autocuration,,,,,12166,BAO_0000019,B,,11087,,,
4258,H,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,496,,,
4259,H,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,496,,,
4260,H,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,F,,13986,,,
4261,H,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,F,,13986,,,
4262,H,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,Autocuration,,RBL-1,,,12166,BAO_0000219,F,,13986,,,
4263,H,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,F,,13986,,,
4264,H,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,Autocuration,,RBL-1,,,12166,BAO_0000219,F,,13986,,,
4265,H,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,F,,13986,,,
4266,H,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,F,,13986,,,
4267,H,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,F,,13986,,,
4268,H,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,F,,13986,,,
4269,D,,,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,Expert,,,,,12166,BAO_0000019,F,,13986,,Rattus norvegicus,10116.0
4270,H,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,Autocuration,,,,,12166,BAO_0000357,B,,10193,,,
4271,H,,,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,Autocuration,,,,,12166,BAO_0000357,B,,9295,,,
4272,H,,702.0,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,4717,,,
4273,H,,702.0,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,4717,,,
4274,H,,702.0,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,11854,,,
4275,H,,702.0,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,11854,,,
4276,H,,702.0,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,11854,,,
4277,H,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,Autocuration,,,,,12166,BAO_0000019,B,,10193,,,
4278,H,,702.0,,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9295,,,
4279,H,,702.0,,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9295,,,
4280,H,,702.0,,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9295,,,
4281,H,,702.0,,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9295,,,
4282,H,,702.0,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,165,,,
4283,H,,,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,Autocuration,,,,,12166,BAO_0000219,B,,11311,,,
4284,H,,702.0,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),Expert,,RBL-1,,,12166,BAO_0000219,B,,10489,,Homo sapiens,9606.0
4285,D,,702.0,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),Expert,,RBL-1,,,12166,BAO_0000219,B,,10489,,Rattus norvegicus,10116.0
4286,D,,702.0,,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),Expert,,RBL-1,,,12166,BAO_0000219,B,,10489,,Rattus norvegicus,10116.0
4287,D,,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,Autocuration,,,,,12166,BAO_0000019,B,,14799,,Rattus norvegicus,10116.0
4288,H,,,,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),Autocuration,,,,,12054,BAO_0000357,B,,9295,,Glycine max,3847.0
4289,U,,,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",Autocuration,,,,,22226,BAO_0000019,B,,16811,,,
4290,H,,,,In vitro inhibition of 5-Lipoxygenase; Inactive.,Expert,,,,,55,BAO_0000357,B,,168,,,
4291,H,,,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,Autocuration,,,,,55,BAO_0000357,B,,6309,,,
4292,H,,,,Inhibitory concentration against 5-lipoxygenase; No inhibition,Autocuration,,,,,55,BAO_0000357,B,,6309,,,
4293,H,,702.0,,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,Autocuration,,RBL-1,,,55,BAO_0000219,B,,3092,,,
4294,H,,,,Inhibitory activity against 5-lipoxygenase.,Expert,,,,,55,BAO_0000357,B,,168,,,
4295,H,,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,Autocuration,,,,,55,BAO_0000357,B,,168,,,
4296,H,,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,Autocuration,,,,,55,BAO_0000357,B,,168,,,
4297,H,,,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,Autocuration,,,,,55,BAO_0000357,B,,168,,,
4298,H,,,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,Expert,,,,,55,BAO_0000019,F,,12338,,,
4299,H,,,,Tested for the inhibitory activity against 5-lipoxygenase,Autocuration,,,,,55,BAO_0000357,B,,4501,,,
4300,H,,,,Compound was tested for its inhibitory activity against 5-lipoxygenase,Autocuration,,,,,55,BAO_0000357,B,,1132,,,
4301,H,,,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,Autocuration,,,,,55,BAO_0000357,B,,2117,,,
4302,H,,,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,Autocuration,,,,,55,BAO_0000357,B,,168,,,
4303,H,,,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,Autocuration,,,,,55,BAO_0000357,B,,168,,,
4304,H,,702.0,,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,13575,,,
4305,H,,,,,Autocuration,,,,,12166,BAO_0000357,B,,11089,,,
4306,H,,,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),Autocuration,,,,,10102,BAO_0000357,B,,216,,,
4307,H,,,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,Autocuration,,,,,10102,BAO_0000019,B,,13165,,,
4308,H,,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,Autocuration,,,,,10102,BAO_0000357,B,,3278,,,
4309,H,,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,Expert,,,,,10102,BAO_0000357,B,,3278,,,
4310,H,,,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,Autocuration,,,,,10102,BAO_0000357,B,,11966,,,
4311,H,,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",Autocuration,,,,,10102,BAO_0000357,B,,175,,,
4312,H,,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",Autocuration,,,,,10102,BAO_0000357,B,,175,,,
4313,H,,,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,Autocuration,,,,,10102,BAO_0000357,B,,13449,,,
4314,H,,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,Autocuration,,,,,11238,BAO_0000019,B,,12014,,,
4315,H,,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),Autocuration,,,,,11238,BAO_0000019,B,,12014,,,
4316,H,,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),Autocuration,,,,,11238,BAO_0000019,B,,12014,,,
4317,S,,,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,Intermediate,,,,,100284,BAO_0000220,B,,99,,,
4318,U,,,,The dark toxicity against 543 human galactophore carcinoma cells,Autocuration,,,,,22226,BAO_0000019,F,,4349,,Homo sapiens,9606.0
4319,N,,390.0,,Tested in vitro for cytotoxicity against 56 human tumor cell lines,Expert,,Panel (56 tumour cell lines),,,80623,BAO_0000219,F,,4071,,Homo sapiens,9606.0
4320,N,,345.0,,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,Expert,,5637,,,80008,BAO_0000219,F,,17589,,Homo sapiens,9606.0
4321,N,,345.0,,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,Intermediate,,5637,,,80008,BAO_0000219,F,,15002,,Homo sapiens,9606.0
4322,N,,345.0,,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",Intermediate,,5637,,,80008,BAO_0000219,F,,13958,,Homo sapiens,9606.0
4323,N,,345.0,,Growth inhibition against human 5637 cell lines,Expert,,5637,,,80008,BAO_0000219,F,,17589,,Homo sapiens,9606.0
4324,N,,345.0,,Antitumor activity against human bladder carcinoma 5637 cells.,Expert,,5637,,,80008,BAO_0000219,F,,16748,,Homo sapiens,9606.0
4325,N,,345.0,,Antitumor activity against human bladder carcinoma 5637 cells,Intermediate,,5637,,,80008,BAO_0000219,F,,16747,,Homo sapiens,9606.0
4326,N,,345.0,,Antitumor activity against human bladder carcinoma 5637 cells,Intermediate,,5637,,,80008,BAO_0000219,F,,16747,,Homo sapiens,9606.0
4327,D,,,,In vitro inhibition of bovine trypsin(Trp).,Expert,,,,,10443,BAO_0000357,B,,15285,,Bos taurus,9913.0
4328,H,,407.0,,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,Expert,,CV-1,,,240,BAO_0000219,B,,3726,,Cercopithecidae,9527.0
4329,H,,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,Autocuration,,,,,10577,BAO_0000357,B,,5033,,,
4330,H,,,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,Autocuration,,,,,104698,BAO_0000019,F,,11756,,,
4331,U,,,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,Autocuration,,,,,22226,BAO_0000218,F,,11953,In vivo,,
4332,D,,,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,Intermediate,,,,,20033,BAO_0000357,B,,5033,,Cavia porcellus,10141.0
4333,H,,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Expert,,,,,17045,BAO_0000251,A,Microsomes,11347,,Rattus norvegicus,10116.0
4334,H,,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Expert,,,,,17045,BAO_0000251,A,Microsomes,11347,,Rattus norvegicus,10116.0
4335,U,,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,Intermediate,,,,,22226,BAO_0000019,F,,1229,,,
4336,U,,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,Intermediate,,,,,22226,BAO_0000019,F,,1229,,,
4337,H,,,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,Expert,,,,,11938,BAO_0000019,B,,17588,,Trypanosoma brucei,5691.0
4338,H,,,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,Autocuration,,,,,11938,BAO_0000019,B,,17588,,Trypanosoma brucei,5691.0
4339,H,,,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,Expert,,,,,11938,BAO_0000019,B,,17588,,Ovis aries,9940.0
4340,H,,,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,Autocuration,,,,,11938,BAO_0000019,B,,17588,,Ovis aries,9940.0
4341,H,,,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,Autocuration,,,,,11938,BAO_0000357,B,,16485,,,
4342,U,,,,Average inhibitory concentration against 60 human cell lines was reported,Intermediate,,,,,22226,BAO_0000019,F,,4337,,Homo sapiens,9606.0
4343,U,,,,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,Expert,,,,,22226,BAO_0000019,F,,4112,,Homo sapiens,9606.0
4344,N,,542.0,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,Intermediate,,Panel NCI-60 (60 carcinoma cell lines),,,80315,BAO_0000219,F,,16160,,Homo sapiens,9606.0
4345,N,,542.0,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,Intermediate,,Panel NCI-60 (60 carcinoma cell lines),,,80315,BAO_0000219,F,,16160,,Homo sapiens,9606.0
4346,N,,542.0,,In vitro mean growth inhibitory activity against 60-cell panel,Expert,,Panel NCI-60 (60 carcinoma cell lines),,,80315,BAO_0000219,F,,17376,,,
4347,N,,542.0,,In vitro mean growth lethal concentration against 60-cell panel,Expert,,Panel NCI-60 (60 carcinoma cell lines),,,80315,BAO_0000219,F,,17376,,,
4348,N,,542.0,,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,Expert,,Panel NCI-60 (60 carcinoma cell lines),,,80315,BAO_0000219,F,,17376,,,
4349,N,,542.0,,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,Expert,,Panel NCI-60 (60 carcinoma cell lines),,,80315,BAO_0000219,F,,17376,,,
4350,H,,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,Autocuration,,,,,104775,BAO_0000019,F,,3241,,,
4351,H,,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,Autocuration,,,,,104775,BAO_0000019,F,,3241,,,
4352,H,,,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,Expert,,,,,275,BAO_0000357,B,,3725,,,
4353,N,,,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,Expert,,,,,50425,BAO_0000218,F,,10805,,Plasmodium falciparum,5833.0
4354,N,,,,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,Expert,,,,,50425,BAO_0000218,F,,10805,,Plasmodium falciparum,5833.0
4355,N,,,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,Expert,,,,,50425,BAO_0000218,F,,10805,,Plasmodium falciparum,5833.0
4356,N,,,,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,Expert,,,,,50425,BAO_0000218,F,,10805,,Plasmodium falciparum,5833.0
4357,N,,,,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,Intermediate,,,,,50425,BAO_0000218,F,,10805,,Plasmodium falciparum,5833.0
4358,N,,850.0,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,Intermediate,,6C3HED,,,80628,BAO_0000218,F,,10144,,Mus musculus,10090.0
4359,N,,850.0,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,Intermediate,,6C3HED,,,80628,BAO_0000218,F,,10144,,Mus musculus,10090.0
4360,N,,850.0,,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,Intermediate,,6C3HED,,,80628,BAO_0000218,F,,10144,,Mus musculus,10090.0
4361,N,,850.0,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,Intermediate,,6C3HED,,,80628,BAO_0000218,F,,10144,,Mus musculus,10090.0
4362,N,,850.0,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,Intermediate,,6C3HED,,,80628,BAO_0000218,F,,10144,,Mus musculus,10090.0
4363,N,,850.0,,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,Intermediate,,6C3HED,,,80628,BAO_0000218,F,,10144,,Mus musculus,10090.0
4364,U,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,Autocuration,,,,,22224,BAO_0000218,F,,10685,In vivo,Mus musculus,10090.0
4365,U,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,Autocuration,,,,,22224,BAO_0000218,F,,10685,In vivo,Mus musculus,10090.0
4366,U,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),Autocuration,,,,,22224,BAO_0000218,F,,10685,In vivo,Mus musculus,10090.0
4367,U,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,Autocuration,,,,,22224,BAO_0000218,F,,10685,In vivo,Mus musculus,10090.0
4368,U,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,Autocuration,,,,,22224,BAO_0000218,F,,10685,In vivo,Mus musculus,10090.0
4369,U,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,Autocuration,,,,,22224,BAO_0000218,F,,10685,In vivo,Mus musculus,10090.0
4370,U,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,Autocuration,,,,,22224,BAO_0000218,F,,10685,In vivo,Mus musculus,10090.0
4371,U,,,,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",Autocuration,,,,,22224,BAO_0000218,F,,10685,In vivo,Mus musculus,10090.0
4372,U,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),Autocuration,,,,,22224,BAO_0000218,F,,10685,In vivo,Mus musculus,10090.0
4373,U,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),Autocuration,,,,,22224,BAO_0000218,F,,10685,In vivo,Mus musculus,10090.0
4374,U,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,Autocuration,,,,,22224,BAO_0000218,F,,10685,In vivo,Mus musculus,10090.0
4375,U,,,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,Autocuration,,,,,22224,BAO_0000218,F,,10144,,Mus musculus,10090.0
4376,U,,,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,Autocuration,,,,,22224,BAO_0000218,F,,10144,,Mus musculus,10090.0
4377,U,,,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,Autocuration,,,,,22224,BAO_0000218,F,,10144,,Mus musculus,10090.0
4378,U,,,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,Autocuration,,,,,22224,BAO_0000218,F,,10144,,Mus musculus,10090.0
4379,U,,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,Autocuration,,,,,22224,BAO_0000218,F,,10685,,Mus musculus,10090.0
4380,U,,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,Autocuration,,,,,22224,BAO_0000218,F,,10685,,Mus musculus,10090.0
4381,U,,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,Autocuration,,,,,22224,BAO_0000218,F,,10685,,Mus musculus,10090.0
4382,U,,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,Autocuration,,,,,22224,BAO_0000218,F,,10685,,Mus musculus,10090.0
4383,U,,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,Autocuration,,,,,22224,BAO_0000218,A,,10685,,Mus musculus,10090.0
4384,U,,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,Autocuration,,,,,22224,BAO_0000218,A,,10685,,Mus musculus,10090.0
4385,U,,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,Autocuration,,,,,22224,BAO_0000218,A,,10685,,Mus musculus,10090.0
4386,U,,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,Autocuration,,,,,22224,BAO_0000218,A,,10685,,Mus musculus,10090.0
4387,N,,850.0,,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",Intermediate,,6C3HED,,,80628,BAO_0000218,F,,8831,,Mus musculus,10090.0
4388,U,,,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,Autocuration,,,,,22224,BAO_0000218,F,,11704,In vivo,,
4389,N,,,,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,Intermediate,,,,,50594,BAO_0000218,A,,11704,,Mus musculus,10090.0
4390,N,,850.0,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,Intermediate,,6C3HED,,,80628,BAO_0000218,F,,10685,In vivo,Mus musculus,10090.0
4391,N,,850.0,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,Intermediate,,6C3HED,,,80628,BAO_0000218,F,,10685,In vivo,Mus musculus,10090.0
4392,N,,850.0,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),Expert,,6C3HED,,,80628,BAO_0000218,F,,11368,,Mus musculus,10090.0
4393,N,,850.0,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),Intermediate,,6C3HED,,,80628,BAO_0000218,F,,11368,,Mus musculus,10090.0
4394,N,,850.0,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),Expert,,6C3HED,,,80628,BAO_0000218,F,,11368,,Mus musculus,10090.0
4395,U,,,,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",Autocuration,,,,,22226,BAO_0000019,B,,17763,,Staphylococcus aureus,1280.0
4396,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4397,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4398,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4399,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4400,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4401,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4402,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4403,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4404,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4405,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4406,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4407,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,,Rattus norvegicus,10116.0
4408,U,,,,The apparent total plasma clearance in monkey,Autocuration,,,,1969.0,22224,BAO_0000218,A,,347,In vivo,Cercopithecidae,9527.0
4409,U,,,,Compound was evaluated for Hepatic clearance in monkey,Autocuration,,,,,22224,BAO_0000218,A,,3341,In vivo,Cercopithecidae,9527.0
4410,U,,,,Lower clearance in monkey (i.v.) at 0.5 mpk,Autocuration,,,,,22224,BAO_0000218,A,,17853,In vivo,Cercopithecidae,9527.0
4411,U,,,,Plasma clearance in rhesus monkey,Autocuration,,,,,22224,BAO_0000218,A,,4514,In vivo,Cercopithecidae,9527.0
4412,U,,,,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,6062,In vivo,Cercopithecidae,9527.0
4413,U,,,,Plasma clearance of compound was determined in monkey,Autocuration,,,,,22224,BAO_0000218,A,,6821,In vivo,Cercopithecidae,9527.0
4414,U,,,,Plasma clearance was calculated in rhesus monkey,Autocuration,,,,,22224,BAO_0000218,A,,6057,In vivo,Cercopithecidae,9527.0
4415,U,,,,Plasma clearance in rhesus monkey,Autocuration,,,,,22224,BAO_0000218,A,,5145,In vivo,Cercopithecidae,9527.0
4416,U,,,,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),Autocuration,,,,,22224,BAO_0000218,A,,6641,In vivo,Cercopithecidae,9527.0
4417,U,,,,Plasma clearance was evaluated in rhesus,Autocuration,,,,,22224,BAO_0000218,A,,5472,In vivo,Cercopithecidae,9527.0
4418,U,,,,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,Autocuration,,,,,22224,BAO_0000218,A,,4257,In vivo,Cercopithecidae,9527.0
4419,U,,,,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,Autocuration,,,,,22224,BAO_0000218,A,,5546,In vivo,Cercopithecidae,9527.0
4420,U,,,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Autocuration,,,,,22224,BAO_0000218,A,,5334,In vivo,Cercopithecidae,9527.0
4421,U,,,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Autocuration,,,,,22224,BAO_0000218,A,,5334,In vivo,Cercopithecidae,9527.0
4422,U,,,,Cmax 24 hr after 2 mg/kg oral administration in monkeys,Autocuration,,,,,22224,BAO_0000218,A,,17509,In vivo,Cercopithecidae,9527.0
4423,U,,,,Cmax in monkey after administration of 1 mg/kg iv,Autocuration,,,,,22224,BAO_0000218,A,,6535,In vivo,Cercopithecidae,9527.0
4424,U,,,,Cmax was determine after peroral administration at 10 mpk in Rhesus,Autocuration,,,,,22224,BAO_0000218,A,,5668,In vivo,Cercopithecidae,9527.0
4425,U,,,,Cmax in cynomolgus monkey by iv administration,Autocuration,,,,,22224,BAO_0000218,A,,5922,In vivo,Cercopithecidae,9527.0
4426,U,,,,Cmax in cynomolgus monkey by po administration,Autocuration,,,,,22224,BAO_0000218,A,,5922,In vivo,Cercopithecidae,9527.0
4427,U,,,,Cmax value evaluated in monkey,Autocuration,,,,,22224,BAO_0000218,A,,6078,In vivo,Cercopithecidae,9527.0
4428,U,,,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,2661,In vivo,Cercopithecidae,9527.0
4429,U,,,,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,Autocuration,,,,1969.0,22224,BAO_0000218,A,,3249,In vivo,Cercopithecidae,9527.0
4430,U,,,,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,Autocuration,,,,1969.0,22224,BAO_0000218,A,,3249,In vivo,Cercopithecidae,9527.0
4431,U,,,,Maximal plasma concentration in squirrel monkeys,Autocuration,,,,1969.0,22224,BAO_0000218,A,,5553,In vivo,Cercopithecidae,9527.0
4432,U,,,,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Autocuration,,,,,22224,BAO_0000218,A,,1916,In vivo,Cercopithecidae,9527.0
4433,U,,,,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,Autocuration,,,,1969.0,22224,BAO_0000218,A,,6227,In vivo,Cercopithecidae,9527.0
4434,U,,,,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),Autocuration,,,,,22224,BAO_0000218,A,,4809,In vivo,Cercopithecidae,9527.0
4435,U,,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,Autocuration,,,,,22224,BAO_0000218,A,,5355,In vivo,Cercopithecidae,9527.0
4436,U,,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,Autocuration,,,,,22224,BAO_0000218,A,,5355,In vivo,Cercopithecidae,9527.0
4437,U,,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,Autocuration,,,,,22224,BAO_0000218,A,,5355,In vivo,Cercopithecidae,9527.0
4438,U,,,,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,Autocuration,,,,,22224,BAO_0000218,A,,5355,In vivo,Cercopithecidae,9527.0
4439,U,,,,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,Autocuration,,,,1969.0,22224,BAO_0000218,A,,6221,In vivo,Cercopithecidae,9527.0
4440,U,,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,Autocuration,,,,,22224,BAO_0000218,A,,167,,Cercopithecidae,9527.0
4441,U,,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,Autocuration,,,,,22224,BAO_0000218,A,,167,,Cercopithecidae,9527.0
4442,U,,,,Absolute bioavailability was evaluated in monkey,Autocuration,,,,,22224,BAO_0000218,A,,4257,In vivo,monkey,9443.0
4443,U,,,,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,Autocuration,,,,,22224,BAO_0000218,A,,6221,In vivo,monkey,9443.0
4444,U,,,,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,Autocuration,,,,,22224,BAO_0000218,A,,17667,In vivo,monkey,9443.0
4445,U,,,,Bioavailability of compound was determined in rhesus monkey,Autocuration,,,,,22224,BAO_0000218,A,,17267,In vivo,Macaca mulatta,9544.0
4446,U,,,,Bioavailability determined after oral administration in marmoset,Autocuration,,,,,22224,BAO_0000218,A,,4256,In vivo,marmosets,38020.0
4447,U,,,,Oral bioavailability in cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,4256,In vivo,Macaca fascicularis,9541.0
4448,U,,,,Bioavailability in monkey (p.o.) at 2.0 mpk,Autocuration,,,,,22224,BAO_0000218,A,,17853,In vivo,monkey,9443.0
4449,U,,,,Bioavailability was evaluated after oral administration in monkey,Autocuration,,,,,22224,BAO_0000218,A,,16365,In vivo,monkey,9443.0
4450,U,,,,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Autocuration,,,,,22224,BAO_0000218,A,,1916,In vivo,Macaca fascicularis,9541.0
4451,U,,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Autocuration,,,,,22224,BAO_0000218,A,,5334,In vivo,Macaca mulatta,9544.0
4452,U,,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Autocuration,,,,,22224,BAO_0000218,A,,5334,In vivo,Macaca mulatta,9544.0
4453,U,,,,Bioavailability of the compound was determined in monkey,Autocuration,,,,,22224,BAO_0000218,A,,17592,In vivo,monkey,9443.0
4454,U,,,,Bioavailability in squirrel monkey (dose 5 mg/kg),Autocuration,,,,,22224,BAO_0000218,A,,1399,In vivo,Saimiri sciureus,9521.0
4455,U,,,,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),Autocuration,,,,,22224,BAO_0000218,A,,4809,In vivo,monkey,9443.0
4456,U,,,,Oral bioavailability in monkey,Autocuration,,,,,22224,BAO_0000218,A,,3341,In vivo,monkey,9443.0
4457,U,,,,Compound was tested for bioavailability in squirrel monkey,Autocuration,,,,,22224,BAO_0000218,A,,64,In vivo,Saimiri sciureus,9521.0
4458,U,,,,Oral bioavailability in Rhesus monkey,Autocuration,,,,,22224,BAO_0000218,A,,5005,In vivo,Macaca mulatta,9544.0
4459,U,,,,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),Autocuration,,,,,22224,BAO_0000218,A,,5005,In vivo,Macaca mulatta,9544.0
4460,U,,,,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,Autocuration,,,,,22224,BAO_0000218,A,,5237,In vivo,Macaca fascicularis,9541.0
4461,U,,,,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,Autocuration,,,,,22224,BAO_0000218,A,,5237,In vivo,Macaca fascicularis,9541.0
4462,U,,,,Oral bioavailability in monkey (dose 5 mg/kg),Autocuration,,,,,22224,BAO_0000218,A,,5302,In vivo,monkey,9443.0
4463,U,,,,Oral bioavailability of compound at 5 mg/kg in monkey,Autocuration,,,,,22224,BAO_0000218,A,,17667,In vivo,monkey,9443.0
4464,N,,,,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,Intermediate,,,,,50588,BAO_0000218,A,,6161,In vivo,Canis lupus familiaris,9615.0
4465,N,,,,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,Intermediate,,,,,50588,BAO_0000218,A,,6161,In vivo,Canis lupus familiaris,9615.0
4466,N,,,,Plasma half life determined,Intermediate,,,,1969.0,50588,BAO_0000218,A,,3854,,Canis lupus familiaris,9615.0
4467,N,,,,Plasma half life in dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,993,,Canis lupus familiaris,9615.0
4468,N,,,,Plasma half-life in Beagle dogs,Intermediate,,,,1969.0,50588,BAO_0000218,A,,4514,,Canis lupus familiaris,9615.0
4469,N,,,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),Intermediate,,,,1969.0,50588,BAO_0000218,A,,5334,In vivo,Canis lupus familiaris,9615.0
4470,N,,,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),Intermediate,,,,1969.0,50588,BAO_0000218,A,,5334,In vivo,Canis lupus familiaris,9615.0
4471,N,,,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,Intermediate,,,,,50588,BAO_0000218,A,,1466,In vivo,Canis lupus familiaris,9615.0
4472,N,,,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,Intermediate,,,,,50588,BAO_0000218,A,,1466,In vivo,Canis lupus familiaris,9615.0
4473,N,,,,Tested for the half life period in dog,Intermediate,,,,,50588,BAO_0000218,A,,5313,,Canis lupus familiaris,9615.0
4474,N,,,,Tested for the half life period in dog at dosage of 10 mpk,Intermediate,,,,,50588,BAO_0000218,A,,5313,In vivo,Canis lupus familiaris,9615.0
4475,N,,,,The compound was tested for half life in dog,Intermediate,,,,,50588,BAO_0000218,A,,3880,,Canis lupus familiaris,9615.0
4476,N,,,,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",Intermediate,,,,1969.0,50588,BAO_0000218,A,,3639,,Canis lupus familiaris,9615.0
4477,N,,,,The half life was determined,Intermediate,,,,,50588,BAO_0000218,A,,3880,,Canis lupus familiaris,9615.0
4478,N,,,,The plasma half-life in dogs,Intermediate,,,,1969.0,50588,BAO_0000218,A,,3918,,Canis lupus familiaris,9615.0
4479,N,,,,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,Intermediate,,,,1969.0,50588,BAO_0000218,A,,16452,,Canis lupus familiaris,9615.0
4480,N,,,,Half life in dog,Intermediate,,,,,50588,BAO_0000218,A,,17796,,Canis lupus familiaris,9615.0
4481,N,,,,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,Intermediate,,,,,50588,BAO_0000218,A,,5983,In vivo,Canis lupus familiaris,9615.0
4482,N,,,,tmax upon peroral administration of 10.0 mg/Kg dose in dog,Intermediate,,,,,50588,BAO_0000218,A,,1466,In vivo,Canis lupus familiaris,9615.0
4483,N,,,,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,16456,In vivo,Canis lupus familiaris,9615.0
4484,N,,,,Cmax in ferrets after 30 mg/kg oral dose,Expert,,,,,50506,BAO_0000218,A,,6113,In vivo,Mustela putorius furo,9669.0
4485,N,,,,Emesis in ferrets at 30 mg/kg oral dose,Expert,,,,,50506,BAO_0000218,F,,6113,In vivo,Mustela putorius furo,9669.0
4486,U,,,,Bioavailability in cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,17796,In vivo,Macaca fascicularis,9541.0
4487,N,,,,Volume of distribution in cynomolgus,Intermediate,,,,,100710,BAO_0000218,A,,17796,In vivo,Macaca fascicularis,9541.0
4488,U,,,,AUC tested in guinea pig when 3 mg/kg dose was given perorally,Autocuration,,,,1969.0,22224,BAO_0000218,A,,5308,,Cavia porcellus,10141.0
4489,U,,,,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,4877,,Cavia porcellus,10141.0
4490,U,,,,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",Autocuration,,,,,22224,BAO_0000218,A,,4876,,Cavia porcellus,10141.0
4491,U,,,,AUC in guinea pig after 3mg/kg oral dose,Autocuration,,,,1969.0,22224,BAO_0000218,A,,4878,In vivo,Cavia porcellus,10141.0
4492,U,,,,Bioavailability in guinea pig was tested,Autocuration,,,,,22224,BAO_0000218,A,,5308,In vivo,Cavia porcellus,10141.0
4493,U,,,,Tested for oral bioavailability in guinea pig at 5 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,4877,In vivo,Cavia porcellus,10141.0
4494,U,,,,Tested for the oral bioavailability of the compound,Autocuration,,,,,22224,BAO_0000218,A,,4876,In vivo,Cavia porcellus,10141.0
4495,U,,,,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,Autocuration,,,,,22224,BAO_0000218,A,,4876,In vivo,Cavia porcellus,10141.0
4496,U,,,,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,Autocuration,,,,,22224,BAO_0000218,A,,5308,In vivo,Cavia porcellus,10141.0
4497,U,,,,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,Autocuration,,,,2048.0,22224,BAO_0000218,A,,4877,In vivo,Cavia porcellus,10141.0
4498,U,,,,Cmax in guinea pig after 3mg/kg oral dose,Autocuration,,,,,22224,BAO_0000218,A,,4878,In vivo,Cavia porcellus,10141.0
4499,U,,,,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,,,,178.0,22224,BAO_0000019,A,,5689,,Cavia porcellus,10141.0
4500,U,,,,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,,,,955.0,22224,BAO_0000019,A,,5689,,Cavia porcellus,10141.0
4501,U,,,,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,,,,,22224,BAO_0000019,A,,5689,,Cavia porcellus,10141.0
4502,U,,,,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,,,,160.0,22224,BAO_0000019,A,,5689,,Cavia porcellus,10141.0
4503,U,,,,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,,,,2113.0,22224,BAO_0000019,A,,5689,,Cavia porcellus,10141.0
4504,U,,,,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,,,,2107.0,22224,BAO_0000019,A,,5689,,Cavia porcellus,10141.0
4505,U,,,,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,,,,,22224,BAO_0000019,A,,5689,,Cavia porcellus,10141.0
4506,U,,,,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,,,,2106.0,22224,BAO_0000019,A,,5689,,Cavia porcellus,10141.0
4507,U,,,,Elimination T1/2 in Guinea pig (PO dose),Autocuration,,,,,22224,BAO_0000218,A,,14465,In vivo,Cavia porcellus,10141.0
4508,U,,,,Partition coefficient was measured as -log (counts per min ),Autocuration,,,,,22224,BAO_0000019,A,,5689,,Cavia porcellus,10141.0
4509,U,,,,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,Autocuration,,,,,22224,BAO_0000218,A,,611,In vivo,Cavia porcellus,10141.0
4510,U,,,,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,Autocuration,,,,,22224,BAO_0000218,A,,611,In vivo,Cavia porcellus,10141.0
4511,U,,,,Elimination T1/2 in Guinea pig (PO dose),Autocuration,,,,,22224,BAO_0000218,A,,14465,In vivo,Cavia porcellus,10141.0
4512,U,,,,"Tested for the half life period of the compound, intravenously",Autocuration,,,,,22224,BAO_0000218,A,,4876,In vivo,Cavia porcellus,10141.0
4513,U,,,,Half-life was measured,Autocuration,,,,,22224,BAO_0000019,A,,5689,,Cavia porcellus,10141.0
4514,U,,,,The time required for onset of inotropy after addition of a single dose of delta F75,Autocuration,,,,,22224,BAO_0000019,A,,7515,,Cavia porcellus,10141.0
4515,U,,,,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,Autocuration,,,,,22224,BAO_0000218,A,,17667,In vivo,Cavia porcellus,10141.0
4516,U,,,,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,Autocuration,,,,,22224,BAO_0000218,A,,17667,In vivo,Cavia porcellus,10141.0
4517,U,,,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,Autocuration,,,,,22224,BAO_0000218,A,,4727,In vivo,Cricetulus griseus,10029.0
4518,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,,,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
4519,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,,,,,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
4520,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,,,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
4521,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,,,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
4522,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,Intermediate,,,,,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
4523,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,,,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
4524,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,,,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
4525,N,,,,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,Intermediate,,,,178.0,50594,BAO_0000218,A,,3655,In vivo,Mus musculus,10090.0
4526,N,,,,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,Intermediate,,,,178.0,50594,BAO_0000218,A,,3655,In vivo,Mus musculus,10090.0
4527,N,,,,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,Intermediate,,,,178.0,50594,BAO_0000218,A,,3655,In vivo,Mus musculus,10090.0
4528,N,,,,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,Intermediate,,,,10000001.0,50594,BAO_0000218,A,,3655,In vivo,Mus musculus,10090.0
4529,N,,,,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,Intermediate,,,,10000001.0,50594,BAO_0000218,A,,3655,In vivo,Mus musculus,10090.0
4530,N,,,,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,Intermediate,,,,10000001.0,50594,BAO_0000218,A,,3655,In vivo,Mus musculus,10090.0
4531,N,,,,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,Intermediate,,,,955.0,50594,BAO_0000218,A,,3655,In vivo,Mus musculus,10090.0
4532,N,,,,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,Intermediate,,,,955.0,50594,BAO_0000218,A,,3655,In vivo,Mus musculus,10090.0
4533,N,,,,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,Intermediate,,,,955.0,50594,BAO_0000218,A,,3655,In vivo,Mus musculus,10090.0
4534,N,,,,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,Intermediate,,,,948.0,50594,BAO_0000218,A,,3655,In vivo,Mus musculus,10090.0
4535,N,,,,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,Intermediate,,,,948.0,50594,BAO_0000218,A,,3655,In vivo,Mus musculus,10090.0
4536,N,,,,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,Intermediate,,,,948.0,50594,BAO_0000218,A,,3655,In vivo,Mus musculus,10090.0
4537,N,,,,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,Intermediate,,,,160.0,50594,BAO_0000218,A,,3655,In vivo,Mus musculus,10090.0
4538,N,,,,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,Intermediate,,,,160.0,50594,BAO_0000218,A,,3655,In vivo,Mus musculus,10090.0
4539,N,,,,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,Intermediate,,,,160.0,50594,BAO_0000218,A,,3655,In vivo,Mus musculus,10090.0
4540,N,,,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,Intermediate,,,,2113.0,50594,BAO_0000218,A,,3655,In vivo,Mus musculus,10090.0
4541,N,,,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,Intermediate,,,,2113.0,50594,BAO_0000218,A,,3655,In vivo,Mus musculus,10090.0
4542,N,,,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,Intermediate,,,,2113.0,50594,BAO_0000218,A,,3655,In vivo,Mus musculus,10090.0
4543,N,,,,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,Intermediate,,,,2107.0,50594,BAO_0000218,A,,3655,In vivo,Mus musculus,10090.0
4544,N,,,,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,Intermediate,,,,2107.0,50594,BAO_0000218,A,,3655,In vivo,Mus musculus,10090.0
4545,N,,,,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,Intermediate,,,,2107.0,50594,BAO_0000218,A,,3655,In vivo,Mus musculus,10090.0
4546,N,,,,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,Intermediate,,,,2048.0,50594,BAO_0000218,A,,3655,In vivo,Mus musculus,10090.0
4547,N,,,,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,Intermediate,,,,2048.0,50594,BAO_0000218,A,,3655,In vivo,Mus musculus,10090.0
4548,N,,,,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,Intermediate,,,,2048.0,50594,BAO_0000218,A,,3655,In vivo,Mus musculus,10090.0
4549,N,,,,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,Intermediate,,,,2385.0,50594,BAO_0000218,A,,3655,In vivo,Mus musculus,10090.0
4550,N,,,,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,Intermediate,,,,2385.0,50594,BAO_0000218,A,,3655,In vivo,Mus musculus,10090.0
4551,N,,,,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,Intermediate,,,,2385.0,50594,BAO_0000218,A,,3655,In vivo,Mus musculus,10090.0
4552,N,,,,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,Intermediate,,,,2106.0,50594,BAO_0000218,A,,3655,In vivo,Mus musculus,10090.0
4553,N,,,,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,Intermediate,,,,2106.0,50594,BAO_0000218,A,,3655,In vivo,Mus musculus,10090.0
4554,N,,,,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,Intermediate,,,,2106.0,50594,BAO_0000218,A,,3655,In vivo,Mus musculus,10090.0
4555,N,,,,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,Intermediate,,,,945.0,50594,BAO_0000218,A,,3655,In vivo,Mus musculus,10090.0
4556,N,,,,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,Intermediate,,,,945.0,50594,BAO_0000218,A,,3655,In vivo,Mus musculus,10090.0
4557,N,,,,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,Intermediate,,,,945.0,50594,BAO_0000218,A,,3655,In vivo,Mus musculus,10090.0
4558,N,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,Intermediate,,,,,50594,BAO_0000218,A,,16597,In vivo,Mus musculus,10090.0
4559,N,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,Intermediate,,,,,50594,BAO_0000218,F,,16597,In vivo,Mus musculus,10090.0
4560,N,,,,MRT value at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,,,,,50594,BAO_0000218,A,,16597,In vivo,Mus musculus,10090.0
4561,N,,,,MRT value at a dose of 10 mg/kg peroral administration in mice.,Intermediate,,,,,50594,BAO_0000218,A,,16597,In vivo,Mus musculus,10090.0
4562,N,,,,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,Intermediate,,,,,50594,BAO_0000218,A,,17764,In vivo,Mus musculus,10090.0
4563,N,,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,Intermediate,,,,,50594,BAO_0000218,F,,17764,In vivo,Mus musculus,10090.0
4564,N,,478.0,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,Intermediate,,A2780,,,81034,BAO_0000219,F,,3830,,Homo sapiens,9606.0
4565,N,,478.0,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,Intermediate,,A2780,,,81034,BAO_0000219,F,,3829,,Homo sapiens,9606.0
4566,N,,478.0,,Compound was evaluated for cytotoxicity against A2780 cell lines.,Intermediate,,A2780,,,81034,BAO_0000219,F,,2040,,Homo sapiens,9606.0
4567,N,,478.0,,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,Intermediate,,A2780,,,81034,BAO_0000219,F,,15684,,Homo sapiens,9606.0
4568,N,,478.0,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,Intermediate,,A2780,,,81034,BAO_0000219,F,,15684,,Homo sapiens,9606.0
4569,N,,478.0,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,Intermediate,,A2780,,,81034,BAO_0000219,F,,15684,,Homo sapiens,9606.0
4570,N,,478.0,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,Intermediate,,A2780,,,81034,BAO_0000219,F,,15684,,Homo sapiens,9606.0
4571,N,,478.0,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,Intermediate,,A2780,,,81034,BAO_0000219,F,,15684,,Homo sapiens,9606.0
4572,N,,478.0,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,Intermediate,,A2780,,,81034,BAO_0000219,F,,15684,,Homo sapiens,9606.0
4573,N,,478.0,,Compound was evaluated for cytotoxicity against A2780 cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,2859,,Homo sapiens,9606.0
4574,N,,478.0,,In vitro inhibitory activity against human tumor cell line A2780,Intermediate,,A2780,,,81034,BAO_0000219,F,,5618,,Homo sapiens,9606.0
4575,N,,478.0,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,Intermediate,,A2780,,,81034,BAO_0000219,F,,15684,,Homo sapiens,9606.0
4576,N,,478.0,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,Intermediate,,A2780,,,81034,BAO_0000219,F,,15684,,Homo sapiens,9606.0
4577,N,,478.0,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,Intermediate,,A2780,,,81034,BAO_0000219,F,,15684,,Homo sapiens,9606.0
4578,N,,478.0,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,Intermediate,,A2780,,,81034,BAO_0000219,F,,15684,,Homo sapiens,9606.0
4579,N,,478.0,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,Intermediate,,A2780,,,81034,BAO_0000219,F,,2113,,Homo sapiens,9606.0
4580,N,,478.0,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,Intermediate,,A2780,,,81034,BAO_0000219,F,,2113,,Homo sapiens,9606.0
4581,N,,478.0,,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,Intermediate,,A2780,,,81034,BAO_0000219,F,,16745,,Homo sapiens,9606.0
4582,N,,478.0,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,Expert,,A2780,,,81034,BAO_0000218,F,,16597,,Homo sapiens,9606.0
4583,N,,478.0,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,Intermediate,,A2780,,,81034,BAO_0000219,F,,15684,,Homo sapiens,9606.0
4584,N,,478.0,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,Intermediate,,A2780,,,81034,BAO_0000219,F,,15684,,Homo sapiens,9606.0
4585,N,,478.0,,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,Intermediate,,A2780,,,81034,BAO_0000219,F,,2040,,Homo sapiens,9606.0
4586,N,,478.0,,Relative resistance factor in A2780 cisplatin-resistant line,Intermediate,,A2780,,,81034,BAO_0000219,F,,2040,,Homo sapiens,9606.0
4587,N,,478.0,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,Intermediate,,A2780,,,81034,BAO_0000219,F,,16165,,Homo sapiens,9606.0
4588,N,,478.0,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,Intermediate,,A2780,,,81034,BAO_0000219,F,,16165,,Homo sapiens,9606.0
4589,N,,478.0,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,Expert,,A2780,,,81034,BAO_0000218,F,,16597,,Homo sapiens,9606.0
4590,N,,478.0,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,Expert,,A2780,,,81034,BAO_0000218,F,,16597,,Homo sapiens,9606.0
4591,N,,478.0,,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,Intermediate,,A2780,,,81034,BAO_0000219,F,,3992,,Homo sapiens,9606.0
4592,N,,478.0,,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,Intermediate,,A2780,,,81034,BAO_0000219,F,,10553,,Homo sapiens,9606.0
4593,N,,478.0,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,Intermediate,,A2780,,,81034,BAO_0000219,F,,15608,,Homo sapiens,9606.0
4594,N,,478.0,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,Intermediate,,A2780,,,81034,BAO_0000219,F,,15608,,Homo sapiens,9606.0
4595,N,,478.0,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,Intermediate,,A2780,,,81034,BAO_0000219,F,,15608,,Homo sapiens,9606.0
4596,N,,478.0,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,Intermediate,,A2780,,,81034,BAO_0000219,F,,15608,,Homo sapiens,9606.0
4597,N,,478.0,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,Intermediate,,A2780,,,81034,BAO_0000219,F,,15608,,Homo sapiens,9606.0
4598,N,,478.0,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,Intermediate,,A2780,,,81034,BAO_0000219,F,,15608,,Homo sapiens,9606.0
4599,N,,478.0,,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,Intermediate,,A2780,,,81034,BAO_0000219,F,,15569,,Homo sapiens,9606.0
4600,N,,478.0,,Antiproliferative effect of compound on A2780/DX cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,17420,,Homo sapiens,9606.0
4601,N,,478.0,,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,Intermediate,,A2780,,,81034,BAO_0000219,F,,17420,,Homo sapiens,9606.0
4602,N,,478.0,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),Intermediate,,A2780,,,81034,BAO_0000219,F,,15099,,Homo sapiens,9606.0
4603,N,,478.0,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),Intermediate,,A2780,,,81034,BAO_0000219,F,,15099,,Homo sapiens,9606.0
4604,N,,478.0,,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,Intermediate,,A2780,,,81034,BAO_0000219,F,,17672,,Homo sapiens,9606.0
4605,N,,478.0,,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,Intermediate,,A2780,,,81034,BAO_0000219,F,,17672,,Homo sapiens,9606.0
4606,N,,478.0,,In vitro cytotoxicity against A2780ADR cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,17270,,Homo sapiens,9606.0
4607,N,,478.0,,In vitro cytotoxicity against A2780CIS cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,17270,,Homo sapiens,9606.0
4608,N,,478.0,,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,Intermediate,,A2780,,,81034,BAO_0000219,F,,5574,,Homo sapiens,9606.0
4609,N,,478.0,,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,Intermediate,,A2780,,,81034,BAO_0000219,F,,2113,,Homo sapiens,9606.0
4610,N,,478.0,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",Intermediate,,A2780,,,81034,BAO_0000219,F,,16913,,Homo sapiens,9606.0
4611,N,,478.0,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",Intermediate,,A2780,,,81034,BAO_0000219,F,,16913,,Homo sapiens,9606.0
4612,U,,,,Oral bioavailability of compound in rhesus macaques,Autocuration,,,,,22224,BAO_0000218,A,,17839,In vivo,Macaca mulatta,9544.0
4613,U,,,,Oral bioavailability in monkey,Autocuration,,,,,22224,BAO_0000218,A,,6821,In vivo,monkey,9443.0
4614,U,,,,Oral bioavailability evaluated in monkey,Autocuration,,,,,22224,BAO_0000218,A,,6078,In vivo,monkey,9443.0
4615,U,,,,Oral bioavailability in monkey (dose 1 mg/kg p.o.),Autocuration,,,,,22224,BAO_0000218,A,,6535,In vivo,monkey,9443.0
4616,U,,,,Oral bioavailability in Rhesus monkey,Autocuration,,,,,22224,BAO_0000218,A,,4449,In vivo,Macaca mulatta,9544.0
4617,U,,,,Oral bioavailability was calculated in rhesus monkey,Autocuration,,,,,22224,BAO_0000218,A,,6057,In vivo,Macaca mulatta,9544.0
4618,U,,,,Oral bioavailability in cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,5922,In vivo,Macaca fascicularis,9541.0
4619,U,,,,Oral bioavailability in monkey,Autocuration,,,,,22224,BAO_0000218,A,,5940,In vivo,monkey,9443.0
4620,U,,,,Oral bioavailability in monkey,Autocuration,,,,,22224,BAO_0000218,A,,6265,In vivo,monkey,9443.0
4621,U,,,,Oral bioavailability in monkey (dose 1 mg/kg),Autocuration,,,,,22224,BAO_0000218,A,,6265,In vivo,monkey,9443.0
4622,U,,,,Oral bioavailability in monkey (dose 5 mg/kg),Autocuration,,,,,22224,BAO_0000218,A,,6265,In vivo,monkey,9443.0
4623,U,,,,Oral bioavailability in monkey,Autocuration,,,,,22224,BAO_0000218,A,,5940,In vivo,monkey,9443.0
4624,U,,,,Oral bioavailability in monkey,Autocuration,,,,,22224,BAO_0000218,A,,5940,In vivo,monkey,9443.0
4625,U,,,,Oral bioavailability in rhesus monkey,Autocuration,,,,,22224,BAO_0000218,A,,4514,In vivo,Macaca mulatta,9544.0
4626,U,,,,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,Autocuration,,,,,22224,BAO_0000218,A,,5546,In vivo,Macaca mulatta,9544.0
4627,U,,,,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,5553,In vivo,Saimiri sciureus,9521.0
4628,U,,,,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),Autocuration,,,,,22224,BAO_0000218,A,,6641,In vivo,monkey,9443.0
4629,U,,,,Oral bioavailability in Rhesus monkey,Autocuration,,,,,22224,BAO_0000218,A,,5472,In vivo,Macaca mulatta,9544.0
4630,U,,,,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),Autocuration,,,,,22224,BAO_0000218,A,,5668,In vivo,Macaca mulatta,9544.0
4631,U,,,,Oral bioavailability in monkey at 10 mg/kg of the compound,Autocuration,,,,,22224,BAO_0000218,A,,5711,In vivo,monkey,9443.0
4632,U,,,,Bioavailability in Rhesus monkey,Autocuration,,,,,22224,BAO_0000218,A,,5145,In vivo,Macaca mulatta,9544.0
4633,U,,,,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,,,22224,BAO_0000218,A,,3443,,Cercopithecidae,9527.0
4634,U,,,,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,,,22224,BAO_0000218,A,,3443,,Cercopithecidae,9527.0
4635,U,,,,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,3249,In vivo,Cercopithecidae,9527.0
4636,U,,,,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,3249,In vivo,Cercopithecidae,9527.0
4637,U,,,,Mean residence time was determined after intravenous administration in cynomolgus monkeys,Autocuration,,,,,22224,BAO_0000218,A,,5355,In vivo,Cercopithecidae,9527.0
4638,U,,,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,Autocuration,,,,,22224,BAO_0000218,A,,5355,In vivo,Cercopithecidae,9527.0
4639,U,,,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,Autocuration,,,,,22224,BAO_0000218,A,,5355,In vivo,Cercopithecidae,9527.0
4640,U,,,,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),Autocuration,,,,,22224,BAO_0000218,A,,4809,In vivo,Cercopithecidae,9527.0
4641,U,,,,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),Autocuration,,,,,22224,BAO_0000218,A,,4809,In vivo,Cercopithecidae,9527.0
4642,U,,,,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),Autocuration,,,,,22224,BAO_0000251,A,Microsomes,14294,,Cercopithecidae,9527.0
4643,U,,,,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),Autocuration,,,,,22224,BAO_0000251,A,Microsomes,14294,,Cercopithecidae,9527.0
4644,U,,,,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),Autocuration,,,,,22224,BAO_0000251,A,Microsomes,14294,,Cercopithecidae,9527.0
4645,U,,,,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),Autocuration,,,,,22224,BAO_0000251,A,Microsomes,14294,,Cercopithecidae,9527.0
4646,U,,,,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,,,22224,BAO_0000218,A,,3443,In vivo,Cercopithecidae,9527.0
4647,U,,,,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,,,22224,BAO_0000218,A,,3443,In vivo,Cercopithecidae,9527.0
4648,U,,,,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,Autocuration,,,,,22224,BAO_0000019,A,,11271,,Cercopithecidae,9527.0
4649,U,,,,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,,,22224,BAO_0000218,A,,3443,,Cercopithecidae,9527.0
4650,U,,,,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,,,22224,BAO_0000218,A,,3443,,Cercopithecidae,9527.0
4651,U,,,,Elimination Half-life of compound was determined in monkey,Autocuration,,,,,22224,BAO_0000019,A,,6821,,Cercopithecidae,9527.0
4652,U,,,,Half life of compound was determined in rhesus monkey,Autocuration,,,,,22224,BAO_0000019,A,,17267,,Cercopithecidae,9527.0
4653,U,,,,Half life in monkey plasma,Autocuration,,,,1969.0,22224,BAO_0000366,A,,5819,,Cercopithecidae,9527.0
4654,U,,,,Half life in monkey plasma; Not detected,Autocuration,,,,1969.0,22224,BAO_0000366,A,,5819,,Cercopithecidae,9527.0
4655,U,,,,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Autocuration,,,,,22224,BAO_0000218,A,,1916,In vivo,Cercopithecidae,9527.0
4656,U,,,,Half-life 24 hr after 2 mg/kg iv administration in monkeys,Autocuration,,,,,22224,BAO_0000218,A,,17509,In vivo,Cercopithecidae,9527.0
4657,U,,,,Terminal half life of the compound.,Autocuration,,,,,22224,BAO_0000019,A,,1399,,Cercopithecidae,9527.0
4658,U,,,,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Autocuration,,,,,22224,BAO_0000218,A,,1916,In vivo,Cercopithecidae,9527.0
4659,U,,,,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),Autocuration,,,,,22224,BAO_0000218,A,,4809,In vivo,Cercopithecidae,9527.0
4660,U,,,,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,Autocuration,,,,,22224,BAO_0000218,A,,5546,,Cercopithecidae,9527.0
4661,U,,,,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,,1088.0,22224,BAO_0000218,A,,3443,,Cercopithecidae,9527.0
4662,U,,,,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,,1088.0,22224,BAO_0000218,A,,3443,,Cercopithecidae,9527.0
4663,U,,,,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,Autocuration,,,,,22224,BAO_0000218,A,,4257,In vivo,Cercopithecidae,9527.0
4664,U,,,,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,Autocuration,,,,,22224,BAO_0000218,A,,6221,In vivo,Cercopithecidae,9527.0
4665,U,,,,Volume of distribution was evaluated in rhesus,Autocuration,,,,,22224,BAO_0000218,A,,5472,In vivo,Cercopithecidae,9527.0
4666,U,,,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,Autocuration,,,,,22224,BAO_0000218,A,,4727,In vivo,Cricetulus griseus,10029.0
4667,U,,,,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,Autocuration,,,,,22224,BAO_0000218,A,,4727,In vivo,Cricetulus griseus,10029.0
4668,U,,,,Bioavailability in hamster was determined,Autocuration,,,,,22224,BAO_0000218,A,,4727,In vivo,Cricetulus griseus,10029.0
4669,U,,,,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,Autocuration,,,,,22224,BAO_0000218,A,,4727,In vivo,Cricetulus griseus,10029.0
4670,U,,,,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,Autocuration,,,,,22224,BAO_0000218,A,,4727,In vivo,Cricetulus griseus,10029.0
4671,U,,,,Half life of compound was determined in hamster blood,Autocuration,,,,178.0,22224,BAO_0000221,A,,4727,,Cricetulus griseus,10029.0
4672,U,,,,Michaelis-Menten constant of the compound.,Autocuration,,,,,22224,BAO_0000019,A,,1452,,Sus scrofa,9823.0
4673,U,,,,Vmax value was measured at 0 uM concentration of silyl ether.,Autocuration,,,,,22224,BAO_0000019,A,,1452,,Sus scrofa,9823.0
4674,U,,,,Vmax value was measured at 10 uM concentration of silyl ether.,Autocuration,,,,,22224,BAO_0000019,A,,1452,,Sus scrofa,9823.0
4675,U,,,,Vmax value was measured at 5 uM concentration of silyl ether.,Autocuration,,,,,22224,BAO_0000019,A,,1452,,Sus scrofa,9823.0
4676,D,,,,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,Expert,,,,,235,BAO_0000357,B,,11706,,Homo sapiens,9606.0
4677,U,,,,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,Autocuration,,,,,22224,BAO_0000218,A,,1916,,Homo sapiens,9606.0
4678,U,,,,Compound was evaluated for area under the curve expressed as (h*ug/ml),Autocuration,,,,,22224,BAO_0000019,A,,17791,,Homo sapiens,9606.0
4679,U,,,,Active metabolite of ifosfamide determined in humans; A-Active,Autocuration,,,,,22224,BAO_0000019,A,,7766,,Homo sapiens,9606.0
4680,U,,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,Autocuration,,,,,22224,BAO_0000019,A,,6567,,Homo sapiens,9606.0
4681,U,,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,Autocuration,,,,,22224,BAO_0000019,A,,6567,,Homo sapiens,9606.0
4682,U,,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,Autocuration,,,,,22224,BAO_0000019,A,,6567,,Homo sapiens,9606.0
4683,U,,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,Autocuration,,,,,22224,BAO_0000019,A,,6567,,Homo sapiens,9606.0
4684,U,,,,Compound was evaluated for oral bioavailability in human,Autocuration,,,,,22224,BAO_0000218,A,,17791,,Homo sapiens,9606.0
4685,U,,,,Metabolite of ifosfamide determined in urine; NF-Not found,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,,Homo sapiens,9606.0
4686,U,,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),Autocuration,,,,,22224,BAO_0000019,A,,6852,,Homo sapiens,9606.0
4687,U,,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,Autocuration,,,,,22224,BAO_0000019,A,,6852,,Homo sapiens,9606.0
4688,U,,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,Autocuration,,,,,22224,BAO_0000019,A,,6852,,Homo sapiens,9606.0
4689,U,,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,Autocuration,,,,,22224,BAO_0000019,A,,6852,,Homo sapiens,9606.0
4690,U,,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,Autocuration,,,,,22224,BAO_0000019,A,,6852,,Homo sapiens,9606.0
4691,U,,,,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),Autocuration,,,,,22224,BAO_0000019,A,,6852,,Homo sapiens,9606.0
4692,U,,,,Percent of compound in healthy individuals (Group D),Autocuration,,,,,22224,BAO_0000019,A,,6852,,Homo sapiens,9606.0
4693,U,,,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,4397,,Homo sapiens,9606.0
4694,U,,,,Binding towards human plasma protein at 10 uM,Autocuration,,,,,22224,BAO_0000019,A,,17409,,Homo sapiens,9606.0
4695,U,,,,Binding towards human plasma protein at 100 uM,Autocuration,,,,,22224,BAO_0000019,A,,17409,,Homo sapiens,9606.0
4696,U,,,,Human plasma protein binding activity was determined,Autocuration,,,,,22224,BAO_0000019,A,,17176,,Homo sapiens,9606.0
4697,U,,,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),Autocuration,,,,,22224,BAO_0000019,A,,15444,,Homo sapiens,9606.0
4698,U,,,,Percent binding of compound towards human plasma protein was determined,Autocuration,,,,,22224,BAO_0000019,A,,17267,,Homo sapiens,9606.0
4699,U,,,,Plasma clearance in human liver microsomes,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,5944,In vitro,Homo sapiens,9606.0
4700,U,,,,In vitro intrinsic clearance in human liver microsome,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,5668,In vitro,Homo sapiens,9606.0
4701,U,,,,In vitro intrinsic clearance in human liver microsome,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,5669,In vitro,Homo sapiens,9606.0
4702,U,,,,In vitro microsome metabolism clearance in human was determined,Autocuration,,,,,22224,BAO_0000251,A,Microsomes,5041,In vitro,Homo sapiens,9606.0
4703,U,,,,In vitro microsome metabolism clearance in human was determined; High,Autocuration,,,,,22224,BAO_0000251,A,Microsomes,5041,In vitro,Homo sapiens,9606.0
4704,U,,,,In vitro microsome metabolism clearance in human was determined; ND denotes no data,Autocuration,,,,,22224,BAO_0000251,A,Microsomes,5041,In vitro,Homo sapiens,9606.0
4705,U,,,,Pharmacokinetic property (clearance) in human liver microsome,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,5676,In vitro,Homo sapiens,9606.0
4706,U,,,,Plasma clearance in human liver microsomes,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,5944,In vitro,Homo sapiens,9606.0
4707,U,,,,In vitro clearance in human liver microsomes,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,17538,In vitro,Homo sapiens,9606.0
4708,U,,,,Intrinsic clearance in human liver microsomes was determined,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,6331,In vitro,Homo sapiens,9606.0
4709,U,,,,Intrinsic clearance in human liver microsomes was determined,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,5948,In vitro,Homo sapiens,9606.0
4710,U,,,,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,Autocuration,,,,,22224,BAO_0000218,A,,5965,In vivo,Homo sapiens,9606.0
4711,U,,,,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,Autocuration,,,,,22224,BAO_0000218,A,,1916,In vivo,Homo sapiens,9606.0
4712,U,,,,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,Autocuration,,,,,22224,BAO_0000218,A,,5965,,Homo sapiens,9606.0
4713,U,,,,Stability in human plasma 2 hr after incubation expressed as percent concentration,Autocuration,,,,,22224,BAO_0000019,A,,1299,,Homo sapiens,9606.0
4714,U,,,,Stability in human plasma 4 hr after incubation expressed as percent concentration,Autocuration,,,,,22224,BAO_0000019,A,,1299,,Homo sapiens,9606.0
4715,U,,,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,,Homo sapiens,9606.0
4716,U,,,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,,Homo sapiens,9606.0
4717,U,,,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,,Homo sapiens,9606.0
4718,U,,,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,,Homo sapiens,9606.0
4719,N,,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,Intermediate,,,,,50594,BAO_0000218,F,,17764,In vivo,Mus musculus,10090.0
4720,N,,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,Intermediate,,,,,50594,BAO_0000218,F,,17764,In vivo,Mus musculus,10090.0
4721,N,,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,Intermediate,,,,,50594,BAO_0000218,F,,17764,In vivo,Mus musculus,10090.0
4722,N,,,,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,Intermediate,,,,,50594,BAO_0000218,F,,17764,In vivo,Mus musculus,10090.0
4723,N,,,,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),Intermediate,,,,,50594,BAO_0000218,A,,14294,,Mus musculus,10090.0
4724,N,,,,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),Intermediate,,,,,50594,BAO_0000218,A,,14294,,Mus musculus,10090.0
4725,N,,,,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),Intermediate,,,,,50594,BAO_0000218,A,,14294,,Mus musculus,10090.0
4726,N,,,,In vitro metabolic potential in mouse liver microsomes,Intermediate,,,,2107.0,50594,BAO_0000218,A,,6251,,Mus musculus,10090.0
4727,N,,,,Ability of compound to bind to plasma protein was evaluated in HSA cells,Intermediate,,,,,50594,BAO_0000218,A,,17582,,Mus musculus,10090.0
4728,N,,,,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),Intermediate,,,,2369.0,50594,BAO_0000218,A,,17811,,Mus musculus,10090.0
4729,N,,,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,Intermediate,,,,955.0,50594,BAO_0000218,A,,17811,,Mus musculus,10090.0
4730,N,,,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,Intermediate,,,,955.0,50594,BAO_0000218,A,,17811,,Mus musculus,10090.0
4731,N,,,,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),Intermediate,,,,,50594,BAO_0000218,A,,17811,,Mus musculus,10090.0
4732,N,,,,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),Intermediate,,,,2113.0,50594,BAO_0000218,A,,17811,,Mus musculus,10090.0
4733,N,,,,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),Intermediate,,,,,50594,BAO_0000218,A,,17811,,Mus musculus,10090.0
4734,N,,,,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,Intermediate,,,,,50594,BAO_0000218,A,,5288,,Mus musculus,10090.0
4735,N,,,,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,Intermediate,,,,1977.0,50594,BAO_0000218,A,,2717,,Mus musculus,10090.0
4736,N,,,,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,Intermediate,,,,1977.0,50594,BAO_0000218,A,,2717,,Mus musculus,10090.0
4737,N,,,,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,Intermediate,,,,1977.0,50594,BAO_0000218,A,,2717,,Mus musculus,10090.0
4738,N,,,,Half life of compound was determined in plasma of mice at 24 mg/Kg,Intermediate,,,,1969.0,50594,BAO_0000218,A,,17753,In vivo,Mus musculus,10090.0
4739,N,,,,Half life of compound was determined in plasma of mice at 40 mg/Kg,Intermediate,,,,1969.0,50594,BAO_0000218,A,,17753,In vivo,Mus musculus,10090.0
4740,N,,,,Half life of compound was determined in plasma of mice at 5 mg/Kg,Intermediate,,,,1969.0,50594,BAO_0000218,A,,17753,In vivo,Mus musculus,10090.0
4741,N,,,,Half life after intraperitoneal administration in mice at 18 uM/kg,Intermediate,,,,,50594,BAO_0000218,F,,17764,In vivo,Mus musculus,10090.0
4742,N,,,,Half life after intraperitoneal administration in mice at 23 uM/kg,Intermediate,,,,,50594,BAO_0000218,F,,17764,In vivo,Mus musculus,10090.0
4743,N,,,,Half life after intraperitoneal administration in mice at 25 uM/kg,Intermediate,,,,,50594,BAO_0000218,F,,17764,In vivo,Mus musculus,10090.0
4744,N,,,,Half life after intraperitoneal administration in mice at 26 uM/kg,Intermediate,,,,,50594,BAO_0000218,F,,17764,In vivo,Mus musculus,10090.0
4745,N,,,,Half life after intravenous administration in mice at 23 uM/kg,Intermediate,,,,,50594,BAO_0000218,F,,17764,In vivo,Mus musculus,10090.0
4746,N,,,,Half life after intravenous administration in mice at 24 uM/kg,Intermediate,,,,,50594,BAO_0000218,A,,17764,In vivo,Mus musculus,10090.0
4747,N,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,Intermediate,,,,,50594,BAO_0000218,A,,16597,In vivo,Mus musculus,10090.0
4748,N,,,,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,Intermediate,,,,,50594,BAO_0000218,A,,2675,In vivo,Mus musculus,10090.0
4749,N,,,,Maximum time required to reach Cp max was evaluated in mice after oral administration,Intermediate,,,,,50594,BAO_0000218,A,,2675,In vivo,Mus musculus,10090.0
4750,N,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),Intermediate,,,,,50594,BAO_0000218,A,,16597,In vivo,Mus musculus,10090.0
4751,N,,,,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",Intermediate,,,,,50594,BAO_0000218,A,,4890,In vivo,Mus musculus,10090.0
4752,N,,,,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,429,In vivo,Mus musculus,10090.0
4753,N,,,,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,Intermediate,,,,178.0,50594,BAO_0000218,A,,17837,In vivo,Mus musculus,10090.0
4754,N,,,,Half life at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,,,,,50594,BAO_0000218,A,,16597,In vivo,Mus musculus,10090.0
4755,N,,,,Half life at a dose of 10 mg/kg peroral administration in mice.,Intermediate,,,,,50594,BAO_0000218,A,,16597,In vivo,Mus musculus,10090.0
4756,N,,,,Half life in ob/ob mice,Intermediate,,,,,50594,BAO_0000218,A,,6619,,Mus musculus,10090.0
4757,N,,,,Half-life at a single subcutaneous administration of 40 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,4066,In vivo,Mus musculus,10090.0
4758,N,,,,Half-life was measured in mouse,Intermediate,,,,,50594,BAO_0000218,A,,4239,,Mus musculus,10090.0
4759,N,,,,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,5969,In vivo,Mus musculus,10090.0
4760,N,,,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,Intermediate,,,,,50594,BAO_0000218,A,,8999,,Mus musculus,10090.0
4761,N,,,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,Intermediate,,,,,50594,BAO_0000218,A,,8999,,Mus musculus,10090.0
4762,N,,,,T2 in brain of mice at the oral dose of 50 mg/kg,Intermediate,,,,955.0,50594,BAO_0000218,A,,17641,,Mus musculus,10090.0
4763,N,,,,T2 in kidney of mice at the oral dose of 50 mg/kg,Intermediate,,,,2113.0,50594,BAO_0000218,A,,17641,,Mus musculus,10090.0
4764,N,,,,T2 in liver of mice at the oral dose of 50 mg/kg,Intermediate,,,,2107.0,50594,BAO_0000218,A,,17641,,Mus musculus,10090.0
4765,N,,,,T2 in lungs of mice at the oral dose of 50 mg/kg,Intermediate,,,,2048.0,50594,BAO_0000218,A,,17641,,Mus musculus,10090.0
4766,N,,,,T2 in spleen of mice at the oral dose of 50 mg/kg,Intermediate,,,,2106.0,50594,BAO_0000218,A,,17641,,Mus musculus,10090.0
4767,N,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,Intermediate,,,,,50594,BAO_0000218,A,,16597,In vivo,Mus musculus,10090.0
4768,N,,,,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",Intermediate,,,,,50594,BAO_0000218,A,,4890,In vivo,Mus musculus,10090.0
4769,N,,,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,429,In vivo,Mus musculus,10090.0
4770,N,,,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,Intermediate,,,,,50594,BAO_0000218,A,,429,In vivo,Mus musculus,10090.0
4771,N,,,,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,5969,In vivo,Mus musculus,10090.0
4772,N,,478.0,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",Intermediate,,A2780,,,81034,BAO_0000219,F,,16913,,Homo sapiens,9606.0
4773,N,,478.0,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",Intermediate,,A2780,,,81034,BAO_0000219,F,,16913,,Homo sapiens,9606.0
4774,N,,478.0,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",Intermediate,,A2780,,,81034,BAO_0000219,F,,16913,,Homo sapiens,9606.0
4775,N,,478.0,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",Intermediate,,A2780,,,81034,BAO_0000219,F,,16913,,Homo sapiens,9606.0
4776,N,,478.0,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",Intermediate,,A2780,,,81034,BAO_0000219,F,,16913,,Homo sapiens,9606.0
4777,N,,478.0,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",Intermediate,,A2780,,,81034,BAO_0000219,F,,16913,,Homo sapiens,9606.0
4778,N,,478.0,,In vitro cytotoxicity against A2780TAX cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,17270,,Homo sapiens,9606.0
4779,N,,481.0,,In vitro inhibitory activity against human tumor cell line A2780cis,Intermediate,,A2780cisR,,,80017,BAO_0000219,F,,5618,,Homo sapiens,9606.0
4780,N,,478.0,,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,Expert,,A2780,,,81034,BAO_0000219,F,,17777,,Homo sapiens,9606.0
4781,N,,481.0,,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,Intermediate,,A2780cisR,,,80017,BAO_0000219,F,,16112,,Homo sapiens,9606.0
4782,N,,481.0,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),Intermediate,,A2780cisR,,,80017,BAO_0000219,F,,15748,,Homo sapiens,9606.0
4783,N,,478.0,,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,Intermediate,,A2780,,,81034,BAO_0000219,F,,6633,,Homo sapiens,9606.0
4784,N,,478.0,,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,Intermediate,,A2780,,,81034,BAO_0000219,F,,16930,,Homo sapiens,9606.0
4785,N,,478.0,,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,17496,,Homo sapiens,9606.0
4786,N,,478.0,,In vitro antitumor activity against A2780cisR cell line.,Expert,,A2780,,,81034,BAO_0000219,F,,12989,,Homo sapiens,9606.0
4787,N,,478.0,,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),Intermediate,,A2780,,,81034,BAO_0000219,F,,4840,,Homo sapiens,9606.0
4788,N,,478.0,,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,Expert,,A2780,,,81034,BAO_0000219,F,,12989,,Homo sapiens,9606.0
4789,N,,481.0,,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,Intermediate,,A2780cisR,,,80017,BAO_0000219,F,,16745,,Homo sapiens,9606.0
4790,N,,478.0,,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,Expert,,A2780,,,81034,BAO_0000219,F,,16597,,Homo sapiens,9606.0
4791,D,,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,Expert,,,,,11736,BAO_0000019,B,,16547,,Rattus norvegicus,10116.0
4792,H,,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),Expert,,,,,11736,BAO_0000019,F,,16547,,,
4793,D,,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),Expert,,,,,11736,BAO_0000019,F,,16547,,Rattus norvegicus,10116.0
4794,D,,722.0,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,Expert,,HEK293,,,278,BAO_0000219,F,,15856,,Homo sapiens,9606.0
4795,D,,722.0,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,Expert,,HEK293,,,278,BAO_0000219,F,,15856,,Homo sapiens,9606.0
4796,D,,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,Expert,,,,,11831,BAO_0000019,B,,16547,,Mus musculus,10090.0
4797,H,,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),Expert,,,,,11831,BAO_0000019,F,,16547,,,
4798,D,,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),Expert,,,,,11831,BAO_0000019,F,,16547,,Mus musculus,10090.0
4799,H,,,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,Expert,,,,,280,BAO_0000357,B,,17402,,,
4800,U,,574.0,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),Autocuration,,T-cells,,,22226,BAO_0000219,F,,11746,,Homo sapiens,9606.0
4801,U,,574.0,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,Autocuration,,T-cells,,,22226,BAO_0000219,F,,11746,,Homo sapiens,9606.0
4802,N,,455.0,,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,Intermediate,,A-375,,,80018,BAO_0000219,F,,5455,,Homo sapiens,9606.0
4803,N,,455.0,,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,Intermediate,,A-375,,,80018,BAO_0000219,F,,2068,,Homo sapiens,9606.0
4804,N,,455.0,,In vitro antitumor activity against A375cell line extracted form melanoma,Intermediate,,A-375,,,80018,BAO_0000219,F,,2683,,Homo sapiens,9606.0
4805,N,,455.0,,Inhibition of cell growth in (A375) melan cell line,Expert,,A-375,,,80018,BAO_0000219,F,,15313,,Homo sapiens,9606.0
4806,N,,455.0,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,Intermediate,,A-375,,,80018,BAO_0000219,F,,13739,,Homo sapiens,9606.0
4807,N,,455.0,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,Intermediate,,A-375,,,80018,BAO_0000219,F,,13739,,Homo sapiens,9606.0
4808,N,,455.0,,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,Intermediate,,A-375,,,80018,BAO_0000219,F,,14750,,Homo sapiens,9606.0
4809,N,,797.0,,Antiproliferative activity measured against A427 human lung carcinoma,Intermediate,,A-427,,,80019,BAO_0000219,F,,14777,,Homo sapiens,9606.0
4810,N,,797.0,,Antiproliferative activity measured against A427 human lung carcinoma,Intermediate,,A-427,,,80019,BAO_0000219,F,,14777,,Homo sapiens,9606.0
4811,N,,797.0,,Cytotoxicity against lung carcinoma A427 tumor cell lines,Intermediate,,A-427,,,80019,BAO_0000219,F,,17672,,Homo sapiens,9606.0
4812,N,,797.0,,Inhibition of large cell lung carcinoma (A427),Intermediate,,A-427,,,80019,BAO_0000219,F,,14368,,Homo sapiens,9606.0
4813,N,,797.0,,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,Intermediate,,A-427,,,80019,BAO_0000219,F,,14368,,Homo sapiens,9606.0
4814,N,,797.0,,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,Intermediate,,A-427,,,80019,BAO_0000219,F,,13866,,Homo sapiens,9606.0
4815,N,,797.0,,Inhibitory concentration in human lung carcinoma A427 cell line,Intermediate,,A-427,,,80019,BAO_0000219,F,,2545,,Homo sapiens,9606.0
4816,N,,797.0,,Inhibitory concentration in human lung carcinoma A427/VCR cell line,Intermediate,,A-427,,,80019,BAO_0000219,F,,2545,,Homo sapiens,9606.0
4817,U,,,,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,6062,In vivo,Cercopithecidae,9527.0
4818,U,,,,Tested for volume of distribution upon iv administration to african green monkey,Autocuration,,,,,22224,BAO_0000218,A,,4578,In vivo,Cercopithecidae,9527.0
4819,U,,,,Volume of distribution in monkey,Autocuration,,,,,22224,BAO_0000218,A,,17592,In vivo,Cercopithecidae,9527.0
4820,U,,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Autocuration,,,,,22224,BAO_0000218,A,,5005,In vivo,Macaca mulatta,9544.0
4821,U,,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,Autocuration,,,,,22224,BAO_0000218,A,,5005,In vivo,Macaca mulatta,9544.0
4822,U,,,,Pharmacokinetic property(Vdss) in cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,5922,In vivo,Cercopithecidae,9527.0
4823,U,,,,The distribution volume after intravenous administration in cynomolgus monkeys,Autocuration,,,,,22224,BAO_0000218,A,,5355,In vivo,Cercopithecidae,9527.0
4824,U,,,,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,Autocuration,,,,,22224,BAO_0000218,A,,5355,In vivo,Cercopithecidae,9527.0
4825,U,,,,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,Autocuration,,,,,22224,BAO_0000218,A,,5355,In vivo,Cercopithecidae,9527.0
4826,U,,,,Volume displacement was calculated in rhesus monkey,Autocuration,,,,,22224,BAO_0000218,A,,6057,In vivo,Cercopithecidae,9527.0
4827,U,,,,Volume of distribution in steady state was determined in rhesus monkey,Autocuration,,,,,22224,BAO_0000218,A,,5145,In vivo,Cercopithecidae,9527.0
4828,U,,,,Volume of distribution of compound was determined in monkey,Autocuration,,,,,22224,BAO_0000218,A,,6821,In vivo,Cercopithecidae,9527.0
4829,U,,,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Autocuration,,,,,22224,BAO_0000218,A,,5334,In vivo,Cercopithecidae,9527.0
4830,U,,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Autocuration,,,,,22224,BAO_0000218,A,,5334,In vivo,Cercopithecidae,9527.0
4831,U,,,,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),Autocuration,,,,,22224,BAO_0000218,A,,6641,In vivo,Cercopithecidae,9527.0
4832,U,,,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,2661,In vivo,Cercopithecidae,9527.0
4833,U,,,,Volume distribution in monkey after administration of 1 mg/kg iv,Autocuration,,,,,22224,BAO_0000218,A,,6535,In vivo,Cercopithecidae,9527.0
4834,U,,,,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),Autocuration,,,,,22224,BAO_0000218,A,,4809,In vivo,Cercopithecidae,9527.0
4835,U,,,,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,6062,In vivo,Cercopithecidae,9527.0
4836,U,,,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,,,22224,BAO_0000218,A,,3443,In vivo,Cercopithecidae,9527.0
4837,U,,,,Oral systemic bioavailability upon iv administration to african green monkey,Autocuration,,,,,22224,BAO_0000218,A,,4578,In vivo,Cercopithecidae,9527.0
4838,U,,,,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),Autocuration,,,,,22224,BAO_0000218,A,,4809,In vivo,Cercopithecidae,9527.0
4839,U,,,,Baboon plasma free fraction. ,Autocuration,,,,,22224,BAO_0000019,A,,11271,,Cercopithecidae,9527.0
4840,U,,,,Area under the curve was calculated in rhesus monkey after iv administration,Autocuration,,,,,22224,BAO_0000218,A,,6057,,Cercopithecidae,9527.0
4841,U,,,,Area under the curve was calculated in rhesus monkey after peroral administration,Autocuration,,,,,22224,BAO_0000019,A,,6057,,Cercopithecidae,9527.0
4842,U,,,,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,Autocuration,,,,,22224,BAO_0000019,A,,17853,,Cercopithecidae,9527.0
4843,U,,,,Half life period in monkey after 5 mg/kg dose,Autocuration,,,,,22224,BAO_0000218,A,,5302,In vivo,Cercopithecidae,9527.0
4844,U,,,,Half-life was determined in monkey after 3 mg/kg of i.v. dose,Autocuration,,,,,22224,BAO_0000218,A,,4257,In vivo,Cercopithecidae,9527.0
4845,U,,,,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,Autocuration,,,,,22224,BAO_0000218,A,,4257,In vivo,Cercopithecidae,9527.0
4846,U,,,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,Autocuration,,,,1969.0,22224,BAO_0000218,A,,13501,In vivo,Cercopithecidae,9527.0
4847,U,,,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,5394,In vivo,Cercopithecidae,9527.0
4848,U,,,,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,2661,In vivo,Cercopithecidae,9527.0
4849,U,,,,Compound was evaluated for terminal half life in monkey,Autocuration,,,,,22224,BAO_0000019,A,,3341,,Cercopithecidae,9527.0
4850,U,,,,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,3045,In vivo,Cercopithecidae,9527.0
4851,U,,,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Autocuration,,,,1969.0,22224,BAO_0000218,A,,5005,In vivo,Macaca mulatta,9544.0
4852,U,,,,Half life of compound was determined in squirrel monkey,Autocuration,,,,,22224,BAO_0000019,A,,4847,,Cercopithecidae,9527.0
4853,U,,,,Half life after iv administration in cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,4256,In vivo,Macaca fascicularis,9541.0
4854,U,,,,Half life in monkey plasma after administration of 1 mg/kg iv,Autocuration,,,,1969.0,22224,BAO_0000218,A,,6535,In vivo,Cercopithecidae,9527.0
4855,U,,,,Half life was calculated in rhesus monkey,Autocuration,,,,,22224,BAO_0000019,A,,6057,,Cercopithecidae,9527.0
4856,U,,,,Half life in monkey,Autocuration,,,,,22224,BAO_0000019,A,,17592,,Cercopithecidae,9527.0
4857,U,,,,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),Autocuration,,,,,22224,BAO_0000218,A,,6641,In vivo,Cercopithecidae,9527.0
4858,U,,,,Half life was evaluated in rhesus,Autocuration,,,,,22224,BAO_0000019,A,,5472,,Cercopithecidae,9527.0
4859,U,,,,Half life period after oral administration (2.5 mg/kg) in monkey was determined,Autocuration,,,,,22224,BAO_0000218,A,,6221,In vivo,Cercopithecidae,9527.0
4860,U,,,,Half life period was determine after peroral administration at 10 mpk in Rhesus,Autocuration,,,,,22224,BAO_0000218,A,,5668,In vivo,Cercopithecidae,9527.0
4861,U,,,,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),Autocuration,,,,,22224,BAO_0000218,A,,4809,In vivo,Cercopithecidae,9527.0
4862,U,,,,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,Autocuration,,,,,22224,BAO_0000218,A,,5546,In vivo,Cercopithecidae,9527.0
4863,U,,,,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,5553,In vivo,Cercopithecidae,9527.0
4864,U,,,,Half-life was calculated in monkey,Autocuration,,,,,22224,BAO_0000019,A,,6078,,Cercopithecidae,9527.0
4865,U,,,,Half-life in Squirrel monkey,Autocuration,,,,,22224,BAO_0000019,A,,5147,,Cercopithecidae,9527.0
4866,U,,,,Half-life in rhesus monkey,Autocuration,,,,,22224,BAO_0000019,A,,5145,,Cercopithecidae,9527.0
4867,U,,,,Half-life was measured in monkey after an iv dose of 1 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,6062,In vivo,Cercopithecidae,9527.0
4868,U,,,,Half-life period after intravenous administration in cynomolgus monkeys,Autocuration,,,,,22224,BAO_0000218,A,,5355,In vivo,Cercopithecidae,9527.0
4869,U,,,,Half-life period after oral administration in cynomolgus monkeys,Autocuration,,,,,22224,BAO_0000218,A,,5355,In vivo,Cercopithecidae,9527.0
4870,U,,,,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,Autocuration,,,,,22224,BAO_0000218,A,,5355,In vivo,Cercopithecidae,9527.0
4871,U,,,,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,,Homo sapiens,9606.0
4872,U,,,,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,,Homo sapiens,9606.0
4873,U,,,,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,,Homo sapiens,9606.0
4874,U,,,,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,,Homo sapiens,9606.0
4875,U,,,,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,,Homo sapiens,9606.0
4876,U,,,,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,,Homo sapiens,9606.0
4877,U,,,,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,,Homo sapiens,9606.0
4878,U,,,,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,,Homo sapiens,9606.0
4879,U,,,,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,Autocuration,,,,,22224,BAO_0000218,A,,1916,In vivo,Homo sapiens,9606.0
4880,U,,,,Oral bioavailability in human,Autocuration,,,,,22224,BAO_0000218,A,,16643,In vivo,Homo sapiens,9606.0
4881,U,,,,Compound was tested for human plasma protein binding,Autocuration,,,,,22224,BAO_0000019,A,,17248,,Homo sapiens,9606.0
4882,U,,,,Compound was tested for human plasma protein binding; Not determined,Autocuration,,,,,22224,BAO_0000019,A,,17248,,Homo sapiens,9606.0
4883,U,,,,Protein binding activity of compound in human plasma; % Free,Autocuration,,,,,22224,BAO_0000019,A,,6241,,Homo sapiens,9606.0
4884,U,,,,Unbound fraction (plasma),Autocuration,,,,,22224,BAO_0000019,A,,17716,,Homo sapiens,9606.0
4885,U,,,,Half life for the hydrolysis of compound in human blood serum,Autocuration,,,,1969.0,22224,BAO_0000366,A,,17605,,Homo sapiens,9606.0
4886,U,,,,Half life period in human plasma using phosphate buffer (0.08 M),Autocuration,,,,1969.0,22224,BAO_0000366,A,,17625,,Homo sapiens,9606.0
4887,U,,,,Half life period in human plasma using phosphate buffer (0.1 M),Autocuration,,,,1969.0,22224,BAO_0000366,A,,17625,,Homo sapiens,9606.0
4888,U,,,,Half-life in human plasma was determined,Autocuration,,,,1969.0,22224,BAO_0000366,A,,17747,,Homo sapiens,9606.0
4889,U,,,,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,Autocuration,,,,,22224,BAO_0000019,A,,15613,,Homo sapiens,9606.0
4890,U,,,,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),Autocuration,,,,,22224,BAO_0000019,A,,354,,Homo sapiens,9606.0
4891,U,,,,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",Autocuration,,,,,22224,BAO_0000019,A,,3741,,Homo sapiens,9606.0
4892,U,,,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",Autocuration,,,,,22224,BAO_0000019,A,,3741,,Homo sapiens,9606.0
4893,U,,,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",Autocuration,,,,,22224,BAO_0000019,A,,3741,,Homo sapiens,9606.0
4894,U,,,,Partition coefficient (logP),Autocuration,,,,,22224,BAO_0000019,A,,17599,,Homo sapiens,9606.0
4895,U,,,,In vitro metabolic stability in human was measured as pmol/min/mg/protein,Autocuration,,,,,22224,BAO_0000019,A,,5486,,Homo sapiens,9606.0
4896,U,,,,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,Autocuration,,,,,22224,BAO_0000251,A,Microsomes,5600,,Homo sapiens,9606.0
4897,U,,,,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),Autocuration,,,,,22224,BAO_0000019,A,,14294,,Homo sapiens,9606.0
4898,U,,,,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),Autocuration,,,,,22224,BAO_0000019,A,,14294,,Homo sapiens,9606.0
4899,U,,,,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),Autocuration,,,,,22224,BAO_0000019,A,,14294,,Homo sapiens,9606.0
4900,U,,,,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),Autocuration,,,,,22224,BAO_0000251,A,Microsomes,14294,,Homo sapiens,9606.0
4901,U,,,,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),Autocuration,,,,,22224,BAO_0000251,A,Microsomes,14294,,Homo sapiens,9606.0
4902,U,,,,Metabolism of compound in human microsomes; Trace,Autocuration,,,,,22224,BAO_0000251,A,Microsomes,14294,,Homo sapiens,9606.0
4903,U,,,,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,6260,,Homo sapiens,9606.0
4904,U,,,,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,Autocuration,,,,,22224,BAO_0000251,A,Microsomes,6187,,Homo sapiens,9606.0
4905,U,,,,In vitro metabolic potential in human liver microsomes,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,6251,,Homo sapiens,9606.0
4906,U,,,,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,Autocuration,,,,,22224,BAO_0000019,A,,3246,,Homo sapiens,9606.0
4907,U,,,,Tested for human plasma protein binding of the compound; Not tested,Autocuration,,,,,22224,BAO_0000019,A,,17313,,Homo sapiens,9606.0
4908,U,,,,Compound was tested for percent protein binding (PB) in human,Autocuration,,,,,22224,BAO_0000019,A,,6227,,Homo sapiens,9606.0
4909,U,,,,Protein binding in human plasma,Autocuration,,,,1969.0,22224,BAO_0000019,A,,5530,,Homo sapiens,9606.0
4910,U,,,,Permeability coefficient (B to A) in Caco-2 cell,Autocuration,,,,,22224,BAO_0000019,A,,6108,,Homo sapiens,9606.0
4911,U,,,,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,Autocuration,,,,,22224,BAO_0000019,A,,6108,,Homo sapiens,9606.0
4912,U,,,,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),Autocuration,,,,,22224,BAO_0000019,A,,2774,,Homo sapiens,9606.0
4913,U,,,,In vitro rate of absorption observed as Caco-2 permeability in humans,Autocuration,,,,,22224,BAO_0000019,A,,16643,,Homo sapiens,9606.0
4914,U,,495.0,,Cellular permeability of compound was determined in Caco-2 cells; High,Autocuration,,Caco-2,,,22224,BAO_0000219,A,,17582,,Homo sapiens,9606.0
4915,U,,495.0,,Permeability in Caco-2 cells of compound,Autocuration,,Caco-2,,,22224,BAO_0000219,A,,6838,,Homo sapiens,9606.0
4916,U,,,,Permeability coefficient (A to B) in Caco-2 cell,Autocuration,,,,,22224,BAO_0000019,A,,6108,,Homo sapiens,9606.0
4917,U,,,,Permeability coefficient (B to A) in Caco-2 cell,Autocuration,,,,,22224,BAO_0000019,A,,6108,,Homo sapiens,9606.0
4918,U,,,,Permeability coefficient (Papp) (Caco-2 cell monolayer),Autocuration,,,,,22224,BAO_0000019,A,,6108,,Homo sapiens,9606.0
4919,U,,,,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,Autocuration,,,,,22224,BAO_0000019,A,,2146,,Homo sapiens,9606.0
4920,U,,,,Compound was tested for protein binding in human plasma,Autocuration,,,,,22224,BAO_0000019,A,,4514,,Homo sapiens,9606.0
4921,U,,,,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,Autocuration,,,,,22224,BAO_0000019,A,,6108,,Homo sapiens,9606.0
4922,U,,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,,Homo sapiens,9606.0
4923,N,,,,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,5969,In vivo,Mus musculus,10090.0
4924,N,,,,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Intermediate,,,,,50594,BAO_0000218,A,,3277,In vivo,Mus musculus,10090.0
4925,N,,,,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,Intermediate,,,,,50594,BAO_0000218,A,,3802,In vivo,Mus musculus,10090.0
4926,N,,,,Time taken to reach maximum concentration in plasma upon oral administration in mouse,Intermediate,,,,1969.0,50594,BAO_0000218,A,,2862,In vivo,Mus musculus,10090.0
4927,N,,,,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Intermediate,,,,1969.0,50594,BAO_0000218,A,,6348,In vivo,Mus musculus,10090.0
4928,N,,,,Tmax after intraperitoneal administration in mice at 23 uM/kg,Intermediate,,,,,50594,BAO_0000218,F,,17764,In vivo,Mus musculus,10090.0
4929,N,,,,Tmax after oral administration at 30 mg/kg in ICR mouse,Intermediate,,,,,50594,BAO_0000218,A,,5781,In vivo,Mus musculus,10090.0
4930,N,,,,Tmax after peroral administration in mice at 2.4 uM/kg,Intermediate,,,,,50594,BAO_0000218,A,,17764,In vivo,Mus musculus,10090.0
4931,N,,,,Tmax at a single subcutaneous administration of 40 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,4066,In vivo,Mus musculus,10090.0
4932,N,,,,Tmax in brain of mice at the oral dose of 50 mg/kg,Intermediate,,,,955.0,50594,BAO_0000218,A,,17641,In vivo,Mus musculus,10090.0
4933,N,,,,Tmax in kidney of mice at the oral dose of 50 mg/kg,Intermediate,,,,2113.0,50594,BAO_0000218,A,,17641,In vivo,Mus musculus,10090.0
4934,N,,,,Tmax in liver of mice at the oral dose of 50 mg/kg,Intermediate,,,,2107.0,50594,BAO_0000218,A,,17641,In vivo,Mus musculus,10090.0
4935,N,,,,Tmax in lungs of mice at the oral dose of 50 mg/kg,Intermediate,,,,2048.0,50594,BAO_0000218,A,,17641,In vivo,Mus musculus,10090.0
4936,N,,,,Tmax in mice at 18 uM/kg i.p. administration,Intermediate,,,,,50594,BAO_0000218,F,,17764,In vivo,Mus musculus,10090.0
4937,N,,,,Tmax in mice at 23 uM/kg i.v. administration,Intermediate,,,,,50594,BAO_0000218,F,,17764,In vivo,Mus musculus,10090.0
4938,N,,,,Tmax in mice at 25 uM/kg i.p. administration,Intermediate,,,,,50594,BAO_0000218,F,,17764,In vivo,Mus musculus,10090.0
4939,N,,,,Tmax in mice at 26 uM/kg i.p. administration,Intermediate,,,,,50594,BAO_0000218,F,,17764,In vivo,Mus musculus,10090.0
4940,N,,,,Tmax in spleen of mice at the oral dose of 50 mg/kg,Intermediate,,,,2106.0,50594,BAO_0000218,A,,17641,In vivo,Mus musculus,10090.0
4941,N,,,,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,,,,,50594,BAO_0000218,A,,16597,In vivo,Mus musculus,10090.0
4942,N,,,,Tmax value at a dose of 10 mg/kg peroral administration in mice.,Intermediate,,,,,50594,BAO_0000218,A,,16597,In vivo,Mus musculus,10090.0
4943,N,,,,Tmax value in IRC mice,Intermediate,,,,,50594,BAO_0000218,A,,5951,,Mus musculus,10090.0
4944,N,,,,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,Intermediate,,,,,50594,BAO_0000218,A,,5506,In vivo,Mus musculus,10090.0
4945,N,,,,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,Intermediate,,,,,50594,BAO_0000218,A,,5506,In vivo,Mus musculus,10090.0
4946,N,,,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),Intermediate,,,,1088.0,50594,BAO_0000218,A,,429,,Mus musculus,10090.0
4947,N,,,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),Intermediate,,,,1088.0,50594,BAO_0000218,A,,429,,Mus musculus,10090.0
4948,N,,,,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),Intermediate,,,,1088.0,50594,BAO_0000218,A,,4066,,Mus musculus,10090.0
4949,N,,,,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,17734,,Mus musculus,10090.0
4950,N,,,,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,17734,,Mus musculus,10090.0
4951,N,,,,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,6062,In vivo,Mus musculus,10090.0
4952,N,,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,5969,In vivo,Mus musculus,10090.0
4953,N,,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,5969,In vivo,Mus musculus,10090.0
4954,N,,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,Intermediate,,,,,50594,BAO_0000218,A,,5969,In vivo,Mus musculus,10090.0
4955,N,,,,Vd in mice,Intermediate,,,,,50594,BAO_0000218,A,,5980,In vivo,Mus musculus,10090.0
4956,N,,,,Volume of distribution in mouse,Intermediate,,,,,50594,BAO_0000218,A,,17592,In vivo,Mus musculus,10090.0
4957,N,,,,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Intermediate,,,,,50594,BAO_0000218,A,,6348,In vivo,Mus musculus,10090.0
4958,N,,,,Volume of distribution of compound in plasma was determined at 24 mg/Kg,Intermediate,,,,,50594,BAO_0000218,A,,17753,In vivo,Mus musculus,10090.0
4959,N,,,,Volume of distribution of compound in plasma was determined at 40 mg/Kg,Intermediate,,,,,50594,BAO_0000218,A,,17753,In vivo,Mus musculus,10090.0
4960,N,,,,Volume of distribution of compound in plasma was determined at 5 mg/Kg,Intermediate,,,,,50594,BAO_0000218,A,,17753,In vivo,Mus musculus,10090.0
4961,N,,,,Pharmacokinetic property (vdss) was measured in mouse,Intermediate,,,,,50594,BAO_0000218,A,,4239,In vivo,Mus musculus,10090.0
4962,N,,,,Value distribution upon iv administration in mouse,Intermediate,,,,,50594,BAO_0000218,A,,2862,In vivo,Mus musculus,10090.0
4963,N,,,,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,17734,In vivo,Mus musculus,10090.0
4964,N,,,,Volume of distribution was evaluated in mice after intravenous administration,Intermediate,,,,,50594,BAO_0000218,A,,2675,In vivo,Mus musculus,10090.0
4965,N,,,,Volume of distribution was evaluated in mice after oral administration,Intermediate,,,,,50594,BAO_0000218,A,,2675,In vivo,Mus musculus,10090.0
4966,N,,,,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,17837,In vivo,Mus musculus,10090.0
4967,N,,,,Steady state volume of distribution was determined in mice,Intermediate,,,,,50594,BAO_0000218,A,,5727,In vivo,Mus musculus,10090.0
4968,N,,,,Volume distribution (steady state) of compound was determined in mouse,Intermediate,,,,,50594,BAO_0000218,A,,17852,In vivo,Mus musculus,10090.0
4969,N,,,,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,Intermediate,,,,,50594,BAO_0000218,A,,17764,In vivo,Mus musculus,10090.0
4970,N,,,,Vss value at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,,,,,50594,BAO_0000218,A,,16597,In vivo,Mus musculus,10090.0
4971,N,,,,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,6062,In vivo,Mus musculus,10090.0
4972,N,,,,Biodistribution of compound (oxidized form) in in kidney tissue,Intermediate,,,,2113.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
4973,N,,,,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,Intermediate,,,,178.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
4974,N,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Intermediate,,,,178.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
4975,N,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,,178.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
4976,N,,797.0,,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,Intermediate,,A-427,,,80019,BAO_0000219,F,,10708,,Homo sapiens,9606.0
4977,N,,500.0,,Inhibition of A431 human squamous cell carcinoma cell proliferation,Expert,,A-431,,,80852,BAO_0000219,F,,16597,,Homo sapiens,9606.0
4978,N,,500.0,,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,Expert,,A-431,,,80852,BAO_0000219,F,,16062,,Homo sapiens,9606.0
4979,N,,500.0,,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,Expert,,A-431,,,80852,BAO_0000219,F,,16062,,Homo sapiens,9606.0
4980,N,,500.0,,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,Expert,,A-431,,,80852,BAO_0000219,F,,16958,,Homo sapiens,9606.0
4981,N,,500.0,,Inhibition of A431 human carcinoma cell proliferation,Expert,,A-431,,,80852,BAO_0000219,F,,6700,,Homo sapiens,9606.0
4982,N,,500.0,,In vitro inhibition of A431 (human carcinoma) cell basal growth.,Expert,,A-431,,,80852,BAO_0000219,F,,17226,,Homo sapiens,9606.0
4983,N,,500.0,,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,Intermediate,,A-431,,,80852,BAO_0000219,F,,6828,,Homo sapiens,9606.0
4984,N,,500.0,,In vitro cytotoxicity against epidermoid carcinoma cell line,Intermediate,,A-431,,,80852,BAO_0000219,F,,12314,,Homo sapiens,9606.0
4985,D,,500.0,,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",Expert,,A-431,,,9,BAO_0000218,F,,13412,,Homo sapiens,9606.0
4986,N,,500.0,,Antiproliferative activity of compound was measured on human tumor cell line A431.,Intermediate,,A-431,,,80852,BAO_0000219,F,,13299,,Homo sapiens,9606.0
4987,N,,500.0,,Antiproliferative effect of compound on A431 cell line expressing mutant p53,Intermediate,,A-431,,,80852,BAO_0000219,F,,17420,,Homo sapiens,9606.0
4988,N,,500.0,,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,Intermediate,,A-431,,,80852,BAO_0000219,F,,13678,,Homo sapiens,9606.0
4989,H,,500.0,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,Expert,,A-431,,,9,BAO_0000219,F,,14171,,,
4990,N,,500.0,,Tested for antiproliferative activity against human A431 cells,Expert,,A-431,,,80852,BAO_0000219,F,,6333,,Homo sapiens,9606.0
4991,D,,500.0,,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,Expert,,A-431,,,9,BAO_0000219,F,,2356,,Homo sapiens,9606.0
4992,N,,500.0,,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,Expert,,A-431,,,80852,BAO_0000219,F,,15578,,Homo sapiens,9606.0
4993,N,,500.0,,Inhibition of A431 cell proliferation,Expert,,A-431,,,80852,BAO_0000219,F,,5126,,Homo sapiens,9606.0
4994,N,,500.0,,Cytotoxic effect on A431 human epidermoid carcinoma cells,Expert,,A-431,,,80852,BAO_0000219,F,,6844,,Homo sapiens,9606.0
4995,N,,500.0,,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),Expert,,A-431,,,80852,BAO_0000219,F,,6844,,Homo sapiens,9606.0
4996,N,,500.0,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,Intermediate,,A-431,,,80852,BAO_0000219,F,,4925,,Homo sapiens,9606.0
4997,N,,500.0,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,Intermediate,,A-431,,,80852,BAO_0000219,F,,4925,,Homo sapiens,9606.0
4998,N,,500.0,,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,Intermediate,,A-431,,,80852,BAO_0000219,F,,13978,,Homo sapiens,9606.0
4999,N,,500.0,,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,Intermediate,,A-431,,,80852,BAO_0000219,F,,16786,,Homo sapiens,9606.0
5000,H,,500.0,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,Expert,,A-431,,,9,BAO_0000219,F,,13412,,,
5001,N,,500.0,,In vivo antiproliferative activity against A431 cell line,Intermediate,,A-431,,,80852,BAO_0000218,F,,17824,,Homo sapiens,9606.0
5002,D,,500.0,,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,Expert,,A-431,,,9,BAO_0000219,F,,12751,,Homo sapiens,9606.0
5003,N,,500.0,,Inhibition of A431 human epidermoid carcinoma cell proliferation,Expert,,A-431,,,80852,BAO_0000219,F,,12380,,Homo sapiens,9606.0
5004,D,,500.0,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,Expert,,A-431,,,9,BAO_0000219,F,,4959,,Homo sapiens,9606.0
5005,N,,500.0,,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),Intermediate,,A-431,,,80852,BAO_0000219,F,,6333,,Homo sapiens,9606.0
5006,N,,500.0,,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),Intermediate,,A-431,,,80852,BAO_0000219,F,,6333,,Homo sapiens,9606.0
5007,N,,500.0,,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),Intermediate,,A-431,,,80852,BAO_0000219,F,,6333,,Homo sapiens,9606.0
5008,D,,,,Inhibition of EGFR overexpressing A431 cell proliferation,Expert,,,,,9,BAO_0000019,F,,5296,,Homo sapiens,9606.0
5009,N,,500.0,,Inhibition of A431 cell proliferation,Expert,,A-431,,,80852,BAO_0000219,F,,12624,,Homo sapiens,9606.0
5010,D,,500.0,,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,Expert,,A-431,,,9,BAO_0000219,F,,14926,,Homo sapiens,9606.0
5011,D,,500.0,,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",Expert,,A-431,,,9,BAO_0000219,F,,14926,,Homo sapiens,9606.0
5012,H,,500.0,,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),Expert,,A-431,,,9,BAO_0000219,F,,14926,,,
5013,N,,500.0,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,Intermediate,,A-431,,,80852,BAO_0000219,F,,15144,,Homo sapiens,9606.0
5014,N,,500.0,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,Intermediate,,A-431,,,80852,BAO_0000219,F,,15144,,Homo sapiens,9606.0
5015,N,,500.0,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,Intermediate,,A-431,,,80852,BAO_0000219,F,,5245,,Homo sapiens,9606.0
5016,N,,500.0,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,Intermediate,,A-431,,,80852,BAO_0000219,F,,5245,,Homo sapiens,9606.0
5017,N,,500.0,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,Intermediate,,A-431,,,80852,BAO_0000219,F,,5245,,Homo sapiens,9606.0
5018,N,,500.0,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,Intermediate,,A-431,,,80852,BAO_0000219,F,,5245,,Homo sapiens,9606.0
5019,N,,500.0,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,Intermediate,,A-431,,,80852,BAO_0000219,F,,5245,,Homo sapiens,9606.0
5020,U,,,,Half-life period in cynomolgus monkey,Autocuration,,,,,22224,BAO_0000019,A,,5922,,Cercopithecidae,9527.0
5021,U,,,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",Autocuration,,,,1969.0,22224,BAO_0000366,A,,1116,In vitro,Cercopithecidae,9527.0
5022,U,,,,Longer half-life in monkey (i.v.) at 0.5 mpk,Autocuration,,,,,22224,BAO_0000218,A,,17853,In vivo,Cercopithecidae,9527.0
5023,U,,,,Plasma half life in monkey,Autocuration,,,,1969.0,22224,BAO_0000366,A,,993,,Cercopithecidae,9527.0
5024,U,,,,Plasma half-life in rhesus monkey,Autocuration,,,,1969.0,22224,BAO_0000366,A,,4514,,Cercopithecidae,9527.0
5025,U,,,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Autocuration,,,,1969.0,22224,BAO_0000218,A,,5334,In vivo,Cercopithecidae,9527.0
5026,U,,,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Autocuration,,,,1969.0,22224,BAO_0000218,A,,5334,In vivo,Cercopithecidae,9527.0
5027,U,,,,Tested for half life upon iv administration to african green monkey,Autocuration,,,,,22224,BAO_0000218,A,,4578,In vivo,Cercopithecidae,9527.0
5028,U,,,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,2661,In vivo,Cercopithecidae,9527.0
5029,U,,,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,Autocuration,,,,,22224,BAO_0000218,A,,5355,In vivo,Cercopithecidae,9527.0
5030,U,,,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,Autocuration,,,,,22224,BAO_0000218,A,,5355,In vivo,Cercopithecidae,9527.0
5031,U,,,,The time for peak concentration value after oral administration in cynomolgus monkeys,Autocuration,,,,,22224,BAO_0000218,A,,5355,In vivo,Cercopithecidae,9527.0
5032,U,,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11271,,Cercopithecidae,9527.0
5033,U,,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11271,,Cercopithecidae,9527.0
5034,U,,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11271,,Cercopithecidae,9527.0
5035,U,,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11271,,Cercopithecidae,9527.0
5036,U,,,,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11271,,Cercopithecidae,9527.0
5037,U,,,,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11271,,Cercopithecidae,9527.0
5038,U,,,,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11271,,Cercopithecidae,9527.0
5039,U,,,,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11271,,Cercopithecidae,9527.0
5040,U,,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11271,,Cercopithecidae,9527.0
5041,U,,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11271,,Cercopithecidae,9527.0
5042,U,,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11271,,Cercopithecidae,9527.0
5043,U,,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11271,,Cercopithecidae,9527.0
5044,U,,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11271,,Cercopithecidae,9527.0
5045,U,,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11271,,Cercopithecidae,9527.0
5046,U,,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11271,,Cercopithecidae,9527.0
5047,U,,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11271,,Cercopithecidae,9527.0
5048,N,,,,Bioavailability in rat (cannulated) (dose 2 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,5809,In vivo,Rattus norvegicus,10116.0
5049,N,,,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17720,In vivo,Rattus norvegicus,10116.0
5050,N,,,,AUC value in rat after IV administration at a dose of 10 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,3546,,Rattus norvegicus,10116.0
5051,N,,,,AUC value in rat after oral administration at a dose of 10 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,3546,,Rattus norvegicus,10116.0
5052,N,,,,Cmax value in rat after oral administration at a dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,3546,In vivo,Rattus norvegicus,10116.0
5053,N,,,,Bioavailability in rat after oral administration at a dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,3546,In vivo,Rattus norvegicus,10116.0
5054,N,,,,Tmax value in rat after oral administration at a dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,3546,In vivo,Rattus norvegicus,10116.0
5055,N,,,,Vc value in rat after IV administration at a dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,3546,,Rattus norvegicus,10116.0
5056,N,,,,Half life period in rat after IV administration at a dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,3546,In vivo,Rattus norvegicus,10116.0
5057,U,,,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,Autocuration,,,,,22224,BAO_0000019,A,,10625,,Papio hamadryas,9557.0
5058,U,,,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),Autocuration,,,,,22224,BAO_0000019,A,,10625,,Papio hamadryas,9557.0
5059,U,,,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),Autocuration,,,,,22224,BAO_0000019,A,,10625,,Papio hamadryas,9557.0
5060,U,,,,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,Autocuration,,,,,22224,BAO_0000019,A,,10625,,Papio hamadryas,9557.0
5061,U,,,,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,Autocuration,,,,,22224,BAO_0000019,A,,10625,,Papio hamadryas,9557.0
5062,U,,,,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,Autocuration,,,,,22224,BAO_0000019,A,,10625,,Papio hamadryas,9557.0
5063,U,,,,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,Autocuration,,,,,22224,BAO_0000019,A,,10625,,Papio hamadryas,9557.0
5064,U,,,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,Autocuration,,,,,22224,BAO_0000019,A,,10625,,Papio hamadryas,9557.0
5065,U,,,,Area under curve after 1 mpk peroral administration to beagles,Autocuration,,,,,22224,BAO_0000019,A,,3510,,beagle,9615.0
5066,U,,,,Area under curve after 2 mpk peroral administration to beagles,Autocuration,,,,,22224,BAO_0000019,A,,3510,,beagle,9615.0
5067,U,,,,Cmax value after 1 mpk peroral administration to beagles,Autocuration,,,,,22224,BAO_0000218,A,,3510,In vivo,beagle,9615.0
5068,U,,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,,Homo sapiens,9606.0
5069,U,,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,,Homo sapiens,9606.0
5070,U,,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,,Homo sapiens,9606.0
5071,U,,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,,Homo sapiens,9606.0
5072,U,,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,,Homo sapiens,9606.0
5073,U,,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,,Homo sapiens,9606.0
5074,U,,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,,Homo sapiens,9606.0
5075,U,,,,Metabolic stability observed at 30 min after administration in human liver microsomes,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,16643,,Homo sapiens,9606.0
5076,U,,,,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,Autocuration,,,,,22224,BAO_0000019,A,,6852,,Homo sapiens,9606.0
5077,U,,,,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,Autocuration,,,,,22224,BAO_0000019,A,,6852,,Homo sapiens,9606.0
5078,U,,,,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,Autocuration,,,,,22224,BAO_0000019,A,,6852,,Homo sapiens,9606.0
5079,U,,,,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,6567,,Homo sapiens,9606.0
5080,U,,,,Metabolic stability (% remaining at 30 mins) in human S9.,Autocuration,,,,,22224,BAO_0000019,A,,6570,,Homo sapiens,9606.0
5081,U,,,,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,Autocuration,,,,,22224,BAO_0000019,A,,6570,,Homo sapiens,9606.0
5082,U,,,,Percent parent compound remaining after 20 min incubation with human liver microsomes,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,5237,,Homo sapiens,9606.0
5083,U,,,,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,5237,,Homo sapiens,9606.0
5084,U,,,,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,5237,,Homo sapiens,9606.0
5085,U,,,,First pass metabolism and metabolic bioavailability using human hepatic microsomes,Autocuration,,,,,22224,BAO_0000218,A,,5202,,Homo sapiens,9606.0
5086,U,,,,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,Autocuration,,,,,22224,BAO_0000019,A,,5481,,Homo sapiens,9606.0
5087,U,,,,Percent remaining in human plasma after incubation for 60 min at 37 C.,Autocuration,,,,,22224,BAO_0000019,A,,5481,,Homo sapiens,9606.0
5088,U,,,,The percent remaining in human plasma after 30 min was determined,Autocuration,,,,,22224,BAO_0000019,A,,3956,,Homo sapiens,9606.0
5089,U,,,,Conversion rate of the prodrug in human plasma,Autocuration,,,,1969.0,22224,BAO_0000366,A,,5074,,Homo sapiens,9606.0
5090,U,,,,Conversion rate of the prodrug in human plasma; ND means no data,Autocuration,,,,1969.0,22224,BAO_0000366,A,,5074,,Homo sapiens,9606.0
5091,U,,,,Half life of compound was determined in human blood,Autocuration,,,,178.0,22224,BAO_0000221,A,,4727,,Homo sapiens,9606.0
5092,U,,,,Half life of compound was determined in man with once daily dosing,Autocuration,,,,,22224,BAO_0000019,A,,5965,,Homo sapiens,9606.0
5093,U,,,,Half life in human microsomes,Autocuration,,,,,22224,BAO_0000251,A,Microsomes,5732,In vitro,Homo sapiens,9606.0
5094,U,,,,Half life in human plasma,Autocuration,,,,1969.0,22224,BAO_0000366,A,,5819,,Homo sapiens,9606.0
5095,U,,,,Half life in human plasma; Not detected,Autocuration,,,,1969.0,22224,BAO_0000366,A,,5819,,Homo sapiens,9606.0
5096,U,,,,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,Autocuration,,,,,22224,BAO_0000218,A,,1916,In vivo,Homo sapiens,9606.0
5097,U,,,,Half-life for oxidative metabolic stability was determined using rat liver microsomes,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,6597,In vitro,Homo sapiens,9606.0
5098,U,,,,Half-life in human plasma,Autocuration,,,,1969.0,22224,BAO_0000366,A,,5229,,Homo sapiens,9606.0
5099,U,,,,Half-life of the parent prodrug in plasma,Autocuration,,,,1969.0,22224,BAO_0000366,A,,5229,,Homo sapiens,9606.0
5100,U,,,,In vitro half life in human plasma was determined,Autocuration,,,,1969.0,22224,BAO_0000366,A,,2192,In vitro,Homo sapiens,9606.0
5101,U,,,,The compound was tested In Vitro for half life in human liver microsomes.,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,3032,In vitro,Homo sapiens,9606.0
5102,U,,,,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,Autocuration,,,,,22224,BAO_0000218,A,,1916,In vivo,Homo sapiens,9606.0
5103,U,,,,Observed volume of distribution,Autocuration,,,,,22224,BAO_0000218,A,,17716,In vivo,Homo sapiens,9606.0
5104,U,,,,Oral bioavailability in human,Autocuration,,,,,22224,BAO_0000218,A,,15778,In vivo,Homo sapiens,9606.0
5105,U,,,,Tested for human plasma protein binding of the compound,Autocuration,,,,,22224,BAO_0000019,A,,17313,,Homo sapiens,9606.0
5106,U,,,,"First order rate constant, k was determined in human plasma",Autocuration,,,,,22224,BAO_0000019,A,,4231,,Homo sapiens,9606.0
5107,U,,,,Observed rate constant in 80% human plasma at 37 degree Centigrade,Autocuration,,,,,22224,BAO_0000019,A,,4755,,Homo sapiens,9606.0
5108,U,,,,Observed rate constant in 80% human plasma at 37 degree Centigrade,Autocuration,,,,,22224,BAO_0000019,A,,4755,,Homo sapiens,9606.0
5109,U,,,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,16907,,Homo sapiens,9606.0
5110,U,,,,The compound was tested for the plasma binding in human,Autocuration,,,,,22224,BAO_0000019,A,,10839,,Homo sapiens,9606.0
5111,U,,,,Plasma protein binding (human),Autocuration,,,,,22224,BAO_0000019,A,,10839,,Homo sapiens,9606.0
5112,U,,,,Compound was evaluated for half-life in human liver microsomes,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,3199,In vitro,Homo sapiens,9606.0
5113,U,,,,Half life measured in vitro for its stability in human blood,Autocuration,,,,178.0,22224,BAO_0000221,A,,1345,In vitro,Homo sapiens,9606.0
5114,U,,,,Half life in human serum,Autocuration,,,,1977.0,22224,BAO_0000019,A,,4297,,Homo sapiens,9606.0
5115,U,,,,Half life in human serum; ND=not determined,Autocuration,,,,1977.0,22224,BAO_0000019,A,,4297,,Homo sapiens,9606.0
5116,U,,,,Half life were determined in CEM-SS cell extract in decomposition step 1,Autocuration,,,,,22224,BAO_0000019,A,,4297,,Homo sapiens,9606.0
5117,U,,,,Half life were determined in CEM-SS cell extract in decomposition step 2,Autocuration,,,,,22224,BAO_0000019,A,,4297,,Homo sapiens,9606.0
5118,U,,,,Half life of the in human plasma,Autocuration,,,,1969.0,22224,BAO_0000366,A,,4231,,Homo sapiens,9606.0
5119,U,,,,Half life period in human hepatic S9 fraction was determined,Autocuration,,,,,22224,BAO_0000220,A,S9,5633,In vitro,Homo sapiens,9606.0
5120,U,,,,Half life period in human liver microsome was determined,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,5633,In vitro,Homo sapiens,9606.0
5121,U,,,,Half life period was determined; 6-7,Autocuration,,,,,22224,BAO_0000019,A,,17791,,Homo sapiens,9606.0
5122,U,,,,Half life period was evaluated in human,Autocuration,,,,,22224,BAO_0000019,A,,17791,,Homo sapiens,9606.0
5123,U,,,,Half life time in human plasma,Autocuration,,,,1969.0,22224,BAO_0000366,A,,3160,,Homo sapiens,9606.0
5124,N,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,,955.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5125,N,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,,,948.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5126,N,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,,948.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5127,N,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,,,2113.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5128,N,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Intermediate,,,,2113.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5129,N,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,,2113.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5130,N,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,,,2107.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5131,N,,,,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,Intermediate,,,,2107.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5132,N,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,,2107.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5133,N,,,,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,Intermediate,,,,2106.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5134,N,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Intermediate,,,,2106.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5135,N,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,,2106.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5136,N,,,,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,,,955.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5137,N,,,,Biodistribution of compound (oxidized form) in blood tissue,Intermediate,,,,178.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5138,N,,,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,,,178.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5139,N,,,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Intermediate,,,,178.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5140,N,,,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,,,178.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5141,N,,,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,,178.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5142,N,,,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",Intermediate,,,,178.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5143,N,,,,Biodistribution of compound (oxidized form) in brain tissue of mice,Intermediate,,,,955.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5144,N,,,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,,,955.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5145,N,,,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,,,955.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5146,N,,,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,,955.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5147,N,,,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Intermediate,,,,955.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5148,N,,,,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",Intermediate,,,,955.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5149,N,,,,Biodistribution of compound (oxidized form) in heart tissue of mice,Intermediate,,,,948.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5150,N,,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,,,948.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5151,N,,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,,,948.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5152,N,,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,,,948.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5153,N,,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,,948.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5154,N,,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Intermediate,,,,948.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5155,N,,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,,,2113.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5156,N,,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Intermediate,,,,2113.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5157,N,,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,,,2113.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5158,N,,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,,2113.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5159,N,,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Intermediate,,,,2113.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5160,N,,,,Biodistribution of compound (oxidized form) in liver tissue,Intermediate,,,,2107.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5161,N,,,,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,,,2107.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5162,N,,,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,,,2107.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
5163,N,,500.0,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,Intermediate,,A-431,,,80852,BAO_0000219,F,,5245,,Homo sapiens,9606.0
5164,N,,500.0,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,Intermediate,,A-431,,,80852,BAO_0000219,F,,5245,,Homo sapiens,9606.0
5165,N,,500.0,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",Expert,,A-431,,,80852,BAO_0000218,F,,16289,,,
5166,N,,500.0,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",Expert,,A-431,,,80852,BAO_0000218,F,,16289,,,
5167,D,,500.0,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,Expert,,A-431,,,9,BAO_0000219,F,,16093,,Homo sapiens,9606.0
5168,N,,500.0,,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",Intermediate,,A-431,,,80852,BAO_0000219,F,,16825,,Homo sapiens,9606.0
5169,N,,500.0,,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,Intermediate,,A-431,,,80852,BAO_0000219,F,,4848,,Homo sapiens,9606.0
5170,D,,500.0,,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,Expert,,A-431,,,9,BAO_0000219,F,,14827,,Homo sapiens,9606.0
5171,D,,500.0,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,Expert,,A-431,,,9,BAO_0000219,F,,14827,,Homo sapiens,9606.0
5172,N,,500.0,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",Expert,,A-431,,,80852,BAO_0000218,F,,16289,,,
5173,N,,500.0,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",Expert,,A-431,,,80852,BAO_0000218,F,,16289,,,
5174,N,,500.0,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",Expert,,A-431,,,80852,BAO_0000218,F,,16289,,,
5175,N,,500.0,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",Expert,,A-431,,,80852,BAO_0000218,F,,16289,,,
5176,N,,500.0,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",Expert,,A-431,,,80852,BAO_0000218,F,,16289,,,
5177,D,,500.0,,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",Expert,,A-431,,,9,BAO_0000219,F,,16289,,Homo sapiens,9606.0
5178,H,,500.0,,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,Expert,,A-431,,,9,BAO_0000219,F,,16289,,,
5179,N,,500.0,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",Expert,,A-431,,,80852,BAO_0000218,F,,16289,,,
5180,N,,500.0,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",Expert,,A-431,,,80852,BAO_0000218,F,,16289,,,
5181,N,,500.0,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",Expert,,A-431,,,80852,BAO_0000218,F,,16289,,,
5182,N,,500.0,,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",Expert,,A-431,,,80852,BAO_0000218,F,,14555,,Mus musculus,10090.0
5183,N,,500.0,,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",Expert,,A-431,,,80852,BAO_0000218,F,,14555,,Mus musculus,10090.0
5184,N,,500.0,,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",Expert,,A-431,,,80852,BAO_0000218,F,,14555,,Mus musculus,10090.0
5185,N,,500.0,,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",Expert,,A-431,,,80852,BAO_0000218,F,,14555,,Mus musculus,10090.0
5186,N,,500.0,,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,Expert,,A-431,,,80852,BAO_0000219,F,,1937,,Homo sapiens,9606.0
5187,N,,500.0,,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,Intermediate,,A-431,,,80852,BAO_0000219,F,,13739,,Homo sapiens,9606.0
5188,N,,500.0,,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,Intermediate,,A-431,,,80852,BAO_0000219,F,,3558,,Homo sapiens,9606.0
5189,N,,500.0,,Dose giving a 50% decrease in the living cell number (A437 cells),Intermediate,,A-431,,,80852,BAO_0000219,F,,3558,,Homo sapiens,9606.0
5190,N,,646.0,,In vitro inhibitory concentration against proliferation of A459 cell line.,Expert,,A549,,,80682,BAO_0000219,F,,17686,,Homo sapiens,9606.0
5191,N,,646.0,,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,Intermediate,,A549,,,80682,BAO_0000219,F,,5305,,Homo sapiens,9606.0
5192,N,,646.0,,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,Intermediate,,A549,,,80682,BAO_0000219,F,,3614,,Homo sapiens,9606.0
5193,N,,624.0,,In vitro antitumor activity against renal A498 tumor cell lines,Intermediate,,A498,,,80021,BAO_0000219,F,,17229,,Homo sapiens,9606.0
5194,N,,624.0,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",Intermediate,,A498,,,80021,BAO_0000219,F,,15935,,Homo sapiens,9606.0
5195,N,,624.0,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",Intermediate,,A498,,,80021,BAO_0000219,F,,15935,,Homo sapiens,9606.0
5196,N,,624.0,,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,Intermediate,,A498,,,80021,BAO_0000219,F,,15560,,Homo sapiens,9606.0
5197,N,,624.0,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,13891,,Homo sapiens,9606.0
5198,N,,624.0,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,Intermediate,,A498,,,80021,BAO_0000219,F,,13891,,Homo sapiens,9606.0
5199,N,,624.0,,Cytotoxicity on kidney carcinoma (A-498) cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,13788,,Homo sapiens,9606.0
5200,N,,624.0,,Compound was evaluated against Human cell line renal A498,Intermediate,,A498,,,80021,BAO_0000219,F,,15403,,Homo sapiens,9606.0
5201,N,,624.0,,Compound was tested for inhibition of A498 human renal cancer cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,1009,,Homo sapiens,9606.0
5202,N,,624.0,,Growth inhibitory activity against A498 human cancer cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,1043,,Homo sapiens,9606.0
5203,N,,624.0,,In vitro antitumor activity against human renal A498 cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,5858,,Homo sapiens,9606.0
5204,N,,624.0,,In vitro cytotoxic activity against renal (A498) cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,5958,,Homo sapiens,9606.0
5205,N,,624.0,,In vitro cytotoxic activity against human renal cancer (A498) cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,5506,,Homo sapiens,9606.0
5206,N,,624.0,,Tested for cytostatic activity against renal A498 cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,12781,,Homo sapiens,9606.0
5207,N,,624.0,,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,Intermediate,,A498,,,80021,BAO_0000219,F,,14399,,Homo sapiens,9606.0
5208,N,,624.0,,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,Expert,,A498,,,80021,BAO_0000219,F,,5958,,Homo sapiens,9606.0
5209,U,,,,Cmax value after 2 mpk peroral administration to beagles,Autocuration,,,,,22224,BAO_0000218,A,,3510,In vivo,beagle,9615.0
5210,U,,,beagle,Bioavailability,Autocuration,,,,,22224,BAO_0000218,A,,3510,In vivo,Canis lupus familiaris,9615.0
5211,U,,,beagle,Bioavailability after 1 mpk peroral administration to beagles,Autocuration,,,,,22224,BAO_0000218,A,,3510,In vivo,Canis lupus familiaris,9615.0
5212,U,,,beagle,Bioavailability after 2 mpk peroral administration to beagles,Autocuration,,,,,22224,BAO_0000218,A,,3510,In vivo,Canis lupus familiaris,9615.0
5213,U,,,,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,Autocuration,,,,,22224,BAO_0000019,A,,3085,,Bos taurus,9913.0
5214,U,,,,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,Autocuration,,,,,22224,BAO_0000019,A,,3085,,Bos taurus,9913.0
5215,U,,,,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,Autocuration,,,,,22224,BAO_0000019,A,,3085,,Bos taurus,9913.0
5216,U,,,,Solubility against bovine alpha-chymotrypsin,Autocuration,,,,,22224,BAO_0000019,A,,9372,,Bos taurus,9913.0
5217,U,,,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,Autocuration,,,,,22224,BAO_0000019,A,,3085,,Bos taurus,9913.0
5218,U,,,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,Autocuration,,,,,22224,BAO_0000019,A,,3085,,Bos taurus,9913.0
5219,U,,,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,Autocuration,,,,2106.0,22224,BAO_0000221,A,,1469,,Bos taurus,9913.0
5220,U,,,,Half life in culture medium containing 10% of heat inactivated foetal calf serum,Autocuration,,,,,22224,BAO_0000019,A,,4297,,Bos taurus,9913.0
5221,U,,,,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,Autocuration,,,,,22224,BAO_0000019,A,,4297,,Bos taurus,9913.0
5222,U,,,,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,Autocuration,,,,,22224,BAO_0000019,A,,17585,,Bos taurus,9913.0
5223,U,,,,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,Autocuration,,,,2106.0,22224,BAO_0000221,A,,1336,,Bos taurus,9913.0
5224,U,,,,Half life in presence of 2 mg/mL BSA at pH 8.8,Autocuration,,,,,22224,BAO_0000019,A,,3085,,Bos taurus,9913.0
5225,U,,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,Autocuration,,,,,22224,BAO_0000019,A,,2857,,Bos taurus,9913.0
5226,U,,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,Autocuration,,,,,22224,BAO_0000019,A,,2857,,Bos taurus,9913.0
5227,U,,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,Autocuration,,,,,22224,BAO_0000019,A,,2857,,Bos taurus,9913.0
5228,U,,,,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),Autocuration,,,,,22224,BAO_0000019,A,,1540,,Bos taurus,9913.0
5229,N,,,,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,6316,,Canis lupus familiaris,9615.0
5230,N,,,,AUC after administration at 100 mg/kg/day in dogs,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17594,,Canis lupus familiaris,9615.0
5231,N,,,,AUC in dog at 0-24 hr by peroral administration at 3 mpk,Intermediate,,,,1969.0,50588,BAO_0000218,A,,4953,,Canis lupus familiaris,9615.0
5232,N,,,,AUC value after 15 mg/kg iv dose in Dogs,Intermediate,,,,1969.0,50588,BAO_0000218,A,,16907,,Canis lupus familiaris,9615.0
5233,N,,,,AUC value after 30 mg/kg po dose in Dogs,Intermediate,,,,1969.0,50588,BAO_0000218,A,,16907,,Canis lupus familiaris,9615.0
5234,N,,,,AUC value after administration of 4 mg/Kg oral dose in dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,2959,,Canis lupus familiaris,9615.0
5235,N,,,,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17594,,Canis lupus familiaris,9615.0
5236,N,,,,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,Intermediate,,,,,50588,BAO_0000218,A,,5356,,Canis lupus familiaris,9615.0
5237,N,,,,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,Intermediate,,,,,50588,BAO_0000218,A,,16807,,Canis lupus familiaris,9615.0
5238,N,,,,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,4527,,Canis lupus familiaris,9615.0
5239,N,,,,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,4527,,Canis lupus familiaris,9615.0
5240,N,,,,Area under curve determined in dogs after intravenous administration of 3 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,15660,,Canis lupus familiaris,9615.0
5241,N,,,,Area under curve determined in dogs after oral administration of 10 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,15660,,Canis lupus familiaris,9615.0
5242,N,,,,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,Intermediate,,,,,50588,BAO_0000218,A,,5802,,Canis lupus familiaris,9615.0
5243,N,,,,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,Expert,,,,,50588,BAO_0000218,A,,3598,,Canis lupus familiaris,9615.0
5244,N,,,,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,Expert,,,,,50588,BAO_0000218,A,,3598,,Canis lupus familiaris,9615.0
5245,N,,,,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,5944,,Canis lupus familiaris,9615.0
5246,N,,,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,Intermediate,,,,,50588,BAO_0000218,A,,5944,,Canis lupus familiaris,9615.0
5247,N,,,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,5944,,Canis lupus familiaris,9615.0
5248,N,,,,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,Intermediate,,,,,50588,BAO_0000218,A,,5944,,Canis lupus familiaris,9615.0
5249,N,,,,Area under curve in dog after administration of 20 mg/kg dose through peroral route,Intermediate,,,,,50588,BAO_0000218,A,,4186,,Canis lupus familiaris,9615.0
5250,N,,,,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,5007,,Canis lupus familiaris,9615.0
5251,N,,,,Area under curve was determine after peroral administration at 10 mpk in dog,Intermediate,,,,,50588,BAO_0000218,A,,5668,,Canis lupus familiaris,9615.0
5252,N,,,,Area under curve was determine after peroral administration at 5 mpk in dog,Intermediate,,,,,50588,BAO_0000218,A,,5668,,Canis lupus familiaris,9615.0
5253,N,,,,Area under curve was determined,Intermediate,,,,,50588,BAO_0000218,A,,5006,,Canis lupus familiaris,9615.0
5254,N,,,,Area under curve in dogs,Intermediate,,,,,50588,BAO_0000218,A,,5006,,Canis lupus familiaris,9615.0
5255,N,,,,Area under curve in dogs at 10 mg/kg dose fo oral administration,Intermediate,,,,,50588,BAO_0000218,A,,3771,,Canis lupus familiaris,9615.0
5256,N,,,,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),Intermediate,,,,,50588,BAO_0000218,A,,3771,,Canis lupus familiaris,9615.0
5257,N,,,,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,Intermediate,,,,,50588,BAO_0000218,A,,3771,,Canis lupus familiaris,9615.0
5258,N,,,,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Intermediate,,,,,50588,BAO_0000218,A,,1916,,Canis lupus familiaris,9615.0
5259,N,,,,Area under curve value in dog at a dose of 5 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,5302,,Canis lupus familiaris,9615.0
5260,N,,,,Area under curve was determined after 0.1 mg/kg iv administration in dog,Intermediate,,,,,50588,BAO_0000218,A,,5600,,Canis lupus familiaris,9615.0
5261,N,,,,Area under curve was determined after 0.3 mg/kg po administration in dog,Intermediate,,,,,50588,BAO_0000218,A,,5600,,Canis lupus familiaris,9615.0
5262,N,,,,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,Intermediate,,,,,50588,BAO_0000218,A,,17764,,Canis lupus familiaris,9615.0
5263,N,,,,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,4368,,Canis lupus familiaris,9615.0
5264,U,,,,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,Autocuration,,,,,22224,BAO_0000019,A,,5318,,Homo sapiens,9606.0
5265,U,,,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,Autocuration,,,,,22224,BAO_0000019,A,,5318,,Homo sapiens,9606.0
5266,U,,,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,Autocuration,,,,,22224,BAO_0000019,A,,5318,,Homo sapiens,9606.0
5267,U,,,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,Autocuration,,,,,22224,BAO_0000019,A,,5318,,Homo sapiens,9606.0
5268,U,,,,Time taken to reduce 50% of the concentration of compound in blood plasma,Autocuration,,,,178.0,22224,BAO_0000221,A,,14518,,Homo sapiens,9606.0
5269,U,,,,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",Autocuration,,,,1969.0,22224,BAO_0000366,A,,2209,,Homo sapiens,9606.0
5270,U,,,,Half life in human plasma,Autocuration,,,,1969.0,22224,BAO_0000366,A,,6787,,Homo sapiens,9606.0
5271,U,,,,Half life in human plasma was reported,Autocuration,,,,1969.0,22224,BAO_0000366,A,,4898,,Homo sapiens,9606.0
5272,U,,,,Half life in human serum,Autocuration,,,,1977.0,22224,BAO_0000019,A,,6072,,Homo sapiens,9606.0
5273,U,,,,Half life upon exposure to human plasma,Autocuration,,,,1969.0,22224,BAO_0000366,A,,16907,,Homo sapiens,9606.0
5274,U,,,,t1/2 in human microsomes,Autocuration,,,,,22224,BAO_0000251,A,Microsomes,5656,In vitro,Homo sapiens,9606.0
5275,U,,,,Half life period in 80% human plasma at 37 degree Centigrade,Autocuration,,,,1969.0,22224,BAO_0000366,A,,4755,,Homo sapiens,9606.0
5276,U,,,,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),Autocuration,,,,14.0,22224,BAO_0000221,A,,17503,,Homo sapiens,9606.0
5277,U,,,,Half-life measured in in vitro Cathepsin B assay in human plasma,Autocuration,,,,1969.0,22224,BAO_0000366,A,,12357,In vitro,Homo sapiens,9606.0
5278,U,,,,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,Autocuration,,,,,22224,BAO_0000019,A,,3076,,Homo sapiens,9606.0
5279,U,,,,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,6410,In vitro,Homo sapiens,9606.0
5280,U,,,,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",Autocuration,,,,1969.0,22224,BAO_0000366,A,,3741,,Homo sapiens,9606.0
5281,U,,,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",Autocuration,,,,1969.0,22224,BAO_0000366,A,,3741,,Homo sapiens,9606.0
5282,U,,,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",Autocuration,,,,1969.0,22224,BAO_0000366,A,,3741,,Homo sapiens,9606.0
5283,U,,,,Half-life in the CEM cell extracts,Autocuration,,,,,22224,BAO_0000019,A,,1540,,Homo sapiens,9606.0
5284,U,,,,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,Autocuration,,,,1969.0,22224,BAO_0000366,A,,2905,,Homo sapiens,9606.0
5285,U,,,,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,Autocuration,,,,1969.0,22224,BAO_0000366,A,,2905,,Homo sapiens,9606.0
5286,U,,,,Half-life was determined,Autocuration,,,,,22224,BAO_0000019,A,,5523,,Homo sapiens,9606.0
5287,U,,,,Half-life (human blood stability),Autocuration,,,,178.0,22224,BAO_0000221,A,,1499,,Homo sapiens,9606.0
5288,U,,,,Half-life (human blood stability); no data,Autocuration,,,,178.0,22224,BAO_0000221,A,,1499,,Homo sapiens,9606.0
5289,U,,,,Half-life in human plasma,Autocuration,,,,1969.0,22224,BAO_0000366,A,,17065,,Homo sapiens,9606.0
5290,U,,,,CYP3A4 metabolism half-life (t1/2),Autocuration,,,,,22224,BAO_0000019,A,,6861,,Homo sapiens,9606.0
5291,U,,,,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),Autocuration,,,,178.0,22224,BAO_0000221,A,,1499,,Homo sapiens,9606.0
5292,U,,,,In vitro half life in human plasma,Autocuration,,,,1969.0,22224,BAO_0000366,A,,530,In vitro,Homo sapiens,9606.0
5293,U,,,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",Autocuration,,,,1969.0,22224,BAO_0000366,A,,1116,In vitro,Homo sapiens,9606.0
5294,U,,,,In vitro hydrolysis in human plasma,Autocuration,,,,1969.0,22224,BAO_0000366,A,,6695,In vitro,Homo sapiens,9606.0
5295,U,,,,In vitro hydrolysis in human plasma; no data,Autocuration,,,,1969.0,22224,BAO_0000366,A,,6695,In vitro,Homo sapiens,9606.0
5296,U,,,,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,10,In vitro,Homo sapiens,9606.0
5297,U,,,,Plasma half life in human,Autocuration,,,,1969.0,22224,BAO_0000366,A,,993,,Homo sapiens,9606.0
5298,U,,,,Stability after incubation with human plasma (at 37 degree C),Autocuration,,,,1969.0,22224,BAO_0000366,A,,15429,,Homo sapiens,9606.0
5299,U,,,,T1/2 was evaluated in human plasma,Autocuration,,,,1969.0,22224,BAO_0000366,A,,1675,,Homo sapiens,9606.0
5300,U,,,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",Autocuration,,,,1969.0,22224,BAO_0000366,A,,2209,,Homo sapiens,9606.0
5301,U,,,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",Autocuration,,,,1969.0,22224,BAO_0000366,A,,2209,,Homo sapiens,9606.0
5302,U,,,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,Autocuration,,,,,22224,BAO_0000019,A,,5318,,Homo sapiens,9606.0
5303,U,,,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,Autocuration,,,,,22224,BAO_0000019,A,,2412,In vitro,Homo sapiens,9606.0
5304,U,,,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,Autocuration,,,,,22224,BAO_0000019,A,,2412,In vitro,Homo sapiens,9606.0
5305,U,,,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,Autocuration,,,,1969.0,22224,BAO_0000366,A,,2906,,Homo sapiens,9606.0
5306,U,,,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,Autocuration,,,,1969.0,22224,BAO_0000366,A,,2906,,Homo sapiens,9606.0
5307,U,,,,Time taken for 50% to be consumed by serum PON1 was determined,Autocuration,,,,,22224,BAO_0000019,A,,5495,,Homo sapiens,9606.0
5308,U,,,,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,Autocuration,,,,,22224,BAO_0000019,A,,5495,,Homo sapiens,9606.0
5309,U,,,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,4397,,Homo sapiens,9606.0
5310,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,,,,,22224,BAO_0000218,A,,2413,,Mus sp.,10095.0
5311,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,,,,22224,BAO_0000218,A,,2413,,Mus sp.,10095.0
5312,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,,,,,22224,BAO_0000218,A,,2413,,Mus sp.,10095.0
5313,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,,,,22224,BAO_0000218,A,,2413,,Mus sp.,10095.0
5314,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,,,,,22224,BAO_0000218,A,,2413,,Mus sp.,10095.0
5315,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,Autocuration,,,,,22224,BAO_0000218,A,,2413,,Mus sp.,10095.0
5316,N,,391.0,,Compound tested for growth inhibition of renal cancer cell line 786-0,Intermediate,,786-0,,,80640,BAO_0000219,F,,6058,,Homo sapiens,9606.0
5317,N,,391.0,,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,Intermediate,,786-0,,,80640,BAO_0000219,F,,17708,,Homo sapiens,9606.0
5318,N,,391.0,,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,Expert,,786-0,,,80640,BAO_0000219,F,,14017,,Homo sapiens,9606.0
5319,N,,391.0,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",Intermediate,,786-0,,,80640,BAO_0000219,F,,16818,,Homo sapiens,9606.0
5320,N,,391.0,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",Intermediate,,786-0,,,80640,BAO_0000219,F,,16818,,Homo sapiens,9606.0
5321,N,,391.0,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",Intermediate,,786-0,,,80640,BAO_0000219,F,,16818,,Homo sapiens,9606.0
5322,N,,391.0,,Tested for cytotoxicity against 786-0 cell lines in renal cancer,Intermediate,,786-0,,,80640,BAO_0000219,F,,11970,,Homo sapiens,9606.0
5323,N,,391.0,,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,Intermediate,,786-0,,,80640,BAO_0000219,F,,12400,,Homo sapiens,9606.0
5324,N,,391.0,,Cytotoxic effect on renal cancer line 786-0,Expert,,786-0,,,80640,BAO_0000219,F,,12888,,Homo sapiens,9606.0
5325,N,,391.0,,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,Intermediate,,786-0,,,80640,BAO_0000219,F,,15300,,Homo sapiens,9606.0
5326,N,,391.0,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),Intermediate,,786-0,,,80640,BAO_0000219,F,,14769,,Homo sapiens,9606.0
5327,N,,391.0,,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",Intermediate,,786-0,,,80640,BAO_0000219,F,,15895,,Homo sapiens,9606.0
5328,N,,391.0,,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,Intermediate,,786-0,,,80640,BAO_0000219,F,,17376,,Homo sapiens,9606.0
5329,N,,391.0,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,Intermediate,,786-0,,,80640,BAO_0000219,F,,14882,,Homo sapiens,9606.0
5330,N,,391.0,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),Intermediate,,786-0,,,80640,BAO_0000219,F,,14882,,Homo sapiens,9606.0
5331,N,,391.0,,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,Intermediate,,786-0,,,80640,BAO_0000219,F,,15176,,Homo sapiens,9606.0
5332,N,,391.0,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,Intermediate,,786-0,,,80640,BAO_0000219,F,,12696,,Homo sapiens,9606.0
5333,N,,391.0,,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),Intermediate,,786-0,,,80640,BAO_0000219,F,,2496,,Homo sapiens,9606.0
5334,N,,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,Intermediate,,791T cell line,,,80641,BAO_0000219,F,,11831,,Homo sapiens,9606.0
5335,N,,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),Intermediate,,791T cell line,,,80641,BAO_0000219,F,,11831,,Homo sapiens,9606.0
5336,N,,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,Intermediate,,791T cell line,,,80641,BAO_0000219,F,,11831,,Homo sapiens,9606.0
5337,N,,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),Intermediate,,791T cell line,,,80641,BAO_0000219,F,,11831,,Homo sapiens,9606.0
5338,N,,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),Intermediate,,791T cell line,,,80641,BAO_0000219,F,,11831,,Homo sapiens,9606.0
5339,N,,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,Intermediate,,791T cell line,,,80641,BAO_0000219,F,,11831,,Homo sapiens,9606.0
5340,N,,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),Intermediate,,791T cell line,,,80641,BAO_0000219,F,,11831,,Homo sapiens,9606.0
5341,N,,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),Intermediate,,791T cell line,,,80641,BAO_0000219,F,,11831,,Homo sapiens,9606.0
5342,N,,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),Intermediate,,791T cell line,,,80641,BAO_0000219,F,,11831,,Homo sapiens,9606.0
5343,N,,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,Intermediate,,791T cell line,,,80641,BAO_0000219,F,,11831,,Homo sapiens,9606.0
5344,N,,391.0,,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,Intermediate,,786-0,,,80640,BAO_0000219,F,,12782,,Homo sapiens,9606.0
5345,U,,,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,Intermediate,,,,,22226,BAO_0000019,F,,1229,,,
5346,N,,741.0,,Inhibition of cell growth in drug resistant 8226 myeloma cell line,Expert,,RPMI-8226,,,80433,BAO_0000219,F,,15313,,Homo sapiens,9606.0
5347,N,,741.0,,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,Expert,,RPMI-8226,,,80433,BAO_0000219,F,,15313,,Homo sapiens,9606.0
5348,N,,741.0,,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,11544,,Homo sapiens,9606.0
5349,N,,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,Homo sapiens,9606.0
5350,N,,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,Homo sapiens,9606.0
5351,N,,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,Homo sapiens,9606.0
5352,N,,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,Homo sapiens,9606.0
5353,N,,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,Homo sapiens,9606.0
5354,N,,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,Homo sapiens,9606.0
5355,N,,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,Homo sapiens,9606.0
5356,N,,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,Homo sapiens,9606.0
5357,N,,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,Homo sapiens,9606.0
5358,N,,624.0,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),Intermediate,,A498,,,80021,BAO_0000219,F,,14769,,Homo sapiens,9606.0
5359,N,,624.0,,Compound was tested for the growth inhibition of A498 renal tumor cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,15354,,Homo sapiens,9606.0
5360,N,,624.0,,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),Intermediate,,A498,,,80021,BAO_0000219,F,,17445,,Homo sapiens,9606.0
5361,N,,624.0,,In vitro inhibitory concentration against renal cancer cell line A498,Intermediate,,A498,,,80021,BAO_0000219,F,,4337,,Homo sapiens,9606.0
5362,N,,624.0,,Cytotoxicity against A 498 tumor cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,15277,,Homo sapiens,9606.0
5363,N,,624.0,,In vitro antitumor activity against A498 human cancer cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,4812,,Homo sapiens,9606.0
5364,N,,624.0,,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),Intermediate,,A498,,,80021,BAO_0000219,F,,4812,,Homo sapiens,9606.0
5365,N,,624.0,,Inhibitory dose required against A498 human tumor cell lines,Intermediate,,A498,,,80021,BAO_0000219,F,,4995,,Homo sapiens,9606.0
5366,N,,624.0,,Anticancer activity against one renal cancer (A498 cell line),Intermediate,,A498,,,80021,BAO_0000219,F,,5847,,Homo sapiens,9606.0
5367,N,,624.0,,In vitro cytotoxicity against melanoma A498 cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,6557,,Homo sapiens,9606.0
5368,N,,624.0,,Compound was tested for growth inhibitory activity against A498 cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,2597,,Homo sapiens,9606.0
5369,N,,624.0,,Compound tested for growth inhibition of renal cancer cell line A498,Intermediate,,A498,,,80021,BAO_0000219,F,,6058,,Homo sapiens,9606.0
5370,N,,624.0,,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,17708,,Homo sapiens,9606.0
5371,N,,624.0,,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,Intermediate,,A498,,,80021,BAO_0000219,F,,15176,,Homo sapiens,9606.0
5372,N,,624.0,,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,Intermediate,,A498,,,80021,BAO_0000219,F,,15300,,Homo sapiens,9606.0
5373,N,,624.0,,Tested for cytotoxicity against A498 cell lines in renal cancer,Intermediate,,A498,,,80021,BAO_0000219,F,,11970,,Homo sapiens,9606.0
5374,N,,624.0,,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,Intermediate,,A498,,,80021,BAO_0000219,F,,12400,,Homo sapiens,9606.0
5375,N,,624.0,,Cytotoxic effect on renal cancer lines A498,Expert,,A498,,,80021,BAO_0000219,F,,12888,,Homo sapiens,9606.0
5376,N,,624.0,,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,Intermediate,,A498,,,80021,BAO_0000219,F,,3030,,Homo sapiens,9606.0
5377,N,,624.0,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),Intermediate,,A498,,,80021,BAO_0000219,F,,14769,,Homo sapiens,9606.0
5378,N,,624.0,,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,17376,,Homo sapiens,9606.0
5379,N,,624.0,,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,Intermediate,,A498,,,80021,BAO_0000219,F,,16558,,Homo sapiens,9606.0
5380,N,,624.0,,Cytotoxicity against human kidney carcinoma cell lines A4982LM,Intermediate,,A498,,,80021,BAO_0000219,F,,5194,,Homo sapiens,9606.0
5381,N,,624.0,,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,Intermediate,,A498,,,80021,BAO_0000219,F,,10708,,Homo sapiens,9606.0
5382,N,,646.0,,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,Expert,,A549,,,80682,BAO_0000219,F,,16880,,Homo sapiens,9606.0
5383,N,,646.0,,Antitumor activity against A549 human lung carcinoma cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,10196,,Homo sapiens,9606.0
5384,N,,646.0,,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,Intermediate,,A549,,,80682,BAO_0000219,F,,10196,,Homo sapiens,9606.0
5385,N,,646.0,,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,Intermediate,,A549,,,80682,BAO_0000219,F,,10196,,Homo sapiens,9606.0
5386,N,,646.0,,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",Intermediate,,A549,,,80682,BAO_0000219,F,,12083,,Homo sapiens,9606.0
5387,N,,646.0,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,Expert,,A549,,,80682,BAO_0000219,F,,16464,,Homo sapiens,9606.0
5388,N,,646.0,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Intermediate,,A549,,,80682,BAO_0000219,F,,16464,,Homo sapiens,9606.0
5389,N,,646.0,,In vitro cytotoxic activity against human lung A549 cell line,Expert,,A549,,,80682,BAO_0000219,F,,16470,,Homo sapiens,9606.0
5390,N,,646.0,,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),Intermediate,,A549,,,80682,BAO_0000219,F,,16470,,Homo sapiens,9606.0
5391,N,,646.0,,In vitro cytotoxic activity against human lung A549 cell line),Intermediate,,A549,,,80682,BAO_0000219,F,,16470,,Homo sapiens,9606.0
5392,N,,646.0,,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,Intermediate,,A549,,,80682,BAO_0000219,F,,16470,,Homo sapiens,9606.0
5393,N,,646.0,,In vitro cytotoxicity against human non small-cell-lung cell line A549.,Expert,,A549,,,80682,BAO_0000219,F,,16582,,Homo sapiens,9606.0
5394,N,,646.0,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",Intermediate,,A549,,,80682,BAO_0000219,F,,15935,,Homo sapiens,9606.0
5395,N,,646.0,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",Intermediate,,A549,,,80682,BAO_0000219,F,,15935,,Homo sapiens,9606.0
5396,N,,646.0,,Inhibition of A549 human lung carcinoma cell proliferation,Expert,,A549,,,80682,BAO_0000219,F,,16597,,Homo sapiens,9606.0
5397,N,,646.0,,Inhibitory activity against A549 lung adenocarcinoma cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,17376,,Homo sapiens,9606.0
5398,N,,646.0,,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,Intermediate,,A549,,,80682,BAO_0000219,F,,16496,,Homo sapiens,9606.0
5399,N,,646.0,,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,16152,,Homo sapiens,9606.0
5400,N,,646.0,,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,16152,,Homo sapiens,9606.0
5401,N,,646.0,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Intermediate,,A549,,,80682,BAO_0000219,F,,16464,,Homo sapiens,9606.0
5402,N,,646.0,,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,2288,,Homo sapiens,9606.0
5403,N,,646.0,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,Intermediate,,A549,,,80682,BAO_0000219,F,,17350,,Homo sapiens,9606.0
5404,N,,646.0,,Inhibition of A549 cancer cell proliferation,Expert,,A549,,,80682,BAO_0000219,F,,4090,,Homo sapiens,9606.0
5405,N,,646.0,,Inhibition of A549 cancer cell proliferation (Not tested),Expert,,A549,,,80682,BAO_0000219,F,,4090,,Homo sapiens,9606.0
5406,N,,646.0,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,Intermediate,,A549,,,80682,BAO_0000219,F,,17350,,Homo sapiens,9606.0
5407,N,,646.0,,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,Intermediate,,A549,,,80682,BAO_0000219,F,,4197,,Homo sapiens,9606.0
5408,N,,646.0,,Antiproliferative potency determined as inhibitory concentration against A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17072,,Homo sapiens,9606.0
5409,N,,646.0,,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,Intermediate,,A549,,,80682,BAO_0000219,F,,17072,,Homo sapiens,9606.0
5410,N,,646.0,,Cytotoxicity against Renal cell lines A549 was determined,Intermediate,,A549,,,80682,BAO_0000219,F,,5194,,Homo sapiens,9606.0
5411,N,,,,Area under curve was determined in dog after a 3 mg/kg of oral dose,Intermediate,,,,,50588,BAO_0000218,A,,4257,,Canis lupus familiaris,9615.0
5412,N,,,,Area under curve was determined in dog after oral administration at 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6123,,Canis lupus familiaris,9615.0
5413,N,,,,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Intermediate,,,,,50588,BAO_0000218,A,,1337,,Canis lupus familiaris,9615.0
5414,N,,,,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Intermediate,,,,,50588,BAO_0000218,A,,1337,,Canis lupus familiaris,9615.0
5415,N,,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),Intermediate,,,,,50588,BAO_0000218,A,,8833,,Canis lupus familiaris,9615.0
5416,N,,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),Intermediate,,,,,50588,BAO_0000218,A,,8833,,Canis lupus familiaris,9615.0
5417,N,,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),Intermediate,,,,,50588,BAO_0000218,A,,8833,,Canis lupus familiaris,9615.0
5418,N,,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),Intermediate,,,,,50588,BAO_0000218,A,,8833,,Canis lupus familiaris,9615.0
5419,N,,,,Area under plasma concentration time curve in dog upon oral administration,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17657,,Canis lupus familiaris,9615.0
5420,N,,,,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17650,,Canis lupus familiaris,9615.0
5421,N,,,,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,Intermediate,,,,,50588,BAO_0000218,A,,1977,,Canis lupus familiaris,9615.0
5422,N,,,,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,Intermediate,,,,,50588,BAO_0000218,A,,1977,,Canis lupus familiaris,9615.0
5423,N,,,,Area under the curve for the compound was obtained when tested in dog,Intermediate,,,,,50588,BAO_0000218,A,,3132,,Canis lupus familiaris,9615.0
5424,N,,,,Area under the curve at a dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,5473,,Canis lupus familiaris,9615.0
5425,N,,,,Area under the curve at a dose of 1 mg/kg (oral),Intermediate,,,,,50588,BAO_0000218,A,,5474,,Canis lupus familiaris,9615.0
5426,N,,,,Area under the curve at i.v. dose of 0.2 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,5474,,Canis lupus familiaris,9615.0
5427,N,,,,Area under the curve was measured in dog after an iv dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6062,,Canis lupus familiaris,9615.0
5428,N,,,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,4709,,Canis lupus familiaris,9615.0
5429,N,,,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,Intermediate,,,,,50588,BAO_0000218,A,,2652,,Canis lupus familiaris,9615.0
5430,N,,,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,Intermediate,,,,,50588,BAO_0000218,A,,2652,,Canis lupus familiaris,9615.0
5431,N,,,,Compound was evaluated for area under the curve in dog blood.,Intermediate,,,,,50588,BAO_0000218,A,,2877,,Canis lupus familiaris,9615.0
5432,N,,,,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,Intermediate,,,,,50588,BAO_0000218,A,,5444,,Canis lupus familiaris,9615.0
5433,N,,,,AUC in dog after oral dose (1 mg/kg),Intermediate,,,,1969.0,50588,BAO_0000218,A,,5130,,Canis lupus familiaris,9615.0
5434,N,,,,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6265,,Canis lupus familiaris,9615.0
5435,N,,,,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",Intermediate,,,,,50588,BAO_0000218,A,,4657,,Canis lupus familiaris,9615.0
5436,N,,,,Pharmacokinetic parameter AUC after intravenous administration to dogs,Intermediate,,,,,50588,BAO_0000218,A,,16367,,Canis lupus familiaris,9615.0
5437,N,,,,Pharmacokinetic parameter AUC after oral administration to dogs,Intermediate,,,,,50588,BAO_0000218,A,,16367,,Canis lupus familiaris,9615.0
5438,N,,,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,Intermediate,,,,,50588,BAO_0000218,A,,9579,,Canis lupus familiaris,9615.0
5439,N,,,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,Intermediate,,,,,50588,BAO_0000218,A,,9579,,Canis lupus familiaris,9615.0
5440,N,,,,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,Intermediate,,,,,50588,BAO_0000218,A,,5983,,Canis lupus familiaris,9615.0
5441,N,,,,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6241,,Canis lupus familiaris,9615.0
5442,N,,,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",Intermediate,,,,,50588,BAO_0000218,A,,5313,,Canis lupus familiaris,9615.0
5443,N,,,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",Intermediate,,,,,50588,BAO_0000218,A,,5313,,Canis lupus familiaris,9615.0
5444,N,,,,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Intermediate,,,,,50588,BAO_0000218,A,,6642,,Canis lupus familiaris,9615.0
5445,N,,,,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Intermediate,,,,,50588,BAO_0000218,A,,6642,,Canis lupus familiaris,9615.0
5446,N,,,,Oral AUCN in dog (dosed at 0.5 mpk iv ),Intermediate,,,,,50588,BAO_0000218,A,,6641,,Canis lupus familiaris,9615.0
5447,N,,,,Oral AUCN in dog (dosed at 0.5 mpk iv ),Intermediate,,,,,50588,BAO_0000218,A,,6642,,Canis lupus familiaris,9615.0
5448,N,,,,Compound was evaluated for oral bioavailability in dog; 90-100,Intermediate,,,,,50588,BAO_0000218,A,,17791,,Canis lupus familiaris,9615.0
5449,N,,,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,Intermediate,,,,,50588,BAO_0000218,A,,17655,,Canis lupus familiaris,9615.0
5450,N,,,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,Intermediate,,,,,50588,BAO_0000218,A,,17655,,Canis lupus familiaris,9615.0
5451,N,,,,PAPP (membrane permeability) in dog kidney cell monolayer assay,Intermediate,,,,,50588,BAO_0000218,A,,6596,,Canis lupus familiaris,9615.0
5452,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,3880,,Canis lupus familiaris,9615.0
5453,N,,,,Bioavailability administered orally at a dose of 10 mg/kg to dogs,Intermediate,,,,,50588,BAO_0000218,A,,16367,,Canis lupus familiaris,9615.0
5454,N,,,,Plasma protein binding towards dog plasma at 10 uM,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17409,,Canis lupus familiaris,9615.0
5455,N,,,,Plasma protein binding towards dog plasma at 100 uM,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17409,,Canis lupus familiaris,9615.0
5456,N,,,,Bioavailability in dog (dose 4 mg/kg p.o.),Intermediate,,,,,50588,BAO_0000218,A,,2959,In vivo,Canis lupus familiaris,9615.0
5457,N,,,,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,Intermediate,,,,,50588,BAO_0000218,A,,13501,In vivo,Canis lupus familiaris,9615.0
5458,N,,,,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,4527,In vivo,Canis lupus familiaris,9615.0
5459,N,,,,Bioavailability in dogs,Intermediate,,,,,50588,BAO_0000218,A,,15145,In vivo,Canis lupus familiaris,9615.0
5460,N,,,,Bioavailability,Intermediate,,,,,50588,BAO_0000218,A,,4219,In vivo,Canis lupus familiaris,9615.0
5461,N,,,,Oral bioavailability in dog (dose 10 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,17538,In vivo,Canis lupus familiaris,9615.0
5462,N,,,,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,Intermediate,,,,,50588,BAO_0000218,A,,17538,In vivo,Canis lupus familiaris,9615.0
5463,N,,,,Bioavailability in dog (dose 10.0 mg/kg p.o.),Intermediate,,,,,50588,BAO_0000218,A,,1466,In vivo,Canis lupus familiaris,9615.0
5464,N,,,,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,Intermediate,,,,,50588,BAO_0000218,A,,17650,In vivo,Canis lupus familiaris,9615.0
5465,N,,,,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,Intermediate,,,,,50588,BAO_0000218,A,,3132,In vivo,Canis lupus familiaris,9615.0
5466,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,,,,22224,BAO_0000218,A,,2413,,Mus sp.,10095.0
5467,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,,,,2107.0,22224,BAO_0000218,A,,2413,,Mus sp.,10095.0
5468,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,Autocuration,,,,2107.0,22224,BAO_0000218,A,,2413,,Mus sp.,10095.0
5469,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,,,2107.0,22224,BAO_0000218,A,,2413,,Mus sp.,10095.0
5470,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,,,,,22224,BAO_0000218,A,,2413,,Mus sp.,10095.0
5471,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,,,,22224,BAO_0000218,A,,2413,,Mus sp.,10095.0
5472,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,,,,2385.0,22224,BAO_0000218,A,,2413,,Mus sp.,10095.0
5473,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,Autocuration,,,,2385.0,22224,BAO_0000218,A,,2413,,Mus sp.,10095.0
5474,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,,,2385.0,22224,BAO_0000218,A,,2413,,Mus sp.,10095.0
5475,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,,,,2106.0,22224,BAO_0000218,A,,2413,,Mus sp.,10095.0
5476,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,,,2106.0,22224,BAO_0000218,A,,2413,,Mus sp.,10095.0
5477,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,,,,,22224,BAO_0000218,A,,2413,,Mus sp.,10095.0
5478,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,Autocuration,,,,,22224,BAO_0000218,A,,2413,,Mus sp.,10095.0
5479,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,,,,22224,BAO_0000218,A,,2413,,Mus sp.,10095.0
5480,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,Autocuration,,,,,22224,BAO_0000218,A,,2413,,Mus sp.,10095.0
5481,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,,,,22224,BAO_0000218,A,,2413,,Mus sp.,10095.0
5482,U,,,,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),Autocuration,,,,,22224,BAO_0000019,A,,17827,,Cercopithecidae,9527.0
5483,U,,,,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),Autocuration,,,,2037.0,22224,BAO_0000019,A,,17827,,Cercopithecidae,9527.0
5484,U,,,,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),Autocuration,,,,1870.0,22224,BAO_0000019,A,,17827,,Cercopithecidae,9527.0
5485,U,,,,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),Autocuration,,,,,22224,BAO_0000019,A,,17827,,Cercopithecidae,9527.0
5486,U,,,,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),Autocuration,,,,2435.0,22224,BAO_0000019,A,,17827,,Cercopithecidae,9527.0
5487,U,,,,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),Autocuration,,,,,22224,BAO_0000019,A,,17827,,Cercopithecidae,9527.0
5488,U,,,,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),Autocuration,,,,2037.0,22224,BAO_0000019,A,,17827,,Cercopithecidae,9527.0
5489,U,,,,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),Autocuration,,,,1870.0,22224,BAO_0000019,A,,17827,,Cercopithecidae,9527.0
5490,U,,,,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),Autocuration,,,,,22224,BAO_0000019,A,,17827,,Cercopithecidae,9527.0
5491,U,,,,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),Autocuration,,,,2435.0,22224,BAO_0000019,A,,17827,,Cercopithecidae,9527.0
5492,U,,,,Compound was evaluated for oral bioavailability in rats,Autocuration,,,,,22224,BAO_0000218,A,,17791,,Cercopithecidae,9527.0
5493,U,,,,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,Autocuration,,,,1969.0,22224,BAO_0000218,A,,17667,In vivo,Cercopithecidae,9527.0
5494,U,,,,Half life period was evaluated in monkey,Autocuration,,,,,22224,BAO_0000019,A,,17791,,Cercopithecidae,9527.0
5495,U,,,,Half-life in rhesus monkeys by intravenous administration of dose,Autocuration,,,,,22224,BAO_0000218,A,,110,In vivo,Cercopithecidae,9527.0
5496,N,,,,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,Intermediate,,,,1969.0,50594,BAO_0000218,A,,5781,,Mus musculus,10090.0
5497,N,,,,AUC after intraperitoneal administration of 100 mg/kg in mice,Intermediate,,,,1969.0,50594,BAO_0000218,A,,17734,,Mus musculus,10090.0
5498,N,,,,AUC value was determined after oral administration,Intermediate,,,,1969.0,50594,BAO_0000218,A,,17718,,Mus musculus,10090.0
5499,N,,,,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,Intermediate,,,,,50594,BAO_0000218,A,,4573,,Mus musculus,10090.0
5500,N,,,,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Intermediate,,,,,50594,BAO_0000218,A,,3277,,Mus musculus,10090.0
5501,N,,,,Area under curve by ioral administration in mouse,Intermediate,,,,,50594,BAO_0000218,A,,2862,,Mus musculus,10090.0
5502,N,,,,Area under curve by iv administration in mouse,Intermediate,,,,,50594,BAO_0000218,A,,2862,,Mus musculus,10090.0
5503,N,,,,Area under curve at 0-8 hr in IRC mice after peroral administration,Intermediate,,,,,50594,BAO_0000218,A,,5951,,Mus musculus,10090.0
5504,N,,,,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,17729,,Mus musculus,10090.0
5505,N,,,,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,17728,,Mus musculus,10090.0
5506,N,,,,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,17728,,Mus musculus,10090.0
5507,N,,,,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,17729,,Mus musculus,10090.0
5508,N,,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,Homo sapiens,9606.0
5509,N,,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,Homo sapiens,9606.0
5510,N,,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,Homo sapiens,9606.0
5511,N,,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,Homo sapiens,9606.0
5512,N,,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,Homo sapiens,9606.0
5513,N,,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,Homo sapiens,9606.0
5514,N,,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,Homo sapiens,9606.0
5515,N,,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,Homo sapiens,9606.0
5516,N,,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,Homo sapiens,9606.0
5517,N,,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,Homo sapiens,9606.0
5518,N,,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,Homo sapiens,9606.0
5519,N,,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,Homo sapiens,9606.0
5520,N,,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,Homo sapiens,9606.0
5521,N,,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,Homo sapiens,9606.0
5522,N,,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,Homo sapiens,9606.0
5523,N,,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,Homo sapiens,9606.0
5524,N,,741.0,,In vitro inhibition of human 8226 myeloma tumor cell line growth.,Expert,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,Homo sapiens,9606.0
5525,N,,741.0,,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,11544,,Homo sapiens,9606.0
5526,N,,741.0,,Cytotoxicity of compound against 8226/DOX1V cells,Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,17378,,Homo sapiens,9606.0
5527,N,,741.0,,Cytotoxicity of compound against 8226/S cells,Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,17378,,Homo sapiens,9606.0
5528,N,,741.0,,Inhibitory concentration against 8226 myeloma cancer cell line,Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,17079,,Homo sapiens,9606.0
5529,N,,741.0,,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,17079,,Homo sapiens,9606.0
5530,N,,854.0,,Inhibition of cell growth was studied in human teratocarcinoma (833K).,Intermediate,,833K,,,80647,BAO_0000219,F,,13466,,Homo sapiens,9606.0
5531,N,,854.0,,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',Intermediate,,833K,,,80647,BAO_0000219,F,,13466,,Homo sapiens,9606.0
5532,N,,854.0,,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,Expert,,833K,,,80647,BAO_0000219,F,,2392,,Homo sapiens,9606.0
5533,N,,854.0,,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,Intermediate,,833K,,,80647,BAO_0000219,F,,2392,,Homo sapiens,9606.0
5534,U,,,,Inhibitory activity against caspase-1,Autocuration,,,,,22226,BAO_0000019,B,,6608,,,
5535,H,,,,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,Autocuration,,,,,45,BAO_0000357,B,,10199,,Enterococcus faecalis,1351.0
5536,N,,705.0,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,Intermediate,,8701-BC,,,80648,BAO_0000219,F,,17749,,Homo sapiens,9606.0
5537,N,,705.0,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,Intermediate,,8701-BC,,,80648,BAO_0000219,F,,17749,,Homo sapiens,9606.0
5538,U,,,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,Intermediate,,,,,22226,BAO_0000019,F,,1229,,,
5539,U,,,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,Intermediate,,,,,22226,BAO_0000019,F,,1229,,,
5540,U,,,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,Intermediate,,,,,22226,BAO_0000019,F,,1229,,,
5541,U,,,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,Autocuration,,,,,22226,BAO_0000019,B,,6390,,,
5542,U,,,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,Autocuration,,,,,22226,BAO_0000019,F,,16219,,Streptococcus pyogenes,1314.0
5543,U,,,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,Autocuration,,,,,22226,BAO_0000019,F,,16219,,Streptococcus pyogenes,1314.0
5544,H,,,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,Autocuration,,,,,11922,BAO_0000357,B,,17043,,,
5545,N,,324.0,,Tested for in vitro cytotoxic potency of compound in 9KB assay,Intermediate,,KB ,,,81115,BAO_0000219,F,,6929,,Homo sapiens,9606.0
5546,N,,324.0,,Tested for in vitro cytotoxic potency of compound in 9KB assay,Intermediate,,KB ,,,81115,BAO_0000219,A,,6929,,Homo sapiens,9606.0
5547,U,,,,In vitro cytotoxicity of compound was tested against 9KB cells.,Autocuration,,,,,22226,BAO_0000219,F,,7083,,Homo sapiens,9606.0
5548,N,,392.0,,Cytotoxic concentration against 9L cells was determined on day 3,Intermediate,,9L,,,80653,BAO_0000219,F,,12446,,Rattus norvegicus,10116.0
5549,N,,392.0,,Tested in vitro for anticancer activity against 9L cells,Expert,,9L,,,80653,BAO_0000219,F,,15345,,Rattus norvegicus,10116.0
5550,N,,392.0,,Tested in vitro for anticancer activity against 9L cells; Not determined,Expert,,9L,,,80653,BAO_0000219,F,,15345,,Rattus norvegicus,10116.0
5551,N,,646.0,,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,Intermediate,,A549,,,80682,BAO_0000219,F,,6301,,Homo sapiens,9606.0
5552,N,,646.0,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,Intermediate,,A549,,,80682,BAO_0000219,F,,4833,,Homo sapiens,9606.0
5553,N,,646.0,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,Intermediate,,A549,,,80682,BAO_0000219,F,,4833,,Homo sapiens,9606.0
5554,N,,646.0,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,Intermediate,,A549,,,80682,BAO_0000219,F,,4833,,Homo sapiens,9606.0
5555,N,,646.0,,Cytotoxicity against human lung carcinoma A549 cell line,Expert,,A549,,,80682,BAO_0000219,F,,13330,,Homo sapiens,9606.0
5556,D,,646.0,,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,Expert,,A549,,,25,BAO_0000219,F,,17517,,Homo sapiens,9606.0
5557,D,,646.0,,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",Expert,,A549,,,25,BAO_0000219,F,,17517,,Homo sapiens,9606.0
5558,N,,646.0,,"In vitro growth inhibition of A549, lung carcinoma",Intermediate,,A549,,,80682,BAO_0000219,F,,14425,,Homo sapiens,9606.0
5559,N,,646.0,,"In vitro growth inhibition of A549, lung carcinoma.",Intermediate,,A549,,,80682,BAO_0000219,F,,14425,,Homo sapiens,9606.0
5560,N,,646.0,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,Expert,,A549,,,80682,BAO_0000219,F,,5228,,Homo sapiens,9606.0
5561,N,,646.0,,Cytotoxic activity against human lung cancer A549 cell line was determined,Intermediate,,A549,,,80682,BAO_0000219,F,,5351,,Homo sapiens,9606.0
5562,N,,646.0,,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,Expert,,A549,,,80682,BAO_0000219,F,,12198,,Homo sapiens,9606.0
5563,N,,646.0,,Cytotoxicity concentration against human lung carcinoma A-549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,13891,,Homo sapiens,9606.0
5564,N,,646.0,,Cytotoxicity in A549 (human carcinoma) cell line.,Expert,,A549,,,80682,BAO_0000219,F,,5677,,Homo sapiens,9606.0
5565,N,,646.0,,Cytotoxicity on lung carcinoma (A-549) cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,13788,,Homo sapiens,9606.0
5566,N,,646.0,,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,Expert,,A549,,,80682,BAO_0000219,F,,13384,,Homo sapiens,9606.0
5567,N,,646.0,,Effective dose of compound against replication of A549 cell line was evaluated,Intermediate,,A549,,,80682,BAO_0000219,F,,6726,,Homo sapiens,9606.0
5568,N,,646.0,,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,Expert,,A549,,,80682,BAO_0000219,F,,3455,,Homo sapiens,9606.0
5569,N,,646.0,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),Intermediate,,A549,,,80682,BAO_0000219,F,,5726,,Homo sapiens,9606.0
5570,N,,646.0,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,Intermediate,,A549,,,80682,BAO_0000219,F,,5726,,Homo sapiens,9606.0
5571,N,,646.0,,The compound was evaluated for antiproliferative activity against A549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,3936,,Homo sapiens,9606.0
5572,N,,646.0,,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,Intermediate,,A549,,,80682,BAO_0000219,F,,14991,,Homo sapiens,9606.0
5573,N,,646.0,,Concentration required for growth inhibition of human lung carcinoma cell line A549,Intermediate,,A549,,,80682,BAO_0000219,F,,5243,,Homo sapiens,9606.0
5574,N,,646.0,,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,12858,,Homo sapiens,9606.0
5575,N,,646.0,,Growth inhibition against A549 cell line was evaluated,Intermediate,,A549,,,80682,BAO_0000219,F,,6776,,Homo sapiens,9606.0
5576,N,,646.0,,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,Intermediate,,A549,,,80682,BAO_0000219,F,,16558,,Homo sapiens,9606.0
5577,N,,646.0,,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,Expert,,A549,,,80682,BAO_0000219,F,,4583,,Homo sapiens,9606.0
5578,N,,646.0,,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,Intermediate,,A549,,,80682,BAO_0000219,F,,13514,,Homo sapiens,9606.0
5579,N,,646.0,,Chemosensitivity against DT-diaphorase rich A549 cell lines,Expert,,A549,,,80682,BAO_0000219,F,,15166,,Homo sapiens,9606.0
5580,N,,646.0,,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,Intermediate,,A549,,,80682,BAO_0000219,F,,13873,,Homo sapiens,9606.0
5581,N,,646.0,,In vitro cytotoxicity against human A549 (lung cancer) cell line.,Expert,,A549,,,80682,BAO_0000219,F,,6447,,Homo sapiens,9606.0
5582,N,,646.0,,In vitro antitumor activity against A549 (lung) human tumor cell lines.,Intermediate,,A549,,,80682,BAO_0000219,F,,2068,,Homo sapiens,9606.0
5583,N,,646.0,,In vitro cytotoxic activity against human lung carcinoma A549 cell line,Expert,,A549,,,80682,BAO_0000219,F,,1863,,Homo sapiens,9606.0
5584,N,,646.0,,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,Intermediate,,A549,,,80682,BAO_0000219,F,,13873,,Homo sapiens,9606.0
5585,N,,646.0,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,Intermediate,,A549,,,80682,BAO_0000219,F,,13873,,Homo sapiens,9606.0
5586,N,,646.0,,Tested against A549 lung carcinoma in the sulforhodamine B assay.,Expert,,A549,,,80682,BAO_0000219,F,,13873,,Homo sapiens,9606.0
5587,N,,646.0,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),Intermediate,,A549,,,80682,BAO_0000219,F,,579,,Homo sapiens,9606.0
5588,N,,646.0,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,Intermediate,,A549,,,80682,BAO_0000219,F,,579,,Homo sapiens,9606.0
5589,N,,646.0,,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,Intermediate,,A549,,,80682,BAO_0000219,F,,4584,,Homo sapiens,9606.0
5590,N,,646.0,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,Expert,,A549,,,80682,BAO_0000219,F,,5421,,Homo sapiens,9606.0
5591,N,,646.0,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,5421,,Homo sapiens,9606.0
5592,N,,646.0,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,Intermediate,,A549,,,80682,BAO_0000219,F,,5421,,Homo sapiens,9606.0
5593,N,,646.0,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,Intermediate,,A549,,,80682,BAO_0000219,F,,5421,,Homo sapiens,9606.0
5594,N,,646.0,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,Intermediate,,A549,,,80682,BAO_0000219,F,,14188,,Homo sapiens,9606.0
5595,N,,646.0,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,Intermediate,,A549,,,80682,BAO_0000219,F,,14188,,Homo sapiens,9606.0
5596,N,,646.0,,Compound was tested for the growth inhibition of A549 lung tumor cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,15354,,Homo sapiens,9606.0
5597,N,,646.0,,Growth inhibition of human non-small-lung carcinoma (A549) cell line,Expert,,A549,,,80682,BAO_0000219,F,,14253,,Homo sapiens,9606.0
5598,N,,646.0,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,Intermediate,,A549,,,80682,BAO_0000219,F,,13873,,Homo sapiens,9606.0
5599,N,,,,Oral bioavailability in dog (conscious),Intermediate,,,,,50588,BAO_0000218,A,,3043,In vivo,Canis lupus familiaris,9615.0
5600,N,,,,Compound was evaluated for the oral bioavailability after oral administration in dog.,Intermediate,,,,,50588,BAO_0000218,A,,3045,In vivo,Canis lupus familiaris,9615.0
5601,N,,,,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,Intermediate,,,,,50588,BAO_0000218,A,,3022,In vivo,Canis lupus familiaris,9615.0
5602,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,4453,In vivo,Canis lupus familiaris,9615.0
5603,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,1696,In vivo,Canis lupus familiaris,9615.0
5604,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,5045,In vivo,Canis lupus familiaris,9615.0
5605,N,,,,Oral bioavailability in dog (fasted),Intermediate,,,,,50588,BAO_0000218,A,,5356,In vivo,Canis lupus familiaris,9615.0
5606,N,,,,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,Intermediate,,,,,50588,BAO_0000218,A,,17764,In vivo,Canis lupus familiaris,9615.0
5607,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,6448,In vivo,Canis lupus familiaris,9615.0
5608,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,1475,In vivo,Canis lupus familiaris,9615.0
5609,N,,,,Percent bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,3788,In vivo,Canis lupus familiaris,9615.0
5610,N,,,,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,Intermediate,,,,,50588,BAO_0000218,A,,3639,In vivo,Canis lupus familiaris,9615.0
5611,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,13397,In vivo,Canis lupus familiaris,9615.0
5612,N,,,,The compound was evaluated for bioavailability in dogs; 34-44,Intermediate,,,,,50588,BAO_0000218,A,,2137,In vivo,Canis lupus familiaris,9615.0
5613,N,,,,Bioavailability in dog (dose 4 mg/kg p.o.),Intermediate,,,,,50588,BAO_0000218,A,,2959,In vivo,Canis lupus familiaris,9615.0
5614,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,6448,In vivo,Canis lupus familiaris,9615.0
5615,N,,,,8 hour trough Blood level in dog was measured after administration of compound,Intermediate,,,,,50588,BAO_0000218,A,,6084,,Canis lupus familiaris,9615.0
5616,N,,,,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,Intermediate,,,,1969.0,50588,BAO_0000218,A,,3639,In vivo,Canis lupus familiaris,9615.0
5617,N,,,,C24 after oral administration at 5 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6316,,Canis lupus familiaris,9615.0
5618,N,,,,Clearance after oral and iv dosing in dogs,Intermediate,,,,,50588,BAO_0000218,A,,5238,,Canis lupus familiaris,9615.0
5619,N,,,,Clearance of the drug was measured in the plasma of dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17796,,Canis lupus familiaris,9615.0
5620,N,,,,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,Intermediate,,,,,50588,BAO_0000218,A,,2652,,Canis lupus familiaris,9615.0
5621,N,,,,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,5654,In vivo,Canis lupus familiaris,9615.0
5622,N,,,,Clearance of compound was determined in dogs,Intermediate,,,,,50588,BAO_0000218,A,,6621,In vivo,Canis lupus familiaris,9615.0
5623,N,,,,Clearance on i.v. administration of 2 mg/kg was measured in dog,Intermediate,,,,,50588,BAO_0000218,A,,6505,In vivo,Canis lupus familiaris,9615.0
5624,N,,,,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,Intermediate,,,,,50588,BAO_0000218,A,,5802,In vivo,Canis lupus familiaris,9615.0
5625,N,,,,Plasma clearance in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,17267,In vivo,Canis lupus familiaris,9615.0
5626,N,,,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,Intermediate,,,,,50588,BAO_0000218,A,,4521,In vivo,Canis lupus familiaris,9615.0
5627,N,,,,Plasma clearance in dog after administration of 0.25 mg/kg iv,Intermediate,,,,,50588,BAO_0000218,A,,6535,In vivo,Canis lupus familiaris,9615.0
5628,N,,,,Plasma clearance in dog after administration of 1 mg/kg iv,Intermediate,,,,,50588,BAO_0000218,A,,6535,In vivo,Canis lupus familiaris,9615.0
5629,N,,,,Plasma clearance in dogs,Intermediate,,,,,50588,BAO_0000218,A,,6535,In vivo,Canis lupus familiaris,9615.0
5630,N,,,,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,5542,In vivo,Canis lupus familiaris,9615.0
5631,N,,,,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,Intermediate,,,,,50588,BAO_0000218,A,,5199,In vivo,Canis lupus familiaris,9615.0
5632,N,,,,Plasma clearance after 15 mg/kg iv dose in Dogs,Intermediate,,,,,50588,BAO_0000218,A,,16907,In vivo,Canis lupus familiaris,9615.0
5633,N,,,,Plasma clearance after 30 mg/kg po dose in Dogs,Intermediate,,,,,50588,BAO_0000218,A,,16907,In vivo,Canis lupus familiaris,9615.0
5634,N,,,,Plasma administration to dogs,Intermediate,,,,,50588,BAO_0000218,A,,16367,In vivo,Canis lupus familiaris,9615.0
5635,N,,,,Plasma clearance was determined,Intermediate,,,,,50588,BAO_0000218,A,,5505,In vivo,Canis lupus familiaris,9615.0
5636,N,,,,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,Intermediate,,,,,50588,BAO_0000218,A,,6215,In vivo,Canis lupus familiaris,9615.0
5637,N,,,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,Intermediate,,,,,50588,BAO_0000218,A,,1466,In vivo,Canis lupus familiaris,9615.0
5638,S,,,,Intrinsic clearance in human liver microsomes,Intermediate,,,,2107.0,102164,BAO_0000251,A,Microsomes,5007,In vitro,Homo sapiens,9606.0
5639,S,,,,Intrinsic clearance in human liver microsomes,Intermediate,,,,2107.0,102164,BAO_0000251,A,Microsomes,5007,In vitro,Homo sapiens,9606.0
5640,N,,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,Intermediate,,,,,50588,BAO_0000218,A,,16452,In vivo,Canis lupus familiaris,9615.0
5641,N,,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,Intermediate,,,,,50588,BAO_0000218,A,,16452,In vivo,Canis lupus familiaris,9615.0
5642,N,,,,Clearance in dog (dose 1 mg/kg i.v.),Intermediate,,,,,50588,BAO_0000218,A,,16452,In vivo,Canis lupus familiaris,9615.0
5643,N,,,,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,6221,In vivo,Canis lupus familiaris,9615.0
5644,N,,,,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,5007,In vivo,Canis lupus familiaris,9615.0
5645,N,,,,Plasma clearance after peroral administration at 10 mpk in dog,Intermediate,,,,,50588,BAO_0000218,A,,5668,In vivo,Canis lupus familiaris,9615.0
5646,N,,,,Plasma clearance after peroral administration at 5 mpk in dog,Intermediate,,,,,50588,BAO_0000218,A,,5668,In vivo,Canis lupus familiaris,9615.0
5647,N,,,,Plasma clearance after peroral administration at 5 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,5668,In vivo,Canis lupus familiaris,9615.0
5648,N,,,,Plasma clearance was measured in dog,Intermediate,,,,,50588,BAO_0000218,A,,15660,In vivo,Canis lupus familiaris,9615.0
5649,N,,,,Plasma clearance was measured in dog,Intermediate,,,,,50588,BAO_0000218,A,,15660,In vivo,Canis lupus familiaris,9615.0
5650,N,,,,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,Intermediate,,,,,50588,BAO_0000218,A,,5983,In vivo,Canis lupus familiaris,9615.0
5651,N,,,,Total clearance was determined after 0.1 mg/kg iv administration in dog,Intermediate,,,,,50588,BAO_0000218,A,,5600,In vivo,Canis lupus familiaris,9615.0
5652,N,,,,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,Intermediate,,,,,50588,BAO_0000218,A,,17764,In vivo,Canis lupus familiaris,9615.0
5653,N,,,,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,6039,In vivo,Canis lupus familiaris,9615.0
5654,N,,,,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,6039,In vivo,Canis lupus familiaris,9615.0
5655,N,,,,Clearance after peroral administration of 0.2 mg/kg in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,6039,In vivo,Canis lupus familiaris,9615.0
5656,N,,,,Clearance by intravenous administration of 1.2 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,4368,In vivo,Canis lupus familiaris,9615.0
5657,N,,,,Clearance by iv administration in dogs at a dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,4305,In vivo,Canis lupus familiaris,9615.0
5658,N,,,,Clearance value was evaluated in dog plasma,Intermediate,,,,1969.0,50588,BAO_0000218,A,,1918,In vivo,Canis lupus familiaris,9615.0
5659,N,,,,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6005,In vivo,Canis lupus familiaris,9615.0
5660,N,,,,Compound was tested for plasma clearance in dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,4839,In vivo,Canis lupus familiaris,9615.0
5661,N,,,,Pharmacokinetic property (Plasma clearance) was measured in dog,Intermediate,,,,,50588,BAO_0000218,A,,4239,In vivo,Canis lupus familiaris,9615.0
5662,N,,,,Area under curve when injected perorally in mice at a dose of 50 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,17729,,Mus musculus,10090.0
5663,N,,,,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,17728,,Mus musculus,10090.0
5664,N,,,,Area under curve value in mouse at a dose of 10 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,5302,,Mus musculus,10090.0
5665,N,,,,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,Intermediate,,,,,50594,BAO_0000218,A,,5506,,Mus musculus,10090.0
5666,N,,,,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,Intermediate,,,,,50594,BAO_0000218,A,,5506,,Mus musculus,10090.0
5667,N,,,,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,Intermediate,,,,,50594,BAO_0000218,F,,17764,,Mus musculus,10090.0
5668,N,,,,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,Intermediate,,,,,50594,BAO_0000218,F,,17764,,Mus musculus,10090.0
5669,N,,,,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,Intermediate,,,,,50594,BAO_0000218,F,,17764,,Mus musculus,10090.0
5670,N,,,,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,Intermediate,,,,,50594,BAO_0000218,F,,17764,,Mus musculus,10090.0
5671,N,,,,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,Intermediate,,,,,50594,BAO_0000218,A,,17764,,Mus musculus,10090.0
5672,N,,,,Area under curve was determined for the compound at 24 mg/Kg,Intermediate,,,,,50594,BAO_0000218,A,,17753,,Mus musculus,10090.0
5673,N,,,,Area under curve was determined for the compound at 40 mg/Kg,Intermediate,,,,,50594,BAO_0000218,A,,17753,,Mus musculus,10090.0
5674,N,,,,Area under curve was determined for the compound at 5 mg/Kg,Intermediate,,,,,50594,BAO_0000218,A,,17753,,Mus musculus,10090.0
5675,N,,,,Area under the curve for the compound is obtained at dose 25 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,3132,,Mus musculus,10090.0
5676,N,,,,Area under the curve for the compound was obtained when tested in mouse,Intermediate,,,,,50594,BAO_0000218,A,,3132,,Mus musculus,10090.0
5677,N,,,,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,17837,,Mus musculus,10090.0
5678,N,,,,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,17837,,Mus musculus,10090.0
5679,N,,,,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,6062,,Mus musculus,10090.0
5680,N,,,,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,4066,,Mus musculus,10090.0
5681,N,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),Intermediate,,,,,50594,BAO_0000218,A,,16597,,Mus musculus,10090.0
5682,N,,,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,14239,,Mus musculus,10090.0
5683,N,,,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,14239,,Mus musculus,10090.0
5684,N,,,,"Compound was evaluated for the pharmacokinetic parameter, area under curve",Intermediate,,,,,50594,BAO_0000218,A,,4890,,Mus musculus,10090.0
5685,N,,,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),Intermediate,,,,,50594,BAO_0000218,A,,429,,Mus musculus,10090.0
5686,N,,,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),Intermediate,,,,,50594,BAO_0000218,A,,429,,Mus musculus,10090.0
5687,N,,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,5969,,Mus musculus,10090.0
5688,N,,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,5969,,Mus musculus,10090.0
5689,N,,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,Intermediate,,,,,50594,BAO_0000218,A,,5969,,Mus musculus,10090.0
5690,N,,,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,Intermediate,,,,,50594,BAO_0000218,A,,6091,,Mus musculus,10090.0
5691,N,,,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,Intermediate,,,,,50594,BAO_0000218,A,,6091,,Mus musculus,10090.0
5692,N,,,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,6091,,Mus musculus,10090.0
5693,N,,,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,Intermediate,,,,,50594,BAO_0000218,A,,6091,,Mus musculus,10090.0
5694,N,,,,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,6178,,Mus musculus,10090.0
5695,N,,,,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,6178,,Mus musculus,10090.0
5696,N,,,,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",Intermediate,,,,,50594,BAO_0000218,A,,6619,,Mus musculus,10090.0
5697,N,,,,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",Intermediate,,,,,50594,BAO_0000218,A,,6619,,Mus musculus,10090.0
5698,N,,,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",Intermediate,,,,,50594,BAO_0000218,A,,3760,,Mus musculus,10090.0
5699,N,,,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",Intermediate,,,,,50594,BAO_0000218,A,,3760,,Mus musculus,10090.0
5700,N,,,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",Intermediate,,,,,50594,BAO_0000218,A,,3760,,Mus musculus,10090.0
5701,N,,,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",Intermediate,,,,,50594,BAO_0000218,A,,3760,,Mus musculus,10090.0
5702,N,,,,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,Intermediate,,,,,50594,BAO_0000218,A,,3192,,Mus musculus,10090.0
5703,N,,,,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,Intermediate,,,,,50594,BAO_0000218,A,,3192,,Mus musculus,10090.0
5704,N,,,,Area under the curve was evaluated in mice after intravenous administration,Intermediate,,,,,50594,BAO_0000218,A,,2675,,Mus musculus,10090.0
5705,N,,,,Area under the curve was evaluated in mice after oral administration,Intermediate,,,,,50594,BAO_0000218,A,,2675,,Mus musculus,10090.0
5706,N,,,,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,,,,1969.0,50594,BAO_0000218,A,,16597,,Mus musculus,10090.0
5707,N,,,,AUC total value at a dose of 10 mg/kg peroral administration in mice.,Intermediate,,,,1969.0,50594,BAO_0000218,A,,16597,,Mus musculus,10090.0
5708,N,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),Intermediate,,,,,50594,BAO_0000218,A,,16597,,Mus musculus,10090.0
5709,N,,,,AUMC after intraperitoneal administration of 100 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,17734,,Mus musculus,10090.0
5710,N,,,,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,Intermediate,,,,178.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5711,N,,392.0,,The compound was tested in vitro for anticancer activity against 9L cells,Intermediate,,9L,,,80653,BAO_0000219,F,,15345,,,
5712,U,,,,Anti proliferation activity determined; Weak effect,Autocuration,,,,,22226,BAO_0000019,F,,2181,,Rattus norvegicus,10116.0
5713,U,,,,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,Autocuration,,,,,22226,BAO_0000219,F,,2181,,Rattus norvegicus,10116.0
5714,U,,,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,Autocuration,,,,,22226,BAO_0000219,F,,2181,,Rattus norvegicus,10116.0
5715,U,,,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,Autocuration,,,,,22226,BAO_0000219,F,,2181,,Rattus norvegicus,10116.0
5716,U,,,,The cytotoxic activity was in vitro tested by 9PS assay method,Autocuration,,,,,22226,BAO_0000019,F,,10486,,Mus musculus,10090.0
5717,U,,,,The cytotoxic activity was in vitro tested by 9PS assay method.,Autocuration,,,,,22226,BAO_0000019,F,,10486,,Mus musculus,10090.0
5718,U,,,,Partition coefficient (logD6.5),Autocuration,,,,,22224,BAO_0000019,A,,15508,,,
5719,N,,478.0,,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,Expert,,A2780,,,81034,BAO_0000219,F,,5242,,Homo sapiens,9606.0
5720,N,,455.0,,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),Intermediate,,A-375,,,80018,BAO_0000219,F,,16167,,Homo sapiens,9606.0
5721,N,,500.0,,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,Expert,,A-431,,,80852,BAO_0000219,F,,4782,,Homo sapiens,9606.0
5722,D,,500.0,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,Expert,,A-431,,,9,BAO_0000219,F,,16093,,Homo sapiens,9606.0
5723,N,,624.0,,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,2596,,Homo sapiens,9606.0
5724,N,,624.0,,in vitro cytotoxicity against A 498 cancer cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,2596,,Homo sapiens,9606.0
5725,N,,624.0,,In vitro cytotoxic activity against renal (A 498) cancer cell line.,Intermediate,,A498,,,80021,BAO_0000219,F,,3239,,Homo sapiens,9606.0
5726,N,,624.0,,Cytotoxic activity against A 498 renal cancer cell lines.,Intermediate,,A498,,,80021,BAO_0000219,F,,1847,,Homo sapiens,9606.0
5727,N,,624.0,,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,Intermediate,,A498,,,80021,BAO_0000219,F,,10553,,Homo sapiens,9606.0
5728,U,,,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,Autocuration,,,,,22226,BAO_0000019,F,,16219,,Staphylococcus aureus,1280.0
5729,U,,,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,Autocuration,,,,,22226,BAO_0000019,F,,16219,,Staphylococcus aureus,1280.0
5730,U,,,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,Autocuration,,,,,22226,BAO_0000019,F,,16219,,Staphylococcus aureus,1280.0
5731,U,,,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,Autocuration,,,,,22226,BAO_0000019,F,,16219,,Staphylococcus aureus,1280.0
5732,N,,646.0,,Inhibitory concentration required against A 549 lung cancer cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,4782,,Homo sapiens,9606.0
5733,N,,646.0,,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,Intermediate,,A549,,,80682,BAO_0000219,F,,11805,,Homo sapiens,9606.0
5734,N,,646.0,,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,Intermediate,,A549,,,80682,BAO_0000219,F,,11805,,Homo sapiens,9606.0
5735,N,,646.0,,In vitro cytotoxicity against lung cancer A 549 cell lines,Intermediate,,A549,,,80682,BAO_0000219,F,,2007,,Homo sapiens,9606.0
5736,N,,646.0,,Compound was tested for its cytotoxicity against A 549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,4594,,Homo sapiens,9606.0
5737,N,,646.0,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",Expert,,A549,,,80682,BAO_0000219,F,,6018,,Homo sapiens,9606.0
5738,N,,646.0,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",Intermediate,,A549,,,80682,BAO_0000219,F,,6018,,Homo sapiens,9606.0
5739,N,,646.0,,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,Expert,,A549,,,80682,BAO_0000219,F,,3599,,Homo sapiens,9606.0
5740,N,,646.0,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,Intermediate,,A549,,,80682,BAO_0000219,F,,2551,,Homo sapiens,9606.0
5741,N,,646.0,,In vitro inhibition of A549 (human lung cancer) cell growth.,Expert,,A549,,,80682,BAO_0000219,F,,16132,,Homo sapiens,9606.0
5742,N,,646.0,,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,Intermediate,,A549,,,80682,BAO_0000219,F,,16132,,Homo sapiens,9606.0
5743,N,,646.0,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,Expert,,A549,,,80682,BAO_0000219,F,,2551,,Homo sapiens,9606.0
5744,N,,646.0,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),Expert,,A549,,,80682,BAO_0000219,F,,2551,,Homo sapiens,9606.0
5745,U,,,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,Autocuration,,,,,22226,BAO_0000218,F,,11913,,,
5746,H,,,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,Autocuration,,,,,104694,BAO_0000218,F,,12621,In vivo,,
5747,H,,,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,Autocuration,,,,,104694,BAO_0000218,F,,12621,In vivo,,
5748,H,,,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,Autocuration,,,,,104694,BAO_0000218,F,,12621,In vivo,,
5749,H,,,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,Autocuration,,,,,104694,BAO_0000218,F,,12621,In vivo,,
5750,H,,,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,Autocuration,,,,,104694,BAO_0000218,F,,12621,In vivo,,
5751,N,,624.0,,Inhibition of A-498 human Renal cell proliferation,Expert,,A498,,,80021,BAO_0000219,F,,3600,,Homo sapiens,9606.0
5752,U,,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",Autocuration,,,,,22226,BAO_0000019,F,,1796,,Rattus norvegicus,10116.0
5753,U,,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",Autocuration,,,,,22226,BAO_0000019,F,,1796,,Rattus norvegicus,10116.0
5754,U,,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",Autocuration,,,,,22226,BAO_0000019,F,,1796,,Rattus norvegicus,10116.0
5755,N,,622.0,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,Expert,,A 172,,,80012,BAO_0000219,F,,16464,,Homo sapiens,9606.0
5756,N,,622.0,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Intermediate,,A 172,,,80012,BAO_0000219,F,,16464,,Homo sapiens,9606.0
5757,N,,622.0,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Intermediate,,A 172,,,80012,BAO_0000219,F,,16464,,Homo sapiens,9606.0
5758,N,,646.0,,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,Expert,,A549,,,80682,BAO_0000219,F,,13617,,Homo sapiens,9606.0
5759,N,,646.0,,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,Intermediate,,A549,,,80682,BAO_0000219,F,,4584,,Homo sapiens,9606.0
5760,N,,646.0,,Cytotoxic activity evaluated against A549 tumor cells,Expert,,A549,,,80682,BAO_0000219,F,,13799,,Homo sapiens,9606.0
5761,N,,646.0,,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,16726,,Homo sapiens,9606.0
5762,N,,646.0,,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,Intermediate,,A549,,,80682,BAO_0000219,F,,16109,,Homo sapiens,9606.0
5763,N,,646.0,,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,Intermediate,,A549,,,80682,BAO_0000219,F,,16109,,Homo sapiens,9606.0
5764,N,,646.0,,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,Intermediate,,A549,,,80682,BAO_0000219,F,,15474,,Homo sapiens,9606.0
5765,N,,646.0,,Cytotoxicity of compound against A549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,6851,,Homo sapiens,9606.0
5766,N,,646.0,,Cytotoxicity against human lung cell carcinoma A549 cell line,Expert,,A549,,,80682,BAO_0000219,F,,17534,,Homo sapiens,9606.0
5767,N,,646.0,,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,Intermediate,,A549,,,80682,BAO_0000219,F,,2621,,Homo sapiens,9606.0
5768,N,,646.0,,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,Intermediate,,A549,,,80682,BAO_0000219,F,,830,,Homo sapiens,9606.0
5769,N,,646.0,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,Intermediate,,A549,,,80682,BAO_0000219,F,,14255,,Homo sapiens,9606.0
5770,N,,646.0,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,Intermediate,,A549,,,80682,BAO_0000219,F,,14255,,Homo sapiens,9606.0
5771,N,,646.0,,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,Intermediate,,A549,,,80682,BAO_0000219,F,,1590,,Homo sapiens,9606.0
5772,N,,646.0,,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,Expert,,A549,,,80682,BAO_0000219,F,,6146,,Homo sapiens,9606.0
5773,N,,646.0,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,Expert,,A549,,,80682,BAO_0000219,F,,17427,,Homo sapiens,9606.0
5774,N,,646.0,,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,Intermediate,,A549,,,80682,BAO_0000219,F,,5280,,Homo sapiens,9606.0
5775,N,,646.0,,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,Intermediate,,A549,,,80682,BAO_0000219,F,,16786,,Homo sapiens,9606.0
5776,N,,646.0,,In vitro cytotoxicity against A549 (human lung cancer),Intermediate,,A549,,,80682,BAO_0000219,F,,5895,,Homo sapiens,9606.0
5777,N,,646.0,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,Expert,,A549,,,80682,BAO_0000219,F,,14297,,Homo sapiens,9606.0
5778,N,,646.0,,In vivo antiproliferative activity against A549 cell line,Intermediate,,A549,,,80682,BAO_0000218,F,,17824,,Homo sapiens,9606.0
5779,N,,646.0,,Inhibition of non-small-cell lung adenocarcinoma (A549),Intermediate,,A549,,,80682,BAO_0000219,F,,14368,,Homo sapiens,9606.0
5780,N,,646.0,,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,Intermediate,,A549,,,80682,BAO_0000219,F,,14368,,Homo sapiens,9606.0
5781,N,,646.0,,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,Intermediate,,A549,,,80682,BAO_0000219,F,,14254,,Homo sapiens,9606.0
5782,N,,646.0,,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),Intermediate,,A549,,,80682,BAO_0000219,F,,15897,,Homo sapiens,9606.0
5783,N,,646.0,,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,Intermediate,,A549,,,80682,BAO_0000219,F,,13866,,Homo sapiens,9606.0
5784,N,,646.0,,Inhibitory activity of compound against human A549 lung carcinoma cell line.,Intermediate,,A549,,,80682,BAO_0000219,F,,13370,,Homo sapiens,9606.0
5785,N,,646.0,,Inhibitory activity against A549 lung cancer cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,4862,,Homo sapiens,9606.0
5786,N,,646.0,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,4862,,Homo sapiens,9606.0
5787,N,,646.0,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,Intermediate,,A549,,,80682,BAO_0000219,F,,4862,,Homo sapiens,9606.0
5788,N,,646.0,,Inhibitory concentration against A549 (lung cancer) cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,15970,,Homo sapiens,9606.0
5789,N,,646.0,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,Expert,,A549,,,80682,BAO_0000219,F,,17713,,Homo sapiens,9606.0
5790,N,,646.0,,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,4833,,Homo sapiens,9606.0
5791,N,,646.0,,Activity against A549 cancer cell line.,Expert,,A549,,,80682,BAO_0000219,F,,13736,,Homo sapiens,9606.0
5792,N,,646.0,,The compound was evaluated for cytotoxicity against A549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,4312,,Homo sapiens,9606.0
5793,N,,646.0,,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,Intermediate,,A549,,,80682,BAO_0000219,F,,5421,,Homo sapiens,9606.0
5794,N,,646.0,,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,5421,,Homo sapiens,9606.0
5795,N,,646.0,,Growth inhibitory activity was measured for human A549 tumor cell line.,Intermediate,,A549,,,80682,BAO_0000219,F,,14717,,Homo sapiens,9606.0
5796,N,,646.0,,Inhibitory activity against A549 lung cancer cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,4634,,Homo sapiens,9606.0
5797,N,,646.0,,Inhibitory activity against A549 cell line; inactive,Intermediate,,A549,,,80682,BAO_0000219,F,,1149,,Homo sapiens,9606.0
5798,N,,646.0,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,Expert,,A549,,,80682,BAO_0000219,F,,5421,,Homo sapiens,9606.0
5799,N,,646.0,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,Expert,,A549,,,80682,BAO_0000219,F,,5421,,Homo sapiens,9606.0
5800,N,,646.0,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,Intermediate,,A549,,,80682,BAO_0000219,F,,5421,,Homo sapiens,9606.0
5801,N,,646.0,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),Intermediate,,A549,,,80682,BAO_0000219,F,,3320,,Homo sapiens,9606.0
5802,N,,646.0,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),Intermediate,,A549,,,80682,BAO_0000219,F,,3320,,Homo sapiens,9606.0
5803,N,,646.0,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),Intermediate,,A549,,,80682,BAO_0000219,F,,3320,,Homo sapiens,9606.0
5804,N,,646.0,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),Intermediate,,A549,,,80682,BAO_0000219,F,,3320,,Homo sapiens,9606.0
5805,N,,646.0,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),Intermediate,,A549,,,80682,BAO_0000219,F,,3320,,Homo sapiens,9606.0
5806,N,,646.0,,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,Intermediate,,A549,,,80682,BAO_0000219,F,,5726,,Homo sapiens,9606.0
5807,N,,,,Plasma clearance (in vivo) in mongrel dogs was determined,Intermediate,,,,,50588,BAO_0000218,A,,17800,In vivo,Canis lupus familiaris,9615.0
5808,N,,,,Plasma clearance was measured in dog,Intermediate,,,,,50588,BAO_0000218,A,,5985,In vivo,Canis lupus familiaris,9615.0
5809,N,,,,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,5530,In vivo,Canis lupus familiaris,9615.0
5810,N,,,,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,5530,In vivo,Canis lupus familiaris,9615.0
5811,N,,,,Tested for plasma clearance in dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,4839,In vivo,Canis lupus familiaris,9615.0
5812,N,,,,The compound was tested for clearance in dog plasma.,Intermediate,,,,,50588,BAO_0000218,A,,3639,In vivo,Canis lupus familiaris,9615.0
5813,N,,,,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",Intermediate,,,,,50588,BAO_0000218,A,,4838,In vivo,Canis lupus familiaris,9615.0
5814,N,,,,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,Intermediate,,,,,50588,BAO_0000218,A,,4137,In vivo,Canis lupus familiaris,9615.0
5815,N,,,,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),Intermediate,,,,1969.0,50588,BAO_0000218,A,,5017,In vivo,Canis lupus familiaris,9615.0
5816,N,,,,In vitro clearance in dog liver microsomes,Intermediate,,,,2107.0,50588,BAO_0000218,A,Microsomes,17538,In vitro,Canis lupus familiaris,9615.0
5817,N,,,,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,Intermediate,,,,,50588,BAO_0000218,A,,6161,In vivo,Canis lupus familiaris,9615.0
5818,N,,,,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,Intermediate,,,,,50588,BAO_0000218,A,,6161,In vivo,Canis lupus familiaris,9615.0
5819,N,,,,Plasma clearance in dog,Intermediate,,,,,50588,BAO_0000218,A,,1696,In vivo,Canis lupus familiaris,9615.0
5820,N,,,,Clearance rate in dog,Intermediate,,,,,50588,BAO_0000218,A,,6762,In vivo,Canis lupus familiaris,9615.0
5821,N,,,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,Intermediate,,,,1969.0,50588,BAO_0000218,A,,5932,In vivo,Canis lupus familiaris,9615.0
5822,N,,,,Clearance in dogs,Intermediate,,,,,50588,BAO_0000218,A,,6305,In vivo,Canis lupus familiaris,9615.0
5823,N,,,,Plasma clearance in dogs,Intermediate,,,,,50588,BAO_0000218,A,,4942,In vivo,Canis lupus familiaris,9615.0
5824,N,,,,Plasma clearance was determined,Intermediate,,,,,50588,BAO_0000218,A,,4219,In vivo,Canis lupus familiaris,9615.0
5825,N,,,,Lower clearance in dog (i.v.) at 0.5 mpk,Intermediate,,,,,50588,BAO_0000218,A,,17853,In vivo,Canis lupus familiaris,9615.0
5826,N,,,,Plasma clearance in Beagle dogs,Intermediate,,,,,50588,BAO_0000218,A,,4514,In vivo,Canis lupus familiaris,9615.0
5827,N,,,,Plasma clearance (Clp) in dog,Intermediate,,,,,50588,BAO_0000218,A,,6448,In vivo,Canis lupus familiaris,9615.0
5828,N,,,,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6227,In vivo,Canis lupus familiaris,9615.0
5829,N,,,,Plasma clearance (pharmacokinetic parameter) in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,6227,In vivo,Canis lupus familiaris,9615.0
5830,N,,,,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6062,In vivo,Canis lupus familiaris,9615.0
5831,N,,,,Plasma clearance of compound was determined in dog,Intermediate,,,,,50588,BAO_0000218,A,,6821,In vivo,Canis lupus familiaris,9615.0
5832,N,,,,Plasma clearance after intravenous administration of 1 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,4709,In vivo,Canis lupus familiaris,9615.0
5833,N,,,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,Intermediate,,,,,50588,BAO_0000218,A,,4521,In vivo,Canis lupus familiaris,9615.0
5834,N,,,,Plasma clearance in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,5374,In vivo,Canis lupus familiaris,9615.0
5835,N,,,,Plasma clearance was calculated in dog,Intermediate,,,,,50588,BAO_0000218,A,,6057,In vivo,Canis lupus familiaris,9615.0
5836,N,,,,Plasma clearance at the dose of 2 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,4727,In vivo,Canis lupus familiaris,9615.0
5837,N,,,,Plasma clearance in dog,Intermediate,,,,,50588,BAO_0000218,A,,5145,In vivo,Canis lupus familiaris,9615.0
5838,N,,,,Plasma clearance in dog,Intermediate,,,,,50588,BAO_0000218,A,,17657,In vivo,Canis lupus familiaris,9615.0
5839,N,,,,Plasma clearance in dog; Unable to calculate,Intermediate,,,,,50588,BAO_0000218,A,,17657,In vivo,Canis lupus familiaris,9615.0
5840,N,,,,Plasma clearance in rhesus monkey,Intermediate,,,,,50588,BAO_0000218,A,,5145,In vivo,Canis lupus familiaris,9615.0
5841,N,,,,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Intermediate,,,,,50588,BAO_0000218,A,,6642,In vivo,Canis lupus familiaris,9615.0
5842,N,,,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Intermediate,,,,,50588,BAO_0000218,A,,6641,In vivo,Canis lupus familiaris,9615.0
5843,N,,,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Intermediate,,,,,50588,BAO_0000218,A,,6642,In vivo,Canis lupus familiaris,9615.0
5844,N,,,,Plasma clearance was evaluated in dog,Intermediate,,,,,50588,BAO_0000218,A,,5472,In vivo,Canis lupus familiaris,9615.0
5845,N,,,,Plasma clearance was evaluated in dog; Not tested,Intermediate,,,,,50588,BAO_0000218,A,,5472,In vivo,Canis lupus familiaris,9615.0
5846,N,,,,Plasma clearance was evaluated in rhesus,Intermediate,,,,,50588,BAO_0000218,A,,5472,In vivo,Canis lupus familiaris,9615.0
5847,N,,,,Plasma clearance was evaluated in rhesus; Not tested,Intermediate,,,,,50588,BAO_0000218,A,,5472,In vivo,Canis lupus familiaris,9615.0
5848,N,,,,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,Intermediate,,,,,50588,BAO_0000218,A,,4257,In vivo,Canis lupus familiaris,9615.0
5849,N,,,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,,,,,50588,BAO_0000218,A,,6679,In vivo,Canis lupus familiaris,9615.0
5850,N,,,,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,Intermediate,,,,,50588,BAO_0000218,A,,5546,In vivo,Canis lupus familiaris,9615.0
5851,N,,,,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Intermediate,,,,,50588,BAO_0000218,A,,6348,In vivo,Canis lupus familiaris,9615.0
5852,N,,,,Clearance value at a dose of 0.2 mg/kg i.v.,Intermediate,,,,,50588,BAO_0000218,A,,5474,In vivo,Canis lupus familiaris,9615.0
5853,N,,,,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,6316,In vivo,Canis lupus familiaris,9615.0
5854,N,,,,Cmax after oral dose of compound at 3 mg/kg in dogs,Intermediate,,,,,50588,BAO_0000218,A,,17594,In vivo,Canis lupus familiaris,9615.0
5855,N,,,,Cmax after single intravenous bolus of 1 mg/kg in dogs,Intermediate,,,,,50588,BAO_0000218,A,,17594,In vivo,Canis lupus familiaris,9615.0
5856,N,,,,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,Intermediate,,,,,50588,BAO_0000218,A,,5802,In vivo,Canis lupus familiaris,9615.0
5857,N,,,,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,Intermediate,,,,,50588,BAO_0000218,A,,6535,In vivo,Canis lupus familiaris,9615.0
5858,N,,,,Cmax in dog after administration of 1 mg/kg iv,Intermediate,,,,,50588,BAO_0000218,A,,6535,In vivo,Canis lupus familiaris,9615.0
5859,N,,,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,1466,In vivo,Canis lupus familiaris,9615.0
5860,N,,,,Cmax on p.o. administration of 10 mg/kg was measured in dog,Intermediate,,,,,50588,BAO_0000218,A,,6505,In vivo,Canis lupus familiaris,9615.0
5861,N,,,,Cmax was determine after peroral administration at 10 mpk in dog,Intermediate,,,,,50588,BAO_0000218,A,,5668,In vivo,Canis lupus familiaris,9615.0
5862,N,,,,Cmax was determine after peroral administration at 5 mpk in dog,Intermediate,,,,,50588,BAO_0000218,A,,5668,In vivo,Canis lupus familiaris,9615.0
5863,N,,,,Cmax was determine after peroral administration at 5 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,5668,In vivo,Canis lupus familiaris,9615.0
5864,N,,,,Cmax after 0.3 mg/kg po administration in dog,Intermediate,,,,,50588,BAO_0000218,A,,5600,In vivo,Canis lupus familiaris,9615.0
5865,N,,,,Cmax after peroral administration in dogs at 2.4 uM/kg,Intermediate,,,,,50588,BAO_0000218,A,,17764,In vivo,Canis lupus familiaris,9615.0
5866,N,,,,Cmax in dog after oral administration at 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6123,In vivo,Canis lupus familiaris,9615.0
5867,N,,,,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,Intermediate,,,,,50588,BAO_0000218,A,,6123,In vivo,Canis lupus familiaris,9615.0
5868,N,,,,Cmax upon oral administration in male Beagle dog at 10 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6757,In vivo,Canis lupus familiaris,9615.0
5869,N,,,,Cmax value after 15 mg/kg iv dose in Dogs,Intermediate,,,,,50588,BAO_0000218,A,,16907,In vivo,Canis lupus familiaris,9615.0
5870,N,,,,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,,178.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5871,N,,,,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,,178.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5872,N,,,,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,,10000001.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5873,N,,,,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,,10000001.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5874,N,,,,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,,10000001.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5875,N,,,,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,,,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5876,N,,,,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,,,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5877,N,,,,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,,,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5878,N,,,,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,,948.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5879,N,,,,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,,948.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5880,N,,,,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,,948.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5881,N,,,,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,,2113.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5882,N,,,,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,,2113.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5883,N,,,,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,,2113.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5884,N,,,,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,,160.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5885,N,,,,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,,160.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5886,N,,,,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,,160.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5887,N,,,,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,,2107.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5888,N,,,,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,,2107.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5889,N,,,,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,,2107.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5890,N,,,,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,,2048.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5891,N,,,,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,,2048.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5892,N,,,,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,,2048.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5893,N,,,,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,,2385.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5894,N,,,,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,,2385.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5895,N,,,,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,,2385.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5896,N,,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,,,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5897,N,,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,,,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5898,N,,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,,,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5899,N,,,,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,,160.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5900,N,,,,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,,160.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5901,N,,,,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,,160.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5902,N,,,,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,,2106.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5903,N,,,,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,,2106.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5904,N,,,,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,,2106.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5905,N,,,,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,,945.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5906,N,,,,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,,945.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
5907,N,,622.0,,Cytotoxicity against A-172 human tumor cell lines,Expert,,A 172,,,80012,BAO_0000219,F,,2036,,Homo sapiens,9606.0
5908,N,,622.0,,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,Intermediate,,A 172,,,80012,BAO_0000219,F,,2357,,Homo sapiens,9606.0
5909,N,,623.0,,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,Intermediate,,A204,,,80014,BAO_0000219,F,,1457,,Homo sapiens,9606.0
5910,N,,478.0,,Tested for antiproliferative activity against A-2780 tumoral cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,4379,,Homo sapiens,9606.0
5911,N,,455.0,,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,Intermediate,,A-375,,,80018,BAO_0000219,F,,1093,,Homo sapiens,9606.0
5912,N,,455.0,,Tested in vitro against A-375 cell line human melanoma,Intermediate,,A-375,,,80018,BAO_0000219,F,,12152,,Homo sapiens,9606.0
5913,N,,797.0,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,Expert,,A-427,,,80019,BAO_0000219,F,,16464,,Homo sapiens,9606.0
5914,N,,797.0,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Intermediate,,A-427,,,80019,BAO_0000219,F,,16464,,Homo sapiens,9606.0
5915,N,,797.0,,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,Expert,,A-427,,,80019,BAO_0000219,F,,16582,,Homo sapiens,9606.0
5916,N,,797.0,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Intermediate,,A-427,,,80019,BAO_0000219,F,,16464,,Homo sapiens,9606.0
5917,N,,797.0,,Antitumor activity on A-427 lung carcinoma cell lines,Intermediate,,A-427,,,80019,BAO_0000219,F,,10413,,Homo sapiens,9606.0
5918,N,,797.0,,Cytotoxic activity against human A-427 lung tumor cell line,Intermediate,,A-427,,,80019,BAO_0000219,F,,6418,,Homo sapiens,9606.0
5919,N,,797.0,,In vitro antitumor effects against human A-427 cell lines.,Expert,,A-427,,,80019,BAO_0000219,F,,17134,,Homo sapiens,9606.0
5920,N,,797.0,,In vitro inhibition of A-427 (human lung cancer) cell growth.,Expert,,A-427,,,80019,BAO_0000219,F,,16132,,Homo sapiens,9606.0
5921,N,,797.0,,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,Intermediate,,A-427,,,80019,BAO_0000219,F,,16132,,Homo sapiens,9606.0
5922,N,,797.0,,Cytotoxic activity of compound against A-427 lung human tumor cell line,Intermediate,,A-427,,,80019,BAO_0000219,F,,16780,,Homo sapiens,9606.0
5923,N,,500.0,,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,Expert,,A-431,,,80852,BAO_0000219,F,,4085,,Homo sapiens,9606.0
5924,N,,624.0,,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,1276,,Homo sapiens,9606.0
5925,N,,624.0,,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,Expert,,A498,,,80021,BAO_0000219,F,,3498,,Homo sapiens,9606.0
5926,N,,624.0,,Cytotoxicity against human kidney carcinoma A-498cell lines,Intermediate,,A498,,,80021,BAO_0000219,F,,1169,,Homo sapiens,9606.0
5927,N,,624.0,,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,4450,,Homo sapiens,9606.0
5928,N,,624.0,,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,Intermediate,,A498,,,80021,BAO_0000219,F,,3311,,Homo sapiens,9606.0
5929,N,,624.0,,Antitumor cytotoxic activity against A-498 cell line was determined,Intermediate,,A498,,,80021,BAO_0000219,F,,4461,,Homo sapiens,9606.0
5930,N,,624.0,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,Intermediate,,A498,,,80021,BAO_0000219,F,,3311,,Homo sapiens,9606.0
5931,N,,624.0,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,Intermediate,,A498,,,80021,BAO_0000219,F,,3311,,Homo sapiens,9606.0
5932,N,,624.0,,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,Intermediate,,A498,,,80021,BAO_0000219,F,,1457,,Homo sapiens,9606.0
5933,N,,624.0,,In vitro inhibitory activity against A-498 ovarian cancer cell lines,Intermediate,,A498,,,80021,BAO_0000219,F,,3664,,Homo sapiens,9606.0
5934,N,,624.0,,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",Intermediate,,A498,,,80021,BAO_0000219,F,,15895,,Homo sapiens,9606.0
5935,N,,646.0,,Inhibition of growth lung non-small cell carcinoma A-549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,11843,,Homo sapiens,9606.0
5936,N,,646.0,,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,11843,,Homo sapiens,9606.0
5937,N,,646.0,,In vitro antiproliferative activity against human A-549 NSCL cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,17705,,Homo sapiens,9606.0
5938,N,,646.0,,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,Intermediate,,A549,,,80682,BAO_0000219,F,,17705,,Homo sapiens,9606.0
5939,N,,646.0,,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,Intermediate,,A549,,,80682,BAO_0000219,F,,4369,,Homo sapiens,9606.0
5940,N,,646.0,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,Intermediate,,A549,,,80682,BAO_0000219,F,,4369,,Homo sapiens,9606.0
5941,N,,646.0,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,Intermediate,,A549,,,80682,BAO_0000219,F,,4369,,Homo sapiens,9606.0
5942,N,,646.0,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,Intermediate,,A549,,,80682,BAO_0000219,F,,4369,,Homo sapiens,9606.0
5943,N,,646.0,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,Intermediate,,A549,,,80682,BAO_0000219,F,,4369,,Homo sapiens,9606.0
5944,N,,646.0,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,Intermediate,,A549,,,80682,BAO_0000219,F,,4369,,Homo sapiens,9606.0
5945,N,,646.0,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,Intermediate,,A549,,,80682,BAO_0000219,F,,4369,,Homo sapiens,9606.0
5946,N,,646.0,,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,Expert,,A549,,,80682,BAO_0000219,F,,4787,,Homo sapiens,9606.0
5947,N,,646.0,,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,Intermediate,,A549,,,80682,BAO_0000219,F,,4787,,Homo sapiens,9606.0
5948,N,,646.0,,Cytotoxic activity against A-549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,6513,,Homo sapiens,9606.0
5949,N,,646.0,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,Intermediate,,A549,,,80682,BAO_0000219,F,,6690,,Homo sapiens,9606.0
5950,N,,646.0,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,Intermediate,,A549,,,80682,BAO_0000219,F,,6690,,Homo sapiens,9606.0
5951,N,,646.0,,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",Expert,,A549,,,80682,BAO_0000219,F,,12263,,Homo sapiens,9606.0
5952,N,,646.0,,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),Intermediate,,A549,,,80682,BAO_0000219,F,,1054,,Homo sapiens,9606.0
5953,N,,646.0,,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),Intermediate,,A549,,,80682,BAO_0000219,F,,1359,,Homo sapiens,9606.0
5954,N,,646.0,,Cytotoxic activity against human lung carcinoma (A-549) cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,3547,,Homo sapiens,9606.0
5955,N,,646.0,,Cytotoxic activity towards A-549 cells,Expert,,A549,,,80682,BAO_0000219,F,,5771,,Homo sapiens,9606.0
5956,N,,646.0,,"In vitro percent inhibition of A549, lung carcinoma.",Intermediate,,A549,,,80682,BAO_0000219,F,,14425,,Homo sapiens,9606.0
5957,N,,646.0,,"In vitro percent inhibition of A549, lung carcinoma",Intermediate,,A549,,,80682,BAO_0000219,F,,14425,,Homo sapiens,9606.0
5958,N,,646.0,,"In vitro percent inhibition of A549, lung carcinoma.",Intermediate,,A549,,,80682,BAO_0000219,F,,14425,,Homo sapiens,9606.0
5959,N,,646.0,,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",Intermediate,,A549,,,80682,BAO_0000219,F,,14425,,Homo sapiens,9606.0
5960,N,,646.0,,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,Intermediate,,A549,,,80682,BAO_0000219,F,,5280,,Homo sapiens,9606.0
5961,N,,646.0,,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,Intermediate,,A549,,,80682,BAO_0000219,F,,15176,,Homo sapiens,9606.0
5962,N,,646.0,,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,Intermediate,,A549,,,80682,BAO_0000219,F,,15300,,Homo sapiens,9606.0
5963,N,,646.0,,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Intermediate,,A549,,,80682,BAO_0000218,F,,17824,,Homo sapiens,9606.0
5964,N,,646.0,,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Intermediate,,A549,,,80682,BAO_0000218,F,,17824,,Homo sapiens,9606.0
5965,N,,646.0,,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Intermediate,,A549,,,80682,BAO_0000218,F,,17824,,Homo sapiens,9606.0
5966,N,,646.0,,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Intermediate,,A549,,,80682,BAO_0000218,F,,17824,,Homo sapiens,9606.0
5967,N,,646.0,,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Intermediate,,A549,,,80682,BAO_0000218,F,,17824,,Homo sapiens,9606.0
5968,N,,646.0,,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",Intermediate,,A549,,,80682,BAO_0000219,F,,17824,,Homo sapiens,9606.0
5969,N,,646.0,,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),Intermediate,,A549,,,80682,BAO_0000218,F,,17528,,Homo sapiens,9606.0
5970,N,,646.0,,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,Expert,,A549,,,80682,BAO_0000219,F,,6870,,Homo sapiens,9606.0
5971,N,,646.0,,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,Intermediate,,A549,,,80682,BAO_0000219,F,,6870,,Homo sapiens,9606.0
5972,N,,646.0,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,Intermediate,,A549,,,80682,BAO_0000219,F,,6870,,Homo sapiens,9606.0
5973,N,,646.0,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,Intermediate,,A549,,,80682,BAO_0000219,F,,6870,,Homo sapiens,9606.0
5974,N,,646.0,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,Intermediate,,A549,,,80682,BAO_0000219,F,,16726,,Homo sapiens,9606.0
5975,N,,646.0,,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",Intermediate,,A549,,,80682,BAO_0000219,F,,6170,,Homo sapiens,9606.0
5976,N,,646.0,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,Expert,,A549,,,80682,BAO_0000219,F,,6583,,Homo sapiens,9606.0
5977,N,,646.0,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,Expert,,A549,,,80682,BAO_0000219,F,,6583,,Homo sapiens,9606.0
5978,N,,646.0,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,Expert,,A549,,,80682,BAO_0000219,F,,6583,,Homo sapiens,9606.0
5979,N,,646.0,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,Expert,,A549,,,80682,BAO_0000219,F,,6583,,Homo sapiens,9606.0
5980,N,,646.0,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,Expert,,A549,,,80682,BAO_0000219,F,,6583,,Homo sapiens,9606.0
5981,N,,646.0,,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,17321,,Homo sapiens,9606.0
5982,N,,646.0,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,Expert,,A549,,,80682,BAO_0000219,F,,17528,,Homo sapiens,9606.0
5983,N,,646.0,,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,Expert,,A549,,,80682,BAO_0000219,F,,12888,,Homo sapiens,9606.0
5984,N,,646.0,,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,4312,,Homo sapiens,9606.0
5985,N,,646.0,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,4312,,Homo sapiens,9606.0
5986,N,,646.0,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,Intermediate,,A549,,,80682,BAO_0000219,F,,4312,,Homo sapiens,9606.0
5987,N,,646.0,,In vitro antiproliferative activity against A549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,17737,,Mus musculus,10090.0
5988,N,,646.0,,Synergism with indomethacin in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,6630,,,
5989,N,,646.0,,Synergism with tolmetin in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,6630,,,
5990,N,,646.0,,Synergism with sulindac in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,6630,,,
5991,N,,646.0,,Antagonism of indomethacin in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,6630,,,
5992,N,,646.0,,Antagonism of sulindac in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,6630,,,
5993,N,,646.0,,Antagonism of tolmetin in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,6630,,,
5994,N,,646.0,,Synergism with indomethacin in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,6630,,,
5995,N,,646.0,,Synergism with sulindac in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,6630,,,
5996,N,,646.0,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,Intermediate,,A549,,,80682,BAO_0000219,F,,6630,,,
5997,N,,,,Cmax value after 30 mg/kg po dose in Dogs,Intermediate,,,,,50588,BAO_0000218,A,,16907,In vivo,Canis lupus familiaris,9615.0
5998,N,,,,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,5944,In vivo,Canis lupus familiaris,9615.0
5999,N,,,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,Intermediate,,,,,50588,BAO_0000218,A,,5944,In vivo,Canis lupus familiaris,9615.0
6000,N,,,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,5944,In vivo,Canis lupus familiaris,9615.0
6001,N,,,,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,Intermediate,,,,,50588,BAO_0000218,A,,5944,In vivo,Canis lupus familiaris,9615.0
6002,N,,,,Cmax value after administration of 4 mg/Kg oral dose in dog,Intermediate,,,,,50588,BAO_0000218,A,,2959,In vivo,Canis lupus familiaris,9615.0
6003,N,,,,Cmax value in dog,Intermediate,,,,,50588,BAO_0000218,A,,6241,In vivo,Canis lupus familiaris,9615.0
6004,N,,,,Cmax value in dogs after oral administration at 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6241,In vivo,Canis lupus familiaris,9615.0
6005,N,,,,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,Intermediate,,,,,50588,BAO_0000218,A,,2652,In vivo,Canis lupus familiaris,9615.0
6006,N,,,,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,Intermediate,,,,1969.0,50588,BAO_0000218,A,,1806,In vivo,Canis lupus familiaris,9615.0
6007,N,,,,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,Intermediate,,,,1969.0,50588,BAO_0000218,A,,1806,In vivo,Canis lupus familiaris,9615.0
6008,N,,,,Concentration maxima after oral dosing in dogs,Intermediate,,,,,50588,BAO_0000218,A,,1021,In vivo,Canis lupus familiaris,9615.0
6009,N,,,,Concentration maxima after oral dosing in dogs; not available,Intermediate,,,,,50588,BAO_0000218,A,,1021,In vivo,Canis lupus familiaris,9615.0
6010,N,,,,Concentration maxima after oral dosing in dogs; not available,Intermediate,,,,,50588,BAO_0000218,A,,1021,In vivo,Canis lupus familiaris,9615.0
6011,N,,,,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,Intermediate,,,,,50588,BAO_0000218,A,,5444,In vivo,Canis lupus familiaris,9615.0
6012,N,,,,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,Intermediate,,,,,50588,BAO_0000218,A,,5444,In vivo,Canis lupus familiaris,9615.0
6013,N,,,,In vivo maximal concentration was calculated at 1 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,5444,In vivo,Canis lupus familiaris,9615.0
6014,N,,,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,Intermediate,,,,,50588,BAO_0000218,A,,5444,In vivo,Canis lupus familiaris,9615.0
6015,N,,,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,Intermediate,,,,,50588,BAO_0000218,A,,5444,In vivo,Canis lupus familiaris,9615.0
6016,N,,,,Cmax in dog plasma after oral dose (1 mg/kg),Intermediate,,,,1969.0,50588,BAO_0000218,A,,5130,In vivo,Canis lupus familiaris,9615.0
6017,N,,,,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,3249,In vivo,Canis lupus familiaris,9615.0
6018,N,,,,Maximal plasma concentration at a dose of 1 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,5473,In vivo,Canis lupus familiaris,9615.0
6019,N,,,,Maximal plasma concentration at a dose of 1 mg/kg (oral),Intermediate,,,,1969.0,50588,BAO_0000218,A,,5474,In vivo,Canis lupus familiaris,9615.0
6020,N,,,,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,Intermediate,,,,1969.0,50588,BAO_0000218,A,,4657,In vivo,Canis lupus familiaris,9615.0
6021,N,,,,Maximum concentration of compound in dog was evaluated.,Intermediate,,,,,50588,BAO_0000218,A,,3031,In vivo,Canis lupus familiaris,9615.0
6022,N,,,,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,4527,In vivo,Canis lupus familiaris,9615.0
6023,N,,,,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,Intermediate,,,,,50588,BAO_0000218,A,,4186,In vivo,Canis lupus familiaris,9615.0
6024,N,,,,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,5007,In vivo,Canis lupus familiaris,9615.0
6025,N,,,,Maximum concentration obtained in dog plasma was determined,Intermediate,,,,1969.0,50588,BAO_0000218,A,,3132,In vivo,Canis lupus familiaris,9615.0
6026,N,,,,Maximum concentration was determined,Intermediate,,,,,50588,BAO_0000218,A,,5006,In vivo,Canis lupus familiaris,9615.0
6027,N,,,,Maximum concentration at the dose of 2 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,4727,In vivo,Canis lupus familiaris,9615.0
6028,N,,,,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Intermediate,,,,,50588,BAO_0000218,A,,1916,In vivo,Canis lupus familiaris,9615.0
6029,N,,,,Maximum concentration was evaluated in dog plasma,Intermediate,,,,1969.0,50588,BAO_0000218,A,,1918,In vivo,Canis lupus familiaris,9615.0
6030,N,,,,Maximum concentration was evaluated after 75 min after administration in dog,Intermediate,,,,,50588,BAO_0000218,A,,3045,In vivo,Canis lupus familiaris,9615.0
6031,N,,,,Maximum plasma concentration determined in dog after oral administration of 17b,Intermediate,,,,1969.0,50588,BAO_0000218,A,,9579,In vivo,Canis lupus familiaris,9615.0
6032,N,,,,Maximum plasma concentration determined in dog after oral administration of 2b,Intermediate,,,,1969.0,50588,BAO_0000218,A,,9579,In vivo,Canis lupus familiaris,9615.0
6033,N,,,,Maximum plasma concentration in dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,933,In vivo,Canis lupus familiaris,9615.0
6034,N,,,,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17839,In vivo,Canis lupus familiaris,9615.0
6035,N,,,,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17839,In vivo,Canis lupus familiaris,9615.0
6036,N,,,,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17839,In vivo,Canis lupus familiaris,9615.0
6037,N,,,,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17839,In vivo,Canis lupus familiaris,9615.0
6038,N,,,,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Intermediate,,,,1969.0,50588,BAO_0000218,A,,6348,In vivo,Canis lupus familiaris,9615.0
6039,N,,,,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,16367,In vivo,Canis lupus familiaris,9615.0
6040,N,,,,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Intermediate,,,,1969.0,50588,BAO_0000218,A,,1337,In vivo,Canis lupus familiaris,9615.0
6041,N,,,,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Intermediate,,,,1969.0,50588,BAO_0000218,A,,1337,In vivo,Canis lupus familiaris,9615.0
6042,N,,,,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,Intermediate,,,,1969.0,50588,BAO_0000218,A,,5199,In vivo,Canis lupus familiaris,9615.0
6043,N,,,,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17650,In vivo,Canis lupus familiaris,9615.0
6044,N,,,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,Intermediate,,,,1969.0,50588,BAO_0000218,A,,6679,In vivo,Canis lupus familiaris,9615.0
6045,N,,,,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,Intermediate,,,,1969.0,50588,BAO_0000218,A,,5356,In vivo,Canis lupus familiaris,9615.0
6046,N,,,,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,Intermediate,,,,1969.0,50588,BAO_0000218,A,,5356,In vivo,Canis lupus familiaris,9615.0
6047,N,,,,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,6227,In vivo,Canis lupus familiaris,9615.0
6048,N,,,,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,6227,In vivo,Canis lupus familiaris,9615.0
6049,N,,,,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,6227,In vivo,Canis lupus familiaris,9615.0
6050,N,,,,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,6227,In vivo,Canis lupus familiaris,9615.0
6051,N,,,,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,Expert,,,,1969.0,50588,BAO_0000218,A,,3598,In vivo,Canis lupus familiaris,9615.0
6052,N,,,,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,4368,In vivo,Canis lupus familiaris,9615.0
6053,N,,,,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6265,In vivo,Canis lupus familiaris,9615.0
6054,N,,,,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,,945.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
6055,N,,,,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,,1088.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
6056,N,,,,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,Intermediate,,,,1088.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
6057,N,,,,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,Intermediate,,,,1088.0,50594,BAO_0000218,A,,7767,In vivo,Mus musculus,10090.0
6058,N,,,,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,Intermediate,,,,,50594,BAO_0000218,A,,17811,,Mus musculus,10090.0
6059,N,,,,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,Intermediate,,,,,50594,BAO_0000218,A,,17811,,Mus musculus,10090.0
6060,N,,,,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),Intermediate,,,,,50594,BAO_0000218,A,,17827,,Mus musculus,10090.0
6061,N,,,,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),Intermediate,,,,178.0,50594,BAO_0000218,A,,17827,,Mus musculus,10090.0
6062,N,,,,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),Intermediate,,,,,50594,BAO_0000218,A,,17827,,Mus musculus,10090.0
6063,N,,,,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),Intermediate,,,,,50594,BAO_0000218,A,,17827,,Mus musculus,10090.0
6064,N,,,,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),Intermediate,,,,,50594,BAO_0000218,A,,17827,,Mus musculus,10090.0
6065,N,,,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),Intermediate,,,,178.0,50594,BAO_0000218,A,,17827,,Mus musculus,10090.0
6066,N,,,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),Intermediate,,,,178.0,50594,BAO_0000218,A,,17827,,Mus musculus,10090.0
6067,N,,,,Compound was evaluated for washout rate in mice (Radiolabeled compound),Intermediate,,,,,50594,BAO_0000218,A,,17827,,Mus musculus,10090.0
6068,N,,,,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,Intermediate,,,,,50594,BAO_0000218,A,,17827,,Mus musculus,10090.0
6069,N,,,,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",Intermediate,,,,,50594,BAO_0000218,A,,17827,,Mus musculus,10090.0
6070,N,,,,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",Intermediate,,,,,50594,BAO_0000218,A,,17827,,Mus musculus,10090.0
6071,N,,,,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",Intermediate,,,,,50594,BAO_0000218,A,,17827,,Mus musculus,10090.0
6072,N,,,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,Intermediate,,,,,50594,BAO_0000218,A,,17257,,Mus musculus,10090.0
6073,N,,,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,Intermediate,,,,,50594,BAO_0000218,A,,17257,,Mus musculus,10090.0
6074,N,,,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,Intermediate,,,,,50594,BAO_0000218,A,,17257,,Mus musculus,10090.0
6075,N,,,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,Intermediate,,,,,50594,BAO_0000218,A,,17257,,Mus musculus,10090.0
6076,N,,,,Time at maximum activity in mice (Radiolabeled compound),Intermediate,,,,,50594,BAO_0000218,A,,17827,,Mus musculus,10090.0
6077,N,,,,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,Intermediate,,,,,50594,BAO_0000218,A,,3760,,Mus musculus,10090.0
6078,N,,,,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,Intermediate,,,,,50594,BAO_0000218,A,,3760,,Mus musculus,10090.0
6079,N,,,,Binding towards mouse plasma protein at 10 uM,Intermediate,,,,,50594,BAO_0000218,A,,17409,,Mus musculus,10090.0
6080,N,,,,Binding towards mouse plasma protein at 100 uM,Intermediate,,,,,50594,BAO_0000218,A,,17409,,Mus musculus,10090.0
6081,N,,,,Bioavailability was evaluated in mice after intravenous administration,Intermediate,,,,,50594,BAO_0000218,A,,2675,In vivo,Mus musculus,10090.0
6082,N,,,,Bioavailability was evaluated in mice after oral administration,Intermediate,,,,,50594,BAO_0000218,A,,2675,In vivo,Mus musculus,10090.0
6083,N,,,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,Intermediate,,,,,50594,BAO_0000218,A,,3132,In vivo,Mus musculus,10090.0
6084,N,,,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,3132,In vivo,Mus musculus,10090.0
6085,N,,,,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,Intermediate,,,,,50594,BAO_0000218,A,,16597,In vivo,Mus musculus,10090.0
6086,N,,,,Oral bioavailability in mouse,Intermediate,,,,,50594,BAO_0000218,A,,2862,In vivo,Mus musculus,10090.0
6087,N,,,,Oral bioavailability after intravenous administration in mice at 24 uM/kg,Intermediate,,,,,50594,BAO_0000218,A,,17764,In vivo,Mus musculus,10090.0
6088,N,,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,955.0,50594,BAO_0000218,A,,846,In vivo,Mus musculus,10090.0
6089,N,,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,955.0,50594,BAO_0000218,A,,846,In vivo,Mus musculus,10090.0
6090,N,,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,955.0,50594,BAO_0000218,A,,846,In vivo,Mus musculus,10090.0
6091,N,,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,955.0,50594,BAO_0000218,A,,846,In vivo,Mus musculus,10090.0
6092,N,,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,955.0,50594,BAO_0000218,A,,846,In vivo,Mus musculus,10090.0
6093,N,,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,955.0,50594,BAO_0000218,A,,846,In vivo,Mus musculus,10090.0
6094,N,,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,948.0,50594,BAO_0000218,A,,846,In vivo,Mus musculus,10090.0
6095,N,,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,948.0,50594,BAO_0000218,A,,846,In vivo,Mus musculus,10090.0
6096,N,,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,948.0,50594,BAO_0000218,A,,846,In vivo,Mus musculus,10090.0
6097,N,,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,948.0,50594,BAO_0000218,A,,846,In vivo,Mus musculus,10090.0
6098,N,,646.0,,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),Intermediate,,A549,,,80682,BAO_0000219,F,,1276,,Homo sapiens,9606.0
6099,N,,646.0,,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,Expert,,A549,,,80682,BAO_0000219,F,,3498,,Homo sapiens,9606.0
6100,N,,646.0,,Cytotoxicity against human lung carcinoma A-549 cell lines,Intermediate,,A549,,,80682,BAO_0000219,F,,1169,,Homo sapiens,9606.0
6101,N,,646.0,,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,4450,,Homo sapiens,9606.0
6102,N,,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549,Intermediate,,A549,,,80682,BAO_0000219,F,,358,,Homo sapiens,9606.0
6103,N,,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,Intermediate,,A549,,,80682,BAO_0000219,F,,358,,Homo sapiens,9606.0
6104,N,,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,Intermediate,,A549,,,80682,BAO_0000219,F,,358,,Homo sapiens,9606.0
6105,N,,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,Intermediate,,A549,,,80682,BAO_0000219,F,,358,,Homo sapiens,9606.0
6106,N,,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,Intermediate,,A549,,,80682,BAO_0000219,F,,358,,Homo sapiens,9606.0
6107,N,,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,Intermediate,,A549,,,80682,BAO_0000219,F,,358,,Homo sapiens,9606.0
6108,N,,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,Intermediate,,A549,,,80682,BAO_0000219,F,,358,,Homo sapiens,9606.0
6109,N,,646.0,,In vitro cytotoxicity against A-549 human lung cancer cells,Intermediate,,A549,,,80682,BAO_0000219,F,,15167,,Homo sapiens,9606.0
6110,N,,646.0,,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,4139,,Homo sapiens,9606.0
6111,N,,646.0,,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,Intermediate,,A549,,,80682,BAO_0000219,F,,833,,Homo sapiens,9606.0
6112,N,,646.0,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,Expert,,A549,,,80682,BAO_0000219,F,,15718,,Homo sapiens,9606.0
6113,N,,646.0,,Tested in vitro for cytotoxicity against A-549 lung cancer cells,Intermediate,,A549,,,80682,BAO_0000219,F,,12373,,Homo sapiens,9606.0
6114,N,,646.0,,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,Intermediate,,A549,,,80682,BAO_0000219,F,,637,,Homo sapiens,9606.0
6115,N,,646.0,,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,Expert,,A549,,,80682,BAO_0000219,F,,14867,,Homo sapiens,9606.0
6116,N,,646.0,,Antitumor cytotoxic activity against A-549 cell line was determined,Intermediate,,A549,,,80682,BAO_0000219,F,,4461,,Homo sapiens,9606.0
6117,N,,646.0,,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",Intermediate,,A549,,,80682,BAO_0000219,F,,5406,,Homo sapiens,9606.0
6118,N,,646.0,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,4457,,Homo sapiens,9606.0
6119,N,,646.0,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,Expert,,A549,,,80682,BAO_0000219,F,,1386,,Homo sapiens,9606.0
6120,N,,646.0,,Antitumoral activity was assayed against A-549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,3265,,Homo sapiens,9606.0
6121,N,,646.0,,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,Intermediate,,A549,,,80682,BAO_0000219,F,,2359,,Homo sapiens,9606.0
6122,N,,646.0,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,4457,,Homo sapiens,9606.0
6123,N,,646.0,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,Expert,,A549,,,80682,BAO_0000219,F,,12454,,Homo sapiens,9606.0
6124,N,,646.0,,Compound was tested for inhibition of cell growth of A-549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,1481,,Homo sapiens,9606.0
6125,N,,646.0,,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,Intermediate,,A549,,,80682,BAO_0000219,F,,1750,,Homo sapiens,9606.0
6126,N,,646.0,,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,Intermediate,,A549,,,80682,BAO_0000219,F,,5065,,Homo sapiens,9606.0
6127,N,,646.0,,In vitro cytotoxicity against A549-human lung carcinoma cells.,Expert,,A549,,,80682,BAO_0000219,F,,808,,Homo sapiens,9606.0
6128,N,,646.0,,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,Expert,,A549,,,80682,BAO_0000219,F,,16364,,Homo sapiens,9606.0
6129,N,,646.0,,Cytotoxic activity against A-549 cell lines.,Intermediate,,A549,,,80682,BAO_0000219,F,,1847,,Homo sapiens,9606.0
6130,N,,646.0,,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,Expert,,A549,,,80682,BAO_0000219,F,,1747,,Homo sapiens,9606.0
6131,N,,646.0,,Cytotoxicity against human A549 non small cell lung cell lines,Intermediate,,A549,,,80682,BAO_0000219,F,,1003,,Homo sapiens,9606.0
6132,N,,646.0,,Inhibition of cell growth in (A-549) lung cell line,Expert,,A549,,,80682,BAO_0000219,F,,15313,,Homo sapiens,9606.0
6133,N,,646.0,,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,3122,,Homo sapiens,9606.0
6134,N,,646.0,,In vitro antitumor activity against A-549 tumor cells.,Intermediate,,A549,,,80682,BAO_0000219,F,,16049,,Homo sapiens,9606.0
6135,N,,646.0,,In vitro antitumor effects against human A-549 cell lines.,Expert,,A549,,,80682,BAO_0000219,F,,17134,,Homo sapiens,9606.0
6136,N,,646.0,,In vitro cytotoxic activity of compound against A-549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,6406,,Homo sapiens,9606.0
6137,N,,646.0,,In vitro cytotoxicity against human lung carcinoma A-549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,627,,Homo sapiens,9606.0
6138,N,,646.0,,In vitro cytotoxicity against human non-small cell lung carcinoma A549,Intermediate,,A549,,,80682,BAO_0000219,F,,12307,,Homo sapiens,9606.0
6139,N,,646.0,,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,Intermediate,,A549,,,80682,BAO_0000219,F,,17861,,Homo sapiens,9606.0
6140,N,,646.0,,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,Expert,,A549,,,80682,BAO_0000219,F,,6682,,Homo sapiens,9606.0
6141,N,,646.0,,Inhibitory concentration of compound against A-549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,6663,,Homo sapiens,9606.0
6142,N,,646.0,,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,Intermediate,,A549,,,80682,BAO_0000219,F,,2454,,Homo sapiens,9606.0
6143,N,,646.0,,cytotoxic activity against leukemia (A-549) cancer cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,14709,,Homo sapiens,9606.0
6144,N,,646.0,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,Expert,,A549,,,80682,BAO_0000219,F,,15718,,Homo sapiens,9606.0
6145,N,,646.0,,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,15718,,Homo sapiens,9606.0
6146,N,,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),Intermediate,,A549,,,80682,BAO_0000219,F,,17130,,Homo sapiens,9606.0
6147,N,,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),Intermediate,,A549,,,80682,BAO_0000219,F,,17130,,Homo sapiens,9606.0
6148,N,,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),Intermediate,,A549,,,80682,BAO_0000219,F,,17130,,Homo sapiens,9606.0
6149,N,,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),Intermediate,,A549,,,80682,BAO_0000219,F,,17130,,Homo sapiens,9606.0
6150,N,,646.0,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,Intermediate,,A549,,,80682,BAO_0000219,F,,6630,,,
6151,N,,646.0,,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,Intermediate,,A549,,,80682,BAO_0000219,F,,16726,,Homo sapiens,9606.0
6152,N,,646.0,,Cytotoxicity against A549 cells; No cytotoxicity,Intermediate,,A549,,,80682,BAO_0000219,F,,17846,,Homo sapiens,9606.0
6153,N,,646.0,,Cytotoxicity against human lung carcinoma (A549) cell lines,Expert,,A549,,,80682,BAO_0000219,F,,3415,,Homo sapiens,9606.0
6154,N,,646.0,,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,Expert,,A549,,,80682,BAO_0000219,F,,3415,,Homo sapiens,9606.0
6155,N,,646.0,,In vitro anticancer activity against human lung (A549) cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,5609,,Homo sapiens,9606.0
6156,N,,646.0,,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,Homo sapiens,9606.0
6157,N,,646.0,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,Homo sapiens,9606.0
6158,N,,646.0,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,Homo sapiens,9606.0
6159,N,,646.0,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,Homo sapiens,9606.0
6160,N,,646.0,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,Homo sapiens,9606.0
6161,N,,646.0,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,Homo sapiens,9606.0
6162,N,,646.0,,Inhibition of A549 human lung tumor cell proliferation,Expert,,A549,,,80682,BAO_0000219,F,,16295,,Homo sapiens,9606.0
6163,N,,646.0,,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",Intermediate,,A549,,,80682,BAO_0000219,F,,16825,,Homo sapiens,9606.0
6164,N,,646.0,,In vitro cytotoxicity against human tumor cell line A549,Expert,,A549,,,80682,BAO_0000219,F,,3439,,Homo sapiens,9606.0
6165,N,,646.0,,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,Intermediate,,A549,,,80682,BAO_0000219,F,,10870,,Homo sapiens,9606.0
6166,N,,646.0,,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,4845,,Homo sapiens,9606.0
6167,N,,646.0,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,5822,,Homo sapiens,9606.0
6168,N,,646.0,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,5822,,Homo sapiens,9606.0
6169,N,,646.0,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,Intermediate,,A549,,,80682,BAO_0000219,F,,5822,,Homo sapiens,9606.0
6170,N,,646.0,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,Intermediate,,A549,,,80682,BAO_0000219,F,,16381,,Homo sapiens,9606.0
6171,N,,646.0,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,Intermediate,,A549,,,80682,BAO_0000219,F,,16381,,Homo sapiens,9606.0
6172,N,,646.0,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,Intermediate,,A549,,,80682,BAO_0000219,F,,16381,,Homo sapiens,9606.0
6173,N,,646.0,,In vitro anticancer activity against human lung (A549) cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,5609,,Homo sapiens,9606.0
6174,N,,646.0,,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,Intermediate,,A549,,,80682,BAO_0000219,F,,4644,,Homo sapiens,9606.0
6175,N,,646.0,,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,Intermediate,,A549,,,80682,BAO_0000219,F,,4644,,Homo sapiens,9606.0
6176,N,,646.0,,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,Intermediate,,A549,,,80682,BAO_0000219,F,,4644,,Homo sapiens,9606.0
6177,N,,646.0,,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,Intermediate,,A549,,,80682,BAO_0000219,F,,4644,,Homo sapiens,9606.0
6178,N,,646.0,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,Intermediate,,A549,,,80682,BAO_0000219,F,,5822,,Homo sapiens,9606.0
6179,N,,646.0,,Percentage inhibition of human lung carcinoma (A549) cell lines,Expert,,A549,,,80682,BAO_0000219,F,,3415,,Homo sapiens,9606.0
6180,N,,646.0,,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,Intermediate,,A549,,,80682,BAO_0000219,F,,16726,,Homo sapiens,9606.0
6181,N,,646.0,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,Homo sapiens,9606.0
6182,N,,646.0,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,Homo sapiens,9606.0
6183,N,,646.0,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,Homo sapiens,9606.0
6184,N,,646.0,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,Homo sapiens,9606.0
6185,N,,646.0,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,Homo sapiens,9606.0
6186,N,,646.0,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,Homo sapiens,9606.0
6187,N,,646.0,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,Homo sapiens,9606.0
6188,N,,646.0,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,Homo sapiens,9606.0
6189,N,,646.0,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,Homo sapiens,9606.0
6190,N,,646.0,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,Homo sapiens,9606.0
6191,N,,646.0,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,Intermediate,,A549,,,80682,BAO_0000219,F,,16726,,Homo sapiens,9606.0
6192,N,,646.0,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,Homo sapiens,9606.0
6193,N,,646.0,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,Homo sapiens,9606.0
6194,N,,646.0,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,Homo sapiens,9606.0
6195,N,,646.0,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,Homo sapiens,9606.0
6196,N,,,,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,Intermediate,,,,,50588,BAO_0000218,A,,6084,In vivo,Canis lupus familiaris,9615.0
6197,N,,,,Pharmacokinetic activity (Cmax) in dog,Intermediate,,,,,50588,BAO_0000218,A,,6084,In vivo,Canis lupus familiaris,9615.0
6198,N,,,,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),Intermediate,,,,,50588,BAO_0000218,A,,4809,In vivo,Canis lupus familiaris,9615.0
6199,N,,,,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,5983,In vivo,Canis lupus familiaris,9615.0
6200,N,,,,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6251,In vivo,Canis lupus familiaris,9615.0
6201,N,,,,Cmax in dog plasma after 30mg/kg oral dose,Intermediate,,,,1969.0,50588,BAO_0000218,A,,5932,In vivo,Canis lupus familiaris,9615.0
6202,N,,,,Tested for the peak blood level in dog,Intermediate,,,,178.0,50588,BAO_0000218,A,,4273,In vivo,Canis lupus familiaris,9615.0
6203,N,,,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",Intermediate,,,,,50588,BAO_0000218,A,,5313,In vivo,Canis lupus familiaris,9615.0
6204,N,,,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",Intermediate,,,,,50588,BAO_0000218,A,,5313,In vivo,Canis lupus familiaris,9615.0
6205,N,,,,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,Intermediate,,,,178.0,50588,BAO_0000218,A,,6221,In vivo,Canis lupus familiaris,9615.0
6206,N,,,,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,4709,,Canis lupus familiaris,9615.0
6207,N,,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,Intermediate,,,,,50588,BAO_0000218,A,,167,,Canis lupus familiaris,9615.0
6208,N,,,,Final plasma concentration in dogs after oral administration at 1 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,6241,,Canis lupus familiaris,9615.0
6209,N,,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,Intermediate,,,,,50588,BAO_0000218,A,,344,,Canis lupus familiaris,9615.0
6210,N,,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,Intermediate,,,,,50588,BAO_0000218,A,,344,,Canis lupus familiaris,9615.0
6211,N,,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,Intermediate,,,,,50588,BAO_0000218,A,,344,,Canis lupus familiaris,9615.0
6212,N,,,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,Intermediate,,,,,50588,BAO_0000218,A,,2189,,Canis lupus familiaris,9615.0
6213,N,,,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,Intermediate,,,,1088.0,50588,BAO_0000218,A,,2189,,Canis lupus familiaris,9615.0
6214,N,,,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,Intermediate,,,,1088.0,50588,BAO_0000218,A,,2189,,Canis lupus familiaris,9615.0
6215,N,,,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,Intermediate,,,,1088.0,50588,BAO_0000218,A,,2189,,Canis lupus familiaris,9615.0
6216,N,,,,Absolute bioavailability was evaluated in dog,Intermediate,,,,,50588,BAO_0000218,A,,4257,In vivo,Canis lupus familiaris,9615.0
6217,N,,,,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,6221,In vivo,Canis lupus familiaris,9615.0
6218,N,,,,Bioavailability after peroral administration (1 mg/kg) was determined in dog,Intermediate,,,,,50588,BAO_0000218,A,,6215,In vivo,Canis lupus familiaris,9615.0
6219,N,,,,Bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,17267,In vivo,Canis lupus familiaris,9615.0
6220,N,,,,Bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,6621,In vivo,Canis lupus familiaris,9615.0
6221,N,,,,Bioavailability after intravenous administration in dogs,Intermediate,,,,,50588,BAO_0000218,A,,3854,In vivo,Canis lupus familiaris,9615.0
6222,N,,,,Bioavailability after peroral administration in dogs,Intermediate,,,,,50588,BAO_0000218,A,,3854,In vivo,Canis lupus familiaris,9615.0
6223,N,,,,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),Intermediate,,,,,50588,BAO_0000218,A,,5007,In vivo,Canis lupus familiaris,9615.0
6224,N,,,,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,Intermediate,,,,,50588,BAO_0000218,A,,4333,In vivo,Canis lupus familiaris,9615.0
6225,N,,,,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,Intermediate,,,,1969.0,50588,BAO_0000218,A,,4333,In vivo,Canis lupus familiaris,9615.0
6226,N,,,,Bioavailability,Intermediate,,,,,50588,BAO_0000218,A,,5006,In vivo,Canis lupus familiaris,9615.0
6227,N,,,,Bioavailability,Intermediate,,,,,50588,BAO_0000218,A,,5199,In vivo,Canis lupus familiaris,9615.0
6228,N,,,,Bioavailability by intravenous administration of 1.2 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,4368,In vivo,Canis lupus familiaris,9615.0
6229,N,,,,Bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,3771,In vivo,Canis lupus familiaris,9615.0
6230,N,,,,Bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,4953,In vivo,Canis lupus familiaris,9615.0
6231,N,,,,Bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,5064,In vivo,Canis lupus familiaris,9615.0
6232,N,,,,Bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,17657,In vivo,Canis lupus familiaris,9615.0
6233,N,,,,Bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,17796,In vivo,Canis lupus familiaris,9615.0
6234,N,,,,Bioavailability in dog (p.o.) at 2.0 mpk,Intermediate,,,,,50588,BAO_0000218,A,,17853,In vivo,Canis lupus familiaris,9615.0
6235,N,,,,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),Intermediate,,,,,50588,BAO_0000218,A,,4521,In vivo,Canis lupus familiaris,9615.0
6236,N,,,,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,Intermediate,,,,,50588,BAO_0000218,A,,4521,In vivo,Canis lupus familiaris,9615.0
6237,N,,,,Bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,5006,In vivo,Canis lupus familiaris,9615.0
6238,N,,,,Bioavailability was evaluated after oral administration in dog,Intermediate,,,,,50588,BAO_0000218,A,,16365,In vivo,Canis lupus familiaris,9615.0
6239,N,,,,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Intermediate,,,,,50588,BAO_0000218,A,,1916,In vivo,Canis lupus familiaris,9615.0
6240,N,,,,Bioavailability was evaluated in dog,Intermediate,,,,,50588,BAO_0000218,A,,1918,In vivo,Canis lupus familiaris,9615.0
6241,N,,,,Bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,4239,In vivo,Canis lupus familiaris,9615.0
6242,N,,,,Bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,6505,In vivo,Canis lupus familiaris,9615.0
6243,N,,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),Intermediate,,,,,50588,BAO_0000218,A,,5334,In vivo,Canis lupus familiaris,9615.0
6244,N,,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),Intermediate,,,,,50588,BAO_0000218,A,,5334,In vivo,Canis lupus familiaris,9615.0
6245,N,,,,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),Intermediate,,,,,50588,BAO_0000218,A,,4809,In vivo,Canis lupus familiaris,9615.0
6246,N,,,,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Intermediate,,,,,50588,BAO_0000218,A,,6348,In vivo,Canis lupus familiaris,9615.0
6247,N,,,,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6005,In vivo,Canis lupus familiaris,9615.0
6248,N,,,,Bioavailability of compound in dog was determined after peroral administration,Intermediate,,,,,50588,BAO_0000218,A,,17804,In vivo,Canis lupus familiaris,9615.0
6249,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,3184,In vivo,Canis lupus familiaris,9615.0
6250,N,,,,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,Intermediate,,,,,50588,BAO_0000218,A,,1806,In vivo,Canis lupus familiaris,9615.0
6251,N,,,,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,Intermediate,,,,,50588,BAO_0000218,A,,1806,In vivo,Canis lupus familiaris,9615.0
6252,N,,,,Compound was evaluated for oral bioavailability in dogs; 37-38 %,Intermediate,,,,,50588,BAO_0000218,A,,1806,In vivo,Canis lupus familiaris,9615.0
6253,N,,,,Bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,4839,In vivo,Canis lupus familiaris,9615.0
6254,N,,,,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),Intermediate,,,,,50588,BAO_0000218,A,,5017,In vivo,Canis lupus familiaris,9615.0
6255,N,,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,948.0,50594,BAO_0000218,A,,846,In vivo,Mus musculus,10090.0
6256,N,,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,948.0,50594,BAO_0000218,A,,846,In vivo,Mus musculus,10090.0
6257,N,,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2113.0,50594,BAO_0000218,A,,846,In vivo,Mus musculus,10090.0
6258,N,,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2113.0,50594,BAO_0000218,A,,846,In vivo,Mus musculus,10090.0
6259,N,,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2113.0,50594,BAO_0000218,A,,846,In vivo,Mus musculus,10090.0
6260,N,,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2113.0,50594,BAO_0000218,A,,846,In vivo,Mus musculus,10090.0
6261,N,,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2113.0,50594,BAO_0000218,A,,846,In vivo,Mus musculus,10090.0
6262,N,,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2113.0,50594,BAO_0000218,A,,846,In vivo,Mus musculus,10090.0
6263,N,,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2107.0,50594,BAO_0000218,A,,846,In vivo,Mus musculus,10090.0
6264,N,,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2107.0,50594,BAO_0000218,A,,846,In vivo,Mus musculus,10090.0
6265,N,,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2107.0,50594,BAO_0000218,A,,846,In vivo,Mus musculus,10090.0
6266,N,,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2107.0,50594,BAO_0000218,A,,846,In vivo,Mus musculus,10090.0
6267,N,,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2107.0,50594,BAO_0000218,A,,846,In vivo,Mus musculus,10090.0
6268,N,,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2107.0,50594,BAO_0000218,A,,846,In vivo,Mus musculus,10090.0
6269,N,,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2048.0,50594,BAO_0000218,A,,846,In vivo,Mus musculus,10090.0
6270,N,,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2048.0,50594,BAO_0000218,A,,846,In vivo,Mus musculus,10090.0
6271,N,,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2048.0,50594,BAO_0000218,A,,846,In vivo,Mus musculus,10090.0
6272,N,,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2048.0,50594,BAO_0000218,A,,846,In vivo,Mus musculus,10090.0
6273,N,,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2048.0,50594,BAO_0000218,A,,846,In vivo,Mus musculus,10090.0
6274,N,,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2048.0,50594,BAO_0000218,A,,846,In vivo,Mus musculus,10090.0
6275,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6276,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6277,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6278,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6279,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6280,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,Intermediate,,CCRF S-180,,955.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6281,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,Intermediate,,CCRF S-180,,955.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6282,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,Intermediate,,CCRF S-180,,955.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6283,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,Intermediate,,CCRF S-180,,955.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6284,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,Intermediate,,CCRF S-180,,955.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6285,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,Intermediate,,CCRF S-180,,948.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6286,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,Intermediate,,CCRF S-180,,948.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6287,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,Intermediate,,CCRF S-180,,948.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6288,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,Intermediate,,CCRF S-180,,948.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6289,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,Intermediate,,CCRF S-180,,948.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6290,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,Intermediate,,CCRF S-180,,2113.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6291,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,Intermediate,,CCRF S-180,,2113.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6292,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,Intermediate,,CCRF S-180,,2113.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6293,N,,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,Intermediate,,A549,,,80682,BAO_0000219,F,,17130,,Homo sapiens,9606.0
6294,N,,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,Intermediate,,A549,,,80682,BAO_0000219,F,,17130,,Homo sapiens,9606.0
6295,N,,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),Intermediate,,A549,,,80682,BAO_0000219,F,,17130,,Homo sapiens,9606.0
6296,N,,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),Intermediate,,A549,,,80682,BAO_0000219,F,,17130,,Homo sapiens,9606.0
6297,N,,646.0,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,Expert,,A549,,,80682,BAO_0000219,F,,3263,,Homo sapiens,9606.0
6298,N,,646.0,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,Expert,,A549,,,80682,BAO_0000219,F,,6663,,Homo sapiens,9606.0
6299,N,,646.0,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,Expert,,A549,,,80682,BAO_0000219,F,,6663,,Homo sapiens,9606.0
6300,N,,646.0,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,Expert,,A549,,,80682,BAO_0000219,F,,6663,,Homo sapiens,9606.0
6301,N,,646.0,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,Expert,,A549,,,80682,BAO_0000219,F,,6663,,Homo sapiens,9606.0
6302,N,,646.0,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,Expert,,A549,,,80682,BAO_0000219,F,,6663,,Homo sapiens,9606.0
6303,N,,646.0,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,Intermediate,,A549,,,80682,BAO_0000219,F,,6663,,Homo sapiens,9606.0
6304,N,,646.0,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,Intermediate,,A549,,,80682,BAO_0000219,F,,6663,,Homo sapiens,9606.0
6305,N,,646.0,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,Intermediate,,A549,,,80682,BAO_0000219,F,,6663,,Homo sapiens,9606.0
6306,N,,646.0,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,Intermediate,,A549,,,80682,BAO_0000219,F,,6663,,Homo sapiens,9606.0
6307,N,,646.0,,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,Intermediate,,A549,,,80682,BAO_0000219,F,,6663,,Homo sapiens,9606.0
6308,N,,646.0,,The compound was evaluated for its cytotoxic potency against A-549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,3983,,Homo sapiens,9606.0
6309,N,,646.0,,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,Expert,,A549,,,80682,BAO_0000219,F,,11141,,Homo sapiens,9606.0
6310,N,,646.0,,Cytotoxic activity of compound against A-549 tumor cell line.,Intermediate,,A549,,,80682,BAO_0000219,F,,5076,,Homo sapiens,9606.0
6311,N,,646.0,,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,Intermediate,,A549,,,80682,BAO_0000219,F,,3311,,Homo sapiens,9606.0
6312,N,,646.0,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,Intermediate,,A549,,,80682,BAO_0000219,F,,3311,,Homo sapiens,9606.0
6313,N,,646.0,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,Intermediate,,A549,,,80682,BAO_0000219,F,,3311,,Homo sapiens,9606.0
6314,N,,646.0,,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,Intermediate,,A549,,,80682,BAO_0000219,F,,5076,,Homo sapiens,9606.0
6315,N,,646.0,,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),Intermediate,,A549,,,80682,BAO_0000219,F,,4150,,Homo sapiens,9606.0
6316,N,,646.0,,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,Expert,,A549,,,80682,BAO_0000219,F,,2150,,Homo sapiens,9606.0
6317,N,,646.0,,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,Intermediate,,A549,,,80682,BAO_0000219,F,,4644,,Homo sapiens,9606.0
6318,N,,646.0,,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,Intermediate,,A549,,,80682,BAO_0000219,F,,263,,Homo sapiens,9606.0
6319,N,,646.0,,Cytotoxic concentration against A-549 tumor cells.,Intermediate,,A549,,,80682,BAO_0000219,F,,11333,,Homo sapiens,9606.0
6320,N,,646.0,,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,Intermediate,,A549,,,80682,BAO_0000219,F,,11333,,Homo sapiens,9606.0
6321,N,,646.0,,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",Intermediate,,A549,,,80682,BAO_0000219,F,,15895,,Homo sapiens,9606.0
6322,N,,,,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,Expert,,,,,50191,BAO_0000218,F,,16677,,Acinetobacter baumannii,470.0
6323,N,,,,Activity against Acinetobacter calcoaceticus (AC54),Intermediate,,,,,50192,BAO_0000218,F,,10624,,Acinetobacter calcoaceticus,471.0
6324,N,,,,In vitro antifungal activity against Aspergillus flavus CM74,Expert,,,,,50274,BAO_0000218,F,,16717,,Aspergillus flavus,5059.0
6325,N,,,,In vitro antifungal activity against Aspergillus flavus CM74,Expert,,,,,50274,BAO_0000218,F,,16717,,Aspergillus flavus,5059.0
6326,N,,,,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,Intermediate,,,,,50416,BAO_0000218,F,,5513,,Aspergillus fumigatus,746128.0
6327,N,,,,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),Intermediate,,,,,50416,BAO_0000218,F,,15962,,Aspergillus fumigatus,746128.0
6328,N,,,,Antimicrobial activity against Aspergillus fumigatus (MIC),Intermediate,,,,,50416,BAO_0000218,F,,15962,,Aspergillus fumigatus,746128.0
6329,N,,,,Antimicrobial activity against Aspergillus fumigatus (MIC),Intermediate,,,,,50416,BAO_0000218,F,,15962,,Aspergillus fumigatus,746128.0
6330,N,,,,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),Intermediate,,,,,50416,BAO_0000218,F,,15962,,Aspergillus fumigatus,746128.0
6331,N,,,,In vitro antifungal activity against Aspergillus fumigatus 48238E,Expert,,,,,50416,BAO_0000218,F,,16717,,Aspergillus fumigatus,746128.0
6332,N,,,,In vitro antifungal activity against Aspergillus fumigatus 48238E,Expert,,,,,50416,BAO_0000218,F,,16717,,Aspergillus fumigatus,746128.0
6333,N,,,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,Intermediate,,,,,50296,BAO_0000218,F,,8117,,Actinomyces naeslundii,1655.0
6334,N,,,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,Intermediate,,,,,50366,BAO_0000218,F,,8117,,Actinomyces viscosus,1656.0
6335,N,,,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),Intermediate,,,,,50535,BAO_0000218,F,,15472,,Acanthocheilonema viteae,6277.0
6336,N,,,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),Intermediate,,,,,50535,BAO_0000218,F,,15472,,Acanthocheilonema viteae,6277.0
6337,N,,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,Intermediate,,,,,50169,BAO_0000218,F,,16443,,Aggregatibacter actinomycetemcomitans,714.0
6338,N,,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,Intermediate,,,,,50169,BAO_0000218,F,,16443,,Aggregatibacter actinomycetemcomitans,714.0
6339,N,,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,Intermediate,,,,,50169,BAO_0000218,F,,16443,,Aggregatibacter actinomycetemcomitans,714.0
6340,N,,646.0,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,Homo sapiens,9606.0
6341,N,,646.0,,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,Homo sapiens,9606.0
6342,N,,646.0,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,Intermediate,,A549,,,80682,BAO_0000219,F,,16381,,Homo sapiens,9606.0
6343,N,,646.0,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,Intermediate,,A549,,,80682,BAO_0000219,F,,16381,,Homo sapiens,9606.0
6344,N,,646.0,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,Intermediate,,A549,,,80682,BAO_0000219,F,,16381,,Homo sapiens,9606.0
6345,N,,646.0,,GI values against A549 cells (lung cancer),Intermediate,,A549,,,80682,BAO_0000219,F,,16381,,Homo sapiens,9606.0
6346,N,,646.0,,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,Homo sapiens,9606.0
6347,N,,646.0,,Inhibitory activity against A549 human adenocarcinoma,Intermediate,,A549,,,80682,BAO_0000219,F,,16325,,Homo sapiens,9606.0
6348,N,,646.0,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,Intermediate,,A549,,,80682,BAO_0000218,F,,10708,,Homo sapiens,9606.0
6349,N,,646.0,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,Intermediate,,A549,,,80682,BAO_0000218,F,,10708,,Homo sapiens,9606.0
6350,N,,646.0,,Inhibitory activity against A549 lung adenocarcinoma cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,17376,,Homo sapiens,9606.0
6351,N,,646.0,,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,Intermediate,,A549,,,80682,BAO_0000219,F,,17376,,Homo sapiens,9606.0
6352,N,,646.0,,Cytotoxicity against human A549 lung cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17488,,Homo sapiens,9606.0
6353,N,,646.0,,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,Intermediate,,A549,,,80682,BAO_0000218,F,,17404,,Homo sapiens,9606.0
6354,N,,646.0,,Growth inhibition of A549 (human lung carcinoma) cell line.,Expert,,A549,,,80682,BAO_0000219,F,,10958,,Homo sapiens,9606.0
6355,N,,646.0,,Effective dose required for inhibitory activity against A549 human tumor cell line.,Expert,,A549,,,80682,BAO_0000219,F,,17099,,Homo sapiens,9606.0
6356,N,,646.0,,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,Intermediate,,A549,,,80682,BAO_0000219,F,,17099,,Homo sapiens,9606.0
6357,N,,646.0,,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,Intermediate,,A549,,,80682,BAO_0000219,F,,4096,,Homo sapiens,9606.0
6358,N,,646.0,,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,Expert,,A549,,,80682,BAO_0000219,F,,4096,,Homo sapiens,9606.0
6359,N,,646.0,,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,Intermediate,,A549,,,80682,BAO_0000219,F,,4096,,Homo sapiens,9606.0
6360,N,,646.0,,In vitro inhibitory activity against A549 tumor cell culture,Intermediate,,A549,,,80682,BAO_0000219,F,,2525,,Homo sapiens,9606.0
6361,N,,646.0,,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,Intermediate,,A549,,,80682,BAO_0000219,F,,2525,,Homo sapiens,9606.0
6362,N,,646.0,,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),Intermediate,,A549,,,80682,BAO_0000219,F,,5302,,Homo sapiens,9606.0
6363,N,,646.0,,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,Intermediate,,A549,,,80682,BAO_0000219,F,,16325,,Homo sapiens,9606.0
6364,N,,646.0,,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,16939,,Homo sapiens,9606.0
6365,N,,646.0,,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,Intermediate,,A549,,,80682,BAO_0000219,F,,17229,,Homo sapiens,9606.0
6366,N,,646.0,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17380,,Homo sapiens,9606.0
6367,N,,646.0,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,Intermediate,,A549,,,80682,BAO_0000219,F,,17380,,Homo sapiens,9606.0
6368,N,,646.0,,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,Intermediate,,A549,,,80682,BAO_0000219,F,,1903,,Homo sapiens,9606.0
6369,N,,646.0,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,Intermediate,,A549,,,80682,BAO_0000219,F,,3838,,Homo sapiens,9606.0
6370,N,,646.0,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,14696,,Homo sapiens,9606.0
6371,N,,646.0,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,Intermediate,,A549,,,80682,BAO_0000219,F,,3838,,Homo sapiens,9606.0
6372,N,,646.0,,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,Intermediate,,A549,,,80682,BAO_0000219,F,,1522,,Homo sapiens,9606.0
6373,N,,646.0,,Tested in vitro for cytotoxicity in A549/ATCC cell lines,Intermediate,,A549,,,80682,BAO_0000219,F,,12400,,Homo sapiens,9606.0
6374,N,,646.0,,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,14696,,Homo sapiens,9606.0
6375,N,,646.0,,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),Intermediate,,A549,,,80682,BAO_0000219,F,,14769,,Homo sapiens,9606.0
6376,N,,646.0,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,Intermediate,,A549,,,80682,BAO_0000219,F,,14696,,Homo sapiens,9606.0
6377,N,,646.0,,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,Intermediate,,A549,,,80682,BAO_0000219,F,,1888,,Homo sapiens,9606.0
6378,N,,646.0,,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,12016,,Homo sapiens,9606.0
6379,N,,646.0,,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,Intermediate,,A549,,,80682,BAO_0000219,F,,6058,,Homo sapiens,9606.0
6380,N,,646.0,,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,17708,,Homo sapiens,9606.0
6381,N,,646.0,,Antitumor activity against A549/ATCC cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,12301,,Homo sapiens,9606.0
6382,N,,646.0,,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,Intermediate,,A549,,,80682,BAO_0000219,F,,11970,,Homo sapiens,9606.0
6383,N,,646.0,,In vitro cytotoxicity against A549/ATCC cell line.,Expert,,A549,,,80682,BAO_0000219,F,,11818,,Homo sapiens,9606.0
6384,N,,646.0,,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,Intermediate,,A549,,,80682,BAO_0000219,F,,12400,,Homo sapiens,9606.0
6385,N,,646.0,,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,Intermediate,,A549,,,80682,BAO_0000219,F,,3381,,Homo sapiens,9606.0
6386,N,,646.0,,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,17376,,Homo sapiens,9606.0
6387,N,,646.0,,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,Intermediate,,A549,,,80682,BAO_0000219,F,,10708,,Homo sapiens,9606.0
6388,U,,,,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,Autocuration,,,,,22226,BAO_0000219,F,,2964,,Homo sapiens,9606.0
6389,U,,,,Compound was tested for oral bioavailability in dogs,Intermediate,,,,,22224,BAO_0000218,A,,5005,In vivo,Canis lupus familiaris,9615.0
6390,N,,,,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,Intermediate,,,,,50588,BAO_0000218,A,,6229,In vivo,Canis lupus familiaris,9615.0
6391,N,,,,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,Intermediate,,,,,50588,BAO_0000218,A,,6229,In vivo,Canis lupus familiaris,9615.0
6392,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,5374,In vivo,Canis lupus familiaris,9615.0
6393,N,,,,Compound was tested for the oral bioavailability in dog; No availability,Intermediate,,,,,50588,BAO_0000218,A,,5374,In vivo,Canis lupus familiaris,9615.0
6394,N,,,,Oral bioavailability in dog (dose 5 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,6265,In vivo,Canis lupus familiaris,9615.0
6395,N,,,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,Intermediate,,,,,50588,BAO_0000218,A,,5654,In vivo,Canis lupus familiaris,9615.0
6396,N,,,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,Intermediate,,,,,50588,BAO_0000218,A,,5654,In vivo,Canis lupus familiaris,9615.0
6397,N,,,,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,16456,In vivo,Canis lupus familiaris,9615.0
6398,N,,,,Oral bioavailability in dog (dose 5 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,5302,In vivo,Canis lupus familiaris,9615.0
6399,N,,,,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),Intermediate,,,,,50588,BAO_0000218,A,,3624,In vivo,Canis lupus familiaris,9615.0
6400,N,,,,Oral bioavailability of active FTIs in dogs,Intermediate,,,,,50588,BAO_0000218,A,,16452,In vivo,Canis lupus familiaris,9615.0
6401,N,,,,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),Intermediate,,,,,50588,BAO_0000218,A,,5802,In vivo,Canis lupus familiaris,9615.0
6402,N,,,,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,Expert,,,,,50588,BAO_0000218,A,,3598,In vivo,Canis lupus familiaris,9615.0
6403,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,17839,In vivo,Canis lupus familiaris,9615.0
6404,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,6762,In vivo,Canis lupus familiaris,9615.0
6405,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,6821,In vivo,Canis lupus familiaris,9615.0
6406,N,,,,Oral bioavailability of compound was determined in dog; Not tested,Intermediate,,,,,50588,BAO_0000218,A,,6821,In vivo,Canis lupus familiaris,9615.0
6407,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,5210,In vivo,Canis lupus familiaris,9615.0
6408,N,,,,Oral bioavailability (10 mg/kg) was determined in dog,Intermediate,,,,,50588,BAO_0000218,A,,6227,In vivo,Canis lupus familiaris,9615.0
6409,N,,,,Oral bioavailability,Intermediate,,,,,50588,BAO_0000218,A,,761,In vivo,Canis lupus familiaris,9615.0
6410,N,,,,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),Intermediate,,,,,50588,BAO_0000218,A,,761,In vivo,Canis lupus familiaris,9615.0
6411,N,,,,Oral bioavailability administered in solution in rats,Intermediate,,,,,50588,BAO_0000218,A,,761,In vivo,Canis lupus familiaris,9615.0
6412,N,,,,Oral bioavailability after 30 mg/kg po dose in Dogs,Intermediate,,,,,50588,BAO_0000218,A,,16907,In vivo,Canis lupus familiaris,9615.0
6413,N,,,,Oral bioavailability at a dose of 1 mg/kg in dogs,Intermediate,,,,,50588,BAO_0000218,A,,5474,In vivo,Canis lupus familiaris,9615.0
6414,N,,,,Oral bioavailability in dog (dose 1 mg/kg p.o.),Intermediate,,,,,50588,BAO_0000218,A,,6535,In vivo,Canis lupus familiaris,9615.0
6415,N,,,,Oral bioavailability in Dog; ND = not determined,Intermediate,,,,,50588,BAO_0000218,A,,6535,In vivo,Canis lupus familiaris,9615.0
6416,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,3352,In vivo,Canis lupus familiaris,9615.0
6417,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,6168,In vivo,Canis lupus familiaris,9615.0
6418,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,5988,In vivo,Canis lupus familiaris,9615.0
6419,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,4942,In vivo,Canis lupus familiaris,9615.0
6420,N,,,,Oral bioavailability in dogs; No data,Intermediate,,,,,50588,BAO_0000218,A,,4942,In vivo,Canis lupus familiaris,9615.0
6421,N,,,,Oral bioavailability measured in dogs,Intermediate,,,,,50588,BAO_0000218,A,,14541,In vivo,Canis lupus familiaris,9615.0
6422,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,4449,In vivo,Canis lupus familiaris,9615.0
6423,N,,,,Oral bioavailability was calculated in dog,Intermediate,,,,,50588,BAO_0000218,A,,6057,In vivo,Canis lupus familiaris,9615.0
6424,N,,,,Oral bioavailability after 0.3 mg/kg po administration in dog,Intermediate,,,,,50588,BAO_0000218,A,,5600,In vivo,Canis lupus familiaris,9615.0
6425,N,,,,Oral bioavailability in dog (i.v. dosing),Intermediate,,,,,50588,BAO_0000218,A,,5542,In vivo,Canis lupus familiaris,9615.0
6426,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,5542,In vivo,Canis lupus familiaris,9615.0
6427,N,,,,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,Intermediate,,,,,50588,BAO_0000218,A,,5546,In vivo,Canis lupus familiaris,9615.0
6428,N,,,,Oral bioavailability in Beagle dogs,Intermediate,,,,,50588,BAO_0000218,A,,4514,In vivo,Canis lupus familiaris,9615.0
6429,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,3624,In vivo,Canis lupus familiaris,9615.0
6430,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,3854,In vivo,Canis lupus familiaris,9615.0
6431,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,5836,In vivo,Canis lupus familiaris,9615.0
6432,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,5940,In vivo,Canis lupus familiaris,9615.0
6433,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,6168,In vivo,Canis lupus familiaris,9615.0
6434,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,6227,In vivo,Canis lupus familiaris,9615.0
6435,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,6251,In vivo,Canis lupus familiaris,9615.0
6436,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,6448,In vivo,Canis lupus familiaris,9615.0
6437,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,6647,In vivo,Canis lupus familiaris,9615.0
6438,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,5940,In vivo,Canis lupus familiaris,9615.0
6439,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,933,In vivo,Canis lupus familiaris,9615.0
6440,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,5210,In vivo,Canis lupus familiaris,9615.0
6441,N,,,,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),Intermediate,,,,,50588,BAO_0000218,A,,6642,In vivo,Canis lupus familiaris,9615.0
6442,N,,,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),Intermediate,,,,,50588,BAO_0000218,A,,6641,In vivo,Canis lupus familiaris,9615.0
6443,N,,,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),Intermediate,,,,,50588,BAO_0000218,A,,6642,In vivo,Canis lupus familiaris,9615.0
6444,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,5472,In vivo,Canis lupus familiaris,9615.0
6445,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,5985,In vivo,Canis lupus familiaris,9615.0
6446,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,15660,In vivo,Canis lupus familiaris,9615.0
6447,N,,,,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),Intermediate,,,,,50588,BAO_0000218,A,,5530,In vivo,Canis lupus familiaris,9615.0
6448,N,,,,Oral bioavailability in dog (dose 1 mg/kg i.v.),Intermediate,,,,,50588,BAO_0000218,A,,5530,In vivo,Canis lupus familiaris,9615.0
6449,N,,,,Oral bioavailability (F) in dogs,Intermediate,,,,,50588,BAO_0000218,A,,6305,In vivo,Canis lupus familiaris,9615.0
6450,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,5210,In vivo,Canis lupus familiaris,9615.0
6451,N,,,,Bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,5238,In vivo,Canis lupus familiaris,9615.0
6452,N,,,,Oral bioavailability in dog (dose 10 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,5668,In vivo,Canis lupus familiaris,9615.0
6453,N,,,,Oral bioavailability after peroral administration at 5 mpk in Dog,Intermediate,,,,,50588,BAO_0000218,A,,5668,In vivo,Canis lupus familiaris,9615.0
6454,N,,,,Oral bioavailability in dog (dose 5 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,5668,In vivo,Canis lupus familiaris,9615.0
6455,N,,,,Oral bioavailability in dog (dose 10 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,6084,In vivo,Canis lupus familiaris,9615.0
6456,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,Intermediate,,CCRF S-180,,2113.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6457,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,Intermediate,,CCRF S-180,,2113.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6458,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,Intermediate,,CCRF S-180,,2107.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6459,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,Intermediate,,CCRF S-180,,2107.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6460,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,Intermediate,,CCRF S-180,,2107.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6461,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,Intermediate,,CCRF S-180,,2107.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6462,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,Intermediate,,CCRF S-180,,2107.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6463,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,Intermediate,,CCRF S-180,,2048.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6464,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,Intermediate,,CCRF S-180,,2048.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6465,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,Intermediate,,CCRF S-180,,2048.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6466,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,Intermediate,,CCRF S-180,,2048.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6467,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,Intermediate,,CCRF S-180,,2048.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6468,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6469,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6470,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6471,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6472,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6473,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,Intermediate,,CCRF S-180,,2106.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6474,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,Intermediate,,CCRF S-180,,2106.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6475,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,Intermediate,,CCRF S-180,,2106.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6476,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,Intermediate,,CCRF S-180,,2106.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6477,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,Intermediate,,CCRF S-180,,2106.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6478,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6479,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6480,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6481,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6482,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6483,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6484,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6485,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6486,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6487,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6488,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,Intermediate,,CCRF S-180,,948.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6489,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,Intermediate,,CCRF S-180,,948.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6490,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,Intermediate,,CCRF S-180,,948.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6491,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,Intermediate,,CCRF S-180,,948.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6492,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,Intermediate,,CCRF S-180,,948.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6493,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,Intermediate,,CCRF S-180,,2107.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6494,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,Intermediate,,CCRF S-180,,2107.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6495,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,Intermediate,,CCRF S-180,,2107.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6496,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,Intermediate,,CCRF S-180,,2107.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6497,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,Intermediate,,CCRF S-180,,2107.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6498,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,Intermediate,,CCRF S-180,,2048.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6499,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,Intermediate,,CCRF S-180,,2048.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6500,N,,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,Intermediate,,,,,50067,BAO_0000218,F,,12269,,aeinetobacter anitrotap,107673.0
6501,N,,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,Intermediate,,,,,50067,BAO_0000218,F,,12269,,Acinetobacter calcoaceticus subsp. anitratus,107673.0
6502,N,,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,Intermediate,,,,,50067,BAO_0000218,F,,12269,,Acinetobacter calcoaceticus subsp. anitratus,107673.0
6503,N,,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,Intermediate,,,,,50067,BAO_0000218,F,,12269,,aeinetobacter anitrotap,107673.0
6504,N,,,,Activity against Acinetobacter calcoaceticus (AC54),Intermediate,,,,,50192,BAO_0000218,F,,10624,,Acinetobacter calcoaceticus,471.0
6505,N,,,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,Intermediate,,,,,50714,BAO_0000218,F,,17216,,Anolis carolinensis,28377.0
6506,N,,,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,Intermediate,,,,,50714,BAO_0000218,F,,17216,,Anolis carolinensis,28377.0
6507,N,,,,Chlorohexidine coefficient for Actinomyces naeslundii 631,Intermediate,,,,,50296,BAO_0000218,F,,9560,,Actinomyces naeslundii,1655.0
6508,N,,,,Chlorohexidine coefficient for Actinomyces naeslundii B74,Intermediate,,,,,50296,BAO_0000218,F,,9560,,Actinomyces naeslundii,1655.0
6509,N,,,,Chlorohexidine coefficient for Actinomyces naeslundii N/3,Intermediate,,,,,50296,BAO_0000218,F,,9560,,Actinomyces naeslundii,1655.0
6510,N,,,,Chlorohexidine coefficient for Actinomyces naeslundii N/9,Intermediate,,,,,50296,BAO_0000218,F,,9560,,Actinomyces naeslundii,1655.0
6511,N,,,,Plaque bactericidal index against Actinomyces naeslundii 631,Intermediate,,,,,50296,BAO_0000218,F,,9560,,Actinomyces naeslundii,1655.0
6512,N,,,,Plaque bactericidal index against Actinomyces naeslundii N/9,Intermediate,,,,,50296,BAO_0000218,F,,9560,,Actinomyces naeslundii,1655.0
6513,N,,,,Plaque bactericidal index against Actinomyces naeslundii B74,Intermediate,,,,,50296,BAO_0000218,F,,9560,,Actinomyces naeslundii,1655.0
6514,N,,,,Plaque bactericidal index against Actinomyces naeslundii N/3,Intermediate,,,,,50296,BAO_0000218,F,,9560,,Actinomyces naeslundii,1655.0
6515,N,,,,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,Intermediate,,,,,50056,BAO_0000218,F,,114,,Artemia salina,85549.0
6516,N,,,,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",Intermediate,,,,,50056,BAO_0000218,F,,114,,Artemia salina,85549.0
6517,N,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,Intermediate,,,,,50532,BAO_0000218,F,,10841,,Ascaris suum,6253.0
6518,N,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,Intermediate,,,,,50532,BAO_0000218,F,,10841,,Ascaris suum,6253.0
6519,N,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,Intermediate,,,,,50532,BAO_0000218,F,,10841,,Ascaris suum,6253.0
6520,N,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,Intermediate,,,,,50532,BAO_0000218,F,,10841,,Ascaris suum,6253.0
6521,N,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,Intermediate,,,,,50532,BAO_0000218,F,,10841,,Ascaris suum,6253.0
6522,N,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,Intermediate,,,,,50532,BAO_0000218,F,,10841,,Ascaris suum,6253.0
6523,N,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,Intermediate,,,,,50532,BAO_0000218,F,,10841,,Ascaris suum,6253.0
6524,N,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,Intermediate,,,,,50532,BAO_0000218,F,,10841,,Ascaris suum,6253.0
6525,N,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,Intermediate,,,,,50532,BAO_0000218,F,,10841,,Ascaris suum,6253.0
6526,N,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,Intermediate,,,,,50532,BAO_0000218,F,,10841,,Ascaris suum,6253.0
6527,N,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,Intermediate,,,,,50532,BAO_0000218,F,,10841,,Ascaris suum,6253.0
6528,N,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,Intermediate,,,,,50532,BAO_0000218,F,,10841,,Ascaris suum,6253.0
6529,N,,,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,Intermediate,,,,,50366,BAO_0000218,F,,8117,,Actinomyces viscosus,1656.0
6530,N,,,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,Intermediate,,,,,50366,BAO_0000218,F,,8117,,Actinomyces viscosus,1656.0
6531,N,,,,Chlorohexidine coefficient for Actinomyces viscosus 8A06,Intermediate,,,,,50366,BAO_0000218,F,,9560,,Actinomyces viscosus,1656.0
6532,N,,,,Chlorohexidine coefficient for Actinomyces viscosus M-100,Expert,,,,,50366,BAO_0000218,F,,9560,,Actinomyces viscosus,1656.0
6533,N,,,,Chlorohexidine coefficient for Actinomyces viscosus M-626,Intermediate,,,,,50366,BAO_0000218,F,,9560,,Actinomyces viscosus,1656.0
6534,N,,,,Chlorohexidine coefficient for Actinomyces viscosus T14V,Intermediate,,,,,50366,BAO_0000218,F,,9560,,Actinomyces viscosus,1656.0
6535,N,,,,Plaque bactericidal index against Actinomyces viscosus 8A06,Intermediate,,,,,50366,BAO_0000218,F,,9560,,Actinomyces viscosus,1656.0
6536,N,,,,Plaque bactericidal index against Actinomyces viscosus M-100,Intermediate,,,,,50366,BAO_0000218,F,,9560,,Actinomyces viscosus,1656.0
6537,N,,,,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,Expert,,,,,50366,BAO_0000218,F,,9560,,Actinomyces viscosus,1656.0
6538,N,,,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",Intermediate,,,,,50366,BAO_0000218,F,,9560,,Actinomyces viscosus,1656.0
6539,N,,,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",Intermediate,,,,,50366,BAO_0000218,F,,9560,,Actinomyces viscosus,1656.0
6540,N,,,,Plaque bactericidal index against Actinomyces viscosus 626,Intermediate,,,,,50366,BAO_0000218,F,,9560,,Actinomyces viscosus,1656.0
6541,N,,,,Plaque bactericidal index against Actinomyces viscosus T14V,Intermediate,,,,,50366,BAO_0000218,F,,9560,,Actinomyces viscosus,1656.0
6542,N,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,Intermediate,,,,,50535,BAO_0000218,F,,10986,,Acanthocheilonema viteae,6277.0
6543,N,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,Intermediate,,,,,50535,BAO_0000218,F,,10986,,Acanthocheilonema viteae,6277.0
6544,N,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,Intermediate,,,,,50535,BAO_0000218,F,,10986,,Acanthocheilonema viteae,6277.0
6545,N,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,Intermediate,,,,,50535,BAO_0000218,F,,10986,,Acanthocheilonema viteae,6277.0
6546,N,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,Intermediate,,,,,50535,BAO_0000218,F,,10986,,Acanthocheilonema viteae,6277.0
6547,N,,165.0,,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,Intermediate,,A673,,,80023,BAO_0000219,F,,10708,,Homo sapiens,9606.0
6548,N,,645.0,,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,Intermediate,,A704,,,80661,BAO_0000219,F,,10708,,Homo sapiens,9606.0
6549,U,,,,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,Autocuration,,,,,22226,BAO_0000219,F,,416,,Rattus norvegicus,10116.0
6550,N,,625.0,,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,Intermediate,,A9,,,80024,BAO_0000219,F,,14354,,Mus musculus,10090.0
6551,N,,625.0,,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,Intermediate,,A9,,,80024,BAO_0000219,F,,14354,,Mus musculus,10090.0
6552,N,,625.0,,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,Intermediate,,A9,,,80024,BAO_0000219,F,,5116,,Homo sapiens,9606.0
6553,N,,625.0,,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,Intermediate,,A9,,,80024,BAO_0000219,F,,5116,,Homo sapiens,9606.0
6554,N,,874.0,,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,Expert,,Human ovarian carcinoma cell line,,,81037,BAO_0000219,F,,15694,,Homo sapiens,9606.0
6555,N,,625.0,,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",Expert,,A9,,,80024,BAO_0000219,F,,13038,,Mus musculus,10090.0
6556,N,,625.0,,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,Expert,,A9,,,80024,BAO_0000219,F,,13038,,Mus musculus,10090.0
6557,N,,625.0,,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,Expert,,A9,,,80024,BAO_0000219,F,,10923,,Mus musculus,10090.0
6558,N,,625.0,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,Intermediate,,A9,,,80024,BAO_0000219,F,,10923,,Mus musculus,10090.0
6559,N,,625.0,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,Intermediate,,A9,,,80024,BAO_0000219,F,,10923,,Mus musculus,10090.0
6560,H,,,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",Expert,,,,,10649,BAO_0000019,F,,10923,,,
6561,N,,625.0,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,Intermediate,,A9,,,80024,BAO_0000219,F,,10923,,Mus musculus,10090.0
6562,N,,625.0,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,Intermediate,,A9,,,80024,BAO_0000219,F,,10923,,Mus musculus,10090.0
6563,N,,975.0,,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,Intermediate,,AA6,,,80663,BAO_0000219,F,,8158,,Cricetulus griseus,10029.0
6564,U,,,,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,Autocuration,,,,,22226,BAO_0000219,F,,15494,,Homo sapiens,9606.0
6565,U,,,,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",Autocuration,,,,,22226,BAO_0000219,F,,15494,,Homo sapiens,9606.0
6566,N,,974.0,,Anti -HIV activity was measured against AA5/HIV-1(IIIB),Intermediate,,AA5,,,80662,BAO_0000219,F,,12348,,Homo sapiens,9606.0
6567,N,,974.0,,Cytotoxicity was measured against AA5/HIV-1(IIIB),Intermediate,,AA5,,,80662,BAO_0000219,F,,12348,,Homo sapiens,9606.0
6568,N,,974.0,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,Intermediate,,AA5,,,80662,BAO_0000219,F,,2726,,Homo sapiens,9606.0
6569,N,,379.0,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,Intermediate,,U-937,,,80566,BAO_0000219,F,,2726,,Homo sapiens,9606.0
6570,N,,274.0,,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,Intermediate,,UV4,,,80578,BAO_0000219,F,,10747,,Cricetulus griseus,10029.0
6571,N,,185.0,,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",Expert,,CHO-AA8,,,80089,BAO_0000219,F,,11005,,Cricetulus griseus,10029.0
6572,N,,185.0,,Average intracellular compound concentration when the hypoxic SER=1.6,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,12687,,Cricetulus griseus,10029.0
6573,N,,185.0,,Average intracellular compound concentration when the hypoxic SER=1.6.,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,12687,,Cricetulus griseus,10029.0
6574,N,,185.0,,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,12687,,Cricetulus griseus,10029.0
6575,N,,185.0,,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,12687,,Cricetulus griseus,10029.0
6576,N,,185.0,,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,12687,,Cricetulus griseus,10029.0
6577,N,,185.0,,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,13436,,Cricetulus griseus,10029.0
6578,N,,185.0,,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,13435,,Cricetulus griseus,10029.0
6579,N,,185.0,,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,13302,,Cricetulus griseus,10029.0
6580,N,,185.0,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,12687,,Cricetulus griseus,10029.0
6581,N,,185.0,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,Intermediate,,CHO-AA8,,,80089,BAO_0000219,A,,12687,,Cricetulus griseus,10029.0
6582,N,,185.0,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,Intermediate,,CHO-AA8,,,80089,BAO_0000219,A,,12687,,Cricetulus griseus,10029.0
6583,N,,185.0,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,Expert,,CHO-AA8,,,80089,BAO_0000219,A,,12878,,Cricetulus griseus,10029.0
6584,N,,185.0,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,Intermediate,,CHO-AA8,,,80089,BAO_0000219,A,,12878,,Cricetulus griseus,10029.0
6585,N,,185.0,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,Expert,,CHO-AA8,,,80089,BAO_0000219,F,,14367,,Cricetulus griseus,10029.0
6586,N,,185.0,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,14367,,Cricetulus griseus,10029.0
6587,N,,185.0,,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,Expert,,CHO-AA8,,,80089,BAO_0000219,F,,12398,,hampster,36483.0
6588,N,,185.0,,Aerobic growth inhibition in Chinese hamster cell line AA8,Expert,,CHO-AA8,,,80089,BAO_0000219,F,,12878,,Cricetulus griseus,10029.0
6589,N,,185.0,,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,Expert,,CHO-AA8,,,80089,BAO_0000219,F,,13820,,Cricetulus griseus,10029.0
6590,N,,185.0,,Inhibition of growth under aerobic conditions in AA8 cells,Expert,,CHO-AA8,,,80089,BAO_0000219,F,,13436,,Cricetulus griseus,10029.0
6591,N,,,,Oral bioavailability in dog (dose 10 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,6084,In vivo,Canis lupus familiaris,9615.0
6592,N,,,,Oral bioavailability in dog at 10 mg/kg of the compound,Intermediate,,,,,50588,BAO_0000218,A,,5711,In vivo,Canis lupus familiaris,9615.0
6593,N,,,,Oral bioavailability in dog (dose 5 uM/kg),Intermediate,,,,,50588,BAO_0000218,A,,4353,In vivo,Canis lupus familiaris,9615.0
6594,N,,,,Oral bioavailability in dog (dose 5 uM/kg),Intermediate,,,,,50588,BAO_0000218,A,,4353,In vivo,Canis lupus familiaris,9615.0
6595,N,,,,Oral bioavailability in dog (mongrel),Intermediate,,,,,50588,BAO_0000218,A,,17800,In vivo,Canis lupus familiaris,9615.0
6596,N,,,,Oral bioavailability in dog (dose 10 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,3994,In vivo,Canis lupus familiaris,9615.0
6597,N,,,,Oral bioavailability in dog (dose 10 mg/kg),Intermediate,,,,,50588,BAO_0000218,F,,3994,In vivo,Canis lupus familiaris,9615.0
6598,N,,,,Bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,5145,In vivo,Canis lupus familiaris,9615.0
6599,N,,,,Bioavailability in dog (dose 1 mg/kg i.v.),Intermediate,,,,,50588,BAO_0000218,A,,16452,In vivo,Canis lupus familiaris,9615.0
6600,N,,,,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),Intermediate,,,,,50588,BAO_0000218,A,,16452,In vivo,Canis lupus familiaris,9615.0
6601,N,,,,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,5983,In vivo,Canis lupus familiaris,9615.0
6602,N,,,,Bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,4273,In vivo,Canis lupus familiaris,9615.0
6603,N,,,,Bioavailability in dog (dose 3-10 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,12500,In vivo,Canis lupus familiaris,9615.0
6604,N,,,,The compound was tested for bioavailability of compound in plasma of dog; Complete,Intermediate,,,,1969.0,50588,BAO_0000218,A,,12500,In vivo,Canis lupus familiaris,9615.0
6605,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,3639,In vivo,Canis lupus familiaris,9615.0
6606,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,3880,In vivo,Canis lupus familiaris,9615.0
6607,N,,,,Bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,4838,In vivo,Canis lupus familiaris,9615.0
6608,N,,,,oral bioavailability was measured in dogs,Intermediate,,,,,50588,BAO_0000218,A,,15600,In vivo,Canis lupus familiaris,9615.0
6609,N,,,,Compound was tested for plasma protein binding in dog; Not determined,Intermediate,,,,,50588,BAO_0000218,A,,17248,,Canis lupus familiaris,9615.0
6610,N,,,,Compound was tested for plasma protein binding of dog,Intermediate,,,,,50588,BAO_0000218,A,,17248,,Canis lupus familiaris,9615.0
6611,N,,,,Compound was tested for plasma protein binding of dog; Not determined,Intermediate,,,,,50588,BAO_0000218,A,,17248,,Canis lupus familiaris,9615.0
6612,N,,,,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,Intermediate,,,,,50588,BAO_0000218,A,,17443,,Canis lupus familiaris,9615.0
6613,N,,,,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,Intermediate,,,,,50588,BAO_0000218,A,,4186,In vivo,Canis lupus familiaris,9615.0
6614,N,,,,Half life was determined,Intermediate,,,,,50588,BAO_0000218,A,,3749,,Canis lupus familiaris,9615.0
6615,N,,,,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,3249,In vivo,Canis lupus familiaris,9615.0
6616,N,,,,Half life was evaluated in dog,Intermediate,,,,,50588,BAO_0000218,A,,3022,,Canis lupus familiaris,9615.0
6617,N,,,,Half life was determined,Intermediate,,,,,50588,BAO_0000218,A,,3749,,Canis lupus familiaris,9615.0
6618,N,,,,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),Intermediate,,,,,50588,BAO_0000218,A,,2517,In vivo,Canis lupus familiaris,9615.0
6619,N,,,,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),Intermediate,,,,948.0,50588,BAO_0000218,A,,2517,In vivo,Canis lupus familiaris,9615.0
6620,N,,,,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),Intermediate,,,,2113.0,50588,BAO_0000218,A,,2517,In vivo,Canis lupus familiaris,9615.0
6621,N,,,,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),Intermediate,,,,2107.0,50588,BAO_0000218,A,,2517,In vivo,Canis lupus familiaris,9615.0
6622,N,,,,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),Intermediate,,,,2048.0,50588,BAO_0000218,A,,2517,In vivo,Canis lupus familiaris,9615.0
6623,N,,,,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),Intermediate,,,,2106.0,50588,BAO_0000218,A,,2517,In vivo,Canis lupus familiaris,9615.0
6624,N,,,,LogP in dog,Intermediate,,,,,50588,BAO_0000218,A,,3639,,Canis lupus familiaris,9615.0
6625,N,,,,Partition coefficient (logP),Intermediate,,,,,50588,BAO_0000218,A,,6227,,Canis lupus familiaris,9615.0
6626,N,,,,Partition coefficient in dog,Intermediate,,,,,50588,BAO_0000218,A,,6227,,Canis lupus familiaris,9615.0
6627,N,,,,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,Intermediate,,,,,50588,BAO_0000218,A,,17764,In vivo,Canis lupus familiaris,9615.0
6628,N,,,,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),Intermediate,,,,,50588,BAO_0000218,A,,4809,In vivo,Canis lupus familiaris,9615.0
6629,N,,,,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,Intermediate,,,,,50588,BAO_0000218,A,,5600,,Canis lupus familiaris,9615.0
6630,N,,,,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),Intermediate,,,,,50588,BAO_0000218,A,,14294,,Canis lupus familiaris,9615.0
6631,N,,,,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),Intermediate,,,,,50588,BAO_0000218,A,,14294,,Canis lupus familiaris,9615.0
6632,N,,,,Metabolism of compound in dog S9 microsomes; Trace,Intermediate,,,,,50588,BAO_0000218,A,,14294,,Canis lupus familiaris,9615.0
6633,N,,,,In vitro metabolic potential in dog liver microsomes,Intermediate,,,,2107.0,50588,BAO_0000218,A,,6251,,Canis lupus familiaris,9615.0
6634,N,,,,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,Intermediate,,,,,50588,BAO_0000218,A,,3748,In vivo,Canis lupus familiaris,9615.0
6635,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,2713,In vivo,Canis lupus familiaris,9615.0
6636,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,6512,In vivo,Canis lupus familiaris,9615.0
6637,N,,,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,,,,,50588,BAO_0000218,A,,6679,In vivo,Canis lupus familiaris,9615.0
6638,N,,,,The compound was tested for bioavailability in dogs,Intermediate,,,,,50588,BAO_0000218,A,,3749,In vivo,Canis lupus familiaris,9615.0
6639,N,,,,The compound was tested for oral bioavailability in dogs,Intermediate,,,,,50588,BAO_0000218,A,,3749,In vivo,Canis lupus familiaris,9615.0
6640,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,6742,In vivo,Canis lupus familiaris,9615.0
6641,N,,,,Compound was tested for percent protein binding (PB) in dog,Intermediate,,,,,50588,BAO_0000218,A,,6227,,Canis lupus familiaris,9615.0
6642,N,,,,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,Intermediate,,,,,50588,BAO_0000218,A,,6874,,Canis lupus familiaris,9615.0
6643,N,,,,Compound was evaluated for plasma clearance.,Intermediate,,,,1969.0,50588,BAO_0000218,A,,2877,In vivo,Canis lupus familiaris,9615.0
6644,N,,,,The compound was tested for plasma clearance in dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,12500,In vivo,Canis lupus familiaris,9615.0
6645,N,,,,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,12500,In vivo,Canis lupus familiaris,9615.0
6646,N,,,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,4709,,Canis lupus familiaris,9615.0
6647,N,,,,In vitro relative rate of metabolism was determined in dog liver microsomes,Intermediate,,,,2107.0,50588,BAO_0000218,A,,5542,,Canis lupus familiaris,9615.0
6648,N,,,,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,Intermediate,,,,,50588,BAO_0000218,A,,17594,In vivo,Canis lupus familiaris,9615.0
6649,N,,,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,Intermediate,,,,,50588,BAO_0000218,A,,2652,In vivo,Canis lupus familiaris,9615.0
6650,N,,,,Half life after intravenous administration in dogs at 1.2 uM/kg,Intermediate,,,,,50588,BAO_0000218,A,,17764,In vivo,Canis lupus familiaris,9615.0
6651,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,Intermediate,,CCRF S-180,,2048.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6652,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,Intermediate,,CCRF S-180,,2048.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6653,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,Intermediate,,CCRF S-180,,2048.0,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6654,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6655,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6656,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6657,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6658,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,Mus musculus,10090.0
6659,N,,,,C2 in brain of mice at the oral dose of 50 mg/kg,Intermediate,,,,955.0,50594,BAO_0000218,A,,17641,,Mus musculus,10090.0
6660,N,,,,C2 in kidney of mice at the oral dose of 50 mg/kg,Intermediate,,,,2113.0,50594,BAO_0000218,A,,17641,,Mus musculus,10090.0
6661,N,,,,C2 in liver of mice at the oral dose of 50 mg/kg,Intermediate,,,,2107.0,50594,BAO_0000218,A,,17641,,Mus musculus,10090.0
6662,N,,,,C2 in lungs of mice at the oral dose of 50 mg/kg,Intermediate,,,,2048.0,50594,BAO_0000218,A,,17641,,Mus musculus,10090.0
6663,N,,,,C2 in spleen of mice at the oral dose of 50 mg/kg,Intermediate,,,,2106.0,50594,BAO_0000218,A,,17641,,Mus musculus,10090.0
6664,N,,,,Plasma clearance in mouse,Intermediate,,,,,50594,BAO_0000218,A,,17852,In vivo,Mus musculus,10090.0
6665,N,,,,Clearance of compound after intravenous administration in mice at 24 uM/kg,Intermediate,,,,,50594,BAO_0000218,A,,17764,In vivo,Mus musculus,10090.0
6666,N,,,,Clearance from mouse blood following i.v. administration of 10 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,17837,In vivo,Mus musculus,10090.0
6667,N,,,,Clearance was evaluated in mice after intravenous administration,Intermediate,,,,,50594,BAO_0000218,A,,2675,In vivo,Mus musculus,10090.0
6668,N,,,,Clearance was evaluated in mice after oral administration,Intermediate,,,,,50594,BAO_0000218,A,,2675,In vivo,Mus musculus,10090.0
6669,N,,,,Pharmacokinetic property (Plasma clearance) was measured in mouse,Intermediate,,,,,50594,BAO_0000218,A,,4239,In vivo,Mus musculus,10090.0
6670,N,,,,Plasma clearance of compound was determined at 40 mg/Kg,Intermediate,,,,,50594,BAO_0000218,A,,17753,In vivo,Mus musculus,10090.0
6671,N,,,,Plasma clearance of at 24 mg/Kg,Intermediate,,,,,50594,BAO_0000218,A,,17753,In vivo,Mus musculus,10090.0
6672,N,,,,Plasma clearance at 24 mg/Kg,Intermediate,,,,,50594,BAO_0000218,A,,17753,In vivo,Mus musculus,10090.0
6673,N,,,,Plasma clearance at 5 mg/Kg,Intermediate,,,,,50594,BAO_0000218,A,,17753,In vivo,Mus musculus,10090.0
6674,N,,,,Plasma clearance in mice,Intermediate,,,,,50594,BAO_0000218,A,,5727,In vivo,Mus musculus,10090.0
6675,N,,,,Plasma clearance value upon iv administration in mouse,Intermediate,,,,,50594,BAO_0000218,A,,2862,In vivo,Mus musculus,10090.0
6676,N,,,,Total plasma clearance in mice,Intermediate,,,,1969.0,50594,BAO_0000218,A,,5980,In vivo,Mus musculus,10090.0
6677,N,,,,Clearance in mouse,Intermediate,,,,,50594,BAO_0000218,A,,17592,In vivo,Mus musculus,10090.0
6678,N,,,,Clearance value was determined,Intermediate,,,,,50594,BAO_0000218,A,,17718,In vivo,Mus musculus,10090.0
6679,N,,,,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,,,,,50594,BAO_0000218,A,,16597,In vivo,Mus musculus,10090.0
6680,U,,,,Calculated partition coefficient (clogP),Intermediate,,,,,22229,BAO_0000100,P,,17384,,,
6681,N,,,,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,6062,In vivo,Mus musculus,10090.0
6682,N,,,,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,17734,In vivo,Mus musculus,10090.0
6683,N,,,,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Intermediate,,,,,50594,BAO_0000218,A,,6348,In vivo,Mus musculus,10090.0
6684,N,,,,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,5969,In vivo,Mus musculus,10090.0
6685,N,,,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,5969,In vivo,Mus musculus,10090.0
6686,N,,,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,Intermediate,,,,,50594,BAO_0000218,A,,5969,In vivo,Mus musculus,10090.0
6687,N,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,Intermediate,,,,,50594,BAO_0000218,A,,16597,In vivo,Mus musculus,10090.0
6688,N,,,,Cmax after oral administration at 30 mg/kg in ICR mouse,Intermediate,,,,,50594,BAO_0000218,A,,5781,In vivo,Mus musculus,10090.0
6689,N,,,,Cmax after peroral administration in mice at 2.4 uM/kg,Intermediate,,,,,50594,BAO_0000218,A,,17764,In vivo,Mus musculus,10090.0
6690,N,,,,Cmax in brain of mice at the oral dose of 50 mg/kg,Intermediate,,,,955.0,50594,BAO_0000218,A,,17641,In vivo,Mus musculus,10090.0
6691,N,,,,Cmax in kidney of mice at the oral dose of 50 mg/kg,Intermediate,,,,2113.0,50594,BAO_0000218,A,,17641,In vivo,Mus musculus,10090.0
6692,N,,,,Cmax in liver of mice at the oral dose of 50 mg/kg,Intermediate,,,,2107.0,50594,BAO_0000218,A,,17641,In vivo,Mus musculus,10090.0
6693,N,,,,Cmax in lungs of mice at the oral dose of 50 mg/kg,Intermediate,,,,2048.0,50594,BAO_0000218,A,,17641,In vivo,Mus musculus,10090.0
6694,N,,,,Cmax in mice at 18 uM/kg i.p. administration,Intermediate,,,,,50594,BAO_0000218,F,,17764,In vivo,Mus musculus,10090.0
6695,N,,,,Cmax in mice at 23 uM/kg i.v. administration,Intermediate,,,,,50594,BAO_0000218,F,,17764,In vivo,Mus musculus,10090.0
6696,N,,,,Cmax in mice at 24 uM/kg i.p. administration,Intermediate,,,,,50594,BAO_0000218,F,,17764,In vivo,Mus musculus,10090.0
6697,N,,,,Cmax in mice at 25 uM/kg i.p. administration,Intermediate,,,,,50594,BAO_0000218,F,,17764,In vivo,Mus musculus,10090.0
6698,N,,,,Cmax in mice at 26 uM/kg i.p. administration,Intermediate,,,,,50594,BAO_0000218,F,,17764,In vivo,Mus musculus,10090.0
6699,N,,,,Cmax in spleen of mice at the oral dose of 50 mg/kg,Intermediate,,,,2106.0,50594,BAO_0000218,A,,17641,In vivo,Mus musculus,10090.0
6700,N,,,,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,,,,,50594,BAO_0000218,A,,16597,In vivo,Mus musculus,10090.0
6701,N,,,,Cmax value at a dose of 10 mg/kg peroral administration in mice.,Intermediate,,,,,50594,BAO_0000218,A,,16597,In vivo,Mus musculus,10090.0
6702,N,,,,Cmax value was determined,Intermediate,,,,,50594,BAO_0000218,A,,5727,In vivo,Mus musculus,10090.0
6703,N,,,,Cmax value in IRC mice,Intermediate,,,,,50594,BAO_0000218,A,,5951,In vivo,Mus musculus,10090.0
6704,N,,,,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,Intermediate,,,,,50594,BAO_0000218,A,,5506,In vivo,Mus musculus,10090.0
6705,N,,,,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,Intermediate,,,,,50594,BAO_0000218,A,,5506,In vivo,Mus musculus,10090.0
6706,N,,,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,Intermediate,,,,1969.0,50594,BAO_0000218,A,,14239,In vivo,Mus musculus,10090.0
6707,N,,,,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",Intermediate,,,,1969.0,50594,BAO_0000218,A,,4890,In vivo,Mus musculus,10090.0
6708,N,,,,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,429,In vivo,Mus musculus,10090.0
6709,N,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,Intermediate,,,,,50535,BAO_0000218,F,,10986,,Acanthocheilonema viteae,6277.0
6710,N,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,Intermediate,,,,,50535,BAO_0000218,F,,10986,,Acanthocheilonema viteae,6277.0
6711,N,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,Intermediate,,,,,50535,BAO_0000218,F,,10986,,Acanthocheilonema viteae,6277.0
6712,N,,455.0,,Inhibitory activity against human tumor cell line A0375 melanoma.,Intermediate,,A-375,,,80018,BAO_0000219,F,,13227,,Homo sapiens,9606.0
6713,D,,,,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,Expert,,,,,12512,BAO_0000249,B,Brain membranes,4481,,Rattus norvegicus,10116.0
6714,D,,,,Forskolin-induced cAMP production at human A1 adenosine receptor,Expert,,,,,114,BAO_0000019,F,,16931,,Homo sapiens,9606.0
6715,H,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,Autocuration,,CHO,,,114,BAO_0000219,F,,3850,,,
6716,H,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,Autocuration,,CHO,,,114,BAO_0000219,F,,3850,,,
6717,H,,449.0,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,Expert,,CHO,,,114,BAO_0000219,F,,3850,,,
6718,H,,449.0,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,Expert,,CHO,,,114,BAO_0000219,F,,3850,,,
6719,H,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,Autocuration,,CHO,,,114,BAO_0000219,F,,3850,,,
6720,H,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,Autocuration,,CHO,,,114,BAO_0000219,F,,3850,,,
6721,H,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,Autocuration,,CHO,,,114,BAO_0000219,F,,3850,,,
6722,D,,449.0,,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,Expert,,CHO,,,114,BAO_0000219,F,,3850,,Homo sapiens,9606.0
6723,H,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,Autocuration,,CHO,,,114,BAO_0000219,F,,3850,,,
6724,H,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,Autocuration,,CHO,,,114,BAO_0000219,F,,3850,,,
6725,H,,449.0,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,Expert,,CHO,,,114,BAO_0000219,F,,3850,,,
6726,H,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,Autocuration,,CHO,,,114,BAO_0000219,F,,3850,,,
6727,H,,449.0,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,Expert,,CHO,,,114,BAO_0000219,F,,3850,,,
6728,H,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,Autocuration,,CHO,,,114,BAO_0000219,F,,3850,,,
6729,H,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,Autocuration,,CHO,,,114,BAO_0000219,F,,3850,,,
6730,H,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,Autocuration,,CHO,,,114,BAO_0000219,F,,3850,,,
6731,H,,449.0,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,Expert,,CHO,,,114,BAO_0000219,F,,3850,,,
6732,H,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,Autocuration,,CHO,,,114,BAO_0000219,F,,3850,,,
6733,H,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,Autocuration,,CHO,,,114,BAO_0000219,F,,3850,,,
6734,H,,449.0,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,Expert,,CHO,,,114,BAO_0000219,F,,3850,,,
6735,N,,164.0,,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,Intermediate,,A10,,,80013,BAO_0000219,F,,12680,,Oryctolagus cuniculus,9986.0
6736,U,,164.0,,In vitro potassium channel opening activity in A10 (smooth muscle) cells,Autocuration,,A10,,,22226,BAO_0000219,F,,1313,,Rattus norvegicus,10116.0
6737,U,,164.0,,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,Autocuration,,A10,,,22226,BAO_0000219,F,,1313,,Rattus norvegicus,10116.0
6738,N,,164.0,,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,Intermediate,,A10,,,80013,BAO_0000219,F,,17567,,Rattus norvegicus,10116.0
6739,N,,164.0,,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,Intermediate,,A10,,,80013,BAO_0000219,F,,17567,,Rattus norvegicus,10116.0
6740,N,,164.0,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,Intermediate,,A10,,,80013,BAO_0000219,F,,11819,,Rattus norvegicus,10116.0
6741,N,,185.0,,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,13436,,Cricetulus griseus,10029.0
6742,N,,185.0,,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,12687,,Cricetulus griseus,10029.0
6743,N,,185.0,,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,12651,,Cricetulus griseus,10029.0
6744,N,,185.0,,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,13300,,Cricetulus griseus,10029.0
6745,N,,185.0,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,15296,,Cricetulus griseus,10029.0
6746,N,,185.0,,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,15328,,Cricetulus griseus,10029.0
6747,N,,185.0,,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,13302,,Cricetulus griseus,10029.0
6748,N,,185.0,,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",Expert,,CHO-AA8,,,80089,BAO_0000219,F,,14367,,Cricetulus griseus,10029.0
6749,N,,185.0,,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,Expert,,CHO-AA8,,,80089,BAO_0000219,F,,17002,,Cricetulus griseus,10029.0
6750,N,,185.0,,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,13436,,Cricetulus griseus,10029.0
6751,N,,185.0,,Inhibitory activity against aerobic growth of AA8 cells.,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,13435,,Cricetulus griseus,10029.0
6752,N,,185.0,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,Intermediate,,CHO-AA8,,,80089,BAO_0000219,A,,10503,,Cricetulus griseus,10029.0
6753,N,,185.0,,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,Expert,,CHO-AA8,,,80089,BAO_0000219,F,,10503,,Cricetulus griseus,10029.0
6754,N,,185.0,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,10503,,Cricetulus griseus,10029.0
6755,N,,185.0,,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,Expert,,CHO-AA8,,,80089,BAO_0000219,F,,15090,,Cricetulus griseus,10029.0
6756,N,,185.0,,Cytotoxicity against AA8 cell line,Expert,,CHO-AA8,,,80089,BAO_0000219,F,,10368,,Cricetulus griseus,10029.0
6757,N,,185.0,,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,12651,,Cricetulus griseus,10029.0
6758,N,,185.0,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),Intermediate,,CHO-AA8,,,80089,BAO_0000219,A,,12687,,Cricetulus griseus,10029.0
6759,N,,185.0,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,12687,,Cricetulus griseus,10029.0
6760,N,,185.0,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),Intermediate,,CHO-AA8,,,80089,BAO_0000219,A,,12687,,Cricetulus griseus,10029.0
6761,N,,185.0,,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,1890,,Cricetulus griseus,10029.0
6762,N,,185.0,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,10747,,Cricetulus griseus,10029.0
6763,N,,185.0,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,10747,,Cricetulus griseus,10029.0
6764,U,,,,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),Autocuration,,,,,22224,BAO_0000218,F,,11616,,Cricetulus griseus,10029.0
6765,N,,185.0,,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,Expert,,CHO-AA8,,,80089,BAO_0000219,F,,11616,,Cricetulus griseus,10029.0
6766,U,,185.0,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,3471,,Cricetulus griseus,10029.0
6767,U,,185.0,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,3471,,Cricetulus griseus,10029.0
6768,U,,185.0,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,3471,,Cricetulus griseus,10029.0
6769,U,,185.0,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,3471,,Cricetulus griseus,10029.0
6770,U,,185.0,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,3471,,Cricetulus griseus,10029.0
6771,U,,185.0,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,3471,,Cricetulus griseus,10029.0
6772,U,,185.0,,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,3471,,Cricetulus griseus,10029.0
6773,N,,185.0,,Concentration required to reduce AA8 cell survival by 10%,Expert,,CHO-AA8,,,80089,BAO_0000219,F,,11616,,Cricetulus griseus,10029.0
6774,U,,185.0,,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,2656,,Cricetulus griseus,10029.0
6775,U,,185.0,,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,10518,,Cricetulus griseus,10029.0
6776,U,,185.0,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,10518,,Cricetulus griseus,10029.0
6777,U,,185.0,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,10518,,Cricetulus griseus,10029.0
6778,U,,185.0,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,10518,,Cricetulus griseus,10029.0
6779,U,,185.0,,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,16156,,Cricetulus griseus,10029.0
6780,U,,185.0,,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,2656,,Cricetulus griseus,10029.0
6781,U,,,,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",Autocuration,,,,,22224,BAO_0000019,F,,11005,,Cricetulus griseus,10029.0
6782,U,,185.0,,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,11942,,Cricetulus griseus,10029.0
6783,U,,185.0,,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,2128,,Cricetulus griseus,10029.0
6784,N,,,,Half life period after 15 mg/kg iv dose in Dogs,Intermediate,,,,,50588,BAO_0000218,A,,16907,In vivo,Canis lupus familiaris,9615.0
6785,N,,,,Half life period after 30 mg/kg po dose in Dogs,Intermediate,,,,,50588,BAO_0000218,A,,16907,In vivo,Canis lupus familiaris,9615.0
6786,N,,,,Half life was measured after oral 2b administration (tested in 6 dogs),Intermediate,,,,,50588,BAO_0000218,A,,9579,In vivo,Canis lupus familiaris,9615.0
6787,N,,,,Half life was measured in dog after oral 17b administration,Intermediate,,,,,50588,BAO_0000218,A,,9579,In vivo,Canis lupus familiaris,9615.0
6788,N,,,,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,Intermediate,,,,,50588,BAO_0000218,A,,9579,In vivo,Canis lupus familiaris,9615.0
6789,N,,,,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,Intermediate,,,,,50588,BAO_0000218,A,,9579,In vivo,Canis lupus familiaris,9615.0
6790,N,,,,Tmax value after 15 mg/kg iv dose in Dogs,Intermediate,,,,,50588,BAO_0000218,A,,16907,In vivo,Canis lupus familiaris,9615.0
6791,N,,,,Tmax value after 30 mg/kg po dose in Dogs,Intermediate,,,,,50588,BAO_0000218,A,,16907,In vivo,Canis lupus familiaris,9615.0
6792,N,,,,Compound was evaluated for its half life when administered intravenously in dog,Intermediate,,,,,50588,BAO_0000218,A,,3184,In vivo,Canis lupus familiaris,9615.0
6793,N,,,,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),Intermediate,,,,1969.0,50588,BAO_0000218,A,,5017,In vivo,Canis lupus familiaris,9615.0
6794,N,,,,Elimination Half-life of compound was determined in dog,Intermediate,,,,,50588,BAO_0000218,A,,6821,,Canis lupus familiaris,9615.0
6795,N,,,,Half life of compound in dog following oral administration,Intermediate,,,,,50588,BAO_0000218,A,,17839,In vivo,Canis lupus familiaris,9615.0
6796,N,,,,Half life of compound was determined in dog,Intermediate,,,,,50588,BAO_0000218,A,,17267,,Canis lupus familiaris,9615.0
6797,N,,,,Half life of compound was determined in dog blood,Intermediate,,,,178.0,50588,BAO_0000218,A,,4727,,Canis lupus familiaris,9615.0
6798,N,,,,Half life after oral and iv dosing in dogs,Intermediate,,,,,50588,BAO_0000218,A,,5238,In vivo,Canis lupus familiaris,9615.0
6799,N,,,,Half life in dogs in hours,Intermediate,,,,,50588,BAO_0000218,A,,4942,,Canis lupus familiaris,9615.0
6800,N,,,,Half life on i.v. administration of 2 mg/kg was measured in dog,Intermediate,,,,,50588,BAO_0000218,A,,6505,In vivo,Canis lupus familiaris,9615.0
6801,N,,,,t1/2 in dog after oral dose (1 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,5130,In vivo,Canis lupus familiaris,9615.0
6802,N,,,,Half life was evaluated in dog,Intermediate,,,,,50588,BAO_0000218,A,,1475,,Canis lupus familiaris,9615.0
6803,N,,,,Half life period of compound was determined after intravenous administration at 2 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,17804,In vivo,Canis lupus familiaris,9615.0
6804,N,,,,Half life period of compound was determined after peroral administration at 2 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,17804,In vivo,Canis lupus familiaris,9615.0
6805,N,,,,Half life period (10 mg/kg) was determined in dog,Intermediate,,,,,50588,BAO_0000218,A,,6084,In vivo,Canis lupus familiaris,9615.0
6806,N,,,,Half life period (10 mg/kg) was determined in dog,Intermediate,,,,,50588,BAO_0000218,A,,6084,In vivo,Canis lupus familiaris,9615.0
6807,N,,,,Half life period by iv administration in dog at a dose of 0.3 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,5542,In vivo,Canis lupus familiaris,9615.0
6808,N,,,,Half life period by po administration in dog at a dose of 0.3 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,5542,In vivo,Canis lupus familiaris,9615.0
6809,N,,,,Half life period in dog,Intermediate,,,,,50588,BAO_0000218,A,,6084,,Canis lupus familiaris,9615.0
6810,N,,,,Half life period in dogs after oral administration at 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6241,In vivo,Canis lupus familiaris,9615.0
6811,N,,,,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Intermediate,,,,,50588,BAO_0000218,A,,1916,In vivo,Canis lupus familiaris,9615.0
6812,N,,,,Half-life of compound was determined in dogs,Intermediate,,,,,50588,BAO_0000218,A,,6621,,Canis lupus familiaris,9615.0
6813,N,,,,Half-life in dog plasma,Intermediate,,,,1969.0,50588,BAO_0000218,A,,1696,,Canis lupus familiaris,9615.0
6814,N,,,,Half-life in mongrel dogs was determined,Intermediate,,,,,50588,BAO_0000218,A,,17800,,Canis lupus familiaris,9615.0
6815,N,,,,Half-life in dog upon oral administration,Intermediate,,,,,50588,BAO_0000218,A,,17657,In vivo,Canis lupus familiaris,9615.0
6816,N,,,,Half-life in dog upon oral administration; Unable to calculate,Intermediate,,,,,50588,BAO_0000218,A,,17657,In vivo,Canis lupus familiaris,9615.0
6817,N,,,,Half-life was measured in dog,Intermediate,,,,,50588,BAO_0000218,A,,4239,,Canis lupus familiaris,9615.0
6818,N,,,,Half-life was measured in dog,Intermediate,,,,,50588,BAO_0000218,A,,5985,,Canis lupus familiaris,9615.0
6819,N,,,,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,Intermediate,,,,,50588,BAO_0000218,A,,9932,,Canis lupus familiaris,9615.0
6820,N,,,,Oral half life was determined,Intermediate,,,,,50588,BAO_0000218,A,,5199,In vivo,Canis lupus familiaris,9615.0
6821,N,,,,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,Intermediate,,,,1969.0,50588,BAO_0000218,A,,5199,In vivo,Canis lupus familiaris,9615.0
6822,N,,,,Plasma half life was evaluated,Intermediate,,,,1969.0,50588,BAO_0000218,A,,1475,,Canis lupus familiaris,9615.0
6823,N,,,,Plasma half life was evaluated in Dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,1475,,Canis lupus familiaris,9615.0
6824,N,,,,Plasma half life was evaluated in dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,1475,,Canis lupus familiaris,9615.0
6825,N,,,,T1/2 (Half-life) was after oral administration at 5 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6316,In vivo,Canis lupus familiaris,9615.0
6826,N,,,,Tested for the half life value in dog,Intermediate,,,,,50588,BAO_0000218,A,,4883,,Canis lupus familiaris,9615.0
6827,N,,,,Maximum time at the dose of 2 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,4727,In vivo,Canis lupus familiaris,9615.0
6828,N,,,,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Intermediate,,,,,50588,BAO_0000218,A,,1916,In vivo,Canis lupus familiaris,9615.0
6829,N,,,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Intermediate,,,,178.0,50588,BAO_0000218,A,,1337,In vivo,Canis lupus familiaris,9615.0
6830,N,,,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Intermediate,,,,178.0,50588,BAO_0000218,A,,1337,In vivo,Canis lupus familiaris,9615.0
6831,N,,,,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6265,In vivo,Canis lupus familiaris,9615.0
6832,N,,,,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),Intermediate,,,,,50588,BAO_0000218,A,,4809,In vivo,Canis lupus familiaris,9615.0
6833,N,,,,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,Intermediate,,,,,50588,BAO_0000218,A,,5983,In vivo,Canis lupus familiaris,9615.0
6834,N,,,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",Intermediate,,,,,50588,BAO_0000218,A,,5313,,Canis lupus familiaris,9615.0
6835,N,,,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",Intermediate,,,,,50588,BAO_0000218,A,,5313,In vivo,Canis lupus familiaris,9615.0
6836,N,,,,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17650,In vivo,Canis lupus familiaris,9615.0
6837,N,,,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,Intermediate,,,,1969.0,50588,BAO_0000218,A,,5199,In vivo,Canis lupus familiaris,9615.0
6838,N,,,,Time taken for maximum plasma concentration in dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,933,,Canis lupus familiaris,9615.0
6839,N,,,,Time to reach Cmax after oral administration to dogs,Intermediate,,,,,50588,BAO_0000218,A,,16367,In vivo,Canis lupus familiaris,9615.0
6840,N,,,,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Intermediate,,,,1969.0,50588,BAO_0000218,A,,6348,In vivo,Canis lupus familiaris,9615.0
6841,N,,,,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6316,In vivo,Canis lupus familiaris,9615.0
6842,N,,,,Tmax after peroral administration (1 mg/kg) was determined in dog,Intermediate,,,,,50588,BAO_0000218,A,,6215,In vivo,Canis lupus familiaris,9615.0
6843,N,,,,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,Expert,,,,,50588,BAO_0000218,A,,3598,In vivo,Canis lupus familiaris,9615.0
6844,N,,,,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,4527,In vivo,Canis lupus familiaris,9615.0
6845,N,,,,Tmax after peroral administration in dogs at 2.4 uM/kg,Intermediate,,,,,50588,BAO_0000218,A,,17764,In vivo,Canis lupus familiaris,9615.0
6846,N,,,,In vivo Cmax in mice at dose of 100 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,5969,In vivo,Mus musculus,10090.0
6847,N,,,,In vivo Cmax in mice at dose of 50 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,5969,In vivo,Mus musculus,10090.0
6848,N,,,,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,Intermediate,,,,,50594,BAO_0000218,A,,4573,In vivo,Mus musculus,10090.0
6849,N,,,,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Intermediate,,,,1969.0,50594,BAO_0000218,A,,3277,In vivo,Mus musculus,10090.0
6850,N,,,,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,Intermediate,,,,1969.0,50594,BAO_0000218,A,,17734,In vivo,Mus musculus,10090.0
6851,N,,,,Maximum concentration obtained in mouse plasma was determined,Intermediate,,,,1969.0,50594,BAO_0000218,A,,3132,In vivo,Mus musculus,10090.0
6852,N,,,,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,Intermediate,,,,1969.0,50594,BAO_0000218,A,,3132,In vivo,Mus musculus,10090.0
6853,N,,,,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Intermediate,,,,1969.0,50594,BAO_0000218,A,,6348,In vivo,Mus musculus,10090.0
6854,N,,,,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,Intermediate,,,,1969.0,50594,BAO_0000218,A,,17729,In vivo,Mus musculus,10090.0
6855,N,,,,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,Intermediate,,,,1969.0,50594,BAO_0000218,A,,17729,In vivo,Mus musculus,10090.0
6856,N,,,,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,Intermediate,,,,1969.0,50594,BAO_0000218,A,,17729,In vivo,Mus musculus,10090.0
6857,N,,,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,Intermediate,,,,1969.0,50594,BAO_0000218,A,,17728,In vivo,Mus musculus,10090.0
6858,N,,,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,Intermediate,,,,1969.0,50594,BAO_0000218,A,,17728,In vivo,Mus musculus,10090.0
6859,N,,,,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,Intermediate,,,,1969.0,50594,BAO_0000218,A,,17728,In vivo,Mus musculus,10090.0
6860,N,,,,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,4066,In vivo,Mus musculus,10090.0
6861,N,,,,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,6178,In vivo,Mus musculus,10090.0
6862,N,,,,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,6178,In vivo,Mus musculus,10090.0
6863,N,,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,Intermediate,,,,,50594,BAO_0000218,A,,3760,In vivo,Mus musculus,10090.0
6864,N,,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,Intermediate,,,,,50594,BAO_0000218,A,,3760,In vivo,Mus musculus,10090.0
6865,N,,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,Intermediate,,,,,50594,BAO_0000218,A,,3760,In vivo,Mus musculus,10090.0
6866,N,,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,Intermediate,,,,,50594,BAO_0000218,A,,3760,In vivo,Mus musculus,10090.0
6868,N,,,,Cmax in male mice after 2 mg/kg oral dose,Intermediate,,,,,50594,BAO_0000218,A,,5961,In vivo,Mus musculus,10090.0
6869,N,,,,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,Intermediate,,,,,50594,BAO_0000218,A,,6137,In vivo,Mus musculus,10090.0
6870,N,,,,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,Intermediate,,,,,50594,BAO_0000218,A,,3802,In vivo,Mus musculus,10090.0
6871,N,,,,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,Intermediate,,,,,50594,BAO_0000218,A,,3535,,Mus musculus,10090.0
6872,N,,,,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,Intermediate,,,,,50594,BAO_0000218,A,,3535,,Mus musculus,10090.0
6873,N,,,,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,Intermediate,,,,,50594,BAO_0000218,A,,3535,,Mus musculus,10090.0
6874,N,,,,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,Intermediate,,,,,50594,BAO_0000218,A,,3535,,Mus musculus,10090.0
6875,N,,,,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,Intermediate,,,,,50594,BAO_0000218,A,,3535,,Mus musculus,10090.0
6876,N,,,,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,Intermediate,,,,,50594,BAO_0000218,A,,3535,,Mus musculus,10090.0
6877,N,,,,Maximum concentration in plasma upon oral administration in mouse,Intermediate,,,,1969.0,50594,BAO_0000218,A,,2862,,Mus musculus,10090.0
6878,N,,,,Maximum plasma concentration was evaluated in mice after oral administration,Intermediate,,,,1969.0,50594,BAO_0000218,A,,2675,,Mus musculus,10090.0
6879,N,,,,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,Intermediate,,,,1969.0,50594,BAO_0000218,A,,2675,In vivo,Mus musculus,10090.0
6880,N,,,,Dose at which the compound induced fecal excretion in mice,Intermediate,,,,,50594,BAO_0000218,A,,5399,,Mus musculus,10090.0
6893,N,,164.0,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,Expert,,A10,,,80013,BAO_0000219,F,,11819,,Rattus norvegicus,10116.0
6894,N,,164.0,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,Expert,,A10,,,80013,BAO_0000219,F,,11819,,Rattus norvegicus,10116.0
6895,N,,164.0,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,Expert,,A10,,,80013,BAO_0000219,F,,11819,,Rattus norvegicus,10116.0
6896,N,,164.0,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,Expert,,A10,,,80013,BAO_0000219,F,,11819,,Rattus norvegicus,10116.0
6897,N,,164.0,,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),Intermediate,,A10,,,80013,BAO_0000219,F,,16361,,Rattus norvegicus,10116.0
6898,N,,393.0,,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,Intermediate,,A121,,,80655,BAO_0000219,F,,2288,,Homo sapiens,9606.0
6899,N,,393.0,,Anticancer activity against human ovarian carcinoma A121 cells,Intermediate,,A121,,,80655,BAO_0000219,F,,10404,,Homo sapiens,9606.0
6900,N,,393.0,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,Intermediate,,A121,,,80655,BAO_0000219,F,,14790,,Homo sapiens,9606.0
6901,N,,393.0,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,Intermediate,,A121,,,80655,BAO_0000219,F,,14790,,Homo sapiens,9606.0
6902,N,,393.0,,Growth inhibition of human ovarian carcinoma (A121) cell line,Expert,,A121,,,80655,BAO_0000219,F,,14253,,Homo sapiens,9606.0
6903,N,,393.0,,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,Expert,,A121,,,80655,BAO_0000219,F,,13617,,Homo sapiens,9606.0
6904,N,,393.0,,Cytotoxicity against human A121 ovarian cells,Intermediate,,A121,,,80655,BAO_0000219,F,,1003,,Homo sapiens,9606.0
6905,N,,393.0,,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,Intermediate,,A121,,,80655,BAO_0000219,F,,830,,Homo sapiens,9606.0
6906,N,,393.0,,In vitro cytotoxicity against human ovarian carcinoma A21,Intermediate,,A121,,,80655,BAO_0000219,F,,12307,,Homo sapiens,9606.0
6907,N,,393.0,,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,Intermediate,,A121,,,80655,BAO_0000219,F,,14254,,Homo sapiens,9606.0
6908,N,,393.0,,Inhibitory activity of compound against human A121 ovarian cell line.,Intermediate,,A121,,,80655,BAO_0000219,F,,13370,,Homo sapiens,9606.0
6909,N,,393.0,,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,Intermediate,,A121,,,80655,BAO_0000219,F,,14790,,Homo sapiens,9606.0
6910,N,,393.0,,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,Intermediate,,A121,,,80655,BAO_0000219,F,,3614,,Homo sapiens,9606.0
6911,N,,622.0,,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,Intermediate,,A 172,,,80012,BAO_0000219,F,,2664,,Homo sapiens,9606.0
6912,N,,622.0,,In vitro cytotoxicity against A172 human tumor cell lines.,Expert,,A 172,,,80012,BAO_0000219,F,,2037,,Homo sapiens,9606.0
6913,N,,622.0,,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,Intermediate,,A 172,,,80012,BAO_0000219,F,,14539,,Homo sapiens,9606.0
6914,N,,622.0,,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,Intermediate,,A 172,,,80012,BAO_0000219,F,,2836,,Homo sapiens,9606.0
6915,N,,622.0,,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,Intermediate,,A 172,,,80012,BAO_0000219,F,,10708,,Homo sapiens,9606.0
6916,H,,,,Association constant against A2 adenosine receptor,Autocuration,,,,,104729,BAO_0000224,B,,8975,,Canis lupus familiaris,9615.0
6917,N,,1085.0,,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,Intermediate,,A2,,,80656,BAO_0000219,F,,7645,,fish,
6918,D,,,,Ratio of Ki for adenosine A2 and A1 receptor binding,Autocuration,,,,,104713,BAO_0000224,B,,11377,,Rattus norvegicus,10116.0
6919,N,,623.0,,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,Expert,,A204,,,80014,BAO_0000219,F,,13528,,Homo sapiens,9606.0
6920,N,,623.0,,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,Expert,,A204,,,80014,BAO_0000219,F,,10160,,Homo sapiens,9606.0
6921,N,,404.0,,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,Intermediate,,A2058,,,80015,BAO_0000219,F,,15144,,Homo sapiens,9606.0
6922,N,,973.0,,Growth inhibition against Human squamous cell line(A 253),Intermediate,,A253 cell line,,,80657,BAO_0000219,F,,13160,,Homo sapiens,9606.0
6923,N,,973.0,,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,Intermediate,,A253 cell line,,,80657,BAO_0000219,F,,12898,,Homo sapiens,9606.0
6924,N,,973.0,,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,Intermediate,,A253 cell line,,,80657,BAO_0000219,F,,13069,,Homo sapiens,9606.0
6925,N,,973.0,,Growth inhibition of A253 cell lines.,Intermediate,,A253 cell line,,,80657,BAO_0000219,F,,15984,,Homo sapiens,9606.0
6926,N,,973.0,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),Intermediate,,A253 cell line,,,80657,BAO_0000219,F,,15564,,Homo sapiens,9606.0
6927,N,,973.0,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,Intermediate,,A253 cell line,,,80657,BAO_0000219,F,,15564,,Homo sapiens,9606.0
6928,N,,973.0,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,Intermediate,,A253 cell line,,,80657,BAO_0000219,F,,15564,,Homo sapiens,9606.0
6929,N,,478.0,,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,4720,,Homo sapiens,9606.0
6930,N,,478.0,,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,16112,,Homo sapiens,9606.0
6931,N,,478.0,,Cytotoxic activity against A2780 human ovarian carcinoma cell line,Expert,,A2780,,,81034,BAO_0000219,F,,16597,,Homo sapiens,9606.0
6932,N,,478.0,,Cytotoxicity against human cancer cell lines A2780 (ovarian),Intermediate,,A2780,,,81034,BAO_0000219,F,,16378,,Homo sapiens,9606.0
6933,N,,478.0,,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,Expert,,A2780,,,81034,BAO_0000219,F,,16085,,Homo sapiens,9606.0
6934,N,,478.0,,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,Intermediate,,A2780,,,81034,BAO_0000219,F,,16317,,Homo sapiens,9606.0
6935,N,,478.0,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),Intermediate,,A2780,,,81034,BAO_0000219,F,,15748,,Homo sapiens,9606.0
6936,N,,478.0,,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,Expert,,A2780,,,81034,BAO_0000219,F,,16597,,Homo sapiens,9606.0
6937,N,,478.0,,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,Expert,,A2780,,,81034,BAO_0000219,F,,16597,,Homo sapiens,9606.0
6938,N,,478.0,,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,Expert,,A2780,,,81034,BAO_0000219,F,,16597,,Homo sapiens,9606.0
6939,N,,478.0,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,Intermediate,,A2780,,,81034,BAO_0000219,F,,15608,,Homo sapiens,9606.0
6940,N,,478.0,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,Intermediate,,A2780,,,81034,BAO_0000219,F,,15608,,Homo sapiens,9606.0
6941,N,,478.0,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,Intermediate,,A2780,,,81034,BAO_0000219,F,,15608,,Homo sapiens,9606.0
6942,U,,,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,Autocuration,,,,,22224,BAO_0000019,F,,15296,,Cricetulus griseus,10029.0
6943,U,,185.0,,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,Autocuration,,CHO-AA8,,,22224,BAO_0000219,A,,10251,,Cricetulus griseus,10029.0
6944,U,,185.0,,Evaluated for growth inhibition of AA8 cells under aerobic conditions,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,10251,,Cricetulus griseus,10029.0
6945,U,,185.0,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,10251,,Cricetulus griseus,10029.0
6946,U,,185.0,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,10251,,Cricetulus griseus,10029.0
6947,U,,,,Growth inhibition against CHO-derived cell line AA8,Autocuration,,,,,22224,BAO_0000019,F,,11858,,Cricetulus griseus,10029.0
6948,U,,185.0,,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,11858,,Cricetulus griseus,10029.0
6949,N,,185.0,,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,Expert,,CHO-AA8,,,80089,BAO_0000219,F,,11616,,hampster,36483.0
6950,N,,185.0,,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,Expert,,CHO-AA8,,,80089,BAO_0000219,F,,11616,,Cricetulus griseus,10029.0
6951,U,,185.0,,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,10518,,Cricetulus griseus,10029.0
6952,U,,185.0,,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,11396,,Cricetulus griseus,10029.0
6953,U,,185.0,,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,10518,,Cricetulus griseus,10029.0
6954,N,,185.0,,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,Expert,,CHO-AA8,,,80089,BAO_0000219,F,,11616,,Cricetulus griseus,10029.0
6955,H,,,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,Autocuration,,,,,12675,BAO_0000019,F,,14837,,,
6956,H,,,,Number of binding sites (n) of isolated serum protein AAG,Autocuration,,,,,12675,BAO_0000019,F,,14837,,,
6957,M,,,,Association constant for binding to AATT duplex,Intermediate,,,,,22222,BAO_0000225,B,,16037,,,
6958,N,,416.0,,Inhibition of ABAE human fibroblast cell proliferation,Expert,,ABAE,,,100090,BAO_0000219,F,,16597,,Homo sapiens,9606.0
6959,N,,1064.0,,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",Intermediate,,AC755,,,80668,BAO_0000218,F,,8831,,Mus musculus,10090.0
6960,D,,,,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,Expert,,,,,102444,BAO_0000218,F,,13419,,Oryctolagus cuniculus,9986.0
6961,D,,,,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,Expert,,,,,102444,BAO_0000218,F,,13419,In vivo,Oryctolagus cuniculus,9986.0
6962,H,,,,Inhibitory activity against angiotensin-converting enzyme (ACE).,Autocuration,,,,,69,BAO_0000357,B,,15778,,,
6963,H,,,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,Autocuration,,,,,69,BAO_0000357,B,,15778,,,
6964,N,,978.0,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,Intermediate,,ACH-2 cell line,,,80669,BAO_0000219,F,,12988,,Homo sapiens,9606.0
6965,N,,978.0,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),Intermediate,,ACH-2 cell line,,,80669,BAO_0000219,F,,12988,,Homo sapiens,9606.0
6966,U,,998.0,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,Autocuration,,T cell line,,,22224,BAO_0000219,F,,12988,,Human immunodeficiency virus 1,11676.0
6967,U,,998.0,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),Autocuration,,T cell line,,,22224,BAO_0000219,F,,12988,,Human immunodeficiency virus 1,11676.0
6968,U,,998.0,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),Autocuration,,T cell line,,,22224,BAO_0000219,F,,12988,,Human immunodeficiency virus 1,11676.0
6969,N,,626.0,,Inhibition of growth of renal cancer ACHN cell line,Intermediate,,ACHN,,,80025,BAO_0000219,F,,11843,,Homo sapiens,9606.0
6970,N,,626.0,,Inhibition of growth of ACHN renal cancer cell line,Intermediate,,ACHN,,,80025,BAO_0000219,F,,16939,,Homo sapiens,9606.0
6971,N,,626.0,,Inhibitory concentration required against ACHN renal cancer cell line,Intermediate,,ACHN,,,80025,BAO_0000219,F,,4782,,Homo sapiens,9606.0
6972,N,,626.0,,Concentration required to inhibit growth of human renal (ACHN) cell line,Expert,,ACHN,,,80025,BAO_0000219,F,,6310,,Homo sapiens,9606.0
6973,N,,626.0,,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,Intermediate,,ACHN,,,80025,BAO_0000219,F,,6310,,Homo sapiens,9606.0
6974,N,,626.0,,Cytotoxic activity against ACHN Renal cancer cell line,Intermediate,,ACHN,,,80025,BAO_0000219,F,,12858,,Homo sapiens,9606.0
6975,N,,626.0,,Cytotoxicity evaluation against ACHN renal cancer cells,Intermediate,,ACHN,,,80025,BAO_0000219,F,,17380,,Homo sapiens,9606.0
6976,N,,626.0,,In vitro antitumor activity against human renal ACHN cell line,Intermediate,,ACHN,,,80025,BAO_0000219,F,,5858,,Homo sapiens,9606.0
6977,N,,626.0,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,Intermediate,,ACHN,,,80025,BAO_0000219,F,,3838,,Homo sapiens,9606.0
6978,N,,626.0,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,Intermediate,,ACHN,,,80025,BAO_0000219,F,,3838,,Homo sapiens,9606.0
6979,N,,626.0,,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",Intermediate,,ACHN,,,80025,BAO_0000219,F,,5406,,Homo sapiens,9606.0
6980,N,,626.0,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,Intermediate,,ACHN,,,80025,BAO_0000219,F,,4071,,Homo sapiens,9606.0
6981,N,,626.0,,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,Expert,,ACHN,,,80025,BAO_0000219,F,,4071,,Homo sapiens,9606.0
6982,N,,626.0,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,Intermediate,,ACHN,,,80025,BAO_0000219,F,,4071,,Homo sapiens,9606.0
6983,N,,626.0,,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,Intermediate,,ACHN,,,80025,BAO_0000219,F,,15002,,Homo sapiens,9606.0
6984,N,,626.0,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),Intermediate,,ACHN,,,80025,BAO_0000219,F,,14769,,Homo sapiens,9606.0
6985,N,,626.0,,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",Intermediate,,ACHN,,,80025,BAO_0000219,F,,13958,,Homo sapiens,9606.0
6986,N,,626.0,,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,Intermediate,,ACHN,,,80025,BAO_0000219,F,,1665,,Homo sapiens,9606.0
6987,N,,626.0,,Compound was tested for the growth inhibition of ACHN renal tumor cell line,Intermediate,,ACHN,,,80025,BAO_0000219,F,,15354,,Homo sapiens,9606.0
6988,N,,626.0,,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,Intermediate,,ACHN,,,80025,BAO_0000219,F,,15354,,Homo sapiens,9606.0
6989,N,,626.0,,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,Intermediate,,ACHN,,,80025,BAO_0000219,F,,13978,,Homo sapiens,9606.0
6990,N,,626.0,,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,Intermediate,,ACHN,,,80025,BAO_0000219,F,,6798,,Homo sapiens,9606.0
6991,N,,,,Tmax value after administration of 4 mg/Kg oral dose in dog,Intermediate,,,,,50588,BAO_0000218,A,,2959,In vivo,Canis lupus familiaris,9615.0
6992,N,,,,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",Intermediate,,,,,50588,BAO_0000218,A,,9932,,Canis lupus familiaris,9615.0
6993,N,,,,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,Intermediate,,,,,50588,BAO_0000218,A,,5546,,Canis lupus familiaris,9615.0
6994,N,,,,Volume distribution after 15 mg/kg iv dose in Dogs,Intermediate,,,,,50588,BAO_0000218,A,,16907,In vivo,Canis lupus familiaris,9615.0
6995,N,,,,Volume distribution after 30 mg/kg po dose in Dogs,Intermediate,,,,,50588,BAO_0000218,A,,16907,In vivo,Canis lupus familiaris,9615.0
6996,N,,,,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,Intermediate,,,,,50588,BAO_0000218,A,,4257,In vivo,Canis lupus familiaris,9615.0
6997,N,,,,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,4305,In vivo,Canis lupus familiaris,9615.0
6998,N,,,,Volume of distribution was evaluated in dog,Intermediate,,,,,50588,BAO_0000218,A,,5472,In vivo,Canis lupus familiaris,9615.0
6999,N,,,,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6062,In vivo,Canis lupus familiaris,9615.0
7000,N,,,,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,Expert,,,,,50588,BAO_0000218,A,,3598,,Canis lupus familiaris,9615.0
7001,N,,,,The compound was tested for volume of distribution in dog,Intermediate,,,,,50588,BAO_0000218,A,,12500,In vivo,Canis lupus familiaris,9615.0
7002,N,,,,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,Intermediate,,,,,50588,BAO_0000218,A,,12500,In vivo,Canis lupus familiaris,9615.0
7003,N,,,,Vd (1 mg/kg) was determined in dog (in vivo),Intermediate,,,,,50588,BAO_0000218,A,,6227,In vivo,Canis lupus familiaris,9615.0
7004,N,,,,Vd in dog,Intermediate,,,,,50588,BAO_0000218,A,,6227,In vivo,Canis lupus familiaris,9615.0
7005,N,,,,Volume distribution was determined,Intermediate,,,,,50588,BAO_0000218,A,,4219,In vivo,Canis lupus familiaris,9615.0
7006,N,,,,Volume of distribution in dog,Intermediate,,,,,50588,BAO_0000218,A,,1696,In vivo,Canis lupus familiaris,9615.0
7007,N,,,,Volume of distribution by as 4 fold increase by iv administration in dogs,Intermediate,,,,,50588,BAO_0000218,A,,5542,In vivo,Canis lupus familiaris,9615.0
7008,N,,,,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,Intermediate,,,,,50588,BAO_0000218,A,,5199,In vivo,Canis lupus familiaris,9615.0
7009,N,,,,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Intermediate,,,,,50588,BAO_0000218,A,,6348,In vivo,Canis lupus familiaris,9615.0
7010,N,,,,Volume distribution at the dose of 2 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,4727,In vivo,Canis lupus familiaris,9615.0
7011,N,,,,Steady state volume of distribution was determined,Intermediate,,,,,50588,BAO_0000218,A,,16367,In vivo,Canis lupus familiaris,9615.0
7012,N,,,,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,Intermediate,,,,,50588,BAO_0000218,A,,2652,In vivo,Canis lupus familiaris,9615.0
7013,N,,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,Intermediate,,,,,50588,BAO_0000218,A,,16452,In vivo,Canis lupus familiaris,9615.0
7014,N,,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,Intermediate,,,,,50588,BAO_0000218,A,,16452,In vivo,Canis lupus familiaris,9615.0
7015,N,,,,Bioavailability in dog (dose 1 mg/kg i.v.),Intermediate,,,,,50588,BAO_0000218,A,,16452,In vivo,Canis lupus familiaris,9615.0
7016,N,,,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),Intermediate,,,,,50588,BAO_0000218,A,,5334,In vivo,Canis lupus familiaris,9615.0
7017,N,,,,Pharmacokinetic property (vdss) was measured in dog,Intermediate,,,,,50588,BAO_0000218,A,,4239,In vivo,Canis lupus familiaris,9615.0
7018,N,,,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,4709,In vivo,Canis lupus familiaris,9615.0
7019,N,,,,Vdss was determined after iv 0.1 mg/kg administration in dog,Intermediate,,,,,50588,BAO_0000218,A,,5600,In vivo,Canis lupus familiaris,9615.0
7020,N,,,,Volume displacement was calculated in dog,Intermediate,,,,,50588,BAO_0000218,A,,6057,In vivo,Canis lupus familiaris,9615.0
7021,N,,,,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,5654,In vivo,Canis lupus familiaris,9615.0
7022,N,,,,Volume distribution constant was determined,Intermediate,,,,,50588,BAO_0000218,A,,5505,In vivo,Canis lupus familiaris,9615.0
7023,N,,,,Volume distribution at a dose of 1 uM/kg in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,4527,In vivo,Canis lupus familiaris,9615.0
7024,N,,,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,Intermediate,,,,,50588,BAO_0000218,A,,4521,In vivo,Canis lupus familiaris,9615.0
7025,N,,,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,Intermediate,,,,,50588,BAO_0000218,A,,4521,In vivo,Canis lupus familiaris,9615.0
7026,N,,,,Volume distribution (Vdss) was measured in dog,Intermediate,,,,,50588,BAO_0000218,A,,15660,In vivo,Canis lupus familiaris,9615.0
7027,N,,,,Volume distribution (Vdss) was measured in dog,Intermediate,,,,,50588,BAO_0000218,A,,15660,In vivo,Canis lupus familiaris,9615.0
7028,N,,,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,,,,,50588,BAO_0000218,A,,6679,In vivo,Canis lupus familiaris,9615.0
7029,N,,,,Volume of distribution in steady state was determined in dog,Intermediate,,,,,50588,BAO_0000218,A,,5145,In vivo,Canis lupus familiaris,9615.0
7030,N,,,,Volume of distribution of compound was determined in dog,Intermediate,,,,,50588,BAO_0000218,A,,6821,In vivo,Canis lupus familiaris,9615.0
7031,N,,,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,Intermediate,,,,,50588,BAO_0000218,A,,4137,In vivo,Canis lupus familiaris,9615.0
7032,N,,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),Intermediate,,,,,50588,BAO_0000218,A,,5334,In vivo,Canis lupus familiaris,9615.0
7033,N,,,,Volume of distribution (Vdss) was measured in dog,Intermediate,,,,,50588,BAO_0000218,A,,15660,In vivo,Canis lupus familiaris,9615.0
7034,N,,,,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Intermediate,,,,,50588,BAO_0000218,A,,6642,In vivo,Canis lupus familiaris,9615.0
7035,N,,,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Intermediate,,,,,50588,BAO_0000218,A,,6641,In vivo,Canis lupus familiaris,9615.0
7036,N,,,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Intermediate,,,,,50588,BAO_0000218,A,,6642,In vivo,Canis lupus familiaris,9615.0
7037,N,,,,Maximum rate of depolarization of the upstroke of the action potential,Intermediate,,,,,50588,BAO_0000218,A,,11659,,Canis lupus familiaris,9615.0
7038,N,,,,Steady state volume distribution in dog,Intermediate,,,,,50588,BAO_0000218,A,,6448,In vivo,Canis lupus familiaris,9615.0
7039,N,,,,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,Intermediate,,,,,50588,BAO_0000218,A,,5474,In vivo,Canis lupus familiaris,9615.0
7040,N,,,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,Intermediate,,,,,50588,BAO_0000218,A,,1466,In vivo,Canis lupus familiaris,9615.0
7041,N,,,,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,Intermediate,,,,,50588,BAO_0000218,A,,6535,In vivo,Canis lupus familiaris,9615.0
7042,N,,,,Volume distribution in dog after administration of 1 mg/kg iv,Intermediate,,,,,50588,BAO_0000218,A,,6535,In vivo,Canis lupus familiaris,9615.0
7043,N,,,,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,Intermediate,,,,,50588,BAO_0000218,A,,17764,In vivo,Canis lupus familiaris,9615.0
7044,N,,,,Vss after intravenous administration (0.5 mg/kg) was determined in dog,Intermediate,,,,,50588,BAO_0000218,A,,6215,In vivo,Canis lupus familiaris,9615.0
7045,N,,,,Vss on i.v. administration of 2 mg/kg was measured in dog,Intermediate,,,,,50588,BAO_0000218,A,,6505,In vivo,Canis lupus familiaris,9615.0
7046,N,,,,Vss was determined,Intermediate,,,,,50588,BAO_0000218,A,,3639,,Canis lupus familiaris,9615.0
7047,N,,,,Vss in dog,Intermediate,,,,,50588,BAO_0000218,A,,3639,,Canis lupus familiaris,9615.0
7048,N,,,,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6062,In vivo,Canis lupus familiaris,9615.0
7049,N,,,,Volume distribution in dogs,Intermediate,,,,,50588,BAO_0000218,A,,4942,In vivo,Canis lupus familiaris,9615.0
7050,N,,,,Volume of distribution in dog,Intermediate,,,,,50588,BAO_0000218,A,,17796,In vivo,Canis lupus familiaris,9615.0
7051,N,,,,Tested for the oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,4883,In vivo,Canis lupus familiaris,9615.0
7060,N,,,,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,17837,In vivo,Mus musculus,10090.0
7061,N,,,,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,Intermediate,,,,,50594,BAO_0000218,A,,17729,In vivo,Mus musculus,10090.0
7062,N,,,,Bioavailability after peroral administration of 50 mg/kg of dose in mice,Intermediate,,,,,50594,BAO_0000218,A,,17729,In vivo,Mus musculus,10090.0
7063,N,,,,Bioavailability was measured in mouse,Intermediate,,,,,50594,BAO_0000218,A,,4239,In vivo,Mus musculus,10090.0
7064,N,,,,Bioavailability in mouse,Intermediate,,,,,50594,BAO_0000218,A,,17592,In vivo,Mus musculus,10090.0
7065,N,,,,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Intermediate,,,,,50594,BAO_0000218,A,,6348,In vivo,Mus musculus,10090.0
7066,N,,,,Bioavailability in mouse,Intermediate,,,,,50594,BAO_0000218,A,,2801,In vivo,Mus musculus,10090.0
7067,N,,,,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,2801,In vivo,Mus musculus,10090.0
7068,N,,,,Oral bioavailability in mouse,Intermediate,,,,,50594,BAO_0000218,A,,17718,In vivo,Mus musculus,10090.0
7069,N,,,,Oral availability at 50 mg/kg po in male mice,Intermediate,,,,,50594,BAO_0000218,A,,5727,In vivo,Mus musculus,10090.0
7070,N,,,,Oral bioavailability in mouse (dose 10 mg/kg),Intermediate,,,,,50594,BAO_0000218,A,,5302,In vivo,Mus musculus,10090.0
7071,N,,,,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,Expert,,,,,50594,BAO_0000218,A,,3598,In vivo,Mus musculus,10090.0
7072,N,,,,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",Intermediate,,,,,50594,BAO_0000218,A,,5961,In vivo,Mus musculus,10090.0
7074,N,,,,Oral bioavailability in mouse,Intermediate,,,,,50594,BAO_0000218,A,,6091,In vivo,Mus musculus,10090.0
7075,N,,,,Oral bioavailability in vivo in mice;ND=Not determined,Intermediate,,,,,50594,BAO_0000218,A,,6091,In vivo,Mus musculus,10090.0
7076,N,,,,Oral bioavailability in mouse at 10 mg/kg of the compound,Intermediate,,,,,50594,BAO_0000218,A,,5711,In vivo,Mus musculus,10090.0
7077,N,,,,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),Intermediate,,,,,50594,BAO_0000218,A,,17728,In vivo,Mus musculus,10090.0
7078,N,,,,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),Intermediate,,,,,50594,BAO_0000218,A,,17728,In vivo,Mus musculus,10090.0
7079,N,,,,Tested for bioavailability of the compound,Intermediate,,,,,50594,BAO_0000218,A,,3802,In vivo,Mus musculus,10090.0
7080,N,,,,Tested for half life at the dose of 10 mg/kg when administered intravenously,Intermediate,,,,,50594,BAO_0000218,A,,3802,In vivo,Mus musculus,10090.0
7081,N,,,,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,Intermediate,,,,1969.0,50594,BAO_0000218,A,,14029,,Mus musculus,10090.0
7082,N,,,,The plasma half life of compound was determined on heparin prepared by human plasma. ,Intermediate,,,,1969.0,50594,BAO_0000218,A,,14029,,Mus musculus,10090.0
7083,N,,,,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,Intermediate,,,,1969.0,50594,BAO_0000218,A,,14029,,Mus musculus,10090.0
7084,N,,,,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,Intermediate,,,,1969.0,50594,BAO_0000218,A,,14029,,Mus musculus,10090.0
7085,N,,,,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,Intermediate,,,,1969.0,50594,BAO_0000218,A,,14029,,Mus musculus,10090.0
7086,N,,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,Intermediate,,,,,50594,BAO_0000218,F,,17753,,Mus musculus,10090.0
7087,N,,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,Intermediate,,,,,50594,BAO_0000218,A,,17753,,Mus musculus,10090.0
7088,N,,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,Intermediate,,,,,50594,BAO_0000218,A,,17753,,Mus musculus,10090.0
7089,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,,178.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7090,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,,,,178.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7091,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,,178.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7092,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,,178.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7093,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,,178.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7094,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,,,178.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7095,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,,178.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7096,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,,10000001.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7097,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Intermediate,,,,10000001.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7098,N,,478.0,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,Intermediate,,A2780,,,81034,BAO_0000219,F,,15608,,Homo sapiens,9606.0
7099,N,,478.0,,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,Expert,,A2780,,,81034,BAO_0000219,F,,3290,,Homo sapiens,9606.0
7100,N,,478.0,,Compound was evaluated for cytotoxicity against A2780 cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,2859,,Homo sapiens,9606.0
7101,N,,478.0,,Inhibition of A2780 cell clonogenic assay,Expert,,A2780,,,81034,BAO_0000219,F,,15688,,Homo sapiens,9606.0
7102,N,,478.0,,Cytotoxic effect on ovarian cancer cell line (A2780),Expert,,A2780,,,81034,BAO_0000219,F,,5642,,Homo sapiens,9606.0
7103,N,,478.0,,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,Intermediate,,A2780,,,81034,BAO_0000219,F,,6633,,Homo sapiens,9606.0
7104,N,,478.0,,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",Intermediate,,A2780,,,81034,BAO_0000219,F,,3906,,Homo sapiens,9606.0
7105,N,,478.0,,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,Expert,,A2780,,,81034,BAO_0000219,F,,6788,,Homo sapiens,9606.0
7106,N,,478.0,,Antiproliferative activity against human A2780 cells,Expert,,A2780,,,81034,BAO_0000219,F,,17582,,Homo sapiens,9606.0
7107,N,,478.0,,Inhibition of human A2780 cell proliferation,Expert,,A2780,,,81034,BAO_0000219,F,,17764,,Homo sapiens,9606.0
7108,N,,478.0,,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,Expert,,A2780,,,81034,BAO_0000219,F,,17764,,Homo sapiens,9606.0
7109,N,,478.0,,Inhibition of human A2780 cell proliferation (No data),Expert,,A2780,,,81034,BAO_0000219,F,,17764,,Homo sapiens,9606.0
7110,N,,478.0,,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,2815,,Homo sapiens,9606.0
7111,N,,478.0,,Compound was evaluated against human Ovarian carcinoma cell line A2780,Intermediate,,A2780,,,81034,BAO_0000219,F,,16930,,Homo sapiens,9606.0
7112,N,,478.0,,Growth inhibition against A2780 wild-type ovarian cell lines,Expert,,A2780,,,81034,BAO_0000219,F,,17777,,Homo sapiens,9606.0
7113,N,,478.0,,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,Intermediate,,A2780,,,81034,BAO_0000219,F,,17777,,Homo sapiens,9606.0
7114,D,,,,Inhibition of tubulin polymerization in human ovarian cancer cell lines,Autocuration,,,,,104766,BAO_0000019,F,,16936,,Homo sapiens,9606.0
7115,N,,478.0,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,Intermediate,,A2780,,,81034,BAO_0000219,F,,13759,,Homo sapiens,9606.0
7116,N,,478.0,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,Intermediate,,A2780,,,81034,BAO_0000219,F,,13759,,Homo sapiens,9606.0
7117,N,,478.0,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,Intermediate,,A2780,,,81034,BAO_0000219,F,,13759,,Homo sapiens,9606.0
7118,N,,478.0,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,Intermediate,,A2780,,,81034,BAO_0000219,F,,13759,,Homo sapiens,9606.0
7119,N,,478.0,,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,Intermediate,,A2780,,,81034,BAO_0000219,F,,15292,,Homo sapiens,9606.0
7120,N,,478.0,,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,Intermediate,,A2780,,,81034,BAO_0000219,F,,15292,,Homo sapiens,9606.0
7121,N,,478.0,,In vitro inhibition of human ovarian cell line A2780,Expert,,A2780,,,81034,BAO_0000219,F,,15069,,Homo sapiens,9606.0
7122,N,,478.0,,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",Expert,,A2780,,,81034,BAO_0000219,F,,15069,,Homo sapiens,9606.0
7123,N,,478.0,,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),Intermediate,,A2780,,,81034,BAO_0000219,F,,14073,,Homo sapiens,9606.0
7124,N,,478.0,,Concentration required to inhibit A2780-cell growth by 50%,Expert,,A2780,,,81034,BAO_0000219,F,,14553,,Homo sapiens,9606.0
7125,N,,478.0,,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,Expert,,A2780,,,81034,BAO_0000219,F,,13040,,Homo sapiens,9606.0
7126,N,,478.0,,Cytotoxic effect on human ovarian (A2780) cancer cell line,Expert,,A2780,,,81034,BAO_0000219,F,,6891,,Homo sapiens,9606.0
7127,N,,478.0,,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,Intermediate,,A2780,,,81034,BAO_0000219,F,,15569,,Homo sapiens,9606.0
7128,N,,478.0,,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,Expert,,A2780,,,81034,BAO_0000219,F,,14190,,Homo sapiens,9606.0
7129,N,,478.0,,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,Expert,,A2780,,,81034,BAO_0000219,F,,15014,,Homo sapiens,9606.0
7130,N,,478.0,,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,Intermediate,,A2780,,,81034,BAO_0000219,F,,15014,,Homo sapiens,9606.0
7131,N,,478.0,,Cytotoxicity against human ovarian carcinoma A2780 cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,17496,,Homo sapiens,9606.0
7132,N,,478.0,,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",Intermediate,,A2780,,,81034,BAO_0000219,F,,13617,,Homo sapiens,9606.0
7133,N,,478.0,,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",Intermediate,,A2780,,,81034,BAO_0000219,F,,13617,,Homo sapiens,9606.0
7134,N,,478.0,,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",Intermediate,,A2780,,,81034,BAO_0000219,F,,13617,,Homo sapiens,9606.0
7135,N,,478.0,,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",Intermediate,,A2780,,,81034,BAO_0000219,F,,13617,,Homo sapiens,9606.0
7136,N,,478.0,,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,Intermediate,,A2780,,,81034,BAO_0000219,F,,17672,,Homo sapiens,9606.0
7137,N,,478.0,,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,Intermediate,,A2780,,,81034,BAO_0000219,F,,4544,,Homo sapiens,9606.0
7138,N,,478.0,,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,Intermediate,,A2780,,,81034,BAO_0000219,F,,4544,,Homo sapiens,9606.0
7139,N,,478.0,,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",Intermediate,,A2780,,,81034,BAO_0000219,F,,16317,,Homo sapiens,9606.0
7140,N,,478.0,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,Intermediate,,A2780,,,81034,BAO_0000219,F,,15099,,Homo sapiens,9606.0
7141,N,,478.0,,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,13978,,Homo sapiens,9606.0
7142,N,,478.0,,In vitro antitumor activity against A2780 cell line.,Expert,,A2780,,,81034,BAO_0000219,F,,12989,,Homo sapiens,9606.0
7143,N,,478.0,,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,Intermediate,,A2780,,,81034,BAO_0000219,F,,5574,,Homo sapiens,9606.0
7144,N,,478.0,,In vitro cytotoxicity against A2780 human ovarian cancer cell line,Expert,,A2780,,,81034,BAO_0000219,F,,13528,,Homo sapiens,9606.0
7145,N,,626.0,,Inhibitory activity against kidney A-CHN tumor cell growth in culture,Intermediate,,ACHN,,,80025,BAO_0000219,F,,12782,,Homo sapiens,9606.0
7146,N,,626.0,,The IC50 value was measured on ACHN cell line in renal tumor type.,Intermediate,,ACHN,,,80025,BAO_0000219,F,,14255,,Homo sapiens,9606.0
7147,N,,626.0,,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,Intermediate,,ACHN,,,80025,BAO_0000219,F,,16364,,Homo sapiens,9606.0
7148,N,,626.0,,In vitro lethal concentration against most sensitive ACHN cell line,Expert,,ACHN,,,80025,BAO_0000219,F,,17376,,Homo sapiens,9606.0
7149,N,,626.0,,Tested for cytotoxic activity against renal cancer ACHN cell line,Intermediate,,ACHN,,,80025,BAO_0000219,F,,12016,,Homo sapiens,9606.0
7150,N,,626.0,,Compound tested for growth inhibition of renal cancer cell line ACHN,Intermediate,,ACHN,,,80025,BAO_0000219,F,,6058,,Homo sapiens,9606.0
7151,N,,626.0,,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,Intermediate,,ACHN,,,80025,BAO_0000219,F,,17708,,Homo sapiens,9606.0
7152,N,,626.0,,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,Intermediate,,ACHN,,,80025,BAO_0000219,F,,15176,,Homo sapiens,9606.0
7153,N,,626.0,,In vitro anticancer activity against ACHN renal cancer cell line,Intermediate,,ACHN,,,80025,BAO_0000219,F,,2806,,Homo sapiens,9606.0
7154,N,,626.0,,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,Intermediate,,ACHN,,,80025,BAO_0000219,F,,15300,,Homo sapiens,9606.0
7155,N,,626.0,,Percent selectivity was evaluated in renal ACHN cell lines,Intermediate,,ACHN,,,80025,BAO_0000219,F,,16364,,Homo sapiens,9606.0
7156,N,,626.0,,In vitro inhibitory activity against renal ACHN cancer cell line,Intermediate,,ACHN,,,80025,BAO_0000219,F,,13859,,Homo sapiens,9606.0
7157,N,,626.0,,Tested for cytotoxicity against ACHN cell lines in renal cancer,Intermediate,,ACHN,,,80025,BAO_0000219,F,,11970,,Homo sapiens,9606.0
7158,N,,626.0,,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,Intermediate,,ACHN,,,80025,BAO_0000219,F,,2450,,Homo sapiens,9606.0
7159,N,,626.0,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,Intermediate,,ACHN,,,80025,BAO_0000219,F,,12696,,Homo sapiens,9606.0
7160,N,,626.0,,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,Intermediate,,ACHN,,,80025,BAO_0000219,F,,12400,,Homo sapiens,9606.0
7161,N,,626.0,,Cytotoxic effect on renal cancer line ACHN,Expert,,ACHN,,,80025,BAO_0000219,F,,12888,,Homo sapiens,9606.0
7162,N,,626.0,,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,Intermediate,,ACHN,,,80025,BAO_0000219,F,,3156,,Homo sapiens,9606.0
7163,N,,626.0,,In vitro inhibition of Renal Cancer ACHN cell lines,Intermediate,,ACHN,,,80025,BAO_0000219,F,,3381,,Homo sapiens,9606.0
7164,N,,626.0,,Antitumor activity against human renal adenocarcinoma ACHN cells,Intermediate,,ACHN,,,80025,BAO_0000219,F,,16747,,Homo sapiens,9606.0
7165,N,,626.0,,Antitumor activity against human renal adenocarcinoma ACHN cells.,Expert,,ACHN,,,80025,BAO_0000219,F,,16748,,Homo sapiens,9606.0
7166,N,,626.0,,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,Intermediate,,ACHN,,,80025,BAO_0000219,F,,12062,,Homo sapiens,9606.0
7167,N,,626.0,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),Intermediate,,ACHN,,,80025,BAO_0000219,F,,14769,,Homo sapiens,9606.0
7168,N,,626.0,,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",Intermediate,,ACHN,,,80025,BAO_0000219,F,,15895,,Homo sapiens,9606.0
7169,N,,626.0,,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,Intermediate,,ACHN,,,80025,BAO_0000219,F,,17376,,Homo sapiens,9606.0
7170,N,,626.0,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,Intermediate,,ACHN,,,80025,BAO_0000219,F,,14882,,Homo sapiens,9606.0
7171,N,,626.0,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,Intermediate,,ACHN,,,80025,BAO_0000219,F,,14882,,Homo sapiens,9606.0
7172,N,,626.0,,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,Intermediate,,ACHN,,,80025,BAO_0000219,F,,15661,,Homo sapiens,9606.0
7173,U,,,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,Autocuration,,,,,22224,BAO_0000019,A,,9680,,,
7174,H,,,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,Autocuration,,,,,10647,BAO_0000019,F,,14579,,,
7175,N,,468.0,,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,Expert,,HEL,,,50529,BAO_0000218,F,,17290,,Cytomegalovirus,10358.0
7176,N,,,,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,Intermediate,,,,,50529,BAO_0000218,F,,17290,,Cytomegalovirus,10358.0
7177,H,,,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),Autocuration,,,,,12159,BAO_0000357,B,,15891,,,
7178,H,,,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),Autocuration,,,,,12159,BAO_0000357,B,,15890,,,
7179,N,,979.0,,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,Intermediate,,ADDP cell line,,,80670,BAO_0000219,F,,3801,,Bos taurus,9913.0
7180,N,,980.0,,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,Intermediate,,ADJ/PC6,,,80671,BAO_0000219,F,,9222,,Mus musculus,10090.0
7181,N,,980.0,,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,Intermediate,,ADJ/PC6,,,80671,BAO_0000219,F,,9222,,Mus musculus,10090.0
7182,N,,980.0,,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",Intermediate,,ADJ/PC6,,,80671,BAO_0000219,F,,7257,,Mus musculus,10090.0
7183,N,,980.0,,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,Intermediate,,ADJ/PC6,,,80671,BAO_0000219,F,,7257,,Mus musculus,10090.0
7184,N,,980.0,,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,Intermediate,,ADJ/PC6,,,80671,BAO_0000219,A,,7257,,Mus musculus,10090.0
7185,N,,980.0,,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,Intermediate,,ADJ/PC6,,,80671,BAO_0000219,F,,8084,,Mus musculus,10090.0
7186,U,,,,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,Autocuration,,,,,22224,BAO_0000019,F,,14943,,Mus musculus,10090.0
7187,U,,,,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,Autocuration,,,,,22224,BAO_0000019,F,,14943,,Mus musculus,10090.0
7188,U,,,,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,Autocuration,,,,,22224,BAO_0000019,F,,14943,,Mus musculus,10090.0
7189,U,,,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),Autocuration,,,,,22224,BAO_0000218,A,,10524,In vivo,Bacillus subtilis,1423.0
7190,N,,,,AUC value in dog after IV administration at a dose of 5 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,3546,,Canis lupus familiaris,9615.0
7191,N,,,,AUC value in dog after oral administration at a dose of 5 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,3546,,Canis lupus familiaris,9615.0
7192,N,,,,Cmax value in dog after oral administration at a dose of 5 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,3546,In vivo,Canis lupus familiaris,9615.0
7193,N,,,,Bioavailability in dog after oral administration at a dose of 5 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,3546,In vivo,Canis lupus familiaris,9615.0
7194,N,,,,Tmax value in dog after oral administration at a dose of 5 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,3546,In vivo,Canis lupus familiaris,9615.0
7195,N,,,,Compound was evaluated for its clearance when administered intravenously in dog,Intermediate,,,,,50588,BAO_0000218,A,,3184,In vivo,Canis lupus familiaris,9615.0
7196,N,,,,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,16456,In vivo,Canis lupus familiaris,9615.0
7197,N,,,,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),Intermediate,,,,,50588,BAO_0000218,A,,4809,In vivo,Canis lupus familiaris,9615.0
7198,U,,,,Calculated partition coefficient (clogP),Intermediate,,,,,22229,BAO_0000100,P,,4219,,,
7199,N,,,,Half life in dog,Intermediate,,,,,50588,BAO_0000218,A,,3748,,Canis lupus familiaris,9615.0
7200,N,,,,Time taken for EC90 was determined when tested in dog,Intermediate,,,,,50588,BAO_0000218,A,,3132,,Canis lupus familiaris,9615.0
7201,N,,,,Half life (iv) was determined,Intermediate,,,,,50588,BAO_0000218,A,,4219,,Canis lupus familiaris,9615.0
7202,N,,,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,Intermediate,,,,2107.0,50588,BAO_0000218,A,,16907,,Canis lupus familiaris,9615.0
7203,N,,,,Area under the curve was calculated in dog after iv administration,Intermediate,,,,,50588,BAO_0000218,A,,6057,,Canis lupus familiaris,9615.0
7204,N,,,,Area under the curve was calculated in dog after peroral administration,Intermediate,,,,,50588,BAO_0000218,A,,6057,,Canis lupus familiaris,9615.0
7205,N,,,,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,Intermediate,,,,,50588,BAO_0000218,A,,17853,,Canis lupus familiaris,9615.0
7206,N,,,,pKa was evaluated in dog,Intermediate,,,,,50588,BAO_0000218,A,,3639,,Canis lupus familiaris,9615.0
7207,N,,,,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,Intermediate,,,,,50588,BAO_0000218,A,,14541,,Canis lupus familiaris,9615.0
7208,N,,,,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,16456,In vivo,Canis lupus familiaris,9615.0
7209,N,,,,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,16456,In vivo,Canis lupus familiaris,9615.0
7210,N,,,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,Intermediate,,,,,50588,BAO_0000218,A,,2652,In vivo,Canis lupus familiaris,9615.0
7211,N,,,,Compound was evaluated for the half-life (t 1/2) in hours,Intermediate,,,,,50588,BAO_0000218,A,,3624,,Canis lupus familiaris,9615.0
7212,N,,,,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Intermediate,,,,178.0,50588,BAO_0000218,A,,1337,In vivo,Canis lupus familiaris,9615.0
7213,N,,,,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Intermediate,,,,178.0,50588,BAO_0000218,A,,1337,In vivo,Canis lupus familiaris,9615.0
7214,N,,,,Half life after intravenous administration of 1 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,4709,In vivo,Canis lupus familiaris,9615.0
7215,N,,,,Half life was measured in dog,Intermediate,,,,,50588,BAO_0000218,A,,15660,,Canis lupus familiaris,9615.0
7216,N,,,,Half life period in dog after 5 mg/kg dose,Intermediate,,,,,50588,BAO_0000218,A,,5302,In vivo,Canis lupus familiaris,9615.0
7217,N,,,,Half life period was evaluated in dog; 4-4.8,Intermediate,,,,,50588,BAO_0000218,A,,17791,,Canis lupus familiaris,9615.0
7218,N,,,,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Intermediate,,,,,50588,BAO_0000218,A,,6348,In vivo,Canis lupus familiaris,9615.0
7219,N,,,,Half-life was determined in dog after a3 mg/kg of iv dose,Intermediate,,,,,50588,BAO_0000218,A,,4257,In vivo,Canis lupus familiaris,9615.0
7220,N,,,,Half-life was determined,Intermediate,,,,,50588,BAO_0000218,A,,3771,,Canis lupus familiaris,9615.0
7221,N,,,,Half life in dogs,Intermediate,,,,,50588,BAO_0000218,A,,6305,,Canis lupus familiaris,9615.0
7222,N,,,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,13501,In vivo,Canis lupus familiaris,9615.0
7223,N,,,,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,Intermediate,,,,,50588,BAO_0000218,A,,17594,In vivo,Canis lupus familiaris,9615.0
7224,N,,,,Compound was evaluated for the half life period after iv administration in Beagle dog.,Intermediate,,,,,50588,BAO_0000218,A,,3045,In vivo,Canis lupus familiaris,9615.0
7225,N,,,,Compound was evaluated for the half life period after oral administration in conscious dog.,Intermediate,,,,,50588,BAO_0000218,A,,3043,In vivo,Canis lupus familiaris,9615.0
7226,N,,,,Compound was tested for half life in dog,Intermediate,,,,,50588,BAO_0000218,A,,4839,,Canis lupus familiaris,9615.0
7227,N,,,,Compound was tested for its half life in dog,Intermediate,,,,,50588,BAO_0000218,A,,4839,,Canis lupus familiaris,9615.0
7228,N,,,,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,Intermediate,,,,,50588,BAO_0000218,A,,5802,In vivo,Canis lupus familiaris,9615.0
7229,N,,,,Half life of compound in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,17839,,Canis lupus familiaris,9615.0
7230,N,,,,Half life (iv) was determined,Intermediate,,,,,50588,BAO_0000218,A,,4219,In vivo,Canis lupus familiaris,9615.0
7231,N,,,,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),Intermediate,,,,178.0,50588,BAO_0000218,A,,13966,,Canis lupus familiaris,9615.0
7232,N,,,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,Intermediate,,,,1969.0,50588,BAO_0000218,A,,3994,In vivo,Canis lupus familiaris,9615.0
7233,N,,,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,Intermediate,,,,1969.0,50588,BAO_0000218,F,,3994,In vivo,Canis lupus familiaris,9615.0
7234,N,,,,Half life in dog,Intermediate,,,,,50588,BAO_0000218,A,,4453,,Canis lupus familiaris,9615.0
7235,N,,,,Half life in dog plasma,Intermediate,,,,1969.0,50588,BAO_0000218,A,,6535,,Canis lupus familiaris,9615.0
7236,N,,,,Half life in dog plasma after administration of 0.25 mg/kg iv,Intermediate,,,,1969.0,50588,BAO_0000218,A,,6535,In vivo,Canis lupus familiaris,9615.0
7237,N,,,,Half life in dog plasma after administration of 1 mg/kg iv,Intermediate,,,,1969.0,50588,BAO_0000218,A,,6535,In vivo,Canis lupus familiaris,9615.0
7238,N,,,,Half life in dog plasma was determined at dose 10 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,3132,In vivo,Canis lupus familiaris,9615.0
7239,N,,,,Half life in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,5374,,Canis lupus familiaris,9615.0
7240,N,,,,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,5007,In vivo,Canis lupus familiaris,9615.0
7241,N,,,,Half life upon exposure to human plasma,Intermediate,,,,1969.0,50588,BAO_0000218,A,,16907,,Canis lupus familiaris,9615.0
7242,N,,,,Half life was calculated in dog,Intermediate,,,,,50588,BAO_0000218,A,,6057,,Canis lupus familiaris,9615.0
7243,N,,,,Half life was determined,Intermediate,,,,,50588,BAO_0000218,A,,5006,,Canis lupus familiaris,9615.0
7244,N,,,,Half life was determined,Intermediate,,,,,50588,BAO_0000218,A,,5473,,Canis lupus familiaris,9615.0
7245,N,,,,Half life by intravenous administration of 1.2 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,4368,In vivo,Canis lupus familiaris,9615.0
7246,N,,,,Half life in dog,Intermediate,,,,,50588,BAO_0000218,A,,6448,,Canis lupus familiaris,9615.0
7247,N,,,,Half life in dog after intra venous administration of the compound,Intermediate,,,,,50588,BAO_0000218,A,,4353,,Canis lupus familiaris,9615.0
7248,N,,,,Half life in dog after intra venous administration of the compound; ND means Not determined,Intermediate,,,,,50588,BAO_0000218,A,,4353,,Canis lupus familiaris,9615.0
7249,N,,,,Half life in dog after po administration of the compound,Intermediate,,,,,50588,BAO_0000218,A,,4353,In vivo,Canis lupus familiaris,9615.0
7250,N,,,,Half life in dog after po administration of the compound; ND means Not determined,Intermediate,,,,,50588,BAO_0000218,A,,4353,In vivo,Canis lupus familiaris,9615.0
7251,N,,,,Half life in dog at the single oral dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6265,In vivo,Canis lupus familiaris,9615.0
7252,N,,,,Half life in dogs,Intermediate,,,,,50588,BAO_0000218,A,,5006,,Canis lupus familiaris,9615.0
7253,N,,,,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,Intermediate,,,,,50588,BAO_0000218,A,,5356,In vivo,Canis lupus familiaris,9615.0
7254,N,,,,Half life in rat,Intermediate,,,,,50588,BAO_0000218,A,,405,,Canis lupus familiaris,9615.0
7255,N,,,,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Intermediate,,,,,50588,BAO_0000218,A,,6642,In vivo,Canis lupus familiaris,9615.0
7256,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,,10000001.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7257,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,,10000001.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7258,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,,10000001.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7259,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,,,10000001.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7260,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,,10000001.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7261,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,,10000004.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7262,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,,,,10000004.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7263,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,,10000004.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7264,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,,10000004.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7265,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,,10000004.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7266,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,,,10000004.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7267,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,,10000004.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7268,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,,948.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7269,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,,,,948.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7270,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,,948.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7271,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,,948.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7272,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,,948.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7273,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,,,948.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7274,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,,948.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7275,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,,2113.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7276,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Intermediate,,,,2113.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7277,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,,2113.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7278,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,,2113.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7279,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,,2113.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7280,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,,,2113.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7281,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,,2113.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7282,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,,2107.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7283,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,,,,2107.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7284,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,,2107.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7285,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,,2107.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7286,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,,2107.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7287,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,,,2107.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7288,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,,2107.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7289,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,,2048.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7290,N,,478.0,,In vitro cytotoxicity against A2780 (human ovarian cancer),Intermediate,,A2780,,,81034,BAO_0000219,F,,5895,,Homo sapiens,9606.0
7291,N,,478.0,,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,Intermediate,,A2780,,,81034,BAO_0000219,F,,6338,,Homo sapiens,9606.0
7292,N,,478.0,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,Intermediate,,A2780,,,81034,BAO_0000219,F,,15163,,Homo sapiens,9606.0
7293,N,,478.0,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,Intermediate,,A2780,,,81034,BAO_0000219,F,,15163,,Homo sapiens,9606.0
7294,N,,478.0,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,Expert,,A2780,,,81034,BAO_0000219,F,,15000,,Homo sapiens,9606.0
7295,N,,478.0,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,Expert,,A2780,,,81034,BAO_0000219,F,,15000,,Homo sapiens,9606.0
7296,N,,478.0,,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,Expert,,A2780,,,81034,BAO_0000219,F,,14729,,Homo sapiens,9606.0
7297,N,,478.0,,In vitro cytotoxicity against A2780 cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,17270,,Homo sapiens,9606.0
7298,N,,478.0,,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,Intermediate,,A2780,,,81034,BAO_0000219,F,,5685,,Homo sapiens,9606.0
7299,N,,478.0,,In vitro inhibitory activity against human ovarian cancer A2780 cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,3563,,Homo sapiens,9606.0
7300,N,,478.0,,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,Intermediate,,A2780,,,81034,BAO_0000218,F,,17753,,Homo sapiens,9606.0
7301,N,,478.0,,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",Intermediate,,A2780,,,81034,BAO_0000219,F,,16317,,Homo sapiens,9606.0
7302,N,,478.0,,Inhibition of tubulin polymerization in analogy of ca.,Intermediate,,A2780,,,81034,BAO_0000219,F,,16936,,Homo sapiens,9606.0
7303,N,,478.0,,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,Intermediate,,A2780,,,81034,BAO_0000219,F,,3801,,Homo sapiens,9606.0
7304,N,,478.0,,Cytotoxic effect in ovarian cancer cell line (A2780),Expert,,A2780,,,81034,BAO_0000219,F,,6181,,Homo sapiens,9606.0
7305,N,,478.0,,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,Intermediate,,A2780,,,81034,BAO_0000219,F,,5318,,Homo sapiens,9606.0
7306,N,,478.0,,Tested for the cytotoxicity in A2780 ovarian cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,4840,,Homo sapiens,9606.0
7307,N,,478.0,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),Intermediate,,A2780,,,81034,BAO_0000219,F,,15748,,Homo sapiens,9606.0
7308,N,,478.0,,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,Intermediate,,A2780,,,81034,BAO_0000219,F,,15748,,Homo sapiens,9606.0
7309,N,,481.0,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,Intermediate,,A2780cisR,,,80017,BAO_0000219,F,,15748,,,
7310,N,,481.0,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),Intermediate,,A2780cisR,,,80017,BAO_0000219,F,,15748,,,
7311,N,,481.0,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,Intermediate,,A2780cisR,,,80017,BAO_0000219,F,,15748,,,
7312,N,,481.0,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),Intermediate,,A2780cisR,,,80017,BAO_0000219,F,,15748,,,
7313,N,,478.0,,In vivo log of cells killed after administration of compound in A2780 cell line,Intermediate,,A2780,,,81034,BAO_0000218,F,,17753,,Homo sapiens,9606.0
7314,N,,478.0,,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,Intermediate,,A2780,,,81034,BAO_0000218,F,,17753,In vivo,Homo sapiens,9606.0
7315,N,,478.0,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,Intermediate,,A2780,,,81034,BAO_0000219,F,,16936,,Homo sapiens,9606.0
7316,N,,478.0,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,Intermediate,,A2780,,,81034,BAO_0000219,F,,16936,,Homo sapiens,9606.0
7317,N,,478.0,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,Intermediate,,A2780,,,81034,BAO_0000219,F,,16936,,Homo sapiens,9606.0
7318,N,,478.0,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,Intermediate,,A2780,,,81034,BAO_0000219,F,,16936,,Homo sapiens,9606.0
7319,N,,478.0,,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),Intermediate,,A2780,,,81034,BAO_0000218,F,,17528,,Homo sapiens,9606.0
7320,N,,478.0,,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,6633,,Homo sapiens,9606.0
7321,N,,478.0,,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,Expert,,A2780,,,81034,BAO_0000219,F,,15000,,Homo sapiens,9606.0
7322,N,,478.0,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,Expert,,A2780,,,81034,BAO_0000219,F,,17528,,Homo sapiens,9606.0
7323,N,,478.0,,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,Intermediate,,A2780,,,81034,BAO_0000219,F,,16936,,Homo sapiens,9606.0
7324,N,,478.0,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,Intermediate,,A2780,,,81034,BAO_0000219,F,,16936,,Homo sapiens,9606.0
7325,N,,478.0,,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,Intermediate,,A2780,,,81034,BAO_0000219,F,,16936,,Homo sapiens,9606.0
7326,N,,478.0,,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",Intermediate,,A2780,,,81034,BAO_0000219,F,,16936,,Homo sapiens,9606.0
7327,N,,478.0,,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),Intermediate,,A2780,,,81034,BAO_0000219,F,,16936,,Homo sapiens,9606.0
7328,N,,478.0,,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",Expert,,A2780,,,81034,BAO_0000219,F,,16936,,Homo sapiens,9606.0
7329,N,,478.0,,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),Intermediate,,A2780,,,81034,BAO_0000219,F,,16936,,Homo sapiens,9606.0
7330,N,,478.0,,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),Intermediate,,A2780,,,81034,BAO_0000219,F,,16936,,Homo sapiens,9606.0
7331,N,,478.0,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),Intermediate,,A2780,,,81034,BAO_0000219,F,,16936,,Homo sapiens,9606.0
7332,N,,478.0,,In vitro antiproliferative activity against A2780 cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,17737,,Mus musculus,10090.0
7333,N,,478.0,,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,Expert,,A2780,,,81034,BAO_0000219,F,,17764,,Mus musculus,10090.0
7334,N,,478.0,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,Intermediate,,A2780,,,81034,BAO_0000219,F,,3830,,Homo sapiens,9606.0
7335,N,,478.0,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,Intermediate,,A2780,,,81034,BAO_0000219,F,,3829,,Homo sapiens,9606.0
7336,N,,,,Vc value in dog after IV administration at a dose of 5 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,3546,,Canis lupus familiaris,9615.0
7337,N,,,,Half life period in dog after IV administration at a dose of 5 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,3546,In vivo,Canis lupus familiaris,9615.0
7338,U,,,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,Autocuration,,,,,22224,BAO_0000019,A,,5668,,Cercopithecidae,9527.0
7339,U,,,,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,,1969.0,22224,BAO_0000218,A,,3443,,Cercopithecidae,9527.0
7340,U,,,,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,,1969.0,22224,BAO_0000218,A,,3443,,Cercopithecidae,9527.0
7341,U,,,,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,4256,In vivo,Macaca fascicularis,9541.0
7342,U,,,,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,4256,In vivo,Macaca fascicularis,9541.0
7343,U,,,,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,4256,In vivo,Macaca fascicularis,9541.0
7344,U,,,,Oral Bioavailability in rat,Autocuration,,,,,22224,BAO_0000218,A,,4256,In vivo,Rattus norvegicus,10116.0
7345,U,,,,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Autocuration,,,,,22224,BAO_0000218,A,,1916,,Cercopithecidae,9527.0
7346,U,,,,Area under curve value in monkey at a dose of 5 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,5302,,Cercopithecidae,9527.0
7347,U,,,,Area under curve was determined in monkey after a 3 mg/kg of oral dose,Autocuration,,,,,22224,BAO_0000218,A,,4257,,Cercopithecidae,9527.0
7348,U,,,,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,Autocuration,,,,,22224,BAO_0000019,A,,5355,,Cercopithecidae,9527.0
7349,U,,,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,Autocuration,,,,,22224,BAO_0000019,A,,5355,,Cercopithecidae,9527.0
7350,U,,,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,Autocuration,,,,,22224,BAO_0000019,A,,5355,,Cercopithecidae,9527.0
7351,U,,,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,Autocuration,,,,,22224,BAO_0000218,A,,6078,,Cercopithecidae,9527.0
7352,U,,,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,Autocuration,,,,,22224,BAO_0000218,A,,6078,,Cercopithecidae,9527.0
7353,U,,,,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,6062,,Cercopithecidae,9527.0
7354,U,,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,2661,,Cercopithecidae,9527.0
7355,U,,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,Autocuration,,,,,22224,BAO_0000019,A,,2661,,Cercopithecidae,9527.0
7356,U,,,,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,5394,,Cercopithecidae,9527.0
7357,U,,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,Autocuration,,,,,22224,BAO_0000218,A,,4397,,Cercopithecidae,9527.0
7358,U,,,,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,Autocuration,,,,,22224,BAO_0000218,A,,17509,,Cercopithecidae,9527.0
7359,U,,,,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,Autocuration,,,,,22224,BAO_0000218,A,,17509,,Cercopithecidae,9527.0
7360,U,,,,Oral AUCN in monkey (dosed at 0.5 mpk iv ),Autocuration,,,,,22224,BAO_0000218,A,,6641,In vivo,Cercopithecidae,9527.0
7361,U,,,,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),Autocuration,,,,,22224,BAO_0000218,A,,5355,,Cercopithecidae,9527.0
7362,U,,,,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,,,22224,BAO_0000218,A,,3443,In vivo,Cercopithecidae,9527.0
7363,U,,,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,,,22224,BAO_0000218,A,,3443,In vivo,Cercopithecidae,9527.0
7364,U,,,,Binding towards monkey plasma protein at 10 uM,Autocuration,,,,,22224,BAO_0000019,A,,17409,,Cercopithecidae,9527.0
7365,U,,,,Binding towards monkey plasma protein at 100 uM,Autocuration,,,,,22224,BAO_0000019,A,,17409,,Cercopithecidae,9527.0
7366,U,,,,Apparent bioavailability in squirrel monkey was determined,Autocuration,,,,,22224,BAO_0000218,A,,1052,In vivo,Cercopithecidae,9527.0
7367,U,,,,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,Autocuration,,,,,22224,BAO_0000218,A,,13501,In vivo,Cercopithecidae,9527.0
7368,U,,,,Bioavailability in monkey (dose 2 mg/kg),Autocuration,,,,,22224,BAO_0000218,A,,17509,In vivo,monkey,9443.0
7369,U,,,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,5394,In vivo,Cercopithecidae,9527.0
7370,U,,,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,2661,In vivo,Cercopithecidae,9527.0
7371,U,,,,Bioavailability in monkey (i.d. dosing),Autocuration,,,,,22224,BAO_0000218,A,,11219,In vivo,monkey,9443.0
7372,U,,,,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,Autocuration,,,,,22224,BAO_0000218,A,,3045,In vivo,Cercopithecidae,9527.0
7373,U,,,,Clearance of the drug was measured in cynomolgus,Autocuration,,,,,22224,BAO_0000019,A,,17796,,Cercopithecidae,9527.0
7374,U,,,,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,1399,In vivo,Cercopithecidae,9527.0
7375,U,,,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,2661,In vivo,Cercopithecidae,9527.0
7376,U,,,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Autocuration,,,,1969.0,22224,BAO_0000218,A,,5005,In vivo,Macaca mulatta,9544.0
7377,U,,,,Plasma clearance in rhesus monkey was determined,Autocuration,,,,,22224,BAO_0000218,A,,17267,In vivo,Cercopithecidae,9527.0
7378,U,,,,Plasma clearance in monkey after administration of 1 mg/kg iv,Autocuration,,,,,22224,BAO_0000218,A,,6535,In vivo,Cercopithecidae,9527.0
7379,U,,,,Plasma clearance in cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,5922,In vivo,Cercopithecidae,9527.0
7380,U,,,,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,Autocuration,,,,,22224,BAO_0000218,A,,6221,In vivo,Cercopithecidae,9527.0
7381,U,,,,Plasma clearance after peroral administration at 10 mpk in Rhesus,Autocuration,,,,,22224,BAO_0000218,A,,5668,In vivo,Cercopithecidae,9527.0
7382,U,,,,The total clearance was determined after intravenous administration in cynomolgus monkeys,Autocuration,,,,,22224,BAO_0000218,A,,5355,In vivo,Cercopithecidae,9527.0
7383,U,,,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,Autocuration,,,,,22224,BAO_0000218,A,,5355,In vivo,Cercopithecidae,9527.0
7384,U,,,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,Autocuration,,,,,22224,BAO_0000218,A,,5355,In vivo,Cercopithecidae,9527.0
7385,U,,,,Tested for Clearance upon iv administration to african green monkey,Autocuration,,,,,22224,BAO_0000218,A,,4578,In vivo,Cercopithecidae,9527.0
7386,U,,,,Clearance in monkey,Autocuration,,,,,22224,BAO_0000218,A,,17592,In vivo,Cercopithecidae,9527.0
7387,N,,,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Intermediate,,,,,50588,BAO_0000218,A,,6641,In vivo,Canis lupus familiaris,9615.0
7388,N,,,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Intermediate,,,,,50588,BAO_0000218,A,,6642,In vivo,Canis lupus familiaris,9615.0
7389,N,,,,Half life was evaluated after intravenous administration to dogs,Intermediate,,,,,50588,BAO_0000218,A,,16367,In vivo,Canis lupus familiaris,9615.0
7390,N,,,,Half life was evaluated in dog,Intermediate,,,,,50588,BAO_0000218,A,,5472,,Canis lupus familiaris,9615.0
7391,N,,,,Half life was evaluated in dog,Intermediate,,,,,50588,BAO_0000218,A,,5474,,Canis lupus familiaris,9615.0
7392,N,,,,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,5654,In vivo,Canis lupus familiaris,9615.0
7393,N,,,,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),Intermediate,,,,,50588,BAO_0000218,A,,6227,In vivo,Canis lupus familiaris,9615.0
7394,N,,,,Half life period after intravenous administration in dog,Intermediate,,,,,50588,BAO_0000218,A,,6227,In vivo,Canis lupus familiaris,9615.0
7395,N,,,,Half life period after oral administration (2.5 mg/kg) in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,6221,In vivo,Canis lupus familiaris,9615.0
7396,N,,,,Half life period at a dose of 1 uM/kg in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,4527,,Canis lupus familiaris,9615.0
7397,N,,,,Half life period was determine after peroral administration at 10 mpk in dog,Intermediate,,,,,50588,BAO_0000218,A,,5668,In vivo,Canis lupus familiaris,9615.0
7398,N,,,,Half life period was determine after peroral administration at 5 mpk in dog,Intermediate,,,,,50588,BAO_0000218,A,,5668,In vivo,Canis lupus familiaris,9615.0
7399,N,,,,Half life period was determined,Intermediate,,,,,50588,BAO_0000218,A,,3854,,Canis lupus familiaris,9615.0
7400,N,,,,Half life period was determined,Intermediate,,,,,50588,BAO_0000218,A,,5505,,Canis lupus familiaris,9615.0
7401,N,,,,Half life period by iv administration in dog at a dose of 6 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6251,In vivo,Canis lupus familiaris,9615.0
7402,N,,,,Half life period was evaluated in dog,Intermediate,,,,,50588,BAO_0000218,A,,1918,,Canis lupus familiaris,9615.0
7403,N,,,,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,Intermediate,,,,,50588,BAO_0000218,A,,5546,In vivo,Canis lupus familiaris,9615.0
7404,N,,,,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),Intermediate,,,,,50588,BAO_0000218,A,,4809,In vivo,Canis lupus familiaris,9615.0
7405,N,,,,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,Intermediate,,,,,50588,BAO_0000218,A,,6215,In vivo,Canis lupus familiaris,9615.0
7406,N,,,,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,4527,In vivo,Canis lupus familiaris,9615.0
7407,N,,,,Half-life after oral dose of compound at 3 mg/kg in dogs,Intermediate,,,,,50588,BAO_0000218,A,,17594,In vivo,Canis lupus familiaris,9615.0
7408,N,,,,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,17839,In vivo,Canis lupus familiaris,9615.0
7409,N,,,,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,17839,In vivo,Canis lupus familiaris,9615.0
7410,N,,,,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,17839,In vivo,Canis lupus familiaris,9615.0
7411,N,,,,Half-life of compound in dog following p.o. administration of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,17839,In vivo,Canis lupus familiaris,9615.0
7412,N,,,,Half-life of compound in plasma of dog was determined,Intermediate,,,,1969.0,50588,BAO_0000218,A,,5210,,Canis lupus familiaris,9615.0
7413,N,,,,Half-life of compound was determined in dogs,Intermediate,,,,,50588,BAO_0000218,A,,5210,,Canis lupus familiaris,9615.0
7414,N,,,,Half-life after administration of 4 mg/Kg oral dose in dog,Intermediate,,,,,50588,BAO_0000218,A,,2959,In vivo,Canis lupus familiaris,9615.0
7415,N,,,,Half-life after intravenous administration of 1 mg/kg/h in dog,Intermediate,,,,,50588,BAO_0000218,A,,4137,In vivo,Canis lupus familiaris,9615.0
7416,N,,,,Half-life in Dog,Intermediate,,,,,50588,BAO_0000218,A,,5064,,Canis lupus familiaris,9615.0
7417,N,,,,Half-life in Dog,Intermediate,,,,,50588,BAO_0000218,A,,5147,,Canis lupus familiaris,9615.0
7418,N,,,,Half-life in dog,Intermediate,,,,,50588,BAO_0000218,A,,5145,,Canis lupus familiaris,9615.0
7419,N,,,,Half-life in dog after oral administration at 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6123,In vivo,Canis lupus familiaris,9615.0
7420,N,,,,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,Intermediate,,,,,50588,BAO_0000218,A,,6123,In vivo,Canis lupus familiaris,9615.0
7421,N,,,,Half-life in dogs,Intermediate,,,,,50588,BAO_0000218,A,,4333,,Canis lupus familiaris,9615.0
7422,N,,,,Half-life in dogs; ND indicates not determined,Intermediate,,,,,50588,BAO_0000218,A,,4333,,Canis lupus familiaris,9615.0
7423,N,,,,Half-life in plasma of dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,12500,,Canis lupus familiaris,9615.0
7424,N,,,,Half-life in plasma of dog at dose of 3-10 mgkg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,12500,,Canis lupus familiaris,9615.0
7425,N,,,,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6005,In vivo,Canis lupus familiaris,9615.0
7426,N,,,,Half-life was measured in dog after an iv dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6062,In vivo,Canis lupus familiaris,9615.0
7427,N,,,,Half-life was measured in dogs after an oral dose of 10 uM/kg,Intermediate,,,,,50588,BAO_0000218,A,,17650,In vivo,Canis lupus familiaris,9615.0
7428,N,,,,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,5530,In vivo,Canis lupus familiaris,9615.0
7429,N,,,,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,5530,In vivo,Canis lupus familiaris,9615.0
7430,N,,,,Half-life of the compound after 0.3 mg/kg po administration in dog,Intermediate,,,,,50588,BAO_0000218,A,,5600,In vivo,Canis lupus familiaris,9615.0
7431,N,,,,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,6039,In vivo,Canis lupus familiaris,9615.0
7432,N,,,,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,6039,In vivo,Canis lupus familiaris,9615.0
7433,N,,,,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,6039,In vivo,Canis lupus familiaris,9615.0
7434,N,,,,t1/2 in dog,Intermediate,,,,,50588,BAO_0000218,A,,6227,,Canis lupus familiaris,9615.0
7435,N,,,,Half-life period measured in dogs,Intermediate,,,,,50588,BAO_0000218,A,,14541,,Canis lupus familiaris,9615.0
7436,N,,,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,Intermediate,,,,,50588,BAO_0000218,A,,4521,In vivo,Canis lupus familiaris,9615.0
7437,N,,,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,Intermediate,,,,,50588,BAO_0000218,A,,4521,In vivo,Canis lupus familiaris,9615.0
7438,N,,,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,,,,,50588,BAO_0000218,A,,6679,In vivo,Canis lupus familiaris,9615.0
7439,N,,,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",Intermediate,,,,1969.0,50588,BAO_0000218,A,,1116,In vitro,Canis lupus familiaris,9615.0
7440,N,,,,In vivo half life period was calculated at 1 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,5444,In vivo,Canis lupus familiaris,9615.0
7441,N,,,,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,Intermediate,,,,,50588,BAO_0000218,A,,5444,In vivo,Canis lupus familiaris,9615.0
7442,N,,,,Longer half-life in dog (i.v.) at 0.5 mpk,Intermediate,,,,,50588,BAO_0000218,A,,17853,In vivo,Canis lupus familiaris,9615.0
7443,N,,,,Oral bioavailability in dog (dose 5 uM/kg),Intermediate,,,,,50588,BAO_0000218,A,,4353,In vivo,Canis lupus familiaris,9615.0
7444,N,,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,Intermediate,,,,,50588,BAO_0000218,A,,16452,In vivo,Canis lupus familiaris,9615.0
7445,N,,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,Intermediate,,,,,50588,BAO_0000218,A,,16452,In vivo,Canis lupus familiaris,9615.0
7446,N,,,,Bioavailability in dog (dose 1 mg/kg i.v.),Intermediate,,,,,50588,BAO_0000218,A,,16452,In vivo,Canis lupus familiaris,9615.0
7447,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Intermediate,,,,2048.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7448,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,,2048.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7449,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,,2048.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7450,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,,2048.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7451,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,,,2048.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7452,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,,2048.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7453,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,,2385.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7454,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Intermediate,,,,2385.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7455,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,,2385.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7456,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,,2385.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7457,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,,2385.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7458,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,,,2385.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7459,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,,2385.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7460,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,,14.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7461,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,,,,14.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7462,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,,14.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7463,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,,14.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7464,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,,14.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7465,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,,,14.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7466,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,,14.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7467,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,,2106.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7468,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,,,,2106.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7469,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,,2106.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7470,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,,2106.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7471,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,,2106.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7472,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,,,2106.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7473,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,,2106.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7474,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,,945.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7475,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,,,,945.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7476,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,,945.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7477,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,,945.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7478,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,,945.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7479,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,,,945.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7480,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,,945.0,50594,BAO_0000218,A,,10107,In vivo,Mus musculus,10090.0
7481,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,4689,In vivo,Rattus norvegicus,10116.0
7482,N,,,,Tested for the bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,4950,In vivo,Rattus norvegicus,10116.0
7483,N,,,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,5328,In vivo,Rattus norvegicus,10116.0
7484,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,406,In vivo,Rattus norvegicus,10116.0
7485,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,12500,In vivo,Rattus norvegicus,10116.0
7486,N,,,,Bioavailability in rat (dose 3-10 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,12500,In vivo,Rattus norvegicus,10116.0
7487,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5247,In vivo,Rattus norvegicus,10116.0
7488,N,,,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4186,In vivo,Rattus norvegicus,10116.0
7489,N,,,,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4186,In vivo,Rattus norvegicus,10116.0
7490,N,,,,Half life after oral administration was determined in rats at 6 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6647,In vivo,Rattus norvegicus,10116.0
7491,N,,,,Half life was determined,Intermediate,,,,,50597,BAO_0000218,A,,6484,,Rattus norvegicus,10116.0
7492,N,,,,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,3249,In vivo,Rattus norvegicus,10116.0
7493,N,,,,Plasma half life in rat at oral dose 2.8 mg/mk body weight,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6281,In vivo,Rattus norvegicus,10116.0
7494,N,,,,Half life in rats,Intermediate,,,,,50597,BAO_0000218,A,,3307,,Rattus norvegicus,10116.0
7495,N,,,,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,Intermediate,,,,178.0,50597,BAO_0000218,A,,12058,In vivo,Rattus norvegicus,10116.0
7496,N,,,,Hill coefficient of the compound,Intermediate,,,,,50597,BAO_0000218,A,,8833,,Rattus norvegicus,10116.0
7497,N,,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,3193,,Rattus norvegicus,10116.0
7498,N,,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,3193,,Rattus norvegicus,10116.0
7499,N,,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,3193,,Rattus norvegicus,10116.0
7500,N,,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,3193,,Rattus norvegicus,10116.0
7501,N,,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,3193,,Rattus norvegicus,10116.0
7502,N,,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,3193,,Rattus norvegicus,10116.0
7503,N,,,,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",Intermediate,,,,178.0,50597,BAO_0000218,A,,3193,,Rattus norvegicus,10116.0
7504,N,,,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,Intermediate,,,,,50597,BAO_0000218,A,,5960,,Rattus norvegicus,10116.0
7505,N,,,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,Intermediate,,,,955.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
7506,N,,,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,Intermediate,,,,955.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
7507,N,,,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,Intermediate,,,,955.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
7508,N,,,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,Intermediate,,,,955.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
7509,N,,,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,Intermediate,,,,955.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
7510,N,,,,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,Intermediate,,,,2046.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
7511,N,,,,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,Intermediate,,,,2046.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
7512,N,,,,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,Intermediate,,,,2046.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
7513,N,,,,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,Intermediate,,,,2046.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
7514,N,,,,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,Intermediate,,,,2046.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
7515,N,,,,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7516,N,,,,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7517,N,,,,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7518,N,,,,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7519,N,,,,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7520,N,,,,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7521,N,,,,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7522,N,,,,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7523,N,,,,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7524,N,,,,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7525,N,,,,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7526,N,,,,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7527,N,,,,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7528,N,,,,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7529,N,,,,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7530,N,,,,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,,,,2048.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7531,N,,,,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,Intermediate,,,,2048.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7532,N,,,,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,,,,2048.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7533,N,,,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,Intermediate,,,,,50597,BAO_0000218,A,,6351,,Rattus norvegicus,10116.0
7534,N,,,,Compound was tested for solubility in water,Intermediate,,,,,50597,BAO_0000218,A,,1465,,Rattus norvegicus,10116.0
7535,U,,,,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),Intermediate,,,,,22229,BAO_0000100,P,,5182,,,
7536,N,,,,Solubility was determined,Intermediate,,,,,50597,BAO_0000218,A,,17847,,Rattus norvegicus,10116.0
7537,N,,,,solubility in water (ug/mL) at 37 degree C.,Intermediate,,,,,50597,BAO_0000218,A,,15339,,Rattus norvegicus,10116.0
7538,N,,,,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,Intermediate,,,,,50597,BAO_0000218,A,,5202,,Rattus norvegicus,10116.0
7539,N,,,,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,Intermediate,,,,,50597,BAO_0000218,A,,1088,,Rattus norvegicus,10116.0
7540,N,,,,Half life in rats,Intermediate,,,,,50597,BAO_0000218,A,,3169,,Rattus norvegicus,10116.0
7541,N,,,,Half life in Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5353,,Rattus norvegicus,10116.0
7542,N,,,,Half life period after 3 mg/kg iv administration,Intermediate,,,,,50597,BAO_0000218,A,,2864,In vivo,Rattus norvegicus,10116.0
7543,N,,,,Half life period after 3 mg/kg iv administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,2864,In vivo,Rattus norvegicus,10116.0
7544,N,,,,Half life period after 3 mg/kg iv administration in the rat,Intermediate,,,,,50597,BAO_0000218,A,,2864,In vivo,Rattus norvegicus,10116.0
7545,N,,,,Half life period in female Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,6362,,Rattus norvegicus,10116.0
7546,N,,,,Half life period in rat,Intermediate,,,,,50597,BAO_0000218,A,,6249,,Rattus norvegicus,10116.0
7547,N,,,,Half-life in rats was determined,Intermediate,,,,,50597,BAO_0000218,A,,3169,,Rattus norvegicus,10116.0
7548,N,,,,Half-life in rats with metabolic oxidation,Intermediate,,,,,50597,BAO_0000218,A,,3169,,Rattus norvegicus,10116.0
7549,N,,,,Half-life in rats,Intermediate,,,,,50597,BAO_0000218,A,,3169,,Rattus norvegicus,10116.0
7550,N,,,,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,Intermediate,,,,,50597,BAO_0000218,A,,17260,In vivo,Rattus norvegicus,10116.0
7551,N,,,,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,Intermediate,,,,,50597,BAO_0000218,A,,17260,In vivo,Rattus norvegicus,10116.0
7552,N,,,,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,Intermediate,,,,,50597,BAO_0000218,A,,17260,In vivo,Rattus norvegicus,10116.0
7553,N,,,,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,Intermediate,,,,,50597,BAO_0000218,A,,17260,In vivo,Rattus norvegicus,10116.0
7554,N,,,,Biological half-life measured in plasma of rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2879,,Rattus norvegicus,10116.0
7555,N,,,,Biological half-life measured in plasma of rat; 22-25,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2879,,Rattus norvegicus,10116.0
7556,N,,,,Biological half-life measured in plasma of rat; 9-16,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2879,,Rattus norvegicus,10116.0
7557,N,,,,Compound was evaluated for its half life when administered intravenously in rat,Intermediate,,,,,50597,BAO_0000218,A,,3184,In vivo,Rattus norvegicus,10116.0
7558,N,,,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,Intermediate,,,,,50597,BAO_0000218,A,,4891,In vivo,Rattus norvegicus,10116.0
7559,N,,,,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,429,In vivo,Rattus norvegicus,10116.0
7560,N,,,,Half life (T1/2) after oral administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,5656,In vivo,Rattus norvegicus,10116.0
7561,N,,,,Half life of compound after iv administration of 20 mg/kg dose in rat,Intermediate,,,,,50597,BAO_0000218,A,,4413,In vivo,Rattus norvegicus,10116.0
7562,N,,,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,Expert,,,,,50597,BAO_0000218,A,,3598,In vivo,Rattus norvegicus,10116.0
7563,N,,,,Half life of compound was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,17267,,Rattus norvegicus,10116.0
7564,N,,,,Half life of compound was determined in rat blood,Intermediate,,,,178.0,50597,BAO_0000218,A,,4727,,Rattus norvegicus,10116.0
7565,N,,,,Half life at 1 mg/kg was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,17651,In vivo,Rattus norvegicus,10116.0
7566,N,,,,Half life at 10 mg/kg was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,17651,In vivo,Rattus norvegicus,10116.0
7567,N,,,,Half life in rats,Intermediate,,,,,50597,BAO_0000218,A,,401,,Rattus norvegicus,10116.0
7568,N,,,,Half life in rats in hours,Intermediate,,,,,50597,BAO_0000218,A,,4942,,Rattus norvegicus,10116.0
7569,N,,,,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,Intermediate,,,,,50597,BAO_0000218,A,,17735,In vivo,Rattus norvegicus,10116.0
7570,N,,,,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6056,In vivo,Rattus norvegicus,10116.0
7571,N,,,,Half life was determined,Intermediate,,,,,50597,BAO_0000218,A,,5213,,Rattus norvegicus,10116.0
7572,N,,,,Half life after i.v. administration,Intermediate,,,,,50597,BAO_0000218,A,,6616,In vivo,Rattus norvegicus,10116.0
7573,N,,,,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5937,In vivo,Rattus norvegicus,10116.0
7574,N,,,,Half life in rat plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5819,,Rattus norvegicus,10116.0
7575,N,,,,Half life in rat plasma; Not detected,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5819,,Rattus norvegicus,10116.0
7576,N,,,,Half life in rats,Intermediate,,,,,50597,BAO_0000218,A,,6803,,Rattus norvegicus,10116.0
7577,N,,,,Half life period of compound was determined after peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,17804,In vivo,Rattus norvegicus,10116.0
7578,N,,,,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,Intermediate,,,,,50597,BAO_0000218,A,,17804,In vivo,Rattus norvegicus,10116.0
7579,N,,,,Half life period in rat,Intermediate,,,,,50597,BAO_0000218,A,,5948,,Rattus norvegicus,10116.0
7580,N,,,,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,Intermediate,,,,,50597,BAO_0000218,A,,1916,In vivo,Rattus norvegicus,10116.0
7581,N,,,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,Intermediate,,,,,50597,BAO_0000218,A,,1916,In vivo,Rattus norvegicus,10116.0
7582,N,,,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,Intermediate,,,,,50597,BAO_0000218,A,,1916,In vivo,Rattus norvegicus,10116.0
7583,N,,,,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,4890,In vivo,Rattus norvegicus,10116.0
7584,N,,,,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,Intermediate,,,,,50597,BAO_0000218,A,,17764,In vivo,Rattus norvegicus,10116.0
7585,N,,,,Half life time in rat the dose of 2 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,4727,In vivo,Rattus norvegicus,10116.0
7586,N,,,,Half-life 24 hr after 10 mg/kg iv administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,17509,In vivo,Rattus norvegicus,10116.0
7587,N,,,,Half-life 24 hr after 2 mg/kg iv administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,17509,In vivo,Rattus norvegicus,10116.0
7588,N,,,,Half-life consistent with the observed metabolic steady state in rats,Intermediate,,,,,50597,BAO_0000218,A,,6597,,Rattus norvegicus,10116.0
7589,N,,,,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,Intermediate,,,,,50597,BAO_0000218,A,,17735,In vivo,Rattus norvegicus,10116.0
7590,N,,,,Half-life for oxidative metabolic stability was determined using male human,Intermediate,,,,,50597,BAO_0000218,A,,6597,,Rattus norvegicus,10116.0
7591,N,,,,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",Intermediate,,,,,50597,BAO_0000218,A,,17670,In vivo,Rattus norvegicus,10116.0
7592,N,,,,Half-life in rat plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1696,,Rattus norvegicus,10116.0
7593,N,,,,Half-life in rat plasma was determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1742,,Rattus norvegicus,10116.0
7594,N,,,,Half-life in rats was determined,Intermediate,,,,,50597,BAO_0000218,A,,17800,,Rattus norvegicus,10116.0
7595,U,,,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,Autocuration,,,,,22224,BAO_0000218,A,,12923,,,
7596,U,,,,Area under curve after oral dose of 0.1 mg//kg,Autocuration,,,,,22224,BAO_0000019,A,,11954,,,
7597,U,,,,Area under curve after oral dose of 0.3 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,,,
7598,U,,,,Area under curve after oral dose of 1 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,,,
7599,U,,,,Area under curve after oral dose of 10 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,,,
7600,U,,,,Area under curve after oral dose of 23.4 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,,,
7601,U,,,,Area under curve after oral dose of 3 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,,,
7602,U,,,,Area under curve after oral dose of 3.87 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,,,
7603,U,,,,Area under curve was determined,Autocuration,,,,,22224,BAO_0000019,A,,5237,,,
7604,U,,,,Area under curve at a dose of 10 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,4026,,,
7605,N,,,,Area under curve was determined; ND=No data,Intermediate,,,,,50597,BAO_0000218,A,,5237,,Rattus norvegicus,10116.0
7606,N,,,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,Intermediate,,,,,50597,BAO_0000218,A,,14793,,Rattus norvegicus,10116.0
7607,N,,,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,Intermediate,,,,,50597,BAO_0000218,A,,14793,,Rattus norvegicus,10116.0
7608,N,,,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,Intermediate,,,,,50597,BAO_0000218,A,,14793,,Rattus norvegicus,10116.0
7609,N,,,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,Intermediate,,,,,50597,BAO_0000218,A,,14793,,Rattus norvegicus,10116.0
7610,N,,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,Intermediate,,,,,50597,BAO_0000218,A,,14793,,Rattus norvegicus,10116.0
7611,N,,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,Intermediate,,,,,50597,BAO_0000218,A,,14793,,Rattus norvegicus,10116.0
7612,N,,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,Intermediate,,,,,50597,BAO_0000218,A,,14793,,Rattus norvegicus,10116.0
7613,N,,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,Intermediate,,,,,50597,BAO_0000218,A,,14793,,Rattus norvegicus,10116.0
7614,N,,,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14793,,Rattus norvegicus,10116.0
7615,N,,,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14793,,Rattus norvegicus,10116.0
7616,N,,,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14793,,Rattus norvegicus,10116.0
7617,N,,,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14793,,Rattus norvegicus,10116.0
7618,N,,,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14793,,Rattus norvegicus,10116.0
7619,N,,,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14793,,Rattus norvegicus,10116.0
7620,N,,,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14793,,Rattus norvegicus,10116.0
7621,N,,,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14793,,Rattus norvegicus,10116.0
7622,N,,,,AUC in mice,Intermediate,,,,1969.0,50594,BAO_0000218,A,,11637,,Mus musculus,10090.0
7623,U,,,,Area under curve was measured from the graph obtained from concentration Vs time,Autocuration,,,,,22224,BAO_0000019,A,,11149,,,
7624,U,,,,Area under curve value of compound per hour after oral administration,Autocuration,,,,,22224,BAO_0000019,A,,10016,,,
7625,N,,,,Area under curve was determined after oral administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,17796,,Rattus norvegicus,10116.0
7626,N,,,,Area under curve was determined after oral administration in rats; No data,Intermediate,,,,,50597,BAO_0000218,A,,17796,,Rattus norvegicus,10116.0
7627,N,,,,Area under curve was determined after oral administration in rats;No data,Intermediate,,,,,50597,BAO_0000218,A,,17796,,Rattus norvegicus,10116.0
7628,N,,,,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,Intermediate,,,,,50588,BAO_0000218,A,,12923,,Canis lupus familiaris,9615.0
7629,N,,,,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,15372,,Rattus norvegicus,10116.0
7630,N,,,,Area under curve was determined for the compound after iv dose of 5.06 in rats,Intermediate,,,,,50597,BAO_0000218,A,,15372,,Rattus norvegicus,10116.0
7631,N,,,,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,15372,,Rattus norvegicus,10116.0
7632,N,,,,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,15372,,Rattus norvegicus,10116.0
7633,N,,,,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,15372,,Rattus norvegicus,10116.0
7634,N,,,,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,15372,,Rattus norvegicus,10116.0
7635,N,,,,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,15372,,Rattus norvegicus,10116.0
7636,N,,,,Area under curve was determined in Dogs after peroral administration,Intermediate,,,,,50588,BAO_0000218,A,,14169,,Canis lupus familiaris,9615.0
7637,N,,,,Area under curve was determined in Rats after peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,14169,,Rattus norvegicus,10116.0
7638,N,,,,Area under curve was determined in carotid blood of rat when administered intradermally,Intermediate,,,,,50597,BAO_0000218,A,,14258,,Rattus norvegicus,10116.0
7639,N,,,,Area under curve was determined in portal blood of rat when administered intradermally,Intermediate,,,,,50597,BAO_0000218,A,,14258,,Rattus norvegicus,10116.0
7640,N,,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,15011,,Mus musculus,10090.0
7641,N,,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,15011,,Mus musculus,10090.0
7642,N,,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),Intermediate,,,,,50594,BAO_0000218,A,,15011,,Mus musculus,10090.0
7643,N,,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,15011,,Mus musculus,10090.0
7644,N,,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),Intermediate,,,,,50594,BAO_0000218,A,,15011,,Mus musculus,10090.0
7645,N,,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,15011,,Mus musculus,10090.0
7646,N,,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),Intermediate,,,,,50594,BAO_0000218,A,,15011,,Mus musculus,10090.0
7647,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,Intermediate,,,,2106.0,50597,BAO_0000218,A,,11195,In vivo,Rattus norvegicus,10116.0
7648,N,,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,Intermediate,,,,178.0,50597,BAO_0000218,A,,10130,,Rattus norvegicus,10116.0
7649,N,,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,Intermediate,,,,955.0,50597,BAO_0000218,A,,10130,,Rattus norvegicus,10116.0
7650,N,,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,Intermediate,,,,948.0,50597,BAO_0000218,A,,10130,,Rattus norvegicus,10116.0
7651,N,,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,Intermediate,,,,2107.0,50597,BAO_0000218,A,,10130,,Rattus norvegicus,10116.0
7652,N,,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,Intermediate,,,,2048.0,50597,BAO_0000218,A,,10130,,Rattus norvegicus,10116.0
7653,N,,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,Intermediate,,,,2385.0,50597,BAO_0000218,A,,10130,,Rattus norvegicus,10116.0
7654,N,,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,Intermediate,,,,,50597,BAO_0000218,A,,10130,,Rattus norvegicus,10116.0
7655,N,,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,Intermediate,,,,2106.0,50597,BAO_0000218,A,,10130,,Rattus norvegicus,10116.0
7656,N,,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,Intermediate,,,,2046.0,50597,BAO_0000218,A,,10130,,Rattus norvegicus,10116.0
7657,N,,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,10130,,Rattus norvegicus,10116.0
7658,N,,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,Intermediate,,,,178.0,50597,BAO_0000218,A,,10130,,Rattus norvegicus,10116.0
7659,N,,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,Intermediate,,,,955.0,50597,BAO_0000218,A,,10130,,Rattus norvegicus,10116.0
7660,N,,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,Intermediate,,,,948.0,50597,BAO_0000218,A,,10130,,Rattus norvegicus,10116.0
7661,N,,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,10130,,Rattus norvegicus,10116.0
7662,N,,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,Intermediate,,,,2107.0,50597,BAO_0000218,A,,10130,,Rattus norvegicus,10116.0
7663,N,,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,Intermediate,,,,2048.0,50597,BAO_0000218,A,,10130,,Rattus norvegicus,10116.0
7664,N,,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,Intermediate,,,,2385.0,50597,BAO_0000218,A,,10130,,Rattus norvegicus,10116.0
7665,N,,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,Intermediate,,,,,50597,BAO_0000218,A,,10130,,Rattus norvegicus,10116.0
7666,N,,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,Intermediate,,,,2106.0,50597,BAO_0000218,A,,10130,,Rattus norvegicus,10116.0
7667,N,,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,Intermediate,,,,2046.0,50597,BAO_0000218,A,,10130,,Rattus norvegicus,10116.0
7668,N,,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,Intermediate,,,,178.0,50597,BAO_0000218,A,,10130,,Rattus norvegicus,10116.0
7669,N,,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,Intermediate,,,,948.0,50597,BAO_0000218,A,,10130,,Rattus norvegicus,10116.0
7670,N,,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,10130,,Rattus norvegicus,10116.0
7671,N,,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,Intermediate,,,,2107.0,50597,BAO_0000218,A,,10130,,Rattus norvegicus,10116.0
7672,N,,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,Intermediate,,,,2385.0,50597,BAO_0000218,A,,10130,,Rattus norvegicus,10116.0
7673,N,,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,Intermediate,,,,2106.0,50597,BAO_0000218,A,,10130,,Rattus norvegicus,10116.0
7674,N,,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,Intermediate,,,,2046.0,50597,BAO_0000218,A,,10130,,Rattus norvegicus,10116.0
7675,N,,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,Intermediate,,,,955.0,50597,BAO_0000218,A,,10130,,Rattus norvegicus,10116.0
7676,N,,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,Intermediate,,,,2048.0,50597,BAO_0000218,A,,10130,,Rattus norvegicus,10116.0
7677,N,,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,Intermediate,,,,,50597,BAO_0000218,A,,10130,,Rattus norvegicus,10116.0
7678,N,,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6295,,Rattus norvegicus,10116.0
7679,N,,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6296,,Rattus norvegicus,10116.0
7680,N,,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,Intermediate,,,,,50597,BAO_0000218,A,,6296,,Rattus norvegicus,10116.0
7681,N,,,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6295,,Rattus norvegicus,10116.0
7682,N,,,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6296,,Rattus norvegicus,10116.0
7683,N,,,,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,Intermediate,,,,,50597,BAO_0000218,A,,17260,In vivo,Rattus norvegicus,10116.0
7684,N,,,,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,Intermediate,,,,,50597,BAO_0000218,A,,17260,In vivo,Rattus norvegicus,10116.0
7685,N,,,,C24h in rat p.o. at 20 mg/kg concentration,Intermediate,,,,,50597,BAO_0000218,A,,17686,,Rattus norvegicus,10116.0
7686,N,,,,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7687,N,,,,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7688,N,,,,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7689,N,,,,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,,,,2106.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7690,N,,,,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,Intermediate,,,,2106.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7691,N,,,,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,,,,2106.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7692,N,,,,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7693,N,,,,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7694,N,,,,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7695,N,,,,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7696,N,,,,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7697,N,,,,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7698,N,,,,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7699,N,,,,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7700,N,,,,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7701,N,,,,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7702,N,,,,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7703,N,,,,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7704,N,,,,Biodistribution in rat blood in the presence of GdDTPA at 15 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7705,N,,,,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7706,N,,,,Biodistribution in rat blood in the presence of GdDTPA at 30 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7707,N,,,,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7708,N,,,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7709,N,,,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7710,N,,,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7711,N,,,,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7712,N,,,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7713,N,,,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7714,N,,,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7715,N,,,,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7716,N,,,,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7717,N,,,,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7718,N,,,,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7719,N,,,,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7720,N,,,,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7721,N,,,,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7722,N,,,,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7723,N,,,,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7724,N,,,,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7725,N,,,,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7726,N,,,,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7727,N,,,,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7728,N,,,,Biodistribution in rat bone in the presence of GdDTPA at 15 min,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7729,N,,,,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7730,N,,,,Biodistribution in rat bone in the presence of GdDTPA at 30 min,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7731,N,,,,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7732,N,,,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7733,N,,,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7734,N,,,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7735,N,,,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7736,N,,,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7737,N,,,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7738,N,,,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7739,N,,,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7740,N,,,,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7741,N,,,,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7742,N,,,,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7743,N,,,,Half-life from rat plasma at a single oral dose of 25 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17752,In vivo,Rattus norvegicus,10116.0
7744,N,,,,Half-life in male rat,Intermediate,,,,,50597,BAO_0000218,A,,5610,,Rattus norvegicus,10116.0
7745,N,,,,Half-life in rat after peroral administration at 10 mg/kg concentration,Intermediate,,,,,50597,BAO_0000218,A,,5939,In vivo,Rattus norvegicus,10116.0
7746,N,,,,Half-life in rat after peroral administration at 5 mg/kg concentration,Intermediate,,,,,50597,BAO_0000218,A,,5939,In vivo,Rattus norvegicus,10116.0
7747,N,,,,Half-life in rat at a dose of 3 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17771,In vivo,Rattus norvegicus,10116.0
7748,N,,,,Half-life was evaluated in rats,Intermediate,,,,,50597,BAO_0000218,A,,1974,,Rattus norvegicus,10116.0
7749,N,,,,Half-life was measured in rat,Intermediate,,,,,50597,BAO_0000218,A,,4239,,Rattus norvegicus,10116.0
7750,N,,,,Half-life period for the compound was determined in rats at 50 mg/kg dose,Intermediate,,,,,50597,BAO_0000218,A,,6681,In vivo,Rattus norvegicus,10116.0
7751,N,,,,Half-life period in rats after intravenous administration at 5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17752,In vivo,Rattus norvegicus,10116.0
7752,N,,,,Half-life period in rat at 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6046,In vivo,Rattus norvegicus,10116.0
7753,N,,,,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,6685,In vivo,Rattus norvegicus,10116.0
7754,N,,,,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",Intermediate,,,,,50597,BAO_0000218,A,,6685,In vivo,Rattus norvegicus,10116.0
7755,N,,,,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",Intermediate,,,,,50597,BAO_0000218,A,,6685,In vivo,Rattus norvegicus,10116.0
7756,N,,,,Half-life time in rat the dose of 2 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,4727,In vivo,Rattus norvegicus,10116.0
7757,N,,,,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,Intermediate,,,,,50597,BAO_0000218,A,,1088,In vivo,Rattus norvegicus,10116.0
7758,N,,,,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5610,In vivo,Rattus norvegicus,10116.0
7759,N,,,,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",Intermediate,,,,1969.0,50597,BAO_0000218,A,,3032,In vivo,Rattus norvegicus,10116.0
7760,N,,,,Oral half life was determined,Intermediate,,,,,50597,BAO_0000218,A,,5199,In vivo,Rattus norvegicus,10116.0
7761,N,,,,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",Intermediate,,,,,50597,BAO_0000218,A,,14941,In vivo,Rattus norvegicus,10116.0
7762,N,,,,Pharmacokinetic property (t1/2) in rat,Intermediate,,,,,50597,BAO_0000218,A,,4408,In vivo,Rattus norvegicus,10116.0
7763,N,,,,Plasma elimination half-life was determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2552,,Rattus norvegicus,10116.0
7764,N,,,,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5199,In vivo,Rattus norvegicus,10116.0
7765,N,,,,Plasma half life was observed after intravenous administration in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15662,In vivo,Rattus norvegicus,10116.0
7766,N,,,,Plasma half-life was determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1465,,Rattus norvegicus,10116.0
7767,N,,,,Plasma half-life following oral administration in Fisher rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1446,In vivo,Rattus norvegicus,10116.0
7768,N,,,,Plasma half-life in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6824,,Rattus norvegicus,10116.0
7769,N,,,,Plasmatic Half-life after intravenous administration to rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17533,In vivo,Rattus norvegicus,10116.0
7770,N,,,,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,Intermediate,,,,,50597,BAO_0000218,A,,5979,In vivo,Rattus norvegicus,10116.0
7771,N,,,,Terminal half life after intravenous administration (1 mg/kg) in rat,Intermediate,,,,,50597,BAO_0000218,A,,4689,In vivo,Rattus norvegicus,10116.0
7772,N,,,,Terminal half life in Rat at a oral dose of 5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,4689,In vivo,Rattus norvegicus,10116.0
7773,N,,,,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,Intermediate,,,,,50597,BAO_0000218,A,,2463,In vivo,Rattus norvegicus,10116.0
7774,N,,,,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4883,In vivo,Rattus norvegicus,10116.0
7775,N,,,,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4883,In vivo,Rattus norvegicus,10116.0
7776,N,,,,plasma half life was observed after intravenous administration in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15662,In vivo,Rattus norvegicus,10116.0
7777,N,,,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,Expert,,,,,50597,BAO_0000218,A,,3598,In vivo,Rattus norvegicus,10116.0
7778,N,,,,Half life of compound determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,4576,,Rattus norvegicus,10116.0
7779,N,,,,Mean residence time determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,4576,,Rattus norvegicus,10116.0
7780,N,,,,Plasma half life determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,4576,,Rattus norvegicus,10116.0
7781,N,,,,Compound was evaluated for Tmax in brain after intravenous administration in male rats,Intermediate,,,,955.0,50597,BAO_0000218,A,,4910,In vivo,Rattus norvegicus,10116.0
7782,N,,,,Compound was evaluated for pharmacokinetic parameter maximum time period,Intermediate,,,,,50597,BAO_0000218,A,,4891,In vivo,Rattus norvegicus,10116.0
7783,N,,,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,429,In vivo,Rattus norvegicus,10116.0
7784,N,,,,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,In vivo,Rattus norvegicus,10116.0
7785,N,,,,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,In vivo,Rattus norvegicus,10116.0
7786,N,,,,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,In vivo,Rattus norvegicus,10116.0
7787,N,,,,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,In vivo,Rattus norvegicus,10116.0
7788,N,,,,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,Intermediate,,,,,50597,BAO_0000218,A,,17582,In vivo,Rattus norvegicus,10116.0
7789,N,,,,Maximum time (Tmax) required to reach Cmax in rats,Intermediate,,,,,50597,BAO_0000218,A,,4026,,Rattus norvegicus,10116.0
7790,N,,,,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,4890,In vivo,Rattus norvegicus,10116.0
7791,N,,,,Maximum time of clearance of compound in rats after peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,6571,In vivo,Rattus norvegicus,10116.0
7792,N,,,,Maximum time at the dose of 2 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4727,,Rattus norvegicus,10116.0
7793,N,,,,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17651,In vivo,Rattus norvegicus,10116.0
7794,N,,,,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17651,In vivo,Rattus norvegicus,10116.0
7795,N,,,,Tmax in Guinea pig (PO dose),Intermediate,,,,,50597,BAO_0000218,A,,14465,In vivo,Rattus norvegicus,10116.0
7796,N,,,,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",Intermediate,,,,,50597,BAO_0000218,A,,14941,In vivo,Rattus norvegicus,10116.0
7797,N,,,,Pharmacokinetic parameter (Tmax) in rat,Intermediate,,,,,50597,BAO_0000218,A,,5960,In vivo,Rattus norvegicus,10116.0
7798,N,,,,Pharmacokinetic parameter (Tmax) was estimated,Intermediate,,,,,50597,BAO_0000218,A,,5022,In vivo,Rattus norvegicus,10116.0
7799,N,,,,Pharmacokinetic property (Tmax) in rat,Intermediate,,,,,50597,BAO_0000218,A,,4408,In vivo,Rattus norvegicus,10116.0
7800,N,,,,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,Intermediate,,,,,50597,BAO_0000218,A,,5983,In vivo,Rattus norvegicus,10116.0
7801,N,,,,T max in Rat at a oral dose of 5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,4689,In vivo,Rattus norvegicus,10116.0
7802,N,,,,T max was determined at 10 mg/kg po dose in rats,Intermediate,,,,,50597,BAO_0000218,A,,2792,In vivo,Rattus norvegicus,10116.0
7803,N,,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),Intermediate,,,,,50594,BAO_0000218,A,,15011,,Mus musculus,10090.0
7804,N,,,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,Intermediate,,,,,50588,BAO_0000218,A,,14180,,Canis lupus familiaris,9615.0
7805,N,,,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,Intermediate,,,,,50597,BAO_0000218,A,,14180,,Rattus norvegicus,10116.0
7806,N,,,,Area under curve was measured after i.v. administration into Beagle dog.,Intermediate,,,,,50588,BAO_0000218,A,,14599,,Canis lupus familiaris,9615.0
7807,N,,,,Area under curve was measured after iv administration into Beagle dog,Intermediate,,,,,50588,BAO_0000218,A,,14599,,Canis lupus familiaris,9615.0
7808,N,,,,Area under curve was measured after po administration into Beagle dog,Intermediate,,,,,50588,BAO_0000218,A,,14599,,Canis lupus familiaris,9615.0
7809,N,,,,Area under curve was measured after po administration into Beagle dog.,Intermediate,,,,,50588,BAO_0000218,A,,14599,,Canis lupus familiaris,9615.0
7810,U,,,,Area under curve was measured at peroral dose of 3 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,15675,,,
7811,U,,,,Area under curve was measured by using concentration Vs time,Autocuration,,,,,22224,BAO_0000019,A,,12706,,,
7812,U,,,,Area under curve was measured by using concentration Vs time; not tested,Autocuration,,,,,22224,BAO_0000019,A,,12706,,,
7813,N,,,,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),Intermediate,,,,,50594,BAO_0000218,A,,9750,,Mus musculus,10090.0
7814,N,,,,Area under curve(AUC) was measured in mice after oral administration.,Intermediate,,,,,50594,BAO_0000218,A,,9750,,Mus musculus,10090.0
7815,U,,,,Area under curve(AUC) value of the compound,Autocuration,,,,,22224,BAO_0000019,A,,14691,,,
7816,U,,,,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,Autocuration,,,,,22224,BAO_0000218,A,,14691,,,
7817,N,,,,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,Intermediate,,,,,50588,BAO_0000218,A,,14691,,Canis lupus familiaris,9615.0
7818,U,,,,Area under curve(carotid artery) was determined by the availability in blood,Autocuration,,,,178.0,22224,BAO_0000019,A,,2939,,,
7819,U,,,,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,Autocuration,,,,178.0,22224,BAO_0000019,A,,2939,,,
7820,U,,,,Area under curve(carotid artery) was determined by the availability in blood; No data,Autocuration,,,,178.0,22224,BAO_0000019,A,,2939,,,
7821,U,,,,Area under curve(portal vein) was determined by the availability in blood,Autocuration,,,,178.0,22224,BAO_0000019,A,,2939,,,
7822,U,,,,Area under curve(portal vein) was determined by the availability in blood; ND means no data,Autocuration,,,,178.0,22224,BAO_0000019,A,,2939,,,
7823,U,,,,Area under curve(portal vein) was determined by the availability in blood; No data,Autocuration,,,,178.0,22224,BAO_0000019,A,,2939,,,
7824,N,,,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",Intermediate,,,,1969.0,50797,BAO_0000218,A,,9552,,Macaca mulatta,9544.0
7825,N,,,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",Intermediate,,,,1969.0,50797,BAO_0000218,A,,9552,,Macaca mulatta,9544.0
7826,N,,,,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,Intermediate,,,,1969.0,50797,BAO_0000218,A,,9552,,Macaca mulatta,9544.0
7827,N,,,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",Intermediate,,,,1969.0,50588,BAO_0000218,A,,9552,,Canis lupus familiaris,9615.0
7828,N,,,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",Intermediate,,,,1969.0,50588,BAO_0000218,A,,9552,,Canis lupus familiaris,9615.0
7829,U,,,,Area under plasma concentration vs time curve observed in rats for 0-3 h,Autocuration,,,,1969.0,22224,BAO_0000019,A,,9552,,,
7830,N,,,,Area under plasma time curve determined in male rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,11911,,Rattus norvegicus,10116.0
7831,U,,,,Area under the MAP curve measured over 5 min.,Autocuration,,,,,22224,BAO_0000019,A,,16618,,,
7832,N,,,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,Intermediate,,,,,50594,BAO_0000218,A,,14387,,Mus musculus,10090.0
7833,N,,,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,Intermediate,,,,,50594,BAO_0000218,A,,14387,,Mus musculus,10090.0
7834,N,,,,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,Intermediate,,,,,50588,BAO_0000218,A,,12836,,Canis lupus familiaris,9615.0
7835,N,,,,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,Intermediate,,,,,100712,BAO_0000218,A,,12836,,Cricetinae,10026.0
7836,N,,,,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,Intermediate,,,,,50597,BAO_0000218,A,,12836,,Rattus norvegicus,10116.0
7837,N,,,,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,Intermediate,,,,,50588,BAO_0000218,A,,14339,,Canis lupus familiaris,9615.0
7838,N,,,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,Intermediate,,,,,50588,BAO_0000218,A,,14339,,Canis lupus familiaris,9615.0
7839,N,,,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,Intermediate,,,,,50588,BAO_0000218,A,,14339,,Canis lupus familiaris,9615.0
7840,N,,,,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,10524,,Canis lupus familiaris,9615.0
7841,N,,,,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,9994,,Canis lupus familiaris,9615.0
7842,N,,,,Serum AUC in marmosets (IV dose),Intermediate,,,,,50588,BAO_0000218,A,,11325,,Canis lupus familiaris,9615.0
7843,U,,,,Area under the curve after intravenous administration at a dose of 10 umol/kg,Autocuration,,,,,22224,BAO_0000019,A,,12536,,,
7844,U,,,,Area under the curve after intravenous administration at a dose of 2 umol/kg,Autocuration,,,,,22224,BAO_0000019,A,,12536,,,
7845,U,,,,Area under the curve after intravenous administration at a dose of 4 umol/kg,Autocuration,,,,,22224,BAO_0000019,A,,12536,,,
7846,U,,,,Area under the curve after intravenous administration at a dose of 40 umol/kg,Autocuration,,,,,22224,BAO_0000019,A,,12536,,,
7847,U,,,,Area under the curve after intravenous administration at a dose of 5 umol/kg,Autocuration,,,,,22224,BAO_0000019,A,,12536,,,
7848,N,,,,Area under the curve for fumarate salt was evaluated in F344 Rats.,Intermediate,,,,,50597,BAO_0000218,A,,15556,,Rattus norvegicus,10116.0
7849,U,,,,Area under the curve for the compound was calculated.,Autocuration,,,,,22224,BAO_0000019,A,,2809,,,
7850,U,,,,Area under the curve in concentration/ time,Autocuration,,,,,22224,BAO_0000019,A,,9511,,,
7851,N,,,,Area under the curve administered intraintestinal in rats.,Intermediate,,,,,50597,BAO_0000218,A,,12818,,Rattus norvegicus,10116.0
7852,N,,,,Area under the curve administered intravenously in rats.,Intermediate,,,,,50597,BAO_0000218,A,,12818,,Rattus norvegicus,10116.0
7853,U,,,,Area under the curve during intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,15118,,,
7854,U,,,,Area under the curve during intravenous administration; Not determined,Autocuration,,,,,22224,BAO_0000019,A,,15118,,,
7855,U,,,,Area under the curve during systemic administration,Autocuration,,,,,22224,BAO_0000019,A,,15118,,,
7856,U,,,,Area under the curve during systemic administration; Not determined,Autocuration,,,,,22224,BAO_0000019,A,,15118,,,
7857,U,,,,Area under the curve was calculated for the compound.,Autocuration,,,,,22224,BAO_0000019,A,,2632,,,
7858,N,,,,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,Intermediate,,,,,50588,BAO_0000218,A,,14346,,Canis lupus familiaris,9615.0
7859,N,,,,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,Intermediate,,,,,50588,BAO_0000218,A,,14346,,Canis lupus familiaris,9615.0
7860,N,,,,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,14346,,Rattus norvegicus,10116.0
7861,N,,,,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,14346,,Rattus norvegicus,10116.0
7862,N,,,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,Intermediate,,,,,50597,BAO_0000218,A,,11149,,Rattus norvegicus,10116.0
7863,N,,,,Clearance of the drug was measured in the plasma of rat; No data,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17796,,Rattus norvegicus,10116.0
7864,N,,,,The pharmacokinetic parameter plasma clearance in vivo in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5247,,Rattus norvegicus,10116.0
7865,N,,,,Plasma clearance at the dose of 2 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4727,,Rattus norvegicus,10116.0
7866,N,,,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,5654,In vivo,Rattus norvegicus,10116.0
7867,N,,,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,5654,In vivo,Rattus norvegicus,10116.0
7868,N,,,,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,Intermediate,,,,,50597,BAO_0000218,A,,17260,In vivo,Rattus norvegicus,10116.0
7869,N,,,,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,Intermediate,,,,,50597,BAO_0000218,A,,17065,In vivo,Rattus norvegicus,10116.0
7870,N,,,,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17671,In vivo,Rattus norvegicus,10116.0
7871,N,,,,Clearance rate in rat,Intermediate,,,,,50597,BAO_0000218,A,,6672,In vivo,Rattus norvegicus,10116.0
7872,N,,,,Clearance rate in rat,Intermediate,,,,,50597,BAO_0000218,A,,6673,In vivo,Rattus norvegicus,10116.0
7873,N,,,,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,In vivo,Rattus norvegicus,10116.0
7874,N,,,,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,In vivo,Rattus norvegicus,10116.0
7875,N,,,,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,In vivo,Rattus norvegicus,10116.0
7876,N,,,,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,In vivo,Rattus norvegicus,10116.0
7877,N,,,,Clearance of compound after iv administration of 20 mg/kg dose in rat,Intermediate,,,,,50597,BAO_0000218,A,,4413,In vivo,Rattus norvegicus,10116.0
7878,N,,,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,2661,In vivo,Rattus norvegicus,10116.0
7879,N,,,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,2661,In vivo,Rattus norvegicus,10116.0
7880,U,,,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Intermediate,,,,1969.0,22224,BAO_0000218,A,,5005,In vivo,Macaca mulatta,9544.0
7881,U,,,,Compound was tested for its plasma clearance rate in Sprague Dawley rats,Intermediate,,,,1969.0,22224,BAO_0000218,A,,5005,In vivo,Rattus norvegicus,10116.0
7882,N,,,,Mean (%CV) PK parameters for CL(mL/min/kg).,Intermediate,,,,,50597,BAO_0000218,A,,15765,In vivo,Rattus norvegicus,10116.0
7883,N,,,,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,Intermediate,,,,,50597,BAO_0000218,A,,3747,In vivo,Rattus norvegicus,10116.0
7884,N,,,,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,Intermediate,,,,1969.0,50597,BAO_0000218,A,,16366,In vivo,Rattus norvegicus,10116.0
7885,N,,,,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,Intermediate,,,,,50597,BAO_0000218,A,,4199,In vivo,Rattus norvegicus,10116.0
7886,N,,,,Plasma clearance in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,17267,In vivo,Rattus norvegicus,10116.0
7887,N,,,,Plasma clearance in rat after administration of 2 mg/kg iv,Intermediate,,,,,50597,BAO_0000218,A,,6535,In vivo,Rattus norvegicus,10116.0
7888,N,,,,Plasma clearance in rat after administration of 2 mg/kg iv,Intermediate,,,,,50597,BAO_0000218,A,,6535,In vivo,Rattus norvegicus,10116.0
7889,N,,,,Plasma clearance was determined,Intermediate,,,,,50597,BAO_0000218,A,,5041,In vivo,Rattus norvegicus,10116.0
7890,N,,,,Plasma clearance in rat,Intermediate,,,,,50597,BAO_0000218,A,,5960,In vivo,Rattus norvegicus,10116.0
7891,N,,,,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5937,In vivo,Rattus norvegicus,10116.0
7892,N,,,,Plasma clearance in rat by iv administration,Intermediate,,,,,50597,BAO_0000218,A,,5871,In vivo,Rattus norvegicus,10116.0
7893,N,,,,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5874,In vivo,Rattus norvegicus,10116.0
7894,N,,,,Plasma clearance in rat p.o.,Intermediate,,,,,50597,BAO_0000218,A,,6504,In vivo,Rattus norvegicus,10116.0
7895,N,,,,Plasma clearance in rats,Intermediate,,,,,50597,BAO_0000218,A,,6803,In vivo,Rattus norvegicus,10116.0
7896,N,,,,Plasma clearance was determined; ND denotes no data,Intermediate,,,,,50597,BAO_0000218,A,,5041,In vivo,Rattus norvegicus,10116.0
7897,N,,,,Plasma clearance was determined; ND denotes not determined,Intermediate,,,,,50597,BAO_0000218,A,,5041,In vivo,Rattus norvegicus,10116.0
7898,N,,,,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,Intermediate,,,,,50597,BAO_0000218,A,,1916,In vivo,Rattus norvegicus,10116.0
7899,N,,,,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,Intermediate,,,,,50597,BAO_0000218,A,,5199,In vivo,Rattus norvegicus,10116.0
7900,N,,,,Plasma administration to rats,Intermediate,,,,,50597,BAO_0000218,A,,16367,In vivo,Rattus norvegicus,10116.0
7901,N,,,,Plasma clearance of the compound in female Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,6362,In vivo,Rattus norvegicus,10116.0
7902,N,,,,Plasma clearance was observed after intravenous administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,15662,In vivo,Rattus norvegicus,10116.0
7903,N,,,,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,6215,In vivo,Rattus norvegicus,10116.0
7904,N,,,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,Intermediate,,,,,50597,BAO_0000218,A,,1466,In vivo,Rattus norvegicus,10116.0
7905,N,,,,plasma clearance was observed after intravenous administration in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15662,In vivo,Rattus norvegicus,10116.0
7906,N,,,,In vivo CL/F determined,Intermediate,,,,,50597,BAO_0000218,A,,4723,In vivo,Rattus norvegicus,10116.0
7907,N,,,,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2792,In vivo,Rattus norvegicus,10116.0
7908,N,,,,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2792,In vivo,Rattus norvegicus,10116.0
7909,N,,,,Compound was tested for the lower blood clearance in rat,Intermediate,,,,,50597,BAO_0000218,A,,5213,In vivo,Rattus norvegicus,10116.0
7910,N,,,,Evaluated for the low clearance in rat (in vivo),Intermediate,,,,,50597,BAO_0000218,A,,4687,In vivo,Rattus norvegicus,10116.0
7911,N,,,,Pharmacokinetic property (CLb)of the compound was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,3371,In vivo,Rattus norvegicus,10116.0
7912,N,,,,Rapid clearance after intravenous administration in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,4690,In vivo,Rattus norvegicus,10116.0
7913,N,,,,Clearance measured in rat,Intermediate,,,,,50597,BAO_0000218,A,,5702,In vivo,Rattus norvegicus,10116.0
7914,N,,,,Compound was evaluated for plasma clearance in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,740,In vivo,Rattus norvegicus,10116.0
7915,N,,,,Low plasma clearance was calculated in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4853,In vivo,Rattus norvegicus,10116.0
7916,N,,,,Pharmacokinetic property (Clp) in rat,Intermediate,,,,,50597,BAO_0000218,A,,5789,In vivo,Rattus norvegicus,10116.0
7917,N,,,,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,4527,In vivo,Rattus norvegicus,10116.0
7918,N,,,,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,4527,In vivo,Rattus norvegicus,10116.0
7919,N,,,,Plasma clearance after IV dosing at 0.5 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6518,In vivo,Rattus norvegicus,10116.0
7920,N,,,,Plasma clearance after IV dosing at 1 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6518,In vivo,Rattus norvegicus,10116.0
7921,N,,,,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7922,N,,,,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7923,N,,,,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7924,N,,,,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7925,N,,,,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7926,N,,,,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7927,N,,,,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7928,N,,,,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7929,N,,,,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7930,N,,,,Biodistribution in rat heart in the presence of GdDTPA at 15 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7931,N,,,,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7932,N,,,,Biodistribution in rat heart in the presence of GdDTPA at 30 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7933,N,,,,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7934,N,,,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7935,N,,,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7936,N,,,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7937,N,,,,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7938,N,,,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7939,N,,,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7940,N,,,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7941,N,,,,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7942,N,,,,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7943,N,,,,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7944,N,,,,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7945,N,,,,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7946,N,,,,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7947,N,,,,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7948,N,,,,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7949,N,,,,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7950,N,,,,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7951,N,,,,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7952,N,,,,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7953,N,,,,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7954,N,,,,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7955,N,,,,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7956,N,,,,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7957,N,,,,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,Intermediate,,,,160.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7958,N,,,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,Intermediate,,,,160.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7959,N,,,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,Intermediate,,,,160.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7960,N,,,,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7961,N,,,,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7962,N,,,,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7963,N,,,,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7964,N,,,,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7965,N,,,,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7966,N,,,,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7967,N,,,,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7968,N,,,,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7969,N,,,,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7970,N,,,,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7971,N,,,,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7972,N,,,,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7973,N,,,,Biodistribution in rat liver in the presence of GdDTPA at 15 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7974,N,,,,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7975,N,,,,Biodistribution in rat liver in the presence of GdDTPA at 30 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7976,N,,,,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7977,N,,,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
7978,N,,,,T max was determined at 3 mg/kg po dose in rats,Intermediate,,,,,50597,BAO_0000218,A,,2792,In vivo,Rattus norvegicus,10116.0
7979,N,,,,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,15078,In vivo,Rattus norvegicus,10116.0
7980,N,,,,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,15078,In vivo,Rattus norvegicus,10116.0
7981,N,,,,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,15022,,Rattus norvegicus,10116.0
7982,N,,,,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,15022,,Rattus norvegicus,10116.0
7983,N,,,,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,15022,,Rattus norvegicus,10116.0
7984,N,,,,Time for maximum plasma concentration determined in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4576,,Rattus norvegicus,10116.0
7985,N,,,,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6681,In vivo,Rattus norvegicus,10116.0
7986,N,,,,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,Intermediate,,,,,50597,BAO_0000218,A,,16365,In vivo,Rattus norvegicus,10116.0
7987,N,,,,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,Intermediate,,,,,50597,BAO_0000218,A,,16365,In vivo,Rattus norvegicus,10116.0
7988,N,,,,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,16365,In vivo,Rattus norvegicus,10116.0
7989,N,,,,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,Intermediate,,,,,50597,BAO_0000218,A,,16365,In vivo,Rattus norvegicus,10116.0
7990,N,,,,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,16365,In vivo,Rattus norvegicus,10116.0
7991,N,,,,Time of maximum plasma concentration in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6824,,Rattus norvegicus,10116.0
7992,N,,,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",Intermediate,,,,1969.0,50597,BAO_0000218,A,,6685,,Rattus norvegicus,10116.0
7993,N,,,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",Intermediate,,,,1969.0,50597,BAO_0000218,A,,6685,,Rattus norvegicus,10116.0
7994,N,,,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",Intermediate,,,,1969.0,50597,BAO_0000218,A,,6685,,Rattus norvegicus,10116.0
7995,N,,,,Time required to reach maximum concentration (Cmax) after oral administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,15662,In vivo,Rattus norvegicus,10116.0
7996,N,,,,Time required to reach maximum concentration in rat plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1742,,Rattus norvegicus,10116.0
7997,N,,,,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2774,In vivo,Rattus norvegicus,10116.0
7998,N,,,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5199,In vivo,Rattus norvegicus,10116.0
7999,N,,,,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,12873,In vivo,Rattus norvegicus,10116.0
8000,N,,,,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,12873,In vivo,Rattus norvegicus,10116.0
8001,N,,,,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1916,In vivo,Rattus norvegicus,10116.0
8002,N,,,,Time to reach Cmax after oral administration to rats,Intermediate,,,,,50597,BAO_0000218,A,,16367,In vivo,Rattus norvegicus,10116.0
8003,N,,,,Time to reach Cmax when a dose of 1 mg/kg is administered orally,Intermediate,,,,,50597,BAO_0000218,A,,16366,In vivo,Rattus norvegicus,10116.0
8004,N,,,,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,Intermediate,,,,,50597,BAO_0000218,A,,216,,Rattus norvegicus,10116.0
8005,N,,,,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6410,In vivo,Rattus norvegicus,10116.0
8006,N,,,,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6410,In vivo,Rattus norvegicus,10116.0
8007,N,,,,Tmax after peroral administration (10 mg/kg) was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,6215,In vivo,Rattus norvegicus,10116.0
8008,N,,,,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,Expert,,,,,50597,BAO_0000218,A,,3598,In vivo,Rattus norvegicus,10116.0
8009,N,,,,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,4527,In vivo,Rattus norvegicus,10116.0
8010,N,,,,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",Intermediate,,,,,50597,BAO_0000218,A,,17670,In vivo,Rattus norvegicus,10116.0
8011,N,,,,Tmax was determined,Intermediate,,,,,50597,BAO_0000218,A,,1465,,Rattus norvegicus,10116.0
8012,N,,,,Tmax was determined,Intermediate,,,,,50597,BAO_0000218,A,,2552,,Rattus norvegicus,10116.0
8013,N,,,,Tmax after oral administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,5656,In vivo,Rattus norvegicus,10116.0
8014,N,,,,Tmax after peroral administration in rats at 2.4 uM/kg,Intermediate,,,,,50597,BAO_0000218,A,,17764,In vivo,Rattus norvegicus,10116.0
8015,N,,,,Tmax in male rat,Intermediate,,,,,50597,BAO_0000218,A,,5610,,Rattus norvegicus,10116.0
8016,N,,,,Tmax in rat at 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6046,In vivo,Rattus norvegicus,10116.0
8017,N,,,,Tmax in rat by po administration at a dose of 40 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5874,In vivo,Rattus norvegicus,10116.0
8018,N,,,,Tmax in rats,Intermediate,,,,,50597,BAO_0000218,A,,17596,,Rattus norvegicus,10116.0
8019,N,,,,Tmax was measured in rats after peroral administration at 5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17804,In vivo,Rattus norvegicus,10116.0
8020,N,,,,Tmax value after oral dose at a dose of 10 mg/kg in rats.,Intermediate,,,,,50597,BAO_0000218,A,,1908,In vivo,Rattus norvegicus,10116.0
8021,N,,,,Tmax value after administration of 20 mg/Kg oral dose in rat,Intermediate,,,,,50597,BAO_0000218,A,,2959,In vivo,Rattus norvegicus,10116.0
8022,N,,,,Tmax value at a dose of 10 mg/kg in male SD rats,Intermediate,,,,,50597,BAO_0000218,A,,6757,In vivo,Rattus norvegicus,10116.0
8023,N,,,,Tmax value at a dose of 100 mg/kg in male SD rats,Intermediate,,,,,50597,BAO_0000218,A,,6757,In vivo,Rattus norvegicus,10116.0
8024,N,,,,Tmax value at a dose of 50 mg/kg in male SD rats,Intermediate,,,,,50597,BAO_0000218,A,,6757,In vivo,Rattus norvegicus,10116.0
8025,N,,,,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4186,In vivo,Rattus norvegicus,10116.0
8026,N,,,,time required to reach maximum concentration (Cmax) after oral administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,15662,In vivo,Rattus norvegicus,10116.0
8027,N,,,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),Intermediate,,,,1088.0,50597,BAO_0000218,A,,429,,Rattus norvegicus,10116.0
8028,N,,,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),Intermediate,,,,1088.0,50597,BAO_0000218,A,,429,,Rattus norvegicus,10116.0
8029,N,,,,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,Intermediate,,,,,50597,BAO_0000218,A,,5546,,Rattus norvegicus,10116.0
8030,N,,,,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,Intermediate,,,,1088.0,50597,BAO_0000218,A,,3173,,Rattus norvegicus,10116.0
8031,N,,,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,Intermediate,,,,1088.0,50597,BAO_0000218,A,,3173,,Rattus norvegicus,10116.0
8032,N,,,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,Intermediate,,,,1088.0,50597,BAO_0000218,A,,3173,,Rattus norvegicus,10116.0
8033,N,,,,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,Intermediate,,,,,50597,BAO_0000218,A,,4257,In vivo,Rattus norvegicus,10116.0
8034,N,,,,Compound distribution in rat tissues was determined,Intermediate,,,,,50597,BAO_0000218,A,,6011,In vivo,Rattus norvegicus,10116.0
8035,N,,,,Volume of distribution was evaluated in rat,Intermediate,,,,,50597,BAO_0000218,A,,5472,In vivo,Rattus norvegicus,10116.0
8036,N,,,,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,14346,,Rattus norvegicus,10116.0
8037,N,,,,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,14346,,Rattus norvegicus,10116.0
8038,N,,,,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,Intermediate,,,,,50588,BAO_0000218,A,,14346,,Canis lupus familiaris,9615.0
8039,N,,,,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,14346,,Rattus norvegicus,10116.0
8040,U,,,,Area under the curve was determined after oral administration (300 uM/Kg),Autocuration,,,,,22224,BAO_0000019,A,,15469,,,
8041,N,,,,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,14346,,Rattus norvegicus,10116.0
8042,N,,,,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,14346,,Rattus norvegicus,10116.0
8043,N,,,,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,14346,,Rattus norvegicus,10116.0
8044,N,,,,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,14346,,Rattus norvegicus,10116.0
8045,N,,,,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,14346,,Rattus norvegicus,10116.0
8046,N,,,,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,15372,,Rattus norvegicus,10116.0
8047,N,,,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,12935,,Canis lupus familiaris,9615.0
8048,N,,,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,12935,,Canis lupus familiaris,9615.0
8049,U,,,,Plasma drug AUC in rat (PO dose),Autocuration,,,,,22224,BAO_0000218,A,,14813,,,
8050,N,,,,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,Intermediate,,,,,50594,BAO_0000218,A,,15792,,Mus musculus,10090.0
8051,U,,,,Area under was determined at a dose of 30 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,3579,,,
8052,N,,,,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,Intermediate,,,,,50506,BAO_0000218,A,,12487,,Mustela putorius furo,9669.0
8053,N,,,,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,Intermediate,,,,,50597,BAO_0000218,A,,12487,,Rattus norvegicus,10116.0
8054,N,,,,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,Intermediate,,,,,50597,BAO_0000218,A,,12487,,Rattus norvegicus,10116.0
8055,N,,,,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,Intermediate,,,,,50506,BAO_0000218,A,,12487,,Mustela putorius furo,9669.0
8056,N,,,,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,Intermediate,,,,,50588,BAO_0000218,A,,12487,,Canis lupus familiaris,9615.0
8057,N,,,,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,Intermediate,,,,,50588,BAO_0000218,A,,12487,,Canis lupus familiaris,9615.0
8058,N,,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",Intermediate,,,,,50597,BAO_0000218,A,,12902,,Rattus norvegicus,10116.0
8059,N,,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",Intermediate,,,,,50597,BAO_0000218,A,,12902,,Rattus norvegicus,10116.0
8060,N,,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",Intermediate,,,,,50597,BAO_0000218,A,,12902,,Rattus norvegicus,10116.0
8061,N,,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",Intermediate,,,,,50597,BAO_0000218,A,,12902,,Rattus norvegicus,10116.0
8062,N,,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",Intermediate,,,,,50597,BAO_0000218,A,,12902,,Rattus norvegicus,10116.0
8063,N,,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",Intermediate,,,,,50597,BAO_0000218,A,,12902,,Rattus norvegicus,10116.0
8064,N,,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",Intermediate,,,,,50597,BAO_0000218,A,,12902,,Rattus norvegicus,10116.0
8065,N,,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",Intermediate,,,,,50597,BAO_0000218,A,,12902,,Rattus norvegicus,10116.0
8066,N,,,,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,Intermediate,,,,,50594,BAO_0000218,A,,12745,,Mus musculus,10090.0
8067,N,,,,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),Intermediate,,,,,50594,BAO_0000218,A,,12745,,Mus musculus,10090.0
8068,N,,,,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,Intermediate,,,,,50594,BAO_0000218,A,,12745,,Mus musculus,10090.0
8069,N,,,,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),Intermediate,,,,,50594,BAO_0000218,A,,12745,,Mus musculus,10090.0
8070,N,,,,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,Intermediate,,,,,50594,BAO_0000218,A,,12745,,Mus musculus,10090.0
8071,N,,,,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),Intermediate,,,,,50594,BAO_0000218,A,,12745,,Mus musculus,10090.0
8072,N,,,,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,Intermediate,,,,,50594,BAO_0000218,A,,12745,,Mus musculus,10090.0
8073,N,,,,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),Intermediate,,,,,50594,BAO_0000218,A,,12745,,Mus musculus,10090.0
8074,U,,,,AUC in mice after oral dose (50 mg/kg),Autocuration,,,,1969.0,22224,BAO_0000218,A,,13298,,,
8075,N,,,,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,Intermediate,,,,1977.0,50594,BAO_0000218,A,,12226,,Mus musculus,10090.0
8076,U,,,,AUC (0-4 hr) ug/ml/h,Autocuration,,,,1969.0,22224,BAO_0000019,A,,12634,,,
8077,N,,,,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,Intermediate,,,,,50597,BAO_0000218,A,,14810,,Rattus norvegicus,10116.0
8078,U,,,,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,Autocuration,,,,,22224,BAO_0000218,A,,13889,,,
8079,N,,,,Compound was evaluated for Area under curve in mice,Intermediate,,,,,50594,BAO_0000218,A,,10018,,Mus musculus,10090.0
8080,N,,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,Intermediate,,,,,50597,BAO_0000218,A,,8758,,Rattus norvegicus,10116.0
8081,U,,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,Autocuration,,,,,22224,BAO_0000218,F,,8758,,,
8082,N,,,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,Intermediate,,,,,50597,BAO_0000218,A,,8758,,Rattus norvegicus,10116.0
8083,U,,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,Autocuration,,,,,22224,BAO_0000019,A,,2249,,,
8084,U,,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,Autocuration,,,,,22224,BAO_0000019,A,,2249,,,
8085,U,,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,Autocuration,,,,,22224,BAO_0000019,A,,2249,,,
8086,U,,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,Autocuration,,,,,22224,BAO_0000019,A,,2249,,,
8087,N,,,,Compound was evaluated for area under curve when administered through oral route in mouse,Intermediate,,,,,50594,BAO_0000218,A,,15115,,Mus musculus,10090.0
8088,N,,,,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,Intermediate,,,,,50597,BAO_0000218,A,,6518,In vivo,Rattus norvegicus,10116.0
8089,N,,,,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,Intermediate,,,,,50597,BAO_0000218,A,,6518,In vivo,Rattus norvegicus,10116.0
8090,N,,,,Plasma clearance in rat,Intermediate,,,,,50597,BAO_0000218,A,,6249,In vivo,Rattus norvegicus,10116.0
8091,N,,,,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,Intermediate,,,,,50597,BAO_0000218,A,,2463,In vivo,Rattus norvegicus,10116.0
8092,N,,,,Plasma clearance rate in Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,4969,In vivo,Rattus norvegicus,10116.0
8093,N,,,,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,Intermediate,,,,,50597,BAO_0000218,F,,17720,In vivo,Rattus norvegicus,10116.0
8094,N,,,,Pharmacokinetic property (total body clearance) in rat,Intermediate,,,,,50597,BAO_0000218,A,,3457,In vivo,Rattus norvegicus,10116.0
8095,N,,,,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,Intermediate,,,,,50597,BAO_0000218,A,,5983,In vivo,Rattus norvegicus,10116.0
8096,N,,,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6295,,Rattus norvegicus,10116.0
8097,N,,,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6296,,Rattus norvegicus,10116.0
8098,N,,,,Cl in rat i.v. at 2 mg/kg concentration,Intermediate,,,,,50597,BAO_0000218,A,,17686,In vivo,Rattus norvegicus,10116.0
8099,N,,,,Clearance of compound after intravenous administration in rats at 24 uM/kg,Intermediate,,,,,50597,BAO_0000218,A,,17764,In vivo,Rattus norvegicus,10116.0
8100,N,,,,Clearance was determined,Intermediate,,,,,50597,BAO_0000218,A,,5503,In vivo,Rattus norvegicus,10116.0
8101,N,,,,Clearance by intravenous administration of 3.4 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4368,In vivo,Rattus norvegicus,10116.0
8102,N,,,,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6005,In vivo,Rattus norvegicus,10116.0
8103,N,,,,Clearance rate after i.v. administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,5031,In vivo,Rattus norvegicus,10116.0
8104,N,,,,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,4890,In vivo,Rattus norvegicus,10116.0
8105,N,,,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,Intermediate,,,,,50597,BAO_0000218,A,,5182,In vivo,Rattus norvegicus,10116.0
8106,N,,,,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,Intermediate,,,,,50597,BAO_0000218,A,,5979,In vivo,Rattus norvegicus,10116.0
8107,N,,,,Clearance (Cl) after oral administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,5656,In vivo,Rattus norvegicus,10116.0
8108,N,,,,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17804,In vivo,Rattus norvegicus,10116.0
8109,N,,,,Compound was tested for plasma clearance in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4839,In vivo,Rattus norvegicus,10116.0
8110,N,,,,In vitro microsome metabolism clearance in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,Microsomes,5041,In vitro,Rattus norvegicus,10116.0
8111,N,,,,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,Intermediate,,,,,50597,BAO_0000218,A,Microsomes,5041,In vitro,Rattus norvegicus,10116.0
8112,N,,,,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,In vivo,Rattus norvegicus,10116.0
8113,N,,,,In vivo plasma clearance was determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5496,In vivo,Rattus norvegicus,10116.0
8114,N,,,,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,Intermediate,,,,,50597,BAO_0000218,A,,5739,In vivo,Rattus norvegicus,10116.0
8115,N,,401.0,,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,Intermediate,,Hepatocyte,,2107.0,50597,BAO_0000218,A,,5676,In vivo,Rattus norvegicus,10116.0
8116,N,,,,Pharmacokinetic property (Plasma clearance) was measured in rat,Intermediate,,,,,50597,BAO_0000218,A,,4239,In vivo,Rattus norvegicus,10116.0
8117,N,,,,Pharmacokinetic property (clearance) in rat i.v.,Intermediate,,,,,50597,BAO_0000218,A,,5676,In vivo,Rattus norvegicus,10116.0
8118,N,,,,"Plasma Clearance was evaluated in rats, iv",Intermediate,,,,,50597,BAO_0000218,A,,1918,In vivo,Rattus norvegicus,10116.0
8119,N,,,,Plasma clearance (in vivo) in rats was determined,Intermediate,,,,,50597,BAO_0000218,A,,17800,In vivo,Rattus norvegicus,10116.0
8120,N,,,,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6056,In vivo,Rattus norvegicus,10116.0
8121,N,,,,Plasma clearance was determined,Intermediate,,,,,50597,BAO_0000218,A,,5496,In vivo,Rattus norvegicus,10116.0
8122,N,,,,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,Intermediate,,,,,50597,BAO_0000218,A,,5939,In vivo,Rattus norvegicus,10116.0
8123,N,,,,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,Intermediate,,,,,50597,BAO_0000218,A,,5939,In vivo,Rattus norvegicus,10116.0
8124,N,,,,Plasma clearance in rats,Intermediate,,,,,50597,BAO_0000218,A,,17752,In vivo,Rattus norvegicus,10116.0
8125,N,,,,Plasma clearance rate determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,4576,In vivo,Rattus norvegicus,10116.0
8126,N,,,,Plasma clearance was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,6011,In vivo,Rattus norvegicus,10116.0
8127,N,,,,Plasma clearance was determined,Intermediate,,,,,50597,BAO_0000218,A,,5510,In vivo,Rattus norvegicus,10116.0
8128,N,,,,Plasma clearance value in rat,Intermediate,,,,,50597,BAO_0000218,A,,5948,In vivo,Rattus norvegicus,10116.0
8129,N,,,,Clearance rate constant using isolated perfused rat liver (IPRL) assay,Intermediate,,,,2107.0,50597,BAO_0000218,A,,6125,Ex vivo,Rattus norvegicus,10116.0
8130,N,,,,Clearance in rat,Intermediate,,,,,50597,BAO_0000218,A,,4839,In vivo,Rattus norvegicus,10116.0
8131,N,,,,Total body clearance in rat i.v. at 2 mg/kg concentration,Intermediate,,,,,50597,BAO_0000218,A,,17686,In vivo,Rattus norvegicus,10116.0
8132,N,,,,Clearance of compound in rats after intravenous administration,Intermediate,,,,,50597,BAO_0000218,A,,6571,In vivo,Rattus norvegicus,10116.0
8133,N,,,,Clearance after iv administration to rats,Intermediate,,,,,50597,BAO_0000218,A,,3364,In vivo,Rattus norvegicus,10116.0
8134,N,,,,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,13569,In vivo,Rattus norvegicus,10116.0
8135,N,,,,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,13569,In vivo,Rattus norvegicus,10116.0
8136,N,,,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,13569,In vivo,Rattus norvegicus,10116.0
8137,N,,,,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,13569,In vivo,Rattus norvegicus,10116.0
8138,N,,,,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,13569,In vivo,Rattus norvegicus,10116.0
8139,N,,,,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,13569,In vivo,Rattus norvegicus,10116.0
8140,N,,,,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,13569,In vivo,Rattus norvegicus,10116.0
8141,N,,,,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",Intermediate,,,,,50597,BAO_0000218,A,,17670,In vivo,Rattus norvegicus,10116.0
8142,N,,,,Clearance in rat,Intermediate,,,,,50597,BAO_0000218,A,,5970,In vivo,Rattus norvegicus,10116.0
8143,N,,,,Clearance in rat after oral administration at 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6495,In vivo,Rattus norvegicus,10116.0
8144,N,,,,Clearance in rat.,Intermediate,,,,,50597,BAO_0000218,A,,4590,In vivo,Rattus norvegicus,10116.0
8145,N,,,,Clearance rate following an oral dose of 20 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,6193,In vivo,Rattus norvegicus,10116.0
8146,N,,,,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,Intermediate,,,,,50597,BAO_0000218,A,,2832,In vivo,Rattus norvegicus,10116.0
8147,N,,,,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1052,In vivo,Rattus norvegicus,10116.0
8148,N,,,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8149,N,,,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8150,N,,,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8151,N,,,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8152,N,,,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8153,N,,,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8154,N,,,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8155,N,,,,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8156,N,,,,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8157,N,,,,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8158,N,,,,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8159,N,,,,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8160,N,,,,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8161,N,,,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8162,N,,,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8163,N,,,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8164,N,,,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8165,N,,,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8166,N,,,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8167,N,,,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8168,N,,,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8169,N,,,,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8170,N,,,,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8171,N,,,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,Intermediate,,,,160.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8172,N,,,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,Intermediate,,,,160.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8173,N,,,,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),Intermediate,,,,160.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8174,N,,,,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,Intermediate,,,,2106.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8175,N,,,,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,Intermediate,,,,2106.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8176,N,,,,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,Intermediate,,,,2106.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8177,N,,,,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,Intermediate,,,,2106.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8178,N,,,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,Intermediate,,,,2106.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8179,N,,,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,Intermediate,,,,2106.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8180,N,,,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,Intermediate,,,,2106.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8181,N,,,,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,Intermediate,,,,2106.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8182,N,,,,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,Intermediate,,,,2106.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8183,N,,,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,Intermediate,,,,945.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8184,N,,,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,Intermediate,,,,945.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8185,N,,,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,Intermediate,,,,945.0,50597,BAO_0000218,A,,9866,In vivo,Rattus norvegicus,10116.0
8186,N,,,,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,178.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8187,N,,,,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,178.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8188,N,,,,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,178.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8189,N,,,,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,178.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8190,N,,,,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,178.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8191,N,,,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,955.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8192,N,,,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,955.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8193,N,,,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,955.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8194,N,,,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,955.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8195,N,,,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,955.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8196,N,,,,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,948.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8197,N,,,,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,948.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8198,N,,,,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,948.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8199,N,,,,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6062,In vivo,Rattus norvegicus,10116.0
8200,N,,,,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,Expert,,,,,50597,BAO_0000218,A,,3598,,Rattus norvegicus,10116.0
8201,N,,,,Vc value after IV dose at a dose of 5 mg/kg in rats.,Intermediate,,,,,50597,BAO_0000218,A,,1908,In vivo,Rattus norvegicus,10116.0
8202,N,,,,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,Intermediate,,,,,50597,BAO_0000218,A,,17596,In vivo,Rattus norvegicus,10116.0
8203,N,,,,Compound was evaluated for pharmacokinetic parameter volume of distribution,Intermediate,,,,,50597,BAO_0000218,A,,4891,In vivo,Rattus norvegicus,10116.0
8204,N,,,,Compound was evaluated for volume of distribution in rat,Intermediate,,,,,50597,BAO_0000218,A,,740,In vivo,Rattus norvegicus,10116.0
8205,N,,,,Steady state volume distribution was determined; steady state(ss),Intermediate,,,,,50597,BAO_0000218,A,,16366,In vivo,Rattus norvegicus,10116.0
8206,N,,,,Steady state volume of distribution after iv administration to rats,Intermediate,,,,,50597,BAO_0000218,A,,3364,In vivo,Rattus norvegicus,10116.0
8207,N,,,,Steady state volume of distribution dosing at 3 mg/kg iv,Intermediate,,,,,50597,BAO_0000218,A,,2552,In vivo,Rattus norvegicus,10116.0
8208,N,,,,The compound was evaluated for volume of distribution in rat,Intermediate,,,,,50597,BAO_0000218,A,,406,In vivo,Rattus norvegicus,10116.0
8209,N,,,,The compound was tested for volume of distribution in rat,Intermediate,,,,,50597,BAO_0000218,A,,12500,In vivo,Rattus norvegicus,10116.0
8210,N,,,,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,Intermediate,,,,,50597,BAO_0000218,A,,12500,In vivo,Rattus norvegicus,10116.0
8211,N,,,,Volume distribution (VD) after oral administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,5656,In vivo,Rattus norvegicus,10116.0
8212,N,,,,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17671,In vivo,Rattus norvegicus,10116.0
8213,N,,,,Volume distribution in rat,Intermediate,,,,,50597,BAO_0000218,A,,1094,In vivo,Rattus norvegicus,10116.0
8214,N,,,,Volume distribution in rat,Intermediate,,,,,50597,BAO_0000218,A,,5833,In vivo,Rattus norvegicus,10116.0
8215,N,,,,Volume distribution in rat after peroral administration at 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5939,In vivo,Rattus norvegicus,10116.0
8216,N,,,,Volume distribution in rat after peroral administration at 5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5939,In vivo,Rattus norvegicus,10116.0
8217,N,,,,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6005,In vivo,Rattus norvegicus,10116.0
8218,N,,,,Volume of distribution in rat.,Intermediate,,,,,50597,BAO_0000218,A,,1696,In vivo,Rattus norvegicus,10116.0
8219,N,,,,Volume of distribution in rat,Intermediate,,,,,50597,BAO_0000218,A,,6672,In vivo,Rattus norvegicus,10116.0
8220,N,,,,Volume of distribution in rat,Intermediate,,,,,50597,BAO_0000218,A,,6673,In vivo,Rattus norvegicus,10116.0
8221,N,,,,Volume of distribution in rat by iv administration,Intermediate,,,,,50597,BAO_0000218,A,,5871,In vivo,Rattus norvegicus,10116.0
8222,N,,,,Volume of distribution in rats,Intermediate,,,,,50597,BAO_0000218,A,,6803,In vivo,Rattus norvegicus,10116.0
8223,N,,,,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,Intermediate,,,,,50597,BAO_0000218,A,,5199,In vivo,Rattus norvegicus,10116.0
8224,N,,,,Volume distribution at the dose of 2 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4727,,Rattus norvegicus,10116.0
8225,N,,,,Steady state volume of distribution was determined,Intermediate,,,,,50597,BAO_0000218,A,,16367,In vivo,Rattus norvegicus,10116.0
8226,U,,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Intermediate,,,,,22224,BAO_0000218,A,,5005,In vivo,Macaca mulatta,9544.0
8227,U,,,,Compound was tested for its plasma volume distribution in Sprague Dawley rats,Intermediate,,,,,22224,BAO_0000218,A,,5005,In vivo,Rattus norvegicus,10116.0
8228,U,,,,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,Intermediate,,,,,22224,BAO_0000218,A,,5005,In vivo,Rattus norvegicus,10116.0
8229,N,,,,Mean (%CV) PK parameters for Vdss(mL/kg).,Intermediate,,,,,50597,BAO_0000218,A,,15765,In vivo,Rattus norvegicus,10116.0
8230,N,,,,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,Intermediate,,,,,50597,BAO_0000218,A,,2792,In vivo,Rattus norvegicus,10116.0
8231,N,,,,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,Intermediate,,,,,50597,BAO_0000218,A,,2792,In vivo,Rattus norvegicus,10116.0
8232,N,,,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5334,In vivo,Rattus norvegicus,10116.0
8233,N,,,,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,Intermediate,,,,,50597,BAO_0000218,A,,5334,In vivo,Rattus norvegicus,10116.0
8234,N,,,,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,Intermediate,,,,,50597,BAO_0000218,A,,5739,In vivo,Rattus norvegicus,10116.0
8235,N,,,,Pharmacokinetic property (Vdss) in rat,Intermediate,,,,,50597,BAO_0000218,A,,5789,In vivo,Rattus norvegicus,10116.0
8236,N,,,,Pharmacokinetic property (vdss) was measured in rat,Intermediate,,,,,50597,BAO_0000218,A,,4239,In vivo,Rattus norvegicus,10116.0
8237,N,,,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4709,In vivo,Rattus norvegicus,10116.0
8238,N,,,,Volume of distribution in rat,Intermediate,,,,,50597,BAO_0000218,A,,6642,In vivo,Rattus norvegicus,10116.0
8239,N,,,,The pharmacokinetic parameter volume of distribution in vivo in rats,Intermediate,,,,,50597,BAO_0000218,A,,5247,In vivo,Rattus norvegicus,10116.0
8240,N,,,,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,Intermediate,,,,,50597,BAO_0000218,F,,17720,In vivo,Rattus norvegicus,10116.0
8241,N,,,,Vdss in rat i.v. at 2 mg/kg concentration,Intermediate,,,,,50597,BAO_0000218,A,,17686,In vivo,Rattus norvegicus,10116.0
8242,N,,,,Volume distribution after intravenous administration (1 mg/kg) in rat,Intermediate,,,,,50597,BAO_0000218,A,,4689,In vivo,Rattus norvegicus,10116.0
8243,N,,,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,5654,In vivo,Rattus norvegicus,10116.0
8244,N,,,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,5654,In vivo,Rattus norvegicus,10116.0
8245,N,,,,Volume distribution at a dose of 10 uM/kg in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,4527,In vivo,Rattus norvegicus,10116.0
8246,N,,,,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,Intermediate,,,,,50597,BAO_0000218,A,,4521,In vivo,Rattus norvegicus,10116.0
8247,N,,,,Volume distribution was calculated in rat,Intermediate,,,,,50597,BAO_0000218,A,,6057,In vivo,Rattus norvegicus,10116.0
8248,N,,,,Volume distribution was determined,Intermediate,,,,,50597,BAO_0000218,A,,5510,In vivo,Rattus norvegicus,10116.0
8249,N,,,,Volume of distribution after intravenous administration was evaluated in rat,Intermediate,,,,,50597,BAO_0000218,A,,2938,In vivo,Rattus norvegicus,10116.0
8250,N,,,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,,,,,50597,BAO_0000218,A,,6679,In vivo,Rattus norvegicus,10116.0
8251,N,,,,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",Intermediate,,,,,50597,BAO_0000218,A,,6685,In vivo,Rattus norvegicus,10116.0
8252,N,,,,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",Intermediate,,,,,50597,BAO_0000218,A,,6685,In vivo,Rattus norvegicus,10116.0
8253,N,,,,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",Intermediate,,,,,50597,BAO_0000218,A,,6685,In vivo,Rattus norvegicus,10116.0
8254,N,,,,Volume of distribution in steady state was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,5145,In vivo,Rattus norvegicus,10116.0
8255,N,,,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,Intermediate,,,,,50597,BAO_0000218,A,,6467,In vivo,Rattus norvegicus,10116.0
8256,N,,,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,Intermediate,,,,,50597,BAO_0000218,A,,6467,In vivo,Rattus norvegicus,10116.0
8257,N,,,,Compound was evaluated for area under curve when administered through oral route to mouse,Intermediate,,,,,50594,BAO_0000218,A,,15115,,Mus musculus,10090.0
8258,N,,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,Intermediate,,,,,50597,BAO_0000218,A,,8758,,Rattus norvegicus,10116.0
8259,N,,,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,Intermediate,,,,,50597,BAO_0000218,A,,8758,,Rattus norvegicus,10116.0
8260,U,,,,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,Autocuration,,,,,22224,BAO_0000218,F,,8267,In vivo,,
8261,N,,,,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,Intermediate,,,,,50588,BAO_0000218,A,,8267,,Canis lupus familiaris,9615.0
8262,N,,,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,14239,,Mus musculus,10090.0
8263,N,,,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,14239,,Mus musculus,10090.0
8264,N,,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,Intermediate,,,,178.0,50594,BAO_0000218,A,,10754,,Mus musculus,10090.0
8265,N,,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,Intermediate,,,,178.0,50594,BAO_0000218,A,,10754,,Mus musculus,10090.0
8266,N,,,,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,Intermediate,,,,,50588,BAO_0000218,A,,10754,,Canis lupus familiaris,9615.0
8267,N,,,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,Intermediate,,,,,50597,BAO_0000218,A,,14681,,Rattus norvegicus,10116.0
8268,N,,,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,Intermediate,,,,,50597,BAO_0000218,A,,14681,,Rattus norvegicus,10116.0
8269,N,,,,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,Intermediate,,,,,50597,BAO_0000218,A,,14681,,Rattus norvegicus,10116.0
8270,U,,,,Concentration of compound in Central nervous system,Autocuration,,,,,22224,BAO_0000019,A,,13118,,,
8271,U,,,,Concentration of compound in Central nervous system; Not detectable,Autocuration,,,,,22224,BAO_0000019,A,,13118,,,
8272,N,,,,"Concentration of diester in the blood, following oral administration in mice",Intermediate,,,,,50594,BAO_0000218,A,,13318,,Mus musculus,10090.0
8273,N,,,,"Concentration of monoester in the blood, following oral administration in mice",Intermediate,,,,,50594,BAO_0000218,A,,13318,,Mus musculus,10090.0
8274,N,,,,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,Intermediate,,,,,50594,BAO_0000218,A,,13318,,Mus musculus,10090.0
8275,U,,,,Evaluated for Pharmacokinetic property: Area under the curve,Autocuration,,,,,22224,BAO_0000019,A,,15692,,,
8276,N,,,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,Intermediate,,,,,50594,BAO_0000218,A,,14839,,Mus musculus,10090.0
8277,N,,,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,Intermediate,,,,,100710,BAO_0000218,A,,14839,,Macaca fascicularis,9541.0
8278,N,,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,Intermediate,,,,,100710,BAO_0000218,A,,14839,,Macaca fascicularis,9541.0
8279,N,,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,Intermediate,,,,,100710,BAO_0000218,A,,14839,,Macaca fascicularis,9541.0
8280,N,,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,Intermediate,,,,,100710,BAO_0000218,A,,14839,,Macaca fascicularis,9541.0
8281,N,,,,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,Intermediate,,,,,100710,BAO_0000218,A,,14839,,Macaca fascicularis,9541.0
8282,N,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",Intermediate,,,,,100710,BAO_0000218,A,,14839,,Macaca fascicularis,9541.0
8283,N,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",Intermediate,,,,,100710,BAO_0000218,A,,14839,,Macaca fascicularis,9541.0
8284,N,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",Intermediate,,,,,100710,BAO_0000218,A,,14839,,Macaca fascicularis,9541.0
8285,N,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",Intermediate,,,,,100710,BAO_0000218,A,,14839,,Macaca fascicularis,9541.0
8286,N,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",Intermediate,,,,,100710,BAO_0000218,A,,14839,,Macaca fascicularis,9541.0
8287,N,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",Intermediate,,,,,100710,BAO_0000218,A,,14839,,Macaca fascicularis,9541.0
8288,N,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",Intermediate,,,,,100710,BAO_0000218,A,,14839,,Macaca fascicularis,9541.0
8289,N,,,,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,Intermediate,,,,,50594,BAO_0000218,A,,14839,,Mus musculus,10090.0
8290,N,,,,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,Intermediate,,,,,50594,BAO_0000218,A,,14839,,Mus musculus,10090.0
8291,N,,,,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,Intermediate,,,,,50594,BAO_0000218,A,,14839,,Mus musculus,10090.0
8292,N,,,,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,Intermediate,,,,,50594,BAO_0000218,A,,14839,,Mus musculus,10090.0
8293,N,,,,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,Intermediate,,,,,50594,BAO_0000218,A,,14839,,Mus musculus,10090.0
8294,N,,,,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,Intermediate,,,,,50594,BAO_0000218,A,,14839,,Mus musculus,10090.0
8295,N,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",Intermediate,,,,,50594,BAO_0000218,A,,14839,,Mus musculus,10090.0
8296,N,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",Intermediate,,,,,50594,BAO_0000218,A,,14839,,Mus musculus,10090.0
8297,N,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",Intermediate,,,,,50594,BAO_0000218,A,,14839,,Mus musculus,10090.0
8298,N,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",Intermediate,,,,,50594,BAO_0000218,A,,14839,,Mus musculus,10090.0
8299,N,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",Intermediate,,,,,50594,BAO_0000218,A,,14839,,Mus musculus,10090.0
8300,N,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",Intermediate,,,,,50594,BAO_0000218,A,,14839,,Mus musculus,10090.0
8301,N,,,,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5408,In vivo,Rattus norvegicus,10116.0
8302,N,,,,High i.v. clearance in Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,6827,In vivo,Rattus norvegicus,10116.0
8303,N,,,,In vitro clearance in rat liver microsomes,Intermediate,,,,2107.0,50597,BAO_0000218,A,Microsomes,17538,In vitro,Rattus norvegicus,10116.0
8304,N,,,,Intrinsic clearance in rat liver microsomes was determined,Intermediate,,,,2107.0,50597,BAO_0000218,A,Microsomes,6331,In vitro,Rattus norvegicus,10116.0
8305,N,,401.0,,Intrinsic clearance in rat hepatocytes was determined,Intermediate,,Hepatocyte,,2107.0,50597,BAO_0000218,A,,5948,In vitro,Rattus norvegicus,10116.0
8306,N,,,,Plasma Clearance was determined,Intermediate,,,,,50597,BAO_0000218,A,,4026,In vivo,Rattus norvegicus,10116.0
8307,N,,,,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,Intermediate,,,,,50597,BAO_0000218,A,,6647,In vivo,Rattus norvegicus,10116.0
8308,N,,,,Plasma clearance in rat.,Intermediate,,,,,50597,BAO_0000218,A,,1696,In vivo,Rattus norvegicus,10116.0
8309,N,,,,Plasma clearance in rats,Intermediate,,,,,50597,BAO_0000218,A,,6597,In vivo,Rattus norvegicus,10116.0
8310,N,,,,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,Intermediate,,,,,50597,BAO_0000218,A,,347,In vivo,Rattus norvegicus,10116.0
8311,N,,,,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,Intermediate,,,,,50597,BAO_0000218,A,,16423,In vivo,Rattus norvegicus,10116.0
8312,N,,,,Plasma clearance was measured in rat,Intermediate,,,,,50597,BAO_0000218,A,,2879,In vivo,Rattus norvegicus,10116.0
8313,N,,,,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,4883,In vivo,Rattus norvegicus,10116.0
8314,N,,,,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",Intermediate,,,,1969.0,50597,BAO_0000218,A,,5328,In vivo,Rattus norvegicus,10116.0
8315,N,,,,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5160,In vivo,Rattus norvegicus,10116.0
8316,N,,,,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,Intermediate,,,,,50597,BAO_0000218,A,,17582,In vivo,Rattus norvegicus,10116.0
8317,N,,,,Total clearance at 1 mg/kg was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,17651,In vivo,Rattus norvegicus,10116.0
8318,N,,,,Total clearance at 10 mg/kg was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,17651,In vivo,Rattus norvegicus,10116.0
8319,N,,,,Clearance in rat,Intermediate,,,,,50597,BAO_0000218,A,,6596,In vivo,Rattus norvegicus,10116.0
8320,N,,,,Plasma clearance rate determined in rats,Intermediate,,,,,50597,BAO_0000218,A,,4796,In vivo,Rattus norvegicus,10116.0
8321,N,,,,Clearance of compound in rat was evaluated,Intermediate,,,,,50597,BAO_0000218,A,,6850,In vivo,Rattus norvegicus,10116.0
8322,N,,,,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5932,In vivo,Rattus norvegicus,10116.0
8323,N,,,,Pharmacokinetic property (blood clearance) in rat,Intermediate,,,,,50597,BAO_0000218,A,,3371,In vivo,Rattus norvegicus,10116.0
8324,N,,,,Plasma clearance in rat,Intermediate,,,,,50597,BAO_0000218,A,,2083,In vivo,Rattus norvegicus,10116.0
8325,N,,,,Plasma clearance in rats,Intermediate,,,,,50597,BAO_0000218,A,,4942,In vivo,Rattus norvegicus,10116.0
8326,N,,,,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,Intermediate,,,,2107.0,50597,BAO_0000218,A,Microsomes,6838,In vitro,Rattus norvegicus,10116.0
8327,N,,,,Clearance in Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5353,In vivo,Rattus norvegicus,10116.0
8328,N,,,,Clearance rat,Intermediate,,,,,50597,BAO_0000218,A,,6641,In vivo,Rattus norvegicus,10116.0
8329,N,,,,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),Intermediate,,,,,50597,BAO_0000218,A,,6641,In vivo,Rattus norvegicus,10116.0
8330,N,,,,Clearance rat; Not determined,Intermediate,,,,,50597,BAO_0000218,A,,6641,In vivo,Rattus norvegicus,10116.0
8331,N,,,,Clearance rate was determined in rat at a dose of 1 mpk i.v.,Intermediate,,,,,50597,BAO_0000218,A,,6444,In vivo,Rattus norvegicus,10116.0
8332,N,,,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,Intermediate,,,,,50597,BAO_0000218,A,,6444,In vivo,Rattus norvegicus,10116.0
8333,N,,,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,Intermediate,,,,,50597,BAO_0000218,A,,6444,In vivo,Rattus norvegicus,10116.0
8334,N,,,,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,6211,In vivo,Rattus norvegicus,10116.0
8335,N,,,,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",Intermediate,,,,1969.0,50597,BAO_0000218,A,,12873,In vivo,Rattus norvegicus,10116.0
8336,N,,,,Clearance of compound in rat after 1 mg/kg i.v. administration,Intermediate,,,,,50597,BAO_0000218,A,,6570,In vivo,Rattus norvegicus,10116.0
8337,N,,,,Compound was evaluated for Hepatic clearance in rat,Intermediate,,,,,50597,BAO_0000218,A,,3341,In vivo,Rattus norvegicus,10116.0
8338,N,,,,In vivo clearance after 5 mg/kg dose,Intermediate,,,,,50597,BAO_0000218,A,,4891,In vivo,Rattus norvegicus,10116.0
8339,N,,,,Compound was tested for plasma clearance in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1094,In vivo,Rattus norvegicus,10116.0
8340,N,,,,Hepatic clearance after intravenous administration was evaluated in rat,Intermediate,,,,,50597,BAO_0000218,A,,2938,In vivo,Rattus norvegicus,10116.0
8341,N,,,,Lower clearance in rat (i.v.) at 0.5 mpk,Intermediate,,,,,50597,BAO_0000218,A,,17853,In vivo,Rattus norvegicus,10116.0
8342,N,,,,Pharmacokinetic parameter expressed as plasma clearance in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6049,In vivo,Rattus norvegicus,10116.0
8343,N,,,,Pharmacokinetic property (Clp) in rat,Intermediate,,,,,50597,BAO_0000218,A,,5789,In vivo,Rattus norvegicus,10116.0
8344,N,,,,Plasma clearance in Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,4514,In vivo,Rattus norvegicus,10116.0
8345,N,,,,Plasma clearance (Clp) in rat,Intermediate,,,,,50597,BAO_0000218,A,,6448,In vivo,Rattus norvegicus,10116.0
8346,N,,,,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6062,In vivo,Rattus norvegicus,10116.0
8347,N,,,,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,Intermediate,,,,,50597,BAO_0000218,A,,5710,In vivo,Rattus norvegicus,10116.0
8348,N,,,,Plasma clearance after intravenous administration of 1 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4709,In vivo,Rattus norvegicus,10116.0
8349,N,,,,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,Intermediate,,,,,50597,BAO_0000218,A,,4521,In vivo,Rattus norvegicus,10116.0
8350,N,,,,Plasma clearance in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,1742,In vivo,Rattus norvegicus,10116.0
8351,N,,,,Plasma clearance measured in rat,Intermediate,,,,,50597,BAO_0000218,A,,6057,In vivo,Rattus norvegicus,10116.0
8352,N,,,,Plasma clearance was calculated in rat,Intermediate,,,,,50597,BAO_0000218,A,,6057,In vivo,Rattus norvegicus,10116.0
8353,N,,,,Plasma clearance in rat,Intermediate,,,,,50597,BAO_0000218,A,,5145,In vivo,Rattus norvegicus,10116.0
8354,N,,,,Plasma clearance in rat,Intermediate,,,,,50597,BAO_0000218,A,,5833,In vivo,Rattus norvegicus,10116.0
8355,N,,,,Plasma clearance in rat,Intermediate,,,,,50597,BAO_0000218,A,,6453,In vivo,Rattus norvegicus,10116.0
8356,N,,,,Plasma clearance in rat,Intermediate,,,,,50597,BAO_0000218,A,,6640,In vivo,Rattus norvegicus,10116.0
8357,N,,,,Plasma clearance in rats,Intermediate,,,,,50597,BAO_0000218,A,,6305,In vivo,Rattus norvegicus,10116.0
8358,N,,,,Plasma clearance in rat,Intermediate,,,,,50597,BAO_0000218,A,,6642,In vivo,Rattus norvegicus,10116.0
8359,N,,,,Plasma clearance was evaluated in rat,Intermediate,,,,,50597,BAO_0000218,A,,5472,In vivo,Rattus norvegicus,10116.0
8360,N,,,,Plasma clearance was evaluated in rat; Not tested,Intermediate,,,,,50597,BAO_0000218,A,,5472,In vivo,Rattus norvegicus,10116.0
8361,N,,,,Plasma clearance rate was determined for the compound in rat,Intermediate,,,,,50597,BAO_0000218,A,,5144,In vivo,Rattus norvegicus,10116.0
8362,N,,,,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",Intermediate,,,,,50597,BAO_0000218,A,,6685,In vivo,Rattus norvegicus,10116.0
8363,N,,,,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",Intermediate,,,,,50597,BAO_0000218,A,,6685,In vivo,Rattus norvegicus,10116.0
8364,N,,,,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",Intermediate,,,,,50597,BAO_0000218,A,,6685,In vivo,Rattus norvegicus,10116.0
8365,N,,,,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,948.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8366,N,,,,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,948.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8367,N,,,,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,160.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8368,N,,,,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,160.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8369,N,,,,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,160.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8370,N,,,,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,160.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8371,N,,,,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,160.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8372,N,,,,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8373,N,,,,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8374,N,,,,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8375,N,,,,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8376,N,,,,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8377,N,,,,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8378,N,,,,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8379,N,,,,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8380,N,,,,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8381,N,,,,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8382,N,,,,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2048.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8383,N,,,,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2048.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8384,N,,,,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2048.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8385,N,,,,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2048.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8386,N,,,,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2048.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8387,N,,,,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2385.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8388,N,,,,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2385.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8389,N,,,,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2385.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8390,N,,,,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2385.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8391,N,,,,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2385.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8392,N,,,,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2106.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8393,N,,,,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2106.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8394,N,,,,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2106.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8395,N,,,,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,Intermediate,,,,2106.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8396,N,,,,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2106.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8397,N,,,,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,945.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8398,N,,,,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,Intermediate,,,,945.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8399,N,,,,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,945.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8400,N,,,,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,945.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8401,N,,,,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,945.0,50597,BAO_0000218,A,,13950,In vivo,Rattus norvegicus,10116.0
8402,N,,,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,Intermediate,,,,2037.0,50597,BAO_0000218,A,,13950,,Rattus norvegicus,10116.0
8403,N,,,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,Intermediate,,,,2037.0,50597,BAO_0000218,A,,13950,,Rattus norvegicus,10116.0
8404,N,,,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,Intermediate,,,,,50597,BAO_0000218,A,,13950,,Rattus norvegicus,10116.0
8405,N,,,,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,Intermediate,,,,,50597,BAO_0000218,A,,6570,In vivo,Rattus norvegicus,10116.0
8406,N,,,,Volume of distribution of compound in rats after intravenous administration,Intermediate,,,,,50597,BAO_0000218,A,,6571,In vivo,Rattus norvegicus,10116.0
8407,N,,,,Volume of distribution in rat,Intermediate,,,,,50597,BAO_0000218,A,,6453,In vivo,Rattus norvegicus,10116.0
8408,N,,,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,Intermediate,,,,,50597,BAO_0000218,A,,6444,In vivo,Rattus norvegicus,10116.0
8409,N,,,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,Intermediate,,,,,50597,BAO_0000218,A,,6444,In vivo,Rattus norvegicus,10116.0
8410,N,,,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,Intermediate,,,,,50597,BAO_0000218,A,,6444,In vivo,Rattus norvegicus,10116.0
8411,N,,,,Volume of distribution was determined in Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5353,In vivo,Rattus norvegicus,10116.0
8412,N,,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5334,In vivo,Rattus norvegicus,10116.0
8413,N,,,,Volume of distribution was reported in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5334,In vivo,Rattus norvegicus,10116.0
8414,N,,,,Volumes of distribution in rat after peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,6641,In vivo,Rattus norvegicus,10116.0
8415,N,,,,Volumes of distribution in rat after po administration,Intermediate,,,,,50597,BAO_0000218,A,,6641,In vivo,Rattus norvegicus,10116.0
8416,N,,,,Volumes of distribution in rat after po administration; Not determined,Intermediate,,,,,50597,BAO_0000218,A,,6641,In vivo,Rattus norvegicus,10116.0
8417,N,,,,Pharmacokinetic property (Volume) in rat i.v.,Intermediate,,,,,50597,BAO_0000218,A,,5676,In vivo,Rattus norvegicus,10116.0
8418,N,,,,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,Intermediate,,,,,50597,BAO_0000218,A,,6410,In vivo,Rattus norvegicus,10116.0
8419,N,,,,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",Intermediate,,,,,50597,BAO_0000218,A,,17670,In vivo,Rattus norvegicus,10116.0
8420,N,,,,Volume distribution in rat after oral administration at 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6495,In vivo,Rattus norvegicus,10116.0
8421,N,,,,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,5408,In vivo,Rattus norvegicus,10116.0
8422,N,,,,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,4883,In vivo,Rattus norvegicus,10116.0
8423,N,,,,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,Intermediate,,,,,50597,BAO_0000218,A,,6647,In vivo,Rattus norvegicus,10116.0
8424,N,,,,Volume of distribution in rats,Intermediate,,,,,50597,BAO_0000218,A,,6495,In vivo,Rattus norvegicus,10116.0
8425,N,,,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,2661,In vivo,Rattus norvegicus,10116.0
8426,N,,,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,2661,In vivo,Rattus norvegicus,10116.0
8427,N,,,,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,In vivo,Rattus norvegicus,10116.0
8428,N,,,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,In vivo,Rattus norvegicus,10116.0
8429,N,,,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,Intermediate,,,,,50597,BAO_0000218,A,,5974,In vivo,Rattus norvegicus,10116.0
8430,N,,,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,In vivo,Rattus norvegicus,10116.0
8431,N,,,,Pharmacokinetic parameter (Vss) in rat,Intermediate,,,,,50597,BAO_0000218,A,,5960,In vivo,Rattus norvegicus,10116.0
8432,N,,,,Pharmacokinetic property (Volume) in rat i.v.,Intermediate,,,,,50597,BAO_0000218,A,,5676,In vivo,Rattus norvegicus,10116.0
8433,N,,,,Pharmacokinetic property (Vss) in rat,Intermediate,,,,,50597,BAO_0000218,A,,5948,,Rattus norvegicus,10116.0
8434,N,,,,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,Intermediate,,,,,50597,BAO_0000218,A,,5979,In vivo,Rattus norvegicus,10116.0
8435,N,,,,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,In vivo,Rattus norvegicus,10116.0
8436,N,,,,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,In vivo,Rattus norvegicus,10116.0
8437,N,,,,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,In vivo,Rattus norvegicus,10116.0
8438,N,,,,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,In vivo,Rattus norvegicus,10116.0
8439,N,,,,Steady state volume distribution in rat,Intermediate,,,,,50597,BAO_0000218,A,,6448,In vivo,Rattus norvegicus,10116.0
8440,N,,,,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",Intermediate,,,,1969.0,50597,BAO_0000218,A,,12873,In vivo,Rattus norvegicus,10116.0
8441,N,,,,Steady state volume of distribution determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,4576,In vivo,Rattus norvegicus,10116.0
8442,N,,,,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,Intermediate,,,,,50597,BAO_0000218,A,,17582,In vivo,Rattus norvegicus,10116.0
8443,N,,,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,Intermediate,,,,,50597,BAO_0000218,A,,1466,In vivo,Rattus norvegicus,10116.0
8444,N,,,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,5182,,Rattus norvegicus,10116.0
8445,N,,,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,Intermediate,,,,,50597,BAO_0000218,A,,5182,,Rattus norvegicus,10116.0
8446,N,,,,Volume distribution in rat after administration of 2 mg/kg iv,Intermediate,,,,,50597,BAO_0000218,A,,6535,In vivo,Rattus norvegicus,10116.0
8447,N,,,,Volume distribution in rat after administration of 2 mg/kg iv,Intermediate,,,,,50597,BAO_0000218,A,,6535,In vivo,Rattus norvegicus,10116.0
8448,N,,,,Volume in steady state distribution value was determined,Intermediate,,,,,50597,BAO_0000218,A,,5041,In vivo,Rattus norvegicus,10116.0
8449,N,,,,Volume in steady state distribution value was determined; ND denotes no data,Intermediate,,,,,50597,BAO_0000218,A,,5041,In vivo,Rattus norvegicus,10116.0
8450,N,,,,Volume in steady state distribution value was determined; ND denotes not determined,Intermediate,,,,,50597,BAO_0000218,A,,5041,In vivo,Rattus norvegicus,10116.0
8451,N,,,,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,Intermediate,,,,,50597,BAO_0000218,A,,17065,In vivo,Rattus norvegicus,10116.0
8452,N,,,,Volume of distribution at steady state was evaluated in rats,Intermediate,,,,,50597,BAO_0000218,A,,6597,In vivo,Rattus norvegicus,10116.0
8453,N,,,,Volume of distribution at steady state was observed after intravenous administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,15662,In vivo,Rattus norvegicus,10116.0
8454,N,,,,Volume of distribution in steady state was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,6485,In vivo,Rattus norvegicus,10116.0
8455,N,,,,Volume of distribution in steady state was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,17655,In vivo,Rattus norvegicus,10116.0
8456,N,,,,Volume of distribution after i.v. administration,Intermediate,,,,,50597,BAO_0000218,A,,6616,In vivo,Rattus norvegicus,10116.0
8457,N,,,,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,Intermediate,,,,,50597,BAO_0000218,A,,1916,In vivo,Rattus norvegicus,10116.0
8458,N,,,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",Intermediate,,,,2107.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
8459,N,,,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,,2107.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
8460,N,,,,Biodistribution of compound (oxidized form) in spleen tissue,Intermediate,,,,2106.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
8461,N,,,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,,,2106.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
8462,N,,,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Intermediate,,,,2106.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
8463,N,,,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,,,2106.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
8464,N,,,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,,2106.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
8465,N,,,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",Intermediate,,,,2106.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
8466,N,,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,Intermediate,,,,178.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
8467,N,,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,,,178.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
8468,N,,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,Intermediate,,,,955.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
8469,N,,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",Intermediate,,,,955.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
8470,N,,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,,,955.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
8471,N,,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,Intermediate,,,,948.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
8472,N,,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",Intermediate,,,,948.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
8473,N,,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,,,948.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
8474,N,,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,Intermediate,,,,2113.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
8475,N,,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",Intermediate,,,,2113.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
8476,N,,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,,,2113.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
8477,N,,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,Intermediate,,,,2107.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
8478,N,,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,,,2107.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
8479,N,,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,Intermediate,,,,2106.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
8480,N,,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",Intermediate,,,,2106.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
8481,N,,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,,,2106.0,50594,BAO_0000218,A,,16438,In vivo,Mus musculus,10090.0
8482,N,,,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,Intermediate,,,,,50594,BAO_0000218,A,,12467,,Mus musculus,10090.0
8483,N,,,,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),Intermediate,,,,955.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8484,N,,,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,955.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8485,N,,,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,955.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8486,N,,,,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,955.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8487,N,,,,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,955.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8488,N,,,,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,955.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8489,N,,,,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),Intermediate,,,,948.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8490,N,,,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,948.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8491,N,,,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,948.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8492,N,,,,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,948.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8493,N,,,,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,948.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8494,N,,,,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,948.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8495,N,,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2113.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8496,N,,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2113.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8497,N,,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2113.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8498,N,,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2113.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8499,N,,,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5089,In vivo,Rattus norvegicus,10116.0
8500,N,,,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5089,In vivo,Rattus norvegicus,10116.0
8501,N,,,,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,Intermediate,,,,,50597,BAO_0000218,A,,4257,In vivo,Rattus norvegicus,10116.0
8502,N,,,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,,,,,50597,BAO_0000218,A,,6679,In vivo,Rattus norvegicus,10116.0
8503,N,,,,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,Intermediate,,,,,50597,BAO_0000218,A,,5546,In vivo,Rattus norvegicus,10116.0
8504,N,,,,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,6141,In vivo,Rattus norvegicus,10116.0
8505,N,,,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5334,In vivo,Rattus norvegicus,10116.0
8506,N,,,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5334,In vivo,Rattus norvegicus,10116.0
8507,N,,,,Plasma clearance was reported in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5334,In vivo,Rattus norvegicus,10116.0
8508,N,,,,Plasma clearance after intravenous administration (1 mg/kg) in rat,Intermediate,,,,,50597,BAO_0000218,A,,4689,In vivo,Rattus norvegicus,10116.0
8509,N,,,,Plasma clearance of compound in rats was evaluated,Intermediate,,,,,50597,BAO_0000218,A,,6848,In vivo,Rattus norvegicus,10116.0
8510,N,,,,Plasma clearance of compound in rats was evaluated; ND indicates not determined,Intermediate,,,,,50597,BAO_0000218,A,,6848,In vivo,Rattus norvegicus,10116.0
8511,N,,,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,Intermediate,,,,,50597,BAO_0000218,A,,6467,In vivo,Rattus norvegicus,10116.0
8512,N,,,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,Intermediate,,,,,50597,BAO_0000218,A,,6467,In vivo,Rattus norvegicus,10116.0
8513,N,,,,Plasma clearance rate in Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,4956,In vivo,Rattus norvegicus,10116.0
8514,N,,,,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,5529,In vivo,Rattus norvegicus,10116.0
8515,N,,,,The compound was evaluated for plasma clearance in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,406,In vivo,Rattus norvegicus,10116.0
8516,N,,,,Total plasma clearance in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17655,In vivo,Rattus norvegicus,10116.0
8517,N,,,,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,Intermediate,,,,178.0,50597,BAO_0000218,A,,3293,In vivo,Rattus norvegicus,10116.0
8518,N,,,,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,Intermediate,,,,178.0,50597,BAO_0000218,A,,4075,In vivo,Rattus norvegicus,10116.0
8519,N,,,,C max was determined at 10 mg/kg po dose in rats,Intermediate,,,,,50597,BAO_0000218,A,,2792,In vivo,Rattus norvegicus,10116.0
8520,N,,,,C max was determined at 3 mg/kg po dose in rats,Intermediate,,,,,50597,BAO_0000218,A,,2792,In vivo,Rattus norvegicus,10116.0
8521,N,,,,Cmax after repeated oral dose of compound at 1 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,17594,In vivo,Rattus norvegicus,10116.0
8522,N,,,,Cmax after single intravenous bolus of 1 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,17594,In vivo,Rattus norvegicus,10116.0
8523,N,,,,Cmax of compound at 5 mg/kg after po administration was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,4762,In vivo,Rattus norvegicus,10116.0
8524,N,,,,Cmax 24 hr after 10 mg/kg oral administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,17509,In vivo,Rattus norvegicus,10116.0
8525,N,,,,Cmax 24 hr after 2 mg/kg oral administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,17509,In vivo,Rattus norvegicus,10116.0
8526,N,,,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1466,In vivo,Rattus norvegicus,10116.0
8527,N,,,,Cmax in rat after administration of 2 mg/kg iv,Intermediate,,,,,50597,BAO_0000218,A,,6535,In vivo,Rattus norvegicus,10116.0
8528,N,,,,Cmax in rat after administration of 2 mg/kg iv,Intermediate,,,,,50597,BAO_0000218,A,,6535,In vivo,Rattus norvegicus,10116.0
8529,N,,,,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,3169,In vivo,Rattus norvegicus,10116.0
8530,N,,,,Cmax wa determined in rat plasma at 30 mg/kg after po administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6515,In vivo,Rattus norvegicus,10116.0
8531,N,,,,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,Intermediate,,,,178.0,50597,BAO_0000218,A,,11149,In vivo,Rattus norvegicus,10116.0
8532,N,,,,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,Intermediate,,,,178.0,50597,BAO_0000218,A,,11149,In vivo,Rattus norvegicus,10116.0
8533,N,,,,Cmax after 10 mg/kg oral administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,17858,In vivo,Rattus norvegicus,10116.0
8534,N,,,,Cmax after IV dosing at 0.5 mg/kg in rat; no data,Intermediate,,,,,50597,BAO_0000218,A,,6518,In vivo,Rattus norvegicus,10116.0
8535,N,,,,Cmax after IV dosing at 1 mg/kg in rat; no data,Intermediate,,,,,50597,BAO_0000218,A,,6518,In vivo,Rattus norvegicus,10116.0
8536,N,,,,Cmax after oral administration at 20 mpk in rats,Intermediate,,,,,50597,BAO_0000218,A,,4426,In vivo,Rattus norvegicus,10116.0
8537,N,,,,Cmax after oral administration at 20 mpk in rats; Not performed.,Intermediate,,,,,50597,BAO_0000218,A,,4426,In vivo,Rattus norvegicus,10116.0
8538,N,,,,Cmax after oral administration at 20 mpk in rats d; Not performed.,Intermediate,,,,,50597,BAO_0000218,A,,4426,In vivo,Rattus norvegicus,10116.0
8539,N,,,,Cmax after oral administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,5656,In vivo,Rattus norvegicus,10116.0
8540,N,,,,Cmax after oral administration at a dose of 2 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6518,In vivo,Rattus norvegicus,10116.0
8541,N,,,,Cmax after oral administration at a dose of 4 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6518,In vivo,Rattus norvegicus,10116.0
8542,N,,,,Cmax in rats after 20 mg/kg oral dose,Intermediate,,,,,50597,BAO_0000218,A,,6113,In vivo,Rattus norvegicus,10116.0
8543,N,,,,Cmax after peroral administration in rats at 2.4 uM/kg,Intermediate,,,,,50597,BAO_0000218,A,,17764,In vivo,Rattus norvegicus,10116.0
8544,N,,,,Cmax at the dose of 2 mg/Kg administered perorally in rats,Intermediate,,,,,50597,BAO_0000218,A,,4756,In vivo,Rattus norvegicus,10116.0
8545,N,,,,Cmax at the dose of 5 mg/Kg administered perorally in rats,Intermediate,,,,,50597,BAO_0000218,A,,4756,In vivo,Rattus norvegicus,10116.0
8546,N,,,,Cmax by administering at 20 mg/kg p.o. in rats,Intermediate,,,,,50597,BAO_0000218,A,,6402,In vivo,Rattus norvegicus,10116.0
8547,N,,,,Cmax in male rat,Intermediate,,,,,50597,BAO_0000218,A,,5610,In vivo,Rattus norvegicus,10116.0
8548,N,,,,Cmax in rat,Intermediate,,,,,50597,BAO_0000218,A,,5207,In vivo,Rattus norvegicus,10116.0
8549,N,,,,Cmax in rat,Intermediate,,,,,50597,BAO_0000218,A,,6011,In vivo,Rattus norvegicus,10116.0
8550,N,,,,Cmax in rat,Intermediate,,,,,50597,BAO_0000218,A,,6504,In vivo,Rattus norvegicus,10116.0
8551,N,,,,Cmax in rat at 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6046,In vivo,Rattus norvegicus,10116.0
8552,N,,,,Cmax in rat at the dose of 1 mg/kg i.v.,Intermediate,,,,,50597,BAO_0000218,A,,6504,In vivo,Rattus norvegicus,10116.0
8553,N,,,,Cmax in rat by po administration at a dose of 40 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5874,In vivo,Rattus norvegicus,10116.0
8554,N,,,,Cmax in rat p.o. at 20 mg/kg concentration,Intermediate,,,,,50597,BAO_0000218,A,,17686,In vivo,Rattus norvegicus,10116.0
8555,N,,,,Cmax in rats,Intermediate,,,,,50597,BAO_0000218,A,,5836,In vivo,Rattus norvegicus,10116.0
8556,N,,,,Cmax in rats,Intermediate,,,,,50597,BAO_0000218,A,,17596,In vivo,Rattus norvegicus,10116.0
8557,N,,,,Cmax was evaluated after 20 uM/kg of peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,16423,In vivo,Rattus norvegicus,10116.0
8558,N,,,,Cmax was measured in rats after peroral administration at 3 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17804,In vivo,Rattus norvegicus,10116.0
8559,N,,,,Cmax value after oral dose at a dose of 10 mg/kg in rats.,Intermediate,,,,,50597,BAO_0000218,A,,1908,In vivo,Rattus norvegicus,10116.0
8560,N,,,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,Intermediate,,,,,50597,BAO_0000218,A,,13950,,Rattus norvegicus,10116.0
8561,N,,,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,Intermediate,,,,1870.0,50597,BAO_0000218,A,,13950,,Rattus norvegicus,10116.0
8562,N,,,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,Intermediate,,,,1870.0,50597,BAO_0000218,A,,13950,,Rattus norvegicus,10116.0
8563,N,,,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,13950,,Rattus norvegicus,10116.0
8564,N,,,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,13950,,Rattus norvegicus,10116.0
8565,N,,,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,Intermediate,,,,,50597,BAO_0000218,A,,13950,,Rattus norvegicus,10116.0
8566,N,,,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,Intermediate,,,,,50597,BAO_0000218,A,,13950,,Rattus norvegicus,10116.0
8567,N,,,,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,Intermediate,,,,1891.0,50597,BAO_0000218,A,,13950,,Rattus norvegicus,10116.0
8568,N,,,,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,Intermediate,,,,1891.0,50597,BAO_0000218,A,,13950,,Rattus norvegicus,10116.0
8569,N,,,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,Intermediate,,,,,50597,BAO_0000218,A,,13950,,Rattus norvegicus,10116.0
8570,N,,,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,Intermediate,,,,,50597,BAO_0000218,A,,13950,,Rattus norvegicus,10116.0
8571,N,,,,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,Intermediate,,,,2435.0,50597,BAO_0000218,A,,13950,,Rattus norvegicus,10116.0
8572,N,,,,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,Intermediate,,,,2435.0,50597,BAO_0000218,A,,13950,,Rattus norvegicus,10116.0
8573,N,,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,,,178.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8574,N,,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,,,,178.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8575,N,,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,,,178.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8576,N,,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,,,178.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8577,N,,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,,,,178.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8578,N,,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,,,,178.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8579,N,,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,,,,178.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8580,N,,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Intermediate,,,,178.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8581,N,,,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,,,,178.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8582,N,,,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,,,,178.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8583,N,,,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,,,,178.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8584,N,,,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,,,,178.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8585,N,,,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,,,,178.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8586,N,,,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,,,,178.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8587,N,,,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,,,,178.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8588,N,,,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,,,,178.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8589,N,,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8590,N,,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8591,N,,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8592,N,,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8593,N,,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8594,N,,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8595,N,,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8596,N,,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8597,N,,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8598,N,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8599,N,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8600,N,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8601,N,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8602,N,,,,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,Intermediate,,,,,50597,BAO_0000218,A,,17764,In vivo,Rattus norvegicus,10116.0
8603,N,,,,Volume of steady state distribution after i.v. administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,5031,In vivo,Rattus norvegicus,10116.0
8604,N,,,,Vss after intravenous administration (5.0 mg/kg) was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,6215,In vivo,Rattus norvegicus,10116.0
8605,N,,,,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17671,In vivo,Rattus norvegicus,10116.0
8606,N,,,,Vss was determined,Intermediate,,,,,50597,BAO_0000218,A,,17752,In vivo,Rattus norvegicus,10116.0
8607,N,,,,Vss in rat,Intermediate,,,,,50597,BAO_0000218,A,,6596,In vivo,Rattus norvegicus,10116.0
8608,N,,,,Vss was evaluated after 10 uM/kg of intra arterial administration,Intermediate,,,,,50597,BAO_0000218,A,,16423,In vivo,Rattus norvegicus,10116.0
8609,N,,,,volume of distribution at steady state was observed after intravenous administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,15662,In vivo,Rattus norvegicus,10116.0
8610,N,,,,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6062,In vivo,Rattus norvegicus,10116.0
8611,N,,,,Pharmacokinetic (PK) parameter Vz in rat,Intermediate,,,,,50597,BAO_0000218,A,,5874,In vivo,Rattus norvegicus,10116.0
8612,N,,,,Volume distribution in rats,Intermediate,,,,,50597,BAO_0000218,A,,4942,In vivo,Rattus norvegicus,10116.0
8613,N,,,,Volume of distribution in rat; No data,Intermediate,,,,,50597,BAO_0000218,A,,17796,In vivo,Rattus norvegicus,10116.0
8614,N,,,,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,4890,In vivo,Rattus norvegicus,10116.0
8615,N,,,,% absorption predicted from in vitro rat ileum transport studies,Intermediate,,,,2116.0,50597,BAO_0000218,A,,15765,,Rattus norvegicus,10116.0
8616,N,,,,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,13569,In vivo,Rattus norvegicus,10116.0
8617,N,,,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,13569,In vivo,Rattus norvegicus,10116.0
8618,N,,,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,13569,In vivo,Rattus norvegicus,10116.0
8619,N,,,,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,13569,In vivo,Rattus norvegicus,10116.0
8620,N,,,,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,13569,In vivo,Rattus norvegicus,10116.0
8621,N,,,,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,13569,In vivo,Rattus norvegicus,10116.0
8622,N,,,,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,13569,In vivo,Rattus norvegicus,10116.0
8623,N,,,,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,13569,In vivo,Rattus norvegicus,10116.0
8624,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,4576,In vivo,Rattus norvegicus,10116.0
8625,N,,,,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,Intermediate,,,,1969.0,50597,BAO_0000218,A,,750,In vivo,Rattus norvegicus,10116.0
8626,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,750,In vivo,Rattus norvegicus,10116.0
8627,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,4590,In vivo,Rattus norvegicus,10116.0
8628,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,1716,In vivo,Rattus norvegicus,10116.0
8629,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,1974,In vivo,Rattus norvegicus,10116.0
8630,N,,,,Oral bioavailability in rat (dose 30 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,4502,In vivo,Rattus norvegicus,10116.0
8631,N,,,,Pharmacokinetic property (cLogP) in rat,Intermediate,,,,,50597,BAO_0000218,A,,3371,,Rattus norvegicus,10116.0
8632,N,,,,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,Intermediate,,,,178.0,50597,BAO_0000218,F,,9099,,Rattus norvegicus,10116.0
8633,N,,,,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,Intermediate,,,,178.0,50597,BAO_0000218,F,,9099,,Rattus norvegicus,10116.0
8634,N,,,,Clearance in rat.,Intermediate,,,,,50597,BAO_0000218,A,,4590,In vivo,Rattus norvegicus,10116.0
8635,N,,,,Compound was evaluated for its clearance when administered intravenously in rat,Intermediate,,,,,50597,BAO_0000218,A,,3184,In vivo,Rattus norvegicus,10116.0
8636,N,,,,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,16456,In vivo,Rattus norvegicus,10116.0
8637,N,,,,Blood: Brain distribution ratio is determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,4199,,Rattus norvegicus,10116.0
8638,N,,,,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,Intermediate,,,,,50597,BAO_0000218,A,,4199,,Rattus norvegicus,10116.0
8639,N,,,,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,Intermediate,,,,,50597,BAO_0000218,A,,4199,,Rattus norvegicus,10116.0
8640,N,,,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,2113.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
8641,N,,,,Percent dose excreted in 0-48 hours administered ip to male rat,Intermediate,,,,,50597,BAO_0000218,F,,7449,,Rattus norvegicus,10116.0
8642,N,,,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2037.0,50597,BAO_0000218,A,,11977,,Rattus norvegicus,10116.0
8643,N,,,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2037.0,50597,BAO_0000218,A,,11977,,Rattus norvegicus,10116.0
8644,N,,,,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,,,2037.0,50597,BAO_0000218,A,,11977,,Rattus norvegicus,10116.0
8645,N,,,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2037.0,50597,BAO_0000218,A,,11977,,Rattus norvegicus,10116.0
8646,N,,,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2037.0,50597,BAO_0000218,A,,11977,,Rattus norvegicus,10116.0
8647,N,,,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,,50597,BAO_0000218,A,,11977,,Rattus norvegicus,10116.0
8648,N,,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,,50597,BAO_0000218,A,,11977,,Rattus norvegicus,10116.0
8649,N,,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,,,,50597,BAO_0000218,A,,11977,,Rattus norvegicus,10116.0
8650,N,,,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,,50597,BAO_0000218,A,,11977,,Rattus norvegicus,10116.0
8651,N,,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,,50597,BAO_0000218,A,,11977,,Rattus norvegicus,10116.0
8652,N,,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,,50597,BAO_0000218,A,,11977,,Rattus norvegicus,10116.0
8653,N,,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,,50597,BAO_0000218,A,,11977,,Rattus norvegicus,10116.0
8654,N,,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2113.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8655,N,,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2113.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8656,N,,,,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2107.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8657,N,,,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2107.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8658,N,,,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2107.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8659,N,,,,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2107.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8660,N,,,,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2107.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8661,N,,,,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2107.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8662,N,,,,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2048.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8663,N,,,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2048.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8664,N,,,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2048.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8665,N,,,,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2048.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8666,N,,,,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2048.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8667,N,,,,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2048.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8668,N,,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2385.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8669,N,,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2385.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8670,N,,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2385.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8671,N,,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2385.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8672,N,,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2385.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8673,N,,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2385.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8674,N,,,,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),Intermediate,,,,14.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8675,N,,,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,14.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8676,N,,,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,14.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8677,N,,,,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,14.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8678,N,,,,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,14.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8679,N,,,,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,14.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8680,N,,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2106.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8681,N,,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2106.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8682,N,,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2106.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8683,N,,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2106.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8684,N,,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2106.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8685,N,,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2106.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8686,N,,,,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),Intermediate,,,,178.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8687,N,,,,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,178.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8688,N,,,,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,178.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8689,N,,,,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,178.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8690,N,,,,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,178.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8691,N,,,,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,178.0,50594,BAO_0000218,A,,17208,In vivo,Mus musculus,10090.0
8692,N,,,,Time taken for EC90 was determined when tested in mouse,Intermediate,,,,,50594,BAO_0000218,A,,3132,,Mus musculus,10090.0
8693,N,,,,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,3132,,Mus musculus,10090.0
8694,N,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),Intermediate,,,,,50594,BAO_0000218,A,,16597,In vivo,Mus musculus,10090.0
8695,N,,,,Half life in mice,Intermediate,,,,,50594,BAO_0000218,A,,5727,,Mus musculus,10090.0
8696,N,,,,Half life period in mouse after 10 mg/Kg dose,Intermediate,,,,,50594,BAO_0000218,A,,5302,In vivo,Mus musculus,10090.0
8697,N,,,,Half life period in mouse after 10 mg/kg dose,Intermediate,,,,,50594,BAO_0000218,A,,5302,In vivo,Mus musculus,10090.0
8698,N,,,,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Intermediate,,,,,50594,BAO_0000218,A,,6348,In vivo,Mus musculus,10090.0
8699,N,,,,Cmax value at 5 mg/kg po was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,5964,In vivo,Rattus norvegicus,10116.0
8700,N,,,,Cmax value evaluated in rat,Intermediate,,,,,50597,BAO_0000218,A,,6078,In vivo,Rattus norvegicus,10116.0
8701,N,,,,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,Intermediate,,,,955.0,50597,BAO_0000218,A,,5206,In vivo,Rattus norvegicus,10116.0
8702,N,,,,Cmax value after administration of 20 mg/Kg oral dose in rat,Intermediate,,,,,50597,BAO_0000218,A,,2959,In vivo,Rattus norvegicus,10116.0
8703,N,,,,Cmax value at 1 mg/kg po in rat,Intermediate,,,,,50597,BAO_0000218,A,,5964,In vivo,Rattus norvegicus,10116.0
8704,N,,,,Cmax value at 5 mg/kg po in rat,Intermediate,,,,,50597,BAO_0000218,A,,5964,In vivo,Rattus norvegicus,10116.0
8705,N,,,,Cmax value at a dose of 10 mg/kg in male SD rats,Intermediate,,,,,50597,BAO_0000218,A,,6757,In vivo,Rattus norvegicus,10116.0
8706,N,,,,Cmax value at a dose of 100 mg/kg in male SD rats,Intermediate,,,,,50597,BAO_0000218,A,,6757,In vivo,Rattus norvegicus,10116.0
8707,N,,,,Cmax value at a dose of 50 mg/kg in male SD rats,Intermediate,,,,,50597,BAO_0000218,A,,6757,In vivo,Rattus norvegicus,10116.0
8708,N,,,,Cmax value in rats at 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17617,In vivo,Rattus norvegicus,10116.0
8709,N,,,,Cmax value was evaluated in rats at a dose of 20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,1445,In vivo,Rattus norvegicus,10116.0
8710,N,,,,Cmax value was determined after peroral administration of 20 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6082,In vivo,Rattus norvegicus,10116.0
8711,N,,,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,Intermediate,,,,,50597,BAO_0000218,A,,1446,In vivo,Rattus norvegicus,10116.0
8712,N,,,,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5407,In vivo,Rattus norvegicus,10116.0
8713,N,,,,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2690,In vivo,Rattus norvegicus,10116.0
8714,N,,,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,2661,In vivo,Rattus norvegicus,10116.0
8715,N,,,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,2661,In vivo,Rattus norvegicus,10116.0
8716,N,,,,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4891,In vivo,Rattus norvegicus,10116.0
8717,N,,,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2807,In vivo,Rattus norvegicus,10116.0
8718,N,,,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2807,In vivo,Rattus norvegicus,10116.0
8719,N,,,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2807,In vivo,Rattus norvegicus,10116.0
8720,N,,,,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,3634,In vivo,Rattus norvegicus,10116.0
8721,N,,,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1881,In vivo,Rattus norvegicus,10116.0
8722,N,,,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1881,In vivo,Rattus norvegicus,10116.0
8723,N,,,,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,429,In vivo,Rattus norvegicus,10116.0
8724,N,,,,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,In vivo,Rattus norvegicus,10116.0
8725,N,,,,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,In vivo,Rattus norvegicus,10116.0
8726,N,,,,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,In vivo,Rattus norvegicus,10116.0
8727,N,,,,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,In vivo,Rattus norvegicus,10116.0
8728,N,,,,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,Intermediate,,,,,50597,BAO_0000218,A,,17582,In vivo,Rattus norvegicus,10116.0
8729,N,,,,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,Intermediate,,,,,50597,BAO_0000218,A,,17582,In vivo,Rattus norvegicus,10116.0
8730,N,,,,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",Intermediate,,,,1969.0,50597,BAO_0000218,A,,3032,In vivo,Rattus norvegicus,10116.0
8731,N,,,,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6295,In vivo,Rattus norvegicus,10116.0
8732,N,,,,Maximal concentration in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,6619,In vivo,Rattus norvegicus,10116.0
8733,N,,,,Maximal concentration after i.v. administration,Intermediate,,,,,50597,BAO_0000218,A,,6616,In vivo,Rattus norvegicus,10116.0
8734,N,,,,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,3249,In vivo,Rattus norvegicus,10116.0
8735,N,,,,Maximal plasma concentration in rat after oral administration at 50 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17791,In vivo,Rattus norvegicus,10116.0
8736,N,,,,Cmax in rat plasma after oral dose (50 mg/Kg),Intermediate,,,,1969.0,50597,BAO_0000218,A,,17791,In vivo,Rattus norvegicus,10116.0
8737,N,,,,Maximal plasma concentration was determined.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1360,In vivo,Rattus norvegicus,10116.0
8738,N,,,,Maximal plasma drug concentration was determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2552,In vivo,Rattus norvegicus,10116.0
8739,N,,,,Maximal concentration in rats after peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,6571,In vivo,Rattus norvegicus,10116.0
8740,N,,,,Maximum concentration in rat after 2 mg/kg peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,6570,In vivo,Rattus norvegicus,10116.0
8741,N,,,,Maximum concentration in rat plasma after 5 mg/kg oral gavage,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6567,In vivo,Rattus norvegicus,10116.0
8742,N,,,,Maximum concentration of compound in rat was evaluated.,Intermediate,,,,,50597,BAO_0000218,A,,3031,In vivo,Rattus norvegicus,10116.0
8743,N,,,,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,3436,In vivo,Rattus norvegicus,10116.0
8744,N,,,,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,3436,In vivo,Rattus norvegicus,10116.0
8745,N,,,,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,Intermediate,,,,,50597,BAO_0000218,A,,2083,In vivo,Rattus norvegicus,10116.0
8746,N,,,,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,3436,In vivo,Rattus norvegicus,10116.0
8747,N,,,,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,4527,In vivo,Rattus norvegicus,10116.0
8748,N,,,,Maximum concentration was evaluated in rats,Intermediate,,,,,50597,BAO_0000218,A,,1974,In vivo,Rattus norvegicus,10116.0
8749,N,,,,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,Intermediate,,,,1359.0,50597,BAO_0000218,A,,3307,In vivo,Rattus norvegicus,10116.0
8750,N,,,,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,3307,In vivo,Rattus norvegicus,10116.0
8751,N,,,,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1916,In vivo,Rattus norvegicus,10116.0
8752,N,,,,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,1500,In vivo,Rattus norvegicus,10116.0
8753,N,,,,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,1500,In vivo,Rattus norvegicus,10116.0
8754,N,,,,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4186,In vivo,Rattus norvegicus,10116.0
8755,N,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8756,N,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8757,N,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8758,N,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8759,N,,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8760,N,,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8761,N,,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8762,N,,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8763,N,,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8764,N,,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8765,N,,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8766,N,,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8767,N,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8768,N,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8769,N,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8770,N,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8771,N,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8772,N,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8773,N,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8774,N,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8775,N,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8776,N,,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,,,955.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8777,N,,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,,,,955.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8778,N,,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,,,955.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8779,N,,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,,,955.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8780,N,,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,,,,955.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8781,N,,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,,,,955.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8782,N,,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,,,,955.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8783,N,,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Intermediate,,,,955.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8784,N,,,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,,,,955.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8785,N,,,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,,,,955.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8786,N,,,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,,,,955.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8787,N,,,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,,,,955.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8788,N,,,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,,,,955.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8789,N,,,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,,,,955.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8790,N,,,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,,,,955.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8791,N,,,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,,,,955.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8792,N,,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,,,,955.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8793,N,,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,,,,955.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8794,N,,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,,,,955.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8795,N,,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,,,955.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8796,N,,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,,,955.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8797,N,,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,,,955.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8798,N,,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,,,955.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8799,N,,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,,,955.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8800,N,,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,,,955.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8801,N,,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,,,,50597,BAO_0000218,A,,11977,,Rattus norvegicus,10116.0
8802,N,,,,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,,50597,BAO_0000218,A,,11977,,Rattus norvegicus,10116.0
8803,N,,,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,10000000.0,50597,BAO_0000218,A,,11977,,Rattus norvegicus,10116.0
8804,N,,,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,10000000.0,50597,BAO_0000218,A,,11977,,Rattus norvegicus,10116.0
8805,N,,,,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,10000000.0,50597,BAO_0000218,A,,11977,,Rattus norvegicus,10116.0
8806,N,,,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,10000000.0,50597,BAO_0000218,A,,11977,,Rattus norvegicus,10116.0
8807,N,,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2435.0,50597,BAO_0000218,A,,11977,,Rattus norvegicus,10116.0
8808,N,,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2435.0,50597,BAO_0000218,A,,11977,,Rattus norvegicus,10116.0
8809,N,,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,,,2435.0,50597,BAO_0000218,A,,11977,,Rattus norvegicus,10116.0
8810,N,,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2435.0,50597,BAO_0000218,A,,11977,,Rattus norvegicus,10116.0
8811,N,,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2435.0,50597,BAO_0000218,A,,11977,,Rattus norvegicus,10116.0
8812,N,,,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,178.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8813,N,,,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,178.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8814,N,,,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,178.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8815,N,,,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,178.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8816,N,,,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,955.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8817,N,,,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,955.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8818,N,,,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,,,955.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8819,N,,,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,955.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8820,N,,,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,955.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8821,N,,,,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,948.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8822,N,,,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,948.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8823,N,,,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,,,948.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8824,N,,,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,948.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8825,N,,,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,948.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8826,N,,,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2113.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8827,N,,,,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2113.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8828,N,,,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2113.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8829,N,,,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2113.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8830,N,,,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2107.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8831,N,,,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2107.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8832,N,,,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,,,2107.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8833,N,,,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2107.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8834,N,,,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2107.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8835,N,,,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2048.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8836,N,,,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2048.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8837,N,,,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,,,2048.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8838,N,,,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2048.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8839,N,,,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2048.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8840,N,,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,,,2385.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8841,N,,,,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,Intermediate,,,,,50594,BAO_0000218,A,,4573,In vivo,Mus musculus,10090.0
8842,N,,,,Half life in mouse plasma was determined at dose 25 mg/kg,Intermediate,,,,1969.0,50594,BAO_0000218,A,,3132,In vivo,Mus musculus,10090.0
8843,N,,,,Half life was determined,Intermediate,,,,,50594,BAO_0000218,A,,17718,,Mus musculus,10090.0
8844,N,,,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,Intermediate,,,,,50594,BAO_0000218,A,,17728,In vivo,Mus musculus,10090.0
8845,N,,,,Half-life in male mice after 1 mg/kg intravenous dose,Intermediate,,,,,50594,BAO_0000218,A,,5961,In vivo,Mus musculus,10090.0
8847,N,,,,Half life in mice plasma,Intermediate,,,,1969.0,50594,BAO_0000218,A,,17731,,Mus musculus,10090.0
8848,N,,,,Half life in mouse,Intermediate,,,,,50594,BAO_0000218,A,,17592,,Mus musculus,10090.0
8849,N,,,,Half life in mouse plasma at dose 25 mg/kg,Intermediate,,,,1969.0,50594,BAO_0000218,A,,3132,In vivo,Mus musculus,10090.0
8850,N,,,,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,Intermediate,,,,,50594,BAO_0000218,A,,17729,In vivo,Mus musculus,10090.0
8851,N,,,,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,Intermediate,,,,,50594,BAO_0000218,A,,17729,In vivo,Mus musculus,10090.0
8852,N,,,,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,Intermediate,,,,,50594,BAO_0000218,A,,17729,In vivo,Mus musculus,10090.0
8853,N,,,,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Intermediate,,,,,50594,BAO_0000218,A,,3277,In vivo,Mus musculus,10090.0
8854,N,,,,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",Intermediate,,,,,50594,BAO_0000218,A,,3760,In vivo,Mus musculus,10090.0
8855,N,,,,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",Intermediate,,,,,50594,BAO_0000218,A,,3760,In vivo,Mus musculus,10090.0
8856,N,,,,Half-life by iv administration in mouse,Intermediate,,,,,50594,BAO_0000218,A,,2862,In vivo,Mus musculus,10090.0
8857,N,,,,Half-life by oral administration in mouse,Intermediate,,,,,50594,BAO_0000218,A,,2862,In vivo,Mus musculus,10090.0
8858,N,,,,Half-life in mice,Intermediate,,,,,50594,BAO_0000218,A,,5980,,Mus musculus,10090.0
8859,N,,,,Half-life using mouse brain homogenate,Intermediate,,,,955.0,50594,BAO_0000218,A,,6159,,Mus musculus,10090.0
8860,N,,,,Half-life was measured in mice,Intermediate,,,,,50594,BAO_0000218,A,,6254,,Mus musculus,10090.0
8861,N,,,,Half-life was measured in mouse after an iv dose of 1 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,6062,In vivo,Mus musculus,10090.0
8862,N,,,,Half-life period was determined in mouse blood,Intermediate,,,,178.0,50594,BAO_0000218,A,,1574,,Mus musculus,10090.0
8863,N,,,,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",Intermediate,,,,955.0,50594,BAO_0000218,A,,56,,Mus musculus,10090.0
8864,N,,,,Plasma half life in mouse,Intermediate,,,,1969.0,50594,BAO_0000218,A,,993,,Mus musculus,10090.0
8865,N,,,,Stability of the peptide in the presence of mouse serum,Intermediate,,,,,50594,BAO_0000218,A,,6652,,Mus musculus,10090.0
8866,N,,,,Terminal half life of compound was determined in mouse,Intermediate,,,,,50594,BAO_0000218,A,,17852,,Mus musculus,10090.0
8867,N,,,,Terminal half life was evaluated in mice after intravenous administration,Intermediate,,,,,50594,BAO_0000218,A,,2675,In vivo,Mus musculus,10090.0
8868,N,,,,Terminal half life was evaluated in mice after oral administration,Intermediate,,,,,50594,BAO_0000218,A,,2675,In vivo,Mus musculus,10090.0
8869,N,,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,Intermediate,,,,,50594,BAO_0000218,A,,499,,Mus musculus,10090.0
8870,N,,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,Intermediate,,,,,50594,BAO_0000218,A,,499,,Mus musculus,10090.0
8871,N,,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,Intermediate,,,,,50594,BAO_0000218,A,,499,,Mus musculus,10090.0
8872,N,,,,half life period is evaluated by administering intravenously at 25 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,14239,In vivo,Mus musculus,10090.0
8873,N,,,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",Intermediate,,,,,50594,BAO_0000218,A,,5506,In vivo,Mus musculus,10090.0
8874,N,,,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",Intermediate,,,,,50594,BAO_0000218,A,,5506,In vivo,Mus musculus,10090.0
8875,N,,,,Half life after intraperitoneal administration of 100 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,17734,,Mus musculus,10090.0
8876,N,,,,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,Intermediate,,,,,50594,BAO_0000218,A,,17728,In vivo,Mus musculus,10090.0
8877,N,,,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,Intermediate,,,,,50594,BAO_0000218,A,,17728,In vivo,Mus musculus,10090.0
8878,N,,,,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,Intermediate,,,,,50594,BAO_0000218,A,,17728,In vivo,Mus musculus,10090.0
8879,N,,,,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,Intermediate,,,,,50594,BAO_0000218,A,,17728,In vivo,Mus musculus,10090.0
8880,N,,,,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,Intermediate,,,,,50594,BAO_0000218,A,,17728,In vivo,Mus musculus,10090.0
8881,U,,,,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),Autocuration,,,,,22224,BAO_0000251,A,Microsomes,14294,,Sus scrofa,9823.0
8882,U,,,,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),Autocuration,,,,,22224,BAO_0000251,A,Microsomes,14294,,Sus scrofa,9823.0
8883,U,,,,Stability to porcine renal DHP-I,Autocuration,,,,,22224,BAO_0000019,A,,6056,,Sus scrofa,9823.0
8884,U,,,,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,Autocuration,,,,,22224,BAO_0000218,A,,1317,In vivo,Sus scrofa,9823.0
8885,U,,,,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,Autocuration,,,,,22224,BAO_0000218,A,,1317,In vivo,Sus scrofa,9823.0
8886,U,,,,Half-life of the parent prodrug in porcine esterase solution,Autocuration,,,,,22224,BAO_0000019,A,,5229,,Sus scrofa,9823.0
8887,U,,,,"First order rate constant, k was determined in in pig liver Esterase",Autocuration,,,,,22224,BAO_0000019,A,,4231,,Sus scrofa,9823.0
8888,U,,,,Half life of the in pig liver Esterase,Autocuration,,,,2107.0,22224,BAO_0000221,A,,4231,,Sus scrofa,9823.0
8889,U,,,,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,Autocuration,,,,2107.0,22224,BAO_0000221,A,,5318,,Sus scrofa,9823.0
8890,U,,,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,Autocuration,,,,2107.0,22224,BAO_0000221,A,,5318,,Sus scrofa,9823.0
8891,U,,,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,Autocuration,,,,2107.0,22224,BAO_0000221,A,,5318,,Sus scrofa,9823.0
8892,U,,,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,Autocuration,,,,2107.0,22224,BAO_0000221,A,,3305,,Sus scrofa,9823.0
8893,U,,,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,Autocuration,,,,2107.0,22224,BAO_0000221,A,,3305,,Sus scrofa,9823.0
8894,U,,,,Half-life in the presence of pig liver esterase(PLE) was evaluated.,Autocuration,,,,2107.0,22224,BAO_0000221,A,,2842,,Sus scrofa,9823.0
8895,U,,,,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,Autocuration,,,,2107.0,22224,BAO_0000221,A,,2842,,Sus scrofa,9823.0
8896,U,,,,Half-life in vitro in pig liver,Autocuration,,,,2107.0,22224,BAO_0000221,A,,889,In vitro,Sus scrofa,9823.0
8897,U,,,,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,Autocuration,,,,2107.0,22224,BAO_0000221,A,,1904,,Sus scrofa,9823.0
8898,N,,,,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4186,In vivo,Rattus norvegicus,10116.0
8899,N,,,,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2774,In vivo,Rattus norvegicus,10116.0
8900,N,,,,Maximum concentration in rat plasma was determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1742,In vivo,Rattus norvegicus,10116.0
8901,N,,,,Maximum concentration in rats,Intermediate,,,,,50597,BAO_0000218,A,,3169,In vivo,Rattus norvegicus,10116.0
8902,N,,,,Maximum concentration in rats at 1-2 hours,Intermediate,,,,,50597,BAO_0000218,A,,3169,In vivo,Rattus norvegicus,10116.0
8903,N,,,,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,Intermediate,,,,,50597,BAO_0000218,A,,2081,In vivo,Rattus norvegicus,10116.0
8904,N,,,,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,Intermediate,,,,955.0,50597,BAO_0000218,A,,3307,In vivo,Rattus norvegicus,10116.0
8905,N,,,,Maximum concentration at the dose of 2 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4727,In vivo,Rattus norvegicus,10116.0
8906,N,,,,Maximum concentration was evaluated in rats,Intermediate,,,,,50597,BAO_0000218,A,,6597,In vivo,Rattus norvegicus,10116.0
8907,N,,,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,16365,In vivo,Rattus norvegicus,10116.0
8908,N,,,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,16365,In vivo,Rattus norvegicus,10116.0
8909,N,,,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,16365,In vivo,Rattus norvegicus,10116.0
8910,N,,,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,16365,In vivo,Rattus norvegicus,10116.0
8911,N,,,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,16365,In vivo,Rattus norvegicus,10116.0
8912,N,,,,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,Intermediate,,,,178.0,50597,BAO_0000218,A,,2591,In vivo,Rattus norvegicus,10116.0
8913,N,,,,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,Intermediate,,,,178.0,50597,BAO_0000218,A,,2591,In vivo,Rattus norvegicus,10116.0
8914,N,,,,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,Intermediate,,,,178.0,50597,BAO_0000218,A,,2591,In vivo,Rattus norvegicus,10116.0
8915,N,,,,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5978,In vivo,Rattus norvegicus,10116.0
8916,N,,,,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5978,In vivo,Rattus norvegicus,10116.0
8917,N,,,,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5978,In vivo,Rattus norvegicus,10116.0
8918,N,,,,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5978,In vivo,Rattus norvegicus,10116.0
8919,N,,,,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5978,In vivo,Rattus norvegicus,10116.0
8920,N,,,,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5978,In vivo,Rattus norvegicus,10116.0
8921,N,,,,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5978,In vivo,Rattus norvegicus,10116.0
8922,N,,,,Cmax in rat (PO dose),Intermediate,,,,,50597,BAO_0000218,A,,14465,In vivo,Rattus norvegicus,10116.0
8923,N,,,,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4723,In vivo,Rattus norvegicus,10116.0
8924,N,,,,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4723,In vivo,Rattus norvegicus,10116.0
8925,N,,,,Maximum plasma concentration determined in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4576,In vivo,Rattus norvegicus,10116.0
8926,N,,,,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,12873,In vivo,Rattus norvegicus,10116.0
8927,N,,,,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,12873,In vivo,Rattus norvegicus,10116.0
8928,N,,,,Maximum plasma concentration in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6824,In vivo,Rattus norvegicus,10116.0
8929,N,,,,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17065,In vivo,Rattus norvegicus,10116.0
8930,N,,,,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2932,In vivo,Rattus norvegicus,10116.0
8931,N,,,,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2932,In vivo,Rattus norvegicus,10116.0
8932,N,,,,Maximum plasma concentration of compound was measured in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2879,In vivo,Rattus norvegicus,10116.0
8933,N,,,,Maximum plasma concentration after 20 mg/kg oral administration in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2864,In vivo,Rattus norvegicus,10116.0
8934,N,,,,Maximum plasma concentration after oral administration to rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,16367,In vivo,Rattus norvegicus,10116.0
8935,N,,,,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17717,In vivo,Rattus norvegicus,10116.0
8936,N,,,,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",Intermediate,,,,1969.0,50597,BAO_0000218,A,,17717,In vivo,Rattus norvegicus,10116.0
8937,N,,,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17717,In vivo,Rattus norvegicus,10116.0
8938,N,,,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17717,In vivo,Rattus norvegicus,10116.0
8939,N,,,,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,Intermediate,,,,1969.0,50597,BAO_0000218,F,,17720,In vivo,Rattus norvegicus,10116.0
8940,N,,,,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,Intermediate,,,,1969.0,50597,BAO_0000218,F,,17720,In vivo,Rattus norvegicus,10116.0
8941,N,,,,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,Intermediate,,,,1969.0,50597,BAO_0000218,F,,17720,In vivo,Rattus norvegicus,10116.0
8942,N,,,,Maximum plasma concentration dosed orally in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4516,In vivo,Rattus norvegicus,10116.0
8943,N,,,,Maximum plasma concentration dosed orally in rats after 6 hours,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4516,In vivo,Rattus norvegicus,10116.0
8944,N,,,,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4516,In vivo,Rattus norvegicus,10116.0
8945,N,,,,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5199,In vivo,Rattus norvegicus,10116.0
8946,N,,,,Maximum plasma concentration in rat after po administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17538,In vivo,Rattus norvegicus,10116.0
8947,N,,,,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",Intermediate,,,,1969.0,50597,BAO_0000218,A,,6685,In vivo,Rattus norvegicus,10116.0
8948,N,,,,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",Intermediate,,,,1969.0,50597,BAO_0000218,A,,6685,In vivo,Rattus norvegicus,10116.0
8949,N,,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,,,948.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8950,N,,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,,,,948.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8951,N,,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,,,948.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8952,N,,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,,,948.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8953,N,,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,,,,948.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8954,N,,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,,,,948.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8955,N,,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,,,,948.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8956,N,,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,Intermediate,,,,948.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8957,N,,,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,,,,948.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8958,N,,,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,,,,948.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8959,N,,,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,,,,948.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8960,N,,,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,,,,948.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8961,N,,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8962,N,,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8963,N,,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8964,N,,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8965,N,,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8966,N,,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8967,N,,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8968,N,,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8969,N,,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8970,N,,,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,,,,948.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8971,N,,,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,,,,948.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8972,N,,,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,,,,948.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8973,N,,,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,,,,948.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8974,N,,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8975,N,,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8976,N,,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8977,N,,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8978,N,,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8979,N,,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8980,N,,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8981,N,,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8982,N,,,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8983,N,,,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8984,N,,,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8985,N,,,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8986,N,,,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8987,N,,,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8988,N,,,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8989,N,,,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8990,N,,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8991,N,,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8992,N,,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
8993,N,,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
8994,N,,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2385.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8995,N,,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2385.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8996,N,,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,,,2385.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8997,N,,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2385.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8998,N,,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2385.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
8999,N,,,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,14.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
9000,N,,,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,14.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
9001,N,,,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,,,14.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
9002,N,,,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,14.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
9003,N,,,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,14.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
9004,N,,,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2106.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
9005,N,,,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2106.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
9006,N,,,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,,,2106.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
9007,N,,,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2106.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
9008,N,,,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2106.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
9009,N,,,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2046.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
9010,N,,,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2046.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
9011,N,,,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,,,2046.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
9012,N,,,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2046.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
9013,N,,,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2046.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
9014,N,,,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2107.0,50597,BAO_0000218,A,,11977,In vivo,Rattus norvegicus,10116.0
9015,N,,,,Half life in rats,Intermediate,,,,,50597,BAO_0000218,A,,3748,,Rattus norvegicus,10116.0
9016,N,,,,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,Intermediate,,,,,50597,BAO_0000218,A,,15765,,Rattus norvegicus,10116.0
9017,N,,,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),Intermediate,,,,,50597,BAO_0000218,A,,4871,,Rattus norvegicus,10116.0
9018,N,,,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,Intermediate,,,,,50597,BAO_0000218,A,,4871,,Rattus norvegicus,10116.0
9019,N,,,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),Intermediate,,,,,50597,BAO_0000218,A,,4872,,Rattus norvegicus,10116.0
9020,N,,,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,Intermediate,,,,,50597,BAO_0000218,A,,4872,,Rattus norvegicus,10116.0
9021,N,,,,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),Intermediate,,,,,50597,BAO_0000218,A,,5413,,Rattus norvegicus,10116.0
9022,N,,,,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,Intermediate,,,,,50597,BAO_0000218,A,,5413,,Rattus norvegicus,10116.0
9023,N,,,,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,15272,In vivo,Rattus norvegicus,10116.0
9024,N,,,,Stability (%) in rat liver microsomes,Intermediate,,,,2107.0,50597,BAO_0000218,A,,4689,,Rattus norvegicus,10116.0
9025,N,,,,Area under curve was calculated after intravenous administration,Intermediate,,,,,50597,BAO_0000218,A,,6057,,Rattus norvegicus,10116.0
9026,N,,,,Area under the curve was calculated after iv administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,6057,,Rattus norvegicus,10116.0
9027,N,,,,Area under the curve was calculated in rat after peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,6057,,Rattus norvegicus,10116.0
9028,N,,,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,6211,,Rattus norvegicus,10116.0
9029,N,,,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,5710,,Rattus norvegicus,10116.0
9030,N,,,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,5710,,Rattus norvegicus,10116.0
9031,N,,,,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,Intermediate,,,,,50597,BAO_0000218,A,,17853,,Rattus norvegicus,10116.0
9032,N,,,,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,Intermediate,,,,,50597,BAO_0000218,A,,17853,,Rattus norvegicus,10116.0
9033,N,,,,p value of the compound,Intermediate,,,,,50597,BAO_0000218,A,,15765,,Rattus norvegicus,10116.0
9034,N,,,,p value of the compound,Intermediate,,,,,50597,BAO_0000218,F,,15765,,Rattus norvegicus,10116.0
9035,N,,,,p value of the compound,Intermediate,,,,,50597,BAO_0000218,A,,15765,,Rattus norvegicus,10116.0
9036,N,,,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Intermediate,,,,945.0,50597,BAO_0000218,A,,6175,,Rattus norvegicus,10116.0
9037,N,,,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Intermediate,,,,945.0,50597,BAO_0000218,A,,6175,,Rattus norvegicus,10116.0
9038,N,,,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Intermediate,,,,945.0,50597,BAO_0000218,A,,6175,,Rattus norvegicus,10116.0
9039,U,,,,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),Autocuration,,,,,22224,BAO_0000019,F,,7991,,Oryctolagus cuniculus,9986.0
9040,U,,,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),Autocuration,,,,,22224,BAO_0000218,A,,429,,Oryctolagus cuniculus,9986.0
9041,U,,,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),Autocuration,,,,,22224,BAO_0000218,A,,429,,Oryctolagus cuniculus,9986.0
9042,U,,,,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,Autocuration,,,,,22224,BAO_0000218,A,,6253,In vivo,Oryctolagus cuniculus,9986.0
9043,U,,,,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,Autocuration,,,,,22224,BAO_0000218,A,,6253,In vivo,Oryctolagus cuniculus,9986.0
9044,U,,,,Clearance rate in rabbits,Autocuration,,,,,22224,BAO_0000218,A,,3615,In vivo,Oryctolagus cuniculus,9986.0
9045,U,,,,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,Autocuration,,,,,22224,BAO_0000218,A,,4059,In vivo,Oryctolagus cuniculus,9986.0
9046,U,,,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,5124,In vivo,Oryctolagus cuniculus,9986.0
9047,U,,,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,5124,In vivo,Oryctolagus cuniculus,9986.0
9048,U,,,,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,5124,In vivo,Oryctolagus cuniculus,9986.0
9049,U,,,,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,429,In vivo,Oryctolagus cuniculus,9986.0
9050,U,,,,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,Autocuration,,,,1969.0,22224,BAO_0000218,A,,4059,In vivo,Oryctolagus cuniculus,9986.0
9051,U,,,,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,9659,,Oryctolagus cuniculus,9986.0
9052,U,,,,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,9659,,Oryctolagus cuniculus,9986.0
9053,U,,,,Dose at which bioavailability of intravenously administered compound was tested in rabbit,Autocuration,,,,,22224,BAO_0000218,A,,3639,,Oryctolagus cuniculus,9986.0
9054,U,,,,Dose at which bioavailability of perorally administered compound was tested in rabbit,Autocuration,,,,,22224,BAO_0000218,A,,3639,,Oryctolagus cuniculus,9986.0
9055,U,,,,The compound was tested for its bioavailability in rabbit (by oral dosage).,Autocuration,,,,,22224,BAO_0000218,A,,3639,In vivo,Oryctolagus cuniculus,9986.0
9056,U,,,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,5124,In vivo,Oryctolagus cuniculus,9986.0
9057,U,,,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,5124,In vivo,Oryctolagus cuniculus,9986.0
9058,U,,,,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,5124,In vivo,Oryctolagus cuniculus,9986.0
9059,U,,,,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),Autocuration,,,,,22224,BAO_0000251,A,Microsomes,14294,,Oryctolagus cuniculus,9986.0
9060,U,,,,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),Autocuration,,,,,22224,BAO_0000251,A,Microsomes,14294,,Oryctolagus cuniculus,9986.0
9061,U,,,,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,429,In vivo,Oryctolagus cuniculus,9986.0
9062,U,,,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,Autocuration,,,,1969.0,22224,BAO_0000218,A,,5124,In vivo,Oryctolagus cuniculus,9986.0
9063,U,,,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,Autocuration,,,,1969.0,22224,BAO_0000218,A,,5124,In vivo,Oryctolagus cuniculus,9986.0
9064,U,,,,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,Autocuration,,,,1969.0,22224,BAO_0000218,A,,5124,In vivo,Oryctolagus cuniculus,9986.0
9065,U,,,,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,429,In vivo,Oryctolagus cuniculus,9986.0
9066,U,,,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),Autocuration,,,,1088.0,22224,BAO_0000218,A,,429,,Oryctolagus cuniculus,9986.0
9067,U,,,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),Autocuration,,,,1088.0,22224,BAO_0000218,A,,429,,Oryctolagus cuniculus,9986.0
9068,U,,,,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,Autocuration,,,,,22224,BAO_0000218,A,,4059,In vivo,Oryctolagus cuniculus,9986.0
9069,U,,,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,Autocuration,,,,,22224,BAO_0000218,A,,4137,In vivo,Oryctolagus cuniculus,9986.0
9070,U,,,,In vitro Biological half-life in crude homogenate of rabbit renal cortex,Autocuration,,,,,22224,BAO_0000221,A,,11672,In vitro,Oryctolagus cuniculus,9986.0
9071,U,,,,Time within which only 10% of the drug was degraded,Autocuration,,,,,22224,BAO_0000019,A,,12886,,Oryctolagus cuniculus,9986.0
9072,U,,,,Half life period in rabbit liver homogenate,Autocuration,,,,2107.0,22224,BAO_0000221,A,,3853,,Oryctolagus cuniculus,9986.0
9073,U,,,,Half life value in rabbits,Autocuration,,,,,22224,BAO_0000019,A,,3615,,Oryctolagus cuniculus,9986.0
9074,U,,,,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,Autocuration,,,,178.0,22224,BAO_0000218,A,,6253,In vivo,Oryctolagus cuniculus,9986.0
9075,U,,,,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,Autocuration,,,,178.0,22224,BAO_0000218,A,,6253,In vivo,Oryctolagus cuniculus,9986.0
9076,U,,,,Half-life period in rabbits following intravenous administration at 2 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,6077,In vivo,Oryctolagus cuniculus,9986.0
9077,N,,,,AUC 0-8 hr value in rats at 10 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17617,,Rattus norvegicus,10116.0
9078,N,,,,AUC after administration at 2000 mg/kg/day in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17594,,Rattus norvegicus,10116.0
9079,N,,,,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6149,,Rattus norvegicus,10116.0
9080,N,,,,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17260,,Rattus norvegicus,10116.0
9081,N,,,,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17260,,Rattus norvegicus,10116.0
9082,N,,,,AUC in rat after oral administration at 10.5 mg/kg dose,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6644,,Rattus norvegicus,10116.0
9083,N,,,,AUC in rat after oral administration at 11.2 mg/kg dose,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6644,,Rattus norvegicus,10116.0
9084,N,,,,AUC in rat after oral administration at 9.7 mg/kg dose,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6644,,Rattus norvegicus,10116.0
9085,N,,,,AUC in rat brain after oral administration at 10 mg/kg,Intermediate,,,,955.0,50597,BAO_0000218,A,,6495,,Rattus norvegicus,10116.0
9086,N,,,,AUC in rat p.o.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6504,,Rattus norvegicus,10116.0
9087,N,,,,AUC in rat p.o. at 20 mg/kg concentration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17686,,Rattus norvegicus,10116.0
9088,N,,,,AUC in rat plasma after oral administration at 10 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6495,,Rattus norvegicus,10116.0
9089,N,,,,AUC in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,216,,Rattus norvegicus,10116.0
9090,N,,,,AUC value after IV dose at a dose of 5 mg/kg in rats.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1908,,Rattus norvegicus,10116.0
9091,N,,,,AUC value after oral dose at a dose of 10 mg/kg in rats.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1908,,Rattus norvegicus,10116.0
9092,N,,,,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",Intermediate,,,,1969.0,50597,BAO_0000218,A,,6685,In vivo,Rattus norvegicus,10116.0
9093,N,,,,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,Intermediate,,,,1969.0,50597,BAO_0000218,A,,216,In vivo,Rattus norvegicus,10116.0
9094,N,,,,Maximum plasma concentration was evaluated in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6049,In vivo,Rattus norvegicus,10116.0
9095,N,,,,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2463,In vivo,Rattus norvegicus,10116.0
9096,N,,,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6679,In vivo,Rattus norvegicus,10116.0
9097,N,,,,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6681,In vivo,Rattus norvegicus,10116.0
9098,N,,,,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4890,In vivo,Rattus norvegicus,10116.0
9099,N,,,,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6410,In vivo,Rattus norvegicus,10116.0
9100,N,,,,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6410,In vivo,Rattus norvegicus,10116.0
9101,N,,,,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,Intermediate,,,,1969.0,50597,BAO_0000218,A,,16366,In vivo,Rattus norvegicus,10116.0
9102,N,,,,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6227,In vivo,Rattus norvegicus,10116.0
9103,N,,,,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,Expert,,,,1969.0,50597,BAO_0000218,A,,3598,In vivo,Rattus norvegicus,10116.0
9104,N,,,,Maximum plasma drug concentration was determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1465,In vivo,Rattus norvegicus,10116.0
9105,N,,,,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4368,In vivo,Rattus norvegicus,10116.0
9106,N,,,,Mean peak plasma concentration was observed after intravenous administration in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15662,In vivo,Rattus norvegicus,10116.0
9107,N,,,,Mean peak plasma concentration was observed after oral administration in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15662,In vivo,Rattus norvegicus,10116.0
9108,N,,,,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,5355,In vivo,Rattus norvegicus,10116.0
9109,N,,,,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,5355,In vivo,Rattus norvegicus,10116.0
9110,N,,,,Peak oral plasma concentration was determined in rats by oral administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1567,In vivo,Rattus norvegicus,10116.0
9111,N,,,,Peak plasma concentration (Cmax) was determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4026,In vivo,Rattus norvegicus,10116.0
9112,N,,,,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6193,In vivo,Rattus norvegicus,10116.0
9113,N,,,,Peak plasma concentration (Cmax) in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4026,In vivo,Rattus norvegicus,10116.0
9114,N,,,,Peak plasma concentration at 1 mg/kg peroral administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6485,In vivo,Rattus norvegicus,10116.0
9115,N,,,,Peak plasma concentration in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17655,In vivo,Rattus norvegicus,10116.0
9116,N,,,,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",Intermediate,,,,1969.0,50597,BAO_0000218,A,,14941,In vivo,Rattus norvegicus,10116.0
9117,N,,,,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5394,In vivo,Rattus norvegicus,10116.0
9118,N,,,,Pharmacokinetic property (Cmax) in rat,Intermediate,,,,,50597,BAO_0000218,A,,4408,In vivo,Rattus norvegicus,10116.0
9119,N,,,,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,Intermediate,,,,,50597,BAO_0000218,A,,5983,In vivo,Rattus norvegicus,10116.0
9120,N,,,,Cmax in rat after 3mg/kg oral dose,Intermediate,,,,,50597,BAO_0000218,A,,4878,In vivo,Rattus norvegicus,10116.0
9121,N,,,Sprague-Dawley,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,Intermediate,,,,,50597,BAO_0000218,A,,5862,In vivo,Rattus norvegicus,10116.0
9122,N,,,,Cmax in rats after 20 mg/kg oral dose,Intermediate,,,,,50597,BAO_0000218,A,,4517,In vivo,Rattus norvegicus,10116.0
9123,N,,,,Cmax in rat plasma after 30mg/kg oral dose,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5932,In vivo,Rattus norvegicus,10116.0
9124,N,,,,Plasma concentration after oral administration of 100 mg/kg to rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5436,In vivo,Rattus norvegicus,10116.0
9125,N,,,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,Intermediate,,,,955.0,50597,BAO_0000218,A,,4910,In vivo,Rattus norvegicus,10116.0
9126,N,,,,Tested for the Cmax in rat at 10 mg/kg per orally,Intermediate,,,,,50597,BAO_0000218,A,,4950,In vivo,Rattus norvegicus,10116.0
9127,N,,,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,15078,In vivo,Rattus norvegicus,10116.0
9128,N,,,,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,15078,In vivo,Rattus norvegicus,10116.0
9129,N,,,,Bioavailability as oral Cmax in rats at 30 mins,Intermediate,,,,,50597,BAO_0000218,A,,3360,In vivo,Rattus norvegicus,10116.0
9130,N,,,,Bioavailability as oral Cmax in rats at 6hr,Intermediate,,,,,50597,BAO_0000218,A,,3360,In vivo,Rattus norvegicus,10116.0
9131,N,,,,The maximum concentration of compound was measured at the dose of 100 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,15022,In vivo,Rattus norvegicus,10116.0
9132,N,,,,The maximum concentration of compound was measured at the dose of 300 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,15022,In vivo,Rattus norvegicus,10116.0
9133,N,,,,The maximum concentration of compound was measured at the dose of 30 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,15022,In vivo,Rattus norvegicus,10116.0
9134,N,,,,The maximum plasma levels for the compounds were determined by LC-MS.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5160,In vivo,Rattus norvegicus,10116.0
9135,N,,,,mean peak plasma concentration was observed after intravenous administration in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15662,In vivo,Rattus norvegicus,10116.0
9136,N,,,,mean peak plasma concentration was observed after oral administration in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15662,In vivo,Rattus norvegicus,10116.0
9137,N,,,,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4709,,Rattus norvegicus,10116.0
9138,N,,,,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,Intermediate,,,,,50597,BAO_0000218,A,,3535,,Rattus norvegicus,10116.0
9139,N,,,,Concentration in plasma (portal) following oral dose in rats at 1 hr,Intermediate,,,,,50597,BAO_0000218,A,,3535,,Rattus norvegicus,10116.0
9140,N,,,,Concentration in plasma (portal) following oral dose in rats at 2 hr,Intermediate,,,,,50597,BAO_0000218,A,,3535,,Rattus norvegicus,10116.0
9141,N,,,,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,Intermediate,,,,,50597,BAO_0000218,A,,3535,,Rattus norvegicus,10116.0
9142,N,,,,Concentration in plasma (systemic) following oral dose in rats at 1 hr,Intermediate,,,,,50597,BAO_0000218,A,,3535,,Rattus norvegicus,10116.0
9143,N,,,,Concentration in plasma (systemic) following oral dose in rats at 2 hr,Intermediate,,,,,50597,BAO_0000218,A,,3535,,Rattus norvegicus,10116.0
9144,U,,,,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,Intermediate,,,,1969.0,22224,BAO_0000218,A,,5005,In vivo,Rattus norvegicus,10116.0
9145,N,,,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",Intermediate,,,,1898.0,50597,BAO_0000218,A,,6326,,Rattus norvegicus,10116.0
9146,N,,,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",Intermediate,,,,1898.0,50597,BAO_0000218,A,,6326,,Rattus norvegicus,10116.0
9147,N,,,,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",Intermediate,,,,,50597,BAO_0000218,A,,6326,,Rattus norvegicus,10116.0
9148,N,,,,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",Intermediate,,,,,50597,BAO_0000218,A,,6326,,Rattus norvegicus,10116.0
9149,N,,,,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17411,,Rattus norvegicus,10116.0
9150,N,,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9151,N,,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9152,N,,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9153,N,,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9154,N,,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9155,N,,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9156,N,,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9157,N,,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9158,N,,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9159,N,,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9160,N,,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9161,N,,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9162,N,,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9163,N,,,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9164,N,,,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9165,N,,,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9166,N,,,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9167,N,,,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9168,N,,,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9169,N,,,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9170,N,,,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9171,N,,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9172,N,,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9173,N,,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9174,N,,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9175,N,,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9176,N,,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9177,N,,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9178,N,,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9179,N,,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9180,N,,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9181,N,,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9182,N,,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9183,N,,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9184,N,,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9185,N,,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9186,N,,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9187,N,,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9188,N,,,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9189,N,,,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9190,N,,,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9191,N,,,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9192,N,,,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9193,N,,,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9194,N,,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9195,N,,,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Intermediate,,,,945.0,50597,BAO_0000218,A,,6175,,Rattus norvegicus,10116.0
9196,N,,,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Intermediate,,,,945.0,50597,BAO_0000218,A,,6175,,Rattus norvegicus,10116.0
9197,N,,,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Intermediate,,,,945.0,50597,BAO_0000218,A,,6175,,Rattus norvegicus,10116.0
9198,N,,,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Intermediate,,,,945.0,50597,BAO_0000218,A,,6175,,Rattus norvegicus,10116.0
9199,N,,,,The compound was tested for the plasma binding in rat,Intermediate,,,,,50597,BAO_0000218,A,,10839,,Rattus norvegicus,10116.0
9200,N,,,,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",Intermediate,,,,,50597,BAO_0000218,A,,16459,,Rattus norvegicus,10116.0
9201,N,,,,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",Intermediate,,,,,50597,BAO_0000218,A,,16459,,Rattus norvegicus,10116.0
9202,N,,,,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",Intermediate,,,,,50597,BAO_0000218,A,,16459,,Rattus norvegicus,10116.0
9203,N,,,,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,16459,,Rattus norvegicus,10116.0
9204,N,,,,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,16459,,Rattus norvegicus,10116.0
9205,N,,,,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,16459,,Rattus norvegicus,10116.0
9206,N,,,,Plasma level at 2 hr after administration of the compound,Intermediate,,,,,50597,BAO_0000218,A,,3278,,Rattus norvegicus,10116.0
9207,N,,,,plasma level at 2 hr after administration of the compound,Intermediate,,,,,50597,BAO_0000218,A,,3278,,Rattus norvegicus,10116.0
9208,N,,,,Stability in rat serum measured as % recovery at 1 min,Intermediate,,,,1977.0,50597,BAO_0000218,A,,4684,,Rattus norvegicus,10116.0
9209,N,,,,Stability in rat serum measured as % recovery at 10 min,Intermediate,,,,1977.0,50597,BAO_0000218,A,,4684,,Rattus norvegicus,10116.0
9210,N,,,,Stability in rat serum measured as % recovery at 10 mins,Intermediate,,,,1977.0,50597,BAO_0000218,A,,4684,,Rattus norvegicus,10116.0
9211,N,,,,Stability in rat serum measured as % recovery at 2 hr,Intermediate,,,,1977.0,50597,BAO_0000218,A,,4684,,Rattus norvegicus,10116.0
9212,N,,,,Stability in rat serum measured as % recovery at 3 min,Intermediate,,,,1977.0,50597,BAO_0000218,A,,4684,,Rattus norvegicus,10116.0
9213,N,,,,Stability in rat serum measured as % recovery at 3 mins,Intermediate,,,,1977.0,50597,BAO_0000218,A,,4684,,Rattus norvegicus,10116.0
9214,N,,,,Stability in rat serum measured as % recovery at 5 min,Intermediate,,,,1977.0,50597,BAO_0000218,A,,4684,,Rattus norvegicus,10116.0
9215,N,,,,Stability in rat serum measured as % recovery at 5 mins,Intermediate,,,,1977.0,50597,BAO_0000218,A,,4684,,Rattus norvegicus,10116.0
9216,N,,,,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,16456,In vivo,Rattus norvegicus,10116.0
9217,N,,,,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,16456,In vivo,Rattus norvegicus,10116.0
9218,N,,,,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,723,,Rattus norvegicus,10116.0
9219,N,,,,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,723,,Rattus norvegicus,10116.0
9220,N,,,,Half life tested in mature male rat at a dose of 30 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5160,In vivo,Rattus norvegicus,10116.0
9221,N,,,,Half life after intravenous administration of 1 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4709,In vivo,Rattus norvegicus,10116.0
9222,N,,,,Half life period after administration (30 mg/kg) in rat,Intermediate,,,,,50597,BAO_0000218,A,,5633,In vivo,Rattus norvegicus,10116.0
9223,N,,,,Half life period in rat after 5 mg/Kg dose,Intermediate,,,,,50597,BAO_0000218,A,,5302,In vivo,Rattus norvegicus,10116.0
9224,N,,,,Half life period in rat after 5 mg/kg dose,Intermediate,,,,,50597,BAO_0000218,A,,5302,In vivo,Rattus norvegicus,10116.0
9225,N,,,,Half life period was determined,Intermediate,,,,,50597,BAO_0000218,A,,17791,,Rattus norvegicus,10116.0
9226,N,,,,Half life period was evaluated in rat,Intermediate,,,,,50597,BAO_0000218,A,,17791,,Rattus norvegicus,10116.0
9227,N,,,,Half life period was evaluated in rat; 0.5-1.0,Intermediate,,,,,50597,BAO_0000218,A,,17791,,Rattus norvegicus,10116.0
9228,N,,,,Half life period was evaluated in rat; 5.9-7.5,Intermediate,,,,,50597,BAO_0000218,A,,17791,,Rattus norvegicus,10116.0
9229,N,,,,Half-life in rat plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14512,,Rattus norvegicus,10116.0
9230,N,,,,Half-life time in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,6230,,Rattus norvegicus,10116.0
9231,N,,,,Terminal half-life after iv administration to rats,Intermediate,,,,,50597,BAO_0000218,A,,3364,In vivo,Rattus norvegicus,10116.0
9232,N,,,,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,6874,In vivo,Rattus norvegicus,10116.0
9233,N,,,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,857,,Rattus norvegicus,10116.0
9234,N,,,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),Intermediate,,,,,50597,BAO_0000218,A,,858,In vivo,Rattus norvegicus,10116.0
9235,N,,,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),Intermediate,,,,,50597,BAO_0000218,A,,858,In vivo,Rattus norvegicus,10116.0
9236,N,,,,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,5355,In vivo,Rattus norvegicus,10116.0
9237,N,,,,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,5355,In vivo,Rattus norvegicus,10116.0
9238,N,,,,Half life in rats,Intermediate,,,,,50597,BAO_0000218,A,,6305,,Rattus norvegicus,10116.0
9239,N,,,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,13501,In vivo,Rattus norvegicus,10116.0
9240,N,,,,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,17594,In vivo,Rattus norvegicus,10116.0
9241,N,,,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4186,In vivo,Rattus norvegicus,10116.0
9242,N,,,,Biological half-life was measured in plasma of rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2932,,Rattus norvegicus,10116.0
9243,N,,,,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,Intermediate,,,,,50597,BAO_0000218,A,,17065,In vivo,Rattus norvegicus,10116.0
9244,N,,,,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,Intermediate,,,,,50597,BAO_0000218,A,,15765,In vivo,Rattus norvegicus,10116.0
9245,N,,,,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,2713,In vivo,Rattus norvegicus,10116.0
9246,N,,,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,2661,In vivo,Rattus norvegicus,10116.0
9247,N,,,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,2661,In vivo,Rattus norvegicus,10116.0
9248,N,,,,Compound was evaluated for plasma half life in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,740,,Rattus norvegicus,10116.0
9249,N,,,,AUC value at a dose of 5 mg/kg (p.o.) in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6597,,Rattus norvegicus,10116.0
9250,N,,,,AUC value after administration of 20 mg/Kg oral dose in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2959,,Rattus norvegicus,10116.0
9251,N,,,,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17594,,Rattus norvegicus,10116.0
9252,N,,,,AUC0-96 after administration at 50 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17596,,Rattus norvegicus,10116.0
9253,N,,,,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17594,,Rattus norvegicus,10116.0
9254,N,,,,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",Intermediate,,,,,50597,BAO_0000218,A,,3293,,Rattus norvegicus,10116.0
9255,N,,,,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,Intermediate,,,,,50597,BAO_0000218,A,,6757,,Rattus norvegicus,10116.0
9256,N,,,,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,Intermediate,,,,,50597,BAO_0000218,A,,6757,,Rattus norvegicus,10116.0
9257,N,,,,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,Intermediate,,,,,50597,BAO_0000218,A,,6757,,Rattus norvegicus,10116.0
9258,N,,,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,Intermediate,,,,2113.0,50597,BAO_0000218,A,,5979,,Rattus norvegicus,10116.0
9259,N,,,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,Intermediate,,,,,50597,BAO_0000218,A,,5979,,Rattus norvegicus,10116.0
9260,N,,,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,Intermediate,,,,,50597,BAO_0000218,A,,5979,,Rattus norvegicus,10116.0
9261,N,,,,Area under curve (AUC) at a dose of 30 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,4026,,Rattus norvegicus,10116.0
9262,N,,,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,5355,,Rattus norvegicus,10116.0
9263,N,,,,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,5355,,Rattus norvegicus,10116.0
9264,N,,,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,5355,,Rattus norvegicus,10116.0
9265,N,,,,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,Intermediate,,,,,50597,BAO_0000218,A,,5633,,Rattus norvegicus,10116.0
9266,N,,,,Area under curve (Pharmacokinetic property) was determined,Intermediate,,,,,50597,BAO_0000218,A,,1716,,Rattus norvegicus,10116.0
9267,N,,,,Area under curve (Pharmacokinetic property) of the compound; Not determined,Intermediate,,,,,50597,BAO_0000218,A,,1716,,Rattus norvegicus,10116.0
9268,N,,,,Area under curve after intravenous administration (1 mg/kg) in rat,Intermediate,,,,,50597,BAO_0000218,A,,4689,,Rattus norvegicus,10116.0
9269,N,,,,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,4527,,Rattus norvegicus,10116.0
9270,N,,,,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,4527,,Rattus norvegicus,10116.0
9271,N,,,,Area under curve in male SD rats was observed after oral administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,15662,,Rattus norvegicus,10116.0
9272,N,,,,Area under curve of compound after iv administration of 20 mg/kg dose in rat,Intermediate,,,,,50597,BAO_0000218,A,,4413,,Rattus norvegicus,10116.0
9273,N,,,,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,Expert,,,,,50597,BAO_0000218,A,,3598,,Rattus norvegicus,10116.0
9274,N,,,,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,Expert,,,,,50597,BAO_0000218,A,,3598,,Rattus norvegicus,10116.0
9275,N,,,,Area under curve at 5 mg/kg po was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,5964,,Rattus norvegicus,10116.0
9276,N,,,,Area under curve in Rat at a oral dose of 5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,4689,,Rattus norvegicus,10116.0
9277,N,,,,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Intermediate,,,,,50597,BAO_0000218,A,,4186,,Rattus norvegicus,10116.0
9278,N,,,,Area under curve was determined,Intermediate,,,,,50597,BAO_0000218,A,,5510,,Rattus norvegicus,10116.0
9279,N,,,,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,Intermediate,,,,,50597,BAO_0000218,A,,17858,,Rattus norvegicus,10116.0
9280,N,,,,Area under curve after intravenous administration at 3 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17804,,Rattus norvegicus,10116.0
9281,N,,,,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,Intermediate,,,,,50597,BAO_0000218,A,,6106,,Rattus norvegicus,10116.0
9282,N,,,,Area under curve at 4 hr in rat,Intermediate,,,,,50597,BAO_0000218,A,,5964,,Rattus norvegicus,10116.0
9283,N,,,,Area under curve at a dose of 30 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,4026,,Rattus norvegicus,10116.0
9284,N,,,,Area under curve at the dose of 2 mg/Kg administered perorally in rats,Intermediate,,,,,50597,BAO_0000218,A,,4756,,Rattus norvegicus,10116.0
9285,N,,,,Area under curve at the dose of 5 mg/Kg administered perorally in rats,Intermediate,,,,,50597,BAO_0000218,A,,4756,,Rattus norvegicus,10116.0
9286,N,,,,Area under curve for a 2-mpk po dose in SD rats,Intermediate,,,,,50597,BAO_0000218,A,,5862,,Rattus norvegicus,10116.0
9287,N,,,,Area under curve in SD rats,Intermediate,,,,,50597,BAO_0000218,A,,5862,,Rattus norvegicus,10116.0
9288,N,,,,Area under curve in rat after oral administration at 13 mg/kg dose,Intermediate,,,,,50597,BAO_0000218,A,,6644,,Rattus norvegicus,10116.0
9289,N,,,,Area under curve in rat by po administration at 0-24 hr,Intermediate,,,,,50597,BAO_0000218,A,,5871,,Rattus norvegicus,10116.0
9290,N,,,,Area under curve in rat plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5919,,Rattus norvegicus,10116.0
9291,N,,,,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5939,,Rattus norvegicus,10116.0
9292,N,,,,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5939,,Rattus norvegicus,10116.0
9293,N,,,,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,Intermediate,,,,,50597,BAO_0000218,A,,10,,Rattus norvegicus,10116.0
9294,N,,,,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,Intermediate,,,,,50597,BAO_0000218,A,,11149,,Rattus norvegicus,10116.0
9295,N,,,,Area under curve value in rat at a dose of 5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5302,,Rattus norvegicus,10116.0
9296,N,,,,Area under curve was determined after oral administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,17796,,Rattus norvegicus,10116.0
9297,N,,,,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,4890,,Rattus norvegicus,10116.0
9298,N,,,,Area under curve was determined after peroral administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,6011,,Rattus norvegicus,10116.0
9299,N,,,,Area under curve was determined at a dose 30 mpk administered orally.,Intermediate,,,,,50597,BAO_0000218,A,,5375,,Rattus norvegicus,10116.0
9300,N,,,,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,Intermediate,,,,,50597,BAO_0000218,A,,17764,,Rattus norvegicus,10116.0
9301,N,,,,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4368,,Rattus norvegicus,10116.0
9302,N,,,,Area under curve was determined in male rat,Intermediate,,,,,50597,BAO_0000218,A,,5610,,Rattus norvegicus,10116.0
9303,N,,,,Area under curve was determined in rat after PO administration,Intermediate,,,,,50597,BAO_0000218,A,,5833,,Rattus norvegicus,10116.0
9304,N,,,,Area under curve was determined in rat after a 3 mg/kg of oral dose,Intermediate,,,,,50597,BAO_0000218,A,,4257,,Rattus norvegicus,10116.0
9305,N,,,,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5937,,Rattus norvegicus,10116.0
9306,N,,,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5932,,Rattus norvegicus,10116.0
9307,N,,,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,Intermediate,,,,,50597,BAO_0000218,A,,5932,,Rattus norvegicus,10116.0
9308,N,,,,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17411,,Rattus norvegicus,10116.0
9309,N,,,,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17411,,Rattus norvegicus,10116.0
9310,N,,,,Peak plasma concentration in rat at a dose of 3 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17771,,Rattus norvegicus,10116.0
9311,N,,,,Plasma concentration at 2 hr in rats was evaluated.,Intermediate,,,,,50597,BAO_0000218,A,,1628,,Rattus norvegicus,10116.0
9312,N,,,,Plasma concentration at 2 hr in rats was evaluated; Not available,Intermediate,,,,,50597,BAO_0000218,A,,1628,,Rattus norvegicus,10116.0
9313,N,,,,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17411,,Rattus norvegicus,10116.0
9314,N,,,,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,Intermediate,,,,,50597,BAO_0000218,A,,4910,,Rattus norvegicus,10116.0
9315,N,,,,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,Intermediate,,,,,50597,BAO_0000218,A,,4910,,Rattus norvegicus,10116.0
9316,N,,,,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4910,,Rattus norvegicus,10116.0
9317,N,,,,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4910,,Rattus norvegicus,10116.0
9318,N,,,,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4910,,Rattus norvegicus,10116.0
9319,N,,,,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4910,,Rattus norvegicus,10116.0
9320,N,,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,Intermediate,,,,,50597,BAO_0000218,A,,5510,,Rattus norvegicus,10116.0
9321,N,,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,Intermediate,,,,,50597,BAO_0000218,A,,5510,,Rattus norvegicus,10116.0
9322,N,,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,Intermediate,,,,,50597,BAO_0000218,A,,5510,,Rattus norvegicus,10116.0
9323,N,,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,Intermediate,,,,,50597,BAO_0000218,A,,5510,,Rattus norvegicus,10116.0
9324,N,,,,PK study was carried to determine the relative absorption ranking in rat.,Intermediate,,,,,50597,BAO_0000218,A,,16427,,Rattus norvegicus,10116.0
9325,N,,,,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4689,In vivo,Rattus norvegicus,10116.0
9326,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",Intermediate,,,,178.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9327,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",Intermediate,,,,178.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9328,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",Intermediate,,,,178.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9329,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",Intermediate,,,,178.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9330,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",Intermediate,,,,178.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9331,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",Intermediate,,,,178.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9332,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",Intermediate,,,,955.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9333,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",Intermediate,,,,955.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9334,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",Intermediate,,,,955.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9335,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",Intermediate,,,,955.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9336,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",Intermediate,,,,955.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9337,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",Intermediate,,,,955.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9338,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",Intermediate,,,,948.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9339,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",Intermediate,,,,948.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9340,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",Intermediate,,,,948.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9341,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",Intermediate,,,,948.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9342,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",Intermediate,,,,948.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9343,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",Intermediate,,,,948.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9344,N,,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9345,N,,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9346,N,,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9347,N,,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9348,N,,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9349,N,,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9350,N,,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9351,N,,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9352,N,,,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9353,N,,,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9354,N,,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9355,N,,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9356,N,,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9357,N,,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9358,N,,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9359,N,,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9360,N,,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9361,N,,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9362,N,,,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9363,N,,,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9364,N,,,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9365,N,,,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9366,N,,,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9367,N,,,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9368,N,,,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9369,N,,,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9370,N,,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9371,N,,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9372,N,,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9373,N,,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9374,N,,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9375,N,,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9376,N,,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9377,N,,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9378,N,,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9379,N,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9380,N,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9381,N,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9382,N,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9383,N,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9384,N,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9385,N,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9386,N,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9387,N,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9388,N,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9389,N,,,,Compound was evaluated for terminal half life in rat,Intermediate,,,,,50597,BAO_0000218,A,,3341,,Rattus norvegicus,10116.0
9390,N,,,,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,Intermediate,,,,1969.0,50597,BAO_0000218,A,,3634,In vivo,Rattus norvegicus,10116.0
9391,N,,,,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,Intermediate,,,,1969.0,50597,BAO_0000218,A,,3634,In vivo,Rattus norvegicus,10116.0
9392,N,,,,Compound was tested for its half life in rat,Intermediate,,,,,50597,BAO_0000218,A,,4839,,Rattus norvegicus,10116.0
9393,U,,,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,Intermediate,,,,1969.0,22224,BAO_0000218,A,,5005,In vivo,Macaca mulatta,9544.0
9394,U,,,,Compound was tested for its plasma half life in Sprague Dawley rats,Intermediate,,,,1969.0,22224,BAO_0000366,A,,5005,,Rattus norvegicus,10116.0
9395,U,,,,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,Intermediate,,,,1969.0,22224,BAO_0000366,A,,5005,,Rattus norvegicus,10116.0
9396,N,,,,Compound was tested for plasma half-life period in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1094,,Rattus norvegicus,10116.0
9397,N,,,,Elimination half life after i.v. administration of compound in rats,Intermediate,,,,,50597,BAO_0000218,A,,5031,In vivo,Rattus norvegicus,10116.0
9398,N,,,,Elimination half-life after IV dosing at 0.5 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6518,In vivo,Rattus norvegicus,10116.0
9399,N,,,,Elimination half-life after IV dosing at 1 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6518,In vivo,Rattus norvegicus,10116.0
9400,N,,,,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6518,In vivo,Rattus norvegicus,10116.0
9401,N,,,,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6518,In vivo,Rattus norvegicus,10116.0
9402,N,,,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,Intermediate,,,,955.0,50597,BAO_0000218,A,,5408,In vivo,Rattus norvegicus,10116.0
9403,N,,,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5408,In vivo,Rattus norvegicus,10116.0
9404,N,,,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,Intermediate,,,,955.0,50597,BAO_0000218,A,,5408,In vivo,Rattus norvegicus,10116.0
9405,N,,,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5408,In vivo,Rattus norvegicus,10116.0
9406,N,,,,Evaluated for the half life in rat (in vivo),Intermediate,,,,,50597,BAO_0000218,A,,4687,In vivo,Rattus norvegicus,10116.0
9407,N,,,,Hafl life in rat,Intermediate,,,,,50597,BAO_0000218,A,,6640,,Rattus norvegicus,10116.0
9408,N,,,,Hafl life rat,Intermediate,,,,,50597,BAO_0000218,A,,6640,,Rattus norvegicus,10116.0
9409,N,,,,Hafl life rat,Intermediate,,,,,50597,BAO_0000218,A,,6641,,Rattus norvegicus,10116.0
9410,N,,,,Hafl life rat; Not determined,Intermediate,,,,,50597,BAO_0000218,A,,6640,,Rattus norvegicus,10116.0
9411,N,,,,Hafl life rat; Not determined,Intermediate,,,,,50597,BAO_0000218,A,,6641,,Rattus norvegicus,10116.0
9412,N,,,,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,,,2113.0,50597,BAO_0000218,A,,17411,In vivo,Rattus norvegicus,10116.0
9413,N,,,,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,,,2107.0,50597,BAO_0000218,A,,17411,In vivo,Rattus norvegicus,10116.0
9414,N,,,,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,,,2048.0,50597,BAO_0000218,A,,17411,In vivo,Rattus norvegicus,10116.0
9415,N,,,,Half life in rat after 1 mg/kg i.v. administration,Intermediate,,,,,50597,BAO_0000218,A,,6570,In vivo,Rattus norvegicus,10116.0
9416,N,,,,Half life in rat after 2 mg/kg peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,6570,In vivo,Rattus norvegicus,10116.0
9417,N,,,,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17411,In vivo,Rattus norvegicus,10116.0
9418,N,,,,Half life of 10 mg/kg oral dose determined in rats,Intermediate,,,,,50597,BAO_0000218,A,,4722,In vivo,Rattus norvegicus,10116.0
9419,N,,,,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,In vivo,Rattus norvegicus,10116.0
9420,N,,,,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,In vivo,Rattus norvegicus,10116.0
9421,N,,,,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,In vivo,Rattus norvegicus,10116.0
9422,N,,,,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,In vivo,Rattus norvegicus,10116.0
9423,N,,,,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,In vivo,Rattus norvegicus,10116.0
9424,N,,,,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,In vivo,Rattus norvegicus,10116.0
9425,N,,,,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,In vivo,Rattus norvegicus,10116.0
9426,N,,,,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,In vivo,Rattus norvegicus,10116.0
9427,N,,,,Half life of compound at 5 mg/kg after po administration was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,4762,In vivo,Rattus norvegicus,10116.0
9428,N,,,,Half life of compound determined after intravenous administration to rat,Intermediate,,,,,50597,BAO_0000218,A,,5327,In vivo,Rattus norvegicus,10116.0
9429,N,,,,Half life of compound was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,4847,,Rattus norvegicus,10116.0
9430,N,,,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17720,In vivo,Rattus norvegicus,10116.0
9431,N,,,,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,,,,50597,BAO_0000218,A,,4723,In vivo,Rattus norvegicus,10116.0
9432,N,,,,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,,,,50597,BAO_0000218,A,,4723,In vivo,Rattus norvegicus,10116.0
9433,U,,,,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,Intermediate,,,,,22224,BAO_0000218,A,,4256,In vivo,Macaca fascicularis,9541.0
9434,U,,,,Half life determined in rat by intravenous administration,Intermediate,,,,,22224,BAO_0000218,A,,4256,In vivo,Rattus norvegicus,10116.0
9435,N,,,,Half life determined in rats after iv administration,Intermediate,,,,,50597,BAO_0000218,A,,4722,In vivo,Rattus norvegicus,10116.0
9436,N,,,,Half life in rat plasma after administration of 2 mg/kg iv,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6535,In vivo,Rattus norvegicus,10116.0
9437,N,,,,Half life in rat plasma after administration of 2 mg/kg iv,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6535,In vivo,Rattus norvegicus,10116.0
9438,N,,,,Half life in rat plasma was determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1435,,Rattus norvegicus,10116.0
9439,N,,,,Half life in rat plasma was determined; NA means not applicable,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1435,,Rattus norvegicus,10116.0
9440,N,,,,Half life in rat was tested,Intermediate,,,,,50597,BAO_0000218,A,,5206,,Rattus norvegicus,10116.0
9441,N,,,,Half life measured in rat plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6080,,Rattus norvegicus,10116.0
9442,N,,,,Half life recorded in rats,Intermediate,,,,,50597,BAO_0000218,A,,4449,,Rattus norvegicus,10116.0
9443,N,,,,Half life was calculated,Intermediate,,,,,50597,BAO_0000218,A,,6057,,Rattus norvegicus,10116.0
9444,N,,,,Half life was calculated in rat,Intermediate,,,,,50597,BAO_0000218,A,,6057,,Rattus norvegicus,10116.0
9445,N,,,,Half life was determined,Intermediate,,,,,50597,BAO_0000218,A,,3747,,Rattus norvegicus,10116.0
9446,N,,,,Half life after 10 mg/kg oral administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,17858,In vivo,Rattus norvegicus,10116.0
9447,N,,,,Half life after administering orally a dose of 10 mg/kg to a fasting rat,Intermediate,,,,,50597,BAO_0000218,A,,16365,In vivo,Rattus norvegicus,10116.0
9448,N,,,,Half life after administering orally a dose of 30 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,16365,In vivo,Rattus norvegicus,10116.0
9449,N,,,,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,5031,,Rattus norvegicus,10116.0
9450,N,,,,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,Intermediate,,,,,50597,BAO_0000218,A,,4722,,Rattus norvegicus,10116.0
9451,N,,,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6078,,Rattus norvegicus,10116.0
9452,N,,,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6078,,Rattus norvegicus,10116.0
9453,N,,,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6078,,Rattus norvegicus,10116.0
9454,N,,,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,Intermediate,,,,,50597,BAO_0000218,A,,6078,,Rattus norvegicus,10116.0
9455,N,,,,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,Intermediate,,,,,50597,BAO_0000218,A,,17065,,Rattus norvegicus,10116.0
9456,N,,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,Intermediate,,,,,50597,BAO_0000218,A,,1353,,Rattus norvegicus,10116.0
9457,N,,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),Intermediate,,,,,50597,BAO_0000218,A,,1353,,Rattus norvegicus,10116.0
9458,N,,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),Intermediate,,,,,50597,BAO_0000218,A,,1353,,Rattus norvegicus,10116.0
9459,N,,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),Intermediate,,,,,50597,BAO_0000218,A,,1353,,Rattus norvegicus,10116.0
9460,N,,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),Intermediate,,,,,50597,BAO_0000218,A,,1353,,Rattus norvegicus,10116.0
9461,N,,,,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,Intermediate,,,,,50597,BAO_0000218,A,,16423,,Rattus norvegicus,10116.0
9462,N,,,,Area under the curve was evaluated after 20 uM/kg of peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,16423,,Rattus norvegicus,10116.0
9463,N,,,,Area under the curve was measured in rat after an iv dose of 1 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6062,,Rattus norvegicus,10116.0
9464,N,,,,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6056,,Rattus norvegicus,10116.0
9465,N,,,,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,Intermediate,,,,,50597,BAO_0000218,A,,5182,,Rattus norvegicus,10116.0
9466,N,,,,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6410,,Rattus norvegicus,10116.0
9467,N,,,,Area under the curve was evaluated at an oral dose of 30 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6410,,Rattus norvegicus,10116.0
9468,N,,,,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,,,,50597,BAO_0000218,A,,4723,,Rattus norvegicus,10116.0
9469,N,,,,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,,,,50597,BAO_0000218,A,,4723,,Rattus norvegicus,10116.0
9470,N,,,,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,,,,50597,BAO_0000218,A,,4723,,Rattus norvegicus,10116.0
9471,N,,,,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,,,,50597,BAO_0000218,A,,4723,,Rattus norvegicus,10116.0
9472,N,,,,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,,,,50597,BAO_0000218,A,,4723,,Rattus norvegicus,10116.0
9473,N,,,,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,,,,50597,BAO_0000218,A,,4723,,Rattus norvegicus,10116.0
9474,N,,,,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2463,,Rattus norvegicus,10116.0
9475,N,,,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4709,,Rattus norvegicus,10116.0
9476,N,,,,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,Intermediate,,,,,50597,BAO_0000218,A,,4075,,Rattus norvegicus,10116.0
9477,N,,,,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,Intermediate,,,,,50597,BAO_0000218,A,,5394,,Rattus norvegicus,10116.0
9478,N,,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,2661,,Rattus norvegicus,10116.0
9479,N,,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,2661,,Rattus norvegicus,10116.0
9480,N,,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,2661,,Rattus norvegicus,10116.0
9481,N,,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,2661,,Rattus norvegicus,10116.0
9482,N,,,,Compound was evaluated for area under the curve expressed as (h*ug/ml),Intermediate,,,,,50597,BAO_0000218,A,,17791,,Rattus norvegicus,10116.0
9483,N,,,,Compound was tested for area under curve in rat,Intermediate,,,,,50597,BAO_0000218,A,,2591,,Rattus norvegicus,10116.0
9484,N,,,,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,Intermediate,,,,,50597,BAO_0000218,A,,6567,,Rattus norvegicus,10116.0
9485,N,,,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,6211,,Rattus norvegicus,10116.0
9486,N,,,,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,5529,,Rattus norvegicus,10116.0
9487,N,,,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,Intermediate,,,,,50597,BAO_0000218,A,,5408,,Rattus norvegicus,10116.0
9488,N,,,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,Intermediate,,,,,50597,BAO_0000218,A,,5408,,Rattus norvegicus,10116.0
9489,N,,,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,Intermediate,,,,,50597,BAO_0000218,A,,5408,,Rattus norvegicus,10116.0
9490,N,,,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,Intermediate,,,,,50597,BAO_0000218,A,,5408,,Rattus norvegicus,10116.0
9491,N,,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),Intermediate,,,,,50597,BAO_0000218,A,,429,,Rattus norvegicus,10116.0
9492,N,,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),Intermediate,,,,,50597,BAO_0000218,A,,429,,Rattus norvegicus,10116.0
9493,N,,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),Intermediate,,,,,50597,BAO_0000218,A,,429,,Rattus norvegicus,10116.0
9494,N,,,,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,Intermediate,,,,,50597,BAO_0000218,A,,4796,,Rattus norvegicus,10116.0
9495,N,,,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,,Rattus norvegicus,10116.0
9496,N,,,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,,Rattus norvegicus,10116.0
9497,N,,,,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,,Rattus norvegicus,10116.0
9498,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",Intermediate,,,,2113.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9499,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",Intermediate,,,,2113.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9500,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",Intermediate,,,,2113.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9501,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",Intermediate,,,,2113.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9502,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",Intermediate,,,,2113.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9503,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",Intermediate,,,,2113.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9504,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",Intermediate,,,,2107.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9505,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",Intermediate,,,,2107.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9506,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",Intermediate,,,,2107.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9507,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",Intermediate,,,,2107.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9508,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",Intermediate,,,,2107.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9509,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",Intermediate,,,,2107.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9510,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",Intermediate,,,,2048.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9511,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",Intermediate,,,,2048.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9512,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",Intermediate,,,,2048.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9513,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",Intermediate,,,,2048.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9514,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",Intermediate,,,,2048.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9515,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",Intermediate,,,,2048.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9516,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",Intermediate,,,,2046.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9517,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",Intermediate,,,,2046.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9518,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",Intermediate,,,,2046.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9519,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",Intermediate,,,,2046.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9520,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",Intermediate,,,,2046.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9521,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",Intermediate,,,,2046.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9522,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",Intermediate,,,,2046.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9523,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",Intermediate,,,,2046.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9524,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",Intermediate,,,,2046.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9525,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",Intermediate,,,,2046.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9526,N,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9527,N,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9528,N,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9529,N,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9530,N,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9531,N,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9532,N,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9533,N,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9534,N,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9535,N,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9536,N,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9537,N,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9538,N,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9539,N,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9540,N,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9541,N,,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9542,N,,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9543,N,,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9544,N,,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9545,N,,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9546,N,,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9547,N,,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9548,N,,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9549,N,,,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9550,N,,,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9551,N,,,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9552,N,,,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9553,N,,,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9554,N,,,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9555,N,,,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9556,N,,,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9557,N,,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9558,N,,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9559,N,,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9560,N,,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9561,N,,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9562,N,,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9563,N,,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9564,N,,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9565,N,,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9566,N,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9567,N,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9568,N,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9569,N,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9570,N,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9571,N,,,,Half life after administering orally a dose of 3 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,16365,In vivo,Rattus norvegicus,10116.0
9572,N,,,,Half life after administering orally a dose of 3 mg/kg to a fasting rat,Intermediate,,,,,50597,BAO_0000218,A,,16365,In vivo,Rattus norvegicus,10116.0
9573,N,,,,Half life after administering intravenously a dose of 1 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,16365,In vivo,Rattus norvegicus,10116.0
9574,N,,,,Half life after oral dosing in rats,Intermediate,,,,,50597,BAO_0000218,A,,526,In vivo,Rattus norvegicus,10116.0
9575,N,,,,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,Intermediate,,,,,50597,BAO_0000218,A,,16365,In vivo,Rattus norvegicus,10116.0
9576,N,,,,Half life by intravenous administration of 3.4 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4368,In vivo,Rattus norvegicus,10116.0
9577,N,,,,Half life in rat,Intermediate,,,,,50597,BAO_0000218,A,,3371,,Rattus norvegicus,10116.0
9578,N,,,,Half life in rat,Intermediate,,,,,50597,BAO_0000218,A,,6448,,Rattus norvegicus,10116.0
9579,N,,,,Half life in rat,Intermediate,,,,,50597,BAO_0000218,A,,6453,,Rattus norvegicus,10116.0
9580,N,,,,Half life in rat after intravenous administration of the compound,Intermediate,,,,,50597,BAO_0000218,A,,4353,In vivo,Rattus norvegicus,10116.0
9581,N,,,,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4353,In vivo,Rattus norvegicus,10116.0
9582,N,,,,Half life in rat after po administration of the compound,Intermediate,,,,,50597,BAO_0000218,A,,4353,In vivo,Rattus norvegicus,10116.0
9583,N,,,,Half life in rat after po administration of the compound; ND means Not determined,Intermediate,,,,,50597,BAO_0000218,A,,4353,In vivo,Rattus norvegicus,10116.0
9584,N,,,,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4353,In vivo,Rattus norvegicus,10116.0
9585,N,,,,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4353,In vivo,Rattus norvegicus,10116.0
9586,N,,,,Half life in rat i.v.,Intermediate,,,,,50597,BAO_0000218,A,,5789,In vivo,Rattus norvegicus,10116.0
9587,N,,,,Half life in rat i.v. at 2 mg/kg concentration,Intermediate,,,,,50597,BAO_0000218,A,,17686,In vivo,Rattus norvegicus,10116.0
9588,N,,,,Half life in rats,Intermediate,,,,,50597,BAO_0000218,A,,6495,,Rattus norvegicus,10116.0
9589,N,,,,Half life in rats after intravenous administration,Intermediate,,,,,50597,BAO_0000218,A,,484,In vivo,Rattus norvegicus,10116.0
9590,N,,,,Half life in rats at the dose of 1.0 mpk by i.v. administration,Intermediate,,,,,50597,BAO_0000218,A,,6467,In vivo,Rattus norvegicus,10116.0
9591,N,,,,Half life in rat,Expert,,,,,50597,BAO_0000218,A,,6642,,Rattus norvegicus,10116.0
9592,N,,,,Half life was evaluated after intravenous administration to rats,Intermediate,,,,,50597,BAO_0000218,A,,16367,In vivo,Rattus norvegicus,10116.0
9593,N,,,,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),Intermediate,,,,,50597,BAO_0000218,A,,1369,,Rattus norvegicus,10116.0
9594,N,,,,Half life was evaluated in rat,Intermediate,,,,,50597,BAO_0000218,A,,5472,,Rattus norvegicus,10116.0
9595,N,,,,Half life was evaluated in rat,Intermediate,,,,,50597,BAO_0000218,A,,6049,,Rattus norvegicus,10116.0
9596,N,,,,Half life was evaluated in rat; Not tested,Intermediate,,,,,50597,BAO_0000218,A,,5472,,Rattus norvegicus,10116.0
9597,N,,,,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,Intermediate,,,,,50597,BAO_0000218,A,,16366,In vivo,Rattus norvegicus,10116.0
9598,N,,,,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,Intermediate,,,,,50597,BAO_0000218,A,,11149,In vivo,Rattus norvegicus,10116.0
9599,N,,,,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,Intermediate,,,,178.0,50597,BAO_0000218,A,,11149,In vivo,Rattus norvegicus,10116.0
9600,U,,,,Half life was measured in monkey at dose of 10 mg/kg by po administration,Intermediate,,,,,22224,BAO_0000218,A,,2891,In vivo,Primates,9443.0
9601,U,,,,Half life was measured in monkey at dose of 10 mg/kg by po administration,Intermediate,,,,,22224,BAO_0000218,A,,2891,In vivo,Primates,9443.0
9602,U,,,,Half life was measured in rat at dose of 30 mg/kg by iv administration,Intermediate,,,,,22224,BAO_0000218,A,,2891,In vivo,Rattus norvegicus,10116.0
9603,U,,,,Half life was measured in rat at dose of 30 mg/kg by po administration,Intermediate,,,,,22224,BAO_0000218,A,,2891,In vivo,Rattus norvegicus,10116.0
9604,N,,,,Half life (t1/2) was determined,Intermediate,,,,,50597,BAO_0000218,A,,4026,,Rattus norvegicus,10116.0
9605,N,,,,Half life period at a dose of 10 uM/kg in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,4527,,Rattus norvegicus,10116.0
9606,N,,,,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,Intermediate,,,,,50597,BAO_0000218,A,,4527,In vivo,Rattus norvegicus,10116.0
9607,N,,,,Half life period was determined,Intermediate,,,,,50597,BAO_0000218,A,,5503,,Rattus norvegicus,10116.0
9608,N,,,,Half life period after intravenous administration at 20 mpk in rats,Intermediate,,,,,50597,BAO_0000218,A,,4426,In vivo,Rattus norvegicus,10116.0
9609,N,,,,Half life period after intravenous administration at 20 mpk in rats; Not performed.,Intermediate,,,,,50597,BAO_0000218,A,,4426,In vivo,Rattus norvegicus,10116.0
9610,N,,,,Half life period after intravenous administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,6109,In vivo,Rattus norvegicus,10116.0
9611,N,,,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,5654,In vivo,Rattus norvegicus,10116.0
9612,N,,,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,5654,In vivo,Rattus norvegicus,10116.0
9613,N,,,,Half life period in 80% rat plasma at 37 degree Centigrade,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4755,,Rattus norvegicus,10116.0
9614,N,,,,Half life period in SD rats,Intermediate,,,,,50597,BAO_0000218,A,,5862,,Rattus norvegicus,10116.0
9615,N,,,,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),Intermediate,,,,1969.0,50597,BAO_0000218,A,,1515,,Rattus norvegicus,10116.0
9616,N,,,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),Intermediate,,,,1969.0,50597,BAO_0000218,A,,1515,,Rattus norvegicus,10116.0
9617,N,,,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1515,,Rattus norvegicus,10116.0
9618,N,,,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1515,,Rattus norvegicus,10116.0
9619,N,,,,Half life period in rat,Intermediate,,,,,50597,BAO_0000218,A,,5960,,Rattus norvegicus,10116.0
9620,N,,,,Half life period in rat,Intermediate,,,,,50597,BAO_0000218,A,,6103,,Rattus norvegicus,10116.0
9621,N,,,,Half life period in rat,Intermediate,,,,,50597,BAO_0000218,A,,6317,,Rattus norvegicus,10116.0
9622,N,,,,Half life period in rat after oral administration at 10.5 mg/kg dose,Intermediate,,,,,50597,BAO_0000218,A,,6644,In vivo,Rattus norvegicus,10116.0
9623,N,,,,Half life period in rat after oral administration at 11.2 mg/kg dose,Intermediate,,,,,50597,BAO_0000218,A,,6644,In vivo,Rattus norvegicus,10116.0
9624,N,,,,Half life period in rat after oral administration at 13 mg/kg dose,Intermediate,,,,,50597,BAO_0000218,A,,6644,In vivo,Rattus norvegicus,10116.0
9625,N,,,,Half life period in rat after oral administration at 9.7 mg/kg dose,Intermediate,,,,,50597,BAO_0000218,A,,6644,In vivo,Rattus norvegicus,10116.0
9626,N,,,,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,,Rattus norvegicus,10116.0
9627,N,,,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6295,,Rattus norvegicus,10116.0
9628,N,,,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6296,,Rattus norvegicus,10116.0
9629,N,,,,PK study was carried to determine AUC (area under curve) value in rat,Intermediate,,,,,50597,BAO_0000218,A,,16427,,Rattus norvegicus,10116.0
9630,N,,,,Pharmacokinetic parameter AUC after intravenous administration to rats,Intermediate,,,,,50597,BAO_0000218,A,,16367,,Rattus norvegicus,10116.0
9631,N,,,,Pharmacokinetic parameter AUC after oral administration to rats,Intermediate,,,,,50597,BAO_0000218,A,,16367,,Rattus norvegicus,10116.0
9632,N,,,,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,16365,,Rattus norvegicus,10116.0
9633,N,,,,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,Intermediate,,,,,50597,BAO_0000218,A,,16365,,Rattus norvegicus,10116.0
9634,N,,,,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,Intermediate,,,,,50597,BAO_0000218,A,,16365,,Rattus norvegicus,10116.0
9635,N,,,,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,Intermediate,,,,,50597,BAO_0000218,A,,16365,,Rattus norvegicus,10116.0
9636,N,,,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,Intermediate,,,,,50597,BAO_0000218,A,,16365,,Rattus norvegicus,10116.0
9637,N,,,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,Intermediate,,,,,50597,BAO_0000218,A,,16365,,Rattus norvegicus,10116.0
9638,N,,,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5394,,Rattus norvegicus,10116.0
9639,N,,,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5394,,Rattus norvegicus,10116.0
9640,N,,,,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,Intermediate,,,,,50597,BAO_0000218,A,,2792,,Rattus norvegicus,10116.0
9641,N,,,,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,Intermediate,,,,,50597,BAO_0000218,A,,2792,,Rattus norvegicus,10116.0
9642,N,,,,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,Intermediate,,,,,50597,BAO_0000218,A,,2792,,Rattus norvegicus,10116.0
9643,N,,,,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,Intermediate,,,,,50597,BAO_0000218,A,,2792,,Rattus norvegicus,10116.0
9644,N,,,,Pharmacokinetic parameter area under curve was reported,Intermediate,,,,,50597,BAO_0000218,A,,5334,,Rattus norvegicus,10116.0
9645,N,,,,Pharmacokinetic property (AUC) in rat,Intermediate,,,,,50597,BAO_0000218,A,,4408,,Rattus norvegicus,10116.0
9646,N,,,,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,Intermediate,,,,,50597,BAO_0000218,A,,5983,,Rattus norvegicus,10116.0
9647,N,,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,Intermediate,,,,,50597,BAO_0000218,A,,4397,,Rattus norvegicus,10116.0
9648,N,,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,Intermediate,,,,,50597,BAO_0000218,A,,4397,,Rattus norvegicus,10116.0
9649,N,,,,Pharmacokinetic property was determined,Intermediate,,,,,50597,BAO_0000218,A,,5491,,Rattus norvegicus,10116.0
9650,N,,,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5491,,Rattus norvegicus,10116.0
9651,N,,,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,Intermediate,,,,,50597,BAO_0000218,A,,5491,,Rattus norvegicus,10116.0
9652,N,,,,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4199,,Rattus norvegicus,10116.0
9653,N,,,,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4199,,Rattus norvegicus,10116.0
9654,N,,,,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4199,,Rattus norvegicus,10116.0
9655,N,,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",Intermediate,,,,,50597,BAO_0000218,A,,5173,,Rattus norvegicus,10116.0
9656,N,,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",Intermediate,,,,,50597,BAO_0000218,A,,5173,,Rattus norvegicus,10116.0
9657,N,,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",Intermediate,,,,,50597,BAO_0000218,A,,5173,,Rattus norvegicus,10116.0
9658,N,,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",Intermediate,,,,,50597,BAO_0000218,A,,5173,,Rattus norvegicus,10116.0
9659,N,,,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,Intermediate,,,,,50597,BAO_0000218,A,,16366,,Rattus norvegicus,10116.0
9660,N,,,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,Intermediate,,,,,50597,BAO_0000218,A,,16366,,Rattus norvegicus,10116.0
9661,N,,,,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,5327,,Rattus norvegicus,10116.0
9662,N,,,,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,Intermediate,,,,,50597,BAO_0000218,A,,6681,,Rattus norvegicus,10116.0
9663,N,,,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),Intermediate,,,,,50597,BAO_0000218,A,,12873,,Rattus norvegicus,10116.0
9664,N,,,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),Intermediate,,,,,50597,BAO_0000218,A,,12873,,Rattus norvegicus,10116.0
9665,N,,,,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,6685,,Rattus norvegicus,10116.0
9666,N,,,,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",Intermediate,,,,,50597,BAO_0000218,A,,6685,,Rattus norvegicus,10116.0
9667,N,,,,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",Intermediate,,,,,50597,BAO_0000218,A,,6685,,Rattus norvegicus,10116.0
9668,N,,,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",Intermediate,,,,,50597,BAO_0000218,A,,6619,,Rattus norvegicus,10116.0
9669,N,,,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",Intermediate,,,,,50597,BAO_0000218,A,,6619,,Rattus norvegicus,10116.0
9670,N,,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,Intermediate,,,,,50597,BAO_0000218,A,,10363,,Rattus norvegicus,10116.0
9671,N,,,,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,Intermediate,,,,,50597,BAO_0000218,A,,4796,,Rattus norvegicus,10116.0
9672,N,,,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,Intermediate,,,,,50597,BAO_0000218,A,,4910,,Rattus norvegicus,10116.0
9673,N,,,,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4910,,Rattus norvegicus,10116.0
9674,N,,,,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,Intermediate,,,,,50597,BAO_0000218,A,,4839,,Rattus norvegicus,10116.0
9675,N,,,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,15078,,Rattus norvegicus,10116.0
9676,N,,,,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,15078,,Rattus norvegicus,10116.0
9677,N,,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,15078,,Rattus norvegicus,10116.0
9678,N,,,,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,15078,,Rattus norvegicus,10116.0
9679,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",Intermediate,,,,2046.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9680,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",Intermediate,,,,2046.0,50597,BAO_0000218,A,,11450,,Rattus norvegicus,10116.0
9681,N,,,,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,Intermediate,,,,,50597,BAO_0000218,A,,8151,,Rattus norvegicus,10116.0
9682,N,,,,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,8151,,Rattus norvegicus,10116.0
9683,N,,,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,Intermediate,,,,1088.0,50597,BAO_0000218,A,,8151,,Rattus norvegicus,10116.0
9684,N,,,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,178.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9685,N,,,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,178.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9686,N,,,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,178.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9687,N,,,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,178.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9688,N,,,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,955.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9689,N,,,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,955.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9690,N,,,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,955.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9691,N,,,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,955.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9692,N,,,,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,Intermediate,,,,955.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9693,N,,,,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,948.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9694,N,,,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,948.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9695,N,,,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,948.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9696,N,,,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,2113.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9697,N,,,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,2113.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9698,N,,,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,2113.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9699,N,,,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,2113.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9700,N,,,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9701,N,,,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9702,N,,,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9703,N,,,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9704,N,,,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9705,N,,,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9706,N,,,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9707,N,,,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9708,N,,,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,2385.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9709,N,,,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,2385.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9710,N,,,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,2385.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9711,N,,,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,2385.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9712,N,,,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,14.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9713,N,,,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,14.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9714,N,,,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,14.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9715,N,,,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,14.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9716,N,,,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,160.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9717,N,,,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,160.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9718,N,,,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,160.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9719,N,,,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,160.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9720,N,,,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,2106.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9721,N,,,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,2106.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9722,N,,,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,2106.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9723,N,,,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,2106.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9724,N,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9725,N,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9726,N,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9727,N,,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9728,N,,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9729,N,,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9730,N,,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9731,N,,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9732,N,,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9733,N,,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9734,N,,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9735,N,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9736,N,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9737,N,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9738,N,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9739,N,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9740,N,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9741,N,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9742,N,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9743,N,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9744,N,,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9745,N,,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9746,N,,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9747,N,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9748,N,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9749,N,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,,,,,50597,BAO_0000218,A,,16434,,Rattus norvegicus,10116.0
9750,N,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,,,,50597,BAO_0000218,F,,16435,,Rattus norvegicus,10116.0
9751,N,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9752,N,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9753,N,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,,,,50597,BAO_0000218,F,,16435,,Rattus norvegicus,10116.0
9754,N,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9755,N,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,Rattus norvegicus,10116.0
9756,N,,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9757,N,,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9758,N,,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9759,N,,,,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9760,N,,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9761,N,,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9762,N,,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9763,N,,,,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9764,N,,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9765,N,,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9766,N,,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9767,N,,,,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9768,N,,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9769,N,,,,Half life period in rat by iv administration at a dose of 3 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5874,In vivo,Rattus norvegicus,10116.0
9770,N,,,,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),Intermediate,,,,1969.0,50597,BAO_0000218,A,,1515,,Rattus norvegicus,10116.0
9771,N,,,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),Intermediate,,,,1969.0,50597,BAO_0000218,A,,1515,,Rattus norvegicus,10116.0
9772,N,,,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1515,,Rattus norvegicus,10116.0
9773,N,,,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1515,,Rattus norvegicus,10116.0
9774,N,,,,Half life period was evaluated in rat plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5491,,Rattus norvegicus,10116.0
9775,N,,,,Half life period was evaluated in rat plasma; Not tested,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5491,,Rattus norvegicus,10116.0
9776,N,,,,Half life period was evaluated in rats,Intermediate,,,,,50597,BAO_0000218,A,,1918,,Rattus norvegicus,10116.0
9777,N,,,,"Half life period was evaluated in rats, iv",Intermediate,,,,,50597,BAO_0000218,A,,1918,In vivo,Rattus norvegicus,10116.0
9778,N,,,,Half life period after intravenous administration at 5 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6113,In vivo,Rattus norvegicus,10116.0
9779,N,,,,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,Intermediate,,,,,50597,BAO_0000218,A,,5546,In vivo,Rattus norvegicus,10116.0
9780,N,,,,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5553,In vivo,Rattus norvegicus,10116.0
9781,N,,,,Half life stability of compound was evaluated in rat plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4188,,Rattus norvegicus,10116.0
9782,N,,,,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,6215,In vivo,Rattus norvegicus,10116.0
9783,N,,,,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,6141,In vivo,Rattus norvegicus,10116.0
9784,N,,,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,Intermediate,,,,,50597,BAO_0000218,A,,5182,In vivo,Rattus norvegicus,10116.0
9785,N,,,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,Intermediate,,,,,50597,BAO_0000218,A,,5182,In vivo,Rattus norvegicus,10116.0
9786,N,,,,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,Intermediate,,,,,50597,BAO_0000218,A,,5710,In vivo,Rattus norvegicus,10116.0
9787,N,,,,Half in rat i.v.,Intermediate,,,,,50597,BAO_0000218,A,,5789,In vivo,Rattus norvegicus,10116.0
9788,N,,,,Half period in rat after intravenous administration,Intermediate,,,,,50597,BAO_0000218,A,,6011,In vivo,Rattus norvegicus,10116.0
9789,N,,,,Half-life after repeated oral dose of compound at 1 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,17594,In vivo,Rattus norvegicus,10116.0
9790,N,,,,Half-life measured in in vitro Cathepsin B assay in rat liver,Intermediate,,,,2107.0,50597,BAO_0000218,A,,12357,In vitro,Rattus norvegicus,10116.0
9791,N,,,,Half-life of compound was determined in rats,Intermediate,,,,,50597,BAO_0000218,A,,5210,,Rattus norvegicus,10116.0
9792,N,,,,Half-life at 10 mg/kg in rat upon intravenous administration,Intermediate,,,,,50597,BAO_0000218,A,,17596,In vivo,Rattus norvegicus,10116.0
9793,N,,,,Half-life determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,6672,,Rattus norvegicus,10116.0
9794,N,,,,Half-life determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,6673,,Rattus norvegicus,10116.0
9795,N,,,,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,Intermediate,,,,955.0,50597,BAO_0000218,A,,4910,In vivo,Rattus norvegicus,10116.0
9796,N,,,,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",Intermediate,,,,1969.0,50597,BAO_0000218,A,,3741,,Rattus norvegicus,10116.0
9797,N,,,,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17671,In vivo,Rattus norvegicus,10116.0
9798,N,,,,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4910,In vivo,Rattus norvegicus,10116.0
9799,N,,,,Half-life in rat plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17537,,Rattus norvegicus,10116.0
9800,N,,,,Half-life in rat plasma was determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4965,,Rattus norvegicus,10116.0
9801,N,,,,Half-life in rat plasma; Not tested,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17537,,Rattus norvegicus,10116.0
9802,N,,,,Half-life in rat serum,Intermediate,,,,1977.0,50597,BAO_0000218,A,,6124,,Rattus norvegicus,10116.0
9803,N,,,,Half-life in rat serum; na is not available,Intermediate,,,,1977.0,50597,BAO_0000218,A,,6124,,Rattus norvegicus,10116.0
9804,N,,,,Half-life was calculated in rat,Intermediate,,,,,50597,BAO_0000218,A,,6078,,Rattus norvegicus,10116.0
9805,N,,,,Half-life was calculated in rat plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17668,,Rattus norvegicus,10116.0
9806,N,,,,Half-life was determined,Intermediate,,,,,50597,BAO_0000218,A,,3185,,Rattus norvegicus,10116.0
9807,N,,,,Half-life was determined,Intermediate,,,,,50597,BAO_0000218,A,,4883,,Rattus norvegicus,10116.0
9808,N,,,,Half-life after administration of 20 mg/Kg oral dose in rat,Intermediate,,,,,50597,BAO_0000218,A,,2959,In vivo,Rattus norvegicus,10116.0
9809,N,,,,Half-life after administration of 3.2 mg/kg intravenously in male rat,Intermediate,,,,,50597,BAO_0000218,A,,4029,In vivo,Rattus norvegicus,10116.0
9810,N,,,,Half-life after intravenous administration in female rat,Intermediate,,,,,50597,BAO_0000218,A,,4029,In vivo,Rattus norvegicus,10116.0
9811,N,,,,Half-life after intravenous administration in male rat,Intermediate,,,,,50597,BAO_0000218,A,,4029,In vivo,Rattus norvegicus,10116.0
9812,N,,,,Half-life after intravenous dose in rat,Intermediate,,,,,50597,BAO_0000218,A,,6180,In vivo,Rattus norvegicus,10116.0
9813,N,,,,Half-life in a rat liver homogenate preparation,Intermediate,,,,2107.0,50597,BAO_0000218,A,,1557,,Rattus norvegicus,10116.0
9814,N,,,,Half-life in plasma of rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,12500,,Rattus norvegicus,10116.0
9815,N,,,,Half-life in plasma of rat at dose of 3-10 mgkg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,12500,,Rattus norvegicus,10116.0
9816,N,,,,Half-life in rat,Intermediate,,,,,50597,BAO_0000218,A,,5064,,Rattus norvegicus,10116.0
9817,N,,,,Half-life in rat,Intermediate,,,,,50597,BAO_0000218,A,,5145,,Rattus norvegicus,10116.0
9818,N,,,,Half-life in rat,Intermediate,,,,,50597,BAO_0000218,A,,5147,,Rattus norvegicus,10116.0
9819,N,,,,Half-life in rat,Intermediate,,,,,50597,BAO_0000218,A,,5833,,Rattus norvegicus,10116.0
9820,N,,,,Half-life in rat,Intermediate,,,,,50597,BAO_0000218,A,,6596,,Rattus norvegicus,10116.0
9821,N,,,,Half-life in rat,Intermediate,,,,,50597,BAO_0000218,A,,17655,,Rattus norvegicus,10116.0
9822,N,,,,Half-life in rat after oral administration at 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6495,In vivo,Rattus norvegicus,10116.0
9823,N,,,,Half-life in rat after po administration at a dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17538,In vivo,Rattus norvegicus,10116.0
9824,N,,,,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,Intermediate,,,,,50597,BAO_0000218,A,,17538,In vivo,Rattus norvegicus,10116.0
9825,N,,,,Half-life in rat at 3 mg/kg dose administered intravenously,Intermediate,,,,,50597,BAO_0000218,A,,10,In vivo,Rattus norvegicus,10116.0
9826,N,,,,Half-life in rat brain homogenate,Intermediate,,,,955.0,50597,BAO_0000218,A,,17669,,Rattus norvegicus,10116.0
9827,N,,,,Half-life in rat plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17065,,Rattus norvegicus,10116.0
9828,N,,,,Half-life in rats,Intermediate,,,,,50597,BAO_0000218,A,,4333,,Rattus norvegicus,10116.0
9829,N,,,,Half-life in Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,6827,,Rattus norvegicus,10116.0
9830,N,,,,Half-life in vitro in rat plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,889,In vitro,Rattus norvegicus,10116.0
9831,N,,,,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,Intermediate,,,,1969.0,50597,BAO_0000218,A,,889,In vitro,Rattus norvegicus,10116.0
9832,N,,,,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",Intermediate,,,,,50597,BAO_0000218,A,,3747,,Rattus norvegicus,10116.0
9833,N,,,,The area under the curve of compound was measured at the dose of 100 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,15022,,Rattus norvegicus,10116.0
9834,N,,,,The area under the curve of compound was measured at the dose of 300 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,15022,,Rattus norvegicus,10116.0
9835,N,,,,The area under the curve of compound was measured at the dose of 30 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,15022,,Rattus norvegicus,10116.0
9836,N,,,,Bioavailability as oral AUC in rats,Intermediate,,,,,50597,BAO_0000218,A,,3360,In vivo,Rattus norvegicus,10116.0
9837,N,,,,The plasma concentration versus time curve (AUC) was determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5334,,Rattus norvegicus,10116.0
9838,N,,,,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17411,,Rattus norvegicus,10116.0
9839,N,,,,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17411,,Rattus norvegicus,10116.0
9840,N,,,,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17411,,Rattus norvegicus,10116.0
9841,N,,,,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,Intermediate,,,,,50597,BAO_0000218,A,,6570,,Rattus norvegicus,10116.0
9842,N,,,,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,Intermediate,,,,,50597,BAO_0000218,A,,6570,,Rattus norvegicus,10116.0
9843,N,,,,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17411,,Rattus norvegicus,10116.0
9844,N,,,,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",Intermediate,,,,1969.0,50597,BAO_0000218,A,,14941,,Rattus norvegicus,10116.0
9845,N,,,,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",Intermediate,,,,1969.0,50597,BAO_0000218,A,,14941,,Rattus norvegicus,10116.0
9846,N,,,,AUC in rat after po administration at a dose of 10 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17538,,Rattus norvegicus,10116.0
9847,N,,,,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17752,,Rattus norvegicus,10116.0
9848,N,,,,Area under curve value 24 hr after 10 mg/kg iv administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,17509,,Rattus norvegicus,10116.0
9849,N,,,,Area under curve value 24 hr after 10 mg/kg oral administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,17509,,Rattus norvegicus,10116.0
9850,N,,,,Area under curve value 24 hr after 2 mg/kg iv administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,17509,,Rattus norvegicus,10116.0
9851,N,,,,Area under curve value 24 hr after 2 mg/kg oral administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,17509,,Rattus norvegicus,10116.0
9852,N,,,,Area under curve value 6 hr after po administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,17509,,Rattus norvegicus,10116.0
9853,N,,,,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,Intermediate,,,,,50597,BAO_0000218,A,,17717,,Rattus norvegicus,10116.0
9854,N,,,,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",Intermediate,,,,,50597,BAO_0000218,A,,17717,,Rattus norvegicus,10116.0
9855,N,,,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,Intermediate,,,,,50597,BAO_0000218,A,,17717,,Rattus norvegicus,10116.0
9856,N,,,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,Intermediate,,,,,50597,BAO_0000218,A,,17717,,Rattus norvegicus,10116.0
9857,N,,,,AUC normalized for dose (AUCN) in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6642,,Rattus norvegicus,10116.0
9858,N,,,,Area under curve in rat after p.o. administration,Intermediate,,,,,50597,BAO_0000218,A,,6640,,Rattus norvegicus,10116.0
9859,N,,,,Area under curve in rat after p.o. administration,Intermediate,,,,,50597,BAO_0000218,A,,6641,,Rattus norvegicus,10116.0
9860,N,,,,Area under curve in rat after p.o. administration; Not determined,Intermediate,,,,,50597,BAO_0000218,A,,6641,,Rattus norvegicus,10116.0
9861,N,,,,Area under curve in rat after peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,6641,,Rattus norvegicus,10116.0
9862,N,,,,Area under curve (carotid artery) value of the compound,Intermediate,,,,,50597,BAO_0000218,A,,3603,,Rattus norvegicus,10116.0
9863,N,,,,Bioavailability expressed as the area under curve of rat carotid artery,Intermediate,,,,,50597,BAO_0000218,A,,3550,,Rattus norvegicus,10116.0
9864,N,,,,Area under curve in male SD rats was observed after intravenous administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,15662,,Rattus norvegicus,10116.0
9865,N,,,,Area under curve of the compound was determined,Intermediate,,,,,50597,BAO_0000218,A,,17720,,Rattus norvegicus,10116.0
9866,N,,,,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,Intermediate,,,,,50597,BAO_0000218,A,,5407,,Rattus norvegicus,10116.0
9867,N,,,,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17752,,Rattus norvegicus,10116.0
9868,N,,,,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17752,,Rattus norvegicus,10116.0
9869,N,,,,Area under curve (portal vein) value of the compound,Intermediate,,,,,50597,BAO_0000218,A,,3603,,Rattus norvegicus,10116.0
9870,N,,,,Bioavailability expressed as the area under curve of rat portal vein,Intermediate,,,,,50597,BAO_0000218,A,,3550,,Rattus norvegicus,10116.0
9871,N,,,,Area Under plasma concentration time curve in rat upon peroral administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17655,,Rattus norvegicus,10116.0
9872,N,,,,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,17582,,Rattus norvegicus,10116.0
9873,N,,,,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,17582,,Rattus norvegicus,10116.0
9874,N,,,,Compound was evaluated for oral bioavailability in rats,Intermediate,,,,,50597,BAO_0000218,A,,17791,,Rattus norvegicus,10116.0
9875,N,,,,Compound was evaluated for oral bioavailability in rats after iv administration,Intermediate,,,,,50597,BAO_0000218,A,,17791,,Rattus norvegicus,10116.0
9876,N,,,,Compound was evaluated for oral bioavailability in rats; 30-80,Intermediate,,,,,50597,BAO_0000218,A,,17791,,Rattus norvegicus,10116.0
9877,N,,,,Compound was evaluated for oral bioavailability in rats; 50-60,Intermediate,,,,,50597,BAO_0000218,A,,17791,,Rattus norvegicus,10116.0
9878,N,,,,Compound was evaluated for oral bioavailability in rats; no data,Intermediate,,,,,50597,BAO_0000218,A,,17791,,Rattus norvegicus,10116.0
9879,N,,,,Compound was evaluated for oral bioavailability in rats; peptide,Intermediate,,,,,50597,BAO_0000218,A,,17791,,Rattus norvegicus,10116.0
9880,N,,,,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",Intermediate,,,,178.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
9881,N,,,,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",Intermediate,,,,178.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
9882,N,,,,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",Intermediate,,,,178.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
9883,N,,,,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",Intermediate,,,,178.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
9884,N,,,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,945.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9885,N,,,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,945.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9886,N,,,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,945.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9887,N,,,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,945.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9888,N,,,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9889,N,,,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9890,N,,,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9891,N,,,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9892,N,,,,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,948.0,50597,BAO_0000218,A,,8677,In vivo,Rattus norvegicus,10116.0
9893,N,,,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,Intermediate,,,,1088.0,50597,BAO_0000218,A,,6899,,Rattus norvegicus,10116.0
9894,N,,,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,Intermediate,,,,1088.0,50597,BAO_0000218,A,,6899,,Rattus norvegicus,10116.0
9895,N,,,,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,Intermediate,,,,2107.0,50597,BAO_0000218,A,,6899,,Rattus norvegicus,10116.0
9896,N,,,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,Intermediate,,,,1088.0,50597,BAO_0000218,A,,6899,,Rattus norvegicus,10116.0
9897,N,,,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,Intermediate,,,,1088.0,50597,BAO_0000218,A,,6899,,Rattus norvegicus,10116.0
9898,N,,,,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,2385.0,50597,BAO_0000218,A,,8677,,Rattus norvegicus,10116.0
9899,N,,,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,Intermediate,,,,,50597,BAO_0000218,A,,6899,,Rattus norvegicus,10116.0
9900,N,,,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,Intermediate,,,,1088.0,50597,BAO_0000218,A,,6899,,Rattus norvegicus,10116.0
9901,N,,,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,Intermediate,,,,,50597,BAO_0000218,A,,2189,,Rattus norvegicus,10116.0
9902,N,,,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,Intermediate,,,,1088.0,50597,BAO_0000218,A,,2189,,Rattus norvegicus,10116.0
9903,N,,,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,Intermediate,,,,1088.0,50597,BAO_0000218,A,,2189,,Rattus norvegicus,10116.0
9904,N,,,,Biodistribution of compound in rat blood after 5 min of administration,Intermediate,,,,178.0,50597,BAO_0000218,A,,10839,In vivo,Rattus norvegicus,10116.0
9905,N,,,,Biodistribution of compound in rat blood after 5 min of administration.,Intermediate,,,,178.0,50597,BAO_0000218,A,,10839,In vivo,Rattus norvegicus,10116.0
9906,N,,,,Biodistribution of compound in rat brain after 5 min of administration,Intermediate,,,,955.0,50597,BAO_0000218,A,,10839,In vivo,Rattus norvegicus,10116.0
9907,N,,,,Biodistribution of compound in rat heart after 5 min of administration,Intermediate,,,,948.0,50597,BAO_0000218,A,,10839,In vivo,Rattus norvegicus,10116.0
9908,N,,,,Biodistribution of compound in rat heart after 5 min of administration.,Intermediate,,,,948.0,50597,BAO_0000218,A,,10839,In vivo,Rattus norvegicus,10116.0
9909,N,,,,Biodistribution of compound in rat kidney after 5 min of administration,Intermediate,,,,2113.0,50597,BAO_0000218,A,,10839,In vivo,Rattus norvegicus,10116.0
9910,N,,,,Biodistribution of compound in rat kidney after 5 min of administration.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,10839,In vivo,Rattus norvegicus,10116.0
9911,N,,,,Biodistribution of compound in rat liver after 5 min of administration,Intermediate,,,,2107.0,50597,BAO_0000218,A,,10839,In vivo,Rattus norvegicus,10116.0
9912,N,,,,Biodistribution of compound in rat liver after 5 min of administration.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,10839,In vivo,Rattus norvegicus,10116.0
9913,N,,,,Biodistribution of compound in rat lung after 5 min of administration,Intermediate,,,,2048.0,50597,BAO_0000218,A,,10839,In vivo,Rattus norvegicus,10116.0
9914,N,,,,Biodistribution of compound in rat lung after 5 min of administration.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,10839,In vivo,Rattus norvegicus,10116.0
9915,N,,,,Biodistribution of compound in rat muscle after 5 min of administration,Intermediate,,,,2385.0,50597,BAO_0000218,A,,10839,In vivo,Rattus norvegicus,10116.0
9916,N,,,,Biodistribution of compound in rat muscle after 5 min of administration.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,10839,In vivo,Rattus norvegicus,10116.0
9917,N,,,,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,,,,948.0,50597,BAO_0000218,A,,4043,,Rattus norvegicus,10116.0
9918,N,,,,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,,,,948.0,50597,BAO_0000218,A,,4043,,Rattus norvegicus,10116.0
9919,N,,,,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,,,,2107.0,50597,BAO_0000218,A,,4043,,Rattus norvegicus,10116.0
9920,N,,,,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,,,,2107.0,50597,BAO_0000218,A,,4043,,Rattus norvegicus,10116.0
9921,N,,,,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,,,,,50597,BAO_0000218,A,,4043,,Rattus norvegicus,10116.0
9922,N,,,,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,,,,,50597,BAO_0000218,A,,4043,,Rattus norvegicus,10116.0
9923,N,,,,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,,,,2106.0,50597,BAO_0000218,A,,4043,,Rattus norvegicus,10116.0
9924,N,,,,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,,,,2106.0,50597,BAO_0000218,A,,4043,,Rattus norvegicus,10116.0
9925,N,,,,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,,,,,50597,BAO_0000218,A,,4043,,Rattus norvegicus,10116.0
9926,N,,,,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,,,,,50597,BAO_0000218,A,,4043,,Rattus norvegicus,10116.0
9927,N,,,,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,Intermediate,,,,,50597,BAO_0000218,A,,1446,,Rattus norvegicus,10116.0
9928,N,,,,Dose required to lower urine osmolality to 300 mOsm/kg in rat,Intermediate,,,,1088.0,50597,BAO_0000218,A,,9971,,Rattus norvegicus,10116.0
9929,N,,,,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,Intermediate,,,,1088.0,50597,BAO_0000218,A,,9971,,Rattus norvegicus,10116.0
9930,N,,,,% Bioavailability after 1 day of the drug administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,5765,In vivo,Rattus norvegicus,10116.0
9931,N,,,,% Bioavailability after 4 day of the drug administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,5765,In vivo,Rattus norvegicus,10116.0
9932,N,,,,Absolute bioavailability was evaluated in rat,Intermediate,,,,,50597,BAO_0000218,A,,4257,In vivo,Rattus norvegicus,10116.0
9933,N,,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9934,N,,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9935,N,,,,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9936,N,,,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9937,N,,,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9938,N,,,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9939,N,,,,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9940,N,,,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9941,N,,,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9942,N,,,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9943,N,,,,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9944,N,,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9945,N,,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9946,N,,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9947,N,,,,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9948,N,,,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,Intermediate,,,,2385.0,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9949,N,,,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,Intermediate,,,,2385.0,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9950,N,,,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,Intermediate,,,,2385.0,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9951,N,,,,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,Intermediate,,,,2385.0,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9952,N,,,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9953,N,,,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,Intermediate,,,,992.0,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9954,N,,,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,Intermediate,,,,992.0,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9955,N,,,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,Intermediate,,,,992.0,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9956,N,,,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,Intermediate,,,,995.0,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9957,N,,,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,Intermediate,,,,995.0,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9958,N,,,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,Intermediate,,,,995.0,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9959,N,,,,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,Intermediate,,,,995.0,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9960,N,,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9961,N,,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9962,N,,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9963,N,,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9964,N,,,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,Intermediate,,,,2385.0,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9965,N,,,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,Intermediate,,,,2385.0,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9966,N,,,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,Intermediate,,,,2385.0,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9967,N,,,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,Intermediate,,,,2385.0,50597,BAO_0000218,A,,13091,,Rattus norvegicus,10116.0
9968,N,,,,Dissociation constant was determined,Intermediate,,,,,50597,BAO_0000218,A,,11977,,Rattus norvegicus,10116.0
9969,N,,,,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",Intermediate,,,,,50597,BAO_0000218,A,,14941,,Rattus norvegicus,10116.0
9970,N,,,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,15078,,Rattus norvegicus,10116.0
9971,N,,,,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,15078,,Rattus norvegicus,10116.0
9972,N,,,,Observed rate constant in 80% rat plasma at 37 degree Centigrade,Intermediate,,,,,50597,BAO_0000218,A,,4755,,Rattus norvegicus,10116.0
9973,N,,,,LogP value was evaluated in the in situ rat gut perfusion assay,Intermediate,,,,,50597,BAO_0000218,A,,589,,Rattus norvegicus,10116.0
9974,N,,,,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,Intermediate,,,,,50597,BAO_0000218,A,,17582,In vivo,Rattus norvegicus,10116.0
9975,N,,,,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,5031,In vivo,Rattus norvegicus,10116.0
9976,N,,,,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,Intermediate,,,,,50597,BAO_0000218,A,,17764,In vivo,Rattus norvegicus,10116.0
9977,N,,,,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,Intermediate,,,,,50597,BAO_0000218,A,,17720,,Rattus norvegicus,10116.0
9978,N,,,,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,Expert,,,,,50597,BAO_0000218,F,,2862,,Rattus norvegicus,10116.0
9979,N,,,,Half-life was evaluated after 10 uM/kg of intra arterial administration,Intermediate,,,,,50597,BAO_0000218,A,,16423,,Rattus norvegicus,10116.0
9980,N,,,,Half-life was evaluated after 20 uM/kg of peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,16423,In vivo,Rattus norvegicus,10116.0
9981,N,,,,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6005,In vivo,Rattus norvegicus,10116.0
9982,N,,,,Half-life was evaluated in plasma of rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2938,,Rattus norvegicus,10116.0
9983,N,,,,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6410,In vivo,Rattus norvegicus,10116.0
9984,N,,,,Half-life was evaluated in rats at an oral dose of 30 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6410,In vivo,Rattus norvegicus,10116.0
9985,N,,,,Half-life was measured in rat after an iv dose of 1 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6062,In vivo,Rattus norvegicus,10116.0
9986,N,,,,Half-life period of compound in rats after peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,6571,In vivo,Rattus norvegicus,10116.0
9987,N,,,,Half-life period of compound was measured in rat plasma.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,3136,,Rattus norvegicus,10116.0
9988,N,,,,Half-life period of compound was measured in rat plasma; ND is not determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,3136,,Rattus norvegicus,10116.0
9989,N,,,,Half-life period of compound was measured in rat plasma; not determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,3136,,Rattus norvegicus,10116.0
9990,N,,,,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,Intermediate,,,,,50597,BAO_0000218,A,,4521,In vivo,Rattus norvegicus,10116.0
9991,N,,,,Half-life period in rat by iv administration,Intermediate,,,,,50597,BAO_0000218,A,,5871,In vivo,Rattus norvegicus,10116.0
9992,N,,,,Half-life period in rats following intravenous administration at 2 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6077,In vivo,Rattus norvegicus,10116.0
9993,N,,,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,,,,,50597,BAO_0000218,A,,6679,In vivo,Rattus norvegicus,10116.0
9994,N,,,,Half-life period was determined for the compound in rat,Intermediate,,,,,50597,BAO_0000218,A,,5144,,Rattus norvegicus,10116.0
9995,N,,,,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",Intermediate,,,,,50597,BAO_0000218,A,,4498,In vivo,Rattus norvegicus,10116.0
9996,N,,,,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",Intermediate,,,,,50597,BAO_0000218,A,,4498,In vivo,Rattus norvegicus,10116.0
9997,N,,,,Half-life value after IV dose at a dose of 5 mg/kg in rats.,Intermediate,,,,,50597,BAO_0000218,A,,1908,In vivo,Rattus norvegicus,10116.0
9998,N,,,,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,6211,In vivo,Rattus norvegicus,10116.0
9999,N,,,,Half-life was determined in rat after intravenous administration (0.5 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,5529,In vivo,Rattus norvegicus,10116.0
10000,N,,,,Half-life was determined in rat at a dose of 1 mpk i.v.,Intermediate,,,,,50597,BAO_0000218,A,,6444,In vivo,Rattus norvegicus,10116.0
10001,N,,,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,Intermediate,,,,,50597,BAO_0000218,A,,6444,In vivo,Rattus norvegicus,10116.0
10002,N,,,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,Intermediate,,,,,50597,BAO_0000218,A,,6444,In vivo,Rattus norvegicus,10116.0
10003,N,,,,Half-life in rat,Intermediate,,,,,50597,BAO_0000218,A,,5207,,Rattus norvegicus,10116.0
10004,N,,,,In vitro half life in rat plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,530,In vitro,Rattus norvegicus,10116.0
10005,N,,,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",Intermediate,,,,1969.0,50597,BAO_0000218,A,,1116,In vitro,Rattus norvegicus,10116.0
10006,N,,,,In vitro half life in rat,Intermediate,,,,,50597,BAO_0000218,A,,3219,In vitro,Rattus norvegicus,10116.0
10007,N,,,,In vivo half life period after intravenous administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,6109,In vivo,Rattus norvegicus,10116.0
10008,N,,,,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,Intermediate,,,,,50597,BAO_0000218,A,,17582,In vivo,Rattus norvegicus,10116.0
10009,N,,,,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,Intermediate,,,,,50597,BAO_0000218,A,,17582,In vivo,Rattus norvegicus,10116.0
10010,N,,,,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,In vivo,Rattus norvegicus,10116.0
10011,N,,,,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,In vivo,Rattus norvegicus,10116.0
10012,N,,,,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,In vivo,Rattus norvegicus,10116.0
10013,N,,,,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,In vivo,Rattus norvegicus,10116.0
10014,N,,,,Longer half-life in rat (i.v.) at 0.5 mpk,Intermediate,,,,,50597,BAO_0000218,A,,17853,In vivo,Rattus norvegicus,10116.0
10015,N,,,,Longer half-life in rat (p.o.) at 2.0 mpk,Intermediate,,,,,50597,BAO_0000218,A,,17853,In vivo,Rattus norvegicus,10116.0
10016,N,,,,Pharmacokinetic property (half life) in rat,Intermediate,,,,,50597,BAO_0000218,A,,3457,,Rattus norvegicus,10116.0
10017,N,,,,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,Intermediate,,,,,50597,BAO_0000218,A,,2792,In vivo,Rattus norvegicus,10116.0
10018,N,,,,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,Intermediate,,,,,50597,BAO_0000218,A,,2792,In vivo,Rattus norvegicus,10116.0
10019,N,,,,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,Intermediate,,,,,50597,BAO_0000218,A,,2792,In vivo,Rattus norvegicus,10116.0
10020,N,,,,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,Intermediate,,,,,50597,BAO_0000218,A,,2792,In vivo,Rattus norvegicus,10116.0
10021,N,,,,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,Intermediate,,,,,50597,BAO_0000218,A,,5739,In vivo,Rattus norvegicus,10116.0
10022,N,,,,Pharmacokinetic half time was determined intravenously in rats.,Intermediate,,,,,50597,BAO_0000218,A,,15765,In vivo,Rattus norvegicus,10116.0
10023,N,,,,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6567,In vivo,Rattus norvegicus,10116.0
10024,N,,,,Plasma half life of hydrolysis of the compound,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2448,,Rattus norvegicus,10116.0
10025,N,,,,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5423,In vivo,Rattus norvegicus,10116.0
10026,N,,,,Plasma half life period was calculated in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4853,,Rattus norvegicus,10116.0
10027,N,,,,Plasma half-life in Sprague-Dawley rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4514,,Rattus norvegicus,10116.0
10028,N,,,,Plasma half-life in Sprague-Dawley rats; Not determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4514,,Rattus norvegicus,10116.0
10029,N,,,,Plasma half-life in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1500,,Rattus norvegicus,10116.0
10030,N,,,,Plasma half-life in rats; <MQL,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1500,,Rattus norvegicus,10116.0
10031,N,,,,Plasma half-life period (0-8 h) was determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5334,,Rattus norvegicus,10116.0
10032,N,,,,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5334,,Rattus norvegicus,10116.0
10033,N,,,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5334,In vivo,Rattus norvegicus,10116.0
10034,N,,,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5334,In vivo,Rattus norvegicus,10116.0
10035,N,,,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4956,,Rattus norvegicus,10116.0
10036,N,,,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4956,,Rattus norvegicus,10116.0
10037,N,,,,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",Intermediate,,,,178.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10038,N,,,,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",Intermediate,,,,178.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10039,N,,,,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",Intermediate,,,,178.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10040,N,,,,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",Intermediate,,,,,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10041,N,,,,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",Intermediate,,,,,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10042,N,,,,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",Intermediate,,,,,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10043,N,,,,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",Intermediate,,,,,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10044,N,,,,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",Intermediate,,,,,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10045,N,,,,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",Intermediate,,,,,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10046,N,,,,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",Intermediate,,,,,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10047,N,,,,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",Intermediate,,,,948.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10048,N,,,,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",Intermediate,,,,948.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10049,N,,,,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",Intermediate,,,,948.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10050,N,,,,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",Intermediate,,,,948.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10051,N,,,,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",Intermediate,,,,948.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10052,N,,,,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",Intermediate,,,,948.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10053,N,,,,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",Intermediate,,,,948.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10054,N,,,,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",Intermediate,,,,2107.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10055,N,,,,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",Intermediate,,,,2107.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10056,N,,,,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",Intermediate,,,,2107.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10057,N,,,,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",Intermediate,,,,2107.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10058,N,,,,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",Intermediate,,,,2107.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10059,N,,,,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",Intermediate,,,,2107.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10060,N,,,,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",Intermediate,,,,2107.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10061,N,,,,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",Intermediate,,,,2048.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10062,N,,,,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",Intermediate,,,,2048.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10063,N,,,,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",Intermediate,,,,2048.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10064,N,,,,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",Intermediate,,,,2048.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10065,N,,,,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",Intermediate,,,,2048.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10066,N,,,,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",Intermediate,,,,2048.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10067,N,,,,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",Intermediate,,,,2048.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10068,N,,,,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",Intermediate,,,,2046.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10069,N,,,,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",Intermediate,,,,2046.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10070,N,,,,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",Intermediate,,,,2046.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10071,N,,,,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",Intermediate,,,,2046.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10072,N,,,,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",Intermediate,,,,2046.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10073,N,,,,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",Intermediate,,,,2046.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10074,N,,,,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",Intermediate,,,,,50597,BAO_0000218,A,,4498,In vivo,Rattus norvegicus,10116.0
10075,N,,,,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",Intermediate,,,,,50597,BAO_0000218,A,,4498,In vivo,Rattus norvegicus,10116.0
10076,N,,,,Bioavailability after a dose of 10 mg/kg p.o.,Intermediate,,,,,50597,BAO_0000218,A,,3603,In vivo,Rattus norvegicus,10116.0
10077,N,,,,Bioavailability after peroral administration (10 mg/kg) was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,6215,In vivo,Rattus norvegicus,10116.0
10078,N,,,,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,Intermediate,,,,,50597,BAO_0000218,A,,5710,In vivo,Rattus norvegicus,10116.0
10079,N,,,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,5710,In vivo,Rattus norvegicus,10116.0
10080,N,,,,Bioavailability in rat po was determined,Intermediate,,,,,50597,BAO_0000218,A,,5676,In vivo,Rattus norvegicus,10116.0
10081,N,,,,Bioavailability of compound at 10 mg/kg in rat after oral administration,Intermediate,,,,,50597,BAO_0000218,A,,17667,In vivo,Rattus norvegicus,10116.0
10082,N,,,,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,Intermediate,,,,,50597,BAO_0000218,A,,17667,In vivo,Rattus norvegicus,10116.0
10083,N,,,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,6848,In vivo,Rattus norvegicus,10116.0
10084,N,,,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,6848,In vivo,Rattus norvegicus,10116.0
10085,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,17267,In vivo,Rattus norvegicus,10116.0
10086,N,,,,Bioavailability in rat (Sprague-Dawley) (female),Intermediate,,,,,50597,BAO_0000218,A,,6362,In vivo,Rattus norvegicus,10116.0
10087,N,,,,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17671,In vivo,Rattus norvegicus,10116.0
10088,N,,,,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,17671,In vivo,Rattus norvegicus,10116.0
10089,N,,,,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,Intermediate,,,,,50597,BAO_0000218,A,,4333,In vivo,Rattus norvegicus,10116.0
10090,N,,,,Bioavailability in rat at an oral dose of 2 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6077,In vivo,Rattus norvegicus,10116.0
10091,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,3278,In vivo,Rattus norvegicus,10116.0
10092,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5964,In vivo,Rattus norvegicus,10116.0
10093,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,4884,In vivo,Rattus norvegicus,10116.0
10094,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,4905,In vivo,Rattus norvegicus,10116.0
10095,N,,,,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,Intermediate,,,,,50597,BAO_0000218,A,,4884,In vivo,Rattus norvegicus,10116.0
10096,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6850,In vivo,Rattus norvegicus,10116.0
10097,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,2864,In vivo,Rattus norvegicus,10116.0
10098,N,,,,Bioavailability was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,5780,In vivo,Rattus norvegicus,10116.0
10099,N,,,,Bioavailability,Intermediate,,,,,50597,BAO_0000218,A,,1465,In vivo,Rattus norvegicus,10116.0
10100,N,,,,Bioavailability,Intermediate,,,,,50597,BAO_0000218,A,,5199,In vivo,Rattus norvegicus,10116.0
10101,N,,,,Bioavailability in rat after 1 day dosing,Intermediate,,,,,50597,BAO_0000218,A,,5765,In vivo,Rattus norvegicus,10116.0
10102,N,,,,Bioavailability in rat after 4 day dosing,Intermediate,,,,,50597,BAO_0000218,A,,5765,In vivo,Rattus norvegicus,10116.0
10103,N,,,,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,Intermediate,,,,,50597,BAO_0000218,A,,6518,In vivo,Rattus norvegicus,10116.0
10104,N,,,,Bioavailability after IV dosing at 1 mg/kg in rat; no data,Intermediate,,,,,50597,BAO_0000218,A,,6518,In vivo,Rattus norvegicus,10116.0
10105,N,,,,Bioavailability after oral administration at a dose of 2 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6518,In vivo,Rattus norvegicus,10116.0
10106,N,,,,Bioavailability after oral administration at a dose of 4 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6518,In vivo,Rattus norvegicus,10116.0
10107,N,,,,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,Intermediate,,,,,50597,BAO_0000218,A,,2083,In vivo,Rattus norvegicus,10116.0
10108,N,,,,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,Intermediate,,,,,50597,BAO_0000218,A,,17260,In vivo,Rattus norvegicus,10116.0
10109,N,,,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,4956,In vivo,Rattus norvegicus,10116.0
10110,N,,,,Bioavailability by intravenous administration of 3.4 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4368,In vivo,Rattus norvegicus,10116.0
10111,N,,,,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17752,In vivo,Rattus norvegicus,10116.0
10112,N,,,,Bioavailability in rat (Fisher) (fasted),Intermediate,,,,,50597,BAO_0000218,A,,1446,In vivo,Rattus norvegicus,10116.0
10113,U,,,,Bioavailability in monkey after po administration of 10 mg/kg dose,Intermediate,,,,,22224,BAO_0000218,A,,2891,In vivo,Primates,9443.0
10114,U,,,,Oral bioavailability in monkey (dose 10 mg/kg),Intermediate,,,,,22224,BAO_0000218,A,,2891,In vivo,Primates,9443.0
10115,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6672,In vivo,Rattus norvegicus,10116.0
10116,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6673,In vivo,Rattus norvegicus,10116.0
10117,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,17655,In vivo,Rattus norvegicus,10116.0
10118,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,17796,In vivo,Rattus norvegicus,10116.0
10119,N,,,,Bioavailability in rat (dose 2.0 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,17853,In vivo,Rattus norvegicus,10116.0
10120,N,,,,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),Intermediate,,,,,50597,BAO_0000218,A,,4521,In vivo,Rattus norvegicus,10116.0
10121,N,,,,Oral bioavailability in rat (dose 5 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,4940,In vivo,Rattus norvegicus,10116.0
10122,U,,,,Bioavailability in rat after po administration of 30 mg/kg dose,Intermediate,,,,,22224,BAO_0000218,A,,2891,In vivo,Rattus norvegicus,10116.0
10123,U,,,,Bioavailability in rat after po administration of 30 mg/kg dose,Intermediate,,,,,22224,BAO_0000218,A,,2891,In vivo,Rattus norvegicus,10116.0
10124,N,,,,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,Intermediate,,,,,50597,BAO_0000218,A,,4521,In vivo,Rattus norvegicus,10116.0
10125,N,,,,Bioavailability in rat (dose 2 mg/kg i.v.),Intermediate,,,,,50597,BAO_0000218,A,,17686,In vivo,Rattus norvegicus,10116.0
10126,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,17796,In vivo,Rattus norvegicus,10116.0
10127,N,,,,Bioavailability in rat; Only traces detected in rat plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17796,In vivo,Rattus norvegicus,10116.0
10128,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5064,In vivo,Rattus norvegicus,10116.0
10129,N,,,,Bioavailability upon oral administration of compound,Intermediate,,,,,50597,BAO_0000218,A,,5147,In vivo,Rattus norvegicus,10116.0
10130,N,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,1916,In vivo,Rattus norvegicus,10116.0
10131,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6049,In vivo,Rattus norvegicus,10116.0
10132,N,,,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",Intermediate,,,,,50597,BAO_0000218,A,,1445,In vivo,Rattus norvegicus,10116.0
10133,N,,,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",Intermediate,,,,,50597,BAO_0000218,A,,1445,In vivo,Rattus norvegicus,10116.0
10134,N,,,,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,Expert,,,,,50597,BAO_0000218,F,,2862,,Rattus norvegicus,10116.0
10135,N,,,,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,Expert,,,,,50597,BAO_0000218,F,,2862,,Rattus norvegicus,10116.0
10136,N,,,,In vitro and metabolic stability was determined,Intermediate,,,,,50597,BAO_0000218,A,,4194,,Rattus norvegicus,10116.0
10137,N,,,,In vitro metabolic stability in rat hepatocytes,Intermediate,,,,,50597,BAO_0000218,A,,4194,,Rattus norvegicus,10116.0
10138,N,,,,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,Intermediate,,,,,50597,BAO_0000218,A,,5486,,Rattus norvegicus,10116.0
10139,N,,401.0,,Metabolic rate for compound was observed in rat hepatocytes,Intermediate,,Hepatocyte,,2107.0,50597,BAO_0000218,A,,17582,In vitro,Rattus norvegicus,10116.0
10140,N,,,,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,Intermediate,,,,,50597,BAO_0000218,A,,5600,,Rattus norvegicus,10116.0
10141,N,,,,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),Intermediate,,,,,50597,BAO_0000218,A,,14294,,Rattus norvegicus,10116.0
10142,N,,,,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),Intermediate,,,,,50597,BAO_0000218,A,,14294,,Rattus norvegicus,10116.0
10143,N,,,,Metabolism of compound in rat S9 microsomes; Trace,Intermediate,,,,,50597,BAO_0000218,A,,14294,,Rattus norvegicus,10116.0
10144,N,,,,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,Intermediate,,,,,50597,BAO_0000218,A,,17847,,Rattus norvegicus,10116.0
10145,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10146,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10147,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10148,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10149,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10150,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10151,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10152,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10153,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10154,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10155,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10156,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10157,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10158,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10159,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10160,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10161,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10162,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10163,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10164,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10165,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10166,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10167,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10168,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10169,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10170,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10171,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10172,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10173,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10174,N,,,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4969,,Rattus norvegicus,10116.0
10175,N,,,,Stability in rat plasma was determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6737,,Rattus norvegicus,10116.0
10176,N,,,,Stability in rat plasma was determined; ND= no data,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6737,,Rattus norvegicus,10116.0
10177,N,,,,Tested for plasma half life period in rat (0-8 hr),Intermediate,,,,1969.0,50597,BAO_0000218,A,,5089,,Rattus norvegicus,10116.0
10178,N,,,,Tested for plasma half life period in rat (0-8 hr); Not determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5089,,Rattus norvegicus,10116.0
10179,N,,,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,Intermediate,,,,,50597,BAO_0000218,A,,1466,In vivo,Rattus norvegicus,10116.0
10180,N,,,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,Intermediate,,,,,50597,BAO_0000218,A,,1466,In vivo,Rattus norvegicus,10116.0
10181,N,,,,Tested for the half life in rat,Intermediate,,,,,50597,BAO_0000218,A,,4950,,Rattus norvegicus,10116.0
10182,N,,,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,Intermediate,,,,,50597,BAO_0000218,A,,2412,In vitro,Rattus norvegicus,10116.0
10183,N,,,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,Intermediate,,,,,50597,BAO_0000218,A,,2412,In vitro,Rattus norvegicus,10116.0
10184,N,,,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,Intermediate,,,,,50597,BAO_0000218,A,,2412,In vitro,Rattus norvegicus,10116.0
10185,N,,,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,Intermediate,,,,,50597,BAO_0000218,A,,2412,In vitro,Rattus norvegicus,10116.0
10186,N,,,,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,Intermediate,,,,,50597,BAO_0000218,A,,2412,In vitro,Rattus norvegicus,10116.0
10187,N,,,,The biological half life the compound was measured at the dose of 100 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,15022,,Rattus norvegicus,10116.0
10188,N,,,,The biological half life the compound was measured at the dose of 30 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,15022,,Rattus norvegicus,10116.0
10189,N,,,,The compound was evaluated for plasma half life period in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,406,,Rattus norvegicus,10116.0
10190,N,,,,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,15078,In vivo,Rattus norvegicus,10116.0
10191,N,,,,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,15078,In vivo,Rattus norvegicus,10116.0
10192,N,,,,The pharmacokinetic parameter half-life period in vivo in rats,Intermediate,,,,,50597,BAO_0000218,A,,5247,In vivo,Rattus norvegicus,10116.0
10193,N,,,,"The pharmacokinetic property, Half-life was determined",Intermediate,,,,,50597,BAO_0000218,A,,5041,In vivo,Rattus norvegicus,10116.0
10194,N,,,,"The pharmacokinetic property, Half-life in rat in vivo",Intermediate,,,,,50597,BAO_0000218,A,,5041,In vivo,Rattus norvegicus,10116.0
10195,N,,,,"The pharmacokinetic property, Half-life was determined; ND denotes no data",Intermediate,,,,,50597,BAO_0000218,A,,5041,In vivo,Rattus norvegicus,10116.0
10196,N,,,,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",Intermediate,,,,,50597,BAO_0000218,A,,5041,In vivo,Rattus norvegicus,10116.0
10197,N,,,,The plasma half life period in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,3918,,Rattus norvegicus,10116.0
10198,N,,,,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,Intermediate,,,,2107.0,50597,BAO_0000218,A,,2906,,Rattus norvegicus,10116.0
10199,N,,,,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,Intermediate,,,,,50597,BAO_0000218,A,,6467,In vivo,Rattus norvegicus,10116.0
10200,N,,,,t1/2 (apparent elimination)of the compound was determined,Intermediate,,,,,50597,BAO_0000218,A,,5510,,Rattus norvegicus,10116.0
10201,N,,,,t1/2 value in rat,Intermediate,,,,,50597,BAO_0000218,A,,3788,,Rattus norvegicus,10116.0
10202,N,,,,Half life in rat,Intermediate,,,,,50597,BAO_0000218,A,,17796,,Rattus norvegicus,10116.0
10203,N,,,,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",Intermediate,,,,1969.0,50597,BAO_0000218,A,,12873,In vivo,Rattus norvegicus,10116.0
10204,N,,,,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,Intermediate,,,,,50597,BAO_0000218,A,,5983,In vivo,Rattus norvegicus,10116.0
10205,N,,,,Half-life period in fasted rats,Intermediate,,,,,50597,BAO_0000218,A,,15765,,Rattus norvegicus,10116.0
10206,N,,,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,2661,In vivo,Rattus norvegicus,10116.0
10207,N,,,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,2661,In vivo,Rattus norvegicus,10116.0
10208,N,,,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,429,In vivo,Rattus norvegicus,10116.0
10209,N,,,,Maximum time required to achieve Cmax was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,17655,,Rattus norvegicus,10116.0
10210,N,,,,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,Intermediate,,,,,50597,BAO_0000218,A,,17717,In vivo,Rattus norvegicus,10116.0
10211,N,,,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,Intermediate,,,,,50597,BAO_0000218,A,,17717,In vivo,Rattus norvegicus,10116.0
10212,N,,,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,Intermediate,,,,,50597,BAO_0000218,A,,17717,In vivo,Rattus norvegicus,10116.0
10213,N,,,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,6570,In vivo,Rattus norvegicus,10116.0
10214,N,,,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,Intermediate,,,,,50597,BAO_0000218,A,,6570,In vivo,Rattus norvegicus,10116.0
10215,N,,,,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,In vivo,Rattus norvegicus,10116.0
10216,N,,,,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,In vivo,Rattus norvegicus,10116.0
10217,N,,,,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,In vivo,Rattus norvegicus,10116.0
10218,N,,,,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,In vivo,Rattus norvegicus,10116.0
10219,N,,,,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17720,In vivo,Rattus norvegicus,10116.0
10220,N,,,,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,,,,50597,BAO_0000218,A,,4723,In vivo,Rattus norvegicus,10116.0
10221,N,,,,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,,,,50597,BAO_0000218,A,,4723,In vivo,Rattus norvegicus,10116.0
10222,N,,,,Tmax at the dose of 2 mg/Kg administered perorally in rats,Intermediate,,,,,50597,BAO_0000218,A,,4756,In vivo,Rattus norvegicus,10116.0
10223,N,,,,Tmax at the dose of 5 mg/Kg administered perorally in rats,Intermediate,,,,,50597,BAO_0000218,A,,4756,In vivo,Rattus norvegicus,10116.0
10224,N,,,,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17720,In vivo,Rattus norvegicus,10116.0
10225,N,,,,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17720,In vivo,Rattus norvegicus,10116.0
10226,N,,,,tmax upon peroral administration of 10.0 mg/Kg dose in rat,Intermediate,,,,,50597,BAO_0000218,A,,1466,In vivo,Rattus norvegicus,10116.0
10227,N,,,,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,Intermediate,,,,,50597,BAO_0000218,F,,7449,,Rattus norvegicus,10116.0
10228,N,,,,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,Intermediate,,,,,50597,BAO_0000218,F,,7449,,Rattus norvegicus,10116.0
10229,N,,,,Percent total excretion of 3-methoxyacetaminophen glucuronide,Intermediate,,,,,50597,BAO_0000218,F,,7449,,Rattus norvegicus,10116.0
10230,N,,,,Percent total excretion of N-methoxyacetaminophen glucuronide,Intermediate,,,,,50597,BAO_0000218,F,,7449,,Rattus norvegicus,10116.0
10231,N,,,,Percent total excretion of N-methoxyacetaminophen sulfate,Intermediate,,,,,50597,BAO_0000218,F,,7449,,Rattus norvegicus,10116.0
10232,N,,,,Percent total excretion of acetaminophen,Intermediate,,,,,50597,BAO_0000218,F,,7449,,Rattus norvegicus,10116.0
10233,N,,,,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",Intermediate,,,,2046.0,50597,BAO_0000218,A,,7768,,Rattus norvegicus,10116.0
10234,N,,,,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",Intermediate,,,,,50597,BAO_0000218,A,,17655,,Rattus norvegicus,10116.0
10235,N,,,,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,Intermediate,,,,,50597,BAO_0000218,A,,17735,,Rattus norvegicus,10116.0
10236,N,,,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,Intermediate,,,,,50597,BAO_0000218,A,,5960,,Rattus norvegicus,10116.0
10237,N,,,,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,Intermediate,,,,,50597,BAO_0000218,A,,17735,,Rattus norvegicus,10116.0
10238,N,,,,Compound was tested for antidiuretic activity in rats,Intermediate,,,,,50597,BAO_0000218,A,,7116,,Rattus norvegicus,10116.0
10239,N,,,,AUC in rat after 3mg/kg oral dose,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4878,In vivo,Rattus norvegicus,10116.0
10240,N,,,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5939,,Rattus norvegicus,10116.0
10241,N,,,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5939,,Rattus norvegicus,10116.0
10242,N,,,,Bioavailability administered orally at a dose of 10 mg/kg to rats,Intermediate,,,,,50597,BAO_0000218,A,,16367,,Rattus norvegicus,10116.0
10243,N,,,,Oral Bioavailability was determined,Intermediate,,,,,50597,BAO_0000218,A,,16366,,Rattus norvegicus,10116.0
10244,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,4426,,Rattus norvegicus,10116.0
10245,N,,,,Oral bioavailability in rat; Not performed.,Intermediate,,,,,50597,BAO_0000218,A,,4426,,Rattus norvegicus,10116.0
10246,N,,,,Bioavailability,Intermediate,,,,,50597,BAO_0000218,A,,5041,,Rattus norvegicus,10116.0
10247,N,,,,Bioavailability was determined; ND denotes no data,Intermediate,,,,,50597,BAO_0000218,A,,5041,,Rattus norvegicus,10116.0
10248,N,,,,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,1500,,Rattus norvegicus,10116.0
10249,N,,,,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,1500,,Rattus norvegicus,10116.0
10250,N,,,,Binding towards rat plasma protein at 10 uM,Intermediate,,,,,50597,BAO_0000218,A,,17409,,Rattus norvegicus,10116.0
10251,N,,,,Binding towards rat plasma protein at 100 uM,Intermediate,,,,,50597,BAO_0000218,A,,17409,,Rattus norvegicus,10116.0
10252,N,,,,Bioavailability in rat (dose 20 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,2959,In vivo,Rattus norvegicus,10116.0
10253,N,,,,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,Intermediate,,,,,50597,BAO_0000218,A,,13501,In vivo,Rattus norvegicus,10116.0
10254,N,,,,Bioavailability in rat after 5 mg/kg oral gavage,Intermediate,,,,,50597,BAO_0000218,A,,6567,In vivo,Rattus norvegicus,10116.0
10255,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6571,In vivo,Rattus norvegicus,10116.0
10256,N,,,,Bioavailability in rat (dose 1 mg/kg i.v.),Intermediate,,,,,50597,BAO_0000218,A,,6715,In vivo,Rattus norvegicus,10116.0
10257,N,,,,Bioavailability in rat (dose 3 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,6715,In vivo,Rattus norvegicus,10116.0
10258,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,2932,In vivo,Rattus norvegicus,10116.0
10259,N,,,,Bioavailability of the compound in rats after administration of 30 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,4171,In vivo,Rattus norvegicus,10116.0
10260,N,,,,Bioavailability after administration of 10 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,17509,In vivo,Rattus norvegicus,10116.0
10261,N,,,,Bioavailability after administration of 2 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,17509,In vivo,Rattus norvegicus,10116.0
10262,N,,,,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,4527,In vivo,Rattus norvegicus,10116.0
10263,N,,,,Bioavailability in dogs was determined; high,Intermediate,,,,,50597,BAO_0000218,A,,4026,In vivo,Rattus norvegicus,10116.0
10264,N,,,,Bioavailability in monkey after intravenous administration at 1 mpk,Intermediate,,,,,50597,BAO_0000218,A,,6659,In vivo,Rattus norvegicus,10116.0
10265,N,,,,Bioavailability in monkey after peroral administration at 10 mpk,Intermediate,,,,,50597,BAO_0000218,A,,6659,In vivo,Rattus norvegicus,10116.0
10266,N,,,,Bioavailability in rat after intravenous administration at 1 mpk,Intermediate,,,,,50597,BAO_0000218,A,,6659,In vivo,Rattus norvegicus,10116.0
10267,N,,,,Bioavailability in rat after intravenous administration at 2 mpk,Intermediate,,,,,50597,BAO_0000218,F,,6659,In vivo,Rattus norvegicus,10116.0
10268,N,,,,Bioavailability in rat after peroral administration at 30 mpk,Intermediate,,,,,50597,BAO_0000218,A,,6659,In vivo,Rattus norvegicus,10116.0
10269,N,,,,Bioavailability in rat after peroral administration at at 100 mpk,Intermediate,,,,,50597,BAO_0000218,F,,6659,In vivo,Rattus norvegicus,10116.0
10270,N,,,,Bioavailability in rats was evaluated,Intermediate,,,,,50597,BAO_0000218,A,,6597,In vivo,Rattus norvegicus,10116.0
10271,N,,,,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,Intermediate,,,,,50597,BAO_0000218,A,,1202,In vivo,Rattus norvegicus,10116.0
10272,N,,,,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,Intermediate,,,,,50597,BAO_0000218,A,,1202,In vivo,Rattus norvegicus,10116.0
10273,N,,,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,Intermediate,,,,,50597,BAO_0000218,A,,1202,In vivo,Rattus norvegicus,10116.0
10274,N,,,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,Intermediate,,,,,50597,BAO_0000218,A,,1202,In vivo,Rattus norvegicus,10116.0
10275,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5207,In vivo,Rattus norvegicus,10116.0
10276,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5970,In vivo,Rattus norvegicus,10116.0
10277,N,,,,Oral bioavailability in rat (dose 10 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,17538,In vivo,Rattus norvegicus,10116.0
10278,N,,,,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,Intermediate,,,,,50597,BAO_0000218,A,,17538,In vivo,Rattus norvegicus,10116.0
10279,N,,,,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,Intermediate,,,,,50597,BAO_0000218,A,,1466,In vivo,Rattus norvegicus,10116.0
10280,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,2879,In vivo,Rattus norvegicus,10116.0
10281,N,,,,Bioavailability was measured in rat after oral administration; 2-4,Intermediate,,,,,50597,BAO_0000218,A,,2879,In vivo,Rattus norvegicus,10116.0
10282,N,,,,Bioavailability was measured in rat after oral administration; 3-7,Intermediate,,,,,50597,BAO_0000218,A,,2879,In vivo,Rattus norvegicus,10116.0
10283,N,,,,Bioavailability in rat (intraduodenal administration),Intermediate,,,,,50597,BAO_0000218,A,,3777,In vivo,Rattus norvegicus,10116.0
10284,N,,,,Bioavailability in rat (intraduodenal administration),Intermediate,,,,,50597,BAO_0000218,A,,3777,In vivo,Rattus norvegicus,10116.0
10285,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,3777,In vivo,Rattus norvegicus,10116.0
10286,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,3777,In vivo,Rattus norvegicus,10116.0
10287,N,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,5423,In vivo,Rattus norvegicus,10116.0
10288,N,,,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,Intermediate,,,,,50597,BAO_0000218,A,,16365,In vivo,Rattus norvegicus,10116.0
10289,N,,,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,Intermediate,,,,,50597,BAO_0000218,A,,16365,In vivo,Rattus norvegicus,10116.0
10290,N,,,,Bioavailability was measured in rat,Intermediate,,,,,50597,BAO_0000218,A,,4239,In vivo,Rattus norvegicus,10116.0
10291,N,,,,Bioavailability was reported,Intermediate,,,,,50597,BAO_0000218,A,,5438,In vivo,Rattus norvegicus,10116.0
10292,N,,,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),Intermediate,,,,,50597,BAO_0000218,A,,5334,In vivo,Rattus norvegicus,10116.0
10293,N,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,5334,In vivo,Rattus norvegicus,10116.0
10294,N,,,,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,4199,In vivo,Rattus norvegicus,10116.0
10295,N,,,,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),Intermediate,,,,,50597,BAO_0000218,A,,4199,In vivo,Rattus norvegicus,10116.0
10296,N,,,,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),Intermediate,,,,,50597,BAO_0000218,A,,4199,In vivo,Rattus norvegicus,10116.0
10297,N,,,,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,4890,In vivo,Rattus norvegicus,10116.0
10298,N,,,,Bioavailability was determined at 3 mg/kg po dose in rats,Intermediate,,,,,50597,BAO_0000218,A,,2792,In vivo,Rattus norvegicus,10116.0
10299,N,,,,Oral bioavailability in rat (dose 2 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,5529,In vivo,Rattus norvegicus,10116.0
10300,N,,,,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,6685,In vivo,Rattus norvegicus,10116.0
10301,N,,,,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",Intermediate,,,,,50597,BAO_0000218,A,,6685,In vivo,Rattus norvegicus,10116.0
10302,N,,,,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",Intermediate,,,,,50597,BAO_0000218,A,,6685,In vivo,Rattus norvegicus,10116.0
10303,N,,,,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6005,In vivo,Rattus norvegicus,10116.0
10304,N,,,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,Intermediate,,,,,50597,BAO_0000218,A,,6410,In vivo,Rattus norvegicus,10116.0
10305,N,,,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6410,In vivo,Rattus norvegicus,10116.0
10306,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6103,In vivo,Rattus norvegicus,10116.0
10307,N,,,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,Intermediate,,,,,50597,BAO_0000218,A,,6410,In vivo,Rattus norvegicus,10116.0
10308,N,,,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6410,In vivo,Rattus norvegicus,10116.0
10309,N,,,,Bioavailability in rat (Sprague-Dawley),Intermediate,,,,,50597,BAO_0000218,A,,5353,In vivo,Rattus norvegicus,10116.0
10310,N,,,,Bioavailability in rat at the dose of 2 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,4727,In vivo,Rattus norvegicus,10116.0
10311,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,17804,In vivo,Rattus norvegicus,10116.0
10312,N,,,,Bioavailability in rat (cannulated) (dose 2 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,5809,In vivo,Rattus norvegicus,10116.0
10313,N,,,,Bioavailability value of compound in rats was determined after peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,17804,In vivo,Rattus norvegicus,10116.0
10314,N,,,,Oral bioavailability in rat (dose 20 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,3634,In vivo,Rattus norvegicus,10116.0
10315,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,3341,In vivo,Rattus norvegicus,10116.0
10316,N,,,,Oral bioavailability in rat (dose 5 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,2690,In vivo,Rattus norvegicus,10116.0
10317,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,3184,In vivo,Rattus norvegicus,10116.0
10318,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,740,In vivo,Rattus norvegicus,10116.0
10319,N,,,,Compound was evaluated for oral bioavailability in rats; 15-27 %,Intermediate,,,,,50597,BAO_0000218,A,,1806,In vivo,Rattus norvegicus,10116.0
10320,N,,,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,Intermediate,,,,,50597,BAO_0000218,A,,4891,In vivo,Rattus norvegicus,10116.0
10321,N,,,,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),Intermediate,,,,,50597,BAO_0000218,A,,3634,In vivo,Rattus norvegicus,10116.0
10322,N,,,,Compound was tested for bioavailability in rats,Intermediate,,,,,50597,BAO_0000218,A,,64,In vivo,Rattus norvegicus,10116.0
10323,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,4839,In vivo,Rattus norvegicus,10116.0
10324,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,1094,In vivo,Rattus norvegicus,10116.0
10325,U,,,,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,Intermediate,,,,,22224,BAO_0000218,A,,5005,In vivo,Macaca mulatta,9544.0
10326,U,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),Intermediate,,,,,22224,BAO_0000218,A,,5005,In vivo,Rattus norvegicus,10116.0
10327,N,,,,Evaluated for the bioavailability in rat (in vivo),Intermediate,,,,,50597,BAO_0000218,A,,4687,In vivo,Rattus norvegicus,10116.0
10328,N,,,,F value of compound in rats was determined after peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,17804,In vivo,Rattus norvegicus,10116.0
10329,N,,,,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,In vivo,Rattus norvegicus,10116.0
10330,N,,,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,In vivo,Rattus norvegicus,10116.0
10331,N,,,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,In vivo,Rattus norvegicus,10116.0
10332,N,,,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,In vivo,Rattus norvegicus,10116.0
10333,N,,,,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",Intermediate,,,,,50597,BAO_0000218,A,,1088,In vivo,Rattus norvegicus,10116.0
10334,N,,,,Maximum fall in carotid flow in rat,Intermediate,,,,,50597,BAO_0000218,A,,1742,In vivo,Rattus norvegicus,10116.0
10335,N,,,,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,Intermediate,,,,,50597,BAO_0000218,A,,4689,In vivo,Rattus norvegicus,10116.0
10336,N,,,,Oral bioavailability in rat (dose 5 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,2463,In vivo,Rattus norvegicus,10116.0
10337,N,,,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,5654,In vivo,Rattus norvegicus,10116.0
10338,N,,,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,5654,In vivo,Rattus norvegicus,10116.0
10339,N,,,,Oral bioavailability in rat (male Wistar),Intermediate,,,,,50597,BAO_0000218,A,,6874,In vivo,Rattus norvegicus,10116.0
10340,N,,,,Oral bioavailability after administration (30 mg/kg) in rat; good,Intermediate,,,,,50597,BAO_0000218,A,,5633,In vivo,Rattus norvegicus,10116.0
10341,N,,,,Oral bioavailability at the dose of 2 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,5496,In vivo,Rattus norvegicus,10116.0
10342,N,,,,Oral bioavailability determined in rats,Intermediate,,,,,50597,BAO_0000218,A,,2358,In vivo,Rattus norvegicus,10116.0
10343,N,,,,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,16456,In vivo,Rattus norvegicus,10116.0
10344,N,,,,Oral bioavailability in rat (dose single 10 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,5302,In vivo,Rattus norvegicus,10116.0
10345,N,,,,Oral bioavailability in rat (dose single 10 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,5302,In vivo,Rattus norvegicus,10116.0
10346,N,,,,Oral bioavailability in rat (dose 5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5302,In vivo,Rattus norvegicus,10116.0
10347,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10348,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10349,N,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10350,N,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10351,N,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10352,N,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10353,N,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10354,N,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10355,N,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10356,N,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10357,N,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10358,N,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10359,N,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10360,N,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10361,N,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10362,N,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10363,N,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10364,N,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10365,N,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10366,N,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10367,N,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10368,N,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10369,N,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10370,N,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10371,N,,,,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10372,N,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10373,N,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10374,N,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10375,N,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10376,N,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10377,N,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10378,N,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10379,N,,,,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10380,N,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10381,N,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10382,N,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10383,N,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10384,N,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10385,N,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10386,N,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10387,N,,,,Percent total excretion of acetaminophen cysteine conjugate,Intermediate,,,,,50597,BAO_0000218,F,,7449,,Rattus norvegicus,10116.0
10388,N,,,,Percent total excretion of acetaminophen glucuronide,Intermediate,,,,,50597,BAO_0000218,F,,7449,,Rattus norvegicus,10116.0
10389,N,,,,Percent total excretion of acetaminophen sulfate,Intermediate,,,,,50597,BAO_0000218,F,,7449,,Rattus norvegicus,10116.0
10390,N,,,,Percent total excretion of acetaminophen-mercapturic acid,Intermediate,,,,,50597,BAO_0000218,F,,7449,,Rattus norvegicus,10116.0
10391,N,,,,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,Intermediate,,,,1088.0,50597,BAO_0000218,A,,3172,,Rattus norvegicus,10116.0
10392,N,,,,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,16456,In vivo,Rattus norvegicus,10116.0
10393,U,,,,Biodistribution of compound in rat muscle after 5 min of administration,Autocuration,,,,2385.0,22224,BAO_0000218,A,,10839,In vivo,ratrat,8656.0
10394,U,,,,Biodistribution of compound in rat muscle after 5 min of administration.,Autocuration,,,,2385.0,22224,BAO_0000218,A,,10839,In vivo,ratrat,8656.0
10395,U,,,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),Autocuration,,,,,22224,BAO_0000218,A,,5334,In vivo,Ovis aries,9940.0
10396,U,,,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),Autocuration,,,,,22224,BAO_0000218,A,,5334,In vivo,Ovis aries,9940.0
10397,U,,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),Autocuration,,,,,22224,BAO_0000218,A,,5334,In vivo,Ovis aries,9940.0
10398,U,,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),Autocuration,,,,,22224,BAO_0000218,A,,5334,In vivo,Ovis aries,9940.0
10399,U,,,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),Autocuration,,,,,22224,BAO_0000218,A,,5334,In vivo,Ovis aries,9940.0
10400,U,,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),Autocuration,,,,,22224,BAO_0000218,A,,5334,In vivo,Ovis aries,9940.0
10401,U,,,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),Autocuration,,,,1969.0,22224,BAO_0000218,A,,5334,In vivo,Ovis aries,9940.0
10402,U,,,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),Autocuration,,,,1969.0,22224,BAO_0000218,A,,5334,In vivo,Ovis aries,9940.0
10403,N,,,,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),Intermediate,,,,,50497,BAO_0000218,A,,1735,,Serpentes,8570.0
10404,N,,,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,Intermediate,,,,,50497,BAO_0000218,A,,1469,,Serpentes,8570.0
10405,N,,,,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,Intermediate,,,,,50497,BAO_0000218,A,,1336,,Serpentes,8570.0
10406,U,,,,The human biological plasma half life of the compound,Autocuration,,,,1969.0,22224,BAO_0000366,A,,12403,,Homo sapiens,9606.0
10407,N,,,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,Intermediate,,,,1088.0,50597,BAO_0000218,A,,8151,,Rattus norvegicus,10116.0
10408,N,,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,Intermediate,,,,,50597,BAO_0000218,A,,8004,,Rattus norvegicus,10116.0
10409,N,,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,Intermediate,,,,,50597,BAO_0000218,A,,8004,,Rattus norvegicus,10116.0
10410,N,,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,Intermediate,,,,,50597,BAO_0000218,A,,8004,,Rattus norvegicus,10116.0
10411,N,,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,Intermediate,,,,,50597,BAO_0000218,A,,8004,,Rattus norvegicus,10116.0
10412,N,,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,Intermediate,,,,,50597,BAO_0000218,A,,8004,,Rattus norvegicus,10116.0
10413,N,,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,Intermediate,,,,,50597,BAO_0000218,A,,8004,,Rattus norvegicus,10116.0
10414,N,,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,Intermediate,,,,,50597,BAO_0000218,A,,8004,,Rattus norvegicus,10116.0
10415,N,,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,Intermediate,,,,,50597,BAO_0000218,A,,8004,,Rattus norvegicus,10116.0
10416,N,,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,Intermediate,,,,,50597,BAO_0000218,A,,8004,,Rattus norvegicus,10116.0
10417,N,,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,Intermediate,,,,,50597,BAO_0000218,A,,8004,,Rattus norvegicus,10116.0
10418,N,,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,Intermediate,,,,,50597,BAO_0000218,A,,8004,,Rattus norvegicus,10116.0
10419,N,,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,Intermediate,,,,,50597,BAO_0000218,A,,8004,,Rattus norvegicus,10116.0
10420,N,,,,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,Intermediate,,,,,50597,BAO_0000218,A,,8004,,Rattus norvegicus,10116.0
10421,N,,,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8004,,Rattus norvegicus,10116.0
10422,N,,,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8004,,Rattus norvegicus,10116.0
10423,D,,,,Dissociation constant against binding to human cyclophilin A,Expert,,,,,180,BAO_0000357,B,,15917,,Homo sapiens,9606.0
10424,H,,,,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,Expert,,,,,11591,BAO_0000019,B,,12396,,Bos taurus,9913.0
10425,U,,,,-Log C was determined by performing the electroshock minimum test,Autocuration,,,,,22224,BAO_0000019,A,,7065,,,
10426,U,,,,-Log C was determined by performing the foot shock test,Autocuration,,,,,22224,BAO_0000019,A,,7065,,,
10427,U,,,,-Log C was determined by performing the incl screen test,Autocuration,,,,,22224,BAO_0000019,A,,7065,,,
10428,U,,,,-Log C was determined by performing the maximum electroshock test,Autocuration,,,,,22224,BAO_0000019,A,,7065,,,
10429,U,,,,-Log C was determined by performing the pentylenetetrazole test,Autocuration,,,,,22224,BAO_0000019,A,,7065,,,
10430,U,,,,Tested for experimental arotinoid inhibitory dose,Autocuration,,,,,22224,BAO_0000019,A,,12415,,,
10431,U,,,,Negative log transformed activity,Autocuration,,,,,22224,BAO_0000019,A,,10256,,,
10432,U,,,,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",Autocuration,,,,,22224,BAO_0000019,A,,7991,,,
10433,N,,,,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,Intermediate,,,,,50512,BAO_0000218,A,,14342,,Cavia porcellus,10141.0
10434,N,,,,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,Intermediate,,,,,50512,BAO_0000218,A,,14342,,Cavia porcellus,10141.0
10435,N,,,,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,Intermediate,,,,,50512,BAO_0000218,A,,14342,,Cavia porcellus,10141.0
10436,N,,,,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,Intermediate,,,,2116.0,50512,BAO_0000218,A,,14342,,Cavia porcellus,10141.0
10437,U,,,,Solubility in water was determined; values expressed as -log,Autocuration,,,,,22229,BAO_0000100,P,,6047,,,
10438,U,,,,Ratio of Kcat to that of Km was determined,Autocuration,,,,,22224,BAO_0000019,A,,17269,,,
10439,U,,,,Observed first order rate constant,Autocuration,,,,,22224,BAO_0000019,A,,10026,,,
10440,U,,,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,Autocuration,,,,,22224,BAO_0000019,A,,14583,,,
10441,N,,,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,2661,In vivo,Rattus norvegicus,10116.0
10442,N,,,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,2661,In vivo,Rattus norvegicus,10116.0
10443,N,,,,Oral Bioavailability after administration of 10 mg/kg in male rat,Intermediate,,,,,50597,BAO_0000218,A,,4029,In vivo,Rattus norvegicus,10116.0
10444,N,,,,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,17735,In vivo,Rattus norvegicus,10116.0
10445,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,4576,In vivo,Rattus norvegicus,10116.0
10446,N,,,,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,Intermediate,,,,,50597,BAO_0000218,A,,17582,In vivo,Rattus norvegicus,10116.0
10447,N,,,,Oral bioavailability at 1 mg/kg was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,17651,In vivo,Rattus norvegicus,10116.0
10448,N,,,,Oral bioavailability at 10 mg/kg was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,17651,In vivo,Rattus norvegicus,10116.0
10449,N,,,,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",Intermediate,,,,,50597,BAO_0000218,A,,17670,In vivo,Rattus norvegicus,10116.0
10450,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5045,In vivo,Rattus norvegicus,10116.0
10451,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,1696,In vivo,Rattus norvegicus,10116.0
10452,N,,,,Oral bioavailability after intravenous administration in rats at 24 uM/kg,Intermediate,,,,,50597,BAO_0000218,A,,17764,In vivo,Rattus norvegicus,10116.0
10453,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6448,In vivo,Rattus norvegicus,10116.0
10454,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6596,In vivo,Rattus norvegicus,10116.0
10455,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,17547,In vivo,Rattus norvegicus,10116.0
10456,N,,,,Oral bioavailability in rat at a dose of 3 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17771,In vivo,Rattus norvegicus,10116.0
10457,N,,,,Oral bioavailability in rat after oral administration at 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6495,In vivo,Rattus norvegicus,10116.0
10458,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,4558,In vivo,Rattus norvegicus,10116.0
10459,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,17596,In vivo,Rattus norvegicus,10116.0
10460,N,,,,Oral bioavailability in Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,6827,In vivo,Rattus norvegicus,10116.0
10461,N,,,,Oral bioavailability,Intermediate,,,,,50597,BAO_0000218,A,,4026,In vivo,Rattus norvegicus,10116.0
10462,N,,,,Oral bioavailability in rat (dose 30 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,10,In vivo,Rattus norvegicus,10116.0
10463,N,,,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,Intermediate,,,,,50597,BAO_0000218,A,,17717,In vivo,Rattus norvegicus,10116.0
10464,N,,,,Bioavailability in rat (dose 3 mg/kg i.v.),Intermediate,,,,,50597,BAO_0000218,A,,17717,In vivo,Rattus norvegicus,10116.0
10465,N,,,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,Intermediate,,,,,50597,BAO_0000218,A,,17717,In vivo,Rattus norvegicus,10116.0
10466,N,,,,Oral bioavailability in rat (dose 60 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,17717,In vivo,Rattus norvegicus,10116.0
10467,N,,,,Percent oral bioavailability determined in rats,Intermediate,,,,,50597,BAO_0000218,A,,4796,In vivo,Rattus norvegicus,10116.0
10468,N,,,,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,4883,In vivo,Rattus norvegicus,10116.0
10469,N,,,,The compound was evaluated for bioavailability in rats; 32-51,Intermediate,,,,,50597,BAO_0000218,A,,2137,In vivo,Rattus norvegicus,10116.0
10470,N,,,,Bioavailability in rat (dose 20 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,2959,In vivo,Rattus norvegicus,10116.0
10471,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,1361,In vivo,Rattus norvegicus,10116.0
10472,N,,,,Bioavailability percent in rat at the dose of 2 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,4727,In vivo,Rattus norvegicus,10116.0
10473,N,,,,Bioavailability was evaluated after 20 uM/kg of peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,16423,In vivo,Rattus norvegicus,10116.0
10474,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5206,In vivo,Rattus norvegicus,10116.0
10475,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6448,In vivo,Rattus norvegicus,10116.0
10476,N,,,,Bioavailability in rats,Intermediate,,,,,50597,BAO_0000218,A,,17723,In vivo,Rattus norvegicus,10116.0
10477,N,,,,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,Intermediate,,,,178.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10478,N,,,,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,Intermediate,,,,178.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10479,N,,,,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,Intermediate,,,,178.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10480,N,,,,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,Intermediate,,,,178.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10481,N,,,,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,Intermediate,,,,178.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10482,N,,,,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10483,N,,,,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10484,N,,,,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10485,N,,,,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10486,N,,,,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,Intermediate,,,,955.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10487,N,,,,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,Intermediate,,,,955.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10488,N,,,,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,Intermediate,,,,955.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10489,N,,,,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,Intermediate,,,,955.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10490,N,,,,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,Intermediate,,,,,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10491,N,,,,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,Intermediate,,,,,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10492,N,,,,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,Intermediate,,,,,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10493,N,,,,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,Intermediate,,,,,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10494,N,,,,Oral bioavailability in rats was determined; High,Intermediate,,,,,50597,BAO_0000218,A,,5237,In vivo,Rattus norvegicus,10116.0
10495,N,,,,Oral bioavailability in the rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,5503,In vivo,Rattus norvegicus,10116.0
10496,N,,,,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,Intermediate,,,,,50597,BAO_0000218,A,,15765,In vivo,Rattus norvegicus,10116.0
10497,N,,,,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),Intermediate,,,,,50597,BAO_0000218,A,,15660,In vivo,Rattus norvegicus,10116.0
10498,N,,,,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,In vivo,Rattus norvegicus,10116.0
10499,N,,,,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,In vivo,Rattus norvegicus,10116.0
10500,N,,,,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,In vivo,Rattus norvegicus,10116.0
10501,N,,,,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,In vivo,Rattus norvegicus,10116.0
10502,N,,,,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,5656,In vivo,Rattus norvegicus,10116.0
10503,N,,,,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,Expert,,,,,50597,BAO_0000218,A,,3598,In vivo,Rattus norvegicus,10116.0
10504,N,,,,Oral bioavailability of compound in Sprague Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,4216,In vivo,Rattus norvegicus,10116.0
10505,N,,,,Oral bioavailability of compound in rat,Intermediate,,,,,50597,BAO_0000218,A,,17839,In vivo,Rattus norvegicus,10116.0
10506,N,,,,Oral bioavailability in rat (dose 2 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,6570,In vivo,Rattus norvegicus,10116.0
10507,N,,,,Oral bioavailability of compound in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,5334,In vivo,Rattus norvegicus,10116.0
10508,N,,,,Oral bioavailability of compound in rats,Intermediate,,,,,50597,BAO_0000218,A,,6886,In vivo,Rattus norvegicus,10116.0
10509,N,,,,Oral bioavailability of compound was determined in rats,Intermediate,,,,,50597,BAO_0000218,A,,5210,In vivo,Rattus norvegicus,10116.0
10510,N,,,,Oral bioavailability at a dose of 30 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,4170,In vivo,Rattus norvegicus,10116.0
10511,N,,,,Oral bioavailability in rat (dose 10 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,6028,In vivo,Rattus norvegicus,10116.0
10512,N,,,,Oral bioavailability in rat (dose 10 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,6028,In vivo,Rattus norvegicus,10116.0
10513,N,,,,Oral bioavailability evaluated in rat,Intermediate,,,,,50597,BAO_0000218,A,,6078,In vivo,Rattus norvegicus,10116.0
10514,N,,,,Oral bioavailability in fasted rat,Intermediate,,,,,50597,BAO_0000218,A,,6168,In vivo,Rattus norvegicus,10116.0
10515,N,,,,Oral bioavailability in fed rat,Intermediate,,,,,50597,BAO_0000218,A,,6168,In vivo,Rattus norvegicus,10116.0
10516,N,,,,Oral bioavailability in rat (mature male) (dose 30 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,5160,In vivo,Rattus norvegicus,10116.0
10517,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6057,In vivo,Rattus norvegicus,10116.0
10518,N,,,,Oral bioavailability in rat (dose 10 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,6535,In vivo,Rattus norvegicus,10116.0
10519,N,,,,Oral bioavailability in rat after administration of 10 mg/kg po,Intermediate,,,,,50597,BAO_0000218,A,,6535,In vivo,Rattus norvegicus,10116.0
10520,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,4194,In vivo,Rattus norvegicus,10116.0
10521,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6230,In vivo,Rattus norvegicus,10116.0
10522,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6619,In vivo,Rattus norvegicus,10116.0
10523,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,17607,In vivo,Rattus norvegicus,10116.0
10524,N,,,,Oral bioavailability in ratrs,Intermediate,,,,,50597,BAO_0000218,A,,4942,In vivo,Rattus norvegicus,10116.0
10525,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,4942,In vivo,Rattus norvegicus,10116.0
10526,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6646,In vivo,Rattus norvegicus,10116.0
10527,N,,,,Oral bioavailability in rats was determined; High,Intermediate,,,,,50597,BAO_0000218,A,,5237,In vivo,Rattus norvegicus,10116.0
10528,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6646,In vivo,Rattus norvegicus,10116.0
10529,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,4449,In vivo,Rattus norvegicus,10116.0
10530,N,,,,Oral bioavailability was calculated in rat,Intermediate,,,,,50597,BAO_0000218,A,,6057,In vivo,Rattus norvegicus,10116.0
10531,N,,,,Oral bioavailability,Intermediate,,,,,50597,BAO_0000218,A,,2552,In vivo,Rattus norvegicus,10116.0
10532,N,,,,Oral bioavailability,Intermediate,,,,,50597,BAO_0000218,A,,5496,In vivo,Rattus norvegicus,10116.0
10533,N,,,,Oral bioavailability,Intermediate,,,,,50597,BAO_0000218,A,,6484,In vivo,Rattus norvegicus,10116.0
10534,N,,,,Oral bioavailability,Intermediate,,,,,50597,BAO_0000218,A,,6485,In vivo,Rattus norvegicus,10116.0
10535,N,,,,Oral bioavailability after i.v. administration,Intermediate,,,,,50597,BAO_0000218,A,,6616,In vivo,Rattus norvegicus,10116.0
10536,N,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),Intermediate,,,,,50597,BAO_0000218,A,,4969,In vivo,Rattus norvegicus,10116.0
10537,N,,,,Oral bioavailability in rat (Sprague-Dawley),Intermediate,,,,,50597,BAO_0000218,A,,5862,In vivo,Rattus norvegicus,10116.0
10538,N,,,,Oral bioavailability in Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,4514,In vivo,Rattus norvegicus,10116.0
10539,N,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),Intermediate,,,,,50597,BAO_0000218,A,,4514,In vivo,Rattus norvegicus,10116.0
10540,N,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,4514,In vivo,Rattus norvegicus,10116.0
10541,N,,,,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,Intermediate,,,,,50597,BAO_0000218,A,,5546,In vivo,Rattus norvegicus,10116.0
10542,N,,,,Oral bioavailability in fasted rat,Intermediate,,,,,50597,BAO_0000218,A,,6168,In vivo,Rattus norvegicus,10116.0
10543,N,,,,Oral bioavailability in fed rat,Intermediate,,,,,50597,BAO_0000218,A,,6168,In vivo,Rattus norvegicus,10116.0
10544,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,3624,In vivo,Rattus norvegicus,10116.0
10545,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5213,In vivo,Rattus norvegicus,10116.0
10546,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5496,In vivo,Rattus norvegicus,10116.0
10547,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5553,In vivo,Rattus norvegicus,10116.0
10548,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5833,In vivo,Rattus norvegicus,10116.0
10549,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5836,In vivo,Rattus norvegicus,10116.0
10550,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5865,In vivo,Rattus norvegicus,10116.0
10551,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5960,In vivo,Rattus norvegicus,10116.0
10552,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6249,In vivo,Rattus norvegicus,10116.0
10553,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6448,In vivo,Rattus norvegicus,10116.0
10554,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6453,In vivo,Rattus norvegicus,10116.0
10555,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6640,In vivo,Rattus norvegicus,10116.0
10556,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,17607,In vivo,Rattus norvegicus,10116.0
10557,N,,,,Oral bioavailability in rat after peroral administration at 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5939,In vivo,Rattus norvegicus,10116.0
10558,N,,,,Oral bioavailability in rat after peroral administration at 5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5939,In vivo,Rattus norvegicus,10116.0
10559,N,,,,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,6281,In vivo,Rattus norvegicus,10116.0
10560,N,,,,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5874,In vivo,Rattus norvegicus,10116.0
10561,N,,,,Oral bioavailability in rat; Not measured,Intermediate,,,,,50597,BAO_0000218,A,,5213,In vivo,Rattus norvegicus,10116.0
10562,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,4964,In vivo,Rattus norvegicus,10116.0
10563,N,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,Intermediate,,,,,50597,BAO_0000218,A,,11020,,Rattus norvegicus,10116.0
10564,N,,,,In vitro metabolic potential in rat liver microsomes,Intermediate,,,,2107.0,50597,BAO_0000218,A,,6251,,Rattus norvegicus,10116.0
10565,N,,,,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",Intermediate,,,,,50597,BAO_0000218,A,,1568,In vivo,Rattus norvegicus,10116.0
10566,N,,,,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",Intermediate,,,,,50597,BAO_0000218,A,,3032,In vivo,Rattus norvegicus,10116.0
10567,N,,,,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,Intermediate,,,,,50597,BAO_0000218,A,,3748,In vivo,Rattus norvegicus,10116.0
10568,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,401,In vivo,Rattus norvegicus,10116.0
10569,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6512,In vivo,Rattus norvegicus,10116.0
10570,N,,,,Oral bioavailability in rats at 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17617,In vivo,Rattus norvegicus,10116.0
10571,N,,,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,,,,,50597,BAO_0000218,A,,6679,In vivo,Rattus norvegicus,10116.0
10572,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6742,In vivo,Rattus norvegicus,10116.0
10573,N,,,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,Intermediate,,,,,50597,BAO_0000218,A,,589,,Rattus norvegicus,10116.0
10574,N,,,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,Intermediate,,,,,50597,BAO_0000218,A,,589,,Rattus norvegicus,10116.0
10575,N,,,,Plasma clearance of the compound,Intermediate,,,,,50597,BAO_0000218,A,,3185,In vivo,Rattus norvegicus,10116.0
10576,N,,,,Plasma clearance at 10 mg/kg in rat upon intravenous administration,Intermediate,,,,,50597,BAO_0000218,A,,17596,In vivo,Rattus norvegicus,10116.0
10577,N,,,,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,2713,In vivo,Rattus norvegicus,10116.0
10578,N,,,,The compound was tested for plasma clearance in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,12500,In vivo,Rattus norvegicus,10116.0
10579,N,,,,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,12500,In vivo,Rattus norvegicus,10116.0
10580,N,,,,Plasma concentration upon oral administration of 1 mg/Kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,2713,,Rattus norvegicus,10116.0
10581,N,,,,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,Intermediate,,,,,50597,BAO_0000218,A,,1446,,Rattus norvegicus,10116.0
10582,N,,,,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,Intermediate,,,,,50597,BAO_0000218,A,,6227,,Rattus norvegicus,10116.0
10583,N,,,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4709,,Rattus norvegicus,10116.0
10584,N,,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",Intermediate,,,,,50597,BAO_0000218,A,,5510,,Rattus norvegicus,10116.0
10585,N,,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",Intermediate,,,,,50597,BAO_0000218,A,,5510,,Rattus norvegicus,10116.0
10586,N,,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",Intermediate,,,,,50597,BAO_0000218,A,,5510,,Rattus norvegicus,10116.0
10587,N,,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",Intermediate,,,,,50597,BAO_0000218,A,,5510,,Rattus norvegicus,10116.0
10588,N,,,,Compound was tested for protein binding in rat plasma,Intermediate,,,,,50597,BAO_0000218,A,,4514,,Rattus norvegicus,10116.0
10589,N,,,,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,Intermediate,,,,,50597,BAO_0000218,A,,2713,,Rattus norvegicus,10116.0
10590,N,,,,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,Intermediate,,,,,50597,BAO_0000218,A,,2713,,Rattus norvegicus,10116.0
10591,N,,,,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,Intermediate,,,,2107.0,50597,BAO_0000218,A,,5340,,Rattus norvegicus,10116.0
10592,N,,,,Area under curve ratio was determined (po/iv) in rat,Intermediate,,,,,50597,BAO_0000218,A,,12058,,Rattus norvegicus,10116.0
10593,N,,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,Intermediate,,,,,50597,BAO_0000218,A,,11195,,Rattus norvegicus,10116.0
10594,N,,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,Intermediate,,,,,50597,BAO_0000218,A,,11195,,Rattus norvegicus,10116.0
10595,N,,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,Intermediate,,,,,50597,BAO_0000218,A,,11195,,Rattus norvegicus,10116.0
10596,N,,,,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6495,,Rattus norvegicus,10116.0
10597,N,,,,Ratio of AUCbrain to AUCplasma,Intermediate,,,,,50597,BAO_0000218,A,,6078,,Rattus norvegicus,10116.0
10598,N,,,,Ratio of brain to plasma,Intermediate,,,,,50597,BAO_0000218,A,,5656,,Rattus norvegicus,10116.0
10599,N,,,,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,Intermediate,,,,,50597,BAO_0000218,A,,4910,,Rattus norvegicus,10116.0
10600,N,,,,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,Intermediate,,,,,50597,BAO_0000218,A,,4910,,Rattus norvegicus,10116.0
10601,N,,,,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,Intermediate,,,,,50597,BAO_0000218,A,,4910,,Rattus norvegicus,10116.0
10602,N,,,,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,Intermediate,,,,,50597,BAO_0000218,A,,10130,,Rattus norvegicus,10116.0
10603,N,,,,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,Intermediate,,,,,50597,BAO_0000218,A,,10130,,Rattus norvegicus,10116.0
10604,N,,,,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,Intermediate,,,,,50597,BAO_0000218,A,,10130,,Rattus norvegicus,10116.0
10605,N,,,,Steady state brain :blood ratio was determined,Intermediate,,,,,50597,BAO_0000218,A,,5213,,Rattus norvegicus,10116.0
10606,N,,,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,Intermediate,,,,,50597,BAO_0000218,A,,4910,,Rattus norvegicus,10116.0
10607,N,,,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,Intermediate,,,,,50597,BAO_0000218,A,,4910,,Rattus norvegicus,10116.0
10608,N,,,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,Intermediate,,,,,50597,BAO_0000218,A,,4910,,Rattus norvegicus,10116.0
10609,N,,,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,Intermediate,,,,,50597,BAO_0000218,A,,4910,,Rattus norvegicus,10116.0
10610,N,,,,Percentage recovery after 3h incubation with rat hapatocytes was determined,Intermediate,,,,,50597,BAO_0000218,A,,2083,,Rattus norvegicus,10116.0
10611,N,,,,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,Intermediate,,,,,50597,BAO_0000218,A,,2082,,Rattus norvegicus,10116.0
10612,N,,,,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,Intermediate,,,,,50597,BAO_0000218,A,,2082,,Rattus norvegicus,10116.0
10613,N,,,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,6351,,Rattus norvegicus,10116.0
10614,U,,,,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",Autocuration,,,,,22224,BAO_0000019,A,,14583,,,
10615,U,,,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,Autocuration,,,,,22224,BAO_0000019,A,,14583,,,
10616,N,,495.0,,In vivo absorption in Caco-2 cell line monolayers was determined,Intermediate,,Caco-2,,,50587,BAO_0000218,A,,4608,,Homo sapiens,9606.0
10617,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,13668,,,
10618,N,,,,Area under curve was determine after peroral administration at 10 mpk in Rat,Intermediate,,,,,50597,BAO_0000218,A,,5669,,Rattus norvegicus,10116.0
10619,N,,,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,Intermediate,,,,,50797,BAO_0000218,A,,5669,,Macaca mulatta,9544.0
10620,N,,,,Area under curve was determine after peroral administration at 160 mpk in Rat,Intermediate,,,,,50597,BAO_0000218,A,,5669,,Rattus norvegicus,10116.0
10621,N,,,,Area under curve was determine after peroral administration at 20 mpk in Rat,Intermediate,,,,,50597,BAO_0000218,A,,5669,,Rattus norvegicus,10116.0
10622,N,,,,Area under curve was determine after peroral administration at 50 mpk in Rat,Intermediate,,,,,50597,BAO_0000218,A,,5669,,Rattus norvegicus,10116.0
10623,U,,,,Calculated partition coefficient (clogP) (AlogP),Autocuration,,,,,22229,BAO_0000100,P,,6472,,,
10624,U,,,,Activated partial thromboplastin time measured,Autocuration,,,,,22224,BAO_0000019,A,,15106,,,
10625,U,,,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),Autocuration,,,,,22224,BAO_0000100,P,,15207,,,
10626,U,,,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),Autocuration,,,,,22224,BAO_0000100,P,,15207,,,
10627,N,,,,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,13941,,Canis lupus familiaris,9615.0
10628,N,,,,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,13941,,Rattus norvegicus,10116.0
10629,N,,,,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,13941,,Rattus norvegicus,10116.0
10630,N,,,,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,13941,,Canis lupus familiaris,9615.0
10631,N,,,,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,Intermediate,,,,1969.0,50512,BAO_0000218,A,,15240,,Cavia porcellus,10141.0
10632,U,,,,AUC in brain,Autocuration,,,,955.0,22224,BAO_0000019,A,,10655,,,
10633,U,,,,AUC in serum,Autocuration,,,,1977.0,22224,BAO_0000019,A,,10655,,,
10634,U,,,,AUC was determined,Autocuration,,,,1969.0,22224,BAO_0000019,A,,6504,,,
10635,U,,,,AUC of the compound.,Autocuration,,,,1969.0,22224,BAO_0000019,A,,10615,,,
10636,U,,,,AUC value (0-4 hr),Autocuration,,,,1969.0,22224,BAO_0000019,A,,10353,,,
10637,U,,,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",Autocuration,,,,1969.0,22224,BAO_0000019,A,,14907,,,
10638,U,,,,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,Autocuration,,,,1969.0,22224,BAO_0000019,A,,14907,,,
10639,U,,,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",Autocuration,,,,1969.0,22224,BAO_0000019,A,,14907,,,
10640,U,,,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",Autocuration,,,,1969.0,22224,BAO_0000019,A,,14907,,,
10641,N,,,,AUC(area under curve) was determined after intravenous administration in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,16359,,Rattus norvegicus,10116.0
10642,N,,,,AUC(area under curve) was determined after oral administration in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,16359,,Rattus norvegicus,10116.0
10643,N,,,,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,Intermediate,,,,1969.0,50512,BAO_0000218,A,,15240,,Cavia porcellus,10141.0
10644,N,,,,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15240,,Rattus norvegicus,10116.0
10645,U,,,,Area Under Curve after oral dosing of 100 uM/Kg,Autocuration,,,,,22224,BAO_0000019,A,,15469,,,
10646,U,,,,Area Under Curve after oral dosing of 30 uM/Kg,Autocuration,,,,,22224,BAO_0000019,A,,15469,,,
10647,U,,,,Area Under Curve was measured by ploting the graph between concentration verses time,Autocuration,,,,,22224,BAO_0000019,A,,13520,,,
10648,N,,,,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,Intermediate,,,,,50588,BAO_0000218,A,,17025,,Canis lupus familiaris,9615.0
10649,U,,,,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,Autocuration,,,,,22224,BAO_0000218,A,,17025,,Simiiformes,314293.0
10650,N,,,,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,Intermediate,,,,,50592,BAO_0000218,A,,17025,,Oryctolagus cuniculus,9986.0
10651,N,,,,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,Intermediate,,,,,50597,BAO_0000218,A,,17025,,Rattus norvegicus,10116.0
10652,N,,,,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,Intermediate,,,,178.0,50597,BAO_0000218,A,,12032,,Rattus norvegicus,10116.0
10653,U,,,,Area under curve (AUC) was determined,Autocuration,,,,,22224,BAO_0000019,A,,10291,,,
10654,U,,,,Area under curve (AUC) following ip administration at 1 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,5767,,,
10655,U,,,,Area under curve (AUC) was determined; ND is Not determined,Autocuration,,,,,22224,BAO_0000019,A,,1434,,,
10656,N,,,,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,Intermediate,,,,,50588,BAO_0000218,A,,14925,,Canis lupus familiaris,9615.0
10657,N,,,,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,Intermediate,,,,,50588,BAO_0000218,A,,14925,,Canis lupus familiaris,9615.0
10658,N,,,,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,Intermediate,,,,,50588,BAO_0000218,A,,14925,,Canis lupus familiaris,9615.0
10659,U,,,,Area under curve (AUR) was determined,Autocuration,,,,,22224,BAO_0000019,A,,1434,,,
10660,U,,,,Area under curve at 1 uM/dg administered intravenously,Autocuration,,,,,22224,BAO_0000019,A,,11883,,,
10661,U,,,,Area under curve at 10 uM/dg administered perorally,Autocuration,,,,,22224,BAO_0000019,A,,11883,,,
10662,U,,,,Area under curve at 2 uM/dg administered intravenously,Autocuration,,,,,22224,BAO_0000019,A,,11883,,,
10663,U,,,,Area under curve at 20 uM/dg administered perorally,Autocuration,,,,,22224,BAO_0000019,A,,11883,,,
10664,N,,,,Area under curve at a peroral dose of 3 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,15233,,Canis lupus familiaris,9615.0
10665,N,,,,Area under curve at a peroral dose of 3 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,15233,,Rattus norvegicus,10116.0
10666,N,,,,Area under curve at an iv dose of 1 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,15233,,Canis lupus familiaris,9615.0
10667,N,,,,Area under curve at an iv dose of 1 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,15233,,Rattus norvegicus,10116.0
10668,U,,,,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,Autocuration,,,,,22224,BAO_0000019,A,,12978,,,
10669,U,,,,Area under curve gives the effective duration for the angiotensin II antagonist effect.,Autocuration,,,,,22224,BAO_0000019,A,,12978,,,
10670,N,,,,Area under curve measured as conc vs time after intravenous administration to mice.,Intermediate,,,,,50594,BAO_0000218,A,,11355,,Mus musculus,10090.0
10671,N,,,,Area under curve measured as conc vs time after peroral administration to mice.,Intermediate,,,,,50594,BAO_0000218,A,,11355,,Mus musculus,10090.0
10672,N,,,,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,Intermediate,,,,,50588,BAO_0000218,A,,12923,,Canis lupus familiaris,9615.0
10673,N,,,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,Intermediate,,,,,50588,BAO_0000218,A,,12923,,Canis lupus familiaris,9615.0
10674,N,,,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,Intermediate,,,,,50588,BAO_0000218,A,,12923,,Canis lupus familiaris,9615.0
10675,N,,,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,Intermediate,,,,,50588,BAO_0000218,A,,12923,,Canis lupus familiaris,9615.0
10676,N,,,,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,Intermediate,,,,948.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10677,N,,,,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,Intermediate,,,,948.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10678,N,,,,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,Intermediate,,,,948.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10679,N,,,,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,Intermediate,,,,948.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10680,N,,,,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10681,N,,,,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10682,N,,,,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10683,N,,,,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10684,N,,,,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10685,N,,,,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,Intermediate,,,,2107.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10686,N,,,,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,Intermediate,,,,2107.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10687,N,,,,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,Intermediate,,,,2107.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10688,N,,,,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,Intermediate,,,,2107.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10689,N,,,,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,Intermediate,,,,2107.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10690,N,,,,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,Intermediate,,,,2048.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10691,N,,,,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,Intermediate,,,,2048.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10692,N,,,,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,Intermediate,,,,2048.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10693,N,,,,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,Intermediate,,,,2048.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10694,N,,,,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,Intermediate,,,,2385.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10695,N,,,,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,Intermediate,,,,2385.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10696,N,,,,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,Intermediate,,,,2385.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10697,N,,,,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,Intermediate,,,,2385.0,50597,BAO_0000218,A,,17738,In vivo,Rattus norvegicus,10116.0
10698,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,Intermediate,,,,178.0,50597,BAO_0000218,A,,11195,In vivo,Rattus norvegicus,10116.0
10699,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,Intermediate,,,,178.0,50597,BAO_0000218,A,,11195,In vivo,Rattus norvegicus,10116.0
10700,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,Intermediate,,,,178.0,50597,BAO_0000218,A,,11195,In vivo,Rattus norvegicus,10116.0
10701,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,Intermediate,,,,955.0,50597,BAO_0000218,A,,11195,In vivo,Rattus norvegicus,10116.0
10702,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,Intermediate,,,,955.0,50597,BAO_0000218,A,,11195,In vivo,Rattus norvegicus,10116.0
10703,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,Intermediate,,,,955.0,50597,BAO_0000218,A,,11195,In vivo,Rattus norvegicus,10116.0
10704,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,Intermediate,,,,948.0,50597,BAO_0000218,A,,11195,In vivo,Rattus norvegicus,10116.0
10705,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,Intermediate,,,,948.0,50597,BAO_0000218,A,,11195,In vivo,Rattus norvegicus,10116.0
10706,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,Intermediate,,,,948.0,50597,BAO_0000218,A,,11195,In vivo,Rattus norvegicus,10116.0
10707,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,Intermediate,,,,2113.0,50597,BAO_0000218,A,,11195,In vivo,Rattus norvegicus,10116.0
10708,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,Intermediate,,,,2113.0,50597,BAO_0000218,A,,11195,In vivo,Rattus norvegicus,10116.0
10709,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,Intermediate,,,,2113.0,50597,BAO_0000218,A,,11195,In vivo,Rattus norvegicus,10116.0
10710,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,Intermediate,,,,2107.0,50597,BAO_0000218,A,,11195,In vivo,Rattus norvegicus,10116.0
10711,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,Intermediate,,,,2107.0,50597,BAO_0000218,A,,11195,In vivo,Rattus norvegicus,10116.0
10712,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,Intermediate,,,,2107.0,50597,BAO_0000218,A,,11195,In vivo,Rattus norvegicus,10116.0
10713,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,Intermediate,,,,2048.0,50597,BAO_0000218,A,,11195,In vivo,Rattus norvegicus,10116.0
10714,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,Intermediate,,,,2048.0,50597,BAO_0000218,A,,11195,In vivo,Rattus norvegicus,10116.0
10715,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,Intermediate,,,,2048.0,50597,BAO_0000218,A,,11195,In vivo,Rattus norvegicus,10116.0
10716,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,Intermediate,,,,2385.0,50597,BAO_0000218,A,,11195,In vivo,Rattus norvegicus,10116.0
10717,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,Intermediate,,,,2385.0,50597,BAO_0000218,A,,11195,In vivo,Rattus norvegicus,10116.0
10718,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,Intermediate,,,,2385.0,50597,BAO_0000218,A,,11195,In vivo,Rattus norvegicus,10116.0
10719,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,Intermediate,,,,14.0,50597,BAO_0000218,A,,11195,In vivo,Rattus norvegicus,10116.0
10720,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,Intermediate,,,,14.0,50597,BAO_0000218,A,,11195,In vivo,Rattus norvegicus,10116.0
10721,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,Intermediate,,,,14.0,50597,BAO_0000218,A,,11195,In vivo,Rattus norvegicus,10116.0
10722,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,Intermediate,,,,2106.0,50597,BAO_0000218,A,,11195,In vivo,Rattus norvegicus,10116.0
10723,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,Intermediate,,,,2106.0,50597,BAO_0000218,A,,11195,In vivo,Rattus norvegicus,10116.0
10724,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6193,In vivo,Rattus norvegicus,10116.0
10725,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6803,In vivo,Rattus norvegicus,10116.0
10726,N,,,,Oral bioavailability in rats at 6 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6647,In vivo,Rattus norvegicus,10116.0
10727,N,,,,Oral bioavailability in rat (dose 6 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,6647,In vivo,Rattus norvegicus,10116.0
10728,N,,,,Oral bioavailability in rats at 6 mg/kg dose; Not tested,Intermediate,,,,,50597,BAO_0000218,A,,6647,In vivo,Rattus norvegicus,10116.0
10729,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6640,In vivo,Rattus norvegicus,10116.0
10730,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6641,In vivo,Rattus norvegicus,10116.0
10731,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6641,In vivo,Rattus norvegicus,10116.0
10732,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6642,In vivo,Rattus norvegicus,10116.0
10733,N,,,,Oral bioavailability,Intermediate,,,,,50597,BAO_0000218,A,,5472,In vivo,Rattus norvegicus,10116.0
10734,N,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,6141,In vivo,Rattus norvegicus,10116.0
10735,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,4390,In vivo,Rattus norvegicus,10116.0
10736,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5472,In vivo,Rattus norvegicus,10116.0
10737,N,,,,Oral bioavailability was evaluated; Not tested,Intermediate,,,,,50597,BAO_0000218,A,,5472,In vivo,Rattus norvegicus,10116.0
10738,N,,,,Oral bioavailability,Intermediate,,,,,50597,BAO_0000218,A,,5438,In vivo,Rattus norvegicus,10116.0
10739,N,,,,Oral bioavailability in rat by oral dosing,Intermediate,,,,,50597,BAO_0000218,A,,4883,In vivo,Rattus norvegicus,10116.0
10740,N,,,,Oral bioavailability in rat (dose 10 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,1908,In vivo,Rattus norvegicus,10116.0
10741,N,,,,Oral bioavailability in rat (Sprague-Dawley),Intermediate,,,,,50597,BAO_0000218,A,,4853,In vivo,Rattus norvegicus,10116.0
10742,N,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),Intermediate,,,,,50597,BAO_0000218,A,,4853,In vivo,Rattus norvegicus,10116.0
10743,N,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),Intermediate,,,,,50597,BAO_0000218,A,,4853,In vivo,Rattus norvegicus,10116.0
10744,N,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,4853,In vivo,Rattus norvegicus,10116.0
10745,N,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,4853,In vivo,Rattus norvegicus,10116.0
10746,N,,,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,4853,In vivo,Rattus norvegicus,10116.0
10747,N,,,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,4853,In vivo,Rattus norvegicus,10116.0
10748,N,,,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,Intermediate,,,,,50597,BAO_0000218,A,,12873,In vivo,Rattus norvegicus,10116.0
10749,N,,,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,Intermediate,,,,,50597,BAO_0000218,A,,12873,In vivo,Rattus norvegicus,10116.0
10750,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,3169,In vivo,Rattus norvegicus,10116.0
10751,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6305,In vivo,Rattus norvegicus,10116.0
10752,N,,,,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,4762,In vivo,Rattus norvegicus,10116.0
10753,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,17847,In vivo,Rattus norvegicus,10116.0
10754,N,,,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,6211,In vivo,Rattus norvegicus,10116.0
10755,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6011,In vivo,Rattus norvegicus,10116.0
10756,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6317,In vivo,Rattus norvegicus,10116.0
10757,N,,,,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,Intermediate,,,,,50597,BAO_0000218,A,,6644,In vivo,Rattus norvegicus,10116.0
10758,N,,,,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,Intermediate,,,,,50597,BAO_0000218,A,,6644,In vivo,Rattus norvegicus,10116.0
10759,N,,,,Oral bioavailability in rat after oral administration at 13 mg/kg dose,Intermediate,,,,,50597,BAO_0000218,A,,6644,In vivo,Rattus norvegicus,10116.0
10760,N,,,,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,Intermediate,,,,,50597,BAO_0000218,A,,6644,In vivo,Rattus norvegicus,10116.0
10761,N,,,,Oral bioavailability (dose 20 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,6113,In vivo,Rattus norvegicus,10116.0
10762,N,,,,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5937,In vivo,Rattus norvegicus,10116.0
10763,N,,,,Oral bioavailability in rat at 10 mg/kg of the compound,Intermediate,,,,,50597,BAO_0000218,A,,5711,In vivo,Rattus norvegicus,10116.0
10764,N,,,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,Intermediate,,,,,50597,BAO_0000218,A,,17717,In vivo,Rattus norvegicus,10116.0
10765,N,,,,Bioavailability in rat (dose 3 mg/kg i.v.),Intermediate,,,,,50597,BAO_0000218,A,,17717,In vivo,Rattus norvegicus,10116.0
10766,N,,,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,Intermediate,,,,,50597,BAO_0000218,A,,17717,In vivo,Rattus norvegicus,10116.0
10767,N,,,,Oral bioavailability in rat (dose 60 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,17717,In vivo,Rattus norvegicus,10116.0
10768,N,,,,Percent bioavailability (F) in rats after iv administration,Intermediate,,,,,50597,BAO_0000218,A,,4722,In vivo,Rattus norvegicus,10116.0
10769,N,,,,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,4722,In vivo,Rattus norvegicus,10116.0
10770,N,,,,Bioavailability in rat (dose 5 uM/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,4353,In vivo,Rattus norvegicus,10116.0
10771,N,,,,Oral bioavailability,Intermediate,,,,,50597,BAO_0000218,A,,15662,In vivo,Rattus norvegicus,10116.0
10772,N,,,,Bioavailability in rat (dose 2 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,4756,In vivo,Rattus norvegicus,10116.0
10773,N,,,,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,Intermediate,,,,,50597,BAO_0000218,A,,4756,In vivo,Rattus norvegicus,10116.0
10774,N,,,,Oral bioavailability in rat (dose 20 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,3436,In vivo,Rattus norvegicus,10116.0
10775,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,17800,In vivo,Rattus norvegicus,10116.0
10776,N,,,,Percent oral bioavailability evaluated in rat,Intermediate,,,,,50597,BAO_0000218,A,,15762,In vivo,Rattus norvegicus,10116.0
10777,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5089,In vivo,Rattus norvegicus,10116.0
10778,N,,,,Percent oral bioavailability in rat; Not determined,Intermediate,,,,,50597,BAO_0000218,A,,5089,In vivo,Rattus norvegicus,10116.0
10779,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,3185,In vivo,Rattus norvegicus,10116.0
10780,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5145,In vivo,Rattus norvegicus,10116.0
10781,N,,,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),Intermediate,,,,,50597,BAO_0000218,A,,3457,In vivo,Rattus norvegicus,10116.0
10782,N,,,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),Intermediate,,,,,50597,BAO_0000218,A,,3457,In vivo,Rattus norvegicus,10116.0
10783,N,,,,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5983,In vivo,Rattus norvegicus,10116.0
10784,N,,,,Oral bioavailability in rat (dose 20 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,5739,In vivo,Rattus norvegicus,10116.0
10785,N,,,,Cmax at a dose of 30 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,3579,In vivo,Rattus norvegicus,10116.0
10786,U,,,,Cmax in monkeys at a dose of 1 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,17788,In vivo,Simiiformes,314293.0
10787,N,,,,Cmax in rat,Intermediate,,,,,50597,BAO_0000218,A,,14956,In vivo,Rattus norvegicus,10116.0
10788,N,,,,Cmax in rats at a dose of 1 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17788,In vivo,Rattus norvegicus,10116.0
10789,N,,,,Cmax was measured in mice after an oral dose of 50 mg/kg.,Intermediate,,,,,50594,BAO_0000218,A,,9750,In vivo,Mus musculus,10090.0
10790,U,,,,"Cmax value at a dose of 12.7 uM/kg, po",Autocuration,,,,,22224,BAO_0000218,A,,12767,In vivo,,
10791,U,,,,"Cmax value at a dose of 6.3 uM/kg, iv",Autocuration,,,,,22224,BAO_0000218,A,,12767,In vivo,,
10792,U,,,,"Cmax value at a dose of 7.1 uM/kg, iv",Autocuration,,,,,22224,BAO_0000218,A,,12767,In vivo,,
10793,U,,,,Cmax value of compound was determined after 1 hr,Autocuration,,,,,22224,BAO_0000218,A,,12703,In vivo,,
10794,U,,,,Cmax value of the compound,Autocuration,,,,,22224,BAO_0000218,A,,15778,In vivo,,
10795,N,,,,Cmax value administered intraintestinal in rats.,Intermediate,,,,,50597,BAO_0000218,A,,12818,In vivo,Rattus norvegicus,10116.0
10796,N,,,,Cmax value administered perorally was determined in rat; Not determined,Intermediate,,,,,50597,BAO_0000218,A,,14964,In vivo,Rattus norvegicus,10116.0
10797,U,,,,Cmax value at the dose of 2.3 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,15808,In vivo,,
10798,U,,,,Cmax value at the dose of 5 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,15808,In vivo,,
10799,U,,,,Cmax value in the period of 8 hr after dosing. ,Autocuration,,,,,22224,BAO_0000218,A,,15778,In vivo,,
10800,U,,,,Cmax value at a oral dose of 20 mg/kg; Not tested,Autocuration,,,,,22224,BAO_0000218,A,,3715,In vivo,,
10801,U,,,,Cmax value at a oral dose of 20 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,3715,In vivo,,
10802,N,,,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,Intermediate,,,,,50597,BAO_0000218,A,,1446,In vivo,Rattus norvegicus,10116.0
10803,N,,,,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,Intermediate,,,,,50512,BAO_0000218,A,,15240,In vivo,Cavia porcellus,10141.0
10804,N,,,,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,Intermediate,,,,,50597,BAO_0000218,A,,15240,In vivo,Rattus norvegicus,10116.0
10805,N,,,,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14810,In vivo,Rattus norvegicus,10116.0
10806,N,,,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,Intermediate,,,,1969.0,50594,BAO_0000218,A,,14239,In vivo,Mus musculus,10090.0
10807,N,,,,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,Intermediate,,,,2107.0,50588,BAO_0000218,A,,12555,In vivo,Canis lupus familiaris,9615.0
10808,N,,,,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,Intermediate,,,,,50588,BAO_0000218,A,,10754,In vivo,Canis lupus familiaris,9615.0
10809,N,,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,Intermediate,,,,178.0,50594,BAO_0000218,A,,10754,In vivo,Mus musculus,10090.0
10810,N,,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,Intermediate,,,,178.0,50594,BAO_0000218,A,,10754,In vivo,Mus musculus,10090.0
10811,N,,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,Intermediate,,,,178.0,50594,BAO_0000218,A,,10754,In vivo,Mus musculus,10090.0
10812,N,,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,Intermediate,,,,178.0,50594,BAO_0000218,A,,10754,In vivo,Mus musculus,10090.0
10813,N,,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,Intermediate,,,,178.0,50594,BAO_0000218,A,,10754,In vivo,Mus musculus,10090.0
10814,N,,,,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,Intermediate,,,,,50588,BAO_0000218,F,,14600,In vivo,Canis lupus familiaris,9615.0
10815,N,,,,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,Intermediate,,,,,50588,BAO_0000218,F,,14600,In vivo,Canis lupus familiaris,9615.0
10816,N,,,,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,Intermediate,,,,,50588,BAO_0000218,F,,14600,In vivo,Canis lupus familiaris,9615.0
10817,N,,,,Bioavailability as maximal plasma concentration in dogs,Intermediate,,,,1969.0,50588,BAO_0000218,A,,13543,In vivo,Canis lupus familiaris,9615.0
10818,N,,,,Bioavailability as maximal plasma concentration in dogs,Intermediate,,,,1969.0,50588,BAO_0000218,A,,13543,In vivo,Canis lupus familiaris,9615.0
10819,N,,,,Bioavailability as maximal plasma concentration in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,13543,In vivo,Rattus norvegicus,10116.0
10820,U,,,,Bioavailability as maximal plasma concentration in rats,Autocuration,,,,1969.0,22224,BAO_0000218,A,,13543,In vivo,Rattus norvegicus,10116.0
10821,N,,,,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Intermediate,,,,178.0,50588,BAO_0000218,A,,14600,In vivo,Canis lupus familiaris,9615.0
10822,N,,,,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Intermediate,,,,178.0,50588,BAO_0000218,A,,14600,In vivo,Canis lupus familiaris,9615.0
10823,N,,,,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Intermediate,,,,178.0,50588,BAO_0000218,A,,14600,In vivo,Canis lupus familiaris,9615.0
10824,N,,,,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,Intermediate,,,,178.0,50588,BAO_0000218,A,,14600,In vivo,Canis lupus familiaris,9615.0
10825,N,,,,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Intermediate,,,,178.0,50588,BAO_0000218,A,,14600,In vivo,Canis lupus familiaris,9615.0
10826,N,,,,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Intermediate,,,,178.0,50588,BAO_0000218,A,,14600,In vivo,Canis lupus familiaris,9615.0
10827,N,,,,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,Intermediate,,,,,50597,BAO_0000218,A,,14681,In vivo,Rattus norvegicus,10116.0
10828,U,,,,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,15905,In vivo,,
10829,U,,,,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,Autocuration,,,,1969.0,22224,BAO_0000218,A,,15905,In vivo,,
10830,N,,,,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",Intermediate,,,,1969.0,50597,BAO_0000218,A,,13304,In vivo,Rattus norvegicus,10116.0
10831,N,,,,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15137,In vivo,Rattus norvegicus,10116.0
10832,N,,,,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15137,In vivo,Rattus norvegicus,10116.0
10833,N,,,,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15137,In vivo,Rattus norvegicus,10116.0
10834,N,,,,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15137,In vivo,Rattus norvegicus,10116.0
10835,N,,,,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15137,In vivo,Rattus norvegicus,10116.0
10836,N,,,,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,Intermediate,,,,1969.0,100710,BAO_0000218,A,,14839,In vivo,Macaca fascicularis,9541.0
10837,N,,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Intermediate,,,,1969.0,50594,BAO_0000218,A,,14839,In vivo,Mus musculus,10090.0
10838,N,,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Intermediate,,,,1969.0,50594,BAO_0000218,A,,14839,In vivo,Mus musculus,10090.0
10839,N,,,,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,Intermediate,,,,1969.0,100710,BAO_0000218,A,,14839,In vivo,Macaca fascicularis,9541.0
10840,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10841,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10842,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10843,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10844,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10845,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10846,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10847,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10848,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10849,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10850,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10851,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10852,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10853,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10854,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10855,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10856,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10857,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10858,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10859,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10860,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10861,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10862,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10863,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10864,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10865,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10866,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10867,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10868,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10869,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10870,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10871,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10872,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10873,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10874,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10875,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10876,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10877,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10878,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10879,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10880,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10881,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10882,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
10883,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
10884,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
10885,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
10886,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
10887,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
10888,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
10889,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
10890,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
10891,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
10892,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
10893,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
10894,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
10895,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
10896,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
10897,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
10898,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
10899,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
10900,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
10901,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
10902,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
10903,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
10904,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
10905,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
10906,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
10907,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
10908,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
10909,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
10910,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
10911,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
10912,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
10913,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
10914,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
10915,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
10916,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
10917,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
10918,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
10919,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
10920,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
10921,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
10922,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
10923,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
10924,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
10925,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
10926,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
10927,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
10928,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
10929,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
10930,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
10931,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
10932,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
10933,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
10934,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
10935,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
10936,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
10937,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
10938,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
10939,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
10940,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
10941,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
10942,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
10943,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
10944,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
10945,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
10946,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
10947,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
10948,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
10949,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
10950,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
10951,N,,,,Compound was evaluated for its bioavailability in the dogs,Intermediate,,,,,50588,BAO_0000218,A,,2249,In vivo,Canis lupus familiaris,9615.0
10952,N,,,,Compound was evaluated for its bioavailability in the rats,Intermediate,,,,,50597,BAO_0000218,A,,2249,In vivo,Rattus norvegicus,10116.0
10953,U,,,,Compound was evaluated for oral bioavailability,Autocuration,,,,,22224,BAO_0000218,A,,17515,In vivo,,
10954,N,,,,Compound was evaluated for percentage of Oral bioavailability in rats,Intermediate,,,,,50597,BAO_0000218,A,,14541,In vivo,Rattus norvegicus,10116.0
10955,U,,,,Bioavailability in guinea pig,Autocuration,,,,,22224,BAO_0000218,A,,12797,In vivo,Cavia porcellus,10141.0
10956,N,,,,Compound was evaluated for the oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,12797,In vivo,Rattus norvegicus,10116.0
10957,N,,,,Compound was evaluated for the oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,12797,In vivo,Canis lupus familiaris,9615.0
10958,N,,,,Compound was evaluated for the oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,12797,In vivo,Rattus norvegicus,10116.0
10959,U,,,,Bioavailability in dog (dosed i.v.),Autocuration,,,,,22224,BAO_0000218,F,,11727,In vivo,Canis lupus familiaris,9615.0
10960,N,,,,Compound was tested for in vivo bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,13249,In vivo,Canis lupus familiaris,9615.0
10961,N,,,,Compound was tested for in vivo bioavailability in hamsters,Intermediate,,,,,100712,BAO_0000218,A,,13249,In vivo,Cricetinae,10026.0
10962,U,,,,Compound was tested for in vivo bioavailability in monkey,Autocuration,,,,,22224,BAO_0000218,A,,13249,In vivo,Simiiformes,314293.0
10963,N,,,,Compound was tested for in vivo bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,13249,In vivo,Rattus norvegicus,10116.0
10964,U,,,,Oral bioavailability in mouse,Autocuration,,,,,22224,BAO_0000218,A,,9552,In vivo,Mus musculus,10090.0
10965,N,,,,Compound was tested for percent of oral bioavailability in mice; 56-74,Intermediate,,,,,50594,BAO_0000218,A,,9552,In vivo,Mus musculus,10090.0
10966,U,,,,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),Autocuration,,,,,22224,BAO_0000218,A,,14839,In vivo,Mus musculus,10090.0
10967,U,,,,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),Autocuration,,,,,22224,BAO_0000218,A,,14839,In vivo,Macaca fascicularis,9541.0
10968,U,,,,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),Autocuration,,,,,22224,BAO_0000218,A,,14839,In vivo,Macaca fascicularis,9541.0
10969,N,,,,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),Intermediate,,,,,50594,BAO_0000218,A,,14839,In vivo,Mus musculus,10090.0
10970,N,,,,Oral bioavailability in nude mice,Intermediate,,,,,50594,BAO_0000218,A,,14839,In vivo,Mus musculus,10090.0
10971,U,,,,Bioavailability in monkey (i.d. dosing),Autocuration,,,,,22224,BAO_0000218,A,,11219,In vivo,Primates,9443.0
10972,U,,,,Bioavailability in rat,Autocuration,,,,,22224,BAO_0000218,A,,9552,In vivo,Rattus norvegicus,10116.0
10973,U,,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,Autocuration,,,,,22224,BAO_0000218,A,,11732,In vivo,,
10974,U,,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,Autocuration,,,,,22224,BAO_0000218,A,,11732,In vivo,,
10975,N,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",Intermediate,,,,,100710,BAO_0000218,A,,14839,In vivo,Macaca fascicularis,9541.0
10976,N,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",Intermediate,,,,,100710,BAO_0000218,A,,14839,In vivo,Macaca fascicularis,9541.0
10977,N,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",Intermediate,,,,,100710,BAO_0000218,A,,14839,In vivo,Macaca fascicularis,9541.0
10978,N,,,,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,Intermediate,,,,1969.0,100710,BAO_0000218,A,,14839,In vivo,Macaca fascicularis,9541.0
10979,N,,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Intermediate,,,,1969.0,50594,BAO_0000218,A,,14839,In vivo,Mus musculus,10090.0
10980,N,,,,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,Intermediate,,,,1969.0,100710,BAO_0000218,A,,14839,In vivo,Macaca fascicularis,9541.0
10981,N,,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Intermediate,,,,1969.0,50594,BAO_0000218,A,,14839,In vivo,Mus musculus,10090.0
10982,N,,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Intermediate,,,,1969.0,50594,BAO_0000218,A,,14839,In vivo,Mus musculus,10090.0
10983,N,,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Intermediate,,,,1969.0,50594,BAO_0000218,A,,14839,In vivo,Mus musculus,10090.0
10984,U,,,,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,Autocuration,,,,1969.0,22224,BAO_0000218,A,,13932,In vivo,,
10985,N,,,,Cmax in mouse plasma,Intermediate,,,,1969.0,50594,BAO_0000218,A,,11637,In vivo,Mus musculus,10090.0
10986,U,,,,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,Autocuration,,,,1969.0,22224,BAO_0000218,A,,11637,In vivo,,
10987,N,,,,Maximal plasma concentration in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,13960,In vivo,Rattus norvegicus,10116.0
10988,N,,,,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15905,In vivo,Rattus norvegicus,10116.0
10989,N,,,,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,14062,In vivo,Rattus norvegicus,10116.0
10990,N,,,,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,14062,In vivo,Rattus norvegicus,10116.0
10991,N,,,,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,14062,In vivo,Rattus norvegicus,10116.0
10992,N,,,,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,14062,In vivo,Rattus norvegicus,10116.0
10993,N,,,,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,14062,In vivo,Rattus norvegicus,10116.0
10994,N,,,,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,14062,In vivo,Rattus norvegicus,10116.0
10995,N,,,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,15011,In vivo,Mus musculus,10090.0
10996,N,,,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,15011,In vivo,Mus musculus,10090.0
10997,N,,,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),Intermediate,,,,,50594,BAO_0000218,A,,15011,In vivo,Mus musculus,10090.0
10998,N,,,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,15011,In vivo,Mus musculus,10090.0
10999,N,,,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,15011,In vivo,Mus musculus,10090.0
11000,U,,,,Maximum Concentration of the compound.,Autocuration,,,,,22224,BAO_0000218,A,,10291,In vivo,,
11001,N,,,,Maximum Concentration was measured after iv administration into Beagle dog,Intermediate,,,,,50588,BAO_0000218,A,,14599,In vivo,Canis lupus familiaris,9615.0
11002,N,,,,Maximum Concentration was measured after iv administration into Beagle dog.,Intermediate,,,,,50588,BAO_0000218,A,,14599,In vivo,Canis lupus familiaris,9615.0
11003,N,,,,Maximum Concentration was measured after po administration into Beagle dog,Intermediate,,,,,50588,BAO_0000218,A,,14599,In vivo,Canis lupus familiaris,9615.0
11004,N,,,,Maximum Concentration was measured after po administration into Beagle dog.,Intermediate,,,,,50588,BAO_0000218,A,,14599,In vivo,Canis lupus familiaris,9615.0
11005,U,,,,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,Autocuration,,,,178.0,22224,BAO_0000218,A,,12767,In vivo,,
11006,U,,,,Maximum blood level reached after an iv dose of 12.2 uM/kg,Autocuration,,,,178.0,22224,BAO_0000218,A,,12767,In vivo,,
11007,U,,,,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,Autocuration,,,,178.0,22224,BAO_0000218,A,,12767,In vivo,,
11008,U,,,,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,Autocuration,,,,178.0,22224,BAO_0000218,A,,12767,In vivo,,
11009,U,,,,Maximum blood level reached after an oral dose of 5.0 mg/kg,Autocuration,,,,178.0,22224,BAO_0000218,A,,12767,In vivo,,
11010,U,,,,Maximum blood level reached at dose of 10.6 uM/kg orally,Autocuration,,,,178.0,22224,BAO_0000218,A,,12767,In vivo,,
11011,N,,,,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,Intermediate,,,,,50512,BAO_0000218,A,,14706,In vivo,Cavia porcellus,10141.0
11012,N,,,,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,Intermediate,,,,,50512,BAO_0000218,A,,14706,In vivo,Cavia porcellus,10141.0
11013,N,,,,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,Intermediate,,,,955.0,50597,BAO_0000218,A,,14793,In vivo,Rattus norvegicus,10116.0
11014,N,,,,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,Intermediate,,,,955.0,50597,BAO_0000218,A,,14793,In vivo,Rattus norvegicus,10116.0
11015,N,,,,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,Intermediate,,,,955.0,50597,BAO_0000218,A,,14793,In vivo,Rattus norvegicus,10116.0
11016,N,,,,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,Intermediate,,,,955.0,50597,BAO_0000218,A,,14793,In vivo,Rattus norvegicus,10116.0
11017,N,,,,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,14793,In vivo,Rattus norvegicus,10116.0
11018,N,,,,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,14793,In vivo,Rattus norvegicus,10116.0
11019,N,,,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,14793,In vivo,Rattus norvegicus,10116.0
11020,N,,,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,14793,In vivo,Rattus norvegicus,10116.0
11021,N,,,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),Intermediate,,,,,50278,BAO_0000218,A,,10524,In vivo,Bacillus subtilis,1423.0
11022,U,,,,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11871,In vivo,Simiiformes,314293.0
11023,N,,,,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,11871,In vivo,Rattus norvegicus,10116.0
11024,U,,,,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,Autocuration,,,,,22224,BAO_0000218,A,,3437,In vivo,,
11025,N,,,,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,12038,In vivo,Mus musculus,10090.0
11026,N,,,,Maximum concentration in male rats after iv administration of 20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,12038,In vivo,Rattus norvegicus,10116.0
11027,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
11028,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
11029,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
11030,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
11031,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
11032,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
11033,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
11034,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
11035,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
11036,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
11037,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
11038,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
11039,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
11040,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
11041,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
11042,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
11043,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
11044,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
11045,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
11046,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
11047,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
11048,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
11049,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
11050,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
11051,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
11052,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
11053,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
11054,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
11055,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
11056,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
11057,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
11058,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
11059,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
11060,N,,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,Intermediate,,,,,50597,BAO_0000218,A,,9796,,Rattus norvegicus,10116.0
11061,N,,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,,,,,50597,BAO_0000218,A,,9796,,Rattus norvegicus,10116.0
11062,N,,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,Intermediate,,,,,50597,BAO_0000218,A,,9796,,Rattus norvegicus,10116.0
11063,N,,,,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,,,,,50597,BAO_0000218,A,,9796,,Rattus norvegicus,10116.0
11064,N,,,,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,,,,,50597,BAO_0000218,A,,9796,,Rattus norvegicus,10116.0
11065,N,,,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9796,,Rattus norvegicus,10116.0
11066,N,,,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9796,,Rattus norvegicus,10116.0
11067,N,,,,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9796,,Rattus norvegicus,10116.0
11068,N,,,,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9796,,Rattus norvegicus,10116.0
11069,N,,,,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9796,,Rattus norvegicus,10116.0
11070,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
11071,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
11072,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
11073,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
11074,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
11075,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
11076,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
11077,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
11078,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
11079,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
11080,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
11081,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
11082,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
11083,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
11084,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
11085,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
11086,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
11087,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
11088,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
11089,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
11090,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
11091,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
11092,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
11093,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
11094,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
11095,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
11096,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
11097,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
11098,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
11099,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
11100,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
11101,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
11102,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
11103,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
11104,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
11105,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
11106,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
11107,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
11108,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
11109,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
11110,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
11111,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
11112,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
11113,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
11114,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
11115,U,,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,Autocuration,,,,,22224,BAO_0000218,A,,11732,In vivo,,
11116,U,,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,Autocuration,,,,,22224,BAO_0000218,A,,11732,In vivo,,
11117,U,,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,Autocuration,,,,,22224,BAO_0000218,A,,11732,In vivo,,
11118,U,,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,Autocuration,,,,,22224,BAO_0000218,A,,11732,In vivo,,
11119,U,,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,Autocuration,,,,,22224,BAO_0000218,A,,11732,In vivo,,
11120,U,,,,Oral bioavailability in rat (dose 10 mg/kg),Autocuration,,,,,22224,BAO_0000218,A,,13359,In vivo,Rattus norvegicus,10116.0
11121,U,,,,Oral bioavailability in rat (Sprague-Dawley),Autocuration,,,,,22224,BAO_0000218,A,,16618,In vivo,Rattus norvegicus,10116.0
11122,U,,,,Oral bioavailability in rat,Autocuration,,,,,22224,BAO_0000218,A,,13960,In vivo,Rattus norvegicus,10116.0
11123,U,,,,Oral bioavailability in rats was determined in vivo,Autocuration,,,,,22224,BAO_0000218,A,,13917,In vivo,Rattus norvegicus,10116.0
11124,U,,,,Oral bioavailability in dog,Autocuration,,,,,22224,BAO_0000218,A,,14266,In vivo,Canis lupus familiaris,9615.0
11125,U,,,,Oral bioavailability of compound in monkey,Autocuration,,,,,22224,BAO_0000218,A,,12359,In vivo,Simiiformes,314293.0
11126,N,,,,Oral bioavailability of compound in rat,Intermediate,,,,,50597,BAO_0000218,A,,12359,In vivo,Rattus norvegicus,10116.0
11127,U,,,,Bioavailability in rat of PMEA prodrug,Autocuration,,,,,22224,BAO_0000218,A,,12359,In vivo,Rattus norvegicus,10116.0
11128,N,,,,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,Intermediate,,,,,50597,BAO_0000218,A,,12359,In vivo,Rattus norvegicus,10116.0
11129,U,,,,Serum conc at 3 hours following 25 mg/kg dose,Autocuration,,,,,22224,BAO_0000218,A,,10791,In vivo,Macaca mulatta,9544.0
11130,U,,,,Urine conc 0-5 hours following 25 mg/kg dose,Autocuration,,,,1088.0,22224,BAO_0000218,A,,10791,In vivo,Macaca mulatta,9544.0
11131,U,,,,Urine conc 0-24 hours following 25 mg/kg dose,Autocuration,,,,1088.0,22224,BAO_0000218,A,,10791,In vivo,Macaca mulatta,9544.0
11132,U,,,,Oral bioavailability in African green monkeys; 20-25,Autocuration,,,,,22224,BAO_0000218,A,,138,In vivo,Chlorocebus aethiops,9534.0
11133,N,,,,Oral bioavailability in cynomolgus monkey.,Intermediate,,,,,100710,BAO_0000218,A,,14521,In vivo,Macaca fascicularis,9541.0
11134,U,,,,Oral bioavailability in dog,Autocuration,,,,,22224,BAO_0000218,A,,13953,In vivo,Canis lupus familiaris,9615.0
11135,N,,,,Oral bioavailability in dog at 10 mg/kg oral dose,Intermediate,,,,,50588,BAO_0000218,A,,12836,In vivo,Canis lupus familiaris,9615.0
11136,N,,,,Oral bioavailability in hamster at 10 mg/kg oral dose,Intermediate,,,,,100712,BAO_0000218,A,,12836,In vivo,Cricetinae,10026.0
11137,N,,,,Oral bioavailability in rat at 10 mg/kg oral dose,Intermediate,,,,,50597,BAO_0000218,A,,12836,In vivo,Rattus norvegicus,10116.0
11138,U,,,,Oral bioavailability in rat,Autocuration,,,,,22224,BAO_0000218,A,,14521,In vivo,Rattus norvegicus,10116.0
11139,U,,,,Oral bioavailability in rat,Autocuration,,,,,22224,BAO_0000218,A,,13953,In vivo,Rattus norvegicus,10116.0
11140,U,,,,Oral bioavailability,Autocuration,,,,,22224,BAO_0000218,A,,6799,In vivo,Eutheria,9347.0
11141,U,,,,Oral bioavailability was determined; range 49-102%,Autocuration,,,,,22224,BAO_0000218,A,,11311,In vivo,,
11142,N,,,,Oral bioavailability was determined in dogs,Intermediate,,,,,50588,BAO_0000218,A,,4013,In vivo,Canis lupus familiaris,9615.0
11143,U,,,,Oral bioavailability in rat,Autocuration,,,,,22224,BAO_0000218,A,,4013,In vivo,Rattus norvegicus,10116.0
11144,U,,,,Oral bioavailability,Autocuration,,,,,22224,BAO_0000218,A,,17591,In vivo,Eutheria,9347.0
11145,U,,,,Oral bioavailability was determined; Not orally available,Autocuration,,,,,22224,BAO_0000218,A,,17591,In vivo,,
11146,N,,,,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),Intermediate,,,,,50594,BAO_0000218,A,,15011,In vivo,Mus musculus,10090.0
11147,U,,,,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),Autocuration,,,,,22224,BAO_0000218,A,,15011,In vivo,Mus musculus,10090.0
11148,U,,,,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,15011,In vivo,Mus musculus,10090.0
11149,U,,,,Oral bioavailability in Rhesus monkey,Autocuration,,,,,22224,BAO_0000218,A,,9552,In vivo,Macaca mulatta,9544.0
11150,U,,,,Oral bioavailability in dog (female mongrel),Autocuration,,,,,22224,BAO_0000218,A,,9552,In vivo,Canis lupus familiaris,9615.0
11151,U,,,,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,Autocuration,,,,,22224,BAO_0000218,A,,3639,In vivo,,
11152,U,,,,Oral bioavailability in dog,Autocuration,,,,,22224,BAO_0000218,A,,13397,In vivo,Canis lupus familiaris,9615.0
11153,U,,,,Percentage Bioavailability was evaluated.,Autocuration,,,,,22224,BAO_0000218,A,,3031,In vivo,,
11154,U,,,,Bioavailability in rat administered i.d.,Autocuration,,,,,22224,BAO_0000218,A,,12818,In vivo,Rattus norvegicus,10116.0
11155,U,,,,Bioavailability,Autocuration,,,,,22224,BAO_0000218,A,,4847,In vivo,Eutheria,9347.0
11156,U,,,,Bioavailability in dog (male Beagle) i.v. administration,Autocuration,,,,,22224,BAO_0000218,A,,12421,In vivo,Canis lupus familiaris,9615.0
11157,U,,,,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",Autocuration,,,,,22224,BAO_0000218,A,,11966,In vivo,Rattus norvegicus,10116.0
11158,U,,,,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),Autocuration,,,,,22224,BAO_0000218,A,,11218,In vivo,Primates,9443.0
11159,U,,,,Oral bioavailability in rat (Sprague-Dawley) (male),Autocuration,,,,,22224,BAO_0000218,A,,13129,In vivo,Rattus norvegicus,10116.0
11160,N,,,,The oral bioavailability was measured on rats after oral administration,Intermediate,,,,,50597,BAO_0000218,A,,12350,In vivo,Rattus norvegicus,10116.0
11161,N,,,,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,2231,In vivo,Rattus norvegicus,10116.0
11162,N,,,,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,Intermediate,,,,,50797,BAO_0000218,A,,2231,In vivo,Macaca mulatta,9544.0
11163,U,,,,Bioavailability in rat (dose 10 mg/kg i.d.),Autocuration,,,,,22224,BAO_0000218,A,,12187,In vivo,Rattus norvegicus,10116.0
11164,U,,,,Bioavailability in dog (male Beagle) i.v. administration,Autocuration,,,,,22224,BAO_0000218,A,,12421,In vivo,Canis lupus familiaris,9615.0
11165,N,,,,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,,50594,BAO_0000218,A,,13256,In vivo,Mus musculus,10090.0
11166,N,,,,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,178.0,50594,BAO_0000218,A,,13256,In vivo,Mus musculus,10090.0
11167,N,,,,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,2037.0,50594,BAO_0000218,A,,13256,In vivo,Mus musculus,10090.0
11168,N,,,,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,,50594,BAO_0000218,A,,13256,In vivo,Mus musculus,10090.0
11169,N,,,,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2231,In vivo,Rattus norvegicus,10116.0
11170,N,,,,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,Intermediate,,,,1969.0,50797,BAO_0000218,A,,2231,In vivo,Macaca mulatta,9544.0
11171,N,,,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),Intermediate,,,,178.0,50597,BAO_0000218,A,,12178,In vivo,Rattus norvegicus,10116.0
11172,U,,,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),Autocuration,,,,178.0,22224,BAO_0000218,A,,12178,In vivo,,
11173,U,,,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),Autocuration,,,,178.0,22224,BAO_0000218,A,,12178,In vivo,,
11174,N,,,,Maximum concentration observed in rats at an oral dose of 50 mg/kg,Expert,,,,,50597,BAO_0000218,A,,15633,In vivo,Rattus norvegicus,10116.0
11175,N,,,,Maximum concentration of compound in plasma administered orally to rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14258,In vivo,Rattus norvegicus,10116.0
11176,N,,,,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",Intermediate,,,,1969.0,50588,BAO_0000218,A,,14224,In vivo,Canis lupus familiaris,9615.0
11177,N,,,,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",Intermediate,,,,1969.0,50588,BAO_0000218,A,,14224,In vivo,Canis lupus familiaris,9615.0
11178,N,,,,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",Intermediate,,,,1969.0,50588,BAO_0000218,A,,14224,In vivo,Canis lupus familiaris,9615.0
11179,U,,,,Maximum concentration after 10 mg/kg by oral administration,Autocuration,,,,,22224,BAO_0000218,A,,5566,In vivo,,
11180,U,,,,Maximum concentration at a dose of 1.5 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,16935,In vivo,,
11181,U,,,,Maximum concentration at a dose of 2.0 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,16935,In vivo,,
11182,N,,,,Maximum concentration in dog plasma,Intermediate,,,,1969.0,50588,BAO_0000218,A,,14224,In vivo,Canis lupus familiaris,9615.0
11183,U,,,,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,Autocuration,,,,1969.0,22224,BAO_0000218,A,,12536,In vivo,,
11184,U,,,,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,Autocuration,,,,1969.0,22224,BAO_0000218,A,,12536,In vivo,,
11185,U,,,,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,Autocuration,,,,1969.0,22224,BAO_0000218,A,,12536,In vivo,,
11186,U,,,,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,Autocuration,,,,1969.0,22224,BAO_0000218,A,,12536,In vivo,,
11187,U,,,,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,Autocuration,,,,1969.0,22224,BAO_0000218,A,,12536,In vivo,,
11188,N,,,,Maximum concentration in plasma after oral administration in dog (25 mg/kg),Intermediate,,,,1969.0,50588,BAO_0000218,A,,9994,In vivo,Canis lupus familiaris,9615.0
11189,U,,,,Maximum concentration in plasma at Tmax,Autocuration,,,,1969.0,22224,BAO_0000218,A,,1434,In vivo,,
11190,N,,,,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,Expert,,,,1969.0,50588,BAO_0000218,A,,12836,In vivo,Canis lupus familiaris,9615.0
11191,N,,,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,Intermediate,,,,1969.0,100712,BAO_0000218,A,,12836,In vivo,Cricetinae,10026.0
11192,N,,,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,Intermediate,,,,1969.0,50597,BAO_0000218,A,,12836,In vivo,Rattus norvegicus,10116.0
11193,N,,,,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,12545,In vivo,Rattus norvegicus,10116.0
11194,N,,,,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,Intermediate,,,,1969.0,50592,BAO_0000218,A,,13856,In vivo,Oryctolagus cuniculus,9986.0
11195,U,,,,Maximum concentration was calculated,Autocuration,,,,,22224,BAO_0000218,A,,3550,In vivo,,
11196,U,,,,Maximum concentration was calculated.,Autocuration,,,,,22224,BAO_0000218,A,,2632,In vivo,,
11197,U,,,,Maximum concentration at a peroral dose of 10 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,5566,In vivo,,
11198,U,,,,Maximum concentration of the drug at 10 uM/dg administered perorally,Autocuration,,,,,22224,BAO_0000218,A,,11883,In vivo,,
11199,U,,,,Maximum concentration of the drug at 2 uM/dg administered intravenously,Autocuration,,,,,22224,BAO_0000218,A,,11883,In vivo,,
11200,N,,,,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",Intermediate,,,,1969.0,50588,BAO_0000218,A,,14122,In vivo,Canis lupus familiaris,9615.0
11201,N,,,,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",Intermediate,,,,1969.0,100712,BAO_0000218,A,,14122,In vivo,Cricetinae,10026.0
11202,N,,,,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",Intermediate,,,,1969.0,50597,BAO_0000218,A,,14122,In vivo,Rattus norvegicus,10116.0
11203,N,,,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,Intermediate,,,,1969.0,50597,BAO_0000218,A,,12542,In vivo,Rattus norvegicus,10116.0
11204,N,,,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,Intermediate,,,,1969.0,50588,BAO_0000218,A,,12542,In vivo,Canis lupus familiaris,9615.0
11205,N,,,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,Intermediate,,,,1969.0,100712,BAO_0000218,A,,12542,In vivo,Cricetinae,10026.0
11206,N,,,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,Intermediate,,,,1969.0,100712,BAO_0000218,A,,12542,In vivo,Cricetinae,10026.0
11207,N,,,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,Intermediate,,,,1969.0,50597,BAO_0000218,A,,12542,In vivo,Rattus norvegicus,10116.0
11208,N,,,,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14080,In vivo,Rattus norvegicus,10116.0
11209,N,,,,Maximum concentration reached following intravenous administration in male rat,Intermediate,,,,,50597,BAO_0000218,A,,11911,In vivo,Rattus norvegicus,10116.0
11210,N,,,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,Intermediate,,,,,50588,BAO_0000218,A,,13204,In vivo,Canis lupus familiaris,9615.0
11211,N,,,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,Intermediate,,,,,50597,BAO_0000218,A,,13204,In vivo,Rattus norvegicus,10116.0
11212,N,,,,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,Intermediate,,,,,50588,BAO_0000218,A,,14346,In vivo,Canis lupus familiaris,9615.0
11213,N,,,,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,14346,In vivo,Rattus norvegicus,10116.0
11214,N,,,,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,14346,In vivo,Rattus norvegicus,10116.0
11215,N,,,,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,14346,In vivo,Rattus norvegicus,10116.0
11216,N,,,,Maximum drug concentration is determined after oral dosing in rats.,Intermediate,,,,,50597,BAO_0000218,A,,14127,In vivo,Rattus norvegicus,10116.0
11217,N,,,,Maximum observed concentration in oral (5 mg/kg) fasted dogs,Intermediate,,,,,50588,BAO_0000218,A,,14339,In vivo,Canis lupus familiaris,9615.0
11218,N,,,,Maximum observed concentration in oral (5 mg/kg) fed dogs,Intermediate,,,,,50588,BAO_0000218,A,,14339,In vivo,Canis lupus familiaris,9615.0
11219,U,,,,Maximum plasma concentration,Autocuration,,,,1969.0,22224,BAO_0000218,A,,13494,In vivo,,
11220,N,,,,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14925,In vivo,Rattus norvegicus,10116.0
11221,N,,,,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14474,In vivo,Rattus norvegicus,10116.0
11222,N,,,,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,14474,In vivo,Canis lupus familiaris,9615.0
11223,U,,,,Maximum plasma concentration following oral administration of 30 umol/kg,Autocuration,,,,1969.0,22224,BAO_0000218,A,,13917,In vivo,,
11224,N,,,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,Intermediate,,,,1969.0,50597,BAO_0000218,A,,9796,,Rattus norvegicus,10116.0
11225,N,,,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,9796,,Rattus norvegicus,10116.0
11226,N,,,,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,9796,,Rattus norvegicus,10116.0
11227,N,,,,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,9796,,Rattus norvegicus,10116.0
11228,N,,,,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,9796,,Rattus norvegicus,10116.0
11229,N,,,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,,,,995.0,50597,BAO_0000218,A,,9796,,Rattus norvegicus,10116.0
11230,N,,,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,Intermediate,,,,995.0,50597,BAO_0000218,A,,9796,,Rattus norvegicus,10116.0
11231,N,,,,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,Intermediate,,,,995.0,50597,BAO_0000218,A,,9796,,Rattus norvegicus,10116.0
11232,N,,,,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,,,,995.0,50597,BAO_0000218,A,,9796,,Rattus norvegicus,10116.0
11233,N,,,,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,,,,995.0,50597,BAO_0000218,A,,9796,,Rattus norvegicus,10116.0
11234,N,,,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),Intermediate,,,,,50597,BAO_0000218,A,,8363,,Rattus norvegicus,10116.0
11235,N,,,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),Intermediate,,,,,50597,BAO_0000218,A,,8363,,Rattus norvegicus,10116.0
11236,N,,,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),Intermediate,,,,,50597,BAO_0000218,A,,8363,,Rattus norvegicus,10116.0
11237,N,,,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),Intermediate,,,,,50597,BAO_0000218,A,,8363,,Rattus norvegicus,10116.0
11238,N,,,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),Intermediate,,,,,50597,BAO_0000218,A,,8363,,Rattus norvegicus,10116.0
11239,N,,,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),Intermediate,,,,,50597,BAO_0000218,A,,8363,,Rattus norvegicus,10116.0
11240,N,,,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),Intermediate,,,,,50597,BAO_0000218,A,,8363,,Rattus norvegicus,10116.0
11241,N,,,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),Intermediate,,,,,50597,BAO_0000218,A,,8363,,Rattus norvegicus,10116.0
11242,N,,,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),Intermediate,,,,,50597,BAO_0000218,A,,8363,,Rattus norvegicus,10116.0
11243,N,,,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),Intermediate,,,,,50597,BAO_0000218,A,,8363,,Rattus norvegicus,10116.0
11244,N,,,,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),Intermediate,,,,,50597,BAO_0000218,A,,8363,,Rattus norvegicus,10116.0
11245,N,,,,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),Intermediate,,,,,50597,BAO_0000218,A,,8363,,Rattus norvegicus,10116.0
11246,N,,,,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",Intermediate,,,,178.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11247,N,,,,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",Intermediate,,,,178.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11248,N,,,,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",Intermediate,,,,178.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11249,N,,,,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",Intermediate,,,,178.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11250,N,,,,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",Intermediate,,,,178.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11251,N,,,,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",Intermediate,,,,178.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11252,N,,,,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",Intermediate,,,,178.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11253,N,,,,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",Intermediate,,,,178.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11254,N,,,,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",Intermediate,,,,955.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11255,N,,,,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",Intermediate,,,,955.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11256,N,,,,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",Intermediate,,,,955.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11257,N,,,,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",Intermediate,,,,955.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11258,N,,,,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",Intermediate,,,,955.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11259,N,,,,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",Intermediate,,,,955.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11260,N,,,,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",Intermediate,,,,955.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11261,N,,,,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",Intermediate,,,,955.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11262,N,,,,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11263,N,,,,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11264,N,,,,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11265,N,,,,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11266,N,,,,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11267,N,,,,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11268,N,,,,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11269,N,,,,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11270,N,,,,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11271,N,,,,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11272,N,,,,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11273,N,,,,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11274,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
11275,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
11276,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
11277,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
11278,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
11279,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
11280,N,,,,Observed diffusion coefficient in organic solvent for Escherichia coli,Intermediate,,,,,50212,BAO_0000218,A,,15599,,Escherichia coli,562.0
11281,N,,,,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Intermediate,,,,178.0,50597,BAO_0000218,A,,9614,,Rattus norvegicus,10116.0
11282,N,,,,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Intermediate,,,,178.0,50597,BAO_0000218,A,,9614,,Rattus norvegicus,10116.0
11283,N,,,,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Intermediate,,,,2081.0,50597,BAO_0000218,A,,9614,,Rattus norvegicus,10116.0
11284,N,,,,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Intermediate,,,,2081.0,50597,BAO_0000218,A,,9614,,Rattus norvegicus,10116.0
11285,N,,,,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Intermediate,,,,,50597,BAO_0000218,A,,9614,,Rattus norvegicus,10116.0
11286,N,,,,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Intermediate,,,,,50597,BAO_0000218,A,,9614,,Rattus norvegicus,10116.0
11287,N,,,,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Intermediate,,,,2107.0,50597,BAO_0000218,A,,9614,,Rattus norvegicus,10116.0
11288,N,,,,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Intermediate,,,,2107.0,50597,BAO_0000218,A,,9614,,Rattus norvegicus,10116.0
11289,N,,,,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Intermediate,,,,2081.0,50597,BAO_0000218,A,,9614,,Rattus norvegicus,10116.0
11290,N,,,,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Intermediate,,,,2081.0,50597,BAO_0000218,A,,9614,,Rattus norvegicus,10116.0
11291,N,,,,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Intermediate,,,,,50597,BAO_0000218,A,,9614,,Rattus norvegicus,10116.0
11292,N,,,,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Intermediate,,,,,50597,BAO_0000218,A,,9614,,Rattus norvegicus,10116.0
11293,N,,,,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Intermediate,,,,2106.0,50597,BAO_0000218,A,,9614,,Rattus norvegicus,10116.0
11294,N,,,,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Intermediate,,,,2106.0,50597,BAO_0000218,A,,9614,,Rattus norvegicus,10116.0
11295,N,,,,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,Intermediate,,,,178.0,50597,BAO_0000218,A,,9071,,Rattus norvegicus,10116.0
11296,N,,,,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,Intermediate,,,,178.0,50597,BAO_0000218,A,,9071,,Rattus norvegicus,10116.0
11297,N,,,,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,Intermediate,,,,948.0,50597,BAO_0000218,A,,9071,,Rattus norvegicus,10116.0
11298,N,,,,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,Intermediate,,,,948.0,50597,BAO_0000218,A,,9071,,Rattus norvegicus,10116.0
11299,N,,,,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,Intermediate,,,,948.0,50597,BAO_0000218,A,,9071,,Rattus norvegicus,10116.0
11300,N,,,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9071,,Rattus norvegicus,10116.0
11301,N,,,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9071,,Rattus norvegicus,10116.0
11302,N,,,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9071,,Rattus norvegicus,10116.0
11303,N,,,,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9071,,Rattus norvegicus,10116.0
11304,N,,,,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9071,,Rattus norvegicus,10116.0
11305,N,,,,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9071,,Rattus norvegicus,10116.0
11306,N,,,,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,Intermediate,,,,2048.0,50597,BAO_0000218,A,,9071,,Rattus norvegicus,10116.0
11307,N,,,,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,Intermediate,,,,2048.0,50597,BAO_0000218,A,,9071,,Rattus norvegicus,10116.0
11308,N,,,,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,Intermediate,,,,2048.0,50597,BAO_0000218,A,,9071,,Rattus norvegicus,10116.0
11309,N,,,,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,Intermediate,,,,2048.0,50597,BAO_0000218,A,,9071,,Rattus norvegicus,10116.0
11310,U,,,,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",Autocuration,,,,,22224,BAO_0000218,A,,10677,,,
11311,N,,,,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,Intermediate,,,,1088.0,50594,BAO_0000218,A,,9750,,Mus musculus,10090.0
11312,N,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11313,N,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11314,N,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11315,N,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11316,N,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11317,N,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11318,N,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11319,N,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11320,N,,,,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,,50594,BAO_0000218,A,,13256,In vivo,Mus musculus,10090.0
11321,N,,,,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,2107.0,50594,BAO_0000218,A,,13256,In vivo,Mus musculus,10090.0
11322,N,,,,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,,50594,BAO_0000218,A,,13256,In vivo,Mus musculus,10090.0
11323,N,,,,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,,50594,BAO_0000218,A,,13256,In vivo,Mus musculus,10090.0
11324,N,,,,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,178.0,50594,BAO_0000218,A,,13256,In vivo,Mus musculus,10090.0
11325,N,,,,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,2037.0,50594,BAO_0000218,A,,13256,In vivo,Mus musculus,10090.0
11326,N,,,,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,,50594,BAO_0000218,A,,13256,In vivo,Mus musculus,10090.0
11327,N,,,,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,,50594,BAO_0000218,A,,13256,In vivo,Mus musculus,10090.0
11328,N,,,,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,2107.0,50594,BAO_0000218,A,,13256,In vivo,Mus musculus,10090.0
11329,N,,,,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,,50594,BAO_0000218,A,,13256,In vivo,Mus musculus,10090.0
11330,N,,,,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,,50594,BAO_0000218,A,,13256,In vivo,Mus musculus,10090.0
11331,N,,,,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,178.0,50594,BAO_0000218,A,,13256,In vivo,Mus musculus,10090.0
11332,N,,,,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,2037.0,50594,BAO_0000218,A,,13256,In vivo,Mus musculus,10090.0
11333,N,,,,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,,50594,BAO_0000218,A,,13256,In vivo,Mus musculus,10090.0
11334,N,,,,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,,50594,BAO_0000218,A,,13256,In vivo,Mus musculus,10090.0
11335,N,,,,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,2107.0,50594,BAO_0000218,A,,13256,In vivo,Mus musculus,10090.0
11336,N,,,,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,,50594,BAO_0000218,A,,13256,In vivo,Mus musculus,10090.0
11337,N,,,,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,,50594,BAO_0000218,A,,13256,In vivo,Mus musculus,10090.0
11338,N,,,,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,178.0,50594,BAO_0000218,A,,13256,In vivo,Mus musculus,10090.0
11339,N,,,,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,2037.0,50594,BAO_0000218,A,,13256,In vivo,Mus musculus,10090.0
11340,N,,,,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,,50594,BAO_0000218,A,,13256,In vivo,Mus musculus,10090.0
11341,N,,,,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,,50594,BAO_0000218,A,,13256,In vivo,Mus musculus,10090.0
11342,N,,,,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,2107.0,50594,BAO_0000218,A,,13256,In vivo,Mus musculus,10090.0
11343,N,,,,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,,50594,BAO_0000218,A,,13256,In vivo,Mus musculus,10090.0
11344,N,,,,Biodistribution in Rat blood after 24 hours of iv administration,Intermediate,,,,178.0,50597,BAO_0000218,A,,8829,In vivo,Rattus norvegicus,10116.0
11345,N,,,,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,Intermediate,,,,178.0,50597,BAO_0000218,A,,8829,In vivo,Rattus norvegicus,10116.0
11346,N,,,,Biodistribution in Rat blood after 30 minutes of iv administration,Intermediate,,,,178.0,50597,BAO_0000218,A,,8829,In vivo,Rattus norvegicus,10116.0
11347,N,,,,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,Intermediate,,,,178.0,50597,BAO_0000218,A,,8829,In vivo,Rattus norvegicus,10116.0
11348,N,,,,Biodistribution in Rat blood after 5 minutes of iv administration,Intermediate,,,,178.0,50597,BAO_0000218,A,,8829,In vivo,Rattus norvegicus,10116.0
11349,N,,,,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,Intermediate,,,,178.0,50597,BAO_0000218,A,,8829,In vivo,Rattus norvegicus,10116.0
11350,N,,,,Biodistribution in Rat heart after 24 hours of iv administration,Intermediate,,,,948.0,50597,BAO_0000218,A,,8829,In vivo,Rattus norvegicus,10116.0
11351,N,,,,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,Intermediate,,,,948.0,50597,BAO_0000218,A,,8829,In vivo,Rattus norvegicus,10116.0
11352,N,,,,Biodistribution in Rat heart after 30 minutes of iv administration,Intermediate,,,,948.0,50597,BAO_0000218,A,,8829,In vivo,Rattus norvegicus,10116.0
11353,N,,,,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,Intermediate,,,,948.0,50597,BAO_0000218,A,,8829,In vivo,Rattus norvegicus,10116.0
11354,N,,,,Biodistribution in Rat heart after 5 minutes of iv administration,Intermediate,,,,948.0,50597,BAO_0000218,A,,8829,In vivo,Rattus norvegicus,10116.0
11355,N,,,,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,Intermediate,,,,948.0,50597,BAO_0000218,A,,8829,In vivo,Rattus norvegicus,10116.0
11356,N,,,,Biodistribution in Rat liver after 24 hours of iv administration,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8829,In vivo,Rattus norvegicus,10116.0
11357,N,,,,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8829,In vivo,Rattus norvegicus,10116.0
11358,N,,,,Biodistribution in Rat liver after 30 minutes of iv administration,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8829,In vivo,Rattus norvegicus,10116.0
11359,N,,,,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8829,In vivo,Rattus norvegicus,10116.0
11360,N,,,,Biodistribution in Rat liver after 30 minutes of iv administration,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8829,In vivo,Rattus norvegicus,10116.0
11361,N,,,,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,Intermediate,,,,1969.0,50588,BAO_0000218,A,,13249,In vivo,Canis lupus familiaris,9615.0
11362,N,,,,Cmax in cynomolgus monkey (PO dose),Intermediate,,,,,100710,BAO_0000218,A,,13622,In vivo,Macaca fascicularis,9541.0
11363,N,,,,Cmax in rat (PO dose),Intermediate,,,,,50597,BAO_0000218,A,,13622,In vivo,Rattus norvegicus,10116.0
11364,N,,,,Cmax in rat (PO dose),Intermediate,,,,,50597,BAO_0000218,A,,13622,In vivo,Rattus norvegicus,10116.0
11365,N,,,,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,13494,In vivo,Rattus norvegicus,10116.0
11366,N,,,,Cmax in rat plasma after oral dose (10 mg/kg),Intermediate,,,,1969.0,50597,BAO_0000218,A,,12170,In vivo,Rattus norvegicus,10116.0
11367,U,,,,Cmax in plasma after oral dose (10 mg/kg),Autocuration,,,,1969.0,22224,BAO_0000218,A,,12170,In vivo,,
11368,N,,,,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17025,In vivo,Canis lupus familiaris,9615.0
11369,U,,,,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,Autocuration,,,,1969.0,22224,BAO_0000218,A,,17025,In vivo,Simiiformes,314293.0
11370,N,,,,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,Intermediate,,,,1969.0,50592,BAO_0000218,A,,17025,In vivo,Oryctolagus cuniculus,9986.0
11371,N,,,,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17025,In vivo,Rattus norvegicus,10116.0
11372,N,,,,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14187,In vivo,Rattus norvegicus,10116.0
11373,N,,,,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,Intermediate,,,,1969.0,50594,BAO_0000218,A,,14816,In vivo,Mus musculus,10090.0
11374,N,,,,Maximum plasma concentration after oral dosing in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17820,In vivo,Rattus norvegicus,10116.0
11375,U,,,,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,Autocuration,,,,1969.0,22224,BAO_0000218,A,,14380,In vivo,,
11376,U,,,,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,Autocuration,,,,1969.0,22224,BAO_0000218,A,,14380,In vivo,,
11377,N,,,,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,Intermediate,,,,1969.0,50588,BAO_0000218,A,,14691,In vivo,Canis lupus familiaris,9615.0
11378,N,,,,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,Intermediate,,,,1969.0,50588,BAO_0000218,A,,14691,In vivo,Canis lupus familiaris,9615.0
11379,N,,,,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,13375,In vivo,Rattus norvegicus,10116.0
11380,U,,,,Maximum plasma concentration was determined,Autocuration,,,,1969.0,22224,BAO_0000218,A,,6236,In vivo,,
11381,U,,,,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,Autocuration,,,,1969.0,22224,BAO_0000218,A,,14380,In vivo,,
11382,U,,,,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,Autocuration,,,,1969.0,22224,BAO_0000218,A,,14380,In vivo,,
11383,U,,,,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,Autocuration,,,,1969.0,22224,BAO_0000218,A,,14380,In vivo,,
11384,U,,,,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,Autocuration,,,,1969.0,22224,BAO_0000218,A,,14380,In vivo,,
11385,U,,,,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,Autocuration,,,,1969.0,22224,BAO_0000218,A,,14380,In vivo,,
11386,U,,,,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,Autocuration,,,,1969.0,22224,BAO_0000218,A,,14380,In vivo,,
11387,U,,,,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,Autocuration,,,,1969.0,22224,BAO_0000218,A,,14380,In vivo,,
11388,U,,,,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,Autocuration,,,,1969.0,22224,BAO_0000218,A,,14380,In vivo,,
11389,N,,,,Plasma Cmax in rat (PO dose),Intermediate,,,,1969.0,50597,BAO_0000218,A,,13622,In vivo,Rattus norvegicus,10116.0
11390,N,,,,Maximum serum concentration after po dose of 5.22 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,15372,In vivo,Rattus norvegicus,10116.0
11391,N,,,,Maximum serum concentration after po dose of 5.46 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,15372,In vivo,Rattus norvegicus,10116.0
11392,N,,,,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,15372,In vivo,Rattus norvegicus,10116.0
11393,N,,,,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,15372,In vivo,Rattus norvegicus,10116.0
11394,N,,,,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,Intermediate,,,,1969.0,50588,BAO_0000218,A,,14925,In vivo,Canis lupus familiaris,9615.0
11395,N,,,,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,Intermediate,,,,1969.0,50588,BAO_0000218,A,,14925,In vivo,Canis lupus familiaris,9615.0
11396,U,,,,Maximum concentration of the drug at 1 uM/dg administered intravenously,Autocuration,,,,,22224,BAO_0000218,A,,11883,In vivo,,
11397,U,,,,Maximum concentration of the drug at 20 uM/dg administered perorally,Autocuration,,,,,22224,BAO_0000218,A,,11883,In vivo,,
11398,U,,,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,13391,In vivo,,
11399,U,,,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,Autocuration,,,,178.0,22224,BAO_0000218,A,,13391,In vivo,,
11400,U,,,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,Autocuration,,,,178.0,22224,BAO_0000218,A,,13391,In vivo,,
11401,U,,,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,Autocuration,,,,178.0,22224,BAO_0000218,A,,13391,In vivo,,
11402,N,,,,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,16360,In vivo,Rattus norvegicus,10116.0
11403,N,,,,Cmax in dog plasma after 1mg/kg oral dose,Intermediate,,,,1969.0,50588,BAO_0000218,A,,3673,In vivo,Canis lupus familiaris,9615.0
11404,N,,,,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,Intermediate,,,,1969.0,50588,BAO_0000218,A,,14431,In vivo,Canis lupus familiaris,9615.0
11405,N,,,,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14431,In vivo,Rattus norvegicus,10116.0
11406,N,,,,Oral maximum concentration in rat,Intermediate,,,,,50597,BAO_0000218,A,,14964,In vivo,Rattus norvegicus,10116.0
11407,N,,,,Oral maximum concentration in rat,Intermediate,,,,,50597,BAO_0000218,A,,14964,In vivo,Rattus norvegicus,10116.0
11408,N,,,,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,Intermediate,,,,1969.0,50594,BAO_0000218,A,,14209,In vivo,Mus musculus,10090.0
11409,N,,,,Peak concentration in blood after intravenous administration to mice,Intermediate,,,,178.0,50594,BAO_0000218,A,,11355,In vivo,Mus musculus,10090.0
11410,N,,,,Peak concentration in blood after peroral administration to mice,Intermediate,,,,178.0,50594,BAO_0000218,A,,11355,In vivo,Mus musculus,10090.0
11411,N,,,,Peak concentration in rat plasma was determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,11966,In vivo,Rattus norvegicus,10116.0
11412,U,,,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,Autocuration,,,,1969.0,22224,BAO_0000218,A,,8918,In vivo,Simiiformes,314293.0
11413,N,,,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,Intermediate,,,,1969.0,50594,BAO_0000218,A,,8918,In vivo,Mus musculus,10090.0
11414,N,,,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,8918,In vivo,Rattus norvegicus,10116.0
11415,N,,,,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11416,N,,,,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11417,N,,,,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11418,N,,,,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11419,N,,,,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",Intermediate,,,,160.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11420,N,,,,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",Intermediate,,,,160.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11421,N,,,,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",Intermediate,,,,160.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11422,N,,,,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",Intermediate,,,,160.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11423,N,,,,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",Intermediate,,,,160.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11424,N,,,,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",Intermediate,,,,160.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11425,N,,,,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",Intermediate,,,,160.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11426,N,,,,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",Intermediate,,,,160.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11427,N,,,,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11428,N,,,,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11429,N,,,,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11430,N,,,,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11431,N,,,,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11432,N,,,,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11433,N,,,,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11434,N,,,,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11435,N,,,,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11436,N,,,,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11437,N,,,,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11438,N,,,,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11439,N,,,,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11440,N,,,,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11441,N,,,,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11442,N,,,,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11443,N,,,,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11444,N,,,,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11445,N,,,,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11446,N,,,,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11447,N,,,,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11448,N,,,,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11449,N,,,,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11450,N,,,,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11451,N,,,,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",Intermediate,,,,2385.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11452,N,,,,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",Intermediate,,,,2385.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11453,N,,,,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",Intermediate,,,,2385.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11454,N,,,,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",Intermediate,,,,2385.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11455,N,,,,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",Intermediate,,,,2385.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11456,N,,,,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",Intermediate,,,,2385.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11457,N,,,,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",Intermediate,,,,2385.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11458,N,,,,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",Intermediate,,,,2385.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11459,N,,,,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11460,N,,,,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11461,N,,,,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11462,N,,,,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11463,N,,,,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11464,N,,,,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11465,N,,,,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11466,N,,,,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11467,N,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11468,N,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11469,N,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11470,N,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11471,N,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11472,N,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11473,N,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11474,N,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11475,N,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11476,N,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11477,N,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11478,N,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11479,N,,,,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,Intermediate,,,,1088.0,50594,BAO_0000218,A,,14571,,Mus musculus,10090.0
11480,N,,,,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,Intermediate,,,,1088.0,50597,BAO_0000218,A,,14571,,Rattus norvegicus,10116.0
11481,N,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11482,N,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11483,N,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11484,N,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11485,N,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11486,N,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11487,N,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11488,N,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11489,N,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11490,N,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11491,N,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11492,N,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11493,N,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11494,N,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11495,N,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11496,N,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11497,N,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11498,N,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11499,N,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11500,N,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,Rattus norvegicus,10116.0
11501,N,,,,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12064,,Rattus norvegicus,10116.0
11502,N,,,,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12064,,Rattus norvegicus,10116.0
11503,N,,,,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12064,,Rattus norvegicus,10116.0
11504,N,,,,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12038,,Rattus norvegicus,10116.0
11505,U,,,,% dose converted to 2-amino-5-chlorophenyl sulfate,Autocuration,,,,,22224,BAO_0000019,A,,14314,,,
11506,U,,,,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),Autocuration,,,,,22224,BAO_0000019,A,,14314,,,
11507,N,,,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",Intermediate,,,,1988.0,50597,BAO_0000218,A,,11488,,Rattus norvegicus,10116.0
11508,N,,,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",Intermediate,,,,1988.0,50597,BAO_0000218,A,,11488,,Rattus norvegicus,10116.0
11509,N,,,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",Intermediate,,,,1988.0,50597,BAO_0000218,A,,11488,,Rattus norvegicus,10116.0
11510,N,,,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",Intermediate,,,,1988.0,50597,BAO_0000218,A,,11488,,Rattus norvegicus,10116.0
11511,N,,,,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8829,In vivo,Rattus norvegicus,10116.0
11512,N,,,,Biodistribution in Rat liver after 5 minutes of iv administration,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8829,In vivo,Rattus norvegicus,10116.0
11513,N,,,,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8829,In vivo,Rattus norvegicus,10116.0
11514,N,,,,Biodistribution in Rat lung after 24 hours of iv administration,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8829,In vivo,Rattus norvegicus,10116.0
11515,N,,,,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8829,In vivo,Rattus norvegicus,10116.0
11516,N,,,,Biodistribution in Rat lung after 30 minutes of iv administration,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8829,In vivo,Rattus norvegicus,10116.0
11517,N,,,,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8829,In vivo,Rattus norvegicus,10116.0
11518,N,,,,Biodistribution in Rat lung after 5 minutes of iv administration,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8829,In vivo,Rattus norvegicus,10116.0
11519,N,,,,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8829,In vivo,Rattus norvegicus,10116.0
11520,N,,,,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",Intermediate,,,,2037.0,50597,BAO_0000218,A,,14972,In vivo,Rattus norvegicus,10116.0
11521,N,,,,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",Intermediate,,,,,50597,BAO_0000218,A,,14972,In vivo,Rattus norvegicus,10116.0
11522,N,,,,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",Intermediate,,,,10000006.0,50597,BAO_0000218,A,,14972,In vivo,Rattus norvegicus,10116.0
11523,N,,,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11524,N,,,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11525,N,,,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11526,U,,,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,Autocuration,,,,10000000.0,22224,BAO_0000218,A,,14608,In vivo,,
11527,U,,,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,Autocuration,,,,10000000.0,22224,BAO_0000218,A,,14608,In vivo,,
11528,U,,,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,Autocuration,,,,10000000.0,22224,BAO_0000218,A,,14608,In vivo,,
11529,N,,,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,,,,955.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11530,N,,,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,,,,955.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11531,N,,,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,,,,955.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11532,N,,,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,,,,2037.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11533,N,,,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,,,,2037.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11534,N,,,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,,,,2037.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11535,N,,,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,,,,,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11536,N,,,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,,,,,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11537,N,,,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,,,,,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11538,N,,,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11539,N,,,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11540,N,,,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11541,N,,,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11542,N,,,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11543,N,,,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11544,N,,,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,,,,2113.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11545,N,,,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,,,,2113.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11546,N,,,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,,,,2113.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11547,N,,,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11548,N,,,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11549,N,,,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11550,N,,,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,,,,2048.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11551,N,,,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,,,,2048.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11552,N,,,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,,,,2048.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11553,N,,,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,,,,2385.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11554,U,,,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,Autocuration,,,,1969.0,22224,BAO_0000218,A,,8918,In vivo,Simiiformes,314293.0
11555,N,,,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,Intermediate,,,,1969.0,50594,BAO_0000218,A,,8918,In vivo,Mus musculus,10090.0
11556,N,,,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,8918,In vivo,Rattus norvegicus,10116.0
11557,N,,,,Peak plasma concentration was measured in dogs,Intermediate,,,,1969.0,50588,BAO_0000218,A,,14470,In vivo,Canis lupus familiaris,9615.0
11558,N,,,,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14393,In vivo,Rattus norvegicus,10116.0
11559,N,,,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,14886,In vivo,Rattus norvegicus,10116.0
11560,N,,,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,14886,In vivo,Rattus norvegicus,10116.0
11561,N,,,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,14886,In vivo,Rattus norvegicus,10116.0
11562,N,,,,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14393,In vivo,Rattus norvegicus,10116.0
11563,N,,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,Intermediate,,,,,50588,BAO_0000218,A,,13465,In vivo,Canis lupus familiaris,9615.0
11564,U,,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,Autocuration,,,,,22224,BAO_0000218,A,,13465,In vivo,Simiiformes,314293.0
11565,N,,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,Intermediate,,,,,50588,BAO_0000218,A,,13465,In vivo,Canis lupus familiaris,9615.0
11566,N,,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,Intermediate,,,,,50588,BAO_0000218,A,,13465,In vivo,Canis lupus familiaris,9615.0
11567,N,,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,Intermediate,,,,,50597,BAO_0000218,A,,13465,In vivo,Rattus norvegicus,10116.0
11568,N,,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,Intermediate,,,,,50597,BAO_0000218,A,,13465,In vivo,Rattus norvegicus,10116.0
11569,N,,,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,Intermediate,,,,,50588,BAO_0000218,A,,13465,In vivo,Canis lupus familiaris,9615.0
11570,N,,,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,Intermediate,,,,,50597,BAO_0000218,A,,13465,In vivo,Rattus norvegicus,10116.0
11571,N,,,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,Intermediate,,,,,50597,BAO_0000218,A,,13465,In vivo,Rattus norvegicus,10116.0
11572,N,,,,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,Intermediate,,,,,50588,BAO_0000218,A,,13465,In vivo,Canis lupus familiaris,9615.0
11573,N,,,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,Intermediate,,,,,50588,BAO_0000218,A,,13465,In vivo,Canis lupus familiaris,9615.0
11574,U,,,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,Autocuration,,,,,22224,BAO_0000218,A,,13465,In vivo,Simiiformes,314293.0
11575,U,,,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,Autocuration,,,,,22224,BAO_0000218,A,,13465,In vivo,Simiiformes,314293.0
11576,N,,,,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,Intermediate,,,,,50597,BAO_0000218,A,,13465,In vivo,Rattus norvegicus,10116.0
11577,N,,,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,Intermediate,,,,,100710,BAO_0000218,A,,14731,In vivo,Macaca fascicularis,9541.0
11578,N,,,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,Intermediate,,,,,50594,BAO_0000218,A,,14731,In vivo,Mus musculus,10090.0
11579,N,,,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,13376,In vivo,Canis lupus familiaris,9615.0
11580,N,,,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,13376,In vivo,Canis lupus familiaris,9615.0
11581,N,,,,Maximum concentration (Cmax) in rat when administered orally,Intermediate,,,,,50597,BAO_0000218,A,,14443,In vivo,Rattus norvegicus,10116.0
11582,U,,,,Maximal concentration in monkey plasma after 25 mg/kg oral dose,Autocuration,,,,1969.0,22224,BAO_0000218,A,,13465,In vivo,Simiiformes,314293.0
11583,U,,,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",Autocuration,,,,,22224,BAO_0000218,A,,16359,In vivo,Rattus norvegicus,10116.0
11584,U,,,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",Autocuration,,,,,22224,BAO_0000218,A,,16359,In vivo,Rattus norvegicus,10116.0
11585,U,,,,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,Autocuration,,,,1969.0,22224,BAO_0000218,A,,15618,In vivo,,
11586,N,,,,Pharmacokinetic profile Cmax was evaluated in rats,Intermediate,,,,,50597,BAO_0000218,A,,14554,In vivo,Rattus norvegicus,10116.0
11587,N,,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,11537,In vivo,Canis lupus familiaris,9615.0
11588,N,,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),Intermediate,,,,,50594,BAO_0000218,A,,11537,In vivo,Mus musculus,10090.0
11589,N,,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,11537,In vivo,Canis lupus familiaris,9615.0
11590,N,,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),Intermediate,,,,,50594,BAO_0000218,A,,11537,In vivo,Mus musculus,10090.0
11591,U,,,,Cmax in rat plasma,Autocuration,,,,1969.0,22224,BAO_0000218,A,,2021,In vivo,Rattus norvegicus,10116.0
11592,N,,,,Cmax in dog plasma after 30mg/kg oral dose,Intermediate,,,,1969.0,50588,BAO_0000218,A,,5932,In vivo,Canis lupus familiaris,9615.0
11593,N,,,,Cmax in rat plasma after 30mg/kg oral dose,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5932,In vivo,Rattus norvegicus,10116.0
11594,N,,,,Plasma level in rats at 30 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17320,In vivo,Rattus norvegicus,10116.0
11595,N,,,,Tested for maximum plasma concentration in mice,Intermediate,,,,1969.0,50594,BAO_0000218,A,,15831,In vivo,Mus musculus,10090.0
11596,N,,,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,15078,In vivo,Rattus norvegicus,10116.0
11597,N,,,,The Cmax values in female wistar rats.,Intermediate,,,,,50597,BAO_0000218,A,,14941,In vivo,Rattus norvegicus,10116.0
11598,N,,,,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,Intermediate,,,,1969.0,50588,BAO_0000218,A,,15343,In vivo,Canis lupus familiaris,9615.0
11599,N,,,,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15343,In vivo,Rattus norvegicus,10116.0
11600,N,,,,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14856,In vivo,Rattus norvegicus,10116.0
11601,N,,,,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,Intermediate,,,,,50597,BAO_0000218,A,,13129,In vivo,Rattus norvegicus,10116.0
11602,N,,,,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,Intermediate,,,,178.0,50597,BAO_0000218,A,,13098,In vivo,Rattus norvegicus,10116.0
11603,N,,,,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,Intermediate,,,,178.0,50597,BAO_0000218,A,,13098,In vivo,Rattus norvegicus,10116.0
11604,N,,,,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,Intermediate,,,,178.0,50597,BAO_0000218,A,,13098,In vivo,Rattus norvegicus,10116.0
11605,U,,,,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,Autocuration,,,,178.0,22224,BAO_0000218,A,,15478,In vivo,Mus musculus,10090.0
11606,N,,,,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,Intermediate,,,,,50588,BAO_0000218,A,,15341,In vivo,Canis lupus familiaris,9615.0
11607,N,,,,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,Intermediate,,,,,50597,BAO_0000218,A,,15341,In vivo,Rattus norvegicus,10116.0
11608,N,,,,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11609,N,,,,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11610,N,,,,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11611,N,,,,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11612,N,,,,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11613,N,,,,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11614,N,,,,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11615,N,,,,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11616,N,,,,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",Intermediate,,,,2106.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11617,N,,,,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",Intermediate,,,,2106.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11618,N,,,,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",Intermediate,,,,2106.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11619,N,,,,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",Intermediate,,,,2106.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11620,N,,,,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",Intermediate,,,,2106.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11621,N,,,,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",Intermediate,,,,2106.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11622,N,,,,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",Intermediate,,,,2106.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11623,N,,,,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",Intermediate,,,,2106.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11624,N,,,,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",Intermediate,,,,995.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11625,N,,,,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",Intermediate,,,,995.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11626,N,,,,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",Intermediate,,,,995.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11627,N,,,,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",Intermediate,,,,995.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11628,N,,,,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",Intermediate,,,,995.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11629,N,,,,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",Intermediate,,,,995.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11630,N,,,,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",Intermediate,,,,995.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11631,N,,,,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",Intermediate,,,,995.0,50597,BAO_0000218,A,,8684,,Rattus norvegicus,10116.0
11632,U,,,,Distribution in the blood after 120 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11633,U,,,,Distribution in the blood after 15 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11634,U,,,,Distribution in the blood after 30 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11635,U,,,,Distribution in the blood after 5 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11636,U,,,,Distribution in the blood after 60 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11637,U,,,,Distribution in the blood after 90 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11638,U,,,,Distribution in the bone after 120 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11639,U,,,,Distribution in the bone after 15 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11640,U,,,,Distribution in the bone after 30 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11641,U,,,,Distribution in the bone after 5 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11642,U,,,,Distribution in the bone after 60 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11643,U,,,,Distribution in the bone after 90 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11644,U,,,,Distribution in the heart after 120 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11645,U,,,,Distribution in the heart after 15 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11646,U,,,,Distribution in the heart after 30 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11647,U,,,,Distribution in the heart after 5 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11648,U,,,,Distribution in the heart after 60 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11649,U,,,,Distribution in the heart after 90 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11650,U,,,,Distribution in the kidneys after 120 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11651,U,,,,Distribution in the kidneys after 15 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11652,U,,,,Distribution in the kidneys after 30 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11653,U,,,,Distribution in the kidneys after 5 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11654,U,,,,Distribution in the kidneys after 60 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11655,U,,,,Distribution in the kidneys after 90 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11656,U,,,,Distribution in the liver after 120 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11657,U,,,,Distribution in the liver after 15 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11658,U,,,,Distribution in the liver after 30 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11659,U,,,,Distribution in the liver after 5 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11660,U,,,,Distribution in the liver after 60 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11661,U,,,,Distribution in the liver after 90 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11662,U,,,,Distribution in the lung after 120 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11663,N,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",Intermediate,,,,,50594,BAO_0000218,A,,14839,,Mus musculus,10090.0
11664,N,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",Intermediate,,,,,50594,BAO_0000218,A,,14839,,Mus musculus,10090.0
11665,N,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",Intermediate,,,,,50594,BAO_0000218,A,,14839,,Mus musculus,10090.0
11666,N,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",Intermediate,,,,,50594,BAO_0000218,A,,14839,,Mus musculus,10090.0
11667,N,,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,Intermediate,,,,,50597,BAO_0000218,A,,12178,,Rattus norvegicus,10116.0
11668,N,,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,Intermediate,,,,,50597,BAO_0000218,A,,12178,,Rattus norvegicus,10116.0
11669,U,,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,Autocuration,,,,,22224,BAO_0000218,A,,12178,,,
11670,N,,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,Intermediate,,,,,100710,BAO_0000218,A,,12186,,Macaca fascicularis,9541.0
11671,N,,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,Intermediate,,,,,100710,BAO_0000218,A,,12186,,Macaca fascicularis,9541.0
11672,N,,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,Intermediate,,,,,100710,BAO_0000218,A,,12186,,Macaca fascicularis,9541.0
11673,N,,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,Intermediate,,,,,100710,BAO_0000218,A,,12186,,Macaca fascicularis,9541.0
11674,U,,,,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,Autocuration,,,,,22224,BAO_0000218,A,,12187,,Simiiformes,314293.0
11675,N,,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,Intermediate,,,,,50506,BAO_0000218,A,,12187,,Mustela putorius furo,9669.0
11676,N,,,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",Intermediate,,,,,50506,BAO_0000218,A,,12187,,Mustela putorius furo,9669.0
11677,U,,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,Autocuration,,,,,22224,BAO_0000218,A,,12187,,Simiiformes,314293.0
11678,U,,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,Autocuration,,,,,22224,BAO_0000218,A,,12187,,Simiiformes,314293.0
11679,N,,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,12187,,Rattus norvegicus,10116.0
11680,N,,,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",Intermediate,,,,,50597,BAO_0000218,A,,12187,,Rattus norvegicus,10116.0
11681,N,,,,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",Intermediate,,,,,50588,BAO_0000218,A,,14122,,Canis lupus familiaris,9615.0
11682,N,,,,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",Intermediate,,,,,100712,BAO_0000218,A,,14122,,Cricetinae,10026.0
11683,N,,,,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",Intermediate,,,,,50597,BAO_0000218,A,,14122,,Rattus norvegicus,10116.0
11684,U,,,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,13391,,,
11685,U,,,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,Autocuration,,,,178.0,22224,BAO_0000218,A,,13391,,,
11686,U,,,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,Autocuration,,,,178.0,22224,BAO_0000218,A,,13391,,,
11687,U,,,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,Autocuration,,,,178.0,22224,BAO_0000218,A,,13391,,,
11688,U,,,,Oral absorption expressed as Area under curve was determined,Autocuration,,,,,22224,BAO_0000019,A,,16360,,,
11689,N,,,,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,Intermediate,,,,,50588,BAO_0000218,A,,3673,,Canis lupus familiaris,9615.0
11690,N,,,,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",Intermediate,,,,,50588,BAO_0000218,A,,14122,,Canis lupus familiaris,9615.0
11691,N,,,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",Intermediate,,,,,100712,BAO_0000218,A,,14122,,Cricetinae,10026.0
11692,N,,,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",Intermediate,,,,,100712,BAO_0000218,A,,14122,,Cricetinae,10026.0
11693,N,,,,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",Intermediate,,,,,50597,BAO_0000218,A,,14122,,Rattus norvegicus,10116.0
11694,U,,,,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,Autocuration,,,,,22224,BAO_0000019,A,,13889,,,
11695,N,,,,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14393,,Rattus norvegicus,10116.0
11696,N,,,,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),Intermediate,,,,,50597,BAO_0000218,A,,17279,,Rattus norvegicus,10116.0
11697,N,,,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,Intermediate,,,,,100710,BAO_0000218,A,,14548,,Macaca fascicularis,9541.0
11698,N,,,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,Intermediate,,,,,100710,BAO_0000218,A,,14548,,Macaca fascicularis,9541.0
11699,N,,,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,Intermediate,,,,,100710,BAO_0000218,A,,14548,,Macaca fascicularis,9541.0
11700,N,,,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,Intermediate,,,,,50588,BAO_0000218,A,,14548,,Canis lupus familiaris,9615.0
11701,N,,,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,Intermediate,,,,,50588,BAO_0000218,A,,14548,,Canis lupus familiaris,9615.0
11702,N,,,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,Intermediate,,,,,50597,BAO_0000218,A,,14548,,Rattus norvegicus,10116.0
11703,N,,,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,Intermediate,,,,,50597,BAO_0000218,A,,14548,,Rattus norvegicus,10116.0
11704,N,,,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,Intermediate,,,,,50597,BAO_0000218,A,,14548,,Rattus norvegicus,10116.0
11705,N,,,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,,,,2385.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11706,N,,,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,,,,2385.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11707,N,,,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,,,,14.0,50594,BAO_0000218,A,,14608,In vivo,Mus musculus,10090.0
11708,N,,,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,,,,14.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11709,N,,,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,,,,14.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11710,N,,,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,,,,2106.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11711,N,,,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,,,,2106.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11712,N,,,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,,,,2106.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11713,N,,,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,,,,2435.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11714,N,,,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,,,,2435.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11715,N,,,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,,,,2435.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11716,N,,,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,,,,2046.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11717,N,,,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,,,,2046.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11718,N,,,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,,,,2046.0,50597,BAO_0000218,A,,14608,In vivo,Rattus norvegicus,10116.0
11719,N,,,,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Intermediate,,,,,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11720,N,,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,Intermediate,,,,,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11721,N,,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,Intermediate,,,,,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11722,N,,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Intermediate,,,,,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11723,N,,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Intermediate,,,,,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11724,N,,,,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Intermediate,,,,955.0,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11725,N,,,,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Intermediate,,,,955.0,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11726,N,,,,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Intermediate,,,,955.0,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11727,N,,,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Intermediate,,,,,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11728,N,,,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Intermediate,,,,,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11729,N,,,,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,Intermediate,,,,2113.0,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11730,N,,,,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Intermediate,,,,2113.0,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11731,N,,,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,Intermediate,,,,2113.0,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11732,N,,,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,Intermediate,,,,2113.0,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11733,N,,,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Intermediate,,,,2113.0,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11734,N,,,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Intermediate,,,,2113.0,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11735,N,,,,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,Intermediate,,,,2107.0,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11736,N,,,,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Intermediate,,,,2107.0,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11737,N,,,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,Intermediate,,,,2107.0,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11738,N,,,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,Intermediate,,,,2107.0,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11739,N,,,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Intermediate,,,,2107.0,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11740,N,,,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Intermediate,,,,2107.0,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11741,N,,,,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Intermediate,,,,2385.0,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11742,N,,,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,Intermediate,,,,2385.0,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11743,N,,,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,Intermediate,,,,2385.0,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11744,N,,,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Intermediate,,,,2385.0,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11745,N,,,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Intermediate,,,,2385.0,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11746,N,,,,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Intermediate,,,,,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11747,N,,,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Intermediate,,,,,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11748,N,,,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Intermediate,,,,,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11749,N,,,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Intermediate,,,,,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11750,N,,,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Intermediate,,,,,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11751,N,,,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,Intermediate,,,,,50597,BAO_0000218,A,,15341,In vivo,Rattus norvegicus,10116.0
11752,N,,,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,Intermediate,,,,,50597,BAO_0000218,A,,15341,In vivo,Rattus norvegicus,10116.0
11753,N,,,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,Intermediate,,,,,50597,BAO_0000218,A,,15341,In vivo,Rattus norvegicus,10116.0
11754,N,,,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,Intermediate,,,,1969.0,50588,BAO_0000218,A,,14906,In vivo,Canis lupus familiaris,9615.0
11755,N,,,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14906,In vivo,Rattus norvegicus,10116.0
11756,N,,,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14906,In vivo,Rattus norvegicus,10116.0
11757,N,,,,The maximum plasma concentration (100 mg/kg) administered orally in human,Intermediate,,,,1969.0,50587,BAO_0000218,A,,14215,In vivo,Homo sapiens,9606.0
11758,U,,,,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,Autocuration,,,,1969.0,22224,BAO_0000218,A,,14215,In vivo,Callithrix,9481.0
11759,U,,,,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,Autocuration,,,,1969.0,22224,BAO_0000218,A,,14215,In vivo,Simiiformes,314293.0
11760,N,,,,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,14215,In vivo,Canis lupus familiaris,9615.0
11761,N,,,,The maximum plasma concentration (200 mg/kg) administered orally in human,Intermediate,,,,1969.0,50587,BAO_0000218,A,,14215,In vivo,Homo sapiens,9606.0
11762,N,,,,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14215,In vivo,Rattus norvegicus,10116.0
11763,U,,,,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,Autocuration,,,,1969.0,22224,BAO_0000218,A,,14215,In vivo,Callithrix,9481.0
11764,U,,,,The maximum plasma concentration (25 mg/kg) administered orally in monkey,Autocuration,,,,1969.0,22224,BAO_0000218,A,,14215,In vivo,Simiiformes,314293.0
11765,U,,,,The maximum plasma concentration (30 mg/kg) administered orally in dog,Autocuration,,,,1969.0,22224,BAO_0000218,A,,14215,In vivo,Canis lupus familiaris,9615.0
11766,N,,,,The maximum plasma concentration (400 mg/kg) administered orally in human,Intermediate,,,,1969.0,50587,BAO_0000218,A,,14215,In vivo,Homo sapiens,9606.0
11767,N,,,,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14215,In vivo,Rattus norvegicus,10116.0
11768,N,,,,The maximum plasma concentration (50 mg/kg) administered orally in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14215,In vivo,Rattus norvegicus,10116.0
11769,N,,,,The maximum plasma concentration (800 mg/kg) administered orally in human,Intermediate,,,,1969.0,50587,BAO_0000218,A,,14215,In vivo,Homo sapiens,9606.0
11770,N,,,,The maximum plasma concentration was measured on rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14067,In vivo,Rattus norvegicus,10116.0
11771,N,,,,The maximum plasma concentration was measured on rats after oral administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,12350,In vivo,Rattus norvegicus,10116.0
11772,N,,,,Plasma drug Cmax in rat (PO dose),Intermediate,,,,1969.0,50597,BAO_0000218,A,,14813,In vivo,Rattus norvegicus,10116.0
11773,U,,,,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,Autocuration,,,,,22224,BAO_0000218,A,,12536,In vivo,,
11774,N,,,,maximum Plasma concentration in Dog was determined after Peroral administration,Intermediate,,,,1969.0,50588,BAO_0000218,A,,14169,In vivo,Canis lupus familiaris,9615.0
11775,N,,,,maximum Plasma concentration in Rats was determined after Peroral administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14169,In vivo,Rattus norvegicus,10116.0
11776,N,,,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,15604,In vivo,Canis lupus familiaris,9615.0
11777,U,,,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,Autocuration,,,,1969.0,22224,BAO_0000218,A,,15604,In vivo,Simiiformes,314293.0
11778,N,,,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15604,In vivo,Rattus norvegicus,10116.0
11779,N,,,,maximum concentration was measured when administered through oral route in mice,Intermediate,,,,,50594,BAO_0000218,A,,14387,In vivo,Mus musculus,10090.0
11780,N,,,,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,Intermediate,,,,,50594,BAO_0000218,A,,15115,,Mus musculus,10090.0
11781,U,,,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,Autocuration,,,,,22224,BAO_0000019,A,,15115,,Simiiformes,314293.0
11782,U,,,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,Autocuration,,,,,22224,BAO_0000019,A,,15115,,Simiiformes,314293.0
11783,U,,,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,Autocuration,,,,,22224,BAO_0000019,A,,15115,,Simiiformes,314293.0
11784,N,,,,Pharmacokinetic parameter was evaluated in rats,Intermediate,,,,,50597,BAO_0000218,A,,16359,,Rattus norvegicus,10116.0
11785,N,,,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,Intermediate,,,,,50594,BAO_0000218,A,,12829,,Mus musculus,10090.0
11786,N,,,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,Intermediate,,,,,50594,BAO_0000218,A,,12829,,Mus musculus,10090.0
11787,N,,,,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,Intermediate,,,,,50594,BAO_0000218,A,,12829,,Mus musculus,10090.0
11788,N,,,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,Intermediate,,,,,50594,BAO_0000218,A,,12829,,Mus musculus,10090.0
11789,N,,,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,Intermediate,,,,,50594,BAO_0000218,A,,12829,,Mus musculus,10090.0
11790,N,,,,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15137,,Rattus norvegicus,10116.0
11791,N,,,,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15137,,Rattus norvegicus,10116.0
11792,N,,,,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15137,,Rattus norvegicus,10116.0
11793,N,,,,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,Intermediate,,,,1969.0,50594,BAO_0000218,A,,15137,,Mus musculus,10090.0
11794,N,,,,Plasma Concentration after 120 min of oral administration to mice,Intermediate,,,,,50594,BAO_0000218,A,,13509,,Mus musculus,10090.0
11795,N,,,,Plasma Concentration after 30 min of oral administration to mice,Intermediate,,,,,50594,BAO_0000218,A,,13509,,Mus musculus,10090.0
11796,N,,,,Plasma Concentration after 60 min of oral administration to mice,Intermediate,,,,,100710,BAO_0000218,A,,13509,,Macaca fascicularis,9541.0
11797,N,,,,Plasma Concentration after 60 min of oral administration to mice; Not determined,Intermediate,,,,,50594,BAO_0000218,A,,13509,,Mus musculus,10090.0
11798,N,,,,Plasma Concentration after 90 min of oral administration to mice,Intermediate,,,,,50594,BAO_0000218,A,,13509,,Mus musculus,10090.0
11799,N,,,,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,12064,,Rattus norvegicus,10116.0
11800,N,,,,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,12064,,Rattus norvegicus,10116.0
11801,N,,,,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,12064,,Rattus norvegicus,10116.0
11802,N,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,Intermediate,,,,,50597,BAO_0000218,A,,10677,,Rattus norvegicus,10116.0
11803,N,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,Intermediate,,,,,50597,BAO_0000218,A,,10677,,Rattus norvegicus,10116.0
11804,U,,,,Distribution in the lung after 15 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11805,U,,,,Distribution in the lung after 30 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11806,U,,,,Distribution in the lung after 5 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11807,U,,,,Distribution in the lung after 60 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11808,U,,,,Distribution in the lung after 90 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,,
11809,U,,,,Distribution in the muscle after 120 min of intravenous administration,Autocuration,,,,2385.0,22224,BAO_0000019,A,,8926,,,
11810,U,,,,Distribution in the muscle after 15 min of intravenous administration,Autocuration,,,,2385.0,22224,BAO_0000019,A,,8926,,,
11811,N,,,,Distribution in the muscle after 30 min of intravenous administration,Intermediate,,,,2385.0,50594,BAO_0000218,A,,8926,,Mus musculus,10090.0
11812,U,,,,Distribution in the muscle after 5 min of intravenous administration,Autocuration,,,,2385.0,22224,BAO_0000019,A,,8926,,,
11813,U,,,,Distribution in the muscle after 60 min of intravenous administration,Autocuration,,,,2385.0,22224,BAO_0000019,A,,8926,,,
11814,U,,,,Distribution in the muscle after 90 min of intravenous administration,Autocuration,,,,2385.0,22224,BAO_0000019,A,,8926,,,
11815,U,,,,Distribution in the spleen after 120 min of intravenous administration,Autocuration,,,,2106.0,22224,BAO_0000019,A,,8926,,,
11816,U,,,,Distribution in the spleen after 15 min of intravenous administration,Autocuration,,,,2106.0,22224,BAO_0000019,A,,8926,,,
11817,U,,,,Distribution in the spleen after 30 min of intravenous administration,Autocuration,,,,2106.0,22224,BAO_0000019,A,,8926,,,
11818,U,,,,Distribution in the spleen after 5 min of intravenous administration,Autocuration,,,,2106.0,22224,BAO_0000019,A,,8926,,,
11819,U,,,,Distribution in the spleen after 60 min of intravenous administration,Autocuration,,,,2106.0,22224,BAO_0000019,A,,8926,,,
11820,U,,,,Distribution in the spleen after 90 min of intravenous administration,Autocuration,,,,2106.0,22224,BAO_0000019,A,,8926,,,
11821,N,,,,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,Intermediate,,,,1235.0,50597,BAO_0000218,A,,7570,,Rattus norvegicus,10116.0
11822,N,,,,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,Intermediate,,,,178.0,50597,BAO_0000218,A,,7570,,Rattus norvegicus,10116.0
11823,N,,,,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,Intermediate,,,,2107.0,50597,BAO_0000218,A,,7570,,Rattus norvegicus,10116.0
11824,N,,,,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,Intermediate,,,,992.0,50597,BAO_0000218,A,,7570,,Rattus norvegicus,10116.0
11825,N,,,,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,Intermediate,,,,2046.0,50597,BAO_0000218,A,,7570,,Rattus norvegicus,10116.0
11826,N,,,,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,Intermediate,,,,1235.0,50597,BAO_0000218,A,,7570,,Rattus norvegicus,10116.0
11827,N,,,,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,Intermediate,,,,178.0,50597,BAO_0000218,A,,7570,,Rattus norvegicus,10116.0
11828,N,,,,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,Intermediate,,,,2107.0,50597,BAO_0000218,A,,7570,,Rattus norvegicus,10116.0
11829,N,,,,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,Intermediate,,,,992.0,50597,BAO_0000218,A,,7570,,Rattus norvegicus,10116.0
11830,N,,,,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,Intermediate,,,,2046.0,50597,BAO_0000218,A,,7570,,Rattus norvegicus,10116.0
11831,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11832,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11833,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11834,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11835,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11836,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11837,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11838,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11839,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11840,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11841,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11842,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11843,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11844,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11845,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11846,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11847,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11848,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11849,N,,,,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,Intermediate,,,,,50594,BAO_0000218,A,,13792,,Mus musculus,10090.0
11850,N,,,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,13376,,Canis lupus familiaris,9615.0
11851,N,,,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,13376,,Canis lupus familiaris,9615.0
11852,U,,,,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,Autocuration,,,,,22224,BAO_0000218,A,,14380,,,
11853,U,,,,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,Autocuration,,,,,22224,BAO_0000218,A,,14380,,,
11854,U,,,,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,Autocuration,,,,,22224,BAO_0000218,A,,14380,,,
11855,U,,,,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,Autocuration,,,,,22224,BAO_0000218,A,,14380,,,
11856,U,,,,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,Autocuration,,,,,22224,BAO_0000218,A,,14380,,,
11857,U,,,,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,Autocuration,,,,,22224,BAO_0000218,A,,14380,,,
11858,U,,,,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,Autocuration,,,,,22224,BAO_0000019,A,,14380,,,
11859,U,,,,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,Autocuration,,,,,22224,BAO_0000218,A,,14380,,,
11860,N,,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,Intermediate,,,,,50594,BAO_0000218,A,,13701,,Mus musculus,10090.0
11861,N,,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,Mus musculus,10090.0
11862,N,,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,Mus musculus,10090.0
11863,N,,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,Mus musculus,10090.0
11864,N,,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,Mus musculus,10090.0
11865,N,,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,Intermediate,,,,,50594,BAO_0000218,A,,13701,,Mus musculus,10090.0
11866,N,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,Mus musculus,10090.0
11867,N,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,Mus musculus,10090.0
11868,N,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,Mus musculus,10090.0
11869,N,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,Mus musculus,10090.0
11870,N,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,Mus musculus,10090.0
11871,N,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,Intermediate,,,,,50594,BAO_0000218,A,,13701,,Mus musculus,10090.0
11872,N,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,Mus musculus,10090.0
11873,N,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,Mus musculus,10090.0
11874,N,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,Mus musculus,10090.0
11875,N,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,Mus musculus,10090.0
11876,N,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,Intermediate,,,,,50594,BAO_0000218,A,,13701,,Mus musculus,10090.0
11877,N,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,Mus musculus,10090.0
11878,N,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,Mus musculus,10090.0
11879,N,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,Intermediate,,,,,50594,BAO_0000218,A,,13701,,Mus musculus,10090.0
11880,N,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,Mus musculus,10090.0
11881,N,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,Mus musculus,10090.0
11882,N,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,Mus musculus,10090.0
11883,N,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,Intermediate,,,,,50594,BAO_0000218,A,,13701,,Mus musculus,10090.0
11884,N,,,,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14393,,Rattus norvegicus,10116.0
11885,N,,,,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,Intermediate,,,,,50594,BAO_0000218,A,,14731,,Mus musculus,10090.0
11886,N,,,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,Intermediate,,,,,100710,BAO_0000218,A,,14731,,Macaca fascicularis,9541.0
11887,N,,,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,Intermediate,,,,,100710,BAO_0000218,A,,14731,,Macaca fascicularis,9541.0
11888,U,,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,Autocuration,,,,955.0,22224,BAO_0000218,A,,13758,,,
11889,U,,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,Autocuration,,,,1977.0,22224,BAO_0000218,A,,13758,,,
11890,U,,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,Autocuration,,,,955.0,22224,BAO_0000218,A,,13758,,,
11891,U,,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,Autocuration,,,,1977.0,22224,BAO_0000218,A,,13758,,,
11892,U,,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),Autocuration,,,,,22224,BAO_0000019,A,,16359,,,
11893,U,,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),Autocuration,,,,,22224,BAO_0000218,A,,16359,,,
11894,N,,,,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Intermediate,,,,2106.0,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11895,N,,,,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Intermediate,,,,2106.0,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11896,N,,,,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Intermediate,,,,2106.0,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11897,N,,,,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Intermediate,,,,,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11898,N,,,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,Intermediate,,,,,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11899,N,,,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Intermediate,,,,,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11900,N,,,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Intermediate,,,,,50594,BAO_0000218,A,,15383,,Mus musculus,10090.0
11901,N,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),Intermediate,,,,,50594,BAO_0000218,A,,14439,,Mus musculus,10090.0
11902,N,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),Intermediate,,,,,50594,BAO_0000218,A,,14439,,Mus musculus,10090.0
11903,N,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),Intermediate,,,,,50594,BAO_0000218,A,,14439,,Mus musculus,10090.0
11904,N,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),Intermediate,,,,,50594,BAO_0000218,A,,14439,,Mus musculus,10090.0
11905,N,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),Intermediate,,,,,50594,BAO_0000218,A,,14439,,Mus musculus,10090.0
11906,N,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),Intermediate,,,,,50594,BAO_0000218,A,,14439,,Mus musculus,10090.0
11907,N,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),Intermediate,,,,,50594,BAO_0000218,A,,14439,,Mus musculus,10090.0
11908,N,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),Intermediate,,,,,50594,BAO_0000218,A,,14439,,Mus musculus,10090.0
11909,N,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),Intermediate,,,,,50594,BAO_0000218,A,,14439,,Mus musculus,10090.0
11910,N,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),Intermediate,,,,,50594,BAO_0000218,A,,14439,,Mus musculus,10090.0
11911,N,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),Intermediate,,,,,50594,BAO_0000218,A,,14439,,Mus musculus,10090.0
11912,N,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),Intermediate,,,,,50594,BAO_0000218,A,,14439,,Mus musculus,10090.0
11913,N,,,,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,,,,,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
11914,N,,,,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",Intermediate,,,,,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
11915,N,,,,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",Intermediate,,,,,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
11916,N,,,,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",Intermediate,,,,,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
11917,N,,,,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Intermediate,,,,,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
11918,N,,,,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,,,,,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
11919,N,,,,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",Intermediate,,,,,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
11920,N,,,,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",Intermediate,,,,,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
11921,N,,,,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",Intermediate,,,,178.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
11922,N,,,,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",Intermediate,,,,178.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
11923,N,,,,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",Intermediate,,,,178.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
11924,N,,,,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Intermediate,,,,178.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
11925,N,,,,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,,,,178.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
11926,N,,,,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",Intermediate,,,,178.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
11927,N,,,,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",Intermediate,,,,178.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
11928,N,,,,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",Intermediate,,,,10000001.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
11929,N,,,,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",Intermediate,,,,10000001.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
11930,N,,,,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Intermediate,,,,10000001.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
11931,N,,,,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,,,,10000001.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
11932,N,,,,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",Intermediate,,,,955.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
11933,N,,,,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",Intermediate,,,,955.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
11934,N,,,,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",Intermediate,,,,955.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
11935,N,,,,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Intermediate,,,,955.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
11936,N,,,,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,,,,955.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
11937,N,,,,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",Intermediate,,,,955.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
11938,N,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,Intermediate,,,,,50597,BAO_0000218,A,,10677,,Rattus norvegicus,10116.0
11939,N,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,Intermediate,,,,,50597,BAO_0000218,A,,10677,,Rattus norvegicus,10116.0
11940,N,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,Intermediate,,,,,50597,BAO_0000218,A,,10677,,Rattus norvegicus,10116.0
11941,N,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,Intermediate,,,,,50597,BAO_0000218,A,,10677,,Rattus norvegicus,10116.0
11942,N,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,Intermediate,,,,,50597,BAO_0000218,A,,10677,,Rattus norvegicus,10116.0
11943,N,,,,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,,,,2369.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11944,N,,,,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2369.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11945,N,,,,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2369.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11946,N,,,,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,Intermediate,,,,2369.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11947,N,,,,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2369.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11948,N,,,,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,,,,178.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11949,N,,,,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,,,,178.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11950,N,,,,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,Intermediate,,,,178.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11951,N,,,,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,,,,178.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11952,N,,,,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,,,,178.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11953,N,,,,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,,,,955.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11954,N,,,,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,,,,955.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11955,N,,,,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,Intermediate,,,,955.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11956,N,,,,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,,,,955.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11957,N,,,,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,Intermediate,,,,955.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11958,N,,,,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,,,,955.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11959,N,,,,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,,,,,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11960,N,,,,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,,,,,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11961,N,,,,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,,,,,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11962,N,,,,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,,,,,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11963,N,,,,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,,,,2113.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11964,N,,,,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2113.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11965,N,,,,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2113.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11966,N,,,,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2113.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11967,N,,,,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,,,,2107.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11968,N,,,,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2107.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11969,N,,,,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2107.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11970,N,,,,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2107.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11971,N,,,,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,,,,2048.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11972,N,,,,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2048.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11973,N,,,,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2048.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11974,N,,,,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2048.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11975,N,,,,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,,,,2385.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11976,N,,,,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2385.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
11977,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11978,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11979,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11980,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11981,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11982,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11983,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11984,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11985,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11986,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11987,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11988,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11989,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11990,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11991,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11992,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11993,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11994,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11995,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11996,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11997,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11998,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
11999,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12000,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12001,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12002,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12003,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12004,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12005,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12006,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12007,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12008,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12009,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12010,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12011,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12012,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",Intermediate,,,,,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12013,U,,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),Autocuration,,,,,22224,BAO_0000218,A,,16359,,,
12014,N,,,,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,Mus musculus,10090.0
12015,N,,,,Pharmacokinetic profile AUC was evaluated in rats,Intermediate,,,,,50597,BAO_0000218,A,,14554,,Rattus norvegicus,10116.0
12016,U,,,,Pharmacokinetic property (Area under curve),Autocuration,,,,,22224,BAO_0000019,A,,6241,,,
12017,N,,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",Intermediate,,,,,50588,BAO_0000218,A,,11537,,Canis lupus familiaris,9615.0
12018,N,,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",Intermediate,,,,,50594,BAO_0000218,A,,11537,,Mus musculus,10090.0
12019,N,,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",Intermediate,,,,,50588,BAO_0000218,A,,11537,,Canis lupus familiaris,9615.0
12020,N,,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",Intermediate,,,,,50594,BAO_0000218,A,,11537,,Mus musculus,10090.0
12021,U,,,,Plasma concentration (AUC) was determined,Autocuration,,,,,22224,BAO_0000019,A,,13118,,,
12022,U,,,,Plasma concentration (AUC) was determined; Not detectable,Autocuration,,,,,22224,BAO_0000019,A,,13118,,,
12023,N,,,,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),Intermediate,,,,,50512,BAO_0000218,A,,9562,,Cavia porcellus,10141.0
12024,N,,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,10363,,Rattus norvegicus,10116.0
12025,N,,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,Intermediate,,,,,50597,BAO_0000218,A,,10363,,Rattus norvegicus,10116.0
12026,N,,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,10363,,Rattus norvegicus,10116.0
12027,N,,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,10363,,Rattus norvegicus,10116.0
12028,N,,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,Intermediate,,,,,50597,BAO_0000218,A,,12504,,Rattus norvegicus,10116.0
12029,N,,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,Intermediate,,,,,50597,BAO_0000218,A,,12504,,Rattus norvegicus,10116.0
12030,N,,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,Intermediate,,,,,50597,BAO_0000218,A,,12504,,Rattus norvegicus,10116.0
12031,N,,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,Intermediate,,,,,50597,BAO_0000218,A,,12504,,Rattus norvegicus,10116.0
12032,N,,,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,Intermediate,,,,,50588,BAO_0000218,A,,13317,,Canis lupus familiaris,9615.0
12033,N,,,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,15078,,Rattus norvegicus,10116.0
12034,N,,,,The AUC(0-infinity) values in female wistar rats.,Intermediate,,,,,50597,BAO_0000218,A,,14941,,Rattus norvegicus,10116.0
12035,N,,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,15078,,Rattus norvegicus,10116.0
12036,N,,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",Intermediate,,,,,50597,BAO_0000218,A,,15078,,Rattus norvegicus,10116.0
12037,N,,,,The AUC(0-t)values in female wistar rats.,Intermediate,,,,,50597,BAO_0000218,A,,14941,,Rattus norvegicus,10116.0
12038,N,,,,The Area under the concentration time curve of compound was measured on rats,Intermediate,,,,,50597,BAO_0000218,A,,14067,,Rattus norvegicus,10116.0
12039,N,,,,The area under curve (100 mg/kg) administered orally in humans,Intermediate,,,,,50587,BAO_0000218,A,,14215,,Homo sapiens,9606.0
12040,U,,,,The area under curve (12.5 mg/kg) administered intravenously in marmoset,Autocuration,,,,,22224,BAO_0000218,A,,14215,,Callithrix,9481.0
12041,U,,,,The area under curve (12.5 mg/kg) administered intravenously in monkey,Autocuration,,,,,22224,BAO_0000218,A,,14215,,Simiiformes,314293.0
12042,N,,,,The area under curve (15 mg/kg) administered intravenously in dog,Intermediate,,,,,50588,BAO_0000218,A,,14215,,Canis lupus familiaris,9615.0
12043,N,,,,The area under curve (200 mg/kg) administered orally in humans,Intermediate,,,,,50587,BAO_0000218,A,,14215,,Homo sapiens,9606.0
12044,N,,,,The area under curve (25 mg/kg) administered intravenously in rat,Intermediate,,,,,50597,BAO_0000218,A,,14215,,Rattus norvegicus,10116.0
12045,U,,,,The area under curve (25 mg/kg) administered orally in marmoset,Autocuration,,,,,22224,BAO_0000218,A,,14215,,Callithrix,9481.0
12046,U,,,,The area under curve (25 mg/kg) administered orally in monkey,Autocuration,,,,,22224,BAO_0000218,A,,14215,,Simiiformes,314293.0
12047,N,,,,The area under curve (30 mg/kg) administered orally in dog,Intermediate,,,,,50588,BAO_0000218,A,,14215,,Canis lupus familiaris,9615.0
12048,N,,,,The area under curve (400 mg/kg) administered orally in humans,Intermediate,,,,,50587,BAO_0000218,A,,14215,,Homo sapiens,9606.0
12049,N,,,,The area under curve (50 mg/kg) administered orally in fasted rat,Intermediate,,,,,50597,BAO_0000218,A,,14215,,Rattus norvegicus,10116.0
12050,N,,,,The area under curve (50 mg/kg) administered orally in rat,Intermediate,,,,,50597,BAO_0000218,A,,14215,,Rattus norvegicus,10116.0
12051,N,,,,The area under curve (800 mg/kg) administered orally in humans,Intermediate,,,,,50587,BAO_0000218,A,,14215,,Homo sapiens,9606.0
12052,U,,,,The compound was evaluated for area under the curve,Autocuration,,,,,22224,BAO_0000019,A,,11324,,,
12053,U,,,,The compound was evaluated for area under the curve in marmosets,Autocuration,,,,,22224,BAO_0000019,A,,11324,,Callithrix,9481.0
12054,U,,,,The compound was evaluated for area under the curve in marmosets,Autocuration,,,,,22224,BAO_0000019,A,,11324,,Callithrix,9481.0
12055,N,,,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,Intermediate,,,,,50597,BAO_0000218,A,,13875,,Rattus norvegicus,10116.0
12056,N,,,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,Intermediate,,,,,50597,BAO_0000218,A,,13875,,Rattus norvegicus,10116.0
12057,U,,,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),Autocuration,,,,,22224,BAO_0000218,A,,13875,,,
12058,N,,,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,Intermediate,,,,,50597,BAO_0000218,A,,13875,,Rattus norvegicus,10116.0
12059,N,,,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,Intermediate,,,,,50597,BAO_0000218,A,,13875,,Rattus norvegicus,10116.0
12060,N,,,,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,Intermediate,,,,,50597,BAO_0000218,A,,13875,,Rattus norvegicus,10116.0
12061,N,,,,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,13807,,Rattus norvegicus,10116.0
12062,N,,,,Total drug exposure is determined after oral dosing in rats.,Intermediate,,,,,50597,BAO_0000218,A,,14127,,Rattus norvegicus,10116.0
12063,U,,,,Total drug exposure (5 mg/kg) when administered intravenously,Autocuration,,,,,22224,BAO_0000218,A,,15116,,,
12064,U,,,,Total drug exposure (5 mg/kg) when administered orally,Autocuration,,,,,22224,BAO_0000218,A,,15116,,,
12065,U,,,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,Autocuration,,,,,22224,BAO_0000218,A,,15604,,Simiiformes,314293.0
12066,N,,,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,Intermediate,,,,,50597,BAO_0000218,A,,15604,,Rattus norvegicus,10116.0
12067,N,,,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,Intermediate,,,,,50588,BAO_0000218,A,,15604,,Canis lupus familiaris,9615.0
12068,N,,,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,Intermediate,,,,,50588,BAO_0000218,A,,15604,,Canis lupus familiaris,9615.0
12069,N,,,,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",Intermediate,,,,955.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12070,N,,,,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,,,,955.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12071,N,,,,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",Intermediate,,,,,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12072,N,,,,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",Intermediate,,,,,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12073,N,,,,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",Intermediate,,,,,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12074,N,,,,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Intermediate,,,,,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12075,N,,,,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,,,,,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12076,N,,,,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",Intermediate,,,,,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12077,N,,,,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",Intermediate,,,,,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12078,N,,,,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",Intermediate,,,,948.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12079,N,,,,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",Intermediate,,,,948.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12080,N,,,,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",Intermediate,,,,948.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12081,N,,,,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Intermediate,,,,948.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12082,N,,,,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,,,,948.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12083,N,,,,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",Intermediate,,,,948.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12084,N,,,,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",Intermediate,,,,948.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12085,N,,,,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",Intermediate,,,,2113.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12086,N,,,,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",Intermediate,,,,2113.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12087,N,,,,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",Intermediate,,,,2113.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12088,N,,,,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Intermediate,,,,2113.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12089,N,,,,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,,,,2113.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12090,N,,,,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",Intermediate,,,,2113.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12091,N,,,,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",Intermediate,,,,2113.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12092,N,,,,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",Intermediate,,,,2107.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12093,N,,,,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",Intermediate,,,,2048.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12094,N,,,,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",Intermediate,,,,2048.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12095,N,,,,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",Intermediate,,,,2048.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12096,N,,,,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Intermediate,,,,2048.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12097,N,,,,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,,,,2048.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12098,N,,,,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",Intermediate,,,,2048.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12099,N,,,,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",Intermediate,,,,2048.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12100,N,,,,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",Intermediate,,,,2385.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12101,N,,,,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",Intermediate,,,,2385.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12102,N,,,,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",Intermediate,,,,2385.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12103,N,,,,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Intermediate,,,,2385.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12104,N,,,,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,,,,2385.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12105,N,,,,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",Intermediate,,,,2385.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12106,N,,,,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",Intermediate,,,,2385.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12107,N,,,,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,,,,,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12108,N,,,,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",Intermediate,,,,2107.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12109,N,,,,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Intermediate,,,,2107.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12110,N,,,,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",Intermediate,,,,2107.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12111,N,,,,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,Intermediate,,,,2385.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
12112,N,,,,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2385.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
12113,N,,,,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2385.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
12114,N,,,,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,,,,992.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
12115,N,,,,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,,,,992.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
12116,N,,,,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,,,,992.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
12117,N,,,,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,Intermediate,,,,992.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
12118,N,,,,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,,,,992.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
12119,N,,,,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,,,,1969.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
12120,N,,,,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,,,,1969.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
12121,N,,,,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,,,,1969.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
12122,N,,,,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,,,,1969.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
12123,N,,,,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,,,,2106.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
12124,N,,,,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2106.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
12125,N,,,,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2106.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
12126,N,,,,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2106.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
12127,N,,,,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,,,,2046.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
12128,N,,,,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2046.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
12129,N,,,,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2046.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
12130,N,,,,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2046.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
12131,N,,,,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,,,,995.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
12132,N,,,,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,,,,995.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
12133,N,,,,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,,,,995.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
12134,N,,,,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,,,,995.0,50597,BAO_0000218,A,,10911,In vivo,Rattus norvegicus,10116.0
12135,U,,,,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,Autocuration,,,,,22224,BAO_0000019,A,,8081,,,
12136,N,,,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),Intermediate,,,,1969.0,100710,BAO_0000218,A,,17248,,Macaca fascicularis,9541.0
12137,N,,,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,Intermediate,,,,1969.0,100710,BAO_0000218,A,,17248,,Macaca fascicularis,9541.0
12138,N,,,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,Intermediate,,,,1969.0,100710,BAO_0000218,A,,17248,,Macaca fascicularis,9541.0
12139,N,,,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),Intermediate,,,,1969.0,50588,BAO_0000218,A,,17248,,Canis lupus familiaris,9615.0
12140,N,,,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17248,,Canis lupus familiaris,9615.0
12141,N,,,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17248,,Canis lupus familiaris,9615.0
12142,N,,,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17248,,Canis lupus familiaris,9615.0
12143,N,,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",Intermediate,,,,,50588,BAO_0000218,A,,15592,,Canis lupus familiaris,9615.0
12144,U,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,Autocuration,,,,,22224,BAO_0000019,A,,7040,,,
12145,U,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,Autocuration,,,,,22224,BAO_0000019,A,,7040,,,
12146,U,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,Autocuration,,,,,22224,BAO_0000019,A,,7040,,,
12147,U,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,Autocuration,,,,,22224,BAO_0000019,A,,7040,,,
12148,U,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,Autocuration,,,,,22224,BAO_0000019,A,,7040,,,
12149,U,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,Autocuration,,,,,22224,BAO_0000019,A,,7040,,,
12150,U,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,Autocuration,,,,,22224,BAO_0000019,A,,7040,,,
12151,N,,,,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",Intermediate,,,,1236.0,50588,BAO_0000218,A,,9614,,Canis lupus familiaris,9615.0
12152,N,,,,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",Intermediate,,,,1236.0,50588,BAO_0000218,A,,9614,,Canis lupus familiaris,9615.0
12153,N,,,,"Concentration of compound in blood of dog 1, after administering intravenously",Intermediate,,,,178.0,50588,BAO_0000218,A,,9614,,Canis lupus familiaris,9615.0
12154,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12155,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12156,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12157,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12158,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12159,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12160,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12161,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12162,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12163,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12164,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12165,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12166,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12167,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12168,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12169,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12170,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12171,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12172,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12173,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12174,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12175,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12176,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12177,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12178,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12179,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12180,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12181,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12182,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12183,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12184,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12185,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12186,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12187,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12188,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12189,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12190,U,,,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,Autocuration,,,,,22224,BAO_0000218,A,,15604,,Simiiformes,314293.0
12191,N,,,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,Intermediate,,,,,50597,BAO_0000218,A,,15604,,Rattus norvegicus,10116.0
12192,U,,,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,Autocuration,,,,1969.0,22224,BAO_0000218,A,,1806,,,
12193,U,,,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,Autocuration,,,,1969.0,22224,BAO_0000218,A,,1806,,,
12194,N,,,,AUC 0-inf in dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17237,,Canis lupus familiaris,9615.0
12195,N,,,,AUC 0-inf in guinea pig,Intermediate,,,,1969.0,50512,BAO_0000218,A,,17237,,Cavia porcellus,10141.0
12196,N,,,,AUC 0-t in dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17237,,Canis lupus familiaris,9615.0
12197,N,,,,AUC 0-t in guinea pig,Intermediate,,,,1969.0,50512,BAO_0000218,A,,17237,,Cavia porcellus,10141.0
12198,N,,,,The compound was tested for brain to plasma partition in rat,Intermediate,,,,,50597,BAO_0000218,A,,15194,,Rattus norvegicus,10116.0
12199,N,,,,The compound was tested for brain to plasma partition in rat.,Intermediate,,,,,50597,BAO_0000218,A,,15194,,Rattus norvegicus,10116.0
12200,U,,,,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,Autocuration,,,,178.0,22224,BAO_0000019,A,,8787,,,
12201,N,,,,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,Intermediate,,,,,50588,BAO_0000218,A,,17025,,Canis lupus familiaris,9615.0
12202,U,,,,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,Autocuration,,,,,22224,BAO_0000218,A,,17025,,Simiiformes,314293.0
12203,N,,,,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,Intermediate,,,,,50592,BAO_0000218,A,,17025,,Oryctolagus cuniculus,9986.0
12204,N,,,,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,Intermediate,,,,,50597,BAO_0000218,A,,17025,,Rattus norvegicus,10116.0
12205,N,,,,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,Intermediate,,,,,50797,BAO_0000218,A,,4236,,Macaca mulatta,9544.0
12206,N,,,,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,Intermediate,,,,,50588,BAO_0000218,A,,15343,,Canis lupus familiaris,9615.0
12207,N,,,,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,Intermediate,,,,,50597,BAO_0000218,A,,15343,,Rattus norvegicus,10116.0
12208,U,,,,Area under curve of the compound was determined,Autocuration,,,,,22224,BAO_0000019,A,,17720,,,
12209,U,,,,AUC in monkeys at a dose of 1 mg/kg,Autocuration,,,,1969.0,22224,BAO_0000218,A,,17788,,Simiiformes,314293.0
12210,N,,,,AUC in rats at a dose of 1 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17788,,Rattus norvegicus,10116.0
12211,U,,,,Compound was evaluated for the overall absorbance loss at pH of 2,Autocuration,,,,,22224,BAO_0000019,A,,8778,,,
12212,U,,,,Compound was evaluated for the overall absorbance loss at pH of 4,Autocuration,,,,,22224,BAO_0000019,A,,8778,,,
12213,U,,,,Compound was evaluated for the overall absorbance loss at pH of 7,Autocuration,,,,,22224,BAO_0000019,A,,8778,,,
12214,N,,,,Compound was evaluated for its absorption in the rats,Intermediate,,,,,50597,BAO_0000218,A,,2249,,Rattus norvegicus,10116.0
12215,N,,,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,8881,,Rattus norvegicus,10116.0
12216,N,,,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,Intermediate,,,,1088.0,50597,BAO_0000218,A,,8881,,Rattus norvegicus,10116.0
12217,N,,,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,8881,,Rattus norvegicus,10116.0
12218,N,,,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,Intermediate,,,,1088.0,50597,BAO_0000218,A,,8881,,Rattus norvegicus,10116.0
12219,N,,,,In vitro percent permeability into rat ileum,Intermediate,,,,,50597,BAO_0000218,A,,15286,,Rattus norvegicus,10116.0
12220,N,,,,In vitro percent permeability into rat ileum; Range is 10-17,Intermediate,,,,,50597,BAO_0000218,A,,15286,,Rattus norvegicus,10116.0
12221,N,,,,In vitro percent permeability into rat ileum; Range is 10-18,Intermediate,,,,,50597,BAO_0000218,A,,15286,,Rattus norvegicus,10116.0
12222,N,,,,In vitro percent permeability into rat ileum; Range is 10-19,Intermediate,,,,,50597,BAO_0000218,A,,15286,,Rattus norvegicus,10116.0
12223,N,,,,In vitro percent permeability into rat ileum; Range is 12-15,Intermediate,,,,,50597,BAO_0000218,A,,15286,,Rattus norvegicus,10116.0
12224,N,,,,In vitro percent permeability into rat ileum; Range is 13-19,Intermediate,,,,,50597,BAO_0000218,A,,15286,,Rattus norvegicus,10116.0
12225,N,,,,In vitro percent permeability into rat ileum; Range is 14-17,Intermediate,,,,,50597,BAO_0000218,A,,15286,,Rattus norvegicus,10116.0
12226,N,,,,In vitro percent permeability into rat ileum; Range is 15-18,Intermediate,,,,,50597,BAO_0000218,A,,15286,,Rattus norvegicus,10116.0
12227,N,,,,In vitro percent permeability into rat ileum; Range is 2-5,Intermediate,,,,,50597,BAO_0000218,A,,15286,,Rattus norvegicus,10116.0
12228,U,,,,In vitro percent permeability into rat ileum; Range is 23-42,Autocuration,,,,2116.0,22224,BAO_0000221,A,,15286,,,
12229,N,,,,In vitro percent permeability into rat ileum; Range is 28-36,Intermediate,,,,,50597,BAO_0000218,A,,15286,,Rattus norvegicus,10116.0
12230,N,,,,In vitro percent permeability into rat ileum; Range is 29-35,Intermediate,,,,,50597,BAO_0000218,A,,15286,,Rattus norvegicus,10116.0
12231,N,,,,In vitro percent permeability into rat ileum; Range is 46-66,Intermediate,,,,,50597,BAO_0000218,A,,15286,,Rattus norvegicus,10116.0
12232,N,,,,In vitro percent permeability into rat ileum; Range is 50-68,Intermediate,,,,,50597,BAO_0000218,A,,15286,,Rattus norvegicus,10116.0
12233,N,,,,In vitro percent permeability into rat ileum; Range is 78-81,Intermediate,,,,,50597,BAO_0000218,A,,15286,,Rattus norvegicus,10116.0
12234,N,,,,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,Intermediate,,,,,50597,BAO_0000218,A,,15286,,Rattus norvegicus,10116.0
12235,N,,,,In vitro percent permeability into rat ileum; nd indicates not detected,Intermediate,,,,,50597,BAO_0000218,A,,15286,,Rattus norvegicus,10116.0
12236,N,,,,In vitro percent permeability into rat ileum; nt indicates not detected,Intermediate,,,,,50597,BAO_0000218,A,,15286,,Rattus norvegicus,10116.0
12237,N,,,,In vitro percent permeability into rat ileum; nt indicates not tested,Intermediate,,,,,50597,BAO_0000218,A,,15286,,Rattus norvegicus,10116.0
12238,N,,,,Compound was tested for oral absorption in bile-duct cannulated rats,Intermediate,,,,,50597,BAO_0000218,A,,13770,,Rattus norvegicus,10116.0
12239,N,,,,Compound was tested for oral absorption in bile-duct cannulated rats.,Intermediate,,,,,50597,BAO_0000218,A,,13770,,Rattus norvegicus,10116.0
12240,N,,,,Oral absorption using Caco-2 cell monolayers.,Intermediate,,,,,50587,BAO_0000218,A,,5202,,Homo sapiens,9606.0
12241,N,,,,Percent of the drug absorbed after administration to humans was determined,Intermediate,,,,,50587,BAO_0000218,A,,14920,,Homo sapiens,9606.0
12242,N,,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,,Rattus norvegicus,10116.0
12243,N,,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,,Rattus norvegicus,10116.0
12244,N,,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,,Rattus norvegicus,10116.0
12245,N,,,,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",Intermediate,,,,2107.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12246,N,,,,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,,,,2107.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12247,N,,,,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",Intermediate,,,,2107.0,50597,BAO_0000218,A,,13751,In vivo,Rattus norvegicus,10116.0
12248,N,,,,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",Intermediate,,,,,50597,BAO_0000218,A,,15807,,Rattus norvegicus,10116.0
12249,N,,,,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",Intermediate,,,,2435.0,50597,BAO_0000218,A,,15807,,Rattus norvegicus,10116.0
12250,N,,,,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",Intermediate,,,,2435.0,50597,BAO_0000218,A,,15807,,Rattus norvegicus,10116.0
12251,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,Intermediate,,,,,50597,BAO_0000218,A,,14950,,Rattus norvegicus,10116.0
12252,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,Intermediate,,,,,50597,BAO_0000218,A,,14950,,Rattus norvegicus,10116.0
12253,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,Intermediate,,,,,50597,BAO_0000218,A,,14950,,Rattus norvegicus,10116.0
12254,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,Intermediate,,,,,50597,BAO_0000218,A,,14950,,Rattus norvegicus,10116.0
12255,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,Intermediate,,,,,50597,BAO_0000218,A,,14950,,Rattus norvegicus,10116.0
12256,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,Intermediate,,,,2113.0,50597,BAO_0000218,A,,14950,,Rattus norvegicus,10116.0
12257,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,Intermediate,,,,2113.0,50597,BAO_0000218,A,,14950,,Rattus norvegicus,10116.0
12258,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,Intermediate,,,,,50597,BAO_0000218,A,,14950,,Rattus norvegicus,10116.0
12259,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,Intermediate,,,,,50597,BAO_0000218,A,,14950,,Rattus norvegicus,10116.0
12260,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,Intermediate,,,,2048.0,50597,BAO_0000218,A,,14950,,Rattus norvegicus,10116.0
12261,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,Intermediate,,,,2048.0,50597,BAO_0000218,A,,14950,,Rattus norvegicus,10116.0
12262,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,Intermediate,,,,2385.0,50597,BAO_0000218,A,,14950,,Rattus norvegicus,10116.0
12263,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,Intermediate,,,,2385.0,50597,BAO_0000218,A,,14950,,Rattus norvegicus,10116.0
12264,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,Intermediate,,,,2367.0,50597,BAO_0000218,A,,14950,,Rattus norvegicus,10116.0
12265,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,Intermediate,,,,2367.0,50597,BAO_0000218,A,,14950,,Rattus norvegicus,10116.0
12266,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,Intermediate,,,,,50597,BAO_0000218,A,,14950,,Rattus norvegicus,10116.0
12267,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,Intermediate,,,,,50597,BAO_0000218,A,,14950,,Rattus norvegicus,10116.0
12268,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,Intermediate,,,,,50597,BAO_0000218,A,,14950,,Rattus norvegicus,10116.0
12269,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,Intermediate,,,,2106.0,50597,BAO_0000218,A,,14950,,Rattus norvegicus,10116.0
12270,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,Intermediate,,,,2106.0,50597,BAO_0000218,A,,14950,,Rattus norvegicus,10116.0
12271,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,Intermediate,,,,2046.0,50597,BAO_0000218,A,,14950,,Rattus norvegicus,10116.0
12272,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,Intermediate,,,,2046.0,50597,BAO_0000218,A,,14950,,Rattus norvegicus,10116.0
12273,N,,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,Intermediate,,,,,50597,BAO_0000218,A,,14950,,Rattus norvegicus,10116.0
12274,N,,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,Intermediate,,,,,50597,BAO_0000218,A,,14950,,Rattus norvegicus,10116.0
12275,N,,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,Intermediate,,,,2385.0,50597,BAO_0000218,A,,14950,,Rattus norvegicus,10116.0
12276,N,,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,Intermediate,,,,,50597,BAO_0000218,A,,14950,,Rattus norvegicus,10116.0
12277,N,,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,Intermediate,,,,2046.0,50597,BAO_0000218,A,,14950,,Rattus norvegicus,10116.0
12278,N,,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,,Rattus norvegicus,10116.0
12279,N,,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,,Rattus norvegicus,10116.0
12280,N,,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,,Rattus norvegicus,10116.0
12281,N,,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,,Rattus norvegicus,10116.0
12282,N,,,,"Concentration of compound in blood of dog 2, after administering intravenously",Intermediate,,,,178.0,50588,BAO_0000218,A,,9614,,Canis lupus familiaris,9615.0
12283,N,,,,"Concentration of compound in left ventricle of dog 1, after administering intravenously",Intermediate,,,,,50588,BAO_0000218,A,,9614,,Canis lupus familiaris,9615.0
12284,N,,,,"Concentration of compound in left ventricle of dog 2, after administering intravenously",Intermediate,,,,,50588,BAO_0000218,A,,9614,,Canis lupus familiaris,9615.0
12285,N,,,,"Concentration of compound in liver of dog 1, after administering intravenously",Intermediate,,,,2107.0,50588,BAO_0000218,A,,9614,,Canis lupus familiaris,9615.0
12286,N,,,,"Concentration of compound in liver of dog 2, after administering intravenously",Intermediate,,,,2107.0,50588,BAO_0000218,A,,9614,,Canis lupus familiaris,9615.0
12287,N,,,,"Concentration of compound in lung of dog 1, after administering intravenously",Intermediate,,,,2048.0,50588,BAO_0000218,A,,9614,,Canis lupus familiaris,9615.0
12288,N,,,,"Concentration of compound in lung of dog 2, after administering intravenously",Intermediate,,,,2048.0,50588,BAO_0000218,A,,9614,,Canis lupus familiaris,9615.0
12289,N,,,,"Concentration of compound in muscle of dog 1, after administering intravenously",Intermediate,,,,2385.0,50588,BAO_0000218,A,,9614,,Canis lupus familiaris,9615.0
12290,N,,,,"Concentration of compound in muscle of dog 2, after administering intravenously",Intermediate,,,,2385.0,50588,BAO_0000218,A,,9614,,Canis lupus familiaris,9615.0
12291,N,,,,"Concentration of compound in spleen of dog 1,after administering intravenously",Intermediate,,,,2106.0,50588,BAO_0000218,A,,9614,,Canis lupus familiaris,9615.0
12292,N,,,,"Concentration of compound in spleen of dog 2, after administering intravenously",Intermediate,,,,2106.0,50588,BAO_0000218,A,,9614,,Canis lupus familiaris,9615.0
12293,U,,,,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,Autocuration,,,,,22224,BAO_0000218,F,,10353,,,
12294,U,,,,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,Autocuration,,,,,22224,BAO_0000218,F,,10353,,,
12295,U,,,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,Autocuration,,,,,22224,BAO_0000218,A,,10353,,,
12296,U,,,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,Autocuration,,,,,22224,BAO_0000218,F,,10353,,,
12297,U,,,,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,Autocuration,,,,,22224,BAO_0000218,F,,10353,,,
12298,U,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12299,U,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12300,U,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12301,U,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12302,U,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12303,U,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12304,U,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12305,U,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12306,U,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12307,U,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12308,U,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12309,U,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12310,U,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12311,U,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12312,U,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12313,U,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12314,U,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12315,U,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12316,U,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12317,U,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12318,U,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12319,U,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12320,U,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12321,U,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12322,U,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12323,U,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12324,U,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12325,U,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12326,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12327,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12328,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12329,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12330,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12331,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12332,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12333,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12334,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12335,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12336,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12337,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12338,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12339,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12340,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12341,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12342,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12343,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,,Rattus norvegicus,10116.0
12344,N,,,,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Intermediate,,,,,50597,BAO_0000218,A,,8085,,Rattus norvegicus,10116.0
12345,N,,,,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Intermediate,,,,,50597,BAO_0000218,A,,8085,,Rattus norvegicus,10116.0
12346,N,,,,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,Intermediate,,,,,50597,BAO_0000218,A,,8085,,Rattus norvegicus,10116.0
12347,N,,,,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Intermediate,,,,995.0,50597,BAO_0000218,A,,8085,,Rattus norvegicus,10116.0
12348,N,,,,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Intermediate,,,,995.0,50597,BAO_0000218,A,,8085,,Rattus norvegicus,10116.0
12349,N,,,,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,Intermediate,,,,995.0,50597,BAO_0000218,A,,8085,,Rattus norvegicus,10116.0
12350,N,,,,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Intermediate,,,,995.0,50597,BAO_0000218,A,,8085,,Rattus norvegicus,10116.0
12351,N,,,,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Intermediate,,,,995.0,50597,BAO_0000218,A,,8085,,Rattus norvegicus,10116.0
12352,N,,,,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,Intermediate,,,,995.0,50597,BAO_0000218,A,,8085,,Rattus norvegicus,10116.0
12353,N,,,,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,Intermediate,,,,995.0,50597,BAO_0000218,A,,8085,,Rattus norvegicus,10116.0
12354,U,,,,Distribution coefficient (D %) between octanol and buffer of pH 7.4,Autocuration,,,,,22224,BAO_0000100,P,,7657,,,
12355,N,,,,Partition coefficient (logD7.4),Intermediate,,,,,50594,BAO_0000218,A,,8935,,Mus musculus,10090.0
12356,N,,,,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",Intermediate,,,,,50594,BAO_0000218,A,,13792,,Mus musculus,10090.0
12357,N,,,,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",Intermediate,,,,955.0,50594,BAO_0000218,A,,13792,,Mus musculus,10090.0
12358,N,,,,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,Intermediate,,,,,50594,BAO_0000218,A,,13792,,Mus musculus,10090.0
12359,N,,,,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,Intermediate,,,,955.0,50594,BAO_0000218,A,,13792,,Mus musculus,10090.0
12360,N,,,,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",Intermediate,,,,,50594,BAO_0000218,A,,13792,,Mus musculus,10090.0
12361,N,,,,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",Intermediate,,,,955.0,50594,BAO_0000218,A,,13792,,Mus musculus,10090.0
12362,N,,,,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,Intermediate,,,,,50594,BAO_0000218,A,,13792,,Mus musculus,10090.0
12363,N,,,,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,Intermediate,,,,955.0,50597,BAO_0000218,A,,13792,,Rattus norvegicus,10116.0
12364,N,,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,,Rattus norvegicus,10116.0
12365,N,,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,,Rattus norvegicus,10116.0
12366,N,,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,,Rattus norvegicus,10116.0
12367,N,,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,,Rattus norvegicus,10116.0
12368,N,,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,,Rattus norvegicus,10116.0
12369,N,,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,,Rattus norvegicus,10116.0
12370,N,,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,,Rattus norvegicus,10116.0
12371,N,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,,Rattus norvegicus,10116.0
12372,N,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,,Rattus norvegicus,10116.0
12373,N,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,,Rattus norvegicus,10116.0
12374,N,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,,Rattus norvegicus,10116.0
12375,N,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,,Rattus norvegicus,10116.0
12376,N,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,,Rattus norvegicus,10116.0
12377,N,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,,Rattus norvegicus,10116.0
12378,N,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,,Rattus norvegicus,10116.0
12379,N,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,,Rattus norvegicus,10116.0
12380,N,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,,Rattus norvegicus,10116.0
12381,N,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,,Rattus norvegicus,10116.0
12382,N,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,,Rattus norvegicus,10116.0
12383,N,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,,Rattus norvegicus,10116.0
12384,N,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,,Rattus norvegicus,10116.0
12385,N,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,,Rattus norvegicus,10116.0
12386,U,,,,Amount of acetic acid produced by the compound,Autocuration,,,,,22224,BAO_0000019,A,,12904,,,
12387,U,,,,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,Autocuration,,,,,22224,BAO_0000019,A,,12904,,,
12388,N,,,,Log of (Cbrain/Cblood) in rats,Intermediate,,,,,50597,BAO_0000218,A,,9663,,Rattus norvegicus,10116.0
12389,U,,,,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),Autocuration,,,,,22224,BAO_0000221,A,,7652,,,
12390,U,,,,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),Autocuration,,,,,22224,BAO_0000221,A,,7652,,,
12391,U,,,,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),Autocuration,,,,,22224,BAO_0000221,A,,7652,,,
12392,U,,,,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),Autocuration,,,,,22224,BAO_0000219,B,,7652,,,
12393,U,,,,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),Autocuration,,,,,22224,BAO_0000221,A,,7652,,,
12394,U,,,,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),Autocuration,,,,,22224,BAO_0000019,A,,7652,,,
12395,U,,,,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),Autocuration,,,,,22224,BAO_0000019,A,,7652,,,
12396,U,,,,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),Autocuration,,,,,22224,BAO_0000019,A,,7652,,,
12397,U,,,,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),Autocuration,,,,,22224,BAO_0000019,A,,7652,,,
12398,U,,,,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),Autocuration,,,,,22224,BAO_0000019,A,,7652,,,
12399,U,,,,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),Autocuration,,,,,22224,BAO_0000019,A,,7652,,,
12400,U,,,,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),Autocuration,,,,,22224,BAO_0000019,A,,7652,,,
12401,U,,,,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),Autocuration,,,,,22224,BAO_0000019,A,,7652,,,
12402,U,,,,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),Autocuration,,,,,22224,BAO_0000019,A,,7652,,,
12403,U,,,,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),Autocuration,,,,,22224,BAO_0000019,A,,7652,,,
12404,U,,,,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),Autocuration,,,,,22224,BAO_0000019,A,,7652,,,
12405,U,,,,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,Autocuration,,,,,22224,BAO_0000218,F,,8267,In vivo,,
12406,N,,,,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,Intermediate,,,,,50588,BAO_0000218,A,,8267,,Canis lupus familiaris,9615.0
12407,U,,,,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,Autocuration,,,,,22224,BAO_0000019,A,,14479,,,
12408,U,,,,Compound was evaluated for total body clearance,Autocuration,,,,,22224,BAO_0000019,A,,17515,,,
12409,U,,,,Compound was evaluated for volume of distribution at steady state,Autocuration,,,,,22224,BAO_0000019,A,,17515,,,
12410,U,,,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,Autocuration,,,,,22224,BAO_0000019,A,,8142,,,
12411,U,,,,Percentage of the diamine which is monoprotonated at pH 7.4,Autocuration,,,,,22224,BAO_0000019,A,,14849,,,
12412,U,,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,Autocuration,,,,,22224,BAO_0000019,A,,7653,,,
12413,N,,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,,Rattus norvegicus,10116.0
12414,N,,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,,Rattus norvegicus,10116.0
12415,N,,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,,Rattus norvegicus,10116.0
12416,N,,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,,Rattus norvegicus,10116.0
12417,N,,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,,Rattus norvegicus,10116.0
12418,N,,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,,Rattus norvegicus,10116.0
12419,N,,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,,Rattus norvegicus,10116.0
12420,N,,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,,Rattus norvegicus,10116.0
12421,N,,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,,Rattus norvegicus,10116.0
12422,N,,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,,Rattus norvegicus,10116.0
12423,N,,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,,Rattus norvegicus,10116.0
12424,N,,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,,Rattus norvegicus,10116.0
12425,N,,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,,Rattus norvegicus,10116.0
12426,N,,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,,Rattus norvegicus,10116.0
12427,N,,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,,Rattus norvegicus,10116.0
12428,N,,,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,,Rattus norvegicus,10116.0
12429,N,,,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,,Rattus norvegicus,10116.0
12430,N,,,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,,Rattus norvegicus,10116.0
12431,N,,,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,,Rattus norvegicus,10116.0
12432,N,,,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,,Rattus norvegicus,10116.0
12433,N,,,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,,Rattus norvegicus,10116.0
12434,N,,,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,,Rattus norvegicus,10116.0
12435,N,,,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,,Rattus norvegicus,10116.0
12436,N,,,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,,Rattus norvegicus,10116.0
12437,U,,,,Maximum biodistribution (Bmax) was determined.,Autocuration,,,,,22224,BAO_0000218,A,,10263,,,
12438,N,,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,Intermediate,,,,,50594,BAO_0000218,A,,12364,,Mus musculus,10090.0
12439,N,,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,Intermediate,,,,,50594,BAO_0000218,A,,12364,,Mus musculus,10090.0
12440,N,,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,Intermediate,,,,,50594,BAO_0000218,A,,12364,,Mus musculus,10090.0
12441,N,,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,Intermediate,,,,,50594,BAO_0000218,A,,12364,,Mus musculus,10090.0
12442,U,,,,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,Autocuration,,,,,22224,BAO_0000218,A,,14793,,,
12443,U,,,,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,Autocuration,,,,,22224,BAO_0000218,A,,14793,,,
12444,U,,,,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,Autocuration,,,,,22224,BAO_0000218,A,,14793,,,
12445,U,,,,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,Autocuration,,,,,22224,BAO_0000218,A,,14793,,,
12446,U,,,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,Autocuration,,,,,22224,BAO_0000218,A,,14793,,,
12447,U,,,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,Autocuration,,,,,22224,BAO_0000218,A,,14793,,,
12448,U,,,,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,Autocuration,,,,,22224,BAO_0000218,A,,14793,,,
12449,U,,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,Autocuration,,,,,22224,BAO_0000218,A,,14793,,,
12450,U,,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,Autocuration,,,,,22224,BAO_0000218,A,,14793,,,
12451,U,,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,Autocuration,,,,,22224,BAO_0000218,A,,14793,,,
12452,U,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12453,U,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12454,U,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12455,N,,,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12456,N,,,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12457,N,,,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12458,N,,,,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12459,N,,,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12460,N,,,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12461,N,,,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12462,N,,,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12463,N,,,,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12464,N,,,,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12465,N,,,,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12466,N,,,,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12467,N,,,,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12468,N,,,,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12469,N,,,,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12470,N,,,,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12471,N,,,,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12472,N,,,,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12473,N,,,,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12474,N,,,,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12475,N,,,,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12476,N,,,,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12477,N,,,,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12478,N,,,,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12479,N,,,,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12480,N,,,,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12481,N,,,,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12482,N,,,,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12483,N,,,,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12484,N,,,,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12485,N,,,,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12486,N,,,,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12487,N,,,,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12488,U,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12489,U,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12490,U,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12491,U,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12492,U,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12493,U,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12494,U,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12495,U,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12496,N,,,,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,Intermediate,,,,,50588,BAO_0000218,A,,12023,,Canis lupus familiaris,9615.0
12497,N,,,,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,Intermediate,,,,,50597,BAO_0000218,A,,12023,,Rattus norvegicus,10116.0
12498,N,,,,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,Intermediate,,,,,100710,BAO_0000218,A,,12023,,Macaca fascicularis,9541.0
12499,U,,,,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,Autocuration,,,,,22224,BAO_0000100,P,,10580,,,
12500,U,,,,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,Autocuration,,,,,22224,BAO_0000100,P,,10580,,,
12501,U,,,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,Autocuration,,,,,22224,BAO_0000019,A,,16032,,,
12502,U,,,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,Autocuration,,,,1088.0,22224,BAO_0000019,A,,16032,,,
12503,N,,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Intermediate,,,,178.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12504,N,,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Intermediate,,,,178.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12505,N,,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Intermediate,,,,178.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12506,N,,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Intermediate,,,,178.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12507,N,,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Intermediate,,,,178.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12508,N,,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Intermediate,,,,178.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12509,N,,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Intermediate,,,,178.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12510,N,,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Intermediate,,,,178.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12511,N,,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Intermediate,,,,178.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12512,N,,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Intermediate,,,,178.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12513,N,,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Intermediate,,,,948.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12514,N,,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Intermediate,,,,948.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12515,N,,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Intermediate,,,,948.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12516,N,,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Intermediate,,,,948.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12517,N,,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Intermediate,,,,948.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12518,N,,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Intermediate,,,,948.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12519,N,,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Intermediate,,,,948.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12520,N,,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Intermediate,,,,948.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12521,N,,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Intermediate,,,,948.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12522,N,,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,Intermediate,,,,948.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12523,N,,,,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",Intermediate,,,,948.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12524,N,,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12525,N,,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12526,N,,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12527,N,,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12528,N,,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12529,N,,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12530,N,,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12531,N,,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12532,N,,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12533,N,,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12534,N,,,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12535,N,,,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12536,N,,,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12537,U,,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),Autocuration,,,,,22224,BAO_0000019,A,,7653,,,
12538,U,,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),Autocuration,,,,,22224,BAO_0000019,A,,7653,,,
12539,U,,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,Autocuration,,,,,22224,BAO_0000019,A,,7653,,,
12540,U,,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,Autocuration,,,,,22224,BAO_0000019,A,,7653,,,
12541,N,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",Intermediate,,,,,50597,BAO_0000218,A,,9104,,Rattus norvegicus,10116.0
12542,N,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",Intermediate,,,,,50597,BAO_0000218,A,,9104,,Rattus norvegicus,10116.0
12543,N,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",Intermediate,,,,,50597,BAO_0000218,A,,9104,,Rattus norvegicus,10116.0
12544,N,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",Intermediate,,,,,50597,BAO_0000218,A,,9104,,Rattus norvegicus,10116.0
12545,N,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",Intermediate,,,,,50597,BAO_0000218,A,,9104,,Rattus norvegicus,10116.0
12546,N,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",Intermediate,,,,,50597,BAO_0000218,A,,9104,,Rattus norvegicus,10116.0
12547,N,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",Intermediate,,,,,50597,BAO_0000218,A,,9104,,Rattus norvegicus,10116.0
12548,N,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",Intermediate,,,,,50597,BAO_0000218,A,,9104,,Rattus norvegicus,10116.0
12549,N,,,,Free level in rat plasma,Intermediate,,,,,50597,BAO_0000218,A,,12902,,Rattus norvegicus,10116.0
12550,U,,,,Level reaching in blood plasma of rat or human was determined,Autocuration,,,,,22224,BAO_0000019,A,,6614,,,
12551,N,,,,Log (Cbrain/Cblood) in rats,Intermediate,,,,,50597,BAO_0000218,A,,9663,,Rattus norvegicus,10116.0
12552,U,,,,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,Autocuration,,,,,22224,BAO_0000019,A,,17658,,,
12553,U,,,,Mean percentage of compound transport through membrane; expressed as membrane transport,Autocuration,,,,,22224,BAO_0000019,A,,17658,,,
12554,U,,,,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,Autocuration,,,,,22224,BAO_0000218,A,,14314,,,
12555,U,,,,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,Autocuration,,,,,22224,BAO_0000019,A,,7385,,,
12556,U,,,,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",Autocuration,,,,,22224,BAO_0000019,A,,7385,,,
12557,U,,,,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,Autocuration,,,,,22224,BAO_0000019,A,,7385,,,
12558,U,,,,Net water uptake by a carrier mediated transport (%cm) mechanism,Autocuration,,,,,22224,BAO_0000019,A,,1329,,,
12559,U,,,,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,Autocuration,,,,,22224,BAO_0000218,A,,12187,,Simiiformes,314293.0
12560,N,,,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,Intermediate,,,,,50506,BAO_0000218,A,,12187,,Mustela putorius furo,9669.0
12561,N,,,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",Intermediate,,,,,50506,BAO_0000218,A,,12187,,Mustela putorius furo,9669.0
12562,U,,,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,Autocuration,,,,,22224,BAO_0000218,A,,12187,,Simiiformes,314293.0
12563,U,,,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",Autocuration,,,,,22224,BAO_0000218,A,,12187,,Simiiformes,314293.0
12564,N,,,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,12187,,Rattus norvegicus,10116.0
12565,N,,,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",Intermediate,,,,,50597,BAO_0000218,A,,12187,,Rattus norvegicus,10116.0
12566,N,,,,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",Intermediate,,,,1969.0,50597,BAO_0000218,A,,9278,,Rattus norvegicus,10116.0
12567,N,,,,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",Intermediate,,,,1969.0,50597,BAO_0000218,A,,9278,,Rattus norvegicus,10116.0
12568,N,,,,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",Intermediate,,,,1969.0,100710,BAO_0000218,A,,9278,,Macaca fascicularis,9541.0
12569,N,,,,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",Intermediate,,,,1969.0,50587,BAO_0000218,A,,9278,,Homo sapiens,9606.0
12570,N,,,,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",Intermediate,,,,1969.0,50597,BAO_0000218,A,,9278,,Rattus norvegicus,10116.0
12571,N,,,,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",Intermediate,,,,1969.0,50597,BAO_0000218,A,,9278,,Rattus norvegicus,10116.0
12572,N,,,,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",Intermediate,,,,1969.0,50597,BAO_0000218,A,,9278,,Rattus norvegicus,10116.0
12573,N,,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,Intermediate,,,,,100710,BAO_0000218,A,,12186,,Macaca fascicularis,9541.0
12574,N,,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,Intermediate,,,,,100710,BAO_0000218,A,,12186,,Macaca fascicularis,9541.0
12575,U,,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,Autocuration,,,,,22224,BAO_0000218,A,,12186,,,
12576,U,,,,% metabolized in monkey S-9 after 2 hours (10 ug/mL),Autocuration,,,,,22224,BAO_0000019,A,,12041,,Simiiformes,314293.0
12577,U,,,,% metabolized in monkey S-9 after 2 hours (1 ug/ml),Autocuration,,,,,22224,BAO_0000019,A,,12041,,Simiiformes,314293.0
12578,U,,,,% metabolized in monkey S-9 after 2 hours (10 ug/ml),Autocuration,,,,,22224,BAO_0000019,A,,12041,,Simiiformes,314293.0
12579,N,,,,Permeability in Caco-2 assay at 10E-6,Intermediate,,,,,50587,BAO_0000218,A,,6737,,Homo sapiens,9606.0
12580,U,,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,Autocuration,,,,955.0,22224,BAO_0000218,A,,13758,,,
12581,U,,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,Autocuration,,,,955.0,22224,BAO_0000218,A,,13758,,,
12582,U,,,,Plasma protein binding was determined,Autocuration,,,,,22224,BAO_0000019,A,,5676,,,
12583,U,,,,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,Autocuration,,,,,22224,BAO_0000218,A,,14793,,,
12584,U,,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,Autocuration,,,,,22224,BAO_0000218,A,,14793,,,
12585,U,,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,Autocuration,,,,,22224,BAO_0000218,A,,14793,,,
12586,U,,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,Autocuration,,,,,22224,BAO_0000218,A,,14793,,,
12587,U,,,,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,Autocuration,,,,,22224,BAO_0000218,A,,14793,,,
12588,U,,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,Autocuration,,,,,22224,BAO_0000218,A,,14793,,,
12589,U,,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,Autocuration,,,,,22224,BAO_0000218,A,,14793,,,
12590,U,,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,Autocuration,,,,,22224,BAO_0000218,A,,14793,,,
12591,U,,,,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,Autocuration,,,,,22224,BAO_0000218,A,,14793,,,
12592,U,,,,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,Autocuration,,,,,22224,BAO_0000218,A,,14793,,,
12593,U,,,,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,Autocuration,,,,,22224,BAO_0000019,A,,14000,,,
12594,U,,,,Partition coefficient (logP),Autocuration,,,,,22224,BAO_0000019,A,,5948,,,
12595,U,,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),Autocuration,,,,,22229,BAO_0000100,P,,13824,,,
12596,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,10778,,,
12597,N,,,,C max in dog,Intermediate,,,,,50588,BAO_0000218,A,,17237,In vivo,Canis lupus familiaris,9615.0
12598,N,,,,C max in guinea pig,Intermediate,,,,,50512,BAO_0000218,A,,17237,In vivo,Cavia porcellus,10141.0
12599,U,,,,C max value was evaluated,Autocuration,,,,,22224,BAO_0000218,A,,2809,In vivo,,
12600,U,,,,Cmax value after oral dose of 0.1 mg//kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,In vivo,,
12601,U,,,,Cmax value after oral dose of 0.3 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,In vivo,,
12602,U,,,,Cmax value after oral dose of 1 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,In vivo,,
12603,U,,,,Cmax value after oral dose of 10 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,In vivo,,
12604,U,,,,Cmax value after oral dose of 23.4 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,In vivo,,
12605,U,,,,Cmax value after oral dose of 3 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,In vivo,,
12606,U,,,,Cmax value after oral dose of 3.87 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,In vivo,,
12607,N,,,,Cmax value in female Beagle dogs,Intermediate,,,,,50588,BAO_0000218,A,,12768,In vivo,Canis lupus familiaris,9615.0
12608,N,,,,Cmax value in male rats,Intermediate,,,,,50597,BAO_0000218,A,,12768,In vivo,Rattus norvegicus,10116.0
12609,N,,,,Cmax value in rat plasma when administered 20 mg/kg perorally,Intermediate,,,,1969.0,50597,BAO_0000218,A,,12780,In vivo,Rattus norvegicus,10116.0
12610,N,,,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,Intermediate,,,,1969.0,50588,BAO_0000218,A,,15592,In vivo,Canis lupus familiaris,9615.0
12611,N,,,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,Intermediate,,,,1969.0,50588,BAO_0000218,A,,15592,In vivo,Canis lupus familiaris,9615.0
12612,N,,,,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,Intermediate,,,,,50588,BAO_0000218,A,,17025,,Canis lupus familiaris,9615.0
12613,U,,,,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,Autocuration,,,,,22224,BAO_0000218,A,,17025,,Simiiformes,314293.0
12614,N,,,,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,Intermediate,,,,,50592,BAO_0000218,A,,17025,,Oryctolagus cuniculus,9986.0
12615,N,,,,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,Intermediate,,,,,50597,BAO_0000218,A,,17025,,Rattus norvegicus,10116.0
12616,N,,,,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,Intermediate,,,,1969.0,50797,BAO_0000218,A,,4236,,Macaca mulatta,9544.0
12617,N,,,,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,15791,,Rattus norvegicus,10116.0
12618,U,,,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,Autocuration,,,,,22224,BAO_0000019,A,,11149,,,
12619,N,,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",Intermediate,,,,,50588,BAO_0000218,A,,15592,,Canis lupus familiaris,9615.0
12620,N,,,,cytotoxicity against HIV protease enzyme.,Intermediate,,,,,50677,BAO_0000218,A,,15778,,Human immunodeficiency virus,12721.0
12621,N,,,,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,Intermediate,,,,,50594,BAO_0000218,A,,12745,,Mus musculus,10090.0
12622,N,,,,Apparent clearance in mice after oral administration of 100 mg/kg of dose,Intermediate,,,,,50594,BAO_0000218,A,,12745,,Mus musculus,10090.0
12623,N,,,,The plasma clearance in dog.,Intermediate,,,,1969.0,50588,BAO_0000218,A,,13941,In vivo,Canis lupus familiaris,9615.0
12624,N,,,,The plasma clearance in rat.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,13941,In vivo,Rattus norvegicus,10116.0
12625,N,,,,Clearance from plasma in male Sprague-Dawley rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,16449,In vivo,Rattus norvegicus,10116.0
12626,N,,,,Clearance from plasma in male cynomolgus monkeys,Intermediate,,,,1969.0,100710,BAO_0000218,A,,16449,In vivo,Macaca fascicularis,9541.0
12627,N,,,,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",Intermediate,,,,1969.0,50588,BAO_0000218,A,,14224,In vivo,Canis lupus familiaris,9615.0
12628,N,,,,Clearance of compound in dog plasma,Intermediate,,,,1969.0,50588,BAO_0000218,A,,14224,In vivo,Canis lupus familiaris,9615.0
12629,N,,,,Clearance of compound in human plasma,Intermediate,,,,1969.0,50587,BAO_0000218,A,,14224,In vivo,Homo sapiens,9606.0
12630,N,,,,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,Intermediate,,,,,50588,BAO_0000218,A,,14317,In vivo,Canis lupus familiaris,9615.0
12631,N,,,,Clearance of compound when administered intravenously as an individual dose to a single dog.,Intermediate,,,,,50588,BAO_0000218,A,,14317,In vivo,Canis lupus familiaris,9615.0
12632,N,,,,"Clearance (10 mg/kg, intravenously) in dog plasma",Intermediate,,,,1969.0,50588,BAO_0000218,A,,14224,In vivo,Canis lupus familiaris,9615.0
12633,N,,,,Clearance value in dog,Intermediate,,,,,50588,BAO_0000218,A,,17237,In vivo,Canis lupus familiaris,9615.0
12634,N,,,,Clearance value in guinea pig,Intermediate,,,,,50512,BAO_0000218,A,,17237,In vivo,Cavia porcellus,10141.0
12635,N,,,,Clearance values in rats after iv administration.,Intermediate,,,,,50597,BAO_0000218,A,,14187,In vivo,Rattus norvegicus,10116.0
12636,U,,,,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,Autocuration,,,,1969.0,22224,BAO_0000218,A,,4806,In vivo,,
12637,N,,,,In vivo clearance (5 mg/kg) was determined in rabbits,Intermediate,,,,,50592,BAO_0000218,A,,15025,In vivo,Oryctolagus cuniculus,9986.0
12638,N,,,,Plasma Clearance rate was determined for the compound in rats,Intermediate,,,,,50597,BAO_0000218,A,,13197,In vivo,Rattus norvegicus,10116.0
12639,U,,,,Plasma Clearance rate was determined for the compound in squirrel monkeys,Autocuration,,,,,22224,BAO_0000218,A,,13197,In vivo,Saimiri,9520.0
12640,N,,,,Plasma clearance in rat,Intermediate,,,,,50597,BAO_0000218,A,,13960,In vivo,Rattus norvegicus,10116.0
12641,U,,,,Plasma clearance of the compound,Autocuration,,,,,22224,BAO_0000218,A,,17820,In vivo,,
12642,N,,,,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,Intermediate,,,,,50512,BAO_0000218,A,,14706,In vivo,Cavia porcellus,10141.0
12643,N,,,,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,Intermediate,,,,,50512,BAO_0000218,A,,14706,In vivo,Cavia porcellus,10141.0
12644,U,,,,Plasma clearance was determined,Autocuration,,,,,22224,BAO_0000218,A,,6504,In vivo,,
12645,N,,,,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,Intermediate,,,,,50588,BAO_0000218,A,,14925,In vivo,Canis lupus familiaris,9615.0
12646,N,,,,Plasma clearance rate was determined for the compound in rats,Intermediate,,,,,50597,BAO_0000218,A,,13197,In vivo,Rattus norvegicus,10116.0
12647,U,,,,Plasma clearance rate was determined for the compound in squirrel monkeys,Autocuration,,,,,22224,BAO_0000218,A,,13197,In vivo,Saimiri,9520.0
12648,U,,,,Slow clearance (CL) was determined,Autocuration,,,,,22224,BAO_0000218,A,,3437,In vivo,,
12649,U,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12650,U,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12651,U,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12652,U,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12653,U,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12654,U,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12655,U,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12656,U,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12657,U,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12658,U,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12659,U,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12660,U,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12661,U,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12662,U,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12663,U,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12664,U,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12665,U,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12666,U,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12667,U,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12668,U,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12669,U,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12670,U,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,,
12671,N,,,,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12672,N,,,,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,,Rattus norvegicus,10116.0
12673,N,,,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,Intermediate,,,,,50597,BAO_0000218,A,,13477,,Rattus norvegicus,10116.0
12674,N,,,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,Intermediate,,,,,50597,BAO_0000218,A,,13477,,Rattus norvegicus,10116.0
12675,N,,,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,Intermediate,,,,,50597,BAO_0000218,A,,13477,,Rattus norvegicus,10116.0
12676,N,,,,Distribution of compound in mice brain was measured after 1 hr,Intermediate,,,,955.0,50594,BAO_0000218,A,,10009,,Mus musculus,10090.0
12677,N,,,,Distribution of compound in mice brain was measured after 24 hr r,Intermediate,,,,955.0,50594,BAO_0000218,A,,10009,,Mus musculus,10090.0
12678,N,,,,Distribution of compound in mice brain was measured after 2 hr,Intermediate,,,,955.0,50594,BAO_0000218,A,,10009,,Mus musculus,10090.0
12679,N,,,,Distribution of compound in mice brain was measured after 3 hr,Intermediate,,,,955.0,50594,BAO_0000218,A,,10009,,Mus musculus,10090.0
12680,N,,,,Distribution of compound in mice brain was measured after 6 hr,Intermediate,,,,955.0,50594,BAO_0000218,A,,10009,,Mus musculus,10090.0
12681,N,,,,Distribution of compound in mice liver was measured after 1 hr,Intermediate,,,,,50594,BAO_0000218,A,,10009,,Mus musculus,10090.0
12682,N,,,,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,Intermediate,,,,,50594,BAO_0000218,A,,10009,,Mus musculus,10090.0
12683,N,,,,Distribution of compound in mice liver was measured after 2 hr,Intermediate,,,,,50594,BAO_0000218,A,,10009,,Mus musculus,10090.0
12684,N,,,,Distribution of compound in mice liver was measured after 3 hr,Intermediate,,,,,50594,BAO_0000218,A,,10009,,Mus musculus,10090.0
12685,N,,,,Distribution of compound in mice liver was measured after 6 hr,Intermediate,,,,,50594,BAO_0000218,A,,10009,,Mus musculus,10090.0
12686,N,,,,Distribution in dog adrenal medulla 30 min after administration.,Intermediate,,,,1236.0,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12687,N,,,,Distribution in dog adrenal medulla 72 hours after administration.,Intermediate,,,,1236.0,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12688,N,,,,Distribution in female dog Ovary 24 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12689,N,,,,Distribution in female dog Ovary 72 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12690,N,,,,Distribution in female dog adipose 24 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12691,N,,,,Distribution in female dog adipose 72 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12692,N,,,,Distribution in female dog adrenal cortex 72 hours after administration.,Intermediate,,,,1235.0,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12693,N,,,,Distribution in female dog adrenal cortex 72 hours after administration.,Intermediate,,,,1235.0,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12694,N,,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12695,N,,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12696,N,,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12697,N,,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12698,N,,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12699,N,,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12700,N,,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12701,N,,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12702,N,,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12703,N,,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12704,N,,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12705,N,,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12706,N,,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12707,N,,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12708,N,,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12709,N,,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12710,N,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12711,N,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12712,N,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12713,N,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12714,N,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12715,N,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12716,N,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12717,N,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12718,N,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12719,N,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12720,N,,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Intermediate,,,,2046.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12721,N,,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Intermediate,,,,2046.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12722,N,,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Intermediate,,,,2046.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12723,N,,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Intermediate,,,,2046.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12724,N,,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Intermediate,,,,2046.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12725,N,,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Intermediate,,,,2046.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12726,N,,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Intermediate,,,,2046.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12727,N,,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Intermediate,,,,2046.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12728,N,,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Intermediate,,,,2046.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12729,N,,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12730,N,,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12731,N,,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12732,N,,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12733,U,,,,Rate of acetate production by the compound was determined,Autocuration,,,,,22224,BAO_0000019,A,,12904,,,
12734,U,,,,Rate of acetate production by the compound was determined; Not determined,Autocuration,,,,,22224,BAO_0000019,A,,12904,,,
12735,U,,,,Rate of hydrolysis of nitrocefin by compound was evaluated in water,Autocuration,,,,,22224,BAO_0000019,A,,3730,,,
12736,U,,,,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,Autocuration,,,,,22224,BAO_0000019,A,,3627,,,
12737,N,,,,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,Intermediate,,,,,50592,BAO_0000218,A,,13799,,Oryctolagus cuniculus,9986.0
12738,N,,,,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,Intermediate,,,,1969.0,50592,BAO_0000218,A,,13799,,Oryctolagus cuniculus,9986.0
12739,N,,,,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,Intermediate,,,,,50594,BAO_0000218,A,,13799,,Mus musculus,10090.0
12740,N,,,,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,Intermediate,,,,,50597,BAO_0000218,A,,13799,,Rattus norvegicus,10116.0
12741,N,,,,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,13799,,Rattus norvegicus,10116.0
12742,N,,,,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,13799,,Rattus norvegicus,10116.0
12743,U,,,,Solubility after at a pH 1.2,Autocuration,,,,,22229,BAO_0000100,P,,6629,,,
12744,U,,,,Solubility after at pH 1.2,Autocuration,,,,,22229,BAO_0000100,P,,6629,,,
12745,U,,,,Solubility after injection of water,Autocuration,,,,,22229,BAO_0000100,P,,6629,,,
12746,U,,,,Statistical significance of IC 50 values; Expressed as R value,Autocuration,,,,,22224,BAO_0000019,A,,14000,,,
12747,U,,,,Systemic availability with respect to methyldopa was determined,Autocuration,,,,,22224,BAO_0000019,A,,8267,,,
12748,N,,,,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,Intermediate,,,,,50597,BAO_0000218,A,,13799,,Rattus norvegicus,10116.0
12749,N,,,,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,13799,,Rattus norvegicus,10116.0
12750,N,,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
12751,N,,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
12752,N,,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
12753,N,,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
12754,N,,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
12755,N,,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
12756,N,,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
12757,N,,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
12758,N,,,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",Intermediate,,,,2113.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
12759,N,,,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
12760,N,,,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
12761,N,,,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
12762,N,,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
12763,N,,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
12764,N,,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
12765,N,,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
12766,N,,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
12767,N,,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
12768,N,,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
12769,N,,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
12770,N,,,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",Intermediate,,,,2113.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
12771,N,,,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
12772,N,,,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
12773,N,,,,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
12774,N,,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,Intermediate,,,,,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
12775,N,,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,Intermediate,,,,,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
12776,N,,,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,Intermediate,,,,,50588,BAO_0000218,A,,13317,In vivo,Canis lupus familiaris,9615.0
12777,N,,,,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,Intermediate,,,,,50588,BAO_0000218,A,,15341,In vivo,Canis lupus familiaris,9615.0
12778,N,,,,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,Intermediate,,,,,50597,BAO_0000218,A,,15341,In vivo,Rattus norvegicus,10116.0
12779,N,,,,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,Intermediate,,,,,50597,BAO_0000218,A,,15341,In vivo,Rattus norvegicus,10116.0
12780,N,,,,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,Intermediate,,,,,50597,BAO_0000218,A,,15341,In vivo,Rattus norvegicus,10116.0
12781,N,,,,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,Intermediate,,,,,50597,BAO_0000218,A,,12801,In vitro,Rattus norvegicus,10116.0
12782,N,,,,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,Intermediate,,,,,50597,BAO_0000218,A,,12801,In vitro,Rattus norvegicus,10116.0
12783,N,,,,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14856,In vivo,Rattus norvegicus,10116.0
12784,N,,,,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,14062,In vivo,Rattus norvegicus,10116.0
12785,N,,,,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,14062,In vivo,Rattus norvegicus,10116.0
12786,N,,,,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,14062,In vivo,Rattus norvegicus,10116.0
12787,N,,,,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,14062,In vivo,Rattus norvegicus,10116.0
12788,N,,,,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,Intermediate,,,,1969.0,50588,BAO_0000218,A,,14346,In vivo,Canis lupus familiaris,9615.0
12789,N,,,,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14346,In vivo,Rattus norvegicus,10116.0
12790,N,,,,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14346,In vivo,Rattus norvegicus,10116.0
12791,N,,,,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14346,In vivo,Rattus norvegicus,10116.0
12792,N,,,,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14346,In vivo,Rattus norvegicus,10116.0
12793,N,,,,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,Intermediate,,,,1969.0,50588,BAO_0000218,A,,14346,In vivo,Canis lupus familiaris,9615.0
12794,N,,,,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14346,In vivo,Rattus norvegicus,10116.0
12795,N,,,,plasma clearance in human,Intermediate,,,,1969.0,50587,BAO_0000218,A,,15711,In vivo,Homo sapiens,9606.0
12796,N,,,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,14886,In vivo,Rattus norvegicus,10116.0
12797,N,,,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,14886,In vivo,Rattus norvegicus,10116.0
12798,N,,,,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,14886,In vivo,Rattus norvegicus,10116.0
12799,U,,,,1-Octanol/water partition coefficient measured at 7.4,Autocuration,,,,,22229,BAO_0000100,P,,4115,,,
12800,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,13733,,,
12801,U,,,,Partition coefficient (logP),Autocuration,,,,,22224,BAO_0000019,A,,12102,,,
12802,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,12676,,,
12803,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,13733,,,
12804,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,13740,,,
12805,U,,,,Calculated partition coefficient (clogP) (relative to BAY K 8644),Autocuration,,,,,22229,BAO_0000100,P,,12766,,,
12806,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,2764,,,
12807,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,12355,,,
12808,U,,,,Calculated partition coefficient of the compound,Autocuration,,,,,22229,BAO_0000100,P,,11314,,,
12809,U,,,,Partition coefficient (logP),Autocuration,,,,,22224,BAO_0000019,A,,12706,,,
12810,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,12645,,,
12811,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,13668,,,
12812,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,12819,,,
12813,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,13668,,,
12814,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,13017,,,
12815,U,,,,Partition coefficient of the compound,Autocuration,,,,,22224,BAO_0000019,A,,2448,,,
12816,U,,,,Partition coefficient of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11526,,,
12817,U,,,,Partition coefficient of compound was determined,Autocuration,,,,,22224,BAO_0000019,A,,12426,,,
12818,U,,,,Partition coefficient was determined,Autocuration,,,,,22224,BAO_0000019,A,,2448,,,
12819,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,12001,,,
12820,U,,,,partition coefficient of compound was determined,Autocuration,,,,,22229,BAO_0000100,P,,12426,,,
12821,N,,,,The total body administered intravenously in dog,Intermediate,,,,,50588,BAO_0000218,A,,13204,In vivo,Canis lupus familiaris,9615.0
12822,N,,,,The total body administered intravenously in rats,Intermediate,,,,,50597,BAO_0000218,A,,13204,In vivo,Rattus norvegicus,10116.0
12823,N,,,,Time taken for the administration to female NIH mice weighing 25-30 g.,Intermediate,,,,,50594,BAO_0000218,A,,13889,,Mus musculus,10090.0
12824,U,,,,Time taken for the administration,Autocuration,,,,,22224,BAO_0000019,A,,13889,,,
12825,N,,,,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,Intermediate,,,,,50588,BAO_0000218,A,,17025,In vivo,Canis lupus familiaris,9615.0
12826,U,,,,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,Autocuration,,,,,22224,BAO_0000218,A,,17025,In vivo,Simiiformes,314293.0
12827,N,,,,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,Intermediate,,,,,50592,BAO_0000218,A,,17025,In vivo,Oryctolagus cuniculus,9986.0
12828,N,,,,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,Intermediate,,,,,50597,BAO_0000218,A,,17025,In vivo,Rattus norvegicus,10116.0
12829,U,,,,Plasma clearance for the compound was determined.,Autocuration,,,,,22224,BAO_0000019,A,,15067,,,
12830,U,,,,CLog P value of the compound,Autocuration,,,,,22224,BAO_0000100,P,,3091,,,
12831,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,15592,,,
12832,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,14738,,,
12833,U,,,,ClogP value of the compound; nd ='no data',Autocuration,,,,,22224,BAO_0000100,P,,14738,,,
12834,U,,,,ClogP value of the compound; nd ='not determined',Autocuration,,,,,22224,BAO_0000100,P,,14738,,,
12835,U,,,,CLog P was determined,Autocuration,,,,,22224,BAO_0000100,P,,6076,,,
12836,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,17840,,,
12837,U,,,,CLogP was calculated,Autocuration,,,,,22224,BAO_0000019,A,,13589,,,
12838,U,,,,CLogP value was determined,Autocuration,,,,,22224,BAO_0000019,A,,17655,,,
12839,U,,,,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,Autocuration,,,,,22224,BAO_0000019,A,,5867,,,
12840,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,5867,,,
12841,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,10783,,,
12842,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,14849,,,
12843,N,,,,Distribution in female dog adrenal medulla 24 hours after administration.,Intermediate,,,,1236.0,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12844,N,,,,Distribution in female dog adrenal medulla 72 hours after administration.,Intermediate,,,,1236.0,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12845,N,,,,Distribution in female dog bile 24 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12846,N,,,,Distribution in female dog bile 72 hr after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12847,N,,,,Distribution in female dog blood 24 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12848,N,,,,Distribution in female dog blood 72 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12849,N,,,,Distribution in female dog heart 24 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12850,N,,,,Distribution in female dog heart 72 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12851,N,,,,Distribution in female dog kidney 24 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12852,N,,,,Distribution in female dog kidney 72 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12853,N,,,,Distribution in female dog large intestine 24 hours after administration.,Intermediate,,,,160.0,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12854,N,,,,Distribution in female dog large intestine 72 hours after administration.,Intermediate,,,,160.0,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12855,N,,,,Distribution in female dog liver 24 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12856,N,,,,Distribution in female dog liver 72 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12857,N,,,,Distribution in female dog lung 24 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12858,N,,,,Distribution in female dog lung 72 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12859,N,,,,Distribution in female dog muscle 24 hours after administration.,Intermediate,,,,2385.0,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12860,N,,,,Distribution in female dog muscle 72 hours after administration.,Intermediate,,,,2385.0,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12861,N,,,,Distribution in female dog pancreas 24 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12862,N,,,,Distribution in female dog pancreas 72 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12863,N,,,,Distribution in female dog small intestine 24 hours after administration.,Intermediate,,,,160.0,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12864,N,,,,Distribution in female dog small intestine 72 hours after administration.,Intermediate,,,,160.0,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12865,N,,,,Distribution in female dog spleen 24 hours after administration.,Intermediate,,,,2106.0,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12866,N,,,,Distribution in female dog spleen 72 hours after administration.,Intermediate,,,,2106.0,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12867,N,,,,Distribution in female dog stomach 24 hours after administration.,Intermediate,,,,945.0,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12868,N,,,,Distribution in female dog stomach 72 hours after administration.,Intermediate,,,,945.0,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12869,N,,,,Distribution in female dog thyroid 24 hours after administration.,Intermediate,,,,2046.0,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12870,N,,,,Distribution in female dog thyroid 72 hours after administration.,Intermediate,,,,2046.0,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12871,N,,,,Distribution in female dog urine 24 hours after administration.,Intermediate,,,,1088.0,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12872,N,,,,Distribution in female dog urine 72 hr after administration.,Intermediate,,,,1088.0,50588,BAO_0000218,A,,8170,,Canis lupus familiaris,9615.0
12873,U,,,,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,Autocuration,,,,1969.0,22224,BAO_0000218,A,,14283,,,
12874,U,,,,Plasma concentration at 7 hr after intravenous dosing,Autocuration,,,,,22224,BAO_0000019,A,,5623,,,
12875,N,,,,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,Intermediate,,,,,50597,BAO_0000218,A,,13477,,Rattus norvegicus,10116.0
12876,N,,,,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,Intermediate,,,,,50597,BAO_0000218,A,,13477,,Rattus norvegicus,10116.0
12877,N,,,,Plasma concentration of 3 mg/kg iv after 1 hr in rats,Intermediate,,,,,50597,BAO_0000218,A,,13477,,Rattus norvegicus,10116.0
12878,N,,,,Plasma concentration of 3 mg/kg iv after 2 hr in rats,Intermediate,,,,,50597,BAO_0000218,A,,13477,,Rattus norvegicus,10116.0
12879,N,,,,Plasma concentration of 3 mg/kg iv after 4 hr in rats,Intermediate,,,,,50597,BAO_0000218,A,,13477,,Rattus norvegicus,10116.0
12880,N,,,,Plasma concentration of 3 mg/kg iv after 6 hr in rats,Intermediate,,,,,50597,BAO_0000218,A,,13477,,Rattus norvegicus,10116.0
12881,N,,,,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,Intermediate,,,,,50597,BAO_0000218,A,,13477,,Rattus norvegicus,10116.0
12882,N,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,Intermediate,,,,,50597,BAO_0000218,A,,13477,,Rattus norvegicus,10116.0
12883,N,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,Intermediate,,,,,50597,BAO_0000218,A,,13477,,Rattus norvegicus,10116.0
12884,N,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,Intermediate,,,,,50597,BAO_0000218,A,,13477,,Rattus norvegicus,10116.0
12885,N,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,Intermediate,,,,,50597,BAO_0000218,A,,13477,,Rattus norvegicus,10116.0
12886,N,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,Intermediate,,,,,50597,BAO_0000218,A,,13477,,Rattus norvegicus,10116.0
12887,N,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,Intermediate,,,,,50597,BAO_0000218,A,,13477,,Rattus norvegicus,10116.0
12888,N,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,Intermediate,,,,,50597,BAO_0000218,A,,13477,,Rattus norvegicus,10116.0
12889,N,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,Intermediate,,,,,50597,BAO_0000218,A,,13477,,Rattus norvegicus,10116.0
12890,U,,,,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,Autocuration,,,,,22224,BAO_0000019,A,,12553,,,
12891,U,,,,The concentration in plasmat; Not determined,Autocuration,,,,1969.0,22224,BAO_0000019,A,,14548,,,
12892,N,,,,Tissue level at 10 mg/kg/po in wistar rats in blood,Intermediate,,,,,50597,BAO_0000218,A,,14393,,Rattus norvegicus,10116.0
12893,N,,,,Tissue level at 10 mg/kg/po in wistar rats in brown fat,Intermediate,,,,,50597,BAO_0000218,A,,14393,,Rattus norvegicus,10116.0
12894,N,,,,Tissue level at 10 mg/kg/po in wistar rats in heart,Intermediate,,,,,50597,BAO_0000218,A,,14393,,Rattus norvegicus,10116.0
12895,N,,,,Tissue level at 10 mg/kg/po in wistar rats in liver,Intermediate,,,,2107.0,50597,BAO_0000218,A,,14393,,Rattus norvegicus,10116.0
12896,N,,,,Tissue level at 10 mg/kg/po in wistar rats in plasma,Intermediate,,,,,50597,BAO_0000218,A,,14393,,Rattus norvegicus,10116.0
12897,N,,,,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,Intermediate,,,,2385.0,50597,BAO_0000218,A,,14393,,Rattus norvegicus,10116.0
12898,N,,,,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,Intermediate,,,,,50597,BAO_0000218,A,,14393,,Rattus norvegicus,10116.0
12899,U,,,,Water solubility at 37 degree C.,Autocuration,,,,,22224,BAO_0000019,A,,1629,,,
12900,U,,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,Autocuration,,,,,22229,BAO_0000100,P,,8194,,,
12901,U,,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,Autocuration,,,,,22229,BAO_0000100,P,,8194,,,
12902,N,,,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Intermediate,,,,178.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12903,N,,,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Intermediate,,,,178.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12904,N,,,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Intermediate,,,,178.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12905,N,,,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Intermediate,,,,178.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12906,N,,,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Intermediate,,,,178.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12907,N,,,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Intermediate,,,,948.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12908,N,,,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Intermediate,,,,948.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12909,N,,,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Intermediate,,,,948.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12910,N,,,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Intermediate,,,,948.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12911,N,,,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Intermediate,,,,948.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12912,N,,,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12913,N,,,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12914,N,,,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12915,N,,,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12916,N,,,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12917,N,,,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12918,N,,,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12919,N,,,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12920,N,,,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12921,N,,,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12922,N,,,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12923,N,,,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12924,N,,,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12925,N,,,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12926,N,,,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12927,N,,,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Intermediate,,,,2046.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12928,N,,,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Intermediate,,,,2046.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12929,N,,,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Intermediate,,,,2046.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12930,N,,,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Intermediate,,,,2046.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12931,N,,,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Intermediate,,,,2046.0,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12932,N,,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12933,N,,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12934,N,,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12935,N,,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12936,N,,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,Rattus norvegicus,10116.0
12937,U,,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,Autocuration,,,,,22224,BAO_0000019,A,,8151,,,
12938,U,,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,Autocuration,,,,,22224,BAO_0000019,A,,8151,,,
12939,N,,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,Intermediate,,,,,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
12940,N,,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,Intermediate,,,,,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
12941,U,,,,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),Autocuration,,,,,22224,BAO_0000019,A,,5797,,,
12942,U,,,,Alkylating activity was determined,Autocuration,,,,,22224,BAO_0000019,A,,7849,,,
12943,U,,,,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),Autocuration,,,,,22224,BAO_0000251,A,Microsomes,14220,,,
12944,N,,,,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",Intermediate,,,,,50592,BAO_0000218,A,,8650,,Oryctolagus cuniculus,9986.0
12945,N,,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",Intermediate,,,,,50592,BAO_0000218,A,,8650,,Oryctolagus cuniculus,9986.0
12946,N,,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",Intermediate,,,,,50592,BAO_0000218,A,,8650,,Oryctolagus cuniculus,9986.0
12947,N,,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",Intermediate,,,,,50592,BAO_0000218,A,,8650,,Oryctolagus cuniculus,9986.0
12948,N,,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",Intermediate,,,,,50592,BAO_0000218,A,,8650,,Oryctolagus cuniculus,9986.0
12949,N,,,,Compound was tested for antidiuretic activity in rats,Intermediate,,,,,50597,BAO_0000218,A,,7116,,Rattus norvegicus,10116.0
12950,U,,,,Compound was tested for inactivation kinetic values,Autocuration,,,,,22224,BAO_0000019,A,,14131,,,
12951,U,,,,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,Autocuration,,,,,22224,BAO_0000218,A,,7415,In vivo,,
12952,U,,,,Dissociation rate calculated from the first-order equation using the t1/2 value,Autocuration,,,,,22224,BAO_0000019,A,,13178,,,
12953,U,,,,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,Autocuration,,,,,22229,BAO_0000100,P,,8815,,,
12954,U,,,,Aqueous solubility was measured,Autocuration,,,,,22229,BAO_0000100,P,,1450,,,
12955,U,,,,Aqueous solubility was measured at a pH 4,Autocuration,,,,,22229,BAO_0000100,P,,1450,,,
12956,U,,,,Aqueous solubility (pH 7),Autocuration,,,,,22229,BAO_0000100,P,,1450,,,
12957,U,,,,Aqueous solubility was measured at a pH 9,Autocuration,,,,,22229,BAO_0000100,P,,1450,,,
12958,U,,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",Autocuration,,,,,22224,BAO_0000019,A,,12711,,,
12959,U,,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",Autocuration,,,,,22224,BAO_0000019,A,,12711,,,
12960,U,,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",Autocuration,,,,,22224,BAO_0000019,A,,12711,,,
12961,U,,,,Aqueous solubility of the compound,Autocuration,,,,,22229,BAO_0000100,P,,15032,,,
12962,U,,,,Aqueous solubility at 37 degree Celsius at pH 7.38,Autocuration,,,,,22229,BAO_0000100,P,,9964,,,
12963,U,,,,Aqueous solubility in pH 7.4 phosphate buffer,Autocuration,,,,,22229,BAO_0000100,P,,14962,,,
12964,N,,,,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,Intermediate,,,,,50588,BAO_0000218,A,,12487,,Canis lupus familiaris,9615.0
12965,N,,,,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,Intermediate,,,,,50588,BAO_0000218,A,,12487,,Canis lupus familiaris,9615.0
12966,N,,,,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,Intermediate,,,,,50587,BAO_0000218,A,,10026,,Homo sapiens,9606.0
12967,N,,,,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,Intermediate,,,,,50587,BAO_0000218,A,,10026,,Homo sapiens,9606.0
12968,N,,,,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,Intermediate,,,,,50587,BAO_0000218,A,,10026,,Homo sapiens,9606.0
12969,N,,,,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,Intermediate,,,,,50587,BAO_0000218,A,,10026,,Homo sapiens,9606.0
12970,N,,,,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,Intermediate,,,,,50587,BAO_0000218,A,,10026,,Homo sapiens,9606.0
12971,U,,,,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,Autocuration,,,,,22224,BAO_0000019,A,,10026,,,
12972,N,,,,Compound was evaluated for the average bile flow rat in rats,Intermediate,,,,,50597,BAO_0000218,A,,7415,,Rattus norvegicus,10116.0
12973,N,,,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",Intermediate,,,,,50592,BAO_0000218,A,,17025,,Oryctolagus cuniculus,9986.0
12974,N,,,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",Intermediate,,,,,50592,BAO_0000218,A,,17025,,Oryctolagus cuniculus,9986.0
12975,U,,,,Average half life period was determined,Autocuration,,,,,22224,BAO_0000019,A,,10184,,,
12976,U,,,,Average half life period was determined,Autocuration,,,,,22224,BAO_0000019,A,,10184,,,
12977,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,Human herpesvirus 1,10298.0
12978,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,Human herpesvirus 1,10298.0
12979,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,Human herpesvirus 1,10298.0
12980,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,Human herpesvirus 1,10298.0
12981,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,Human herpesvirus 1,10298.0
12982,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,Human herpesvirus 1,10298.0
12983,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,Human herpesvirus 1,10298.0
12984,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,Human herpesvirus 1,10298.0
12985,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,Human herpesvirus 1,10298.0
12986,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,6030,,,
12987,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,6147,,,
12988,U,,,,Calculated partition coefficient (clogP) (MacLogP),Autocuration,,,,,22229,BAO_0000100,P,,14556,,,
12989,U,,,,Hydrophilicity was determined,Autocuration,,,,,22224,BAO_0000019,A,,768,,,
12990,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,14452,,,
12991,U,,,,Increased absorption was determined,Autocuration,,,,,22224,BAO_0000019,A,,5237,,,
12992,U,,,,Lipophilicity value was evaluated,Autocuration,,,,,22224,BAO_0000100,P,,14378,,,
12993,U,,,,Log P value of the compound.,Autocuration,,,,,22224,BAO_0000100,P,,14418,,,
12994,U,,,,Partition coefficient of compound was determined,Autocuration,,,,,22224,BAO_0000019,A,,5249,,,
12995,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,14621,,,
12996,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,12542,,,
12997,U,,,,Partition coefficient was measured by medchem software; Not calculated,Autocuration,,,,,22224,BAO_0000019,A,,12542,,,
12998,U,,,,Partition coefficient was measured by octanol-water using standard shake-flask method,Autocuration,,,,,22224,BAO_0000100,P,,12542,,,
12999,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,15462,,,
13000,U,,,,Partition coefficient (logP),Autocuration,,,,,22224,BAO_0000019,A,,14884,,,
13001,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,16526,,,
13002,U,,,,The Octanol/Water partition coefficient CLogP,Autocuration,,,,,22229,BAO_0000100,P,,13693,,,
13003,U,,,,The pharmacokinetic parameter C Log p was reported,Autocuration,,,,,22224,BAO_0000019,A,,13693,,,
13004,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,13779,,,
13005,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,14772,,,
13006,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,14393,,,
13007,N,,,,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14793,In vivo,Rattus norvegicus,10116.0
13008,N,,,,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14793,In vivo,Rattus norvegicus,10116.0
13009,N,,,,Compound was administered intravenously in dog to evaluate plasma clearance values,Intermediate,,,,1969.0,50588,BAO_0000218,A,,13744,In vivo,Canis lupus familiaris,9615.0
13010,U,,,,Compound was administered intravenously in monkey to evaluate plasma clearance values,Autocuration,,,,1969.0,22224,BAO_0000218,A,,13744,In vivo,Simiiformes,314293.0
13011,N,,,,Compound was administered intravenously in mouse to evaluate plasma clearance values,Intermediate,,,,1969.0,50594,BAO_0000218,A,,13744,In vivo,Mus musculus,10090.0
13012,N,,,,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,13207,In vivo,Canis lupus familiaris,9615.0
13013,N,,,,Intrinsic clearance in Rhesus liver microsome,Intermediate,,,,2107.0,50797,BAO_0000218,A,Microsomes,5669,In vitro,Macaca mulatta,9544.0
13014,N,,,,Intrinsic clearance in dog liver microsome,Intermediate,,,,2107.0,50588,BAO_0000218,A,Microsomes,5669,In vitro,Canis lupus familiaris,9615.0
13015,N,,,,Intrinsic clearance in rat liver microsome,Intermediate,,,,2107.0,50597,BAO_0000218,A,Microsomes,5669,In vitro,Rattus norvegicus,10116.0
13016,N,,,,Low plasma clearance was calculated in rhesus monkey,Intermediate,,,,1969.0,50797,BAO_0000218,A,,4853,In vivo,Macaca mulatta,9544.0
13017,N,,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,Intermediate,,,,,50588,BAO_0000218,A,,16452,In vivo,Canis lupus familiaris,9615.0
13018,U,,,,Plasma clearance after intravenous dose of 0.3 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,In vivo,,
13019,U,,,,Plasma clearance after intravenous dose of 1 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,In vivo,,
13020,U,,,,Plasma clearance after intravenous dose of 3 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,In vivo,,
13021,U,,,,Plasma clearance after intravenous dose of 3.87 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,In vivo,,
13022,N,,,,Plasma clearance after peroral administration at 10 mpk in Rat,Intermediate,,,,,50597,BAO_0000218,A,,5669,In vivo,Rattus norvegicus,10116.0
13023,N,,,,Plasma clearance after peroral administration at 10 mpk in Rhesus,Intermediate,,,,,50797,BAO_0000218,A,,5669,In vivo,Macaca mulatta,9544.0
13024,N,,,,Plasma clearance after peroral administration at 10 mpk in dog,Intermediate,,,,,50588,BAO_0000218,A,,5669,In vivo,Canis lupus familiaris,9615.0
13025,N,,,,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,Intermediate,,,,,50597,BAO_0000218,A,,13662,In vivo,Rattus norvegicus,10116.0
13026,U,,,,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),Autocuration,,,,,22224,BAO_0000019,A,,8272,,,
13027,U,,,,Critical Micellar concentration was determined,Autocuration,,,,,22224,BAO_0000019,A,,13410,,,
13028,U,,,,Critical Micellar concentration of the compound. was determined,Autocuration,,,,,22224,BAO_0000019,A,,13410,,,
13029,U,,,,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,Autocuration,,,,,22224,BAO_0000019,A,,12628,,,
13030,U,,,,Critical micellar concentration was measured in water by the dye solubilization method,Autocuration,,,,,22224,BAO_0000019,A,,9675,,,
13031,U,,,,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,Autocuration,,,,,22224,BAO_0000019,B,,12628,,,
13032,U,,,,CMR value (relative to BAY K 8644),Autocuration,,,,,22224,BAO_0000019,A,,12766,,,
13033,U,,,,Carbamoylating activity was determined,Autocuration,,,,,22224,BAO_0000019,A,,7849,,,
13034,U,,,,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,Autocuration,,,,,22224,BAO_0000218,A,,12187,,Simiiformes,314293.0
13035,U,,,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,Autocuration,,,,,22224,BAO_0000019,A,,2040,,,
13036,U,,,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,Autocuration,,,,,22224,BAO_0000019,A,,2040,,,
13037,N,,,,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,Intermediate,,,,1969.0,50588,BAO_0000218,A,,14180,In vivo,Canis lupus familiaris,9615.0
13038,N,,,,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14180,In vivo,Rattus norvegicus,10116.0
13039,N,,,,"Clearance rate at 0.46 mg/kg, iv, in dogs",Intermediate,,,,,50588,BAO_0000218,A,,14474,In vivo,Canis lupus familiaris,9615.0
13040,N,,,,"Clearance rate at 5.5 mg/kg, iv, in rat",Intermediate,,,,,50597,BAO_0000218,A,,14474,In vivo,Rattus norvegicus,10116.0
13041,N,,,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,Intermediate,,,,,100710,BAO_0000218,A,,14548,In vivo,Macaca fascicularis,9541.0
13042,N,,,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,Intermediate,,,,,100710,BAO_0000218,A,,14548,In vivo,Macaca fascicularis,9541.0
13043,N,,,,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,Intermediate,,,,,50588,BAO_0000218,A,,14548,In vivo,Canis lupus familiaris,9615.0
13044,N,,,,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,Intermediate,,,,,50597,BAO_0000218,A,,14548,In vivo,Rattus norvegicus,10116.0
13045,N,,,,Clearance rate constant using isolated perfused rat liver (IPRL) assay,Intermediate,,,,2107.0,50597,BAO_0000218,A,,6125,Ex vivo,Rattus norvegicus,10116.0
13046,U,,,,Tested for the total clearance of the compound,Autocuration,,,,,22224,BAO_0000218,A,,6874,In vivo,,
13047,N,,,,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,Intermediate,,,,,50588,BAO_0000218,A,,15343,In vivo,Canis lupus familiaris,9615.0
13048,U,,,,Total body clearance was determined,Autocuration,,,,,22224,BAO_0000218,A,,6236,In vivo,,
13049,N,,,,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13050,N,,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13051,U,,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,Autocuration,,,,,22229,BAO_0000100,P,,8194,,,
13052,U,,,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,Autocuration,,,,,22229,BAO_0000100,P,,8194,,,
13053,U,,,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,Autocuration,,,,,22229,BAO_0000100,P,,8194,,,
13054,U,,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,Autocuration,,,,,22229,BAO_0000100,P,,8194,,,
13055,U,,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,Autocuration,,,,,22229,BAO_0000100,P,,8194,,,
13056,U,,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,Autocuration,,,,,22229,BAO_0000100,P,,8194,,,
13057,N,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),Intermediate,,,,,50339,BAO_0000218,A,,13273,,Pneumocystis carinii,4754.0
13058,N,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,Intermediate,,,,,50339,BAO_0000218,A,,13273,,Pneumocystis carinii,4754.0
13059,N,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,Intermediate,,,,,50339,BAO_0000218,A,,13273,,Pneumocystis carinii,4754.0
13060,N,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,Intermediate,,,,,50339,BAO_0000218,A,,13273,,Pneumocystis carinii,4754.0
13061,N,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,Intermediate,,,,,50339,BAO_0000218,A,,13273,,Pneumocystis carinii,4754.0
13062,N,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,Intermediate,,,,,50339,BAO_0000218,A,,13273,,Pneumocystis carinii,4754.0
13063,N,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),Intermediate,,,,,50339,BAO_0000218,A,,13273,,Pneumocystis carinii,4754.0
13064,N,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),Intermediate,,,,,50339,BAO_0000218,A,,13273,,Pneumocystis carinii,4754.0
13065,N,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),Intermediate,,,,,50339,BAO_0000218,A,,13273,,Pneumocystis carinii,4754.0
13066,N,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),Intermediate,,,,,50339,BAO_0000218,A,,13273,,Pneumocystis carinii,4754.0
13067,N,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),Intermediate,,,,,50339,BAO_0000218,A,,13273,,Pneumocystis carinii,4754.0
13068,N,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),Intermediate,,,,,50339,BAO_0000218,A,,13273,,Pneumocystis carinii,4754.0
13069,U,,,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,Autocuration,,,,,22224,BAO_0000019,A,,13118,,,
13070,U,,,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,Autocuration,,,,,22224,BAO_0000019,A,,13118,,,
13071,U,,,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,Autocuration,,,,,22224,BAO_0000019,A,,13118,,,
13072,U,,,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,Autocuration,,,,,22224,BAO_0000019,A,,13118,,,
13073,U,,,,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,Autocuration,,,,,22224,BAO_0000019,A,,13118,,,
13074,U,,,,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,Autocuration,,,,,22224,BAO_0000019,A,,13118,,,
13075,N,,,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",Intermediate,,,,,50597,BAO_0000218,A,,10633,,Rattus norvegicus,10116.0
13076,N,,,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",Intermediate,,,,,50597,BAO_0000218,A,,10633,,Rattus norvegicus,10116.0
13077,N,,,,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",Intermediate,,,,,50597,BAO_0000218,A,,10633,,Rattus norvegicus,10116.0
13078,N,,,,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",Intermediate,,,,,50597,BAO_0000218,A,,10633,,Rattus norvegicus,10116.0
13079,U,,,,Cp max following ip administration at 1 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,5767,,,
13080,U,,,,Maximum concentration in plasma was reported at 0.5 hour,Autocuration,,,,1969.0,22224,BAO_0000218,A,,3302,In vivo,,
13081,U,,,,Maximum concentration in plasma was reported at 2 hour,Autocuration,,,,1969.0,22224,BAO_0000218,A,,3302,In vivo,,
13082,N,,,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,Intermediate,,,,,50594,BAO_0000218,A,,12467,,Mus musculus,10090.0
13083,U,,,,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),Autocuration,,,,,22229,BAO_0000100,P,,11778,,,
13084,U,,,,Steady state concentration was evaluated,Autocuration,,,,,22224,BAO_0000019,A,,4321,,,
13085,U,,,,Partition coefficient (logP),Autocuration,,,,,22224,BAO_0000019,A,,14884,,,
13086,U,,,,Partition coefficient (logD7.4),Autocuration,,,,,22224,BAO_0000019,A,,15234,,,
13087,N,,,,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,Intermediate,,,,2107.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13088,N,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13089,N,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,Intermediate,,,,2037.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13090,N,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13091,N,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13092,N,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,Intermediate,,,,948.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13093,N,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,Intermediate,,,,160.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13094,U,,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,Autocuration,,,,,22224,BAO_0000019,A,,8151,,,
13095,U,,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,Autocuration,,,,,22224,BAO_0000019,A,,8151,,,
13096,U,,,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,Autocuration,,,,1088.0,22224,BAO_0000019,A,,8151,,,
13097,U,,,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,Autocuration,,,,1088.0,22224,BAO_0000019,A,,8151,,,
13098,U,,,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,Autocuration,,,,1088.0,22224,BAO_0000019,A,,8151,,,
13099,N,,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,Intermediate,,,,,50597,BAO_0000218,A,,8151,,Rattus norvegicus,10116.0
13100,N,,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,8151,,Rattus norvegicus,10116.0
13101,N,,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,Intermediate,,,,,50597,BAO_0000218,A,,8151,,Rattus norvegicus,10116.0
13102,N,,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,8151,,Rattus norvegicus,10116.0
13103,N,,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,Intermediate,,,,,50597,BAO_0000218,A,,8151,,Rattus norvegicus,10116.0
13104,N,,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,Intermediate,,,,,50597,BAO_0000218,A,,8151,,Rattus norvegicus,10116.0
13105,N,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13106,N,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13107,N,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13108,N,,,,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,Expert,,,,,50588,BAO_0000218,F,,6996,,Canis lupus familiaris,9615.0
13109,N,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13110,N,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13111,N,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13112,N,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13113,N,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13114,N,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13115,N,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13116,N,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13117,N,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13118,N,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13119,N,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13120,N,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13121,N,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13122,N,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13123,U,,,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",Autocuration,,,,,22224,BAO_0000218,B,,6996,,,
13124,N,,,,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13125,N,,,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",Expert,,,,,50597,BAO_0000218,F,,6996,,Rattus norvegicus,10116.0
13126,U,,,,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,Autocuration,,,,,22224,BAO_0000218,B,,6996,,,
13127,N,,,,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,Expert,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
13128,N,,,,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
13129,U,,,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,Autocuration,,,,,22224,BAO_0000019,A,,7114,,,
13130,N,,,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,Intermediate,,,,,50597,BAO_0000218,A,,7114,,Rattus norvegicus,10116.0
13131,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,Human herpesvirus 1,10298.0
13132,N,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,Intermediate,,,,,50602,BAO_0000218,A,,8613,,Human herpesvirus 1,10298.0
13133,N,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,Human herpesvirus 1,10298.0
13134,N,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,Intermediate,,,,,50602,BAO_0000218,A,,8613,,Human herpesvirus 1,10298.0
13135,N,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,Human herpesvirus 1,10298.0
13136,N,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,Human herpesvirus 1,10298.0
13137,N,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,Intermediate,,,,,50602,BAO_0000218,A,,8613,,Human herpesvirus 1,10298.0
13138,N,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,Human herpesvirus 1,10298.0
13139,N,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,Human herpesvirus 1,10298.0
13140,N,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,Human herpesvirus 1,10298.0
13141,N,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,Human herpesvirus 1,10298.0
13142,N,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,Intermediate,,,,,50594,BAO_0000218,A,,8613,,Mus musculus,10090.0
13143,N,,,,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",Intermediate,,,,,50506,BAO_0000218,A,,11219,,Mustela putorius furo,9669.0
13144,N,,,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",Intermediate,,,,,50506,BAO_0000218,A,,11219,,Mustela putorius furo,9669.0
13145,N,,,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",Intermediate,,,,,50506,BAO_0000218,A,,11219,,Mustela putorius furo,9669.0
13146,N,,,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,Intermediate,,,,,50506,BAO_0000218,A,,11219,,Mustela putorius furo,9669.0
13147,N,,,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,Intermediate,,,,,50506,BAO_0000218,A,,11219,,Mustela putorius furo,9669.0
13148,N,,,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,Intermediate,,,,,50506,BAO_0000218,A,,11219,,Mustela putorius furo,9669.0
13149,N,,,,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,Intermediate,,,,,50506,BAO_0000218,A,,11219,,Mustela putorius furo,9669.0
13150,U,,,,Pharmacokinetic parameter :drug bound to plasma was reported,Autocuration,,,,,22224,BAO_0000019,A,,14837,,,
13151,U,,,,compound was evaluated for drug bound in plasma,Autocuration,,,,,22224,BAO_0000019,A,,14837,,,
13152,N,,,,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,Intermediate,,,,,50597,BAO_0000218,A,,15343,,Rattus norvegicus,10116.0
13153,U,,,,Bioavailability,Autocuration,,,,,22224,BAO_0000218,A,,13761,,Eutheria,9347.0
13154,N,,,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,Intermediate,,,,,50597,BAO_0000218,A,,14810,,Rattus norvegicus,10116.0
13155,N,,,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,Intermediate,,,,,50597,BAO_0000218,A,,14810,,Rattus norvegicus,10116.0
13156,N,,,,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,Intermediate,,,,,50588,BAO_0000218,A,,13249,,Canis lupus familiaris,9615.0
13157,N,,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,Intermediate,,,,1970.0,50597,BAO_0000218,A,,9267,,Rattus norvegicus,10116.0
13158,N,,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,Intermediate,,,,1970.0,50597,BAO_0000218,A,,9267,,Rattus norvegicus,10116.0
13159,N,,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,Intermediate,,,,1970.0,50597,BAO_0000218,A,,9267,,Rattus norvegicus,10116.0
13160,N,,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,Intermediate,,,,1970.0,50597,BAO_0000218,A,,9267,,Rattus norvegicus,10116.0
13161,N,,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,Intermediate,,,,1970.0,50597,BAO_0000218,A,,9267,,Rattus norvegicus,10116.0
13162,N,,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,Intermediate,,,,1970.0,50597,BAO_0000218,A,,9267,,Rattus norvegicus,10116.0
13163,N,,,,In vitro protein binding in human serum at 5 ug/ml,Intermediate,,,,1977.0,50587,BAO_0000218,A,,15549,,Homo sapiens,9606.0
13164,U,,,,Serum protein binding ability was measured,Autocuration,,,,,22224,BAO_0000019,A,,10929,,,
13165,U,,,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),Autocuration,,,,,22224,BAO_0000019,A,,15444,,,
13166,U,,,,Oral bioavailability in dog,Autocuration,,,,,22224,BAO_0000218,A,,12860,In vivo,Canis lupus familiaris,9615.0
13167,N,,,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,Intermediate,,,,,50597,BAO_0000218,A,,12170,In vivo,Rattus norvegicus,10116.0
13168,U,,,,Absolute oral bioavailability at an iv dose of 14 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,15173,In vivo,,
13169,U,,,,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,15173,In vivo,,
13170,U,,,,Oral bioavailability (dose 15 mg/kg i.v.),Autocuration,,,,,22224,BAO_0000218,A,,15173,In vivo,Eutheria,9347.0
13171,U,,,,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,Autocuration,,,,,22224,BAO_0000218,A,,15173,In vivo,,
13172,U,,,,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,Autocuration,,,,,22224,BAO_0000218,A,,15173,In vivo,,
13173,U,,,,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,Autocuration,,,,,22224,BAO_0000218,A,,15173,In vivo,,
13174,U,,,,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,Autocuration,,,,,22224,BAO_0000218,A,,15173,In vivo,,
13175,N,,,,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,Intermediate,,,,,50588,BAO_0000218,A,,11767,In vivo,Canis lupus familiaris,9615.0
13176,U,,,,Bioavailability in ferret,Autocuration,,,,,22224,BAO_0000218,A,,11219,In vivo,Mustela putorius furo,9669.0
13177,N,,,,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,Intermediate,,,,,100710,BAO_0000218,A,,12186,In vivo,Macaca fascicularis,9541.0
13178,N,,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13179,N,,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13180,N,,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13181,N,,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13182,N,,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13183,N,,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13184,N,,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13185,N,,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13186,N,,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13187,N,,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13188,N,,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13189,N,,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13190,N,,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13191,N,,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13192,N,,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13193,N,,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13194,N,,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13195,N,,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13196,N,,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13197,N,,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13198,N,,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13199,N,,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13200,N,,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13201,N,,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13202,N,,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13203,N,,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13204,N,,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13205,U,,,,Total body clearance was measured at given dose,Autocuration,,,,,22224,BAO_0000019,A,,7199,,,
13206,U,,,,Total body clearance was measured at given dose.,Autocuration,,,,,22224,BAO_0000218,A,,7199,,,
13207,N,,,,Metabolic clearance from the body in rat,Intermediate,,,,,50597,BAO_0000218,A,,7095,,Rattus norvegicus,10116.0
13208,U,,,,Renal clearance from the body,Autocuration,,,,,22224,BAO_0000218,A,,7095,In vivo,,
13209,N,,,,Renal clearance from the body in rat,Intermediate,,,,,50597,BAO_0000218,A,,7095,In vivo,Rattus norvegicus,10116.0
13210,N,,,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,12528,In vivo,Rattus norvegicus,10116.0
13211,N,,,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,12528,In vivo,Canis lupus familiaris,9615.0
13212,N,,,,Total clearance from the body in rat,Intermediate,,,,,50597,BAO_0000218,A,,7095,,Rattus norvegicus,10116.0
13213,N,,,,Clearance into cortex from rat plasma or PBS,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14223,In vivo,Rattus norvegicus,10116.0
13214,U,,,,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,Autocuration,,,,,22224,BAO_0000218,A,,13569,In vivo,,
13215,U,,,,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,Autocuration,,,,,22224,BAO_0000218,A,,13569,In vivo,,
13216,U,,,,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,Autocuration,,,,,22224,BAO_0000218,A,,13569,In vivo,,
13217,U,,,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,Autocuration,,,,,22224,BAO_0000218,A,,13569,In vivo,,
13218,U,,,,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,Autocuration,,,,,22224,BAO_0000218,A,,13569,In vivo,,
13219,U,,,,Clearance was determined,Autocuration,,,,,22224,BAO_0000218,A,,13979,In vivo,,
13220,N,,,,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,Intermediate,,,,,50594,BAO_0000218,A,,14315,In vivo,Mus musculus,10090.0
13221,N,,,,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,Intermediate,,,,,50592,BAO_0000218,A,,14315,In vivo,Oryctolagus cuniculus,9986.0
13222,N,,,,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,Intermediate,,,,,50597,BAO_0000218,A,,14315,In vivo,Rattus norvegicus,10116.0
13223,N,,,,Clearance in rat after iv dose (100 ug/kg),Intermediate,,,,,50597,BAO_0000218,A,,12174,In vivo,Rattus norvegicus,10116.0
13224,U,,,,Clearance in guinea pig,Autocuration,,,,,22224,BAO_0000218,A,,12797,In vivo,Cavia porcellus,10141.0
13225,N,,,,Compound was evaluated for clearance in rat,Intermediate,,,,,50597,BAO_0000218,A,,12797,In vivo,Rattus norvegicus,10116.0
13226,N,,,,Compound was evaluated for the clearance in dog,Intermediate,,,,,50588,BAO_0000218,A,,12797,In vivo,Canis lupus familiaris,9615.0
13227,N,,,,Compound was evaluated for the clearance in rat,Intermediate,,,,,50597,BAO_0000218,A,,12797,In vivo,Rattus norvegicus,10116.0
13228,N,,,,Compound was tested in vivo for clearance after iv administration in the rat,Intermediate,,,,,50597,BAO_0000218,A,,11500,In vivo,Rattus norvegicus,10116.0
13229,U,,,,IV clearance determined at an iv dose of 14 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,15173,In vivo,,
13230,U,,,,IV clearance determined at an iv dose of 15.2 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,15173,In vivo,,
13231,U,,,,IV clearance determined at an iv dose of 15 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,15173,In vivo,,
13232,U,,,,IV clearance determined at an peroral dose of 30 mg/kg.,Autocuration,,,,,22224,BAO_0000218,A,,15173,In vivo,,
13233,U,,,,IV clearance determined at an peroral dose of 30.2 mg/kg.,Autocuration,,,,,22224,BAO_0000218,A,,15173,In vivo,,
13234,U,,,,IV clearance determined at an peroral dose of 30.3 mg/kg.,Autocuration,,,,,22224,BAO_0000218,A,,15173,In vivo,,
13235,N,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,Intermediate,,,,2113.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13236,N,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,Intermediate,,,,2107.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13237,N,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,Intermediate,,,,2048.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13238,N,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,Intermediate,,,,2385.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13239,N,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13240,N,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13241,N,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,Intermediate,,,,2106.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13242,N,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,Intermediate,,,,3126.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13243,N,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13244,N,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,Intermediate,,,,2037.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13245,N,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13246,N,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13247,N,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,Intermediate,,,,948.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13248,N,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13249,N,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,Intermediate,,,,2113.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13250,N,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,Intermediate,,,,2107.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13251,N,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,Intermediate,,,,2048.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13252,N,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,Intermediate,,,,2385.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13253,N,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13254,N,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13255,N,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,Intermediate,,,,2106.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13256,N,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,Intermediate,,,,3126.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13257,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13258,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,Intermediate,,,,2037.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13259,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13260,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13261,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,Intermediate,,,,948.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13262,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,Intermediate,,,,160.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13263,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,Intermediate,,,,2113.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13264,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,Intermediate,,,,2107.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13265,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,Intermediate,,,,2048.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13266,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,Intermediate,,,,2385.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13267,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13268,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13269,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,Intermediate,,,,2106.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13270,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,Intermediate,,,,3126.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13271,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13272,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,Intermediate,,,,2037.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13273,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13274,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13275,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,Intermediate,,,,948.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13276,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,Intermediate,,,,160.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13277,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,Intermediate,,,,2113.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13278,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,Intermediate,,,,2048.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13279,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,Intermediate,,,,2385.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13280,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13281,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13282,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,Intermediate,,,,2106.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13283,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,Intermediate,,,,3126.0,50597,BAO_0000218,A,,14198,In vivo,Rattus norvegicus,10116.0
13284,N,,,,Normal diffusion coefficient in water for Escherichia coli,Intermediate,,,,,50212,BAO_0000218,A,,15599,,Escherichia coli,562.0
13285,U,,,,Average max percent decrease in RVR (renal vascular resistance) was determined,Autocuration,,,,,22224,BAO_0000019,A,,8204,,,
13286,U,,,,Average max percent decrease in RVR (renal vascular resistance) was determined.,Autocuration,,,,,22224,BAO_0000019,A,,8204,,,
13287,U,,,,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,Autocuration,,,,,22224,BAO_0000019,A,,6154,,,
13288,U,,,,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,Autocuration,,,,,22224,BAO_0000019,A,,6154,,,
13289,U,,,,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,Autocuration,,,,,22224,BAO_0000019,A,,6154,,,
13290,U,,,,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,Autocuration,,,,,22224,BAO_0000019,A,,6154,,,
13291,U,,,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,Autocuration,,,,,22224,BAO_0000019,A,,7114,,,
13292,N,,,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,Intermediate,,,,,50597,BAO_0000218,A,,7114,,Rattus norvegicus,10116.0
13293,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,,Canis lupus familiaris,9615.0
13294,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,,Canis lupus familiaris,9615.0
13295,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,,Canis lupus familiaris,9615.0
13296,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,,Canis lupus familiaris,9615.0
13297,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,,Canis lupus familiaris,9615.0
13298,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,,Canis lupus familiaris,9615.0
13299,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,,Canis lupus familiaris,9615.0
13300,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,,Canis lupus familiaris,9615.0
13301,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,,Canis lupus familiaris,9615.0
13302,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,,Canis lupus familiaris,9615.0
13303,U,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",Autocuration,,,,1088.0,22224,BAO_0000218,A,,8133,,Simiiformes,314293.0
13304,U,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",Autocuration,,,,1088.0,22224,BAO_0000218,A,,8133,,Simiiformes,314293.0
13305,U,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",Autocuration,,,,1088.0,22224,BAO_0000218,A,,8133,,Simiiformes,314293.0
13306,U,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",Autocuration,,,,1088.0,22224,BAO_0000218,A,,8133,,Simiiformes,314293.0
13307,U,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",Autocuration,,,,1088.0,22224,BAO_0000218,A,,8133,,Simiiformes,314293.0
13308,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13309,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13310,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13311,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13312,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13313,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13314,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13315,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13316,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13317,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13318,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13319,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13320,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13321,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,,Canis lupus familiaris,9615.0
13322,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,,Canis lupus familiaris,9615.0
13323,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,,Canis lupus familiaris,9615.0
13324,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,,Canis lupus familiaris,9615.0
13325,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,,Canis lupus familiaris,9615.0
13326,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,,Canis lupus familiaris,9615.0
13327,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,,Canis lupus familiaris,9615.0
13328,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,,Canis lupus familiaris,9615.0
13329,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,,Canis lupus familiaris,9615.0
13330,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,,Canis lupus familiaris,9615.0
13331,U,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",Autocuration,,,,1088.0,22224,BAO_0000218,A,,8133,,Simiiformes,314293.0
13332,U,,,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,Autocuration,,,,,22224,BAO_0000218,A,,12170,In vivo,Rattus norvegicus,10116.0
13333,U,,,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,Autocuration,,,,,22224,BAO_0000218,A,,12170,In vivo,Rattus norvegicus,10116.0
13334,U,,,,Bioavailability (dose 20 mg/kg),Autocuration,,,,,22224,BAO_0000218,A,,4985,In vivo,Eutheria,9347.0
13335,U,,,,Bioavailability in dog,Autocuration,,,,,22224,BAO_0000218,A,,15145,In vivo,Canis lupus familiaris,9615.0
13336,U,,,,Bioavailability in rat (Sprague-Dawley) (male),Autocuration,,,,,22224,BAO_0000218,A,,14080,In vivo,Rattus norvegicus,10116.0
13337,U,,,,Bioavailability in monkey (dose 10 mg/kg i.d.),Autocuration,,,,,22224,BAO_0000218,A,,11219,In vivo,Primates,9443.0
13338,U,,,,Bioavailability in rat,Autocuration,,,,,22224,BAO_0000218,A,,15145,In vivo,Rattus norvegicus,10116.0
13339,U,,,,Bioavailability in rat,Autocuration,,,,,22224,BAO_0000218,A,,15145,In vivo,Rattus norvegicus,10116.0
13340,U,,,,Bioavailability in dog (dose 3.0 mg/kg p.o.),Autocuration,,,,,22224,BAO_0000218,A,,1202,In vivo,Canis lupus familiaris,9615.0
13341,U,,,,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,1202,In vivo,Canis lupus familiaris,9615.0
13342,N,,,,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,Intermediate,,,,,50505,BAO_0000218,A,,1202,In vivo,Pan troglodytes,9598.0
13343,U,,,,Bioavailability,Autocuration,,,,,22224,BAO_0000218,A,,4026,In vivo,Eutheria,9347.0
13344,U,,,,Bioavailability in squirrel monkey,Autocuration,,,,,22224,BAO_0000218,A,,1492,In vivo,Saimiri,9520.0
13345,N,,,,Bioavailability was evaluated in dog,Intermediate,,,,,50588,BAO_0000218,A,,12793,In vivo,Canis lupus familiaris,9615.0
13346,N,,,,Bioavailability was evaluated in hamster,Intermediate,,,,,100712,BAO_0000218,A,,12793,In vivo,Cricetinae,10026.0
13347,U,,,,Bioavailability in rat,Autocuration,,,,,22224,BAO_0000218,A,,12793,In vivo,Rattus norvegicus,10116.0
13348,N,,,,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14793,In vivo,Rattus norvegicus,10116.0
13349,N,,,,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14793,In vivo,Rattus norvegicus,10116.0
13350,U,,,,Bioavailability in rat (dose 10 mg/kg p.o.),Autocuration,,,,,22224,BAO_0000218,A,,14793,In vivo,Rattus norvegicus,10116.0
13351,N,,,,Bioavailability was measured in cynomolgus monkeys.,Intermediate,,,,,100710,BAO_0000218,A,,14731,In vivo,Macaca fascicularis,9541.0
13352,N,,,,Bioavailability was measured in nude mice.,Intermediate,,,,,50594,BAO_0000218,A,,14731,In vivo,Mus musculus,10090.0
13353,U,,,,Bioavailability in ferret (dose 10 mg/kg i.d.),Autocuration,,,,,22224,BAO_0000218,A,,12187,In vivo,Mustela putorius furo,9669.0
13354,U,,,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),Autocuration,,,,,22224,BAO_0000218,A,,12187,In vivo,Simiiformes,314293.0
13355,U,,,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",Autocuration,,,,,22224,BAO_0000218,A,,12187,In vivo,Simiiformes,314293.0
13356,U,,,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),Autocuration,,,,,22224,BAO_0000218,A,,12187,In vivo,Simiiformes,314293.0
13357,U,,,,Bioavailability in rat (dose 10 mg/kg i.d.),Autocuration,,,,,22224,BAO_0000218,A,,12187,In vivo,Rattus norvegicus,10116.0
13358,N,,,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",Intermediate,,,,,50597,BAO_0000218,A,,12187,In vivo,Rattus norvegicus,10116.0
13359,U,,,,Bioavailability was determined; extremely poor,Autocuration,,,,,22224,BAO_0000218,A,,17431,In vivo,,
13360,N,,,,% bioavailability in mice after oral administration of prodrug,Intermediate,,,,,50594,BAO_0000218,A,,13318,In vivo,Mus musculus,10090.0
13361,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13362,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13363,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13364,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13365,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13366,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13367,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13368,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13369,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13370,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13371,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13372,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13373,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13374,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13375,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13376,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13377,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13378,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13379,U,,,,IV clearance determined at an peroral dose of 15 mg/kg.,Autocuration,,,,,22224,BAO_0000218,A,,15173,In vivo,,
13380,N,,,,Mouse oral clearance was measured against Hymenolepiasis nana.,Expert,,,,,50064,BAO_0000218,F,,7732,In vivo,Hymenolepis nana,102285.0
13381,N,,,,Mouse oral clearance was measured against Nematospiroides dubius,Expert,,,,,50545,BAO_0000218,F,,7732,In vivo,Heligmosomoides polygyrus,6339.0
13382,U,,,,Mouse oral clearance was measured against N. dubius; NT is Not Tested,Autocuration,,,,,22224,BAO_0000218,F,,7732,In vivo,,
13383,N,,,,Mouse oral clearance was measured against N. nana; NT is Not Tested,Intermediate,,,,,50594,BAO_0000218,A,,7732,In vivo,Mus musculus,10090.0
13384,U,,,,Mouse oral clearance was measured against N. nana; NT is Not Tested,Autocuration,,,,,22224,BAO_0000218,B,,7732,In vivo,,
13385,U,,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,Autocuration,,,,,22224,BAO_0000218,A,,8328,In vivo,,
13386,U,,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,Autocuration,,,,,22224,BAO_0000218,A,,8328,In vivo,,
13387,U,,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,Autocuration,,,,,22224,BAO_0000218,A,,8328,In vivo,,
13388,U,,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,Autocuration,,,,,22224,BAO_0000218,A,,8328,In vivo,,
13389,U,,,,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,Autocuration,,,,,22224,BAO_0000218,A,,8328,In vivo,,
13390,U,,,,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,Autocuration,,,,,22224,BAO_0000218,A,,8328,In vivo,,
13391,U,,,,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,Autocuration,,,,,22224,BAO_0000218,A,,8328,In vivo,,
13392,U,,,,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,Autocuration,,,,,22224,BAO_0000218,A,,8328,In vivo,,
13393,U,,,,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,Autocuration,,,,,22224,BAO_0000218,A,,8328,In vivo,,
13394,N,,,,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,13376,In vivo,Canis lupus familiaris,9615.0
13395,N,,,,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,Intermediate,,,,,50797,BAO_0000218,A,,13477,In vivo,Macaca mulatta,9544.0
13396,N,,,,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,Intermediate,,,,,50597,BAO_0000218,A,,13477,In vivo,Rattus norvegicus,10116.0
13397,N,,,,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,13477,In vivo,Rattus norvegicus,10116.0
13398,N,,,,Plasma clearance was determined for the compound in rats,Intermediate,,,,,50597,BAO_0000218,A,,13313,In vivo,Rattus norvegicus,10116.0
13399,N,,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,Intermediate,,,,,50597,BAO_0000218,A,,12504,In vivo,Rattus norvegicus,10116.0
13400,N,,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,Intermediate,,,,,50597,BAO_0000218,A,,12504,In vivo,Rattus norvegicus,10116.0
13401,N,,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,Intermediate,,,,,50597,BAO_0000218,A,,12504,In vivo,Rattus norvegicus,10116.0
13402,N,,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,Intermediate,,,,,50597,BAO_0000218,A,,12504,In vivo,Rattus norvegicus,10116.0
13403,N,,,,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,Intermediate,,,,,50597,BAO_0000218,A,,13129,In vivo,Rattus norvegicus,10116.0
13404,N,,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,Intermediate,,,,,50545,BAO_0000218,A,,7732,In vivo,Heligmosomoides polygyrus,6339.0
13405,N,,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,Intermediate,,,,,50545,BAO_0000218,A,,7732,In vivo,Heligmosomoides polygyrus,6339.0
13406,N,,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,Intermediate,,,,,50545,BAO_0000218,A,,7732,In vivo,Heligmosomoides polygyrus,6339.0
13407,N,,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,Intermediate,,,,,50545,BAO_0000218,A,,7732,In vivo,Heligmosomoides polygyrus,6339.0
13408,N,,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,Intermediate,,,,,50545,BAO_0000218,A,,7732,In vivo,Heligmosomoides polygyrus,6339.0
13409,U,,,,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,Autocuration,,,,1088.0,22224,BAO_0000218,A,,9278,In vivo,Rattus norvegicus,10116.0
13410,U,,,,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,Autocuration,,,,,22224,BAO_0000218,A,,9278,In vivo,Rattus norvegicus,10116.0
13411,U,,,,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,Autocuration,,,,,22224,BAO_0000218,A,,9278,In vivo,Rattus norvegicus,10116.0
13412,U,,,,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,Autocuration,,,,1088.0,22224,BAO_0000218,A,,9278,In vivo,Rattus norvegicus,10116.0
13413,U,,,,Urinary clearance was determined in rat at 25 mg/kg os dosage,Autocuration,,,,1088.0,22224,BAO_0000218,A,,9278,In vivo,Rattus norvegicus,10116.0
13414,N,,,,Urinary clearance was determined at 100 mg/kg oral dosage in human,Intermediate,,,,1088.0,50587,BAO_0000218,A,,9278,In vivo,Homo sapiens,9606.0
13415,N,,,,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,Intermediate,,,,1088.0,50588,BAO_0000218,A,,9278,In vivo,Canis lupus familiaris,9615.0
13416,N,,,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,Intermediate,,,,1969.0,50588,BAO_0000218,A,,5932,In vivo,Canis lupus familiaris,9615.0
13417,N,,,,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5932,In vivo,Rattus norvegicus,10116.0
13418,N,,,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,Intermediate,,,,,50597,BAO_0000218,A,,5182,In vivo,Rattus norvegicus,10116.0
13419,N,,,,Clearance rate in dogs,Intermediate,,,,,50588,BAO_0000218,A,,10499,In vivo,Canis lupus familiaris,9615.0
13420,U,,,,Compound was measured for intrinsic clearance,Autocuration,,,,,22224,BAO_0000019,A,,6051,In vitro,,
13421,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,17508,,,
13422,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,6228,,,
13423,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,6231,,,
13424,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,17740,,,
13425,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,6495,,,
13426,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,2171,,,
13427,U,,,,Partition coefficient of the compound,Autocuration,,,,,22224,BAO_0000019,A,,3255,,,
13428,U,,,,Permeability,Autocuration,,,,,22224,BAO_0000019,A,,6821,,,
13429,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,2685,,,
13430,U,,,,Partition coefficient (logD),Autocuration,,,,,22224,BAO_0000019,A,,17584,,,
13431,U,,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),Autocuration,,,,,22229,BAO_0000100,P,,13824,,,
13432,U,,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),Autocuration,,,,,22229,BAO_0000100,P,,13824,,,
13433,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,16479,,,
13434,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,11997,,,
13435,U,,,,Calculated logarithm of partition coefficient (P) was determined,Autocuration,,,,,22229,BAO_0000100,P,,2988,,,
13436,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,931,,,
13437,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,4381,,,
13438,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,4397,,,
13439,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,5889,,,
13440,U,,,,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,Autocuration,,,,,22224,BAO_0000019,A,,6154,,,
13441,U,,,,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,Autocuration,,,,,22224,BAO_0000019,A,,6154,,,
13442,U,,,,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,Autocuration,,,,,22224,BAO_0000019,A,,6154,,,
13443,U,,,,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,Autocuration,,,,,22224,BAO_0000019,A,,6154,,,
13444,U,,,,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,Autocuration,,,,,22224,BAO_0000019,A,,6154,,,
13445,U,,,,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,Autocuration,,,,,22224,BAO_0000019,A,,6154,,,
13446,U,,,,Percent degradation of compound at a pH of 1 over a 18 hr period,Autocuration,,,,,22224,BAO_0000019,A,,6887,,,
13447,U,,,,Percent degradation of compound at pH of 1 over an 18 hr period,Autocuration,,,,,22224,BAO_0000019,A,,6887,,,
13448,U,,,,Delta Logarithm of Partition Coefficient value was determined.,Autocuration,,,,,22224,BAO_0000019,A,,14116,,,
13449,U,,,,Delta logPoct-cyc,Autocuration,,,,,22224,BAO_0000019,A,,11137,,,
13450,U,,,,Lipophilicity estimated on reversed phase TLC,Autocuration,,,,,22224,BAO_0000100,P,,7230,,,
13451,U,,,,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,Autocuration,,,,,22224,BAO_0000019,A,,15741,,,
13452,U,,,,Delta logPoct-cyc,Autocuration,,,,,22224,BAO_0000019,A,,9663,,,
13453,U,,,,Change in logarithm of partition coefficient of the compound,Autocuration,,,,,22229,BAO_0000100,P,,9663,,,
13454,U,,,,Delta logD (pH 6.5),Autocuration,,,,,22224,BAO_0000019,A,,13807,,,
13455,U,,,,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",Autocuration,,,,,22224,BAO_0000100,P,,13807,,,
13456,U,,,,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,Autocuration,,,,,22224,BAO_0000019,A,,17425,,,
13457,U,,,,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),Autocuration,,,,,22224,BAO_0000019,A,,12143,,,
13458,U,,,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,Autocuration,,,,,22224,BAO_0000219,A,,12608,,,
13459,U,,,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,Autocuration,,,,,22224,BAO_0000219,A,,12608,,,
13460,N,,,,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,Intermediate,,,,,50597,BAO_0000218,A,,8649,,Rattus norvegicus,10116.0
13461,N,,,,Amount of deuterium retained was reported after normal workup in rats,Intermediate,,,,,50597,BAO_0000218,A,,8649,,Rattus norvegicus,10116.0
13462,N,,,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,Intermediate,,,,,50597,BAO_0000218,A,,8649,,Rattus norvegicus,10116.0
13463,N,,,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,Intermediate,,,,,50597,BAO_0000218,A,,8649,,Rattus norvegicus,10116.0
13464,N,,,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,Intermediate,,,,,50597,BAO_0000218,A,,8649,,Rattus norvegicus,10116.0
13465,N,,,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,Intermediate,,,,,50597,BAO_0000218,A,,8649,,Rattus norvegicus,10116.0
13466,N,,,,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,Intermediate,,,,,50597,BAO_0000218,A,,8649,,Rattus norvegicus,10116.0
13467,U,,,,Compound was subjected to electrochemical oxidation,Autocuration,,,,,22224,BAO_0000019,A,,9659,,,
13468,U,,,,Compound was subjected to photochemical oxidation,Autocuration,,,,,22224,BAO_0000019,A,,9659,,,
13469,U,,,,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,Autocuration,,,,,22224,BAO_0000019,A,,9659,,,
13470,U,,,,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,Autocuration,,,,,22224,BAO_0000019,A,,9659,,,
13471,U,,,,Oxidation of compound by methemoglobin in presence of hydroperoxide,Autocuration,,,,,22224,BAO_0000019,A,,9659,,,
13472,N,,,,Percent diffusion through fuzzy rat skin after 48 h of incubation,Intermediate,,,,,50597,BAO_0000218,A,,9607,,Rattus norvegicus,10116.0
13473,U,,,,Dissociation constant (pKa),Autocuration,,,,,22229,BAO_0000100,P,,7057,,,
13474,U,,,,Dissociation constant value of the compound; ND means not determined.,Autocuration,,,,,22224,BAO_0000100,P,,7057,,,
13475,N,,,,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,Intermediate,,,,178.0,50597,BAO_0000218,A,,7911,,Rattus norvegicus,10116.0
13476,N,,,,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,Intermediate,,,,178.0,50597,BAO_0000218,A,,7911,,Rattus norvegicus,10116.0
13477,N,,,,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,Intermediate,,,,,50597,BAO_0000218,A,,7911,,Rattus norvegicus,10116.0
13478,N,,,,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,Intermediate,,,,,50597,BAO_0000218,A,,7911,,Rattus norvegicus,10116.0
13479,N,,,,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,Intermediate,,,,2107.0,50597,BAO_0000218,A,,7911,,Rattus norvegicus,10116.0
13480,N,,,,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,Intermediate,,,,2107.0,50597,BAO_0000218,A,,7911,,Rattus norvegicus,10116.0
13481,N,,,,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,Intermediate,,,,2106.0,50597,BAO_0000218,A,,7911,,Rattus norvegicus,10116.0
13482,N,,,,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,Intermediate,,,,2106.0,50597,BAO_0000218,A,,7911,,Rattus norvegicus,10116.0
13483,N,,,,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,Intermediate,,,,,50597,BAO_0000218,A,,7911,,Rattus norvegicus,10116.0
13484,N,,,,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,Intermediate,,,,1088.0,50597,BAO_0000218,A,,7911,,Rattus norvegicus,10116.0
13485,N,,,,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,Intermediate,,,,1988.0,50597,BAO_0000218,A,,7911,,Rattus norvegicus,10116.0
13486,N,,,,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,Intermediate,,,,1088.0,50597,BAO_0000218,A,,7911,,Rattus norvegicus,10116.0
13487,N,,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,Intermediate,,,,2037.0,50594,BAO_0000218,A,,13792,,Mus musculus,10090.0
13488,N,,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,Intermediate,,,,955.0,50594,BAO_0000218,A,,13792,,Mus musculus,10090.0
13489,U,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",Autocuration,,,,1088.0,22224,BAO_0000218,A,,8133,,Simiiformes,314293.0
13490,U,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",Autocuration,,,,1088.0,22224,BAO_0000218,A,,8133,,Simiiformes,314293.0
13491,U,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",Autocuration,,,,1088.0,22224,BAO_0000218,A,,8133,,Simiiformes,314293.0
13492,U,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",Autocuration,,,,1088.0,22224,BAO_0000218,A,,8133,,Simiiformes,314293.0
13493,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13494,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13495,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13496,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13497,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13498,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13499,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13500,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13501,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13502,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13503,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13504,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13505,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13506,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,,Canis lupus familiaris,9615.0
13507,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,,Canis lupus familiaris,9615.0
13508,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,,Canis lupus familiaris,9615.0
13509,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,,Canis lupus familiaris,9615.0
13510,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,,Canis lupus familiaris,9615.0
13511,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,,Canis lupus familiaris,9615.0
13512,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,,Canis lupus familiaris,9615.0
13513,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,,Canis lupus familiaris,9615.0
13514,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,,Canis lupus familiaris,9615.0
13515,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,,Canis lupus familiaris,9615.0
13516,U,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",Autocuration,,,,1088.0,22224,BAO_0000218,A,,8133,,Simiiformes,314293.0
13517,U,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",Autocuration,,,,1088.0,22224,BAO_0000218,A,,8133,,Simiiformes,314293.0
13518,U,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",Autocuration,,,,1088.0,22224,BAO_0000218,A,,8133,,Simiiformes,314293.0
13519,U,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",Autocuration,,,,1088.0,22224,BAO_0000218,A,,8133,,Simiiformes,314293.0
13520,U,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",Autocuration,,,,1088.0,22224,BAO_0000218,A,,8133,,Simiiformes,314293.0
13521,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13522,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13523,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13524,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13525,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13526,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13527,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13528,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13529,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13530,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13531,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13532,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13533,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13534,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13535,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13536,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13537,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13538,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13539,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13540,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13541,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13542,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13543,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13544,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13545,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13546,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13547,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13548,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13549,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13550,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13551,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13552,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13553,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13554,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13555,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13556,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13557,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13558,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13559,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13560,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,Intermediate,,,,,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13561,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,Intermediate,,,,,50597,BAO_0000218,A,,9025,In vivo,Rattus norvegicus,10116.0
13562,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,In vivo,Canis lupus familiaris,9615.0
13563,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,6448,,,
13564,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,17221,,,
13565,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,6545,,,
13566,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,577,,,
13567,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,6285,,,
13568,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,6500,,,
13569,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,6716,,,
13570,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,13658,,,
13571,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,6549,,,
13572,U,,,,Calculated partition coefficient (clogP) (MacLogP),Autocuration,,,,,22229,BAO_0000100,P,,14685,,,
13573,U,,,,Partition coefficient (logP),Autocuration,,,,,22224,BAO_0000019,A,,6893,,,
13574,U,,,,Kinetic parameter was determined,Autocuration,,,,,22224,BAO_0000019,A,,3687,,,
13575,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,4207,,,
13576,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,4626,,,
13577,U,,,,Lipophilicity was determined,Autocuration,,,,,22224,BAO_0000100,P,,1021,,,
13578,U,,,,Lipophilicity was determined,Autocuration,,,,,22224,BAO_0000100,P,,3777,,,
13579,U,,,,Lipophilicity was determined,Autocuration,,,,,22224,BAO_0000100,P,,17533,,,
13580,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,6524,,,
13581,U,,,,Lipophilicity was determined,Autocuration,,,,,22224,BAO_0000100,P,,17533,,,
13582,U,,,,Lipophilicity in octanol-water,Autocuration,,,,,22224,BAO_0000100,P,,6480,,,
13583,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,17606,,,
13584,U,,,,Octanol-water partition coefficient was determined,Autocuration,,,,,22229,BAO_0000100,P,,6863,,,
13585,U,,,,Partition coefficient (logP),Autocuration,,,,,22224,BAO_0000019,A,,1356,,,
13586,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,3326,,,
13587,U,,,,Partition coefficient was determined; ND means not determined,Autocuration,,,,,22224,BAO_0000019,A,,1356,,,
13588,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,12984,,,
13589,U,,,,Partition coefficient of the compound,Autocuration,,,,,22224,BAO_0000019,A,,17363,,,
13590,U,,,,Permeability was determined,Autocuration,,,,,22224,BAO_0000019,A,,6827,,,
13591,U,,,,The compound was evaluated for the partition coefficient,Autocuration,,,,,22229,BAO_0000100,P,,261,,,
13592,U,,,,Partition coefficient (logP),Autocuration,,,,,22224,BAO_0000019,A,,2685,,,
13593,U,,,,The lipophilicity was reported,Autocuration,,,,,22224,BAO_0000100,P,,414,,,
13594,U,,,,logarithm of the octanol-water partition coefficient for the compound,Autocuration,,,,,22229,BAO_0000100,P,,15769,,,
13595,U,,,,Clogp value was determined,Autocuration,,,,,22224,BAO_0000019,A,,17248,,,
13596,U,,,,Clp at a dose of 1.5 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,16935,In vivo,,
13597,U,,,,Clp at a dose of 2.0 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,16935,In vivo,,
13598,U,,,,"Clp, plasma clearance at a dose of 10 mg/kg",Autocuration,,,,1969.0,22224,BAO_0000218,A,,14832,In vivo,,
13599,U,,,,"Clp, plasma clearance at a dose of 50 mg/kg",Autocuration,,,,1969.0,22224,BAO_0000218,A,,14832,In vivo,,
13600,N,,,,Compound was tested for plasma clearance in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2399,In vivo,Rattus norvegicus,10116.0
13601,N,,,,Compound was tested for plasma clearance in rat; Not determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2399,In vivo,Rattus norvegicus,10116.0
13602,N,,,,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6227,In vivo,Rattus norvegicus,10116.0
13603,N,,,,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,Intermediate,,,,,50797,BAO_0000218,A,,6227,In vivo,Macaca mulatta,9544.0
13604,U,,,,Plasma clearance by iv administration at a dose 0.003 ug/mL,Autocuration,,,,,22224,BAO_0000218,A,,5623,In vivo,,
13605,U,,,,Plasma clearance determined,Autocuration,,,,,22224,BAO_0000218,A,,4854,In vivo,,
13606,N,,,,Plasma clearance after iv administration at 3 mg/kg in hamster,Intermediate,,,,,100712,BAO_0000218,A,,4493,In vivo,Cricetinae,10026.0
13607,N,,,,Plasma clearance after iv administration at 4 mg/kg in hamster,Intermediate,,,,,100712,BAO_0000218,A,,4493,In vivo,Cricetinae,10026.0
13608,N,,,,Rate of clearance in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,14956,In vivo,Rattus norvegicus,10116.0
13609,N,,,,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15372,In vivo,Rattus norvegicus,10116.0
13610,N,,,,Total plasma clearance after iv dose of 5.10 mg/kg in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15372,In vivo,Rattus norvegicus,10116.0
13611,N,,,,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15372,In vivo,Rattus norvegicus,10116.0
13612,N,,,,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15372,In vivo,Rattus norvegicus,10116.0
13613,U,,,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,Autocuration,,,,1969.0,22224,BAO_0000218,A,,15604,In vivo,Simiiformes,314293.0
13614,N,,,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15604,In vivo,Rattus norvegicus,10116.0
13615,N,,,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,15604,In vivo,Canis lupus familiaris,9615.0
13616,N,,,,Clpl value in rat,Intermediate,,,,,50597,BAO_0000218,A,,14964,In vivo,Rattus norvegicus,10116.0
13617,N,,,,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,Intermediate,,,,,50512,BAO_0000218,A,,15240,In vivo,Cavia porcellus,10141.0
13618,N,,,,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,16449,In vivo,Rattus norvegicus,10116.0
13619,N,,,,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,Intermediate,,,,,100710,BAO_0000218,A,,16449,In vivo,Macaca fascicularis,9541.0
13620,U,,,,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,Autocuration,,,,,22224,BAO_0000218,A,,12902,In vivo,,
13621,U,,,,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,Autocuration,,,,,22224,BAO_0000218,A,,12902,In vivo,,
13622,U,,,,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,Autocuration,,,,,22224,BAO_0000218,A,,12902,In vivo,,
13623,U,,,,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,Autocuration,,,,,22224,BAO_0000218,A,,12902,In vivo,,
13624,U,,,,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,Autocuration,,,,,22224,BAO_0000218,A,,12902,In vivo,,
13625,U,,,,Cmax in minutes at a po dose of 10.0(pmol/g/h).,Autocuration,,,,,22224,BAO_0000218,A,,12902,In vivo,,
13626,U,,,,Cmax in minutes at a po dose of 20.0(pmol/g/h).,Autocuration,,,,,22224,BAO_0000218,A,,12902,In vivo,,
13627,U,,,,Cmax in minutes at a po dose of 40.0(pmol/g/h).,Autocuration,,,,,22224,BAO_0000218,A,,12902,In vivo,,
13628,U,,,,Cmax was calculated as maximum concentration reached in the blood,Autocuration,,,,178.0,22224,BAO_0000218,A,,11149,In vivo,,
13629,U,,,,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,Autocuration,,,,178.0,22224,BAO_0000218,A,,11149,In vivo,,
13630,N,,,,Cmax was determine after peroral administration at 10 mpk in Rat,Intermediate,,,,,50597,BAO_0000218,A,,5669,In vivo,Rattus norvegicus,10116.0
13631,N,,,,Cmax was determine after peroral administration at 10 mpk in Rhesus,Intermediate,,,,,50797,BAO_0000218,A,,5669,In vivo,Macaca mulatta,9544.0
13632,N,,,,Cmax was determine after peroral administration at 10 mpk in dog,Intermediate,,,,,50588,BAO_0000218,A,,5669,In vivo,Canis lupus familiaris,9615.0
13633,N,,,,Cmax was determine after peroral administration at 160 mpk in Rat,Intermediate,,,,,50597,BAO_0000218,A,,5669,In vivo,Rattus norvegicus,10116.0
13634,N,,,,Cmax was determine after peroral administration at 20 mpk in Rat,Intermediate,,,,,50597,BAO_0000218,A,,5669,In vivo,Rattus norvegicus,10116.0
13635,N,,,,Cmax was determine after peroral administration at 50 mpk in Rat,Intermediate,,,,,50597,BAO_0000218,A,,5669,In vivo,Rattus norvegicus,10116.0
13636,U,,,,Cmax was determined,Autocuration,,,,,22224,BAO_0000218,A,,4236,In vivo,,
13637,N,,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,Intermediate,,,,955.0,50594,BAO_0000218,A,,13792,,Mus musculus,10090.0
13638,N,,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,Intermediate,,,,955.0,50594,BAO_0000218,A,,13792,,Mus musculus,10090.0
13639,N,,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,Intermediate,,,,955.0,50594,BAO_0000218,A,,13792,,Mus musculus,10090.0
13640,N,,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,Intermediate,,,,955.0,50594,BAO_0000218,A,,13792,,Mus musculus,10090.0
13641,N,,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,Intermediate,,,,2435.0,50594,BAO_0000218,A,,13792,,Mus musculus,10090.0
13642,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13643,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13644,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13645,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13646,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13647,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13648,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13649,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13650,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13651,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13652,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13653,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13654,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13655,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13656,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13657,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13658,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13659,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13660,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13661,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,Intermediate,,,,,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13662,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,Intermediate,,,,,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13663,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,Intermediate,,,,,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13664,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,Intermediate,,,,,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13665,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,Intermediate,,,,,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13666,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,Intermediate,,,,,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13667,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,Intermediate,,,,,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13668,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,Intermediate,,,,,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13669,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,Intermediate,,,,,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13670,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,Intermediate,,,,,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13671,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,Intermediate,,,,,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13672,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,Intermediate,,,,,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13673,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,Intermediate,,,,,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13674,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,Intermediate,,,,,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13675,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,Intermediate,,,,,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13676,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,Intermediate,,,,,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13677,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,Intermediate,,,,,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13678,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,Intermediate,,,,,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13679,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,Intermediate,,,,,50597,BAO_0000218,A,,8418,,Rattus norvegicus,10116.0
13680,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13681,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13682,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,,Rattus norvegicus,10116.0
13683,N,,,,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
13684,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
13685,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
13686,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
13687,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
13688,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
13689,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
13690,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
13691,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
13692,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
13693,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
13694,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
13695,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
13696,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
13697,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
13698,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
13699,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
13700,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
13701,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
13702,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
13703,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
13704,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
13705,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
13706,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
13707,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,Rattus norvegicus,10116.0
13708,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13709,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13710,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13711,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13712,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13713,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13714,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13715,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13716,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13717,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13718,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13719,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13720,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13721,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13722,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13723,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13724,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,Canis lupus familiaris,9615.0
13725,N,,,,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,,,,14.0,50594,BAO_0000218,A,,9716,In vivo,Mus musculus,10090.0
13726,N,,,,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,,,,14.0,50594,BAO_0000218,A,,9716,In vivo,Mus musculus,10090.0
13727,N,,,,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,,,,2106.0,50594,BAO_0000218,A,,9716,In vivo,Mus musculus,10090.0
13728,N,,,,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,,,,2106.0,50594,BAO_0000218,A,,9716,In vivo,Mus musculus,10090.0
13729,N,,,,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,,,,2106.0,50594,BAO_0000218,A,,9716,In vivo,Mus musculus,10090.0
13730,N,,,,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,,,,2106.0,50594,BAO_0000218,A,,9716,In vivo,Mus musculus,10090.0
13731,N,,,,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,,,,945.0,50594,BAO_0000218,A,,9716,In vivo,Mus musculus,10090.0
13732,N,,,,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,,,,945.0,50594,BAO_0000218,A,,9716,In vivo,Mus musculus,10090.0
13733,N,,,,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,,,,945.0,50594,BAO_0000218,A,,9716,In vivo,Mus musculus,10090.0
13734,N,,,,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,,,,945.0,50594,BAO_0000218,A,,9716,In vivo,Mus musculus,10090.0
13735,N,,,,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,,,,,50594,BAO_0000218,A,,9716,In vivo,Mus musculus,10090.0
13736,N,,,,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,,,,,50594,BAO_0000218,A,,9716,In vivo,Mus musculus,10090.0
13737,N,,,,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,,,,,50594,BAO_0000218,A,,9716,In vivo,Mus musculus,10090.0
13738,N,,,,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,,,,,50594,BAO_0000218,A,,9716,In vivo,Mus musculus,10090.0
13739,N,,,,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),Intermediate,,,,2113.0,50594,BAO_0000218,A,,12192,,Mus musculus,10090.0
13740,N,,,,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,Intermediate,,,,2113.0,50594,BAO_0000218,A,,12192,,Mus musculus,10090.0
13741,N,,,,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),Intermediate,,,,2113.0,50594,BAO_0000218,A,,12192,,Mus musculus,10090.0
13742,N,,,,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,Intermediate,,,,,50594,BAO_0000218,A,,12192,,Mus musculus,10090.0
13743,N,,,,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),Intermediate,,,,,50594,BAO_0000218,A,,12192,,Mus musculus,10090.0
13744,N,,,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,Intermediate,,,,,50594,BAO_0000218,A,,12192,,Mus musculus,10090.0
13745,N,,,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),Intermediate,,,,,50594,BAO_0000218,A,,12192,,Mus musculus,10090.0
13746,N,,,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,Intermediate,,,,,50594,BAO_0000218,A,,12192,,Mus musculus,10090.0
13747,N,,,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),Intermediate,,,,,50594,BAO_0000218,A,,12192,,Mus musculus,10090.0
13748,N,,,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,Intermediate,,,,,50594,BAO_0000218,A,,12192,,Mus musculus,10090.0
13749,N,,,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),Intermediate,,,,,50594,BAO_0000218,A,,12192,,Mus musculus,10090.0
13750,U,,,,Removal of 238-Plutonium(IV) in feces at 24 h,Autocuration,,,,1988.0,22224,BAO_0000019,A,,12192,,,
13751,U,,,,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),Autocuration,,,,1988.0,22224,BAO_0000019,A,,12192,,,
13752,U,,,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,Autocuration,,,,,22224,BAO_0000019,A,,12192,,,
13753,U,,,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),Autocuration,,,,,22224,BAO_0000019,A,,12192,,,
13754,U,,,,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),Autocuration,,,,1088.0,22224,BAO_0000019,A,,12192,,,
13755,U,,,,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),Autocuration,,,,1088.0,22224,BAO_0000019,A,,12192,,,
13756,U,,,,Removal of 238-Plutonium(IV) in urine after 0-24 h,Autocuration,,,,1088.0,22224,BAO_0000019,A,,12192,,,
13757,U,,,,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),Autocuration,,,,1088.0,22224,BAO_0000019,A,,12192,,,
13758,U,,,,Removal of 238-Plutonium(IV) in urine after 0-4 h,Autocuration,,,,1088.0,22224,BAO_0000019,A,,12192,,,
13759,U,,,,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),Autocuration,,,,1088.0,22224,BAO_0000019,A,,12192,,,
13760,U,,,,Removal of 238-Plutonium(IV) in urine after 4-24 h,Autocuration,,,,1088.0,22224,BAO_0000019,A,,12192,,,
13761,U,,,,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),Autocuration,,,,1088.0,22224,BAO_0000019,A,,12192,,,
13762,U,,,,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),Autocuration,,,,1088.0,22224,BAO_0000019,A,,12192,,,
13763,U,,,,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),Autocuration,,,,1088.0,22224,BAO_0000019,A,,12192,,,
13764,N,,,,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,178.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13765,N,,,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,178.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13766,N,,,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,178.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13767,N,,,,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,178.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13768,N,,,,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,178.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13769,N,,,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13770,N,,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13771,N,,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13772,N,,,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13773,N,,,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13774,N,,,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,Intermediate,,,,,50597,BAO_0000218,A,,11836,,Rattus norvegicus,10116.0
13775,N,,,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,Intermediate,,,,,50597,BAO_0000218,A,,11836,,Rattus norvegicus,10116.0
13776,N,,,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,Intermediate,,,,,50597,BAO_0000218,A,,11836,,Rattus norvegicus,10116.0
13777,N,,,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,Intermediate,,,,2385.0,50597,BAO_0000218,A,,11836,,Rattus norvegicus,10116.0
13778,N,,,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,Intermediate,,,,2385.0,50597,BAO_0000218,A,,11836,,Rattus norvegicus,10116.0
13779,N,,,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,Intermediate,,,,2385.0,50597,BAO_0000218,A,,11836,,Rattus norvegicus,10116.0
13780,N,,,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,Intermediate,,,,2385.0,50597,BAO_0000218,A,,11836,,Rattus norvegicus,10116.0
13781,N,,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,Intermediate,,,,2385.0,50597,BAO_0000218,A,,11836,,Rattus norvegicus,10116.0
13782,N,,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,Intermediate,,,,2385.0,50597,BAO_0000218,A,,11836,,Rattus norvegicus,10116.0
13783,N,,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,Intermediate,,,,2385.0,50597,BAO_0000218,A,,11836,,Rattus norvegicus,10116.0
13784,N,,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,Intermediate,,,,2385.0,50597,BAO_0000218,A,,11836,,Rattus norvegicus,10116.0
13785,N,,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,Intermediate,,,,2385.0,50597,BAO_0000218,A,,11836,,Rattus norvegicus,10116.0
13786,N,,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,Intermediate,,,,2385.0,50597,BAO_0000218,A,,11836,,Rattus norvegicus,10116.0
13787,N,,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,Intermediate,,,,2385.0,50597,BAO_0000218,A,,11836,,Rattus norvegicus,10116.0
13788,N,,,,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,Intermediate,,,,,50597,BAO_0000218,A,,11836,,Rattus norvegicus,10116.0
13789,N,,,,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,Intermediate,,,,995.0,50597,BAO_0000218,A,,11836,,Rattus norvegicus,10116.0
13790,U,,,,Tested in vitro for intrinsic activity relative to quinpirole,Autocuration,,,,,22224,BAO_0000019,A,,12640,,,
13791,U,,,,"Relative ion enhancement, determined in pulsed ultrafiltration",Autocuration,,,,,22224,BAO_0000019,A,,14218,,,
13792,U,,,,% ionization at the pH 7.4 at 37 degree Centigrade,Autocuration,,,,,22224,BAO_0000019,A,,11296,,,
13793,U,,,,Percentage ionization was measured,Autocuration,,,,,22224,BAO_0000019,A,,10929,,,
13794,N,,,,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,Intermediate,,,,,50591,BAO_0000218,A,,13841,,Bos taurus,9913.0
13795,U,,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,Autocuration,,,,,22224,BAO_0000019,A,,10431,,,
13796,U,,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,Autocuration,,,,,22224,BAO_0000019,A,,10431,,,
13797,U,,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,Autocuration,,,,,22224,BAO_0000019,A,,10431,,,
13798,U,,,,Compound was evaluated for the partition coefficient in octanol/water,Autocuration,,,,,22229,BAO_0000100,P,,8826,,,
13799,U,,,,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),Autocuration,,,,,22229,BAO_0000100,P,,8826,,,
13800,U,,,,Equilibrium constant measured by the pulse radiolysis at pH 7,Autocuration,,,,,22224,BAO_0000019,A,,9884,,,
13801,N,,,,In vitro hydrolytic rate constant determined in human blood,Intermediate,,,,,50587,BAO_0000218,A,,9827,,Homo sapiens,9606.0
13802,N,,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,Intermediate,,,,,50587,BAO_0000218,A,,10009,,Homo sapiens,9606.0
13803,U,,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,Autocuration,,,,,22224,BAO_0000019,A,,10009,,,
13804,N,,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,Intermediate,,,,,50594,BAO_0000218,A,,10009,,Mus musculus,10090.0
13805,N,,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,Intermediate,,,,,50594,BAO_0000218,A,,10009,,Mus musculus,10090.0
13806,N,,,,In vitro oxidation of compound in presence of human plasma,Intermediate,,,,,50587,BAO_0000218,A,,10009,,Homo sapiens,9606.0
13807,U,,,,In vitro oxidation of compound in presence of hydrogen peroxide,Autocuration,,,,,22224,BAO_0000019,A,,10009,,,
13808,N,,,,In vitro oxidation of compound in presence of mouse brain homogenate,Intermediate,,,,,50594,BAO_0000218,A,,10009,,Mus musculus,10090.0
13809,N,,,,In vitro oxidation of compound in presence of mouse liver homogenate,Intermediate,,,,,50594,BAO_0000218,A,,10009,,Mus musculus,10090.0
13810,N,,,,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13811,N,,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13812,N,,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13813,N,,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13814,N,,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13815,N,,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13816,N,,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13817,N,,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13818,N,,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13819,N,,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13820,N,,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13821,N,,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13822,N,,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13823,N,,,,Biodistribution in rat blood at 240 minutes after dose administration.,Intermediate,,,,178.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13824,N,,,,Biodistribution in rat blood at 30 minutes after dose administration.,Intermediate,,,,178.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13825,N,,,,Biodistribution in rat blood at 360 minutes after dose administration.,Intermediate,,,,178.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13826,N,,,,Biodistribution in rat blood at 3 hr after dose administration.,Intermediate,,,,178.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13827,N,,,,Biodistribution in rat blood at 60 minutes after dose administration.,Intermediate,,,,178.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13828,N,,,,Biodistribution in rat cerebellum at 120 minutes after dose administration.,Intermediate,,,,2037.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13829,N,,,,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,Intermediate,,,,2037.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13830,N,,,,Biodistribution in rat cerebellum at 15 minutes after dose administration.,Intermediate,,,,2037.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13831,N,,,,Biodistribution in rat cerebellum at 240 minutes after dose administration.,Intermediate,,,,2037.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13832,N,,,,Biodistribution in rat cerebellum at 30 minutes after dose administration.,Intermediate,,,,2037.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13833,N,,,,Biodistribution in rat cerebellum at 360 minutes after dose administration.,Intermediate,,,,2037.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13834,N,,,,Biodistribution in rat cerebellum at 3 hr after dose administration.,Intermediate,,,,2037.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13835,N,,,,Biodistribution in rat cerebellum at 60 minutes after dose administration.,Intermediate,,,,2037.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13836,N,,,,Biodistribution in rat cortex at 120 minutes after dose administration.,Intermediate,,,,,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13837,N,,,,Biodistribution in rat cortex at 1440 minutes after dose administration.,Intermediate,,,,,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13838,N,,,,Biodistribution in rat cortex at 15 minutes after dose administration.,Intermediate,,,,,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13839,N,,,,Biodistribution in rat cortex at 240 minutes after dose administration.,Intermediate,,,,,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13840,N,,,,Biodistribution in rat cortex at 30 minutes after dose administration.,Intermediate,,,,,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13841,N,,,,Biodistribution in rat cortex at 360 minutes after dose administration.,Intermediate,,,,,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13842,N,,,,Biodistribution in rat cortex at 3 hr after dose administration.,Intermediate,,,,,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13843,N,,,,Biodistribution in rat cortex at 60 minutes after dose administration.,Intermediate,,,,,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13844,N,,,,Biodistribution in rat heart at 120 minutes after dose administration.,Intermediate,,,,948.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13845,N,,,,Biodistribution in rat heart at 15 minutes after dose administration.,Intermediate,,,,948.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13846,N,,,,Biodistribution in rat heart at 240 minutes after dose administration.,Intermediate,,,,948.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13847,N,,,,Biodistribution in rat heart at 30 minutes after dose administration.,Intermediate,,,,948.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13848,N,,,,Biodistribution in rat heart at 360 minutes after dose administration.,Intermediate,,,,948.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13849,N,,,,Biodistribution in rat heart at 3 hr after dose administration.,Intermediate,,,,948.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13850,N,,,,Biodistribution in rat heart at 60 minutes after dose administration.,Intermediate,,,,948.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13851,N,,,,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13852,N,,,,Biodistribution in rat hippocampus at 240 minutes after dose administration.,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13853,N,,,,Biodistribution in rat hippocampus at 30 minutes after dose administration.,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13854,N,,,,Biodistribution in rat hippocampus at 360 minutes after dose administration.,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13855,N,,,,Biodistribution in rat hippocampus at 15 minutes after dose administration.,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13856,N,,,,Biodistribution in rat kidney at 120 minutes after dose administration.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13857,N,,,,Biodistribution in rat kidney at 1440 minutes after dose administration.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13858,N,,,,Biodistribution in rat kidney at 15 minutes after dose administration.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13859,N,,,,Biodistribution in rat kidney at 240 minutes after dose administration.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13860,N,,,,Biodistribution in rat kidney at 30 minutes after dose administration.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13861,N,,,,Biodistribution in rat kidney at 360 minutes after dose administration.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13862,N,,,,Biodistribution in rat kidney at 60 minutes after dose administration.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13863,N,,,,Biodistribution in rat liver at 120 minutes after dose administration.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13864,N,,,,Biodistribution in rat liver at 1440 minutes after dose administration.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13865,N,,,,Biodistribution in rat liver at 15 minutes after dose administration.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13866,N,,,,Biodistribution in rat liver at 240 minutes after dose administration.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13867,N,,,,Biodistribution in rat liver at 30 minutes after dose administration.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13868,N,,,,Biodistribution in rat liver at 360 minutes after dose administration.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13869,N,,,,Biodistribution in rat liver at 60 minutes after dose administration.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13870,N,,,,Biodistribution in rat lung at 120 minutes after dose administration.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13871,N,,,,Biodistribution in rat lung at 1440 minutes after dose administration.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13872,N,,,,Biodistribution in rat lung at 15 minutes after dose administration.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13873,N,,,,Biodistribution in rat lung at 240 minutes after dose administration.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13874,N,,,,Biodistribution in rat lung at 30 minutes after dose administration.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13875,N,,,,Biodistribution in rat lung at 360 minutes after dose administration.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
13876,N,,,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,Intermediate,,,,1515.0,50597,BAO_0000218,A,,12361,,Rattus norvegicus,10116.0
13877,N,,,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,Intermediate,,,,1515.0,50597,BAO_0000218,A,,12361,,Rattus norvegicus,10116.0
13878,N,,,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,Intermediate,,,,1515.0,50597,BAO_0000218,A,,12361,,Rattus norvegicus,10116.0
13879,N,,,,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,Intermediate,,,,1515.0,50597,BAO_0000218,A,,12361,,Rattus norvegicus,10116.0
13880,N,,,,Percent of maximal contractile response to compound in rat thoracic aorta strips v,Intermediate,,,,1515.0,50597,BAO_0000218,A,,12361,,Rattus norvegicus,10116.0
13881,N,,,,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,Intermediate,,,,1515.0,50597,BAO_0000218,A,,12361,,Rattus norvegicus,10116.0
13882,N,,,,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,Intermediate,,,,1515.0,50597,BAO_0000218,A,,12361,,Rattus norvegicus,10116.0
13883,N,,,,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12712,,Rattus norvegicus,10116.0
13884,N,,,,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,Intermediate,,,,1988.0,50597,BAO_0000218,A,,7415,,Rattus norvegicus,10116.0
13885,N,,,,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,Intermediate,,,,1088.0,50597,BAO_0000218,A,,7415,,Rattus norvegicus,10116.0
13886,N,,,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,7415,,Rattus norvegicus,10116.0
13887,N,,,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,7415,,Rattus norvegicus,10116.0
13888,N,,,,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",Intermediate,,,,1988.0,50597,BAO_0000218,A,,7415,,Rattus norvegicus,10116.0
13889,N,,,,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",Intermediate,,,,1088.0,50597,BAO_0000218,A,,7415,,Rattus norvegicus,10116.0
13890,N,,,,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",Intermediate,,,,,50597,BAO_0000218,A,,7415,,Rattus norvegicus,10116.0
13891,N,,,,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,Intermediate,,,,,50594,BAO_0000218,A,,8050,,Mus musculus,10090.0
13892,N,,,,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,Intermediate,,,,,50594,BAO_0000218,A,,8050,,Mus musculus,10090.0
13893,N,,,,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,Intermediate,,,,,50594,BAO_0000218,A,,8050,,Mus musculus,10090.0
13894,N,,,,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,Intermediate,,,,,50594,BAO_0000218,A,,8050,,Mus musculus,10090.0
13895,N,,,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,Intermediate,,,,1088.0,50594,BAO_0000218,A,,8050,,Mus musculus,10090.0
13896,N,,,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,Intermediate,,,,1088.0,50594,BAO_0000218,A,,8050,,Mus musculus,10090.0
13897,N,,,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,Intermediate,,,,1088.0,50594,BAO_0000218,A,,8050,,Mus musculus,10090.0
13898,N,,,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,Intermediate,,,,1088.0,50594,BAO_0000218,A,,8050,,Mus musculus,10090.0
13899,N,,,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,Intermediate,,,,1088.0,50594,BAO_0000218,A,,8050,,Mus musculus,10090.0
13900,N,,,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,Intermediate,,,,1088.0,50594,BAO_0000218,A,,8050,,Mus musculus,10090.0
13901,N,,,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,Intermediate,,,,1088.0,50594,BAO_0000218,A,,8050,,Mus musculus,10090.0
13902,N,,,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,Intermediate,,,,1088.0,50594,BAO_0000218,A,,8050,,Mus musculus,10090.0
13903,N,,,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,Intermediate,,,,1088.0,50594,BAO_0000218,A,,8050,,Mus musculus,10090.0
13904,N,,,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,Intermediate,,,,1088.0,50594,BAO_0000218,A,,8050,,Mus musculus,10090.0
13905,N,,,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,Intermediate,,,,1088.0,50594,BAO_0000218,A,,8050,,Mus musculus,10090.0
13906,N,,,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,Intermediate,,,,1088.0,50594,BAO_0000218,A,,8050,,Mus musculus,10090.0
13907,N,,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
13908,N,,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
13909,N,,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
13910,N,,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
13911,N,,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
13912,N,,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
13913,N,,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
13914,N,,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
13915,N,,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
13916,N,,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
13917,N,,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
13918,N,,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
13919,N,,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
13920,N,,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
13921,N,,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
13922,N,,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
13923,N,,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
13924,N,,,,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2113.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13925,N,,,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2113.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13926,N,,,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2113.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13927,N,,,,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2113.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13928,N,,,,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2113.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13929,N,,,,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13930,N,,,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13931,N,,,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13932,N,,,,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13933,N,,,,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13934,N,,,,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2048.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13935,N,,,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2048.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13936,N,,,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2048.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13937,N,,,,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2048.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13938,N,,,,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2048.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13939,N,,,,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2385.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13940,N,,,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2385.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13941,N,,,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2385.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13942,N,,,,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2385.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13943,N,,,,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2385.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13944,N,,,,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13945,N,,,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13946,N,,,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13947,N,,,,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13948,N,,,,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13949,N,,,,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2046.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13950,N,,,,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2046.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13951,N,,,,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2046.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13952,N,,,,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2046.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13953,N,,,,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2046.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13954,N,,,,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13955,N,,,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13956,N,,,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13957,N,,,,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13958,N,,,,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13959,N,,,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13960,N,,,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13961,N,,,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13962,N,,,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13963,N,,,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13964,N,,,,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
13965,N,,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13966,N,,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13967,N,,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13968,N,,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13969,N,,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13970,N,,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13971,N,,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13972,N,,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13973,N,,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13974,N,,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13975,N,,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13976,N,,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13977,N,,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13978,N,,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13979,N,,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13980,N,,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
13981,U,,,,Octanol:water partition coefficient is evaluated,Autocuration,,,,,22229,BAO_0000100,P,,8362,,,
13982,U,,,,Partition coefficient in 1-octanol/water system,Autocuration,,,,,22224,BAO_0000100,P,,8257,,,
13983,U,,,,Partition coefficient in 1-octanol/water system measured using radio active compounds,Autocuration,,,,,22224,BAO_0000100,P,,8257,,,
13984,U,,,,Partition coefficient in octanol/water system was determined,Autocuration,,,,,22224,BAO_0000100,P,,9468,,,
13985,U,,,,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,Autocuration,,,,,22224,BAO_0000100,P,,9468,,,
13986,U,,,,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,Autocuration,,,,,22224,BAO_0000019,A,,10568,,,
13987,U,,,,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",Autocuration,,,,,22224,BAO_0000019,A,,10568,,,
13988,U,,,,Pseudo-first-order rate constant of the compound,Autocuration,,,,,22224,BAO_0000019,A,,15359,,,
13989,U,,,,Pseudo-first-order rate constant with 1-min time point,Autocuration,,,,,22224,BAO_0000019,A,,15359,,,
13990,U,,,,Pseudo-first-order rate constant without 1-min time point,Autocuration,,,,,22224,BAO_0000019,A,,15359,,,
13991,U,,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,Autocuration,,,,,22224,BAO_0000019,A,,10431,,,
13992,U,,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,Autocuration,,,,,22224,BAO_0000019,A,,10431,,,
13993,U,,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,Autocuration,,,,,22224,BAO_0000019,A,,10431,,,
13994,U,,,,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,Autocuration,,,,,22224,BAO_0000019,A,,15704,,,
13995,U,,,,The alkaline hydrolysis second order rate constant(K OH) of the compound,Autocuration,,,,,22224,BAO_0000019,A,,15287,,,
13996,U,,,,The efflux rate constant of the compound,Autocuration,,,,,22224,BAO_0000019,A,,7516,,,
13997,U,,,,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,Autocuration,,,,,22224,BAO_0000019,A,,12973,,,
13998,U,,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,Autocuration,,,,,22224,BAO_0000019,A,,12973,,,
13999,U,,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,Autocuration,,,,,22224,BAO_0000019,F,,12973,,,
14000,U,,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,Autocuration,,,,,22224,BAO_0000019,A,,12973,,,
14001,U,,,,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,Autocuration,,,,,22224,BAO_0000019,A,,8696,,,
14002,U,,,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,Autocuration,,,,,22224,BAO_0000019,A,,15052,,,
14003,U,,,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,Autocuration,,,,,22224,BAO_0000019,A,,15052,,,
14004,U,,,,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),Autocuration,,,,,22224,BAO_0000019,A,,10503,,,
14005,U,,,,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,,
14006,U,,,,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,,
14007,U,,,,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,,
14008,U,,,,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,,
14009,U,,,,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,,
14010,U,,,,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,Autocuration,,,,,22224,BAO_0000019,A,,10503,,,
14011,U,,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,,
14012,U,,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,,
14013,U,,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,,
14014,U,,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,,
14015,N,,,,Biodistribution in rat lung at 60 minutes after dose administration.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
14016,N,,,,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,Intermediate,,,,,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
14017,N,,,,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,Intermediate,,,,,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
14018,N,,,,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,Intermediate,,,,,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
14019,N,,,,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,Intermediate,,,,,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
14020,N,,,,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,Intermediate,,,,,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
14021,N,,,,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,Intermediate,,,,,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
14022,N,,,,Biodistribution in rat striatum at 120 minutes after dose administration.,Intermediate,,,,2435.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
14023,N,,,,Biodistribution in rat striatum at 1440 minutes after dose administration.,Intermediate,,,,2435.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
14024,N,,,,Biodistribution in rat striatum at 15 minutes after dose administration.,Intermediate,,,,2435.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
14025,N,,,,Biodistribution in rat striatum at 240 minutes after dose administration.,Intermediate,,,,2435.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
14026,N,,,,Biodistribution in rat striatum at 30 minutes after dose administration.,Intermediate,,,,2435.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
14027,N,,,,Biodistribution in rat striatum at 360 minutes after dose administration.,Intermediate,,,,2435.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
14028,N,,,,Biodistribution in rat striatum at 3 hr after dose administration.,Intermediate,,,,2435.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
14029,N,,,,Biodistribution in rat striatum at 60 minutes after dose administration.,Intermediate,,,,2435.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
14030,N,,,,Biodistribution in rat thyroid at 120 minutes after dose administration.,Intermediate,,,,2046.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
14031,N,,,,Biodistribution in rat thyroid at 1440 minutes after dose administration.,Intermediate,,,,2046.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
14032,N,,,,Biodistribution in rat thyroid at 15 minutes after dose administration.,Intermediate,,,,2046.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
14033,N,,,,Biodistribution in rat thyroid at 240 minutes after dose administration.,Intermediate,,,,2046.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
14034,N,,,,Biodistribution in rat thyroid at 30 minutes after dose administration.,Intermediate,,,,2046.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
14035,N,,,,Biodistribution in rat thyroid at 360 minutes after dose administration.,Intermediate,,,,2046.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
14036,N,,,,Biodistribution in rat thyroid at 60 minutes after dose administration.,Intermediate,,,,2046.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
14037,N,,,,Biodistribution in rest of brain of rat 120 minutes after dose administration.,Intermediate,,,,955.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
14038,N,,,,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,Intermediate,,,,955.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
14039,N,,,,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,Intermediate,,,,955.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
14040,N,,,,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,Intermediate,,,,955.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
14041,N,,,,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,Intermediate,,,,955.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
14042,N,,,,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,Intermediate,,,,955.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
14043,N,,,,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,Intermediate,,,,955.0,50597,BAO_0000218,A,,13100,In vivo,Rattus norvegicus,10116.0
14044,U,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",Autocuration,,,,,22224,BAO_0000019,A,,13331,,,
14045,U,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",Autocuration,,,,,22224,BAO_0000019,A,,13331,,,
14046,U,,,,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),Autocuration,,,,,22224,BAO_0000019,A,,13331,,,
14047,U,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",Autocuration,,,,,22224,BAO_0000019,A,,13331,,,
14048,U,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",Autocuration,,,,,22224,BAO_0000019,A,,13331,,,
14049,U,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",Autocuration,,,,,22224,BAO_0000019,A,,13331,,,
14050,U,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",Autocuration,,,,,22224,BAO_0000019,A,,13331,,,
14051,U,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",Autocuration,,,,,22224,BAO_0000019,A,,13331,,,
14052,N,,,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,Intermediate,,,,1088.0,50597,BAO_0000218,A,,10086,,Rattus norvegicus,10116.0
14053,U,,,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,Autocuration,,,,1088.0,22224,BAO_0000218,F,,10086,,,
14054,N,,,,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,Intermediate,,,,1088.0,50597,BAO_0000218,A,,10086,,Rattus norvegicus,10116.0
14055,U,,,,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,Autocuration,,,,1088.0,22224,BAO_0000218,F,,10086,,,
14056,N,,,,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,Intermediate,,,,1088.0,50597,BAO_0000218,A,,10086,,Rattus norvegicus,10116.0
14057,N,,,,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,Intermediate,,,,1088.0,50597,BAO_0000218,A,,10086,,Rattus norvegicus,10116.0
14058,N,,,,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,Intermediate,,,,1088.0,50597,BAO_0000218,A,,10086,,Rattus norvegicus,10116.0
14059,N,,,,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,Intermediate,,,,1088.0,50597,BAO_0000218,A,,10086,,Rattus norvegicus,10116.0
14060,N,,,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,Intermediate,,,,,50597,BAO_0000218,A,,13248,,Rattus norvegicus,10116.0
14061,N,,,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,Intermediate,,,,,50597,BAO_0000218,A,,13248,,Rattus norvegicus,10116.0
14062,N,,,,In vitro metabolism in human liver microsomes,Intermediate,,,,2107.0,50587,BAO_0000218,A,,14527,,Homo sapiens,9606.0
14063,N,,,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,Intermediate,,,,,50587,BAO_0000218,A,,3008,,Homo sapiens,9606.0
14064,N,,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14065,N,,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14066,N,,,,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14067,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14068,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14069,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14070,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14071,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14072,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14073,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14074,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14075,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14076,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14077,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14078,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14079,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14080,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14081,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14082,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14083,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14084,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14085,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14086,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14087,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14088,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14089,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14090,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14091,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14092,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14093,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14094,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14095,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14096,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14097,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14098,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14099,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14100,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14101,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14102,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14103,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14104,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14105,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14106,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14107,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14108,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14109,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14110,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14111,N,,,,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14112,N,,,,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,995.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14113,N,,,,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,995.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14114,N,,,,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,995.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14115,N,,,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),Intermediate,,,,178.0,50597,BAO_0000218,A,,14045,In vivo,Rattus norvegicus,10116.0
14116,N,,,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),Intermediate,,,,178.0,50597,BAO_0000218,A,,14045,In vivo,Rattus norvegicus,10116.0
14117,N,,,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),Intermediate,,,,178.0,50597,BAO_0000218,A,,14045,In vivo,Rattus norvegicus,10116.0
14118,N,,,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),Intermediate,,,,178.0,50597,BAO_0000218,A,,14045,In vivo,Rattus norvegicus,10116.0
14119,N,,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),Intermediate,,,,955.0,50597,BAO_0000218,A,,14045,In vivo,Rattus norvegicus,10116.0
14120,N,,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),Intermediate,,,,955.0,50597,BAO_0000218,A,,14045,In vivo,Rattus norvegicus,10116.0
14121,N,,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),Intermediate,,,,955.0,50597,BAO_0000218,A,,14045,In vivo,Rattus norvegicus,10116.0
14122,N,,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),Intermediate,,,,955.0,50597,BAO_0000218,A,,14045,In vivo,Rattus norvegicus,10116.0
14123,N,,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),Intermediate,,,,,50597,BAO_0000218,A,,14045,In vivo,Rattus norvegicus,10116.0
14124,N,,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),Intermediate,,,,,50597,BAO_0000218,A,,14045,In vivo,Rattus norvegicus,10116.0
14125,N,,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),Intermediate,,,,,50597,BAO_0000218,A,,14045,In vivo,Rattus norvegicus,10116.0
14126,N,,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),Intermediate,,,,,50597,BAO_0000218,A,,14045,In vivo,Rattus norvegicus,10116.0
14127,N,,,,Biodistribution in mice bladder plus excreted urine was determined,Intermediate,,,,,50594,BAO_0000218,A,,14045,In vivo,Mus musculus,10090.0
14128,N,,,,"Percentage biodistribution in mouse blood, 10 minutes post injection",Intermediate,,,,,50594,BAO_0000218,A,,14045,,Mus musculus,10090.0
14129,N,,,,"Percentage biodistribution in mouse blood, 30 minutes post injection",Intermediate,,,,,50594,BAO_0000218,A,,14045,,Mus musculus,10090.0
14130,N,,,,"Percentage biodistribution in mouse blood, 5 minutes post injection",Intermediate,,,,,50594,BAO_0000218,A,,14045,,Mus musculus,10090.0
14131,N,,,,"Percentage biodistribution in mouse blood, 60 minutes post injection",Intermediate,,,,,50594,BAO_0000218,A,,14045,,Mus musculus,10090.0
14132,N,,,,"Percentage biodistribution in mouse brain, 10 minutes post injection",Intermediate,,,,955.0,50594,BAO_0000218,A,,14045,,Mus musculus,10090.0
14133,N,,,,"Percentage biodistribution in mouse brain, 30 minutes post injection",Intermediate,,,,955.0,50594,BAO_0000218,A,,14045,,Mus musculus,10090.0
14134,N,,,,"Percentage biodistribution in mouse brain, 5 minutes post injection",Intermediate,,,,955.0,50594,BAO_0000218,A,,14045,,Mus musculus,10090.0
14135,N,,,,"Percentage biodistribution in mouse brain, 60 minutes post injection",Intermediate,,,,955.0,50594,BAO_0000218,A,,14045,,Mus musculus,10090.0
14136,N,,,,"Percentage biodistribution in mouse heart, 10 minutes post injection",Intermediate,,,,,50594,BAO_0000218,A,,14045,,Mus musculus,10090.0
14137,N,,,,"Percentage biodistribution in mouse heart, 30 minutes post injection",Intermediate,,,,,50594,BAO_0000218,A,,14045,,Mus musculus,10090.0
14138,N,,,,"Percentage biodistribution in mouse heart, 5 minutes post injection",Intermediate,,,,,50594,BAO_0000218,A,,14045,,Mus musculus,10090.0
14139,N,,,,"Percentage biodistribution in mouse heart, 60 minutes post injection",Intermediate,,,,,50594,BAO_0000218,A,,14045,,Mus musculus,10090.0
14140,N,,,,"Percentage biodistribution in mouse intestine, 10 minutes post injection",Intermediate,,,,160.0,50594,BAO_0000218,A,,14045,,Mus musculus,10090.0
14141,N,,,,"Percentage biodistribution in mouse intestine, 30 minutes post injection",Intermediate,,,,160.0,50594,BAO_0000218,A,,14045,,Mus musculus,10090.0
14142,N,,,,"Percentage biodistribution in mouse intestine, 5 minutes post injection",Intermediate,,,,160.0,50594,BAO_0000218,A,,14045,,Mus musculus,10090.0
14143,N,,,,"Percentage biodistribution in mouse intestine, 60 minutes post injection",Intermediate,,,,160.0,50594,BAO_0000218,A,,14045,,Mus musculus,10090.0
14144,N,,,,"Percentage biodistribution in mouse liver, 10 minutes post injection",Intermediate,,,,2107.0,50594,BAO_0000218,A,,14045,,Mus musculus,10090.0
14145,N,,,,"Percentage biodistribution in mouse liver, 30 minutes of post injection",Intermediate,,,,2107.0,50594,BAO_0000218,A,,14045,,Mus musculus,10090.0
14146,N,,,,"Percentage biodistribution in mouse liver, 5 minutes post injection",Intermediate,,,,2107.0,50594,BAO_0000218,A,,14045,,Mus musculus,10090.0
14147,N,,,,Biodistribution in mice liver at 60 minutes of post injection,Intermediate,,,,2107.0,50594,BAO_0000218,A,,14045,In vivo,Mus musculus,10090.0
14148,N,,,,Biodistribution in mice lungs at 10 min of post injection,Intermediate,,,,2048.0,50594,BAO_0000218,A,,14045,In vivo,Mus musculus,10090.0
14149,N,,,,"Percentage biodistribution in mouse lung, 30 minutes post injection",Intermediate,,,,,50594,BAO_0000218,A,,14045,,Mus musculus,10090.0
14150,N,,,,"Percentage biodistribution in mousee lung, 5 minutes post injection",Intermediate,,,,,50594,BAO_0000218,A,,14045,,Mus musculus,10090.0
14151,N,,,,Biodistribution in mice lungs at 60 min of post injection,Intermediate,,,,2048.0,50594,BAO_0000218,A,,14045,In vivo,Mus musculus,10090.0
14152,N,,,,Percentage biodistribution in mouse spleen,Intermediate,,,,2106.0,50594,BAO_0000218,A,,14045,,Mus musculus,10090.0
14153,N,,,,Percentage biodistribution in mouse stomach,Intermediate,,,,945.0,50594,BAO_0000218,A,,14045,,Mus musculus,10090.0
14154,N,,,,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,Intermediate,,,,1088.0,50594,BAO_0000218,A,,11745,,Mus musculus,10090.0
14155,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,Autocuration,,,,1255.0,22224,BAO_0000218,A,,13257,In vivo,,
14156,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,Autocuration,,,,178.0,22224,BAO_0000218,A,,13257,In vivo,,
14157,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,Autocuration,,,,1474.0,22224,BAO_0000218,A,,13257,In vivo,,
14158,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,Autocuration,,,,,22224,BAO_0000218,A,,13257,In vivo,,
14159,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,Autocuration,,,,2113.0,22224,BAO_0000218,A,,13257,In vivo,,
14160,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,Autocuration,,,,2107.0,22224,BAO_0000218,A,,13257,In vivo,,
14161,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,Autocuration,,,,2048.0,22224,BAO_0000218,A,,13257,In vivo,,
14162,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,Autocuration,,,,2385.0,22224,BAO_0000218,A,,13257,In vivo,,
14163,U,,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,,
14164,N,,,,Affinity for protein binding expressed as association constant in fresh rat serum,Intermediate,,,,1977.0,50597,BAO_0000218,A,,7095,,Rattus norvegicus,10116.0
14165,U,,,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,Autocuration,,,,,22224,BAO_0000019,A,,12185,,,
14166,U,,,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,Autocuration,,,,,22224,BAO_0000019,A,,12185,,,
14167,U,,,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,Autocuration,,,,,22224,BAO_0000019,A,,12185,,,
14168,U,,,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,Autocuration,,,,,22224,BAO_0000019,A,,12185,,,
14169,U,,,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,Autocuration,,,,,22224,BAO_0000019,A,,12686,,,
14170,U,,,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",Autocuration,,,,,22224,BAO_0000019,A,,12686,,,
14171,U,,,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,Autocuration,,,,,22224,BAO_0000019,A,,12686,,,
14172,U,,,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",Autocuration,,,,,22224,BAO_0000019,A,,12686,,,
14173,U,,,,Apparent rate constant Koff for inactivation of dTMP synthase.,Autocuration,,,,,22224,BAO_0000019,A,,8057,,,
14174,U,,,,The irreversible inhibitor activity by second order rate equation.,Autocuration,,,,,22224,BAO_0000019,A,,15778,,,
14175,N,,,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,Intermediate,,,,,50597,BAO_0000218,A,,12375,,Rattus norvegicus,10116.0
14176,N,,,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,Intermediate,,,,,50597,BAO_0000218,A,,12375,,Rattus norvegicus,10116.0
14177,N,,,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,Intermediate,,,,,50597,BAO_0000218,A,,12375,,Rattus norvegicus,10116.0
14178,U,,,,Dissociation rate calculated from the first-order equation using t1/2 value,Autocuration,,,,,22224,BAO_0000019,A,,13588,,,
14179,U,,,,The compound was tested for Binding constant against DNA,Autocuration,,,,,22224,BAO_0000019,A,,15039,,,
14180,U,,,,First order rate constant for cyclization of the compound,Autocuration,,,,,22224,BAO_0000019,A,,9500,,,
14181,U,,,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,Autocuration,,,,,22224,BAO_0000019,A,,10014,,,
14182,U,,,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,Autocuration,,,,,22224,BAO_0000019,A,,10014,,,
14183,U,,,,Hydrolysis rate constant was determined,Autocuration,,,,,22224,BAO_0000019,A,,568,,,
14184,U,,,,Observed first order rate constant,Autocuration,,,,,22224,BAO_0000019,A,,10026,,,
14185,U,,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,Autocuration,,,,,22224,BAO_0000019,A,,10281,,,
14186,U,,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,Autocuration,,,,,22224,BAO_0000019,A,,10281,,,
14187,U,,,,Second-order rate constant for attack on PNPA at 25 degree Centigrade,Autocuration,,,,,22224,BAO_0000019,A,,9680,,,
14188,U,,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,,
14189,U,,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,,
14190,U,,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,,
14191,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,,
14192,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,,
14193,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,,
14194,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,,
14195,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,,
14196,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,,
14197,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,,
14198,U,,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,,
14199,U,,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,,
14200,U,,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,,
14201,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,,
14202,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,,
14203,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,,
14204,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,,
14205,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,,
14206,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,,
14207,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,,
14208,N,,,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,Intermediate,,,,,50587,BAO_0000218,A,,3008,,Homo sapiens,9606.0
14209,N,,,,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,Intermediate,,,,,50587,BAO_0000218,A,,4509,,Homo sapiens,9606.0
14210,N,,,,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,Intermediate,,,,,50587,BAO_0000218,A,,4509,,Homo sapiens,9606.0
14211,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,Intermediate,,,,,50602,BAO_0000218,A,,8613,,Human herpesvirus 1,10298.0
14212,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,Intermediate,,,,,50602,BAO_0000218,A,,8613,,Human herpesvirus 1,10298.0
14213,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,Intermediate,,,,,50602,BAO_0000218,A,,8613,,Human herpesvirus 1,10298.0
14214,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,Intermediate,,,,,50602,BAO_0000218,A,,8613,,Human herpesvirus 1,10298.0
14215,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,Intermediate,,,,,50602,BAO_0000218,A,,8613,,Human herpesvirus 1,10298.0
14216,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,Intermediate,,,,,50602,BAO_0000218,A,,8613,,Human herpesvirus 1,10298.0
14217,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,Intermediate,,,,,50602,BAO_0000218,A,,8613,,Human herpesvirus 1,10298.0
14218,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,Intermediate,,,,,50602,BAO_0000218,A,,8613,,Human herpesvirus 1,10298.0
14219,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,Intermediate,,,,,50602,BAO_0000218,A,,8613,,Human herpesvirus 1,10298.0
14220,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,Intermediate,,,,,50602,BAO_0000218,A,,8613,,Human herpesvirus 1,10298.0
14221,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,Intermediate,,,,,50602,BAO_0000218,A,,8613,,Human herpesvirus 1,10298.0
14222,U,,,,Calculated partition coefficient (clogP) (MlogP),Autocuration,,,,,22229,BAO_0000100,P,,6021,,,
14223,U,,,,Equipotent potent ratio relative to carbachol (nicotinic activity),Autocuration,,,,,22224,BAO_0000019,A,,9348,,,
14224,N,,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",Intermediate,,,,,50588,BAO_0000218,A,,15592,,Canis lupus familiaris,9615.0
14225,N,,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",Intermediate,,,,,50588,BAO_0000218,A,,15592,,Canis lupus familiaris,9615.0
14226,U,,,,Solubility at pH 7.4 in micro g/mL;NA denotes available,Autocuration,,,,,22229,BAO_0000100,P,,15592,,,
14227,U,,,,Solubility at pH 7.4 in micro g/mL;NA denotes not available,Autocuration,,,,,22229,BAO_0000100,P,,15592,,,
14228,U,,,,Solubility at pH 7.4 in ug/mL;NA denotes not available,Autocuration,,,,,22229,BAO_0000100,P,,15592,,,
14229,N,,,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,Intermediate,,,,1969.0,50588,BAO_0000218,A,,15592,In vivo,Canis lupus familiaris,9615.0
14230,N,,,,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,Intermediate,,,,1977.0,50597,BAO_0000218,A,,7095,,Rattus norvegicus,10116.0
14231,U,,,,Area under the MAP curve measured over 5 min; ND means Not determined,Autocuration,,,,,22224,BAO_0000019,A,,16618,,,
14232,U,,,,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,Autocuration,,,,,22224,BAO_0000100,P,,16835,,,
14233,U,,,,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,Autocuration,,,,,22229,BAO_0000100,P,,15284,,,
14234,U,,,,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,Autocuration,,,,,22224,BAO_0000019,A,,15750,,,
14235,N,,,,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,Intermediate,,,,,50597,BAO_0000218,A,,16618,In vivo,Rattus norvegicus,10116.0
14236,U,,,,Half life after oral tested,Autocuration,,,,,22224,BAO_0000218,A,,16618,In vivo,,
14237,N,,,,Half life was determined in plasma of rat; NT indicates not tested,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15812,,Rattus norvegicus,10116.0
14238,N,,,,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,Intermediate,,,,,50597,BAO_0000218,A,,16618,In vivo,Rattus norvegicus,10116.0
14239,U,,,,Oral bioavailability after oral tested,Autocuration,,,,,22224,BAO_0000218,A,,16618,In vivo,,
14240,N,,,,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),Intermediate,,,,,50597,BAO_0000218,A,,13098,,Rattus norvegicus,10116.0
14241,N,,,,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),Intermediate,,,,,50597,BAO_0000218,A,,13098,,Rattus norvegicus,10116.0
14242,N,,,,half life was determined in plasma of rat; NT indicates not tested,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15812,,Rattus norvegicus,10116.0
14243,N,,,,half life was determined in plasma of rat; NT means not tested,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15812,,Rattus norvegicus,10116.0
14244,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14245,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); inactive,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14246,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14247,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14248,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14249,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14250,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14251,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14252,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14253,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14254,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14255,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14256,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14257,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14258,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14259,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14260,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14261,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14262,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14263,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14264,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14265,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14266,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14267,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14268,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14269,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14270,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14271,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14272,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14273,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14274,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14275,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14276,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14277,N,,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14278,N,,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14279,N,,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14280,N,,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14281,N,,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14282,N,,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14283,N,,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14284,N,,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14285,N,,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14286,N,,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14287,N,,,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14288,N,,,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14289,N,,,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14290,N,,,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14291,N,,,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14292,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14293,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14294,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14295,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14296,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14297,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14298,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14299,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14300,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14301,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14302,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14303,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14304,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14305,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14306,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14307,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14308,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),Autocuration,,,,2367.0,22224,BAO_0000218,A,,13257,In vivo,,
14309,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,Autocuration,,,,2367.0,22224,BAO_0000218,A,,13257,In vivo,,
14310,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,Autocuration,,,,2385.0,22224,BAO_0000218,A,,13257,In vivo,,
14311,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),Autocuration,,,,2367.0,22224,BAO_0000218,A,,13257,In vivo,,
14312,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,Autocuration,,,,,22224,BAO_0000218,A,,13257,In vivo,,
14313,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,Autocuration,,,,2385.0,22224,BAO_0000218,A,,13257,In vivo,,
14314,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,Autocuration,,,,2106.0,22224,BAO_0000218,A,,13257,In vivo,,
14315,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,Autocuration,,,,1255.0,22224,BAO_0000218,A,,13257,In vivo,,
14316,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,Autocuration,,,,178.0,22224,BAO_0000218,A,,13257,In vivo,,
14317,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,Autocuration,,,,1474.0,22224,BAO_0000218,A,,13257,In vivo,,
14318,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,Autocuration,,,,,22224,BAO_0000218,A,,13257,In vivo,,
14319,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,Autocuration,,,,2113.0,22224,BAO_0000218,A,,13257,In vivo,,
14320,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,Autocuration,,,,2107.0,22224,BAO_0000218,A,,13257,In vivo,,
14321,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,Autocuration,,,,2048.0,22224,BAO_0000218,A,,13257,In vivo,,
14322,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,Autocuration,,,,2385.0,22224,BAO_0000218,A,,13257,In vivo,,
14323,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),Autocuration,,,,2367.0,22224,BAO_0000218,A,,13257,In vivo,,
14324,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,Autocuration,,,,2385.0,22224,BAO_0000218,A,,13257,In vivo,,
14325,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),Autocuration,,,,2367.0,22224,BAO_0000218,A,,13257,In vivo,,
14326,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,Autocuration,,,,,22224,BAO_0000218,A,,13257,In vivo,,
14327,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,Autocuration,,,,2385.0,22224,BAO_0000218,A,,13257,In vivo,,
14328,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,Autocuration,,,,2106.0,22224,BAO_0000218,A,,13257,In vivo,,
14329,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,Autocuration,,,,2367.0,22224,BAO_0000218,A,,13257,In vivo,,
14330,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,Autocuration,,,,1255.0,22224,BAO_0000218,A,,13257,In vivo,,
14331,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,Autocuration,,,,178.0,22224,BAO_0000218,A,,13257,In vivo,,
14332,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,Autocuration,,,,1474.0,22224,BAO_0000218,A,,13257,In vivo,,
14333,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,Autocuration,,,,,22224,BAO_0000218,A,,13257,In vivo,,
14334,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,Autocuration,,,,2113.0,22224,BAO_0000218,A,,13257,In vivo,,
14335,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,Autocuration,,,,2107.0,22224,BAO_0000218,A,,13257,In vivo,,
14336,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,Autocuration,,,,2048.0,22224,BAO_0000218,A,,13257,In vivo,,
14337,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,Autocuration,,,,2385.0,22224,BAO_0000218,A,,13257,In vivo,,
14338,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),Autocuration,,,,2367.0,22224,BAO_0000218,A,,13257,In vivo,,
14339,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,Autocuration,,,,2367.0,22224,BAO_0000218,A,,13257,In vivo,,
14340,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,Autocuration,,,,2385.0,22224,BAO_0000218,A,,13257,In vivo,,
14341,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),Autocuration,,,,2367.0,22224,BAO_0000218,A,,13257,In vivo,,
14342,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,Autocuration,,,,,22224,BAO_0000218,A,,13257,In vivo,,
14343,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,Autocuration,,,,2385.0,22224,BAO_0000218,A,,13257,In vivo,,
14344,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,Autocuration,,,,2106.0,22224,BAO_0000218,A,,13257,In vivo,,
14345,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,Autocuration,,,,1255.0,22224,BAO_0000218,A,,13257,In vivo,,
14346,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,Autocuration,,,,178.0,22224,BAO_0000218,A,,13257,In vivo,,
14347,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,Autocuration,,,,1474.0,22224,BAO_0000218,A,,13257,In vivo,,
14348,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,Autocuration,,,,,22224,BAO_0000218,A,,13257,In vivo,,
14349,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,Autocuration,,,,2107.0,22224,BAO_0000218,A,,13257,In vivo,,
14350,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,Autocuration,,,,2048.0,22224,BAO_0000218,A,,13257,In vivo,,
14351,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,Autocuration,,,,2385.0,22224,BAO_0000218,A,,13257,In vivo,,
14352,U,,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,Autocuration,,,,,22224,BAO_0000019,A,,2193,,,
14353,U,,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,Autocuration,,,,,22224,BAO_0000019,A,,2193,,,
14354,U,,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,Autocuration,,,,,22224,BAO_0000019,A,,2193,,,
14355,U,,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,Autocuration,,,,,22224,BAO_0000019,A,,2193,,,
14356,U,,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,Autocuration,,,,,22224,BAO_0000019,A,,2193,,,
14357,U,,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,Autocuration,,,,,22224,BAO_0000019,A,,2193,,,
14358,U,,,,Hydrolysis rate constant was determined,Autocuration,,,,,22224,BAO_0000019,A,,568,,,
14359,U,,,,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",Autocuration,,,,,22224,BAO_0000019,A,,9680,,,
14360,U,,,,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",Autocuration,,,,,22224,BAO_0000019,A,,9680,,,
14361,U,,,,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",Autocuration,,,,,22224,BAO_0000019,A,,9680,,,
14362,U,,,,Observed second order rate constant,Autocuration,,,,,22224,BAO_0000019,A,,10026,,,
14363,U,,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,Autocuration,,,,,22224,BAO_0000019,A,,10281,,,
14364,U,,,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,Autocuration,,,,,22224,BAO_0000019,A,,10014,,,
14365,U,,,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,Autocuration,,,,,22224,BAO_0000019,A,,10014,,,
14366,U,,,,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",Autocuration,,,,,22224,BAO_0000019,A,,9680,,,
14367,U,,,,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",Autocuration,,,,,22224,BAO_0000019,A,,9680,,,
14368,U,,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,,
14369,U,,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,,
14370,U,,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,,
14371,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,,
14372,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,,
14373,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,,
14374,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,,
14375,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,,
14376,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,,
14377,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,,
14378,N,,,,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,Intermediate,,,,,50597,BAO_0000218,A,,10014,,Rattus norvegicus,10116.0
14379,U,,,,Association constant for compound at 31 degree C was determined,Autocuration,,,,,22224,BAO_0000019,A,,9962,,,
14380,U,,,,Calculated antagonist equilibrium dissociation constant of the compound,Autocuration,,,,,22224,BAO_0000019,A,,12029,,,
14381,U,,,,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,Autocuration,,,,,22224,BAO_0000019,A,,12029,,,
14382,N,,,,Dissociation constants vs LTE4 on guinea pig trachea,Intermediate,,,,3126.0,50512,BAO_0000218,A,,10583,,Cavia porcellus,10141.0
14383,U,,,,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",Autocuration,,,,,22224,BAO_0000019,A,,568,,,
14384,U,,,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",Autocuration,,,,,22224,BAO_0000019,A,,568,,,
14385,U,,,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",Autocuration,,,,,22224,BAO_0000019,A,,568,,,
14386,U,,,,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",Autocuration,,,,,22224,BAO_0000019,A,,568,,,
14387,U,,,,Affinity constant KD value was derived from TMP,Autocuration,,,,,22224,BAO_0000019,A,,7493,,,
14388,U,,,,Apparent dissociation (binding) rate constant was evaluated,Autocuration,,,,,22224,BAO_0000019,A,,8371,,,
14389,U,,,,Dissociation constant (KD) of the compound,Autocuration,,,,,22224,BAO_0000100,P,,13114,,,
14390,U,,,,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,Autocuration,,,,,22224,BAO_0000100,P,,15515,,,
14391,U,,,,Dissociation constant from ESR titration experiments,Autocuration,,,,,22224,BAO_0000100,P,,522,,,
14392,U,,,,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),Autocuration,,,,,22224,BAO_0000019,,,13888,,,
14393,U,,,,Dissociation constant was evaluated.,Autocuration,,,,,22224,BAO_0000100,P,,2616,,,
14394,U,,,,Dissociation constant was reported,Autocuration,,,,,22224,BAO_0000100,P,,3798,,,
14395,N,,,,Dissociation constant was determined in rat pituitary cells.,Intermediate,,,,,50597,BAO_0000218,A,,8731,,Rattus norvegicus,10116.0
14396,U,,,,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,Autocuration,,,,,22224,BAO_0000019,A,,11892,,,
14397,U,,,,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,Autocuration,,,,,22224,BAO_0000019,A,,11892,,,
14398,U,,,,Equilibrium dissociation constant of the compound,Autocuration,,,,,22224,BAO_0000019,A,,2582,,,
14399,U,,,,Equilibrium dissociation constant was determined,Autocuration,,,,,22224,BAO_0000019,A,,11892,,,
14400,U,,,,Kinetic constant KD was evaluated,Autocuration,,,,,22224,BAO_0000019,A,,13396,,,
14401,U,,,,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,Autocuration,,,,,22224,BAO_0000019,A,,603,,,
14402,U,,,,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,Autocuration,,,,,22224,BAO_0000019,A,,15673,,,
14403,U,,,,Rate constant for hydrolysis in aqueous acetone.,Autocuration,,,,,22224,BAO_0000019,A,,10368,,,
14404,U,,,,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,Autocuration,,,,,22224,BAO_0000019,A,,14228,,,
14405,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14406,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14407,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14408,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14409,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14410,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14411,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14412,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14413,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14414,N,,,,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14415,N,,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14416,N,,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14417,N,,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14418,N,,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14419,N,,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14420,N,,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14421,N,,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14422,N,,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14423,N,,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14424,N,,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14425,N,,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14426,N,,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14427,N,,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14428,N,,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14429,N,,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14430,N,,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14431,N,,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14432,N,,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14433,N,,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14434,N,,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14435,N,,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14436,N,,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14437,N,,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14438,N,,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14439,N,,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14440,N,,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14441,N,,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14442,N,,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,Rattus norvegicus,10116.0
14443,N,,,,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,Intermediate,,,,,50588,BAO_0000218,A,,8310,,Canis lupus familiaris,9615.0
14444,N,,,,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,Intermediate,,,,,50588,BAO_0000218,A,,8310,,Canis lupus familiaris,9615.0
14445,N,,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,Intermediate,,,,,50594,BAO_0000218,A,,8310,,Mus musculus,10090.0
14446,N,,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,Intermediate,,,,,50594,BAO_0000218,A,,8310,,Mus musculus,10090.0
14447,N,,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,Intermediate,,,,,50594,BAO_0000218,A,,8310,,Mus musculus,10090.0
14448,N,,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,Intermediate,,,,,50594,BAO_0000218,A,,8310,,Mus musculus,10090.0
14449,N,,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,Intermediate,,,,,50594,BAO_0000218,A,,8310,,Mus musculus,10090.0
14450,N,,,,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,Intermediate,,,,,50588,BAO_0000218,A,,8310,,Canis lupus familiaris,9615.0
14451,N,,,,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,Intermediate,,,,,50594,BAO_0000218,A,,8310,,Mus musculus,10090.0
14452,N,,,,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,Intermediate,,,,,50588,BAO_0000218,A,,8310,,Canis lupus familiaris,9615.0
14453,N,,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,Intermediate,,,,,50588,BAO_0000218,A,,8310,,Canis lupus familiaris,9615.0
14454,N,,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,Intermediate,,,,,50594,BAO_0000218,A,,8310,,Mus musculus,10090.0
14455,N,,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,Intermediate,,,,,50594,BAO_0000218,A,,8310,,Mus musculus,10090.0
14456,N,,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,Intermediate,,,,,50594,BAO_0000218,A,,8310,,Mus musculus,10090.0
14457,N,,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,Intermediate,,,,,50594,BAO_0000218,A,,8310,,Mus musculus,10090.0
14458,N,,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,Intermediate,,,,,50594,BAO_0000218,A,,8310,,Mus musculus,10090.0
14459,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14460,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14461,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14462,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14463,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14464,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14465,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14466,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14467,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14468,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14469,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14470,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14471,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14472,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14473,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14474,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14475,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14476,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14477,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14478,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14479,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14480,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14481,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14482,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14483,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14484,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14485,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14486,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14487,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14488,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14489,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14490,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14491,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14492,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14493,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14494,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14495,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14496,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14497,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14498,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14499,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14500,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14501,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14502,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14503,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14504,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14505,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14506,N,,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14507,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),Autocuration,,,,2367.0,22224,BAO_0000218,A,,13257,In vivo,,
14508,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),Autocuration,,,,2367.0,22224,BAO_0000218,A,,13257,In vivo,,
14509,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,Autocuration,,,,,22224,BAO_0000218,A,,13257,In vivo,,
14510,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,Autocuration,,,,2385.0,22224,BAO_0000218,A,,13257,In vivo,,
14511,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,Autocuration,,,,2106.0,22224,BAO_0000218,A,,13257,In vivo,,
14512,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,Autocuration,,,,2113.0,22224,BAO_0000218,A,,13257,In vivo,,
14513,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,Autocuration,,,,1255.0,22224,BAO_0000218,A,,13257,In vivo,,
14514,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,Autocuration,,,,178.0,22224,BAO_0000218,A,,13257,In vivo,,
14515,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,Autocuration,,,,1474.0,22224,BAO_0000218,A,,13257,In vivo,,
14516,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,Autocuration,,,,,22224,BAO_0000218,A,,13257,In vivo,,
14517,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,Autocuration,,,,2113.0,22224,BAO_0000218,A,,13257,In vivo,,
14518,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,Autocuration,,,,2107.0,22224,BAO_0000218,A,,13257,In vivo,,
14519,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,Autocuration,,,,2048.0,22224,BAO_0000218,A,,13257,In vivo,,
14520,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,Autocuration,,,,2385.0,22224,BAO_0000218,A,,13257,In vivo,,
14521,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),Autocuration,,,,2367.0,22224,BAO_0000218,A,,13257,In vivo,,
14522,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,Autocuration,,,,2367.0,22224,BAO_0000218,A,,13257,In vivo,,
14523,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,Autocuration,,,,2385.0,22224,BAO_0000218,A,,13257,In vivo,,
14524,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),Autocuration,,,,2367.0,22224,BAO_0000218,A,,13257,In vivo,,
14525,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,Autocuration,,,,,22224,BAO_0000218,A,,13257,In vivo,,
14526,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,Autocuration,,,,2385.0,22224,BAO_0000218,A,,13257,In vivo,,
14527,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,Autocuration,,,,2106.0,22224,BAO_0000218,A,,13257,In vivo,,
14528,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,Autocuration,,,,2367.0,22224,BAO_0000218,A,,13257,In vivo,,
14529,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,Autocuration,,,,2385.0,22224,BAO_0000218,A,,13257,In vivo,,
14530,N,,,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,Intermediate,,,,,50597,BAO_0000218,A,,15413,In vivo,Rattus norvegicus,10116.0
14531,N,,,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,Intermediate,,,,,50597,BAO_0000218,A,,15413,In vivo,Rattus norvegicus,10116.0
14532,N,,,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,Intermediate,,,,,50597,BAO_0000218,A,,15413,In vivo,Rattus norvegicus,10116.0
14533,N,,,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,Intermediate,,,,,50597,BAO_0000218,A,,15413,In vivo,Rattus norvegicus,10116.0
14534,N,,,,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,15413,In vivo,Rattus norvegicus,10116.0
14535,N,,,,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,15413,In vivo,Rattus norvegicus,10116.0
14536,N,,,,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,Intermediate,,,,1898.0,50597,BAO_0000218,A,,15413,In vivo,Rattus norvegicus,10116.0
14537,N,,,,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,Intermediate,,,,1898.0,50597,BAO_0000218,A,,15413,In vivo,Rattus norvegicus,10116.0
14538,N,,,,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,Intermediate,,,,,50597,BAO_0000218,A,,15413,In vivo,Rattus norvegicus,10116.0
14539,N,,,,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,Intermediate,,,,,50597,BAO_0000218,A,,15413,In vivo,Rattus norvegicus,10116.0
14540,N,,,,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,15413,In vivo,Rattus norvegicus,10116.0
14541,N,,,,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,Intermediate,,,,1898.0,50597,BAO_0000218,A,,15413,In vivo,Rattus norvegicus,10116.0
14542,N,,,,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,Intermediate,,,,,50597,BAO_0000218,A,,15413,In vivo,Rattus norvegicus,10116.0
14543,N,,,,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,Intermediate,,,,,50597,BAO_0000218,A,,15413,In vivo,Rattus norvegicus,10116.0
14544,N,,,,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,15413,In vivo,Rattus norvegicus,10116.0
14545,N,,,,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,Intermediate,,,,1898.0,50597,BAO_0000218,A,,15413,In vivo,Rattus norvegicus,10116.0
14546,N,,,,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,Intermediate,,,,2037.0,50597,BAO_0000218,A,,15413,In vivo,Rattus norvegicus,10116.0
14547,N,,,,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,Intermediate,,,,2037.0,50597,BAO_0000218,A,,15413,In vivo,Rattus norvegicus,10116.0
14548,N,,,,Biodistribution of the [11C]-radiolabeled compound in rat cortex,Intermediate,,,,,50597,BAO_0000218,A,,15413,In vivo,Rattus norvegicus,10116.0
14549,N,,,,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,Intermediate,,,,,50597,BAO_0000218,A,,15413,In vivo,Rattus norvegicus,10116.0
14550,N,,,,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,15413,In vivo,Rattus norvegicus,10116.0
14551,N,,,,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,15413,In vivo,Rattus norvegicus,10116.0
14552,N,,,,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,Intermediate,,,,1898.0,50597,BAO_0000218,A,,15413,In vivo,Rattus norvegicus,10116.0
14553,N,,,,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,Intermediate,,,,1898.0,50597,BAO_0000218,A,,15413,In vivo,Rattus norvegicus,10116.0
14554,N,,,,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,Intermediate,,,,2037.0,50597,BAO_0000218,A,,15413,In vivo,Rattus norvegicus,10116.0
14555,N,,,,Biodistribution of the [18F]-radiolabeled compound in rat cortex,Intermediate,,,,,50597,BAO_0000218,A,,15413,In vivo,Rattus norvegicus,10116.0
14556,U,,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,Autocuration,,,,,22224,BAO_0000019,A,,12404,,,
14557,U,,,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",Autocuration,,,,,22224,BAO_0000019,A,,568,,,
14558,U,,,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",Autocuration,,,,,22224,BAO_0000019,A,,568,,,
14559,U,,,,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",Autocuration,,,,,22224,BAO_0000019,A,,568,,,
14560,U,,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,Autocuration,,,,,22224,BAO_0000019,A,,12404,,,
14561,N,,,,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,Intermediate,,,,,50212,BAO_0000218,A,,7624,,Escherichia coli,562.0
14562,N,,,,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",Intermediate,,,,,50597,BAO_0000218,A,,7624,,Rattus norvegicus,10116.0
14563,N,,,,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",Intermediate,,,,,50597,BAO_0000218,A,,7624,,Rattus norvegicus,10116.0
14564,U,,,,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",Autocuration,,,,,22224,BAO_0000019,A,,4643,,,
14565,U,,,,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,Autocuration,,,,,22224,BAO_0000019,A,,11532,,,
14566,U,,,,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,Autocuration,,,,,22224,BAO_0000019,A,,11018,,,
14567,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",Autocuration,,,,,22224,BAO_0000019,A,,2276,,,
14568,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",Autocuration,,,,,22224,BAO_0000019,A,,2276,,,
14569,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",Autocuration,,,,,22224,BAO_0000019,A,,2276,,,
14570,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",Autocuration,,,,,22224,BAO_0000019,A,,2276,,,
14571,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",Autocuration,,,,,22224,BAO_0000019,A,,2276,,,
14572,U,,,,Michaelis constant (KM) was evaluated,Autocuration,,,,,22224,BAO_0000019,A,,8949,,,
14573,U,,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,Autocuration,,,,,22224,BAO_0000019,A,,12404,,,
14574,U,,,,Substrate concentration for half maximal velocity was reported for rat hexokinase I,Autocuration,,,,,22224,BAO_0000019,B,,7625,,,
14575,U,,,,Substrate concentration for half maximal velocity was reported for rat hexokinase II,Autocuration,,,,,22224,BAO_0000019,B,,7625,,,
14576,U,,,,Substrate concentration for half maximal velocity was reported for rat hexokinase III,Autocuration,,,,,22224,BAO_0000019,B,,7625,,,
14577,U,,,,Substrate concentration for half maximal velocity was reported for yeast hexokinase,Autocuration,,,,,22224,BAO_0000019,B,,7625,,,
14578,U,,,,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,Autocuration,,,,,22224,BAO_0000019,A,,12908,,,
14579,U,,,,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,Autocuration,,,,,22224,BAO_0000019,A,,10368,,,
14580,U,,,,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),Autocuration,,,,,22224,BAO_0000019,A,,13108,,,
14581,U,,,,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),Autocuration,,,,,22224,BAO_0000019,A,,13108,,,
14582,U,,,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,Autocuration,,,,,22224,BAO_0000019,A,,15217,,,
14583,U,,,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,Autocuration,,,,,22224,BAO_0000019,A,,15217,,,
14584,U,,,,Binding constant was determined,Autocuration,,,,,22224,BAO_0000019,A,,10933,,,
14585,U,,,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,Autocuration,,,,,22224,BAO_0000019,A,,2363,,,
14586,U,,,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,Autocuration,,,,,22224,BAO_0000019,A,,2363,,,
14587,U,,,,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,Autocuration,,,,,22224,BAO_0000019,A,,2276,,,
14588,U,,,,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,Autocuration,,,,,22224,BAO_0000100,P,,14915,,,
14589,U,,,,Catalytic rate constant of the compound,Autocuration,,,,,22224,BAO_0000019,A,,8847,,,
14590,U,,,,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,Autocuration,,,,,22224,BAO_0000019,B,,15357,,,
14591,U,,,,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),Autocuration,,,,,22224,BAO_0000019,A,,2869,,,
14592,U,,,,Catalytic rate constant against phospholipase A2 was determined,Autocuration,,,,,22224,BAO_0000019,A,,3484,,,
14593,U,,,,"Compound was evaluated for catalytic constant, Kcat",Autocuration,,,,,22224,BAO_0000019,A,,1373,,,
14594,U,,,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,Autocuration,,,,,22224,BAO_0000019,A,,8142,,,
14595,U,,,,Kcat calculated from 0.693/T1/2,Autocuration,,,,,22224,BAO_0000019,A,,14131,,,
14596,U,,,,Kcat was determined,Autocuration,,,,,22224,BAO_0000019,A,,17269,,,
14597,U,,,,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,Autocuration,,,,,22224,BAO_0000019,A,,3485,,,
14598,U,,,,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,Autocuration,,,,,22224,BAO_0000019,A,,3485,,,
14599,U,,,,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,Autocuration,,,,,22224,BAO_0000019,A,,3485,,,
14600,U,,,,Kcat value was determined,Autocuration,,,,,22224,BAO_0000019,A,,5962,,,
14601,U,,,,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,Autocuration,,,,,22224,BAO_0000019,A,,3133,,,
14602,U,,,,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,Autocuration,,,,,22224,BAO_0000019,A,,3133,,,
14603,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",Autocuration,,,,,22224,BAO_0000019,A,,2276,,,
14604,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",Autocuration,,,,,22224,BAO_0000019,A,,2276,,,
14605,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",Autocuration,,,,,22224,BAO_0000019,A,,2276,,,
14606,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",Autocuration,,,,,22224,BAO_0000019,A,,2276,,,
14607,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",Autocuration,,,,,22224,BAO_0000019,A,,2276,,,
14608,U,,,,Kinetic parameter for rate of conversion to PABA was determined,Autocuration,,,,,22224,BAO_0000019,A,,4892,,,
14609,U,,,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,Autocuration,,,,,22224,BAO_0000019,A,,3133,,,
14610,N,,,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",Intermediate,,,,1988.0,50597,BAO_0000218,A,,11488,,Rattus norvegicus,10116.0
14611,N,,,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",Intermediate,,,,1088.0,50597,BAO_0000218,A,,11488,,Rattus norvegicus,10116.0
14612,N,,,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",Intermediate,,,,1088.0,50597,BAO_0000218,A,,11488,,Rattus norvegicus,10116.0
14613,N,,,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",Intermediate,,,,1088.0,50597,BAO_0000218,A,,11488,,Rattus norvegicus,10116.0
14614,N,,,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",Intermediate,,,,1088.0,50597,BAO_0000218,A,,11488,,Rattus norvegicus,10116.0
14615,N,,,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",Intermediate,,,,1088.0,50597,BAO_0000218,A,,11488,,Rattus norvegicus,10116.0
14616,N,,,,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,Rattus norvegicus,10116.0
14617,N,,,,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,Rattus norvegicus,10116.0
14618,N,,,,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,Rattus norvegicus,10116.0
14619,N,,,,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,Rattus norvegicus,10116.0
14620,N,,,,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,Rattus norvegicus,10116.0
14621,N,,,,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,Rattus norvegicus,10116.0
14622,N,,,,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,Rattus norvegicus,10116.0
14623,N,,,,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,Rattus norvegicus,10116.0
14624,N,,,,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,Rattus norvegicus,10116.0
14625,N,,,,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,Rattus norvegicus,10116.0
14626,N,,,,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,Rattus norvegicus,10116.0
14627,N,,,,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,Rattus norvegicus,10116.0
14628,N,,,,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,Rattus norvegicus,10116.0
14629,N,,,,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,Rattus norvegicus,10116.0
14630,N,,,,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,Rattus norvegicus,10116.0
14631,N,,,,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,Rattus norvegicus,10116.0
14632,N,,,,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,Rattus norvegicus,10116.0
14633,N,,,,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,Rattus norvegicus,10116.0
14634,N,,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
14635,N,,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
14636,N,,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
14637,N,,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
14638,N,,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
14639,N,,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
14640,N,,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
14641,N,,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
14642,N,,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
14643,N,,,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
14644,N,,,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
14645,N,,,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
14646,N,,,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
14647,N,,,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
14648,N,,,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
14649,N,,,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
14650,N,,,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
14651,N,,,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,,Oryctolagus cuniculus,9986.0
14652,N,,,,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,178.0,50597,BAO_0000218,A,,13925,In vivo,Rattus norvegicus,10116.0
14653,N,,,,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,178.0,50597,BAO_0000218,A,,13925,In vivo,Rattus norvegicus,10116.0
14654,N,,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14655,N,,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14656,N,,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14657,N,,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14658,N,,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14659,N,,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14660,N,,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14661,N,,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14662,N,,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14663,N,,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14664,N,,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14665,N,,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14666,N,,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14667,N,,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14668,N,,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14669,N,,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14670,N,,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14671,N,,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,,Canis lupus familiaris,9615.0
14672,N,,,,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14673,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14674,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14675,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14676,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14677,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14678,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14679,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14680,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14681,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14682,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14683,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14684,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14685,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14686,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14687,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14688,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14689,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14690,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14691,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14692,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14693,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14694,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14695,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14696,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14697,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14698,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14699,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14700,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14701,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14702,N,,,,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,15413,In vivo,Rattus norvegicus,10116.0
14703,N,,,,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,Intermediate,,,,1898.0,50597,BAO_0000218,A,,15413,In vivo,Rattus norvegicus,10116.0
14704,N,,,,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,Intermediate,,,,1898.0,50597,BAO_0000218,A,,15413,In vivo,Rattus norvegicus,10116.0
14705,N,,,,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,178.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14706,N,,,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,178.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14707,N,,,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,178.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14708,N,,,,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,178.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14709,N,,,,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,178.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14710,N,,,,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,178.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14711,N,,,,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,178.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14712,N,,,,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,178.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14713,N,,,,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,178.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14714,N,,,,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,178.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14715,N,,,,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,178.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14716,N,,,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14717,N,,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14718,N,,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14719,N,,,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14720,N,,,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14721,N,,,,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14722,N,,,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14723,N,,,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14724,N,,,,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14725,N,,,,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14726,N,,,,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2113.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14727,N,,,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2113.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14728,N,,,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2113.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14729,N,,,,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2113.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14730,N,,,,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2113.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14731,N,,,,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2113.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14732,N,,,,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2113.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14733,N,,,,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2113.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14734,N,,,,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2113.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14735,N,,,,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2113.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14736,N,,,,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2113.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14737,N,,,,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14738,N,,,,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14739,N,,,,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14740,N,,,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14741,N,,,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14742,N,,,,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14743,N,,,,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14744,N,,,,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14745,N,,,,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14746,U,,,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,Autocuration,,,,,22224,BAO_0000019,A,,3133,,,
14747,U,,,,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,Autocuration,,,,,22224,BAO_0000019,A,,2742,,,
14748,U,,,,Compound was tested for amidase rate in the presence of N62C screen enzyme,Autocuration,,,,,22224,BAO_0000019,A,,2742,,,
14749,U,,,,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,Autocuration,,,,,22224,BAO_0000019,A,,2742,,,
14750,U,,,,Compound was tested for amidase rate in the presence of S166C screen enzyme,Autocuration,,,,,22224,BAO_0000019,A,,2742,,,
14751,U,,,,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,Autocuration,,,,,22224,BAO_0000019,A,,2742,,,
14752,U,,,,Compound was tested for esterase rate in the presence of N62C screen enzyme,Autocuration,,,,,22224,BAO_0000019,A,,2742,,,
14753,U,,,,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,Autocuration,,,,,22224,BAO_0000019,A,,2742,,,
14754,U,,,,Compound was tested for esterase rate in the presence of S166C screen enzyme,Autocuration,,,,,22224,BAO_0000019,A,,2742,,,
14755,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",Autocuration,,,,,22224,BAO_0000019,A,,2276,,,
14756,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",Autocuration,,,,,22224,BAO_0000019,A,,2276,,,
14757,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",Autocuration,,,,,22224,BAO_0000019,A,,2276,,,
14758,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",Autocuration,,,,,22224,BAO_0000019,A,,2276,,,
14759,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",Autocuration,,,,,22224,BAO_0000019,A,,2276,,,
14760,U,,,,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",Autocuration,,,,,22224,BAO_0000019,A,,2276,,,
14761,U,,,,Ratio of Kcat to that of Km was determined,Autocuration,,,,,22224,BAO_0000019,A,,17269,,,
14762,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",Autocuration,,,,,22224,BAO_0000019,A,,2276,,,
14763,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",Autocuration,,,,,22224,BAO_0000019,A,,2276,,,
14764,U,,,,"Compound was evaluated for constant, Kd",Autocuration,,,,,22224,BAO_0000019,A,,15917,,,
14765,U,,,,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,Autocuration,,,,,22224,BAO_0000019,A,,10933,,,
14766,U,,,,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,Autocuration,,,,,22224,BAO_0000019,A,,10933,,,
14767,U,,,,Dissociation Constant of compound determined,Autocuration,,,,,22224,BAO_0000019,A,,14293,,,
14768,U,,,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,Autocuration,,,,,22224,BAO_0000019,B,,6698,,,
14769,U,,,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,Autocuration,,,,,22224,BAO_0000019,B,,6698,,,
14770,U,,,,Dissociation constant of compound with Fructose was determined,Autocuration,,,,,22224,BAO_0000100,P,,4318,,,
14771,U,,,,Dissociation constant of compound with Fructose was determined; Not determined,Autocuration,,,,,22224,BAO_0000100,P,,4318,,,
14772,U,,,,Dissociation constant of compound with Lactulose was determined,Autocuration,,,,,22224,BAO_0000100,P,,4318,,,
14773,U,,,,Dissociation constant of compound with Lactulose was determined; Not determined,Autocuration,,,,,22224,BAO_0000100,P,,4318,,,
14774,U,,,,Dissociation constant of the Compound,Autocuration,,,,,22224,BAO_0000100,P,,14959,,,
14775,U,,,,Dissociation constant by non-linear regression analysis,Autocuration,,,,,22224,BAO_0000100,P,,5913,,,
14776,U,,,,Dissociation constant was determined,Autocuration,,,,,22224,BAO_0000100,P,,14218,,,
14777,U,,,,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,Autocuration,,,,,22224,BAO_0000100,P,,10689,,,
14778,U,,,,Dissociation constant was determined,Autocuration,,,,,22224,BAO_0000100,P,,13925,,,
14779,U,,,,Dissociation constant was determined,Autocuration,,,,,22224,BAO_0000100,P,,16359,,,
14780,N,,,,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,Intermediate,,,,2385.0,50597,BAO_0000218,A,,10944,,Rattus norvegicus,10116.0
14781,U,,,,The dissociation constant determined by fluorescence displacement assay,Autocuration,,,,,22224,BAO_0000019,A,,11080,,,
14782,U,,,,kd value surface plasmon resonance (SPR) method,Autocuration,,,,,22224,BAO_0000019,A,,17805,,,
14783,N,,,,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,Intermediate,,,,2385.0,50597,BAO_0000218,A,,10944,,Rattus norvegicus,10116.0
14784,U,,,,First dissociation constant of the binding of compound to V30M TTR,Autocuration,,,,,22224,BAO_0000019,F,,16645,,,
14785,U,,,,Second dissociation constant of the binding of compound to V30M TTR,Autocuration,,,,,22224,BAO_0000019,F,,16645,,,
14786,U,,,,"Compound was evaluated for equilibrium constant, Ke",Autocuration,,,,,22224,BAO_0000019,A,,7793,,,
14787,U,,,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,Autocuration,,,,1898.0,22224,BAO_0000019,A,,12199,,,
14788,U,,,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,Autocuration,,,,1898.0,22224,BAO_0000019,A,,12199,,,
14789,U,,,,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,Autocuration,,,,,22224,BAO_0000019,A,,9680,,,
14790,U,,,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,Autocuration,,,,,22224,BAO_0000019,A,,9680,,,
14791,U,,,,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,Autocuration,,,,,22224,BAO_0000019,A,,9680,,,
14792,N,,,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,Intermediate,,,,,50594,BAO_0000218,A,,13758,,Mus musculus,10090.0
14793,N,,,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,Intermediate,,,,,50594,BAO_0000218,A,,13758,,Mus musculus,10090.0
14794,N,,,,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,Intermediate,,,,,50594,BAO_0000218,A,,13758,,Mus musculus,10090.0
14795,N,,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,Intermediate,,,,,50594,BAO_0000218,A,,13758,,Mus musculus,10090.0
14796,N,,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,Intermediate,,,,,50594,BAO_0000218,A,,13758,,Mus musculus,10090.0
14797,N,,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,Intermediate,,,,,50594,BAO_0000218,A,,13758,,Mus musculus,10090.0
14798,N,,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,Intermediate,,,,,50594,BAO_0000218,A,,13758,,Mus musculus,10090.0
14799,N,,,,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,Intermediate,,,,,50594,BAO_0000218,A,,13758,,Mus musculus,10090.0
14800,N,,,,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14393,,Rattus norvegicus,10116.0
14801,N,,,,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14393,,Rattus norvegicus,10116.0
14802,N,,,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,15078,,Rattus norvegicus,10116.0
14803,N,,,,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,955.0,50597,BAO_0000218,A,,13925,In vivo,Rattus norvegicus,10116.0
14804,N,,,,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,955.0,50597,BAO_0000218,A,,13925,In vivo,Rattus norvegicus,10116.0
14805,N,,,,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,948.0,50597,BAO_0000218,A,,13925,In vivo,Rattus norvegicus,10116.0
14806,N,,,,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,948.0,50597,BAO_0000218,A,,13925,In vivo,Rattus norvegicus,10116.0
14807,N,,,,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13925,In vivo,Rattus norvegicus,10116.0
14808,N,,,,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13925,In vivo,Rattus norvegicus,10116.0
14809,N,,,,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13925,In vivo,Rattus norvegicus,10116.0
14810,N,,,,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13925,In vivo,Rattus norvegicus,10116.0
14811,N,,,,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,2048.0,50597,BAO_0000218,A,,13925,In vivo,Rattus norvegicus,10116.0
14812,N,,,,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,Intermediate,,,,2048.0,50597,BAO_0000218,A,,13925,In vivo,Rattus norvegicus,10116.0
14813,N,,,,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,2385.0,50597,BAO_0000218,A,,13925,In vivo,Rattus norvegicus,10116.0
14814,N,,,,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,2385.0,50597,BAO_0000218,A,,13925,In vivo,Rattus norvegicus,10116.0
14815,N,,,,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,14.0,50597,BAO_0000218,A,,13925,In vivo,Rattus norvegicus,10116.0
14816,N,,,,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,14.0,50597,BAO_0000218,A,,13925,In vivo,Rattus norvegicus,10116.0
14817,N,,,,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,2106.0,50597,BAO_0000218,A,,13925,In vivo,Rattus norvegicus,10116.0
14818,N,,,,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,2106.0,50597,BAO_0000218,A,,13925,In vivo,Rattus norvegicus,10116.0
14819,N,,,,Biodistribution of Compound in rat blood after 15 minutes of administration,Intermediate,,,,178.0,50597,BAO_0000218,A,,9712,In vivo,Rattus norvegicus,10116.0
14820,N,,,,Biodistribution of Compound in rat blood after 2 minutes of administration,Intermediate,,,,178.0,50597,BAO_0000218,A,,9712,In vivo,Rattus norvegicus,10116.0
14821,N,,,,Biodistribution of Compound in rat brain after 15 minutes of administration,Intermediate,,,,955.0,50597,BAO_0000218,A,,9712,In vivo,Rattus norvegicus,10116.0
14822,N,,,,Biodistribution of Compound in rat brain after 2 minutes of administration,Intermediate,,,,955.0,50597,BAO_0000218,A,,9712,In vivo,Rattus norvegicus,10116.0
14823,N,,,,Biodistribution of Compound in rat heart after 15 minutes of administration,Intermediate,,,,948.0,50597,BAO_0000218,A,,9712,In vivo,Rattus norvegicus,10116.0
14824,N,,,,Biodistribution of Compound in rat heart after 2 minutes of administration,Intermediate,,,,948.0,50597,BAO_0000218,A,,9712,In vivo,Rattus norvegicus,10116.0
14825,N,,,,Biodistribution of Compound in rat liver after 15 minutes of administration,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9712,In vivo,Rattus norvegicus,10116.0
14826,N,,,,Biodistribution of Compound in rat liver after 2 minutes of administration,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9712,In vivo,Rattus norvegicus,10116.0
14827,N,,,,Biodistribution of Compound in rat lung after 15 minutes of administration,Intermediate,,,,2048.0,50597,BAO_0000218,A,,9712,In vivo,Rattus norvegicus,10116.0
14828,N,,,,Biodistribution of Compound in rat lung after 2 minutes of administration,Intermediate,,,,2048.0,50597,BAO_0000218,A,,9712,In vivo,Rattus norvegicus,10116.0
14829,N,,,,Biodistribution of Compound in rat muscle after 15 minutes of administration,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9712,In vivo,Rattus norvegicus,10116.0
14830,N,,,,Biodistribution of Compound in rat muscle after 2 minutes of administration,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9712,In vivo,Rattus norvegicus,10116.0
14831,N,,,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,Intermediate,,,,,50597,BAO_0000218,A,,13925,,Rattus norvegicus,10116.0
14832,N,,,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,Intermediate,,,,,50597,BAO_0000218,A,,13925,,Rattus norvegicus,10116.0
14833,N,,,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,Intermediate,,,,,50597,BAO_0000218,A,,13925,,Rattus norvegicus,10116.0
14834,N,,,,Organ distribution in rat blood 2 minutes after intravenous injection,Intermediate,,,,,50597,BAO_0000218,A,,6941,,Rattus norvegicus,10116.0
14835,N,,,,Organ distribution in rat blood 2 hr after intravenous injection,Intermediate,,,,,50597,BAO_0000218,A,,6941,,Rattus norvegicus,10116.0
14836,N,,,,Organ distribution in rat blood 30 minutes after intravenous injection,Intermediate,,,,,50597,BAO_0000218,A,,6941,,Rattus norvegicus,10116.0
14837,N,,,,Organ distribution in rat blood 30 min after intravenous injection,Intermediate,,,,,50597,BAO_0000218,A,,6941,,Rattus norvegicus,10116.0
14838,N,,,,Organ distribution in rat brain 2 minutes after intravenous injection,Intermediate,,,,,50597,BAO_0000218,A,,6941,,Rattus norvegicus,10116.0
14839,N,,,,Organ distribution in rat brain 2 hr after intravenous injection,Intermediate,,,,,50597,BAO_0000218,A,,6941,,Rattus norvegicus,10116.0
14840,N,,,,Organ distribution in rat brain 30 minutes after intravenous injection,Intermediate,,,,,50597,BAO_0000218,A,,6941,,Rattus norvegicus,10116.0
14841,N,,,,Organ distribution in rat heart 2 minutes after intravenous injection,Intermediate,,,,,50597,BAO_0000218,A,,6941,,Rattus norvegicus,10116.0
14842,N,,,,Organ distribution in rat heart 2 hr after intravenous injection,Intermediate,,,,,50597,BAO_0000218,A,,6941,,Rattus norvegicus,10116.0
14843,N,,,,Organ distribution in rat heart 30 minutes after intravenous injection,Intermediate,,,,,50597,BAO_0000218,A,,6941,,Rattus norvegicus,10116.0
14844,N,,,,Organ distribution in rat kidney 2 minutes after intravenous injection,Intermediate,,,,,50597,BAO_0000218,A,,6941,,Rattus norvegicus,10116.0
14845,N,,,,Organ distribution in rat kidney 2 hr after intravenous injection,Intermediate,,,,,50597,BAO_0000218,A,,6941,,Rattus norvegicus,10116.0
14846,N,,,,Organ distribution in rat kidney 30 minutes after intravenous injection,Intermediate,,,,,50597,BAO_0000218,A,,6941,,Rattus norvegicus,10116.0
14847,N,,,,Organ distribution in rat liver 2 minutes after intravenous injection,Intermediate,,,,2107.0,50597,BAO_0000218,A,,6941,,Rattus norvegicus,10116.0
14848,N,,,,Organ distribution in rat liver 2 hr after intravenous injection,Intermediate,,,,2107.0,50597,BAO_0000218,A,,6941,,Rattus norvegicus,10116.0
14849,N,,,,Organ distribution in rat liver 30 minutes after intravenous injection,Intermediate,,,,2107.0,50597,BAO_0000218,A,,6941,,Rattus norvegicus,10116.0
14850,N,,,,Organ distribution in rat lung 2 minutes after intravenous injection,Intermediate,,,,,50597,BAO_0000218,A,,6941,,Rattus norvegicus,10116.0
14851,N,,,,Organ distribution in rat lung 2 hr after intravenous injection,Intermediate,,,,,50597,BAO_0000218,A,,6941,,Rattus norvegicus,10116.0
14852,N,,,,Organ distribution in rat lung 30 minutes after intravenous injection,Intermediate,,,,,50597,BAO_0000218,A,,6941,,Rattus norvegicus,10116.0
14853,N,,,,Organ distribution in rat muscle 2 minutes after intravenous injection,Intermediate,,,,2385.0,50597,BAO_0000218,A,,6941,,Rattus norvegicus,10116.0
14854,N,,,,Organ distribution in rat muscle 2 hr after intravenous injection,Intermediate,,,,2385.0,50597,BAO_0000218,A,,6941,,Rattus norvegicus,10116.0
14855,N,,,,Organ distribution in rat muscle 30 minutes after intravenous injection,Intermediate,,,,2385.0,50597,BAO_0000218,A,,6941,,Rattus norvegicus,10116.0
14856,N,,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),Intermediate,,,,,50594,BAO_0000218,A,,14439,In vivo,Mus musculus,10090.0
14857,N,,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),Intermediate,,,,,50594,BAO_0000218,A,,14439,In vivo,Mus musculus,10090.0
14858,N,,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),Intermediate,,,,,50594,BAO_0000218,A,,14439,In vivo,Mus musculus,10090.0
14859,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14860,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14861,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14862,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14863,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14864,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14865,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14866,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14867,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14868,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14869,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14870,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14871,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14872,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14873,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14874,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14875,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14876,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14877,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14878,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14879,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14880,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14881,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14882,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14883,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14884,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14885,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14886,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14887,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14888,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,,Rattus norvegicus,10116.0
14889,N,,,,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",Intermediate,,,,,50597,BAO_0000218,A,,7415,,Rattus norvegicus,10116.0
14890,U,,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,Autocuration,,,,,22224,BAO_0000019,A,,7313,,,
14891,U,,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,Autocuration,,,,,22224,BAO_0000019,A,,7313,,,
14892,U,,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,Autocuration,,,,,22224,BAO_0000019,A,,7313,,,
14893,U,,,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,Autocuration,,,,1235.0,22224,BAO_0000019,A,,7570,,,
14894,U,,,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,Autocuration,,,,1235.0,22224,BAO_0000019,A,,7570,,,
14895,U,,,,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,Autocuration,,,,,22224,BAO_0000019,A,,7570,,,
14896,U,,,,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,Autocuration,,,,,22224,BAO_0000019,A,,7570,,,
14897,U,,,,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,Autocuration,,,,1235.0,22224,BAO_0000019,A,,7570,,,
14898,U,,,,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,Autocuration,,,,1235.0,22224,BAO_0000019,A,,7570,,,
14899,U,,,,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,Autocuration,,,,,22224,BAO_0000019,A,,7570,,,
14900,U,,,,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,Autocuration,,,,,22224,BAO_0000019,A,,7570,,,
14901,U,,,,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,Autocuration,,,,,22224,BAO_0000019,A,,7570,,,
14902,U,,,,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,Autocuration,,,,,22224,BAO_0000019,A,,7570,,,
14903,U,,,,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,Autocuration,,,,1235.0,22224,BAO_0000019,A,,7570,,,
14904,U,,,,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,Autocuration,,,,,22224,BAO_0000019,A,,7570,,,
14905,U,,,,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,Autocuration,,,,,22224,BAO_0000019,A,,7570,,,
14906,U,,,,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,Autocuration,,,,1235.0,22224,BAO_0000019,A,,7570,,,
14907,U,,,,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,Autocuration,,,,,22224,BAO_0000019,A,,7570,,,
14908,U,,,,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,Autocuration,,,,,22224,BAO_0000019,A,,7570,,,
14909,U,,,,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",Autocuration,,,,,22224,BAO_0000218,A,,14122,In vivo,Canis lupus familiaris,9615.0
14910,U,,,,Absolute bioavailability in male cynomolgus monkeys,Autocuration,,,,,22224,BAO_0000218,A,,16449,In vivo,Macaca fascicularis,9541.0
14911,U,,,,Absolute bioavailability in maleSprague-Dawley rats,Autocuration,,,,,22224,BAO_0000218,A,,16449,In vivo,Rattus norvegicus,10116.0
14912,N,,,,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14913,N,,,,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14914,N,,,,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14915,N,,,,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2048.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14916,N,,,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2048.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14917,N,,,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2048.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14918,N,,,,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2048.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14919,N,,,,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2048.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14920,N,,,,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2048.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14921,N,,,,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2048.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14922,N,,,,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2048.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14923,N,,,,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2048.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14924,N,,,,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2048.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14925,N,,,,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2385.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14926,N,,,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2385.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14927,N,,,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2385.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14928,N,,,,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2385.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14929,N,,,,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2385.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14930,N,,,,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2385.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14931,N,,,,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2385.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14932,N,,,,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2385.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14933,N,,,,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2385.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14934,N,,,,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2385.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14935,N,,,,Biodistribution in normal mice blood after 120 hr,Intermediate,,,,178.0,50594,BAO_0000218,A,,15045,In vivo,Mus musculus,10090.0
14936,N,,,,Biodistribution in normal mice blood after 24 hr,Intermediate,,,,178.0,50594,BAO_0000218,A,,15045,In vivo,Mus musculus,10090.0
14937,N,,,,Biodistribution in normal mice blood after 4 hr,Intermediate,,,,178.0,50594,BAO_0000218,A,,15045,In vivo,Mus musculus,10090.0
14938,N,,,,Biodistribution in normal mice bone after 120 hr,Intermediate,,,,10000001.0,50594,BAO_0000218,A,,15045,In vivo,Mus musculus,10090.0
14939,N,,,,Biodistribution in normal mice bone after 24 hr,Intermediate,,,,10000001.0,50594,BAO_0000218,A,,15045,In vivo,Mus musculus,10090.0
14940,N,,,,Biodistribution in normal mice bone after 4 hr,Intermediate,,,,10000001.0,50594,BAO_0000218,A,,15045,In vivo,Mus musculus,10090.0
14941,N,,,,Biodistribution in normal mice heart after 120 hr,Intermediate,,,,948.0,50594,BAO_0000218,A,,15045,In vivo,Mus musculus,10090.0
14942,N,,,,Biodistribution in normal mice heart after 24 hr,Intermediate,,,,948.0,50594,BAO_0000218,A,,15045,In vivo,Mus musculus,10090.0
14943,N,,,,Biodistribution in normal mice heart after 4 hr,Intermediate,,,,948.0,50594,BAO_0000218,A,,15045,In vivo,Mus musculus,10090.0
14944,N,,,,Biodistribution in normal mice kidney after 120 hr,Intermediate,,,,2113.0,50594,BAO_0000218,A,,15045,In vivo,Mus musculus,10090.0
14945,N,,,,Biodistribution in normal mice kidney after 24 hr,Intermediate,,,,2113.0,50594,BAO_0000218,A,,15045,In vivo,Mus musculus,10090.0
14946,N,,,,Biodistribution in normal mice kidney after 4 hr,Intermediate,,,,2113.0,50594,BAO_0000218,A,,15045,In vivo,Mus musculus,10090.0
14947,N,,,,Biodistribution in normal mice liver after 120 hr,Intermediate,,,,2107.0,50594,BAO_0000218,A,,15045,In vivo,Mus musculus,10090.0
14948,N,,,,Biodistribution in normal mice liver after 24 hr,Intermediate,,,,2107.0,50594,BAO_0000218,A,,15045,In vivo,Mus musculus,10090.0
14949,N,,,,Biodistribution in normal mice liver after 4 hr,Intermediate,,,,2107.0,50594,BAO_0000218,A,,15045,In vivo,Mus musculus,10090.0
14950,N,,,,Biodistribution in normal mice spleen after 120 hr,Intermediate,,,,2106.0,50594,BAO_0000218,A,,15045,In vivo,Mus musculus,10090.0
14951,N,,,,Biodistribution in normal mice spleen after 24 hr,Intermediate,,,,2106.0,50594,BAO_0000218,A,,15045,In vivo,Mus musculus,10090.0
14952,N,,,,Biodistribution in normal mice spleen after 4 hr,Intermediate,,,,2106.0,50594,BAO_0000218,A,,15045,In vivo,Mus musculus,10090.0
14953,N,,,,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14954,N,,,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14955,N,,,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14956,N,,,,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14957,N,,,,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14958,N,,,,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14959,N,,,,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14960,N,,,,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14961,N,,,,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14962,N,,,,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14963,N,,,,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2046.0,50597,BAO_0000218,A,,12017,In vivo,Rattus norvegicus,10116.0
14964,N,,,,The Kel values in female wistar rats.,Intermediate,,,,,50597,BAO_0000218,A,,14941,,Rattus norvegicus,10116.0
14965,U,,,,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,Autocuration,,,,,22224,BAO_0000019,A,,4646,,,
14966,U,,,,Hydrolysis rate constant of the compound,Autocuration,,,,,22224,BAO_0000019,A,,8847,,,
14967,U,,,,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,Autocuration,,,,,22229,BAO_0000100,P,,11778,,,
14968,U,,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",Autocuration,,,,,22224,BAO_0000019,A,,2363,,,
14969,U,,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",Autocuration,,,,,22224,BAO_0000019,A,,2363,,,
14970,U,,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",Autocuration,,,,,22224,BAO_0000019,A,,2363,,,
14971,U,,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",Autocuration,,,,,22224,BAO_0000019,A,,2363,,,
14972,U,,,,Apparent inactivation rate constant was evaluated,Autocuration,,,,,22224,BAO_0000019,A,,8371,,,
14973,U,,,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,Autocuration,,,,,22224,BAO_0000019,A,,14883,,,
14974,U,,,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,Autocuration,,,,,22224,BAO_0000019,A,,14883,,,
14975,U,,,,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,Autocuration,,,,,22224,BAO_0000019,A,,4643,,,
14976,U,,,,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,Autocuration,,,,,22224,BAO_0000019,A,,3519,,,
14977,U,,,,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,Autocuration,,,,,22224,BAO_0000019,A,,10600,,,
14978,U,,,,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,Autocuration,,,,,22224,BAO_0000019,F,,8501,,,
14979,U,,,,Dissociation constant was determined,Autocuration,,,,,22224,BAO_0000100,P,,8505,,,
14980,U,,,,Dissociation constant was determined,Autocuration,,,,,22224,BAO_0000100,P,,9778,,,
14981,U,,,,Dissociation constant at pH 7.4,Autocuration,,,,,22224,BAO_0000100,P,,9778,,,
14982,U,,,,Dissociation constant in presence of 1 mM dithiothreitol,Autocuration,,,,,22224,BAO_0000100,P,,9778,,,
14983,U,,,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,Autocuration,,,,,22224,BAO_0000019,A,,13007,,,
14984,U,,,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,Autocuration,,,,,22224,BAO_0000019,A,,13007,,,
14985,U,,,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,Autocuration,,,,,22224,BAO_0000019,A,,13007,,,
14986,U,,,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,Autocuration,,,,,22224,BAO_0000019,A,,13007,,,
14987,U,,,,Kinetic constant for aromatization of androstenedione,Autocuration,,,,,22224,BAO_0000019,A,,11482,,,
14988,U,,,,Kinetic constant for aromatization of testosterone,Autocuration,,,,,22224,BAO_0000019,A,,11482,,,
14989,U,,,,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,Autocuration,,,,,22224,BAO_0000019,A,,2303,,,
14990,U,,,,Local inhibition constant was determined,Autocuration,,,,,22224,BAO_0000019,A,,11964,,,
14991,N,,,,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,Intermediate,,,,,50347,BAO_0000218,A,,3140,,Saccharomyces cerevisiae,4932.0
14992,U,,,,Dissociation constant value of the compound,Autocuration,,,,,22224,BAO_0000100,P,,10650,,,
14993,U,,,,In vitro permeability through cornea without epithelium,Autocuration,,,,964.0,22224,BAO_0000019,A,,4667,,,
14994,U,,,,In vitro permeability through intact cornea,Autocuration,,,,964.0,22224,BAO_0000019,A,,4667,,,
14995,N,,,,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,Intermediate,,,,964.0,50592,BAO_0000218,A,,9199,,Oryctolagus cuniculus,9986.0
14996,U,,,,Rate of enzyme inactivation for the compound was determined,Autocuration,,,,,22224,BAO_0000019,A,,11966,,,
14997,U,,,,In vitro permeability through cornea without epithelium,Autocuration,,,,964.0,22224,BAO_0000019,A,,4667,,,
14998,U,,,,In vitro permeability through intact cornea,Autocuration,,,,964.0,22224,BAO_0000019,A,,4667,,,
14999,U,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,,
15000,U,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,,
15001,U,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,,
15002,U,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,,
15003,U,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,,
15004,U,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,,
15005,U,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,,
15006,U,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,,
15007,U,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,,
15008,U,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,,
15009,U,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,,
15010,U,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,,
15011,U,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,,
15012,U,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,,
15013,U,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,,
15014,N,,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),Intermediate,,,,,50594,BAO_0000218,A,,14439,In vivo,Mus musculus,10090.0
15015,N,,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,Intermediate,,,,,50587,BAO_0000218,A,,14439,In vivo,Homo sapiens,9606.0
15016,N,,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),Intermediate,,,,,50594,BAO_0000218,A,,14439,In vivo,Mus musculus,10090.0
15017,N,,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),Intermediate,,,,,50594,BAO_0000218,A,,14439,In vivo,Mus musculus,10090.0
15018,N,,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),Intermediate,,,,,50594,BAO_0000218,A,,14439,In vivo,Mus musculus,10090.0
15019,N,,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),Intermediate,,,,,50594,BAO_0000218,A,,14439,In vivo,Mus musculus,10090.0
15020,N,,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,Intermediate,,,,,50594,BAO_0000218,A,,14439,In vivo,Mus musculus,10090.0
15021,N,,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),Intermediate,,,,,50594,BAO_0000218,A,,14439,In vivo,Mus musculus,10090.0
15022,N,,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),Intermediate,,,,,50594,BAO_0000218,A,,14439,In vivo,Mus musculus,10090.0
15023,N,,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),Intermediate,,,,,50594,BAO_0000218,A,,14439,In vivo,Mus musculus,10090.0
15024,N,,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),Intermediate,,,,,50594,BAO_0000218,A,,14439,In vivo,Mus musculus,10090.0
